Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Aberrant Crypt Foci
Inhibition by dietary curcumin of azoxymethane-induced ornithine decarboxylase, tyrosine protein kinase, arachidonic acid metabolism and aberrant crypt foci formation in the rat colon.
Aberrant Crypt Foci
Inhibitory effect of caffeic acid esters on azoxymethane-induced biochemical changes and aberrant crypt foci formation in rat colon.
Abscess
Expression of transforming growth factor-beta1, 2, 3 isoforms and type I and II receptors in acute focal cerebral ischemia: an immunohistochemical study in rat after transient and permanent occlusion of middle cerebral artery.
Acantholysis
Focal adhesion kinase is expressed in acantholytic keratinocytes associated with pemphigus vulgaris and pemphigus foliaceus.
Acantholysis
Neural nitric oxide synthase participates in pemphigus vulgaris acantholysis through upregulation of Rous sarcoma, mammalian target of rapamycin and focal adhesion kinase.
Acantholysis
Pemphigus vulgaris autoimmune globulin induces Src-dependent tyrosine-phosphorylation of plakophilin 3 and its detachment from desmoglein 3.
Acidosis
A central role for Pyk2-Src interaction in coupling diverse stimuli to increased epithelial NBC activity.
Acidosis
Dominant negative c-Src inhibits angiotensin II induced activation of NHE3 in OKP cells.
Acne Vulgaris
Activation of Janus kinase signaling pathway in acne lesions.
Acne Vulgaris
Rapid remission of refractory synovitis, acne, pustulosis, hyperostosis, and osteitis syndrome in response to the Janus kinase inhibitor tofacitinib: A case report.
Acquired Hyperostosis Syndrome
Exosomal proteome from the serum, bone marrow, and palm and toe pustular skin tissues of a single patient with SAPHO syndrome.
Acquired Immunodeficiency Syndrome
Assessment of azithromycin as an anticancer agent for treatment of imatinib sensitive and resistant CML cells.
Acquired Immunodeficiency Syndrome
Dys-regulated activation of a Src tyroine kinase Hck at the Golgi disturbs N-glycosylation of a cytokine receptor Fms.
Acquired Immunodeficiency Syndrome
HIV envelope-directed signaling aberrancies and cell death of CD4+ T cells in the absence of TCR co-stimulation.
Acquired Immunodeficiency Syndrome
HIV-1 Nef perturbs the function, structure, and signaling of the golgi through the Src kinase Hck.
Acquired Immunodeficiency Syndrome
Identification of an allosteric signaling network within Tec family kinases.
Acquired Immunodeficiency Syndrome
Interaction between Hck and HIV-1 Nef negatively regulates cell surface expression of M-CSF receptor.
Acquired Immunodeficiency Syndrome
Methodological comparison of two anti-ZAP-70 antibodies.
Acquired Immunodeficiency Syndrome
Role of the F-BAR Family Member PSTPIP2 in Autoinflammatory Diseases.
Acquired Immunodeficiency Syndrome
The crystal structure of HIV-1 Nef protein bound to the Fyn kinase SH3 domain suggests a role for this complex in altered T cell receptor signaling.
Acquired Immunodeficiency Syndrome
The Src kinase Lyn is required for CCR5 signaling in response to MIP-1beta and R5 HIV-1 gp120 in human macrophages.
Acromegaly
Janus kinase (JAK) 2 V617F mutation as the cause of primary thrombocythemia in acromegaly with severe visceromegaly and divergence between growth hormone and insulin-like growth factor-1 concentrations during the follow-up: causal or casual association?
Activated Protein C Resistance
Recurrent thrombosis after carotid endarterectomy secondary to activated protein C resistance and essential thrombocytosis: A case report.
Acute Coronary Syndrome
Insufficient deactivation of the protein tyrosine kinase lck amplifies T-cell responsiveness in acute coronary syndrome.
Acute Coronary Syndrome
The Role of FAK in the Secretion of MMP9 after CD147 Stimulation in Macrophages.
Acute Kidney Injury
Amelioration of sepsis-induced acute kidney injury through inhibition of inflammatory cytokines and oxidative stress in dendritic cells and neutrophils respectively in mice: Role of spleen tyrosine kinase signaling.
Acute Kidney Injury
Bruton's tyrosine kinase inhibition attenuates oxidative stress in systemic immune cells and renal compartment during sepsis-induced acute kidney injury in mice.
Acute Kidney Injury
Diffuse Alveolar Hemorrhage Secondary to Ibrutinib Therapy in a Patient With Refractory Mantle Cell Lymphoma.
Acute Kidney Injury
Focal adhesion kinase signaling mediates acute renal injury induced by ischemia/reperfusion.
Acute Kidney Injury
Fyn Kinase: A Potential Therapeutic Target in Acute Kidney Injury.
Acute Kidney Injury
Inhibition of JAK2/STAT3 signaling pathway protects mice from the DDP-induced acute kidney injury in lung cancer.
Acute Kidney Injury
M1 macrophage triggered by Mincle leads to a deterioration of acute kidney injury.
Acute Kidney Injury
Negative Regulation of Tec Kinase Alleviates LPS-Induced Acute Kidney Injury in Mice via theTLR4/NF-?B Signaling Pathway.
Acute Kidney Injury
Pharmacological inhibition of Src kinase protects against acute kidney injury in a murine model of renal ischemia/reperfusion.
Acute Kidney Injury
The Bcr-Abl inhibitor GNF-7 inhibits necroptosis and ameliorates acute kidney injury by targeting RIPK1 and RIPK3 kinases.
Acute Kidney Injury
WITHDRAWN: Spleen tyrosine kinase (SYK) protects renal tubular epithelial cell against hypoxia injury in children with acute kidney injury.
Acute Kidney Injury
[Cancer treatment-induced nephrotoxicity: BCR-Abl and VEGF inhibitors.]
Acute Lung Injury
Attenuation of murine acute lung injury by PF-573,228, an inhibitor of focal adhesion kinase.
Acute Lung Injury
Induced Pluripotent Stem Cells Attenuate Endothelial Leakage in Acute Lung Injury via Tissue Inhibitor of Metalloproteinases-1 to Reduce Focal Adhesion Kinase Activity.
Acute Lung Injury
Inhibiting Bruton's Tyrosine Kinase Rescues Mice from Lethal Influenza Induced Acute Lung Injury.
Acute Lung Injury
Inhibition of spleen tyrosine kinase signaling protects against acute lung injury through blockade of NADPH oxidase and IL-17A in neutrophils and ?? T cells respectively in mice.
Acute Lung Injury
JAK2/STAT1-mediated HMGB1 translocation increases inflammation and cell death in a ventilator-induced lung injury model.
Acute Lung Injury
Nonstructural Protein 1 (NS1)-Mediated Inhibition of c-Abl Results in Acute Lung Injury and Priming for Bacterial Coninfections: Insights Into 1918 H1N1 Pandemic?
Acute Lung Injury
Retrograde perfusion in isolated perfused mouse lungs-Feasibility and effects on cytokine levels and pulmonary oedema formation.
Acute Lung Injury
Shockingly: the loss of Lyn leads to leakiness.
Acute Lung Injury
Silencing Bruton's tyrosine kinase in alveolar neutrophils protects mice from LPS/immune complex-induced acute lung injury.
Acute Lung Injury
Src kinase inhibition with dasatinib impairs neutrophil function and clearance of Escherichia coli infection in a murine model of acute lung injury.
Acute Lung Injury
Src tyrosine kinase inhibition prevents pulmonary ischemia-reperfusion-induced acute lung injury.
Acute Lung Injury
The potential of nanoscale combinations of self-assembling peptides and amino acids of the Src tyrosine kinase inhibitor in acute lung injury therapy.
Acute Lung Injury
Transforming growth factor beta1 inhibits cystic fibrosis transmembrane conductance regulator-dependent cAMP-stimulated alveolar epithelial fluid transport via a phosphatidylinositol 3-kinase-dependent mechanism.
Acute Lung Injury
[Src protein tyrosine kinase family and acute lung injury]
Adenocarcinoma
3-substitued indoles: one-pot synthesis and evaluation of anticancer and Src kinase inhibitory activities.
Adenocarcinoma
A chemical genomics-aggrephagy integrated method studying functional analysis of autophagy inducers.
Adenocarcinoma
A phase II trial of the Src kinase inhibitor saracatinib (AZD0530) in patients with metastatic or locally advanced gastric or gastro esophageal junction (GEJ) adenocarcinoma: a trial of the PMH phase II consortium.
Adenocarcinoma
A small molecule FAK kinase inhibitor, GSK2256098, inhibits growth and survival of pancreatic ductal adenocarcinoma cells.
Adenocarcinoma
Activation of Src kinase in primary colorectal carcinoma: an indicator of poor clinical prognosis.
Adenocarcinoma
Afatinib in NSCLC With HER2 Mutations: Results of the Prospective, Open-Label Phase II NICHE Trial of European Thoracic Oncology Platform (ETOP).
Adenocarcinoma
Alteration of cell growth and morphology by overexpression of transforming growth factor beta type II receptor in human lung adenocarcinoma cells.
Adenocarcinoma
An Integrative Informatics Approach to Explain the Mechanism of Action of Novel N1-(Anthraquinon-2-yl) Amidrazones as BCR/ABL Inhibitors.
Adenocarcinoma
An Update on Inherited Colon Cancer and Gastrointestinal Polyposis.
Adenocarcinoma
Antimetastatic Potential of Amide-linked Local Anesthetics: Inhibition of Lung Adenocarcinoma Cell Migration and Inflammatory Src Signaling Independent of Sodium Channel Blockade.
Adenocarcinoma
Ascl1-induced Wnt11 regulates neuroendocrine differentiation, cell proliferation, and E-cadherin expression in small-cell lung cancer and Wnt11 regulates small-cell lung cancer biology.
Adenocarcinoma
Association between focal adhesion kinase and matrix metalloproteinase-9 expression in prostate adenocarcinoma and their influence on the progression of prostatic adenocarcinoma.
Adenocarcinoma
Association of BDNF and BMPR1A with clinicopathologic parameters in benign and malignant gallbladder lesions.
Adenocarcinoma
Association of polymorphisms in transforming growth factor-? receptors with susceptibility to gastric cardia adenocarcinoma.
Adenocarcinoma
CEACAM6 cross-linking induces caveolin-1-dependent, Src-mediated focal adhesion kinase phosphorylation in BxPC3 pancreatic adenocarcinoma cells.
Adenocarcinoma
Co-overexpression of AXL and c-ABL predicts a poor prognosis in esophageal adenocarcinoma and promotes cancer cell survival.
Adenocarcinoma
Constitutive activation of Jak-2 and Tyk-2 in a v-Src-transformed human gallbladder adenocarcinoma cell line.
Adenocarcinoma
Constitutively decreased TGFBR1 allelic expression is a common finding in colorectal cancer and is associated with three TGFBR1 SNPs.
Adenocarcinoma
Critical role for the receptor tyrosine kinase EPHB4 in esophageal cancers.
Adenocarcinoma
Differential requirement for focal adhesion kinase signaling in cancer progression in the transgenic adenocarcinoma of mouse prostate model.
Adenocarcinoma
Direct tumorigenic conversion of human gallbladder carcinoma cells by v-src but not by activated c-H-ras oncogene.
Adenocarcinoma
Dissecting the role of TGF-beta type I receptor/ALK5 in pancreatic ductal adenocarcinoma: Smad activation is crucial for both the tumor suppressive and prometastatic function.
Adenocarcinoma
Dual tyrosine kinase inhibitor for focal adhesion kinase and insulin-like growth factor-I receptor exhibits anticancer effect in esophageal adenocarcinoma in vitro and in vivo.
Adenocarcinoma
Effects of combining erlotinib and RNA-interfered downregulation of focal adhesion kinase expression on gastric cancer.
Adenocarcinoma
Efficacy of the highly selective focal adhesion kinase inhibitor BI 853520 in adenocarcinoma xenograft models is linked to a mesenchymal tumor phenotype.
Adenocarcinoma
eIF5A-PEAK1 Signaling Regulates YAP1/TAZ Protein Expression and Pancreatic Cancer Cell Growth.
Adenocarcinoma
ERBB2 FISH and Chromosome Microarray Testing of Gastroesophageal Adenocarcinomas at a Single Institution.
Adenocarcinoma
Esophageal Adenocarcinoma Cells and Xenograft Tumors Exposed to Erb-b2 Receptor Tyrosine Kinase 2 and 3 Inhibitors Activate Transforming Growth Factor Beta Signaling, Which Induces Epithelial to Mesenchymal Transition.
Adenocarcinoma
Evaluation of the Clinical Significance of Focal Adhesion Kinase and Src Expression in Human Pancreatic Ductal Adenocarcinoma.
Adenocarcinoma
Expression and clinical significance of focal adhesion kinase in the two distinct histological types, intestinal and diffuse, of human gastric adenocarcinoma.
Adenocarcinoma
Expression of cortactin and focal adhesion kinase in colorectal adenocarcinoma: correlation with clinicopathologic parameters and their prognostic implication.
Adenocarcinoma
Expression of FAK and PTEN in Bronchioloalveolar carcinoma and lung adenocarcinoma.
Adenocarcinoma
Expression of transforming growth factor-beta receptor type I and type II in rat ventral prostate and Dunning R3327 PAP adenocarcinoma in response to castration and oestrogen treatment.
Adenocarcinoma
Fibrinogen activates focal adhesion kinase (FAK) promoting colorectal adenocarcinoma growth.
Adenocarcinoma
Focal adhesion kinase gene silencing promotes anoikis and suppresses metastasis of human pancreatic adenocarcinoma cells.
Adenocarcinoma
Focal adhesion kinase inhibition synergizes with nab-paclitaxel to target pancreatic ductal adenocarcinoma.
Adenocarcinoma
Focal adhesion kinase-promoted tumor glucose metabolism is associated with a shift of mitochondrial respiration to glycolysis.
Adenocarcinoma
Focal Adhesion Kinase: A promising therapeutic target in pancreatic adenocarcinoma.
Adenocarcinoma
Genomic alterations of ground-glass nodular lung adenocarcinoma.
Adenocarcinoma
Glucose Drives Growth Factor-Independent Esophageal Cancer Proliferation via Phosphohistidine-Focal Adhesion Kinase Signaling.
Adenocarcinoma
HER2 Heterogeneity in Gastroesophageal Cancer Detected by Testing Biopsy and Resection Specimens.
Adenocarcinoma
HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology.
Adenocarcinoma
HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology.
Adenocarcinoma
High JAK2 Protein Expression Predicts a Poor Prognosis in Patients with Resectable Pancreatic Ductal Adenocarcinoma.
Adenocarcinoma
Immunohistochemical expression of TGF beta (TGF-?), TGF beta receptor 1 (TGFBR1), and Ki67 in intestinal variant of gastric adenocarcinomas.
Adenocarcinoma
Inhibition of SRC expression and activity inhibits tumor progression and metastasis of human pancreatic adenocarcinoma cells in an orthotopic nude mouse model.
Adenocarcinoma
Inhibition of SRC tyrosine kinase impairs inherent and acquired gemcitabine resistance in human pancreatic adenocarcinoma cells.
Adenocarcinoma
M2 Macrophages Mediate the Resistance of Gastric Adenocarcinoma Cells to 5-Fluorouracil through the Expression of Integrin ?3, Focal Adhesion Kinase, and Cofilin.
Adenocarcinoma
Molecular cloning and characterization of human WNT11.
Adenocarcinoma
Mullerian inhibiting substance inhibits breast cancer cell growth through an NFkappa B-mediated pathway.
Adenocarcinoma
Mullerian-inhibiting substance regulates NF-kappa B signaling in the prostate in vitro and in vivo.
Adenocarcinoma
Mutated CEACAMs Disrupt Transforming Growth Factor Beta Signaling and Alter the Intestinal Microbiome to Promote Colorectal Carcinogenesis.
Adenocarcinoma
Mutations and reduced expression of the transforming growth factor-beta receptor II gene in rat lung adenocarcinomas induced by N-nitrosobis-(2-hydroxypropyl)amine.
Adenocarcinoma
Oncogenic Ras/Src cooperativity in pancreatic neoplasia.
Adenocarcinoma
One-pot regioselective synthesis of tetrahydroindazolones and evaluation of their antiproliferative and Src kinase inhibitory activities.
Adenocarcinoma
Pathological significance and predictive value for biochemical recurrence of c-Fes expression in prostate cancer.
Adenocarcinoma
Phase 1 dose-escalation study of momelotinib, a Janus kinase 1/2 inhibitor, combined with gemcitabine and nab-paclitaxel in patients with previously untreated metastatic pancreatic ductal adenocarcinoma.
Adenocarcinoma
Prostate tumor progression is mediated by a paracrine TGF-beta/Wnt3a signaling axis.
Adenocarcinoma
Rap1 reverses transcriptional repression of TGF-beta type II receptor by a mechanism involving AP-1 in the human pancreatic cancer cell line, UK Pan-1.
Adenocarcinoma
Reduced expression of focal adhesion kinase in liver metastases compared with matched primary human colorectal adenocarcinomas.
Adenocarcinoma
Reduced transforming growth factor-beta type II receptor (TGF-beta RII) expression in adenocarcinoma of the lung.
Adenocarcinoma
Requirement for focal adhesion kinase in the early phase of mammary adenocarcinoma lung metastasis formation.
Adenocarcinoma
RNA interference targeting focal adhesion kinase enhances pancreatic adenocarcinoma gemcitabine chemosensitivity.
Adenocarcinoma
Roles of the transforming growth factor beta 1 and its type I and II receptors in the development of a pulmonary adenocarcinoma: results of an immunohistochemical study.
Adenocarcinoma
Src activation in malignant and premalignant epithelia of Barrett's esophagus.
Adenocarcinoma
Src tyrosine kinase but not activated Ras augments sensitivity to taxanes through apoptosis in human adenocarcinoma cells.
Adenocarcinoma
Syk tyrosine kinase acts as a pancreatic adenocarcinoma tumor suppressor by regulating cellular growth and invasion.
Adenocarcinoma
Synthesis of 3-phenylpyrazolopyrimidine-1,2,3-triazole conjugates and evaluation of their Src kinase inhibitory and anticancer activities.
Adenocarcinoma
Targeted inhibition of SRC kinase signaling attenuates pancreatic tumorigenesis.
Adenocarcinoma
TGFBR1 and cancer susceptibility.
Adenocarcinoma
Tgfbr1 haploinsufficiency is a potent modifier of colorectal cancer development.
Adenocarcinoma
The extracellular matrix and focal adhesion kinase signaling regulate cancer stem cell function in pancreatic ductal adenocarcinoma.
Adenocarcinoma
The human splice variant ?16HER2 induces rapid tumor onset in a reporter transgenic mouse.
Adenocarcinoma
The nuclear factor kappa-B signaling pathway as a therapeutic target against thyroid cancers.
Adenocarcinoma
The Src family kinase inhibitors PP2 and PP1 effectively block TGF-beta1-induced cell migration and invasion in both established and primary carcinoma cells.
Adenocarcinoma
The Src kinase pathway promotes tamoxifen agonist action in Ishikawa endometrial cells through phosphorylation-dependent stabilization of estrogen receptor (alpha) promoter interaction and elevated steroid receptor coactivator 1 activity.
Adenocarcinoma
Transforming growth factor beta receptor type II inactivation promotes the establishment and progression of colon cancer.
Adenocarcinoma
Transforming growth factor-beta 1 and its receptors in human lung cancer and mouse lung carcinogenesis.
Adenocarcinoma
Tyrosine nitration of c-SRC tyrosine kinase in human pancreatic ductal adenocarcinoma.
Adenocarcinoma
Tyrosine Phosphoproteomics of Patient-Derived Xenografts Reveals Ephrin Type-B Receptor 4 Tyrosine Kinase as a Therapeutic Target in Pancreatic Cancer.
Adenocarcinoma
v-src induces cisplatin resistance by increasing the repair of cisplatin-DNA interstrand cross-links in human gallbladder adenocarcinoma cells.
Adenocarcinoma
[Oncogenes in human gastric carcinoma]
Adenocarcinoma of Lung
ABL kinase inhibition sensitizes primary lung adenocarcinomas to chemotherapy by promoting tumor cell differentiation.
Adenocarcinoma of Lung
ABT-263, a Bcl-2 inhibitor, enhances the susceptibility of lung adenocarcinoma cells treated with Src inhibitors to anoikis.
Adenocarcinoma of Lung
Activation of Focal Adhesion Kinase and Src Mediates Acquired Sorafenib Resistance in A549 Human Lung Adenocarcinoma Xenografts.
Adenocarcinoma of Lung
Afatinib in NSCLC With HER2 Mutations: Results of the Prospective, Open-Label Phase II NICHE Trial of European Thoracic Oncology Platform (ETOP).
Adenocarcinoma of Lung
Bosutinib inhibits migration and invasion via ACK1 in KRAS mutant non-small cell lung cancer.
Adenocarcinoma of Lung
Clinically relevant concentrations of lidocaine and ropivacaine inhibit TNF?-induced invasion of lung adenocarcinoma cells in vitro by blocking the activation of Akt and focal adhesion kinase.
Adenocarcinoma of Lung
Correction: ABL kinase inhibition sensitizes primary lung adenocarcinomas to chemotherapy by promoting tumor cell differentiation.
Adenocarcinoma of Lung
Dual EGFR and ABL Tyrosine Kinase Inhibitor Treatment in a Patient with Concomitant EGFR-Mutated Lung Adenocarcinoma and BCR-ABL1-Positive CML.
Adenocarcinoma of Lung
EphB4 as a Novel Target for the EGFR-Independent Suppressive Effects of Osimertinib on Cell Cycle Progression in Non-Small Cell Lung Cancer.
Adenocarcinoma of Lung
Fer protein-tyrosine kinase promotes lung adenocarcinoma cell invasion and tumor metastasis.
Adenocarcinoma of Lung
High CC chemokine receptor 7 expression improves postoperative prognosis of lung adenocarcinoma patients.
Adenocarcinoma of Lung
Honokiol Inhibits Proliferation, Invasion and Induces Apoptosis Through Targeting Lyn Kinase in Human Lung Adenocarcinoma Cells.
Adenocarcinoma of Lung
IL-6 regulates MMP-10 expression via JAK2/STAT3 signaling pathway in a human lung adenocarcinoma cell line.
Adenocarcinoma of Lung
Involvement of syk and VEGF-C in invasion of lung adenocarcinoma A549 cells.
Adenocarcinoma of Lung
Lyn, a Src family kinase, regulates activation of epidermal growth factor receptors in lung adenocarcinoma cells.
Adenocarcinoma of Lung
MicroRNA-106a targets autophagy and enhances sensitivity of lung cancer cells to Src inhibitors.
Adenocarcinoma of Lung
MicroRNA-204 deregulation in lung adenocarcinoma controls the biological behaviors of endothelial cells potentially by modulating Janus kinase 2-signal transducer and activator of transcription 3 pathway.
Adenocarcinoma of Lung
MicroRNA-29b is involved in the Src-ID1 signaling pathway and is dysregulated in human lung adenocarcinoma.
Adenocarcinoma of Lung
Mutations and reduced expression of the transforming growth factor-beta receptor II gene in rat lung adenocarcinomas induced by N-nitrosobis-(2-hydroxypropyl)amine.
Adenocarcinoma of Lung
Pulse Afatinib for ERBB2 Exon 20 Insertion-Mutated Lung Adenocarcinomas.
Adenocarcinoma of Lung
SRC tyrosine kinase inhibitor, m475271, suppresses subcutaneous growth and production of lung metastasis via inhibition of proliferation, invasion, and vascularization of human lung adenocarcinoma cells.
Adenocarcinoma of Lung
The expressions of EphB4 and ephrinB2 in lung adenocarcinomas: a high level of the EphB4 protein is associated with lymph node metastasis.
Adenocarcinoma of Lung
The RNA-editing enzyme ADAR promotes lung adenocarcinoma migration and invasion by stabilizing FAK.
Adenocarcinoma of Lung
Therapeutic Targeting of the Premetastatic Stage in Human Lung-to-Brain Metastasis.
Adenocarcinoma of Lung
Tumor prone phenotype of mice deficient in a novel apoptosis-inducing gene, drs.
Adenocarcinoma of Lung
WZ4002, a third-generation EGFR inhibitor, can overcome anoikis resistance in EGFR-mutant lung adenocarcinomas more efficiently than Src inhibitors.
Adenocarcinoma of Lung
[The possible mechanisms of simvastatin on apoptosis of lung adenocarcinoma cells].
Adenocarcinoma of Lung
[Tyrosin kinase inhibitors in oncology].
Adenocarcinoma, Follicular
Epidermal growth factor stimulates matrix metalloproteinase-9 expression and invasion in human follicular thyroid carcinoma cells through Focal adhesion kinase.
Adenocarcinoma, Follicular
The nuclear factor kappa-B signaling pathway as a therapeutic target against thyroid cancers.
Adenocarcinoma, Mucinous
Individual tumorigenesis pathways of sporadic colorectal adenocarcinomas are associated with the biological behavior of tumors.
Adenoma
A role for epidermal growth factor receptor, c-Src and focal adhesion kinase in an in vitro model for the progression of colon cancer.
Adenoma
An EphB-Abl signaling pathway is associated with intestinal tumor initiation and growth.
Adenoma
Association of BDNF and BMPR1A with clinicopathologic parameters in benign and malignant gallbladder lesions.
Adenoma
B lymphocytes repress hepatic tumorigenesis but not development in Hras12V transgenic mice.
Adenoma
Decreased transforming growth factor beta type II receptor expression in intestinal adenomas from Min/+ mice is associated with increased cyclin D1 and cyclin-dependent kinase 4 expression.
Adenoma
Effects of the Janus Kinase Inhibitor, Tofacitinib, on Testicular Leydig Cell Hyperplasia and Adenoma in Rats, and on Prolactin Signaling in Cultured Primary Rat Leydig Cells.
Adenoma
Elevated c-yes tyrosine kinase activity in premalignant lesions of the colon.
Adenoma
Enhanced tumorigenesis and reduced transforming growth factor-beta type II receptor in lung tumors from mice with reduced gene dosage of transforming growth factor-beta1.
Adenoma
Expression of bone morphogenetic protein-6 and bone morphogenetic protein receptors in myoepithelial cells of canine mammary gland tumors.
Adenoma
Expression of the signal transducer and activator of transcription factor 3 and Janus kinase 3 in colorectal carcinomas, colonic adenomas and ulcerative colitis.
Adenoma
Genetic alterations are frequent in APC but rare in the TGF-beta type II receptor gene in cancer in adenomas of the colon.
Adenoma
Genome-wide association studies and meta-analysis reveal novel quantitative trait loci and pleiotropic loci for swine head-related traits.
Adenoma
Hepatic silicosis, cirrhosis, and liver tumors in mice and hamsters: studies of transforming growth factor beta expression.
Adenoma
Increased dosage and amplification of the focal adhesion kinase gene in human cancer cells.
Adenoma
Infrequent detection of germline allele-specific expression of TGFBR1 in lymphoblasts and tissues of colon cancer patients.
Adenoma
Microsatellite instability in the adenoma-carcinoma sequence of the stomach.
Adenoma
Protein western array analysis in human pituitary tumours: insights and limitations.
Adenoma
Reduction in transforming growth factor-beta type II receptor in mouse lung carcinogenesis.
Adenoma
Transforming growth factor beta receptor type II inactivation promotes the establishment and progression of colon cancer.
Adenoma
Transforming growth factor beta type II receptor gene mutations in adenomas from hereditary nonpolyposis colorectal cancer.
Adenoma
Transforming growth factor-beta 1 and its receptors in human lung cancer and mouse lung carcinogenesis.
Adenoma
Vessels' morphology in SMAD4 and BMPR1A-related juvenile polyposis.
Adenoma
[Hereditary nonpolyposis colorectal cancer]
Adenoma, Liver Cell
Hepatic silicosis, cirrhosis, and liver tumors in mice and hamsters: studies of transforming growth factor beta expression.
Adenoma, Liver Cell
Recurrent chromosomal rearrangements of ROS1, FRK and IL6 activating JAK/STAT pathway in inflammatory hepatocellular adenomas.
Adenomatous Polyposis Coli
An EphB-Abl signaling pathway is associated with intestinal tumor initiation and growth.
Adenomatous Polyposis Coli
Chibby drives ? catenin cytoplasmic accumulation leading to activation of the unfolded protein response in BCR-ABL1+ cells.
Adenomatous Polyposis Coli
Effect of targeting janus kinase 3 on the development of intestinal tumors in the adenomatous polyposis coli(min) mouse model of familial adenomatous polyposis.
Adenomatous Polyposis Coli
Expanding the genotype-phenotype spectrum in hereditary colorectal cancer by gene panel testing.
Adenomatous Polyposis Coli
Genetic testing by cancer site: stomach.
Adenomatous Polyposis Coli
Hotspot Mutations Detectable by Next-generation Sequencing in Exhaled Breath Condensates from Patients with Lung Cancer.
Adenomatous Polyposis Coli
Mechanisms and Significance of Eryptosis, the Suicidal Death of Erythrocytes.
Adenomatous Polyposis Coli
Mutations of the transforming growth factor-beta type II receptor gene and genomic instability in hereditary nonpolyposis colorectal cancer.
Adenomatous Polyposis Coli
Tanshinone IIA promotes cardiac differentiation and improves cell motility by modulating the Wnt/??catenin signaling pathway.
Adenomatous Polyposis Coli
The receptor tyrosine kinase EPHB4 has tumor suppressor activities in intestinal tumorigenesis.
Adenomatous Polyposis Coli
Whole-exome sequencing of duodenal adenocarcinoma identifies recurrent Wnt/?-catenin signaling pathway mutations.
Adenomyosis
Expression of focal adhesion kinase in the eutopic endometrium of women with adenomyosis varies with dysmenorrhea and pelvic pain.
Adenomyosis
FAK regulates epithelial?mesenchymal transition in adenomyosis.
Adenomyosis
Overexpression of erythropoietin-producing hepatocyte receptor B4 and ephrin-B2 is associated with estrogen receptor expression in endometrial adenocarcinoma.
adenosine deaminase deficiency
Host natural killer immunity is a key indicator of permissiveness for donor cell engraftment in patients with severe combined immunodeficiency.
Adenoviridae Infections
Novel model of innate immunity in corneal infection.
Adenovirus Infections, Human
Fatal disseminated mouse adenovirus type 1 infection in mice lacking B cells or Bruton's tyrosine kinase.
Adrenocortical Carcinoma
Restoration of transforming growth factor-beta type II receptor reduces tumorigenicity in the human adrenocortical carcinoma SW-13 cell line.
Agammaglobulinemia
A Btk transgene restores the antiviral TI-2 antibody responses of xid mice in a dose-dependent fashion.
Agammaglobulinemia
A case of Fabry's disease with congenital agammaglobulinemia.
Agammaglobulinemia
A case of X-linked agammaglobulinemia diagnosed in adulthood.
Agammaglobulinemia
A genotype-phenotype correlation study in a group of 54 patients with X-linked agammaglobulinemia.
Agammaglobulinemia
A mutation in the pleckstrin homology (PH) domain of the FGD1 gene in an Italian family with faciogenital dysplasia (Aarskog-Scott syndrome).
Agammaglobulinemia
A novel
Agammaglobulinemia
A novel Bruton tyrosine kinase gene variation was found in an adult with X-linked agammaglobulinemia during blood cross-matching prior to surgical operation.
Agammaglobulinemia
A novel Bruton's tyrosine kinase gene (BTK) invariant splice site mutation in a Malaysian family with X-linked agammaglobulinemia.
Agammaglobulinemia
A novel Bruton's tyrosine kinase gene (BTK) missense mutation in a Chinese family with X-linked agammaglobulinemia.
Agammaglobulinemia
A Novel BTK Gene Mutation in a Child With Atypical X-Linked Agammaglobulinemia and Recurrent Hemophagocytosis: A Case Report.
Agammaglobulinemia
A novel deletion mutation and structural abnormality in the Bruton's tyrosine kinase gene identified in a Chinese patient with X-linked agammaglobulinemia.
Agammaglobulinemia
A novel mutation (Cys145-->Stop) in Bruton's tyrosine kinase is associated with newly diagnosed X-linked agammaglobulinemia in a 51-year-old male.
Agammaglobulinemia
A novel mutation leading to a deletion in the SH3 domain of Bruton's tyrosine kinase.
Agammaglobulinemia
A novel single basepair insertion in exon 6 of the Bruton's tyrosine kinase (Btk) gene from a Japanese X-linked agammaglobulinemia patient with growth hormone insufficiency.
Agammaglobulinemia
A phosphorylation site in Bruton's tyrosine kinase selectively regulates B cell calcium signaling efficiency by altering phospholipase C-gamma activation.
Agammaglobulinemia
A postmeningitic cochlear implant patient who was postoperatively diagnosed as having X-linked agammaglobulinemia.
Agammaglobulinemia
A role for Bruton's tyrosine kinase in B cell antigen receptor-mediated activation of phospholipase C-gamma 2.
Agammaglobulinemia
Absence of memory B cells in patients with common variable immunodeficiency.
Agammaglobulinemia
Advances in basic and clinical immunology in 2012.
Agammaglobulinemia
An essential role for Bruton's [corrected] tyrosine kinase in the regulation of B-cell apoptosis.
Agammaglobulinemia
Analysis of clinical presentations of bruton disease: a review of 20 years of accumulated data from pediatric patients at severance hospital.
Agammaglobulinemia
Analysis of the Bruton's tyrosine kinase gene promoter reveals critical PU.1 and SP1 sites.
Agammaglobulinemia
Analysis of the genetic alterations in a case of juvenile multiple colon carcinoma with hypogammaglobulinemia.
Agammaglobulinemia
Autoimmunity and immunodeficiency.
Agammaglobulinemia
B cell-specific lentiviral gene therapy leads to sustained B-cell functional recovery in a murine model of X-linked agammaglobulinemia.
Agammaglobulinemia
B-cell antigen receptor stimulation activates the human Bruton's tyrosine kinase, which is deficient in X-linked agammaglobulinemia.
Agammaglobulinemia
Brief report: a point mutation in the SH2 domain of Bruton's tyrosine kinase in atypical X-linked agammaglobulinemia.
Agammaglobulinemia
Bruton tyrosine kinase (BTK) in X-linked agammaglobulinemia (XLA).
Agammaglobulinemia
Bruton tyrosine kinase gene mutations in Turkish patients with presumed X-linked agammaglobulinemia.
Agammaglobulinemia
Bruton tyrosine kinase is tyrosine phosphorylated and activated in pre-B lymphocytes and receptor-ligated B cells.
Agammaglobulinemia
Bruton's agammaglobulinemia in an adult male due to a novel mutation: a case report.
Agammaglobulinemia
Bruton's tyrosine kinase activity is negatively regulated by Sab, the Btk-SH3 domain-binding protein.
Agammaglobulinemia
Bruton's tyrosine kinase inhibitors for the treatment of rheumatoid arthritis.
Agammaglobulinemia
Bruton's tyrosine kinase is not essential for LPS-induced activation of human monocytes.
Agammaglobulinemia
Bruton's tyrosine kinase is required for activation of IkappaB kinase and nuclear factor kappaB in response to B cell receptor engagement.
Agammaglobulinemia
Bruton's tyrosine kinase is required for lipopolysaccharide-induced tumor necrosis factor alpha production.
Agammaglobulinemia
Bruton's tyrosine kinase is required for TLR-dependent heme oxygenase-1 gene activation via Nrf2 in macrophages.
Agammaglobulinemia
Bruton's Tyrosine Kinase Is Required for TLR2 and TLR4-Induced TNF, but Not IL-6, Production.
Agammaglobulinemia
Bruton's tyrosine kinase mutations in 8 Chinese families with X-linked agammaglobulinemia.
Agammaglobulinemia
Bruton's tyrosine kinase: cell biology, sequence conservation, mutation spectrum, siRNA modifications, and expression profiling.
Agammaglobulinemia
Bruton's tyrosine kinase: from X-linked agammaglobulinemia toward targeted therapy for B-cell malignancies.
Agammaglobulinemia
BTK gene targeting by homologous recombination using a helper-dependent adenovirus/adeno-associated virus hybrid vector.
Agammaglobulinemia
BTK inhibition targets in vivo CLL proliferation through its effects on B-cell receptor signaling activity.
Agammaglobulinemia
BTK mediated apoptosis, a possible mechanism for failure to generate high titer retroviral producer clones.
Agammaglobulinemia
BTK Signaling in B Cell Differentiation and Autoimmunity.
Agammaglobulinemia
BTK, the tyrosine kinase affected in X-linked agammaglobulinemia.
Agammaglobulinemia
Btk29A-mediated tyrosine phosphorylation of armadillo/?-catenin promotes ring canal growth in Drosophila oogenesis.
Agammaglobulinemia
BTKbase: the mutation database for X-linked agammaglobulinemia.
Agammaglobulinemia
Characterization of Bruton's tyrosine kinase mutations in Mexican patients with X-linked agammaglobulinemia.
Agammaglobulinemia
Characterization of germline mutations of the gene encoding Bruton's tyrosine kinase in families with X-linked agammaglobulinemia.
Agammaglobulinemia
Characterization of mutations, including a novel regulatory defect in the first intron, in Bruton's tyrosine kinase gene from seven Korean X-linked agammaglobulinemia families.
Agammaglobulinemia
Characterization of novel Bruton's tyrosine kinase gene mutations in Central European patients with agammaglobulinemia.
Agammaglobulinemia
Characterization of the pleckstrin homology domain of Btk as an inositol polyphosphate and phosphoinositide binding domain.
Agammaglobulinemia
Clinical and Genetic Study of X-linked Agammaglobulinemia Patients (The Benefit of Early Diagnosis).
Agammaglobulinemia
Clinical and mutational characteristics of X-linked agammaglobulinemia and its carrier identified by flow cytometric assessment combined with genetic analysis.
Agammaglobulinemia
Clinical characteristics and molecular analysis of 21 chinese children with congenital agammaglobulinemia.
Agammaglobulinemia
Clinical characteristics and prenatal diagnosis for 22 families in Henan Province of China with X-linked agammaglobulinemia (XLA) related to Bruton's tyrosine kinase (BTK) gene mutations.
Agammaglobulinemia
Clinical findings leading to the diagnosis of X-linked agammaglobulinemia.
Agammaglobulinemia
Comparison of clinical and immunological features and mortality in common variable immunodeficiency and agammaglobulinemia patients.
Agammaglobulinemia
Concomitant diagnosis of immune deficiency and Pseudomonas sepsis in a 19 month old with ecthyma gangrenosum by host whole-genome sequencing.
Agammaglobulinemia
Conservation and covariance in PH domain sequences: physicochemical profile and information theoretical analysis of XLA-causing mutations in the Btk PH domain.
Agammaglobulinemia
Constitutive membrane association potentiates activation of Bruton tyrosine kinase.
Agammaglobulinemia
Correction of B-cell development in Btk-deficient mice using lentiviral vectors with codon-optimized human BTK.
Agammaglobulinemia
Crystal structure of Bruton's tyrosine kinase domain suggests a novel pathway for activation and provides insights into the molecular basis of X-linked agammaglobulinemia.
Agammaglobulinemia
Cutting edge: lack of peripheral B cells and severe agammaglobulinemia in mice simultaneously lacking Bruton's tyrosine kinase and the B cell-specific transcriptional coactivator OBF-1.
Agammaglobulinemia
De novo mutation in the BTK gene of atypical X-linked agammaglobulinemia in a patient with recurrent pyoderma.
Agammaglobulinemia
Debilitating progressive encephalitis in a patient with BTK deficiency.
Agammaglobulinemia
Defective B cell development and function in Btk-deficient mice.
Agammaglobulinemia
Deficient expression of Bruton's tyrosine kinase in monocytes from X-linked agammaglobulinemia as evaluated by a flow cytometric analysis and its clinical application to carrier detection.
Agammaglobulinemia
Deletion within the Src homology domain 3 of Bruton's tyrosine kinase resulting in X-linked agammaglobulinemia (XLA).
Agammaglobulinemia
Dendritic and T Cell Response to Influenza is Normal in the Patients with X-Linked Agammaglobulinemia.
Agammaglobulinemia
Detection of a novel mutation in the SRC homology domain 2 (SH2) of Bruton's tyrosine kinase and direct female carrier evaluation in a family with X-linked agammaglobulinemia.
Agammaglobulinemia
Distinct Clinical Features and Novel Mutations in Taiwanese Patients With X-Linked Agammaglobulinemia.
Agammaglobulinemia
Disturbed Transcription of TLRs' Negative Regulators and Cytokines Secretion among TLR4- and 9-Activated PBMCs of Agammaglobulinemic Patients.
Agammaglobulinemia
Dynamic Allostery Mediated by a Conserved Tryptophan in the Tec Family Kinases.
Agammaglobulinemia
Early arrest in B cell development in transgenic mice that express the E41K Bruton's tyrosine kinase mutant under the control of the CD19 promoter region.
Agammaglobulinemia
Ecthyma gangrenosum due to Pseudomonas aeruginosa sepsis as initial manifestation of X-linked agammaglobulinemia: a case report.
Agammaglobulinemia
Effective, safe, and sustained correction of murine XLA using a UCOE-BTK promoter-based lentiviral vector.
Agammaglobulinemia
Expression of Bruton's tyrosine kinase protein within the B cell lineage.
Agammaglobulinemia
Female agammaglobulinemia due to the Bruton tyrosine kinase deficiency caused by extremely skewed X-chromosome inactivation.
Agammaglobulinemia
Functional analysis of peripheral blood B cells in patients with X-linked agammaglobulinemia.
Agammaglobulinemia
G Protein beta gamma subunits act on the catalytic domain to stimulate Bruton's agammaglobulinemia tyrosine kinase.
Agammaglobulinemia
Genetic analysis of patients with defects in early B-cell development.
Agammaglobulinemia
Genetic defect in human X-linked agammaglobulinemia impedes a maturational evolution of pro-B cells into a later stage of pre-B cells in the B-cell differentiation pathway.
Agammaglobulinemia
Genetics in community-acquired pneumonia.
Agammaglobulinemia
Genomic organization and structure of Bruton agammaglobulinemia tyrosine kinase: localization of mutations associated with varied clinical presentations and course in X chromosome-linked agammaglobulinemia.
Agammaglobulinemia
Genomic organization of the Btk gene and exon scanning for mutations in patients with X-linked agammaglobulinemia.
Agammaglobulinemia
HIV-mediated expression of Btk in hematopoietic stem cells is not sufficient to restore B cell function in X-linked immunodeficient mice.
Agammaglobulinemia
Ibrutinib (PCI-32765), the First BTK (Bruton's Tyrosine Kinase) Inhibitor in Clinical Trials.
Agammaglobulinemia
Ibrutinib inhibition of Bruton protein-tyrosine kinase (BTK) in the treatment of B cell neoplasms.
Agammaglobulinemia
Identification and characterization of a molecule, BAM11, that associates with the pleckstrin homology domain of mouse Btk.
Agammaglobulinemia
Identification and characterization of a novel SH3-domain binding protein, Sab, which preferentially associates with Bruton's tyrosine kinase (BtK).
Agammaglobulinemia
Identification of a new Bruton's tyrosine kinase (BTK) mutation associated with a mild phenotype in a child with X-linked agammaglobulinemia (XLA).
Agammaglobulinemia
Identification of Bruton's tyrosine kinase (Btk) gene mutations and characterization of the derived proteins in 35 X-linked agammaglobulinemia families: a nationwide study of Btk deficiency in Japan.
Agammaglobulinemia
Identification of mutations in the Bruton's tyrosine kinase gene, including a novel genomic rearrangements resulting in large deletion, in Korean X-linked agammaglobulinemia patients.
Agammaglobulinemia
Identification of mutations of Bruton's tyrosine kinase gene (BTK) in Brazilian patients with X-linked agammaglobulinemia.
Agammaglobulinemia
Identification of nine novel mutations in the Bruton's tyrosine kinase gene in X-linked agammaglobulinaemia patients.
Agammaglobulinemia
Identification of the bruton tyrosine kinase (BTK) gene mutations in 20 Australian families with X-linked agammaglobulinemia (XLA).
Agammaglobulinemia
Impact of amino acid substitution in the kinase domain of Bruton tyrosine kinase and its association with X-linked agammaglobulinemia.
Agammaglobulinemia
Impaired polysaccharide responsiveness without agammaglobulinemia in three patients with hypomorphic mutations in Bruton Tyrosine Kinase - no detection by newborn screening for primary immunodeficiences.
Agammaglobulinemia
Impaired Toll-like receptor 8-mediated IL-6 and TNF-alpha production in antigen-presenting cells from patients with X-linked agammaglobulinemia.
Agammaglobulinemia
In vitro Correction of a Novel Splicing Alteration in the BTK Gene by Using Antisense Morpholino Oligonucleotides.
Agammaglobulinemia
Inflammatory Response: Role of B1 Cell.
Agammaglobulinemia
Inhibition of IgE-mediated secretion from human basophils with a highly selective Bruton's tyrosine kinase, Btk, inhibitor.
Agammaglobulinemia
Inositol polyphosphates promote T cell-independent humoral immunity via the regulation of Bruton's tyrosine kinase.
Agammaglobulinemia
Long-lasting memory-resting and memory-effector CD4+ T cells in human X-linked agammaglobulinemia.
Agammaglobulinemia
Metastatic colorectal cancer and severe hypocalcemia following irinotecan administration in a patient with X-linked agammaglobulinemia: a case report.
Agammaglobulinemia
Missense mutations affecting a conserved cysteine pair in the TH domain of Btk.
Agammaglobulinemia
Molecular analysis of Bruton's tyrosine kinase gene in Spain.
Agammaglobulinemia
Molecular analysis of the pre-BCR complex in a large cohort of patients affected by autosomal-recessive agammaglobulinemia.
Agammaglobulinemia
Molecular and structural characterization of five novel mutations in the Bruton's tyrosine kinase gene from patients with X-linked agammaglobulinemia.
Agammaglobulinemia
Molecular characterization of Bruton's tyrosine kinase deficiency in 12 Iranian patients with presumed X-linked agammaglobulinemia.
Agammaglobulinemia
Multiple colorectal neoplasms in X-linked agammaglobulinemia.
Agammaglobulinemia
Mutation analysis of the Bruton's tyrosine kinase gene in X-linked agammaglobulinemia: identification of a mutation which affects the same codon as is altered in immunodeficient xid mice.
Agammaglobulinemia
Mutation analysis of the gene encoding Bruton's tyrosine kinase in a family with a sporadic case of X-linked agammaglobulinemia reveals three female carriers.
Agammaglobulinemia
Mutation of the BTK gene and clinical feature of X-linked agammaglobulinemia in mainland China.
Agammaglobulinemia
Mutation pattern in the Bruton's tyrosine kinase gene in 26 unrelated patients with X-linked agammaglobulinemia.
Agammaglobulinemia
Mutations in Bruton's tyrosine kinase impair IgA responses.
Agammaglobulinemia
Mutations in the mu heavy-chain gene in patients with agammaglobulinemia.
Agammaglobulinemia
Mutations of Bruton's tyrosine kinase gene in Brazilian patients with X-linked agammaglobulinemia.
Agammaglobulinemia
Mutations of the Btk gene in 12 unrelated families with X-linked agammaglobulinemia in Japan.
Agammaglobulinemia
Mutations of the human BTK gene coding for bruton tyrosine kinase in X-linked agammaglobulinemia.
Agammaglobulinemia
Neutrophil development and function critically depend on Bruton tyrosine kinase in a mouse model of X-linked agammaglobulinemia.
Agammaglobulinemia
Novel BTK mutation in X-linked agammaglobulinemia: Report of a 17-year-old male.
Agammaglobulinemia
Novel BTK mutation presenting with vaccine-associated paralytic poliomyelitis.
Agammaglobulinemia
Novel deletion mutation in Bruton's tyrosine kinase results in X-linked agammaglobulinemia: A case report.
Agammaglobulinemia
Novel Igalpha (CD79a) gene mutation in a Turkish patient with B cell-deficient agammaglobulinemia.
Agammaglobulinemia
Novel immunodeficiency data servers.
Agammaglobulinemia
Novel insertions of Bruton tyrosine kinase in patients with X-linked agammaglobulinemia.
Agammaglobulinemia
Optimizing Integration and Expression of Transgenic Bruton's Tyrosine Kinase for CRISPR-Cas9-Mediated Gene Editing of X-Linked Agammaglobulinemia.
Agammaglobulinemia
Ovarian polarity and cell shape determination by Btk29A in Drosophila.
Agammaglobulinemia
PBMC-derived integration-free iPSCs line SDQLCHi039-A from a patient with X-linked agammaglobulinemia carrying a novel 9-bp in-frame deletion in BTK gene.
Agammaglobulinemia
Phosphatidylinositol 3-kinase-dependent membrane association of the Bruton's tyrosine kinase pleckstrin homology domain visualized in single living cells.
Agammaglobulinemia
Phosphorylation of CD19 Y484 and Y515, and linked activation of phosphatidylinositol 3-kinase, are required for B cell antigen receptor-mediated activation of Bruton's tyrosine kinase.
Agammaglobulinemia
Phosphorylation of two regulatory tyrosine residues in the activation of Bruton's tyrosine kinase via alternative receptors.
Agammaglobulinemia
Phylogenetic Profiles Reveal Structural and Functional Determinants of Lipid-binding.
Agammaglobulinemia
PKCbeta modulates antigen receptor signaling via regulation of Btk membrane localization.
Agammaglobulinemia
Point mutation in intron 11 of Bruton's tyrosine kinase in atypical X-linked agammaglobulinemia.
Agammaglobulinemia
Posttranscriptional regulation of Bruton's tyrosine kinase expression in antigen receptor-stimulated splenic B cells.
Agammaglobulinemia
Predominantly Antibody-Deficient Patients With Non-infectious Complications Have Reduced Naive B, Treg, Th17, and Tfh17 Cells.
Agammaglobulinemia
Preimplantation genetic diagnosis for X-linked agammaglobulinemia: a case report.
Agammaglobulinemia
Presentation of a case of Bruton type primary agammaglobulinemia in Guinea.
Agammaglobulinemia
Primary immunodeficiency diseases associated with increased susceptibility to viral infections and malignancies.
Agammaglobulinemia
Production of monoclonal antibodies to Bruton's tyrosine kinase.
Agammaglobulinemia
Progressive engineering of a homing endonuclease genome editing reagent for the murine X-linked immunodeficiency locus.
Agammaglobulinemia
Progressive multifocal leukoencephalopathy in a patient with common variable immunodeficiency and abnormal CD8+ T-cell subset distribution.
Agammaglobulinemia
Recent insights in primary immunodeficiency diseases: the role of T-lymphocytes and innate immunity.
Agammaglobulinemia
Recent progress in the diagnosis and treatment of patients with defects in early B-cell development.
Agammaglobulinemia
Reconstitution of Btk signaling by the atypical tec family tyrosine kinases Bmx and Txk.
Agammaglobulinemia
Recurrent pneumonia with mild hypogammaglobulinemia diagnosed as X-linked agammaglobulinemia in adults.
Agammaglobulinemia
Regulation and function of WASp in platelets by the collagen receptor, glycoprotein VI.
Agammaglobulinemia
Regulation of nuclear localization and transcriptional activity of TFII-I by Bruton's tyrosine kinase.
Agammaglobulinemia
Relapsing Campylobacter jejuni Systemic Infections in a Child with X-Linked Agammaglobulinemia.
Agammaglobulinemia
Role of Bruton's tyrosine kinase in immunodeficiency.
Agammaglobulinemia
Role of the PHTH module in protein substrate recognition by Bruton's agammaglobulinemia tyrosine kinase.
Agammaglobulinemia
Screening of genomic DNA to identify mutations in the gene for Bruton's tyrosine kinase.
Agammaglobulinemia
Screening of the Bruton Tyrosine Kinase (BTK) Gene Mutations in 13 Iranian Patients with Presumed X-Linked Agammaglobulinemia.
Agammaglobulinemia
SH3 domain of Bruton's tyrosine kinase can bind to proline-rich peptides of TH domain of the kinase and p120cbl.
Agammaglobulinemia
Six X-linked agammaglobulinemia-causing missense mutations in the Src homology 2 domain of Bruton's tyrosine kinase: phosphotyrosine-binding and circular dichroism analysis.
Agammaglobulinemia
Solution structure of the human BTK SH3 domain complexed with a proline-rich peptide from p120cbl.
Agammaglobulinemia
Solution structure of the SH3 domain from Bruton's tyrosine kinase.
Agammaglobulinemia
Splice-correcting oligonucleotides restore BTK function in X-linked agammaglobulinemia model.
Agammaglobulinemia
Splice-correction strategies for treatment of x-linked agammaglobulinemia.
Agammaglobulinemia
Stability and peptide binding specificity of Btk SH2 domain: molecular basis for X-linked agammaglobulinemia.
Agammaglobulinemia
Structural basis for chromosome X-linked agammaglobulinemia: a tyrosine kinase disease.
Agammaglobulinemia
Structural basis of SH2 domain mutations in X-linked agammaglobulinemia.
Agammaglobulinemia
Structure of the high affinity complex of inositol trisphosphate with a phospholipase C pleckstrin homology domain.
Agammaglobulinemia
Sustained correction of B-cell development and function in a murine model of X-linked agammaglobulinemia (XLA) using retroviral-mediated gene transfer.
Agammaglobulinemia
The genomic structure of human BTK, the defective gene in X-linked agammaglobulinemia.
Agammaglobulinemia
The pleckstrin homology domain of Bruton tyrosine kinase interacts with protein kinase C.
Agammaglobulinemia
The protein defective in X-linked agammaglobulinemia, Bruton's tyrosine kinase, shows increased autophosphorylation activity in vitro when isolated from cells in which the B cell receptor has been cross-linked.
Agammaglobulinemia
The protein product of the c-cbl protooncogene is phosphorylated after B cell receptor stimulation and binds the SH3 domain of Bruton's tyrosine kinase.
Agammaglobulinemia
The role of Bruton's tyrosine kinase in B-cell development and function: a genetic perspective.
Agammaglobulinemia
The Role of Bruton's Tyrosine Kinase in Immune Cell Signaling and Systemic Autoimmunity.
Agammaglobulinemia
The Tec family of cytoplasmic tyrosine kinases: mammalian Btk, Bmx, Itk, Tec, Txk and homologs in other species.
Agammaglobulinemia
The tec family tyrosine kinase Btk Regulates RANKL-induced osteoclast maturation.
Agammaglobulinemia
The X-linked immunodeficiency defect in the mouse is corrected by expression of human Bruton's tyrosine kinase from a yeast artificial chromosome transgene.
Agammaglobulinemia
Toll-like receptor signaling is impaired in dendritic cells from patients with X-linked agammaglobulinemia.
Agammaglobulinemia
Transcriptional regulatory defects in the first intron of Bruton's tyrosine kinase.
Agammaglobulinemia
Transcriptional regulatory elements within the first intron of Bruton's tyrosine kinase.
Agammaglobulinemia
Transient myelodysplastic syndrome in X-linked agammaglobulinemia with a novel Btk mutation.
Agammaglobulinemia
Treosulfan-based reduced toxicity hematopoietic stem cell transplantation in X-linked agammaglobulinemia: A cost-effective alternative to long-term immunoglobulin replacement in developing countries.
Agammaglobulinemia
Type I and III Interferon Productions Are Impaired in X-Linked Agammaglobulinemia Patients Toward Poliovirus but Not Influenza Virus.
Agammaglobulinemia
Unimpaired activation of c-Jun NH2-terminal kinase (JNK) 1 upon CD40 stimulation in B cells of patients with X-linked agammaglobulinemia.
Agammaglobulinemia
Unique mutations of Bruton's tyrosine kinase in fourteen unrelated X-linked agammaglobulinemia families.
Agammaglobulinemia
Unusual mutations in Btk: an insertion, a duplication, an inversion, and four large deletions.
Agammaglobulinemia
Unusual patterns of exon skipping in Bruton tyrosine kinase are associated with mutations involving the intron 17 3' splice site.
Agammaglobulinemia
Update on X-linked hypogammaglobulinemia with isolated growth hormone deficiency.
Agammaglobulinemia
von Recklinghausen disease in a patient with X-linked agammaglobulinemia.
Agammaglobulinemia
WHI-131 Promotes Osteoblast Differentiation and Prevents Osteoclast Formation and Resorption in Mice.
Agammaglobulinemia
X-chromosome inactivation and mutation pattern in the Bruton's tyrosine kinase gene in patients with X-linked agammaglobulinemia. Italian XLA Collaborative Group.
Agammaglobulinemia
X-linked agammaglobulinemia (XLA): a genetic tyrosine kinase (Btk) disease.
Agammaglobulinemia
X-linked agammaglobulinemia - first case with Bruton tyrosine kinase mutation from Pakistan.
Agammaglobulinemia
X-linked agammaglobulinemia and Bruton's tyrosine kinase.
Agammaglobulinemia
X-linked agammaglobulinemia associated with B-precursor acute lymphoblastic leukemia.
Agammaglobulinemia
X-Linked Agammaglobulinemia Case with TH Domain Missense Mutation in Bruton Tyrosine Kinase.
Agammaglobulinemia
X-linked agammaglobulinemia combined with juvenile idiopathic arthritis and invasive Klebsiella pneumoniae polyarticular septic arthritis.
Agammaglobulinemia
X-linked agammaglobulinemia diagnosed in adulthood: a case report.
Agammaglobulinemia
X-linked agammaglobulinemia in a 10-year-old boy with a novel non-invariant splice-site mutation in Btk gene.
Agammaglobulinemia
X-linked agammaglobulinemia in northern Thailand.
Agammaglobulinemia
X-Linked Agammaglobulinemia Presenting as Neutropenia: Case Report and an Overview of Literature.
Agammaglobulinemia
X-Linked Agammaglobulinemia With Chronic Meningoencephalitis: A Diagnostic Challenge.
Agammaglobulinemia
X-linked agammaglobulinemia: report on a United States registry of 201 patients.
Agammaglobulinemia
xid affects events leading to B cell cycle entry.
Agammaglobulinemia
xid mice reveal the interplay of homeostasis and Bruton's tyrosine kinase-mediated selection at multiple stages of B cell development.
Agammaglobulinemia
[Clinical features of X-linked agammaglobulinemia: analysis of 8 cases]
Agammaglobulinemia
[Detection of Bruton's tyrosine kinase gene mutations and clinical analysis of 6 patients with X-linked agammaglobulinemia].
Agammaglobulinemia
[Gene diagnosis of X-linked agammaglobulinemia]
Albuminuria
Evidence for a role of transforming growth factor (TGF)-beta1 in the induction of postglomerular albuminuria in diabetic nephropathy: amelioration by soluble TGF-beta type II receptor.
Alopecia
A case of inflammatory nonscarring alopecia associated with the tyrosine kinase inhibitor nilotinib.
Alopecia
A Comprehensive Literature Review of JAK Inhibitors in Treatment of Alopecia Areata.
Alopecia
A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results.
Alopecia
Alopecia in patients treated with molecularly targeted anticancer therapies.
Alopecia
Alopecia universalis unresponsive to treatment with tofacinitib: report of a case with a brief review of the literature.
Alopecia
At the crossroads of 2 alopecias: Androgenetic alopecia pattern of hair regrowth in patients with alopecia areata treated with oral Janus kinase inhibitors.
Alopecia
Frontal fibrosing alopecia shows robust T helper 1 and Janus kinase 3 skewing.
Alopecia
New Treatments for Hair Loss.
Alopecia
Ruxolitinib found to cause eyelash growth: a case report.
Alopecia
Ruxolitinib-conjugated gold nanoparticles for topical administration: An alternative for treating alopecia?
Alopecia
Tofacitinib for the treatment of lichen planopilaris: A case series.
Alopecia
Treatment of alopecia universalis with topical Janus kinase inhibitors - a double blind, placebo, and active controlled pilot study.
Alopecia
Unexpected Hair Regrowth in a Patient with Longstanding Alopecia Universalis During Treatment of Recalcitrant Dermatomyositis with the Janus Kinase Inhibitor Ruxolitinib.
Alopecia Areata
A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results.
Alopecia Areata
Alopecia Areata: New Treatment Options Including Janus Kinase Inhibitors.
Alopecia Areata
Alopecia universalis unresponsive to treatment with tofacinitib: report of a case with a brief review of the literature.
Alopecia Areata
At the crossroads of 2 alopecias: Androgenetic alopecia pattern of hair regrowth in patients with alopecia areata treated with oral Janus kinase inhibitors.
Alopecia Areata
Drugs targeting the JAK/STAT pathway for the treatment of immune-mediated inflammatory skin diseases: protocol for a scoping review.
Alopecia Areata
Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: Phase 2 results from a randomized controlled study.
Alopecia Areata
Evaluation of the alopecia areata patients on tofacitinib treatment during the COVID-19 pandemic.
Alopecia Areata
Inhibiting Janus kinases to treat alopecia areata.
Alopecia Areata
JAK-inhibitors. New players in the field of immune-mediated diseases, beyond rheumatoid arthritis.
Alopecia Areata
Janus kinase inhibition in Down syndrome: 2 cases of therapeutic benefit for alopecia areata.
Alopecia Areata
Janus kinase inhibitors against other biological treatments in alopecia areata.
Alopecia Areata
Janus Kinase Inhibitors for the Treatment of Severe Alopecia Areata: An Open-Label Comparative Study.
Alopecia Areata
Janus kinase inhibitors for the use of alopecia areata: A promising therapeutic of the future.
Alopecia Areata
Janus Kinase Inhibitors in Dermatology: Part 1 - General Considerations and Applications in Vitiligo and Alopecia Areata.
Alopecia Areata
Janus Kinase Inhibitors: A Review of Their Emerging Applications in Dermatology
Alopecia Areata
Janus kinase inhibitors: An innovative treatment for alopecia areata.
Alopecia Areata
New Treatments for Hair Loss.
Alopecia Areata
PF-06651600, a Dual JAK3/TEC Family Kinase Inhibitor.
Alopecia Areata
Role of janus kinase inhibitors in the treatment of alopecia areata.
Alopecia Areata
Successful Treatment of Severe Alopecia Areata With Oral or Topical Tofacitinib.
Alopecia Areata
The role of Janus kinase inhibitors in the treatment of alopecia areata: A systematic review.
Alopecia Areata
The status and outcomes of registered clinical trials for Janus kinase inhibitors in alopecia areata: are unpublished trials being overlooked?
Alopecia Areata
The Use of Janus Kinase Inhibitors in Alopecia Areata: A Review of the Literature.
Alopecia Areata
Tofacitinib (Selective Janus Kinase Inhibitor 1 and 3): A Promising Therapy for the Treatment of Alopecia Areata: A Case Report of Six Patients.
Alopecia Areata
Tofacitinib 2% ointment, a topical Janus kinase inhibitor, for the treatment of alopecia areata: A pilot study of 10 patients.
Alopecia Areata
Tofacitinib for the treatment of lichen planopilaris: A case series.
Alopecia Areata
Tofacitinib Loaded Squalenyl Nanoparticles for Targeted Follicular Delivery in Inflammatory Skin Diseases.
Alopecia Areata
Topical Janus kinase inhibitors for the treatment of pediatric alopecia areata.
Alopecia Areata
Transient Efficacy of Tofacitinib in Alopecia Areata Universalis.
Alopecia Areata
Translational Positioning of Janus Kinase (JAK) Inhibitors in Alopecia Areata.
Alopecia Areata
Treatment of alopecia universalis with topical Janus kinase inhibitors - a double blind, placebo, and active controlled pilot study.
alpha-n-acetylgalactosaminide alpha-2,6-sialyltransferase deficiency
ST6Gal-I restrains CD22-dependent antigen receptor endocytosis and Shp-1 recruitment in normal and pathogenic immune signaling.
Alveolar Bone Loss
Microbe-Dependent Exacerbated Alveolar Bone Destruction in Heterozygous Cherubism Mice.
Alzheimer Disease
A Link Between Alzheimer's and Type II Diabetes Mellitus? Ca+2 -Mediated Signal Control and Protein Localization.
Alzheimer Disease
Abelson Kinases Mediate the Depression of Spontaneous Synaptic Activity Induced by Amyloid Beta 1-42 Peptides.
Alzheimer Disease
Adaptors for disorders of the brain? The cancer signaling proteins NEDD9, CASS4, and PTK2B in Alzheimer's disease.
Alzheimer Disease
Altered Subcellular Distribution of c-Abl in Alzheimer's Disease.
Alzheimer Disease
Alzheimer's disease pathological lesions activate the spleen tyrosine kinase.
Alzheimer Disease
Alzheimer's disease risk factor lymphocyte-specific protein tyrosine kinase regulates long-term synaptic strengthening, spatial learning and memory.
Alzheimer Disease
American Chemical Society - 240th national meeting - chemistry for preventing and combating disease: part 2.
Alzheimer Disease
Amyloid-ß induced signaling by cellular prion protein and Fyn kinase in Alzheimer disease.
Alzheimer Disease
An isoform-specific role of FynT tyrosine kinase in Alzheimer's disease.
Alzheimer Disease
Artificial intelligence-based computational framework for drug-target prioritization and inference of novel repositionable drugs for Alzheimer's disease.
Alzheimer Disease
Association and interaction effects of Alzheimer's disease-associated genes and lifestyle on cognitive aging in older adults in a Taiwanese population.
Alzheimer Disease
Blocking TGF-beta-Smad2/3 innate immune signaling mitigates Alzheimer-like pathology.
Alzheimer Disease
c-Abl modulates AICD dependent cellular responses: transcriptional induction and apoptosis.
Alzheimer Disease
c-Abl stabilizes HDAC2 levels by tyrosine phosphorylation repressing neuronal gene expression in Alzheimer's disease.
Alzheimer Disease
c-Abl Tyrosine Kinase-Mediated Neuronal Apoptosis in Subarachnoid Hemorrhage by Modulating the LRP-1-Dependent Akt/GSK3? Survival Pathway.
Alzheimer Disease
Canonical JAK-STAT signaling is pivotal for long-term depression at adult hippocampal temporoammonic-CA1 synapses.
Alzheimer Disease
Common variant in PTK2B is associated with late-onset Alzheimer's disease: A replication study and meta-analyses.
Alzheimer Disease
Corrigendum to "Common variant in PTK2B is associated with late-onset Alzheimer's disease: A replication study and meta-analyses" [Neurosci. Lett. 621 (2016) 83-87].
Alzheimer Disease
Defining functional variants associated with Alzheimer's disease in the induced immune response.
Alzheimer Disease
Differential expression of transforming growth factor-beta isoforms in human prion diseases.
Alzheimer Disease
Exploring the mechanistic insights of Cas scaffolding protein family member 4 with protein tyrosine kinase 2 in Alzheimer's disease by evaluating protein interactions through molecular docking and dynamic simulations.
Alzheimer Disease
Frontotemporal dementia mutant Tau promotes aberrant Fyn nanoclustering in hippocampal dendritic spines.
Alzheimer Disease
Fyn depletion ameliorates tauP301L-induced neuropathology.
Alzheimer Disease
Fyn inhibition rescues established memory and synapse loss in Alzheimer mice.
Alzheimer Disease
Fyn kinase induces synaptic and cognitive impairments in a transgenic mouse model of Alzheimer's disease.
Alzheimer Disease
Fyn kinase inhibition as a novel therapy for Alzheimer's disease.
Alzheimer Disease
Fyn Tyrosine Kinase Elicits Amyloid Precursor Protein Tyr682 Phosphorylation in Neurons from Alzheimer's Disease Patients.
Alzheimer Disease
Gene-based aggregate SNP associations between candidate AD genes and cognitive decline.
Alzheimer Disease
Genetic Association of FERMT2, HLA-DRB1, CD2AP, and PTK2B Polymorphisms With Alzheimer's Disease Risk in the Southern Chinese Population.
Alzheimer Disease
Glucosylpolyphenols as inhibitors of A?-induced Fyn kinase activation and Tau phosphorylation: synthesis, membrane permeability, and exploratory target assessment within the scope of type 2 diabetes and Alzheimer's disease.
Alzheimer Disease
Hot off the Press.
Alzheimer Disease
Identification of abelson tyrosine kinase inhibitors as potential therapeutics for Alzheimer's disease using multiple e-pharmacophore modeling and molecular dynamics.
Alzheimer Disease
In silico Analysis of Gamma-Secretase-Complex Mutations in Hidradenitis Suppurativa Demonstrates Disease-Specific Substrate Recognition and Cleavage Alterations.
Alzheimer Disease
Inhibition of Bruton's Tyrosine Kinase Modulates Microglial Phagocytosis: Therapeutic Implications for Alzheimer's Disease.
Alzheimer Disease
Inhibition of Src kinase activity attenuates amyloid associated microgliosis in a murine model of Alzheimer's disease.
Alzheimer Disease
Isoform-specific upregulation of FynT kinase expression is associated with tauopathy and glial activation in Alzheimer's disease and Lewy body dementias.
Alzheimer Disease
Lemur Tyrosine Kinase 2 (LMTK2) Level Inversely Correlates with Phospho-Tau in Neuropathological Stages of Alzheimer's Disease.
Alzheimer Disease
Lymphocyte-specific protein tyrosine kinase is a novel risk gene for Alzheimer disease.
Alzheimer Disease
Metabotropic glutamate receptor 5 couples cellular prion protein to intracellular signalling in Alzheimer's disease.
Alzheimer Disease
Neuronal c-Abl Overexpression Leads to Neuronal Loss and Neuroinflammation in the Mouse Forebrain.
Alzheimer Disease
Neuropathological characterization of Lemur tyrosine kinase 2 (LMTK2) in Alzheimer's disease and neocortical Lewy body disease.
Alzheimer Disease
No genetic association between Fyn kinase gene polymorphisms (-93A/G, IVS10+37T/C and Ex12+894T/G) and Japanese sporadic Alzheimer's disease.
Alzheimer Disease
Oligomers of Amyloid ? Prevent Physiological Activation of the Cellular Prion Protein-Metabotropic Glutamate Receptor 5 Complex by Glutamate in Alzheimer Disease.
Alzheimer Disease
Oxidative Stress, DNA Damage, and c-Abl Signaling: At the Crossroad in Neurodegenerative Diseases?
Alzheimer Disease
Phosphorylation of actin-depolymerizing factor/cofilin by LIM-kinase mediates amyloid beta-induced degeneration: a potential mechanism of neuronal dystrophy in Alzheimer's disease.
Alzheimer Disease
Polymorphism rs11867353 of Tyrosine Kinase Non-Receptor 1 (TNK1) Gene Is a Novel Genetic Marker for Alzheimer's Disease.
Alzheimer Disease
PTK2B/Pyk2 overexpression improves a mouse model of Alzheimer's disease.
Alzheimer Disease
Pyk2 is a Novel Tau Tyrosine Kinase that is Regulated by the Tyrosine Kinase Fyn.
Alzheimer Disease
Pyk2 overexpression in postsynaptic neurons blocks amyloid ?1-42-induced synaptotoxicity in microfluidic co-cultures.
Alzheimer Disease
Reduction of Blood Amyloid-? Oligomers in Alzheimer's Disease Transgenic Mice by c-Abl Kinase Inhibition.
Alzheimer Disease
Selective induction of alternatively spliced FynT isoform by TNF facilitates persistent inflammatory responses in astrocytes.
Alzheimer Disease
STI571 prevents apoptosis, tau phosphorylation and behavioural impairments induced by Alzheimer's beta-amyloid deposits.
Alzheimer Disease
Targeting Fyn Kinase in Alzheimer's Disease.
Alzheimer Disease
The prion protein constitutively controls neuronal store-operated Ca(2+) entry through Fyn kinase.
Alzheimer Disease
The protein tyrosine kinase, fyn, in Alzheimer's disease pathology.
Alzheimer Disease
The relationship between four GWAS-identified loci in Alzheimer's disease and the risk of Parkinson's disease, amyotrophic lateral sclerosis, and multiple system atrophy.
Alzheimer Disease
Transforming growth factor-beta protects human hNT cells from degeneration induced by beta-amyloid peptide: involvement of the TGF-beta type II receptor.
Alzheimer Disease
Treatment With Nilvadipine Mitigates Inflammatory Pathology and Improves Spatial Memory in Aged hTau Mice After Repetitive Mild TBI.
Alzheimer Disease
Tyrosine phosphorylation of tau regulates its interactions with Fyn SH2 domains, but not SH3 domains, altering the cellular localization of tau.
Alzheimer Disease
[Analysis of the fyn kinase gene in Alzheimer's disease and schizophrenia]
Ameloblastoma
Focal Adhesion Kinase Expression in Ameloblastoma: A Preliminary Observational Study.
Ameloblastoma
Invadopodia proteins, cortactin, N-WASP and WIP differentially promote local invasiveness in ameloblastoma.
Amyloidosis
Biologic therapy for amyloid A amyloidosis secondary to rheumatoid arthritis treated with interleukin 6 therapy: Case report and review of literature.
Amyloidosis
Small-Molecule Screening for Genetic Diseases.
Amyotrophic Lateral Sclerosis
c-Abl inhibition delays motor neuron degeneration in the G93A mouse, an animal model of amyotrophic lateral sclerosis.
Amyotrophic Lateral Sclerosis
Partial suppression of M1 microglia by Janus kinase 2 inhibitor does not protect against neurodegeneration in animal models of amyotrophic lateral sclerosis.
Amyotrophic Lateral Sclerosis
PTK2/FAK regulates UPS impairment via SQSTM1/p62 phosphorylation in TARDBP/TDP-43 proteinopathies.
Anaphylaxis
4-Chlorotetrazolo[1,5-a]quinoxaline inhibits activation of Syk kinase to suppress mast cells in vitro and mast cell-mediated passive cutaneous anaphylaxis in mice.
Anaphylaxis
A novel druglike spleen tyrosine kinase binder prevents anaphylactic shock when administered orally.
Anaphylaxis
Antiallergic effect of fisetin on IgE-mediated mast cell activation in vitro and on passive cutaneous anaphylaxis (PCA).
Anaphylaxis
Bruton's tyrosine kinase inhibition effectively protects against human IgE-mediated anaphylaxis.
Anaphylaxis
Bruton's tyrosine kinase-mediated interleukin-2 gene activation in mast cells. Dependence on the c-Jun N-terminal kinase activation pathway.
Anaphylaxis
Lyn but not Fyn kinase controls IgG-mediated systemic anaphylaxis.
Anaphylaxis
Optimizing drug inhibition of IgE-mediated anaphylaxis in mice.
Anaphylaxis
Structure-activity relationship studies of imidazo[1,2-c]pyrimidine derivatives as potent and orally effective Syk family kinases inhibitors.
Anaphylaxis
Targeting Janus kinase 3 in mast cells prevents immediate hypersensitivity reactions and anaphylaxis.
Anaphylaxis
Targeting the Fc?RI Pathway as a Potential Strategy to Prevent Food-Induced Anaphylaxis.
Anaphylaxis
The Fab fragment of anti-IgE C?2 domain prevents allergic reactions through interacting with IgE-Fc?RI? complex on rat mast cells.
Anaphylaxis
The role of Src family kinases in mast cell effector function.
Anaphylaxis
The Src Family Kinase Fgr Is Critical for Activation of Mast Cells and IgE-Mediated Anaphylaxis in Mice.
Anaphylaxis
The vascular endothelial specific IL-4 receptor alpha-ABL1 kinase signaling axis regulates the severity of IgE-mediated anaphylactic reactions.
Anemia
A Phase 1 Study of ACE-536, a Regulator of Erythroid Differentiation, in Healthy Volunteers.
Anemia
Anemia and survival in childhood acute lymphoblastic leukemia.
Anemia
Cell surface expression of CD25 antigen (surface IL-2 receptor alpha-chain) is not a prognostic marker in chronic lymphocytic leukemia: results of a retrospective study of 281 patients.
Anemia
Disappearance of Bone Marrow Fibrosis in a Patient with Chronic Myeloid Leukemia Treated with Dasatinib.
Anemia
Disease expression in juvenile polyposis syndrome: a retrospective survey on a cohort of 221 European patients and comparison with a literature-derived cohort of 473 SMAD4/BMPR1A pathogenic variant carriers.
Anemia
Expression of v-src induces a myeloproliferative disease in bone-marrow-reconstituted mice.
Anemia
Identification of e6a2 bcr-abl fusion in a Philadelphia-positive cml with marked basophilia: implications for treatment strategy.
Anemia
Mechanisms and Significance of Eryptosis, the Suicidal Death of Erythrocytes.
Anemia
Momelotinib inhibits ACVR1/ALK2, decreases hepcidin production, and ameliorates anemia of chronic disease in rodents.
Anemia
Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosis.
Anemia
Primary Myelofibrosis: Update on Definition, Pathogenesis, and Treatment.
Anemia
RAP-011, an activin receptor ligand trap, increases hemoglobin concentration in hepcidin transgenic mice.
Anemia
[Effects of Yisui Jiedu Recipe on JAK2-STAT5 signal transduction pathway in bone marrow hematopoietic cells from patients with myelodysplastic syndrome-refractory anemia]
Anemia, Aplastic
T-cell expression of Bruton's tyrosine kinase promotes autoreactive T-cell activation and exacerbates aplastic anemia.
Anemia, Diamond-Blackfan
RAP-011, an activin receptor ligand trap, increases hemoglobin concentration in hepcidin transgenic mice.
Anemia, Hemolytic, Autoimmune
Fostamatinib: First Global Approval.
Anemia, Hemolytic, Autoimmune
Increased serum BAFF (B-cell activating factor of the TNF family) level is a peculiar feature associated with familial chronic lymphocytic leukemia.
Anemia, Refractory
Engraftment of HLA-matched sibling hematopoietic stem cells after immunosuppressive conditioning regimen in patients with hematologic neoplasias.
Anemia, Refractory, with Excess of Blasts
Engraftment of HLA-matched sibling hematopoietic stem cells after immunosuppressive conditioning regimen in patients with hematologic neoplasias.
Anemia, Sickle Cell
Development of a Predictive Pharmacophore Model and a 3D-QSAR Study for an in silico Screening of New Potent Bcr-Abl Kinase Inhibitors.
Anemia, Sickle Cell
Mechanisms and Significance of Eryptosis, the Suicidal Death of Erythrocytes.
Anemia, Sickle Cell
NLRP3 inflammasome and bruton tyrosine kinase inhibition interferes with upregulated platelet aggregation and in vitro thrombus formation in sickle cell mice.
Anemia, Sickle Cell
The platelet NLRP3 inflammasome is upregulated in sickle cell disease via HMGB1/TLR4 and Bruton tyrosine kinase.
Anemia, Sideroblastic
Mixed myelodysplastic and myeloproliferative syndromes.
Aneurysm
Evolution of the face in Loeys-Dietz syndrome type II: longitudinal observations from infancy in seven cases.
Aneurysm
First genetic analysis of aneurysm genes in familial and sporadic abdominal aortic aneurysm.
Aneurysm
hiPSC Modeling of Lineage-Specific Smooth Muscle Cell Defects Caused by TGFBR1A230T Variant, and its Therapeutic Implications for Loeys-Dietz Syndrome.
Aneurysm
Reversible cerebral vasoconstriction syndrome and posterior reversible encephalopathy syndrome in a boy with Loeys-Dietz syndrome.
Aneurysm, Dissecting
International Registry of Patients Carrying TGFBR1 or TGFBR2 Mutations: Results of the MAC (Montalcino Aortic Consortium).
Aneurysm, Dissecting
Role of c-Abl in Ang II-induced aortic dissection formation: Potential regulatory efficacy on phenotypic transformation and apoptosis of VSMCs.
Angiofibroma
Hypoxia-Inducible Factor-1? (HIF-1?) Expression on Endothelial Cells in Juvenile Nasopharyngeal Angiofibroma: A Review of 70 cases and Tissue Microarray Analysis.
Anorectal Malformations
Involvement of the WNT and FGF signaling pathways in non-isolated anorectal malformations: Sequencing analysis of WNT3A, WNT5A, WNT11, DACT1, FGF10, FGFR2 and the T gene.
Anorectal Malformations
The expression analysis of Bmpr1a and Bmp2 during hindgut development in rat embryos with anorectal malformations.
Anti-Glomerular Basement Membrane Disease
Targeting the tyrosine kinase signalling pathways for treatment of immune-mediated glomerulonephritis: from bench to bedside and beyond.
Antiphospholipid Syndrome
Evaluation of The Presence of Hereditary And Acquired Thrombophilias In Brazilian Children And Adolescents With Diagnoses of Portal Vein Thrombosis.
Anus Neoplasms
Inhibition of mTOR reduces anal carcinogenesis in transgenic mouse model.
Aortic Aneurysm
Activation of TGF-? signaling in an aortic aneurysm in a patient with Loeys-Dietz syndrome caused by a novel loss-of-function variant of TGFBR1.
Aortic Aneurysm
An X-linked Myh11-CreER(T2) mouse line resulting from Y to X chromosome-translocation of the Cre allele.
Aortic Aneurysm
Cyclophilin A contributes to aortopathy induced by postnatal loss of smooth muscle TGFBR1.
Aortic Aneurysm
FBN1, TGFBR1, and the Marfan-craniosynostosis/mental retardation disorders revisited.
Aortic Aneurysm
Focal Adhesion Kinase Promotes the Progression of Aortic Aneurysm by Modulating Macrophage Behavior.
Aortic Aneurysm
Genetic Risk for Aortic Aneurysm in Adolescent Idiopathic Scoliosis.
Aortic Aneurysm
Germline TGF-beta receptor mutations and skeletal fragility: a report on two patients with Loeys-Dietz syndrome.
Aortic Aneurysm
Multiple Facial Milia in Patients With Loeys-Dietz Syndrome.
Aortic Aneurysm
Mutation of ACTA2 gene as an important cause of familial and nonfamilial nonsyndromatic thoracic aortic aneurysm and/or dissection (TAAD).
Aortic Aneurysm
Pregnancy after aortic root replacement in Loeys-Dietz syndrome: High risk of aortic dissection.
Aortic Aneurysm
Smooth muscle cell-specific Tgfbr1 deficiency promotes aortic aneurysm formation by stimulating multiple signaling events.
Aortic Aneurysm
TGFBR1 and TGFBR2 mutations in patients with features of Marfan syndrome and Loeys-Dietz syndrome.
Aortic Aneurysm, Abdominal
ACE and TGFBR1 genes interact in influencing the susceptibility to abdominal aortic aneurysm.
Aortic Aneurysm, Abdominal
The transforming growth factor-? receptor genes and the risk of intracranial aneurysms.
Aortic Aneurysm, Thoracic
Analysis of multigenerational families with thoracic aortic aneurysms and dissections due to TGFBR1 or TGFBR2 mutations.
Aortic Aneurysm, Thoracic
Association of the TGF-beta receptor genes with abdominal aortic aneurysm.
Aortic Aneurysm, Thoracic
Identification and surgical repair of familial thoracic aortic aneurysm and dissection caused by TGFBR1 mutation.
Aortic Aneurysm, Thoracic
Identification of 23 TGFBR2 and 6 TGFBR1 gene mutations and genotype-phenotype investigations in 457 patients with Marfan syndrome type I and II, Loeys-Dietz syndrome and related disorders.
Aortic Aneurysm, Thoracic
Recent progress in genetics of Marfan syndrome and Marfan-associated disorders.
Aortic Aneurysm, Thoracic
Testing patterns for genetically triggered aortic and arterial aneurysms and dissections at an academic center.
Aortic Aneurysm, Thoracic
TGFBR1 Rare Variant Associated With Thoracic Aortic Aneurysm, Double Chamber Left Ventricle, Coronary Anomaly, and Inducible Ventricular Tachycardia.
Aortic Aneurysm, Thoracic
TGFBR2 mutations alter smooth muscle cell phenotype and predispose to thoracic aortic aneurysms and dissections.
Aortic Aneurysm, Thoracic
The transforming growth factor-? receptor genes and the risk of intracranial aneurysms.
Aortic Aneurysm, Thoracic
Three-generation family with novel contiguous gene deletion on chromosome 2p22 associated with thoracic aortic aneurysm syndrome.
Aortic Diseases
International Registry of Patients Carrying TGFBR1 or TGFBR2 Mutations: Results of the MAC (Montalcino Aortic Consortium).
Arachnodactyly
FBN2, FBN1, TGFBR1, and TGFBR2 analyses in congenital contractural arachnodactyly.
Arrhythmias, Cardiac
Acute Effects of Ibrutinib on Ventricular Arrhythmia in Spontaneously Hypertensive Rats.
Arrhythmias, Cardiac
c-Src Kinase Inhibition Reduces Arrhythmia Inducibility and Connexin43 Dysregulation After Myocardial Infarction.
Arrhythmias, Cardiac
Cellular and Molecular Mechanisms of Arrhythmia by Oxidative Stress.
Arteriosclerosis
Prevention of cardiac allograft arteriosclerosis by protein-tyrosine kinase inhibitor selective for platelet-derived growth factor receptor.
Arteriovenous Malformations
EPHB4 gene polymorphisms and risk of intracranial hemorrhage in patients with brain arteriovenous malformations.
Arteriovenous Malformations
Janus-faced EPHB4-associated disorders: novel pathogenic variants and unreported intrafamilial overlapping phenotypes.
Arteriovenous Malformations
Notch1 activation in mice causes arteriovenous malformations phenocopied by ephrinB2 and EphB4 mutants.
Arthralgia
Imatinib: new preparation. For Chronic myeloid leukaemia: further assessment required.
Arthritis
A Novel Triazolopyridine-Based Spleen Tyrosine Kinase Inhibitor That Arrests Joint Inflammation.
Arthritis
A quantitative mechanistic PK/PD model directly connects Btk target engagement and in vivo efficacy.
Arthritis
Altered thymic T-cell selection due to a mutation of the ZAP-70 gene causes autoimmune arthritis in mice.
Arthritis
An allosteric hot spot in the tandem-SH2 domain of ZAP-70 regulates T-cell signaling.
Arthritis
Anti- and non-tumor necrosis factor-?-targeted therapies effects on insulin resistance in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.
Arthritis
Anti-rheumatoid arthritis effects in adjuvant-induced arthritis in rats and molecular docking studies of Polygonum orientale L. extracts.
Arthritis
B cell subsets in the joint compartments of seropositive and seronegative RA and non-RA arthritides express memory markers and ZAP-70 and characterize the aggregate pattern irrespectively of the autoantibody status.
Arthritis
Beta-glucan triggers spondyloarthropathy and Crohn's-like ileitis in SKG mice.
Arthritis
Bruton's tyrosine kinase deficiency inhibits autoimmune arthritis but fails to block immune complex-mediated inflammatory arthritis.
Arthritis
Btk inhibition suppresses agonist-induced human macrophage activation and inflammatory gene expression in RA synovial tissue explants.
Arthritis
Can rheumatologists stop causing demyelinating disease?
Arthritis
Deletion of Syk in neutrophils prevents immune complex arthritis.
Arthritis
Effect of Janus Kinase Inhibitor Treatment on Anterior Uveitis and Associated Macular Edema in an Adult Patient with Juvenile Idiopathic Arthritis.
Arthritis
EphB4 Expressing Stromal Cells Exhibit an Enhanced Capacity for Hematopoietic Stem Cell Maintenance.
Arthritis
Focal adhesion kinase is required for synovial fibroblast invasion, but not murine inflammatory arthritis.
Arthritis
Formation of invadopodia-like structures by synovial cells promotes cartilage breakdown in arthritis. Involvement of the protein tyrosine kinase src.
Arthritis
HM71224, a novel Bruton's tyrosine kinase inhibitor, suppresses B cell and monocyte activation and ameliorates arthritis in a mouse model: a potential drug for rheumatoid arthritis.
Arthritis
Impaired T cell receptor signaling and development of T cell-mediated autoimmune arthritis.
Arthritis
JAK Inhibitors in Rheumatology: Implications for Paediatric Syndromes?
Arthritis
Measuring the T-cell down-regulation of TCR-zeta, ZAP-70 and CD28 in arthritis patients: An old tool for new biomarkers.
Arthritis
Mice with the xid B cell defect are less susceptible to developing Staphylococcus aureus-induced arthritis.
Arthritis
Nod2 Deficiency Augments Th17 Responses and Exacerbates Autoimmune Arthritis.
Arthritis
Novel 1H-pyrazolo[3,4-d]pyrimidin-6-amino derivatives as potent selective Janus kinase 3 (JAK3) inhibitors. Evaluation of their improved effect for the treatment of rheumatoid arthritis.
Arthritis
Novel concepts and treatments for autoimmune disease: ten focal points.
Arthritis
Resveratrol inhibits Src tyrosine kinase, STAT3, and Wnt signaling pathway in collagen induced arthritis model.
Arthritis
RN486, a Selective Bruton's Tyrosine Kinase Inhibitor, Abrogates Immune Hypersensitivity Responses and Arthritis in Rodents.
Arthritis
RPTP? phosphatase activity is allosterically regulated by the membrane-distal catalytic domain.
Arthritis
Selective spleen tyrosine kinase inhibition delays autoimmune arthritis in mice.
Arthritis
Sitagliptin and tofacitinib ameliorate adjuvant induced arthritis via modulating the cross talk between JAK/STAT and TLR-4/NF-?B signaling pathways.
Arthritis
Spondyloarthritis: new insights into clinical aspects, translational immunology and therapeutics.
Arthritis
Spontaneous development of autoimmune arthritis due to genetic anomaly of T cell signal transduction: Part 1.
Arthritis
Src and podoplanin forge a path to destruction.
Arthritis
State-of-the-art treatment of systemic lupus erythematosus.
Arthritis
Synovial fluid-derived T helper 17 cells correlate with inflammatory activity in arthritis, irrespectively of diagnosis.
Arthritis
Tec family kinases in inflammation and disease.
Arthritis
The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells.
Arthritis
The inhibition of Src kinase suppresses the production of matrix metalloproteinases in from synovial fibroblasts and inhibits MAPK and STATs pathways
Arthritis
The SKG mutation in ZAP-70 also confers arthritis susceptibility in C57 Black mouse strains.
Arthritis
Tofacitinib Use in Adults with Chronic Inflammatory Disease During the Severe Acute Respiratory Syndrome Coronavirus 2 Pandemic: What Is Known So Far?
Arthritis
ZAP-70 Regulates Autoimmune Arthritis via Alterations in T Cell Activation and Apoptosis.
Arthritis
ZYBT1, a potent, irreversible Bruton's Tyrosine Kinase (BTK) inhibitor that inhibits the C481S BTK with profound efficacy against arthritis and cancer.
Arthritis
[Total saponins of Clematis inhibits JAK2/STAT3 signal pathway of adjuvant-induced arthritis rats].
Arthritis, Experimental
5,7,3'-Triacetyl hesperetin suppresses adjuvant-induced arthritis in rats through modulating JAK2/STAT3 pathway.
Arthritis, Experimental
Antiarthritis effect of a novel Bruton's tyrosine kinase (BTK) inhibitor in rat collagen-induced arthritis and mechanism-based pharmacokinetic/pharmacodynamic modeling: relationships between inhibition of BTK phosphorylation and efficacy.
Arthritis, Experimental
Baicalin Ameliorates Collagen-Induced Arthritis Through the Suppression of Janus Kinase 1 (JAK1)/Signal Transducer and Activator of Transcription 3 (STAT3) Signaling in Mice.
Arthritis, Experimental
Changes in focal adhesion kinase expression in rats with collagen-induced arthritis and efficacy of intervention with disease modifying anti-rheumatic drugs alone or in combination.
Arthritis, Experimental
Intracellular signal transduction pathways: good therapeutic targets for joint destruction in rheumatoid arthritis.
Arthritis, Experimental
Preclinical to clinical translation of tofacitinib, a Janus kinase inhibitor, in rheumatoid arthritis.
Arthritis, Experimental
RN486, a Selective Bruton's Tyrosine Kinase Inhibitor, Abrogates Immune Hypersensitivity Responses and Arthritis in Rodents.
Arthritis, Experimental
Selective spleen tyrosine kinase inhibition delays autoimmune arthritis in mice.
Arthritis, Experimental
SOCS3 participates in cholinergic pathway regulation of synovitis in rheumatoid arthritis.
Arthritis, Experimental
Tetrandrine attenuates the bone erosion in collagen-induced arthritis rats by inhibiting osteoclastogenesis via spleen tyrosine kinase.
Arthritis, Experimental
The adaptor molecule SAP is essential in mechanisms involving the Fyn tyrosine kinase for induction and progression of collagen-induced arthritis.
Arthritis, Experimental
Transcriptome-Wide High-Throughput m6A Sequencing of Differential m6A Methylation Patterns in the Human Rheumatoid Arthritis Fibroblast-Like Synoviocytes Cell Line MH7A.
Arthritis, Juvenile
Effect of Janus Kinase Inhibitor Treatment on Anterior Uveitis and Associated Macular Edema in an Adult Patient with Juvenile Idiopathic Arthritis.
Arthritis, Juvenile
Tofacitinib Use in Adults with Chronic Inflammatory Disease During the Severe Acute Respiratory Syndrome Coronavirus 2 Pandemic: What Is Known So Far?
Arthritis, Psoriatic
A novel treatment for psoriatic arthritis: Janus kinase inhibitors.
Arthritis, Psoriatic
An Integrated Analysis of the Safety of Tofacitinib in Psoriatic Arthritis across Phase III and Long-Term Extension Studies with Comparison to Real-World Observational Data.
Arthritis, Psoriatic
Application of Physiologically Based Pharmacokinetic Modeling to Predict Drug Exposure and Support Dosing Recommendations for Potential Drug-Drug Interactions or in Special Populations: An Example Using Tofacitinib.
Arthritis, Psoriatic
Contribution of a European-Prevalent Variant near CD83 and an East Asian-Prevalent Variant near IL17RB to Herpes Zoster Risk in Tofacitinib Treatment: Results of Genome-Wide Association Study Meta-Analyses.
Arthritis, Psoriatic
Disease-specific composite measures for psoriatic arthritis are highly responsive to a Janus kinase inhibitor treatment that targets multiple domains of disease.
Arthritis, Psoriatic
Effect of filgotinib on health-related quality of life in active psoriatic arthritis: a randomized phase 2 trial (EQUATOR).
Arthritis, Psoriatic
Effect of tofacitinib on patient-reported outcomes in patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors in the phase III, randomised controlled trial: OPAL Beyond.
Arthritis, Psoriatic
Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial.
Arthritis, Psoriatic
Efficacy and safety of tofacitinib by background methotrexate dose in psoriatic arthritis: post hoc exploratory analysis from two phase III trials.
Arthritis, Psoriatic
Efficacy of Tofacitinib for the Treatment of Psoriatic Arthritis: Pooled Analysis of Two Phase 3 Studies.
Arthritis, Psoriatic
Efficacy of Tofacitinib in the Treatment of Psoriatic Arthritis: A Systematic Review.
Arthritis, Psoriatic
Experimental and Investigational Pharmacotherapy for Psoriatic Arthritis: Drugs of the Future.
Arthritis, Psoriatic
Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data.
Arthritis, Psoriatic
Infection risk in patients undergoing treatment for inflammatory arthritis: non-biologics versus biologics.
Arthritis, Psoriatic
Inhibition of JAK/STAT signaling in rheumatologic disorders: the expanding spectrum.
Arthritis, Psoriatic
JAK inhibitors and infections risk: focus on herpes zoster.
Arthritis, Psoriatic
JAK Inhibitors in Rheumatology: Implications for Paediatric Syndromes?
Arthritis, Psoriatic
JAK inhibitors, psoriatic arthritis, and axial spondyloarthritis: a critical review of clinical trials.
Arthritis, Psoriatic
Off-label studies on tofacitinib in dermatology: a review.
Arthritis, Psoriatic
Oral tofacitinib efficacy, safety and tolerability in Japanese patients with moderate to severe plaque psoriasis and psoriatic arthritis: A randomized, double-blind, phase 3 study.
Arthritis, Psoriatic
Performance of Janus kinase inhibitors in psoriatic arthritis with axial involvement in indirect comparison with ankylosing spondylitis: a retrospective analysis from pooled data.
Arthritis, Psoriatic
Phase 1 Dose-Escalation Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Tofacitinib in Japanese Healthy Volunteers.
Arthritis, Psoriatic
Pneumocystis Jirovecii Pneumonia after Initiation of Tofacitinib Therapy in Rheumatoid Arthritis: Case-Based Review.
Arthritis, Psoriatic
Population pharmacokinetics of tofacitinib in patients with psoriatic arthritis?.
Arthritis, Psoriatic
Psoriatic arthritis treatment patterns and costs among pharmacologic treatment-naïve patients.
Arthritis, Psoriatic
Rapid remission of refractory synovitis, acne, pustulosis, hyperostosis, and osteitis syndrome in response to the Janus kinase inhibitor tofacitinib: A case report.
Arthritis, Psoriatic
Safety and Efficacy of Tofacitinib in Patients with Active Psoriatic Arthritis: Interim Analysis of OPAL Balance, an Open-Label, Long-Term Extension Study.
Arthritis, Psoriatic
State of the art: approved and emerging JAK inhibitors for rheumatoid arthritis.
Arthritis, Psoriatic
The role of microRNA-146a (miR-146a) and its target IL-1R-associated kinase (IRAK1) in psoriatic arthritis susceptibility.
Arthritis, Psoriatic
Tofacitinib downregulates antiviral immune defence in keratinocytes and reduces T cell activation.
Arthritis, Psoriatic
Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors.
Arthritis, Psoriatic
Tofacitinib for the treatment of psoriasis and psoriatic arthritis.
Arthritis, Psoriatic
Tofacitinib in the management of active psoriatic arthritis: patient selection and perspectives.
Arthritis, Psoriatic
Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis.
Arthritis, Psoriatic
Tofacitinib or adalimumab versus placebo: patient-reported outcomes from OPAL Broaden-a phase III study of active psoriatic arthritis in patients with an inadequate response to conventional synthetic disease-modifying antirheumatic drugs.
Arthritis, Psoriatic
Tofacitinib Use in Adults with Chronic Inflammatory Disease During the Severe Acute Respiratory Syndrome Coronavirus 2 Pandemic: What Is Known So Far?
Arthritis, Psoriatic
Tofacitinib: A Review in Psoriatic Arthritis.
Arthritis, Psoriatic
Treatment With Tofacitinib in Refractory Psoriatic Arthritis: A National Multicenter Study of the First 87 Patients in Clinical Practice.
Arthritis, Psoriatic
Trial of Upadacitinib and Adalimumab for Psoriatic Arthritis.
Arthritis, Psoriatic
Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2.
Arthritis, Psoriatic
Upadacitinib in Patients with Psoriatic Arthritis and Inadequate Response to Biologics: 56-Week Data from the Randomized Controlled Phase 3 SELECT-PsA 2 Study.
Arthritis, Psoriatic
Upadacitinib Pharmacokinetics and Exposure-Response Analyses of Efficacy and Safety in Psoriatic Arthritis Patients - Analyses of Phase 3 Clinical Trials.
Arthritis, Psoriatic
[Modern disease-modifying antirheumatic drugs].
Arthritis, Rheumatoid
'Should we stop or continue conventional synthetic (including glucocorticoids) and targeted DMARDs before surgery in patients with inflammatory rheumatic diseases?'
Arthritis, Rheumatoid
4-Amino-pyrrolopyridine-5-carboxamide: a novel scaffold for JAK1-selective inhibitors.
Arthritis, Rheumatoid
A budget impact analysis for making treatment decisions based on anti-cyclic citrullinated peptide (anti-CCP) testing in rheumatoid arthritis.
Arthritis, Rheumatoid
A Budget Impact and Cost Per Additional Responder Analysis for Baricitinib for the Treatment of Moderate-to-Severe Rheumatoid Arthritis in Patients with an Inadequate Response to Tumor Necrosis Factor Inhibitors in the USA.
Arthritis, Rheumatoid
A combined experimental and computational study of Vam3, a derivative of resveratrol, and Syk interaction.
Arthritis, Rheumatoid
A highly selective, orally active inhibitor of Janus kinase 2, CEP-33779, ablates disease in two mouse models of rheumatoid arthritis.
Arthritis, Rheumatoid
A Hydrophilic Interaction Liquid Chromatography-Tandem Mass Spectrometry Quantitative Method for Determination of Baricitinib in Plasma, and Its Application in a Pharmacokinetic Study in Rats.
Arthritis, Rheumatoid
A JAK inhibitor tofacitinib regulates synovitis through inhibition of IFN-? and IL-17 production by human CD4(+) T cells.
Arthritis, Rheumatoid
A Matching-Adjusted Indirect Comparison of Upadacitinib Versus Tofacitinib in Adults with Moderate-to-Severe Rheumatoid Arthritis.
Arthritis, Rheumatoid
A modeling framework for the economic evaluation of baricitinib in moderate-to-severe rheumatoid arthritis.
Arthritis, Rheumatoid
A Network Meta-Analysis to Compare Effectiveness of Baricitinib and Other Treatments in Rheumatoid Arthritis Patients with Inadequate Response to Methotrexate.
Arthritis, Rheumatoid
A novel reaction mediated by human aldehyde oxidase: amide hydrolysis of GDC-0834.
Arthritis, Rheumatoid
A Peptide-Based Biosensor Assay To Detect Intracellular Syk Kinase Activation and Inhibition.
Arthritis, Rheumatoid
A Phase 2b Study of ABT-494, a Selective JAK1 Inhibitor, in Patients With Rheumatoid Arthritis and an Inadequate Response to Anti-TNF Therapy.
Arthritis, Rheumatoid
A Randomized Phase 2b Study of ABT-494, a Selective JAK1 Inhibitor in Patients with Rheumatoid Arthritis and an Inadequate Response to Methotrexate.
Arthritis, Rheumatoid
A retrospective comparison of respiratory events with JAK inhibitors or rituximab for rheumatoid arthritis in patients with pulmonary disease.
Arthritis, Rheumatoid
A Semi-Mechanistic Model of CP-690,550-Induced Reduction in Neutrophil Counts in Patients With Rheumatoid Arthritis.
Arthritis, Rheumatoid
A study on the risk of fungal infection with tofacitinib (CP-690550), a novel oral agent for rheumatoid arthritis.
Arthritis, Rheumatoid
Absence of Pharmacokinetic Interactions between the Bruton's Tyrosine Kinase Inhibitor Fenebrutinib and Methotrexate.
Arthritis, Rheumatoid
Activation of dickkopf-1 and focal adhesion kinase pathway by tumour necrosis factor ? induces enhanced migration of fibroblast-like synoviocytes in rheumatoid arthritis.
Arthritis, Rheumatoid
ADAM15 in apoptosis resistance of synovial fibroblasts: converting Fas/CD95 death signals into the activation of pro-survival pathways by calmodulin recruitment.
Arthritis, Rheumatoid
An Economic Evaluation of Tofacitinib Treatment in Rheumatoid Arthritis: Modeling the Cost of Treatment Strategies in the United States.
Arthritis, Rheumatoid
An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis.
Arthritis, Rheumatoid
An oral syk kinase inhibitor in the treatment of rheumatoid arthritis: A 3 month randomized placebo controlled phase 2 study in patients with active RA who had failed biologic agents.
Arthritis, Rheumatoid
An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis: a three-month randomized, placebo-controlled, phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents.
Arthritis, Rheumatoid
An Update on Calcineurin Inhibitor-Free Regimens: The Need Persists, but the Landscape has Changed.
Arthritis, Rheumatoid
Analysis of non-melanoma skin cancer across the tofacitinib rheumatoid arthritis clinical programme.
Arthritis, Rheumatoid
Analysis of Spontaneous Postmarket Case Reports Submitted to the FDA Regarding Thromboembolic Adverse Events and JAK Inhibitors.
Arthritis, Rheumatoid
Antiarthritis effect of a novel Bruton's tyrosine kinase (BTK) inhibitor in rat collagen-induced arthritis and mechanism-based pharmacokinetic/pharmacodynamic modeling: relationships between inhibition of BTK phosphorylation and efficacy.
Arthritis, Rheumatoid
Application of Physiologically Based Pharmacokinetic Modeling to Predict Drug Exposure and Support Dosing Recommendations for Potential Drug-Drug Interactions or in Special Populations: An Example Using Tofacitinib.
Arthritis, Rheumatoid
Application of Physiologically-Based Pharmacokinetic Modeling for the Prediction of Tofacitinib Exposure in Japanese.
Arthritis, Rheumatoid
Approaching the active conformation of 1,3-diaminopyrimidine based covalent inhibitors of Bruton's tyrosine kinase for treatment of Rheumatoid arthritis.
Arthritis, Rheumatoid
Arthritis-associated osteoclastogenic macrophages (AtoMs) participate in pathological bone erosion in rheumatoid arthritis.
Arthritis, Rheumatoid
Association of a haplotype in the promoter region of the interferon regulatory factor 5 gene with rheumatoid arthritis.
Arthritis, Rheumatoid
Associations between Patient Global Assessment scores and pain, physical function, and fatigue in rheumatoid arthritis: a post hoc analysis of data from phase 3 trials of tofacitinib.
Arthritis, Rheumatoid
Baricitinib Attenuates Autoimmune Phenotype and Podocyte Injury in a Murine Model of Systemic Lupus Erythematosus.
Arthritis, Rheumatoid
Baricitinib in Patients with Refractory Rheumatoid Arthritis.
Arthritis, Rheumatoid
Baricitinib in patients with rheumatoid arthritis with inadequate response to methotrexate: results from a phase 3 study.
Arthritis, Rheumatoid
Baricitinib inhibits structural joint damage progression in patients with rheumatoid arthritis-a comprehensive review.
Arthritis, Rheumatoid
Baricitinib, a Janus kinase inhibitor, in the treatment of rheumatoid arthritis: a systematic literature review and meta-analysis of randomized controlled trials.
Arthritis, Rheumatoid
Baricitinib: The Second FDA-Approved JAK Inhibitor for the Treatment of Rheumatoid Arthritis.
Arthritis, Rheumatoid
Bruton's Tyrosine Kinase Inhibition for the Treatment of Rheumatoid Arthritis.
Arthritis, Rheumatoid
Bruton's tyrosine kinase inhibitor BMS-986142 in experimental models of rheumatoid arthritis enhances efficacy of agents representing clinical standard-of-care.
Arthritis, Rheumatoid
Bruton's tyrosine kinase inhibitors for the treatment of rheumatoid arthritis.
Arthritis, Rheumatoid
Bruton's Tyrosine Kinase mediates platelet receptor-induced generation of microparticles: A potential mechanism for amplification of inflammatory responses in rheumatoid arthritis synovial joints.
Arthritis, Rheumatoid
Cardiovascular Safety During Treatment with Baricitinib in Rheumatoid Arthritis.
Arthritis, Rheumatoid
Cardiovascular safety findings in patients with rheumatoid arthritis treated with tofacitinib, an oral Janus kinase inhibitor.
Arthritis, Rheumatoid
Caring for patients in a new pandemic: the necessity and challenges of observational research.
Arthritis, Rheumatoid
Cartilage preservation by inhibition of Janus kinase 3 in two rodent models of rheumatoid arthritis.
Arthritis, Rheumatoid
Changes in focal adhesion kinase expression in rats with collagen-induced arthritis and efficacy of intervention with disease modifying anti-rheumatic drugs alone or in combination.
Arthritis, Rheumatoid
Changes in synovial tissue Jak-STAT expression in rheumatoid arthritis in response to successful DMARD treatment.
Arthritis, Rheumatoid
Characterization and changes of lymphocyte subsets in baricitinib-treated patients with rheumatoid arthritis: an integrated analysis.
Arthritis, Rheumatoid
Characterization of the Effect of Hepatic Impairment on Upadacitinib Pharmacokinetics.
Arthritis, Rheumatoid
Characterization of the Effect of Renal Impairment on Upadacitinib Pharmacokinetics.
Arthritis, Rheumatoid
Chemical genetic transcriptional fingerprinting for selectivity profiling of kinase inhibitors.
Arthritis, Rheumatoid
Clinical Aspects of Janus Kinase (JAK) Inhibitors in the Cardiovascular System in Patients with Rheumatoid Arthritis.
Arthritis, Rheumatoid
Clinical Confirmation that the Selective JAK1 Inhibitor Filgotinib (GLPG0634) has a Low Liability for Drug-drug Interactions.
Arthritis, Rheumatoid
Co-administration of the JAK inhibitor CP-690,550 and methotrexate is well tolerated in patients with rheumatoid arthritis without need for dose adjustment.
Arthritis, Rheumatoid
Comparative effectiveness and safety of non-tumour necrosis factor biologics and Janus kinase inhibitors in patients with active rheumatoid arthritis showing insufficient response to tumour necrosis factor inhibitors: A Bayesian network meta-analysis of randomized controlled trials.
Arthritis, Rheumatoid
Comparative effectiveness of antitumour necrosis factor agents, biologics with an alternative mode of action and tofacitinib in an observational cohort of patients with rheumatoid arthritis in Switzerland.
Arthritis, Rheumatoid
Comparative efficacy and safety of Janus kinase inhibitors and biological disease-modifying antirheumatic drugs in rheumatoid arthritis: a systematic review and network meta-analysis.
Arthritis, Rheumatoid
Comparative Efficacy of JAK Inhibitors for Moderate-To-Severe Rheumatoid Arthritis: A Network Meta-Analysis.
Arthritis, Rheumatoid
Comparing the effects of tofacitinib, methotrexate and the combination, on bone marrow oedema, synovitis and bone erosion in methotrexate-naive, early active rheumatoid arthritis: results of an exploratory randomised MRI study incorporating semiquantitative and quantitative techniques.
Arthritis, Rheumatoid
Comparison of Janus kinase inhibitors in the treatment of rheumatoid arthritis: a systemic literature review.
Arthritis, Rheumatoid
Comparison of the effects of baricitinib and tocilizumab on disease activity in patients with rheumatoid arthritis: a propensity score matching analysis.
Arthritis, Rheumatoid
Contribution of a European-Prevalent Variant near CD83 and an East Asian-Prevalent Variant near IL17RB to Herpes Zoster Risk in Tofacitinib Treatment: Results of Genome-Wide Association Study Meta-Analyses.
Arthritis, Rheumatoid
Cost-effectiveness analysis of baricitinib versus adalimumab for the treatment of moderate-to-severe rheumatoid arthritis in Spain.
Arthritis, Rheumatoid
Cost-Effectiveness of a JAK1/JAK2 Inhibitor vs a Biologic Disease-Modifying Antirheumatic Drug (bDMARD) in a Treat-to-Target Strategy for Rheumatoid Arthritis.
Arthritis, Rheumatoid
Cost-effectiveness of Tofacitinib in the Treatment of Moderate to Severe Rheumatoid Arthritis in South Korea.
Arthritis, Rheumatoid
Critical Assessment of Pharmacokinetic Drug-Drug Interaction Potential of Tofacitinib, Baricitinib and Upadacitinib, the Three Approved Janus Kinase Inhibitors for Rheumatoid Arthritis Treatment.
Arthritis, Rheumatoid
Current Status in the Discovery of Covalent Janus Kinase 3 (JAK3) inhibitors.
Arthritis, Rheumatoid
Design and Synthesis of Novel Amino-triazine Analogues as Selective Bruton's Tyrosine Kinase Inhibitors for Treatment of Rheumatoid Arthritis.
Arthritis, Rheumatoid
Design of novel JAK3 Inhibitors towards Rheumatoid Arthritis using molecular docking analysis.
Arthritis, Rheumatoid
Design, synthesis and biological evaluation of 7H-pyrrolo[2,3-d]pyrimidin-4-amine derivatives as selective Btk inhibitors with improved pharmacokinetic properties for the treatment of rheumatoid arthritis.
Arthritis, Rheumatoid
Design, synthesis and evaluation of novel 7H-pyrrolo[2,3-d]pyrimidin-4-amine derivatives as potent, selective and reversible Bruton's tyrosine kinase (BTK) inhibitors for the treatment of rheumatoid arthritis.
Arthritis, Rheumatoid
Design, synthesis and structure-activity relationship study of aminopyridine derivatives as novel inhibitors of Janus kinase 2.
Arthritis, Rheumatoid
Determination of Real Time in Vivo Drug Receptor Occupancy for a Covalent Binding Drug as a Clinical Pharmacodynamic Biomarker by Immunocapture-LC-MS/MS.
Arthritis, Rheumatoid
Development and Characterization of a JAK-2-specific Antibody Suitable for Immunohistochemical Investigative Studies.
Arthritis, Rheumatoid
Development and validation of an HPLC-MS/MS method for the determination of filgotinib, a selective Janus kinase 1 inhibitor: Application to a metabolic stability study.
Arthritis, Rheumatoid
Development of a Janus Kinase Inhibitor Prodrug for the Treatment of Rheumatoid Arthritis.
Arthritis, Rheumatoid
Development of Bruton's tyrosine kinase Inhibitors for Rheumatoid Arthritis.
Arthritis, Rheumatoid
Development of In Vitro-In Vivo Correlation for Upadacitinib Extended-Release Tablet Formulation.
Arthritis, Rheumatoid
Development of piperidinyl dipyrrrolopyridine-based dual inhibitors of Janus kinase and Bruton's tyrosine kinase: a potential therapeutic probability to deal with rheumatoid arthritis.
Arthritis, Rheumatoid
Development of severe thrombocytopenia with TAFRO syndrome-like features in a patient with rheumatoid arthritis treated with a Janus kinase inhibitor: A case report.
Arthritis, Rheumatoid
Developments with investigational Janus kinase inhibitors for rheumatoid arthritis.
Arthritis, Rheumatoid
Diamino-1,2,4-triazole derivatives are selective inhibitors of TYK2 and JAK1 over JAK2 and JAK3.
Arthritis, Rheumatoid
Differential expression of the FAK family kinases in rheumatoid arthritis and osteoarthritis synovial tissues.
Arthritis, Rheumatoid
Discovery of 4-Aminoquinoline-3-carboxamide Derivatives as Potent Reversible Bruton's Tyrosine Kinase Inhibitors for the Treatment of Rheumatoid Arthritis.
Arthritis, Rheumatoid
Discovery of Potent and Selective Tricyclic Inhibitors of Bruton's Tyrosine Kinase with Improved Druglike Properties.
Arthritis, Rheumatoid
Discovery of the Macrocycle (9E)-15-(2-(Pyrrolidin-1-yl)ethoxy)-7,12,25-trioxa-19,21,24-triaza-tetracyclo[18.3.1.1(2,5).1(14,18)]hexacosa-1(24),2,4,9,14(26),15,17,20,22-nonaene (SB1578), a Potent Inhibitor of Janus Kinase 2/Fms-LikeTyrosine Kinase-3 (JAK2/FLT3) for the Treatment of Rheumatoid Arthritis.
Arthritis, Rheumatoid
Drug Interactions Between Peficitinib, an Orally Administered, Once-Daily Janus Kinase Inhibitor, and Rosuvastatin in Healthy Subjects.
Arthritis, Rheumatoid
Drug retention of 7 biologics and tofacitinib in biologics-naïve and biologics-switched patients with rheumatoid arthritis: the ANSWER cohort study.
Arthritis, Rheumatoid
Drug retention of secondary biologics or JAK inhibitors after tocilizumab or abatacept failure as first biologics in patients with rheumatoid arthritis -the ANSWER cohort study.
Arthritis, Rheumatoid
Drug survival rates of biological disease-modifying antirheumatic drugs and Janus kinase-inhibitor therapy in 801 rheumatoid arthritis patients: a 14 year-retrospective study from a rheumatology clinic in Japan.
Arthritis, Rheumatoid
Eco-Friendly UPLC-MS/MS Method for Determination of a Fostamatinib Metabolite, Tamatinib, in Plasma: Pharmacokinetic Application in Rats.
Arthritis, Rheumatoid
Effect of Discontinuation or Initiation of Methotrexate or Glucocorticoids on Tofacitinib Efficacy in Patients with Rheumatoid Arthritis: A Post Hoc Analysis.
Arthritis, Rheumatoid
Effect of janus kinase inhibitors and methotrexate combination on malignancy in patients with rheumatoid arthritis: a systematic review and meta-analysis of randomized controlled trials.
Arthritis, Rheumatoid
Effectiveness and safety of tofacitinib in rheumatoid arthritis: a cohort study.
Arthritis, Rheumatoid
Effects of Diabetes Mellitus on the Disposition of Tofacitinib, a Janus Kinase Inhibitor, in Rats.
Arthritis, Rheumatoid
Effects of Fostamatinib (R788), an Oral Spleen Tyrosine Kinase Inhibitor, on Health-related Quality of Life in Patients with Active Rheumatoid Arthritis: Analyses of Patient-reported Outcomes from a Randomized, Double-blind, Placebo-controlled Trial.
Arthritis, Rheumatoid
Effects of Fostamatinib on the Pharmacokinetics of Oral Contraceptive, Warfarin, and the Statins Rosuvastatin and Simvastatin: Results From Phase I Clinical Studies.
Arthritis, Rheumatoid
Effects of fostamatinib, an oral spleen tyrosine kinase inhibitor, in rheumatoid arthritis patients with an inadequate response to methotrexate: results from a phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
Arthritis, Rheumatoid
Effects of Janus kinase inhibitor tofacitinib on circulating serum amyloid A and interleukin-6 during treatment for rheumatoid arthritis.
Arthritis, Rheumatoid
Effects of one-year tofacitinib therapy on bone metabolism in rheumatoid arthritis.
Arthritis, Rheumatoid
Effects of the Janus Kinase Inhibitor, Tofacitinib, on Testicular Leydig Cell Hyperplasia and Adenoma in Rats, and on Prolactin Signaling in Cultured Primary Rat Leydig Cells.
Arthritis, Rheumatoid
Effects of the oral Janus kinase inhibitor tofacitinib on patient-reported outcomes in patients with active rheumatoid arthritis: results of two Phase 2 randomised controlled trials.
Arthritis, Rheumatoid
Effects of tofacitinib monotherapy on patient-reported outcomes in a randomized phase 3 study of patients with active rheumatoid arthritis and inadequate responses to DMARDs.
Arthritis, Rheumatoid
Efficacy and Pharmacodynamic Modeling of the BTK Inhibitor Evobrutinib in Autoimmune Disease Models.
Arthritis, Rheumatoid
Efficacy and safety of baricitinib in 446 patients with rheumatoid arthritis: a real-life multicentre study.
Arthritis, Rheumatoid
Efficacy and Safety of Baricitinib in Chinese Rheumatoid Arthritis Patients and the Subgroup Analyses: Results from Study RA-BALANCE.
Arthritis, Rheumatoid
Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to conventional DMARDs: a randomised, double-blind, placebo-controlled phase III trial (RAJ3).
Arthritis, Rheumatoid
Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III randomised, double-blind, placebo-controlled trial (RAJ4) in Japan.
Arthritis, Rheumatoid
Efficacy and safety of the oral Janus kinase inhibitor peficitinib (ASP015K) monotherapy in patients with moderate to severe rheumatoid arthritis in Japan: a 12-week, randomised, double-blind, placebo-controlled phase IIb study.
Arthritis, Rheumatoid
Efficacy and Safety of Tofacitinib in Chinese Patients with Rheumatoid Arthritis.
Arthritis, Rheumatoid
Efficacy and safety of tofacitinib in older and younger patients with rheumatoid arthritis.
Arthritis, Rheumatoid
Efficacy and safety of tofacitinib in patients with active rheumatoid arthritis: review of key Phase 2 studies.
Arthritis, Rheumatoid
Efficacy and safety of tofacitinib in US and non-US rheumatoid arthritis patients: pooled analyses of phase II and III.
Arthritis, Rheumatoid
Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial.
Arthritis, Rheumatoid
Efficacy and safety of tofacitinib versus baricitinib in patients with rheumatoid arthritis in real clinical practice: analyses with propensity score-based inverse probability of treatment weighting.
Arthritis, Rheumatoid
Efficacy of tofacitinib in patients with rheumatoid arthritis stratified by background methotrexate dose group.
Arthritis, Rheumatoid
Efficacy of tofacitinib monotherapy in methotrexate-naive patients with early or established rheumatoid arthritis.
Arthritis, Rheumatoid
Entangled Conditional Adversarial Autoencoder for de Novo Drug Discovery.
Arthritis, Rheumatoid
Evaluation of disease activity in patients with rheumatoid arthritis treated with tofacitinib by RAPID3: post hoc analyses from two phase 3 trials.
Arthritis, Rheumatoid
Evaluation of the effect of tofacitinib on measured glomerular filtration rate in patients with active rheumatoid arthritis: results from a randomised controlled trial.
Arthritis, Rheumatoid
Exposure vs. response of blood pressure in patients with rheumatoid arthritis following treatment with fostamatinib.
Arthritis, Rheumatoid
Exposure-Response Analyses for Upadacitinib Efficacy in Subjects With Atopic Dermatitis-Analyses of Phase 2b Study to Support Selection of Phase 3 Doses.
Arthritis, Rheumatoid
Exposure-Response Analyses of Upadacitinib Efficacy in Phase II Trials in Rheumatoid Arthritis and Basis for Phase III Dose Selection.
Arthritis, Rheumatoid
Extended-release Once-daily Formulation of Tofacitinib: Evaluation of Pharmacokinetics Compared with Immediate-release Tofacitinib and Impact of Food.
Arthritis, Rheumatoid
Fenebrutinib versus Placebo or Adalimumab in Rheumatoid Arthritis: A Randomized, Double-Blind, Phase II Trial (ANDES Study).
Arthritis, Rheumatoid
Fifty-Two-Week Results of Clinical and Imaging Assessments of a Patient with Rheumatoid Arthritis Complicated by Systemic Sclerosis with Interstitial Pneumonia and Type 1 Diabetes despite Multiple Disease-Modifying Antirheumatic Drug Therapy That Was Successfully Treated with Baricitinib: A Novel Case Report.
Arthritis, Rheumatoid
Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1).
Arthritis, Rheumatoid
Filgotinib (GLPG0634/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2).
Arthritis, Rheumatoid
Filgotinib in Rheumatoid Arthritis: A Profile of Its Use.
Arthritis, Rheumatoid
Filgotinib, a JAK1 Inhibitor, Modulates Disease-Related Biomarkers in Rheumatoid Arthritis: Results from Two Randomized, Controlled Phase 2b Trials.
Arthritis, Rheumatoid
Filgotinib, a novel JAK1-preferential inhibitor for the treatment of rheumatoid arthritis: An overview from clinical trials.
Arthritis, Rheumatoid
Fostamatinib, a Syk inhibitor prodrug for the treatment of inflammatory diseases.
Arthritis, Rheumatoid
Fostamatinib, an oral spleen tyrosine kinase inhibitor, in the treatment of rheumatoid arthritis: a meta-analysis of randomized controlled trials.
Arthritis, Rheumatoid
Frequency of Prescription Claims for Drugs that May Interact with Janus Kinase Inhibitors Among Patients with Rheumatoid Arthritis in the US.
Arthritis, Rheumatoid
Helicobacter canis bacteraemia in a rheumatoid arthritis patient treated with tofacitinib: case report and literature review.
Arthritis, Rheumatoid
Herpes zoster as a cause of atypical chronic ulcerations associated with tofacitinib.
Arthritis, Rheumatoid
High avidity autoreactive T cells with a low signalling capacity through the T-cell receptor: central to rheumatoid arthritis pathogenesis?
Arthritis, Rheumatoid
HM71224, a novel Bruton's tyrosine kinase inhibitor, suppresses B cell and monocyte activation and ameliorates arthritis in a mouse model: a potential drug for rheumatoid arthritis.
Arthritis, Rheumatoid
Hypereosinophilic syndrome-a rare adverse event of anti-cytokine treatment in rheumatoid arthritis resolved after Janus kinase inhibitor therapy.
Arthritis, Rheumatoid
Identification of distinct disease activity trajectories in methotrexate-naïve patients with rheumatoid arthritis receiving tofacitinib over 24 months.
Arthritis, Rheumatoid
Identification of pyrazolopyridine derivatives as novel spleen tyrosine kinase inhibitors.
Arthritis, Rheumatoid
Immunologic effects of chronic administration of tofacitinib, a Janus kinase inhibitor, in cynomolgus monkeys and rats - Comparison of juvenile and adult responses.
Arthritis, Rheumatoid
Impact of Different JAK Inhibitors and Methotrexate on Lymphocyte Proliferation and DNA Damage.
Arthritis, Rheumatoid
Impact of Janus kinase inhibitors on risk of cardiovascular events in patients with rheumatoid arthritis: systematic review and meta-analysis of randomised controlled trials.
Arthritis, Rheumatoid
Impact of Janus kinase inhibitors on the risk of cardiovascular events in patients with rheumatoid arthritis: systematic review and meta-analysis of randomised controlled trials.
Arthritis, Rheumatoid
Impaired T cell receptor signaling and development of T cell-mediated autoimmune arthritis.
Arthritis, Rheumatoid
Improved pain, physical functioning, and health status in rheumatoid arthritis patients treated with CP-690,550, an orally active Janus kinase (JAK)inhibitor: results from a randomized, double-blind, placebo-controlled trial.
Arthritis, Rheumatoid
In Vitro and In Vivo Antiviral Activity of Gingerenone A on Influenza A Virus Is Mediated by Targeting Janus Kinase 2.
Arthritis, Rheumatoid
Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data.
Arthritis, Rheumatoid
Incidence Rates of Interstitial Lung Disease Events in Tofacitinib-Treated Rheumatoid Arthritis Patients: Post Hoc Analysis From 21 Clinical Trials.
Arthritis, Rheumatoid
Infection risk in patients undergoing treatment for inflammatory arthritis: non-biologics versus biologics.
Arthritis, Rheumatoid
Infections in baricitinib clinical trials for patients with active rheumatoid arthritis.
Arthritis, Rheumatoid
Influence of age and renal impairment on the steady state pharmacokinetics of filgotinib, a selective JAK1 inhibitor.
Arthritis, Rheumatoid
Influence of Janus Kinase Inhibition on Interleukin 6-mediated Induction of Acute-phase Serum Amyloid A in Rheumatoid Synovium.
Arthritis, Rheumatoid
Inhibition of JAK/STAT signaling in rheumatologic disorders: the expanding spectrum.
Arthritis, Rheumatoid
Inhibition of JAK/STAT signaling pathway in rheumatoid synovial fibroblasts using small molecule compounds.
Arthritis, Rheumatoid
Inhibition of Spleen Tyrosine Kinase for Rheumatoid Arthritis.
Arthritis, Rheumatoid
Inhibition of spleen tyrosine kinase in the treatment of rheumatoid arthritis.
Arthritis, Rheumatoid
Initial Experience With Tofacitinib in Clinical Practice: Treatment Patterns and Costs of Tofacitinib Administered as Monotherapy or in Combination With Conventional Synthetic DMARDs in 2 US Health Care Claims Databases.
Arthritis, Rheumatoid
Interactions of janus kinase inhibitors with drug transporters and consequences for pharmacokinetics and toxicity.
Arthritis, Rheumatoid
Interpretation of network meta-analyses of the efficacy of rheumatoid arthritis drugs.
Arthritis, Rheumatoid
Investigation of Potential Drug-Drug Interactions between Peficitinib (ASP015K) and Methotrexate in Patients with Rheumatoid Arthritis.
Arthritis, Rheumatoid
Investigational Bruton's tyrosine kinase inhibitors for the treatment of rheumatoid arthritis.
Arthritis, Rheumatoid
JAK inhibition in inflammatory bowel disease.
Arthritis, Rheumatoid
JAK inhibition increases bone mass in steady-state conditions and ameliorates pathological bone loss by stimulating osteoblast function.
Arthritis, Rheumatoid
JAK inhibition with tofacitinib suppresses arthritic joint structural damage through decreased RANKL production.
Arthritis, Rheumatoid
JAK inhibitors and infections risk: focus on herpes zoster.
Arthritis, Rheumatoid
JAK Inhibitors in Rheumatoid Arthritis: An Evidence-Based Review on the Emerging Clinical Data.
Arthritis, Rheumatoid
JAK Inhibitors in Rheumatology: Implications for Paediatric Syndromes?
Arthritis, Rheumatoid
JAK inhibitors: A broadening approach in rheumatoid arthritis.
Arthritis, Rheumatoid
JAK Inhibitors: What Is New?
Arthritis, Rheumatoid
JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib.
Arthritis, Rheumatoid
JAK-inhibitor tofacitinib suppresses interferon alfa production by plasmacytoid dendritic cells and inhibits arthrogenic and antiviral effects of interferon alfa.
Arthritis, Rheumatoid
JAK-Inhibitors for the Treatment of Rheumatoid Arthritis: A Focus on the Present and an Outlook on the Future.
Arthritis, Rheumatoid
JAK-STAT inhibitors for the treatment of immunomediated diseases.
Arthritis, Rheumatoid
Janus kinase (JAK)-inhibitors and coronavirus disease 2019 (Covid-19) outcomes: a systematic review and meta-analysis.
Arthritis, Rheumatoid
Janus kinase inhibitors for rheumatoid arthritis.
Arthritis, Rheumatoid
Janus kinase inhibitors for the treatment of rheumatoid arthritis demonstrate similar profiles of in vitro cytokine receptor inhibition.
Arthritis, Rheumatoid
Janus Kinase Inhibitors for the Treatment of Rheumatoid Arthritis.
Arthritis, Rheumatoid
Janus kinase inhibitors prevent migration of rheumatoid arthritis neutrophils towards interleukin-8, but do not inhibit priming of the respiratory burst or reactive oxygen species production.
Arthritis, Rheumatoid
Joint Location-Specific JAK-STAT Signaling in Rheumatoid Arthritis Fibroblast-like Synoviocytes.
Arthritis, Rheumatoid
Kinase inhibitors in the treatment of immune-mediated disease.
Arthritis, Rheumatoid
Lipid profile and effect of statin treatment in pooled phase II and phase III baricitinib studies.
Arthritis, Rheumatoid
Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5?years: integrated analysis of data from the global clinical trials.
Arthritis, Rheumatoid
Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme.
Arthritis, Rheumatoid
Malignancy and Janus Kinase Inhibition.
Arthritis, Rheumatoid
Managing Osteoporosis and Joint Damage in Patients with Rheumatoid Arthritis: An Overview.
Arthritis, Rheumatoid
Mechanism of baricitinib supports artificial intelligence-predicted testing in COVID-19 patients.
Arthritis, Rheumatoid
Metformin one in a million efficient medicines for rheumatoid arthritis complications: inflammation, Osteoblastogenesis, Cardiovascular disease, Malignancies.
Arthritis, Rheumatoid
Methotrexate and a spleen tyrosine kinase inhibitor cooperate to inhibit responses to peripheral blood B cells in rheumatoid arthritis.
Arthritis, Rheumatoid
Model-Based Comparison of Dose-Response Profiles of Tofacitinib in Japanese Versus Western Rheumatoid Arthritis Patients.
Arthritis, Rheumatoid
Model-Informed Development and Registration of a Once-Daily Regimen of Extended-Release Tofacitinib.
Arthritis, Rheumatoid
Modeling Combined Anti-Inflammatory Effects of Dexamethasone and Tofacitinib in Arthritic Rats.
Arthritis, Rheumatoid
Modulation of activation-loop phosphorylation by JAK inhibitors is binding mode dependent.
Arthritis, Rheumatoid
Molecular modeling studies of pyrrolo[2,3-d]pyrimidin-4-amine derivatives as JAK1 inhibitors based on 3D-QSAR, molecular docking, molecular dynamics (MD) and MM-PBSA calculations.
Arthritis, Rheumatoid
More Unnecessary Imaginary Worlds - Part 1: The Institute for Clinical and Economic Review's Evidence Report on Janus Kinase (JAK) Inhibitors in Rheumatoid Arthritis.
Arthritis, Rheumatoid
Nanoparticle-delivered siRNA targeting Bruton's tyrosine kinase for rheumatoid arthritis therapy.
Arthritis, Rheumatoid
New drug therapies on the horizon for IBD.
Arthritis, Rheumatoid
New insights into IFN-? in rheumatoid arthritis: role in the era of JAK inhibitors.
Arthritis, Rheumatoid
Novel 1H-pyrazolo[3,4-d]pyrimidin-6-amino derivatives as potent selective Janus kinase 3 (JAK3) inhibitors. Evaluation of their improved effect for the treatment of rheumatoid arthritis.
Arthritis, Rheumatoid
Novel concepts and treatments for autoimmune disease: ten focal points.
Arthritis, Rheumatoid
Off-label studies on tofacitinib in dermatology: a review.
Arthritis, Rheumatoid
Open-label tofacitinib and double-blind atorvastatin in rheumatoid arthritis patients: a randomised study.
Arthritis, Rheumatoid
Oral janus kinase inhibitor for the treatment of rheumatoid arthritis: tofacitinib.
Arthritis, Rheumatoid
Orchestrated modulation of rheumatoid arthritis via crosstalking intracellular signaling pathways.
Arthritis, Rheumatoid
Palmoplantar Pustulosis-like Eruption Induced by Baricitinib for Treatment of Rheumatoid Arthritis.
Arthritis, Rheumatoid
Patient Preferences Regarding Rheumatoid Arthritis Therapies: A Conjoint Analysis.
Arthritis, Rheumatoid
Patient- and physician-reported outcomes from two phase 3 randomized studies (RAJ3 and RAJ4) of peficitinib (ASP015K) in Asian patients with rheumatoid arthritis.
Arthritis, Rheumatoid
Peficitinib hydrobromide to treat rheumatoid arthritis.
Arthritis, Rheumatoid
Peficitinib Inhibits the Chemotactic Activity of Monocytes via Proinflammatory Cytokine Production in Rheumatoid Arthritis Fibroblast-Like Synoviocytes.
Arthritis, Rheumatoid
Peficitinib: First Global Approval.
Arthritis, Rheumatoid
Persistence of Tofacitinib in the Treatment of Rheumatoid Arthritis in Open-Label, Long-Term Extension Studies up to 9.5 Years.
Arthritis, Rheumatoid
PF-06651600, a Dual JAK3/TEC Family Kinase Inhibitor.
Arthritis, Rheumatoid
Pharmacokinetic Drug Interaction between Tofacitinib and Voriconazole in Rats.
Arthritis, Rheumatoid
Pharmacokinetic Properties of Fostamatinib in Patients With Renal or Hepatic Impairment: Results From 2 Phase I Clinical Studies.
Arthritis, Rheumatoid
Pharmacokinetic-pharmacodynamic modeling of fostamatinib efficacy on ACR20 to support dose selection in patients with rheumatoid arthritis (RA).
Arthritis, Rheumatoid
Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Modeling of Filgotinib (GLPG0634), a Selective JAK1 Inhibitor, in Support of Phase IIB Dose Selection.
Arthritis, Rheumatoid
Pharmacokinetics and Safety of a Single Oral Dose of Peficitinib (ASP015K) in Japanese Subjects With Normal and Impaired Hepatic Function.
Arthritis, Rheumatoid
Pharmacokinetics of Fostamatinib, a SYK Inhibitor, in Healthy Human Subjects Following Single and Multiple Oral Dosing In Three Phase I Studies.
Arthritis, Rheumatoid
Pharmacokinetics of Upadacitinib With the Clinical Regimens of the Extended-Release Formulation Utilized in Rheumatoid Arthritis Phase 3 Trials.
Arthritis, Rheumatoid
Pharmacophore modeling and virtual screening in search of novel Bruton's tyrosine kinase inhibitors.
Arthritis, Rheumatoid
Phase 1 Dose-Escalation Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Tofacitinib in Japanese Healthy Volunteers.
Arthritis, Rheumatoid
Placebo and nocebo responses in randomized controlled trials of Janus kinase inhibitor monotherapy for rheumatoid arthritis : A meta-analysis.
Arthritis, Rheumatoid
Placebo and nocebo responses in randomized controlled trials of non-tumor necrosis factor biologics and Janus kinase inhibitors in patients with active rheumatoid arthritis showing insufficient response to tumor necrosis factor inhibitors: A meta-analysis.
Arthritis, Rheumatoid
Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis.
Arthritis, Rheumatoid
Pneumocystis Jirovecii Pneumonia after Initiation of Tofacitinib Therapy in Rheumatoid Arthritis: Case-Based Review.
Arthritis, Rheumatoid
Population Pharmacokinetics of Upadacitinib in Healthy Subjects and Subjects with Rheumatoid Arthritis: Analyses of Phase I and II Clinical Trials.
Arthritis, Rheumatoid
Population Pharmacokinetics of Upadacitinib Using the Immediate-Release and Extended-Release Formulations in Healthy Subjects and Subjects with Rheumatoid Arthritis: Analyses of Phase I-III Clinical Trials.
Arthritis, Rheumatoid
Population Pharmacokinetics, Efficacy Exposure-response Analysis, and Model-based Meta-analysis of Fenebrutinib in Subjects with Rheumatoid Arthritis [corrected].
Arthritis, Rheumatoid
Postapproval Comparative Safety Study of Tofacitinib and Biological Disease-Modifying Antirheumatic Drugs: 5-Year Results from a United States-Based Rheumatoid Arthritis Registry.
Arthritis, Rheumatoid
Potent anti-inflammatory effects of the narrow spectrum kinase inhibitor RV1088 on rheumatoid arthritis synovial membrane cells.
Arthritis, Rheumatoid
Preclinical to clinical translation of tofacitinib, a Janus kinase inhibitor, in rheumatoid arthritis.
Arthritis, Rheumatoid
Preferential Inhibition of JAK1 Relative to JAK3 by Upadacitinib: Exposure-Response Analyses of Ex Vivo Data From 2 Phase 1 Clinical Trials and Comparison to Tofacitinib.
Arthritis, Rheumatoid
Pregnancy Outcomes in the Tofacitinib Safety Databases for Rheumatoid Arthritis and Psoriasis.
Arthritis, Rheumatoid
Prevention of fostamatinib-induced blood pressure elevation by antihypertensive agents.
Arthritis, Rheumatoid
Progress in understanding the safety and efficacy of Janus kinase inhibitors for treatment of rheumatoid arthritis.
Arthritis, Rheumatoid
PROTAC-Mediated Degradation of Janus Kinase as a Therapeutic Strategy for Cancer and Rheumatoid Arthritis.
Arthritis, Rheumatoid
Protein kinase small molecule inhibitors for rheumatoid arthritis: Medicinal chemistry/clinical perspectives.
Arthritis, Rheumatoid
Protein tyrosine phosphatase non-receptor 22 and C-Src tyrosine kinase genes are down-regulated in patients with rheumatoid arthritis.
Arthritis, Rheumatoid
Quantitative tracking of inflammatory activity at the peak and trough plasma levels of tofacitinib, a Janus kinase inhibitor, via in vivo 18 F-FDG PET.
Arthritis, Rheumatoid
Rapid Onset of Efficacy of Baricitinib in Chinese Patients with Moderate to Severe Rheumatoid Arthritis: Results from Study RA-BALANCE.
Arthritis, Rheumatoid
Rapid remission of refractory synovitis, acne, pustulosis, hyperostosis, and osteitis syndrome in response to the Janus kinase inhibitor tofacitinib: A case report.
Arthritis, Rheumatoid
Rational design of highly selective spleen tyrosine kinase inhibitors.
Arthritis, Rheumatoid
Re-establishment of efficacy of tofacitinib, an oral JAK inhibitor, after temporary discontinuation in patients with rheumatoid arthritis.
Arthritis, Rheumatoid
Real-World Analysis of Therapeutic Patterns in Patients Affected by Rheumatoid Arthritis in Italy: A Focus on Baricitinib.
Arthritis, Rheumatoid
Real-World Evidence to Contextualize Clinical Trial Results and Inform Regulatory Decisions: Tofacitinib Modified-Release Once-Daily vs Immediate-Release Twice-Daily for Rheumatoid Arthritis.
Arthritis, Rheumatoid
Real-world experience with tofacitinib for treatment of rheumatoid arthritis.
Arthritis, Rheumatoid
Recent advances in the opioid mu receptor based pharmacotherapy for rheumatoid arthritis.
Arthritis, Rheumatoid
Regulation of inflammatory responses in tumor necrosis factor - activated and rheumatoid arthritis synovial macrophages by Janus kinase inhibitors.
Arthritis, Rheumatoid
Remission of anti-tumor necrosis factor-? antibody-induced palmoplantar pustulosis with the Janus kinase inhibitor baricitinib in a patient with rheumatoid arthritis.
Arthritis, Rheumatoid
Repurposed JAK1/JAK2 Inhibitor Reverses Established Autoimmune Insulitis in NOD Mice.
Arthritis, Rheumatoid
Resolution of ocular and mediastinal sarcoidosis after Janus kinase inhibitor therapy for concomitant rheumatoid arthritis.
Arthritis, Rheumatoid
Response to: 'Impact of Janus kinase inhibitors on the risk of cardiovascular events in patients with rheumatoid arthritis: systematic review and meta-analysis of randomised controlled trials' by Lee and Song.
Arthritis, Rheumatoid
Risk of infection associated with Janus Kinase (JAK) inhibitors and biological therapies in inflammatory intestinal disease and rheumatoid arthritis. Prevention strategies.
Arthritis, Rheumatoid
RN486, a Selective Bruton's Tyrosine Kinase Inhibitor, Abrogates Immune Hypersensitivity Responses and Arthritis in Rodents.
Arthritis, Rheumatoid
Role of Janus Kinase inhibitors in rheumatoid arthritis treatment.
Arthritis, Rheumatoid
Role of spleen tyrosine kinase inhibitors in the management of rheumatoid arthritis.
Arthritis, Rheumatoid
Safety and effectiveness of peficitinib (ASP015K) in patients with rheumatoid arthritis: interim data (22.7 months mean peficitinib treatment) from a long-term, open-label extension study in Japan, Korea, and Taiwan.
Arthritis, Rheumatoid
Safety and Efficacy of Poseltinib, Bruton's Tyrosine Kinase-Inhibitor, in Patients With Rheumatoid Arthritis: A Randomized, Double-Blind, Placebo-Controlled, 2-Part Phase-2 Study.
Arthritis, Rheumatoid
Safety and Efficacy of Tofacitinib, an Oral Janus Kinase Inhibitor, for the Treatment of Rheumatoid Arthritis in Open-label, Longterm Extension Studies.
Arthritis, Rheumatoid
Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial.
Arthritis, Rheumatoid
Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial.
Arthritis, Rheumatoid
Safety and maintenance of response for tofacitinib monotherapy and combination therapy in rheumatoid arthritis: an analysis of pooled data from open-label long-term extension studies.
Arthritis, Rheumatoid
Safety of the Methotrexate-leflunomide Combination in Rheumatoid Arthritis: Results of a Multicentric, Registry-based, Cohort Study (BiobadaBrasil).
Arthritis, Rheumatoid
Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in Treatment.
Arthritis, Rheumatoid
Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme.
Arthritis, Rheumatoid
Safety signal detection and evaluation in clinical development programs: A case study of tofacitinib.
Arthritis, Rheumatoid
Selective Janus kinase inhibitors: Promising drugs for rheumatoid arthritis.
Arthritis, Rheumatoid
Selective spleen tyrosine kinase inhibition delays autoimmune arthritis in mice.
Arthritis, Rheumatoid
Selectivity of Janus Kinase Inhibitors in Rheumatoid Arthritis and Other Immune-Mediated Inflammatory Diseases: Is Expectation the Root of All Headache?
Arthritis, Rheumatoid
Significant Species Difference in Amide Hydrolysis of GDC-0834, a Novel Potent and Selective Bruton's Tyrosine Kinase (BTK) Inhibitor.
Arthritis, Rheumatoid
Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis.
Arthritis, Rheumatoid
Specific inhibition of spleen tyrosine kinase suppresses leukocyte immune function and inflammation in animal models of rheumatoid arthritis.
Arthritis, Rheumatoid
Spectrophotometric method to quantify tofacitinib in lyotropic liquid crystalline nanoparticles and skin layers: Application in ex vivo dermal distribution studies.
Arthritis, Rheumatoid
Spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis.
Arthritis, Rheumatoid
Spleen tyrosine kinase inhibitors for rheumatoid arthritis: where are we now?
Arthritis, Rheumatoid
Spleen tyrosine kinase: a novel target for therapeutic intervention of rheumatoid arthritis.
Arthritis, Rheumatoid
Spleen tyrosine kinases: biology, therapeutic targets and drugs.
Arthritis, Rheumatoid
Stereochemical Differences in Fluorocyclopropyl Amides Enable Tuning of Btk Inhibition and Off-Target Activity.
Arthritis, Rheumatoid
Structural damage progression in patients with early rheumatoid arthritis treated with methotrexate, baricitinib, or baricitinib plus methotrexate based on clinical response in the phase 3 RA-BEGIN study.
Arthritis, Rheumatoid
Structure Based Drug Design of RN486, a Potent and Selective Bruton's Tyrosine Kinase (BTK) Inhibitor, for the Treatment of Rheumatoid Arthritis.
Arthritis, Rheumatoid
Successful Treatment of Severe Alopecia Areata With Oral or Topical Tofacitinib.
Arthritis, Rheumatoid
Super-enhancers delineate disease-associated regulatory nodes in T cells.
Arthritis, Rheumatoid
Switching between Janus kinase inhibitor upadacitinib and adalimumab following insufficient response: efficacy and safety in patients with rheumatoid arthritis.
Arthritis, Rheumatoid
Switching from adalimumab to tofacitinib in the treatment of patients with rheumatoid arthritis.
Arthritis, Rheumatoid
Syk kinase inhibitors for rheumatoid arthritis: trials and tribulations.
Arthritis, Rheumatoid
Synovial B cells of rheumatoid arthritis express ZAP-70 which increases the survival and correlates with the inflammatory and autoimmune phenotype.
Arthritis, Rheumatoid
Synovial fluid-derived T helper 17 cells correlate with inflammatory activity in arthritis, irrespectively of diagnosis.
Arthritis, Rheumatoid
Synthesis and biological activity of thieno[3,2-d]pyrimidines as potent JAK3 inhibitors for the treatment of idiopathic pulmonary fibrosis.
Arthritis, Rheumatoid
Systematic review and meta-analysis of serious infections with tofacitinib and biologic disease-modifying antirheumatic drug treatment in rheumatoid arthritis clinical trials.
Arthritis, Rheumatoid
Systemic inflammatory responses after orthopedic surgery in patients with rheumatoid arthritis treated with tofacitinib.
Arthritis, Rheumatoid
Tapering Janus kinase inhibitors in rheumatoid arthritis with low disease activity or remission: reality or dream?
Arthritis, Rheumatoid
The autoimmunity-associated BLK haplotype exhibits cis-regulatory effects on mRNA and protein expression that are prominently observed in B cells early in development.
Arthritis, Rheumatoid
The effect of mild and moderate hepatic impairment on the pharmacokinetics of tofacitinib, an orally active Janus kinase inhibitor.
Arthritis, Rheumatoid
The Effect of Verapamil, a P-Glycoprotein Inhibitor, on the Pharmacokinetics of Peficitinib, an Orally Administered, Once-Daily JAK Inhibitor.
Arthritis, Rheumatoid
The effectiveness of tofacitinib, a novel Janus kinase inhibitor, in the treatment of rheumatoid arthritis: a systematic review and meta-analysis.
Arthritis, Rheumatoid
The effects of the spleen tyrosine kinase inhibitor fostamatinib on ambulatory blood pressure in patients with active rheumatoid arthritis: results of the OSKIRA-ABPM (ambulatory blood pressure monitoring) randomized trial.
Arthritis, Rheumatoid
The emerging safety profile of JAK inhibitors in rheumatic disease.
Arthritis, Rheumatoid
The JAK inhibitor CP-690,550 (tofacitinib) inhibits TNF-induced chemokine expression in fibroblast-like synoviocytes: autocrine role of type I interferon.
Arthritis, Rheumatoid
The JAK inhibitor tofacitinib ameliorates immune?mediated liver injury in mice.
Arthritis, Rheumatoid
The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis.
Arthritis, Rheumatoid
The JAK inhibitor, tofacitinib, reduces the T cell stimulatory capacity of human monocyte-derived dendritic cells.
Arthritis, Rheumatoid
The Janus kinase 1/2 inhibitor baricitinib reduces biomarkers of joint destruction in moderate to severe rheumatoid arthritis.
Arthritis, Rheumatoid
The Janus Kinase inhibitor tofacitinib impacts human dendritic cell differentiation and favours M1 macrophage development.
Arthritis, Rheumatoid
The mechanism of action of tofacitinib - an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis.
Arthritis, Rheumatoid
The oral spleen tyrosine kinase inhibitor fostamatinib attenuates inflammation and atherogenesis in low-density lipoprotein receptor-deficient mice.
Arthritis, Rheumatoid
The Pharmacokinetics, Pharmacodynamics and Safety of Baricitinib, an Oral JAK 1/2 Inhibitor, in Healthy Volunteers.
Arthritis, Rheumatoid
The Safety Profile of Upadacitinib in Patients with Rheumatoid Arthritis in Japan.
Arthritis, Rheumatoid
Therapeutic Maintenance of Baricitinib and Tofacitinib in Real Life.
Arthritis, Rheumatoid
Thromboembolism with Janus Kinase (JAK) Inhibitors for Rheumatoid Arthritis: How Real is the Risk?
Arthritis, Rheumatoid
Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial.
Arthritis, Rheumatoid
Tofacitinib 5 mg Twice Daily in Patients with Rheumatoid Arthritis and Inadequate Response to Disease-Modifying Antirheumatic Drugs: A Comprehensive Review of Phase 3 Efficacy and Safety.
Arthritis, Rheumatoid
Tofacitinib ameliorates atherosclerosis and reduces foam cell formation in apoE deficient mice.
Arthritis, Rheumatoid
Tofacitinib downregulates antiviral immune defence in keratinocytes and reduces T cell activation.
Arthritis, Rheumatoid
Tofacitinib facilitates the expansion of myeloid-derived suppressor cells and ameliorates arthritis in SKG mice.
Arthritis, Rheumatoid
Tofacitinib for the treatment of psoriasis and psoriatic arthritis.
Arthritis, Rheumatoid
Tofacitinib in Combination with Conventional DMARDs in Patients with Active Rheumatoid Arthritis: PROs from a Phase 3 Randomized Controlled Trial.
Arthritis, Rheumatoid
Tofacitinib in Combination with Methotrexate in Patients with Rheumatoid Arthritis: Clinical Efficacy, Radiographic and Safety Outcomes from the 24-Month Phase 3 ORAL Scan Study.
Arthritis, Rheumatoid
Tofacitinib in combination with methotrexate in patients with rheumatoid arthritis: patient-reported outcomes from the 24-month Phase 3 ORAL Scan study.
Arthritis, Rheumatoid
Tofacitinib in the treatment of Indian patients with rheumatoid arthritis: A post hoc analysis of efficacy and safety in Phase 3 and long-term extension studies over 7 years.
Arthritis, Rheumatoid
Tofacitinib in the treatment of moderate-to-severe rheumatoid arthritis: a cost-effectiveness analysis compared with adalimumab in Taiwan.
Arthritis, Rheumatoid
Tofacitinib or adalimumab versus placebo in rheumatoid arthritis.
Arthritis, Rheumatoid
Tofacitinib prevents radiographic progression in rheumatoid arthritis.
Arthritis, Rheumatoid
Tofacitinib restores the balance of ??Treg/??T17 cells in rheumatoid arthritis by inhibiting the NLRP3 inflammasome.
Arthritis, Rheumatoid
Tofacitinib suppresses disease activity and febrile attacks in a patient with coexisting rheumatoid arthritis and familial Mediterranean fever.
Arthritis, Rheumatoid
Tofacitinib treatment aggravates Staphylococcus aureus septic arthritis, but attenuates sepsis and enterotoxin induced shock in mice.
Arthritis, Rheumatoid
Tofacitinib Use in Adults with Chronic Inflammatory Disease During the Severe Acute Respiratory Syndrome Coronavirus 2 Pandemic: What Is Known So Far?
Arthritis, Rheumatoid
Tofacitinib versus Biologic Treatments in Moderate-to-Severe Rheumatoid Arthritis Patients Who Have Had an Inadequate Response to Nonbiologic DMARDs: Systematic Literature Review and Network Meta-Analysis.
Arthritis, Rheumatoid
Tofacitinib Versus Biologic Treatments in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Tumor Necrosis Factor Inhibitors: Results From a Network Meta-analysis.
Arthritis, Rheumatoid
Tofacitinib versus methotrexate in rheumatoid arthritis.
Arthritis, Rheumatoid
Tofacitinib with conventional synthetic disease-modifying antirheumatic drugs in Chinese patients with rheumatoid arthritis: Patient-reported outcomes from a Phase 3 randomized controlled trial.
Arthritis, Rheumatoid
Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study.
Arthritis, Rheumatoid
Tofacitinib, an oral Janus kinase inhibitor, for the treatment of Latin American patients with rheumatoid arthritis: Pooled efficacy and safety analyses of Phase 3 and long-term extension studies.
Arthritis, Rheumatoid
Tofacitinib, an oral Janus kinase inhibitor, in patients from Brazil with rheumatoid arthritis: Pooled efficacy and safety analyses.
Arthritis, Rheumatoid
Tofacitinib, an oral Janus kinase inhibitor, in patients from Mexico with rheumatoid arthritis: Pooled efficacy and safety analyses from Phase 3 and LTE studies.
Arthritis, Rheumatoid
Tofacitinib, an oral Janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical development programme.
Arthritis, Rheumatoid
Tofacitinib, an Oral Janus Kinase Inhibitor: Pooled Efficacy and Safety Analyses in an Australian Rheumatoid Arthritis Population.
Arthritis, Rheumatoid
Tofacitinib-induced subacute cutaneous lupus erythematosus in a patient with rheumatoid arthritis.
Arthritis, Rheumatoid
Tofacitinib: Real-World Data and Treatment Persistence in Rheumatoid Arthritis.
Arthritis, Rheumatoid
Tofacitinib: The First Janus Kinase (JAK) inhibitor for the treatment of rheumatoid arthritis.
Arthritis, Rheumatoid
Tolerogenic Dendritic Cells Generated with Tofacitinib Ameliorate Experimental Autoimmune Encephalomyelitis through Modulation of Th17/Treg Balance.
Arthritis, Rheumatoid
Treating active rheumatoid arthritis with Janus kinase inhibitors.
Arthritis, Rheumatoid
Treatment of rheumatoid arthritis with a Syk kinase inhibitor: a twelve-week, randomized, placebo-controlled trial.
Arthritis, Rheumatoid
Treatment Persistence and Healthcare Costs Among Patients with Rheumatoid Arthritis After a Change in Targeted Therapy.
Arthritis, Rheumatoid
Trial of Upadacitinib or Abatacept in Rheumatoid Arthritis.
Arthritis, Rheumatoid
Two-Year Safety and Effectiveness of Peficitinib in Moderate-To-Severe Rheumatoid Arthritis: A Phase IIb, Open-Label Extension Study.
Arthritis, Rheumatoid
Tyrosine kinase inhibitors as potential drugs for B-cell lymphoid malignancies and autoimmune disorders.
Arthritis, Rheumatoid
Tyrosine kinases regulate chondrocyte hypertrophy: promising drug targets for Osteoarthritis.
Arthritis, Rheumatoid
Ultrasound efficacy of targeted-synthetic disease-modifying anti-rheumatic drug treatment in rheumatoid arthritis: a multicenter prospective cohort study in Japan.
Arthritis, Rheumatoid
Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study.
Arthritis, Rheumatoid
Upadacitinib Pharmacokinetics and Exposure-Response Analyses of Efficacy and Safety in Psoriatic Arthritis Patients - Analyses of Phase 3 Clinical Trials.
Arthritis, Rheumatoid
Upadacitinib: First Approval.
Arthritis, Rheumatoid
Use of a risk characterisation approach to contextualise the safety profile of new rheumatoid arthritis treatments: a case study using tofacitinib.
Arthritis, Rheumatoid
Use of Early Clinical Trial Data to Support Thorough QT Study Waiver for Upadacitinib and Utility of Food Effect to Demonstrate ECG Assay Sensitivity.
Arthritis, Rheumatoid
Use of Tofacitinib for the Treatment of Arthritis Associated With Ulcerative Colitis.
Arthritis, Rheumatoid
Using ovality to predict nonmutagenic, orally efficacious pyridazine amides as cell specific spleen tyrosine kinase inhibitors.
Arthritis, Rheumatoid
Utility of a simplified ultrasonography scoring system among patients with rheumatoid arthritis: A multicenter cohort study.
Arthritis, Rheumatoid
Utilizing structure based drug design and metabolic soft spot identification to optimize the in vitro potency and in vivo pharmacokinetic properties leading to the discovery of novel reversible Bruton's tyrosine kinase inhibitors.
Arthritis, Rheumatoid
VX-509 (Decernotinib)-Mediated CYP3A Time-Dependent Inhibition: An Aldehyde Oxidase Metabolite as a Perpetrator of Drug-Drug Interactions.
Arthritis, Rheumatoid
Worldwide, 3-Year, Post-Marketing Surveillance Experience with Tofacitinib in Rheumatoid Arthritis.
Arthritis, Rheumatoid
ZYBT1, a potent, irreversible Bruton's Tyrosine Kinase (BTK) inhibitor that inhibits the C481S BTK with profound efficacy against arthritis and cancer.
Arthritis, Rheumatoid
[JAK inhibitors in the management of rheumatoid arthritis].
Arthritis, Rheumatoid
[JAK inhibitors: Perspectives in internal medicine].
Arthritis, Rheumatoid
[Modern disease-modifying antirheumatic drugs].
Arthritis, Rheumatoid
[Severe Hepatitis E virus infection in a patient with rheumatoid arthritis treated with baricitinib].
Arthritis, Rheumatoid
[Small molecules treatment in rheumatoid arthritis].
Arthritis, Rheumatoid
[Tofacitinib].
Aspergillosis
Cerebral Invasive Aspergillosis in a Case of Chronic Lymphocytic Leukemia with Bruton Tyrosine Kinase Inhibitor.
Aspergillosis
Ibrutinib in PCNSL: The Curious Cases of Clinical Responses and Aspergillosis.
Aspergillosis
Neurologic Complications in Patients With Cancer.
Asthenozoospermia
Correlative study on the JAK-STAT/PSM?3 signal transduction pathway in asthenozoospermia.
Asthma
A novel druglike spleen tyrosine kinase binder prevents anaphylactic shock when administered orally.
Asthma
A novel Syk kinase inhibitor suitable for inhalation: R-343(?)--WO-2009031011.
Asthma
Attenuation of immunological symptoms of allergic asthma in mice lacking the tyrosine kinase ITK.
Asthma
Banhahubak-Tang Tablet, a Standardized Medicine Attenuates Allergic Asthma via Inhibition of Janus Kinase 1 (JAK1)/ Signal Transducer and Activator of Transcription 6 (STAT6) Signal Pathway.
Asthma
Chemical genetic transcriptional fingerprinting for selectivity profiling of kinase inhibitors.
Asthma
Design and Synthesis of Novel Amino-triazine Analogues as Selective Bruton's Tyrosine Kinase Inhibitors for Treatment of Rheumatoid Arthritis.
Asthma
Discovery and optimization of indazoles as potent and selective interleukin-2 inducible T cell kinase (ITK) inhibitors.
Asthma
Discovery of dual ZAP70 and Syk kinases inhibitors by docking into a rare C-helix-out conformation of Syk.
Asthma
Effects of a Janus kinase inhibitor, pyridone 6, on airway responses in a murine model of asthma.
Asthma
Eighty-eight variants highlight the role of T cell regulation and airway remodeling in asthma pathogenesis.
Asthma
Fragment Molecular Orbital Method Applied to Lead Optimization of Novel Interleukin-2 Inducible T-Cell Kinase (ITK) Inhibitors.
Asthma
Identification of pyrazolopyridine derivatives as novel spleen tyrosine kinase inhibitors.
Asthma
Identification of Type-II Inhibitors Using Kinase Structures.
Asthma
Immunomodulators for allergic respiratory disorders.
Asthma
Immunomodulators in asthma therapy.
Asthma
Inhaled Janus Kinase (JAK) inhibitors for the treatment of asthma.
Asthma
Inhibition of Bruton's tyrosine kinase and IL-2 inducible T-cell kinase suppresses both neutrophilic and eosinophilic airway inflammation in a cockroach allergen extract-induced mixed granulocytic mouse model of asthma using preventative and therapeutic strategy.
Asthma
Inhibition of spleen tyrosine kinase (SYK) attenuates allergen-mediated airway constriction.
Asthma
JAK and Src tyrosine kinase signaling in asthma.
Asthma
JAK-1 rs2780895 C-Related Genotype and Allele but not JAK-1 rs10789166, rs4916008, rs2780885, rs17127114, and rs3806277 Are Associated with Higher Susceptibility to Asthma.
Asthma
Lung-restricted inhibition of Janus kinase 1 is effective in rodent models of asthma.
Asthma
Lyn kinase represses mucus hypersecretion by regulating IL-13-induced endoplasmic reticulum stress in asthma.
Asthma
Lyn-deficient mice develop severe, persistent asthma: Lyn is a critical negative regulator of Th2 immunity.
Asthma
MicroRNA-203 negatively regulates c-Abl, ERK1/2 phosphorylation, and proliferation in smooth muscle cells.
Asthma
Rational design of highly selective spleen tyrosine kinase inhibitors.
Asthma
Role of Tyk-2 in Th9 and Th17 cells in allergic asthma.
Asthma
Spleen tyrosine kinase (Syk) as a novel target for allergic asthma and rhinitis.
Asthma
Spleen tyrosine kinase inhibition attenuates airway hyperresponsiveness and pollution-induced enhanced airway response in a chronic mouse model of asthma.
Asthma
Spleen tyrosine kinases: biology, therapeutic targets and drugs.
Asthma
Status of serine tyrosine kinase at germline and expressional levels in asthma patients.
Asthma
Structure-based design and synthesis of potent benzothiazole inhibitors of interleukin-2 inducible T cell kinase (ITK).
Asthma
TGF? receptor mutations impose a strong predisposition for human allergic disease.
Asthma
The Dynamic Actin Cytoskeleton in Smooth Muscle.
Asthma
The effect of siRNA-mediated lymphocyte-specific protein tyrosine kinase (Lck) inhibition on pulmonary inflammation in a mouse model of asthma.
Asthma
The oral spleen tyrosine kinase inhibitor fostamatinib attenuates inflammation and atherogenesis in low-density lipoprotein receptor-deficient mice.
Asthma
Treatment of allergic asthma by targeting janus kinase 3-dependent leukotriene synthesis in mast cells with 4-(3', 5'-dibromo-4'-hydroxyphenyl)amino-6,7-dimethoxyquinazoline (WHI-P97).
Asthma
Tyrosine kinase inhibitors as potential drugs for B-cell lymphoid malignancies and autoimmune disorders.
Asthma
Using ovality to predict nonmutagenic, orally efficacious pyridazine amides as cell specific spleen tyrosine kinase inhibitors.
Asthma
[The Involvement of Src in Airway Inflammation Induced by Repeated Exposure to Lipopolysaccharide in Mice].
Asthma
[The transcription levels of linker for activation of T cell and its upstream regulatory factors in T cells of asthmatic patients]
Astrocytoma
Astrocytoma adhesion to extracellular matrix: functional significance of integrin and focal adhesion kinase expression.
Astrocytoma
Bone morphogenetic protein type IB receptor is progressively expressed in malignant glioma tumours.
Astrocytoma
Development and malignant progression of astrocytomas in GFAP-v-src transgenic mice.
Astrocytoma
Focal adhesion kinase enhances signaling through the Shc/extracellular signal-regulated kinase pathway in anaplastic astrocytoma tumor biopsy samples.
Astrocytoma
Focal adhesion kinase is expressed in the angiogenic blood vessels of malignant astrocytic tumors in vivo and promotes capillary tube formation of brain microvascular endothelial cells.
Astrocytoma
Gliomatosis cerebri: no evidence for a separate brain tumor entity.
Astrocytoma
Increased expression in human astrocytomas of a 100 kDa protein with sequence homology to the ros tyrosine kinase domain.
Astrocytoma
Neurotrophic Receptor Tyrosine Kinase 2 (NTRK2) Alterations in Low-Grade Gliomas: Report of a Novel Gene Fusion Partner in a Pilocytic Astrocytoma and Review of the Literature.
Astrocytoma
No complementation between TP53 or RB-1 and v-src in astrocytomas of GFAP-v-src transgenic mice.
Astrocytoma
p125 focal adhesion kinase promotes malignant astrocytoma cell proliferation in vivo.
Astrocytoma
PTEN-independent induction of caspase-mediated cell death and reduced invasion by the focal adhesion targeting domain (FAT) in human astrocytic brain tumors which highly express focal adhesion kinase (FAK).
Astrocytoma
Tumour induction in fetal brain transplants exposed to the viral oncogenes polyoma middle T and v-src.
Astrocytoma
[Detecting protein expression of EphrinB2 ligand and its receptor EphB4 in astrocytoma using confocal laser scanning microscopy]
Ataxia
GTPase Regulator Associated with Focal Adhesion Kinase 1 (GRAF1) Immunoglobulin-Associated Ataxia and Neuropathy.
Ataxia
Inhibition of c-Abl tyrosine kinase activity by filamentous actin.
Ataxia Telangiectasia
Ataxia telangiectasia mutant protein activates c-Abl tyrosine kinase in response to ionizing radiation.
Ataxia Telangiectasia
c-Abl mediates high NaCl-induced phosphorylation and activation of the transcription factor TonEBP/OREBP.
Ataxia Telangiectasia
c-Abl tyrosine kinase is not essential for ataxia telangiectasia mutated functions in chromosomal maintenance.
Ataxia Telangiectasia
Delayed activation of Bax by DNA damage in embryonic stem cells with knock-in mutations of the Abl nuclear localization signals.
Ataxia Telangiectasia
Determination of cell fate by c-Abl activation in the response to DNA damage.
Ataxia Telangiectasia
Evaluation of 122 advanced-stage cutaneous squamous cell carcinomas by comprehensive genomic profiling opens the door for new routes to targeted therapies.
Ataxia Telangiectasia
Functional role for the c-Abl tyrosine kinase in meiosis I.
Ataxia Telangiectasia
Identification of proteins in the hamster DNA end-binding complex.
Ataxia Telangiectasia
Identification of small molecule inhibitors of phosphatidylinositol 3-kinase and autophagy.
Ataxia Telangiectasia
Mismatch repair and DNA damage signalling.
Ataxia Telangiectasia
Werner Syndrome Protein and DNA Replication.
Atherosclerosis
A Disintegrin and Metalloproteinase 15 Contributes to Atherosclerosis by Mediating Endothelial Barrier Dysfunction via Src Family Kinase Activity.
Atherosclerosis
A spleen tyrosine kinase inhibitor attenuates the proliferation and migration of vascular smooth muscle cells.
Atherosclerosis
CircRNA?0044073 is upregulated in atherosclerosis and increases the proliferation and invasion of cells by targeting miR?107.
Atherosclerosis
Evaluation of therapeutic effects of FAK inhibition in murine models of atherosclerosis.
Atherosclerosis
Hypertension promotes phosphorylation of focal adhesion kinase and proline-rich tyrosine kinase 2 in rats: implication for the pathogenesis of hypertensive vascular disease.
Atherosclerosis
Imatinib mesylate stimulates low-density lipoprotein receptor-related protein 1-mediated ERK phosphorylation in insulin-producing cells.
Atherosclerosis
Mulberry water extracts inhibit atherosclerosis through suppression of the integrin-??/focal adhesion kinase complex and downregulation of nuclear factor ?B signaling in vivo and in vitro.
Atherosclerosis
Mycophenolic acid regulates spleen tyrosine kinase to repress tumour necrosis factor-alpha-induced monocyte chemotatic protein-1 production in cultured human aortic endothelial cells.
Atherosclerosis
Silencing MR-1 attenuates atherosclerosis in ApoE
Atherosclerosis
The critical role of IL-1 receptor-associated kinase 4-mediated NF-kappaB activation in modified low-density lipoprotein-induced inflammatory gene expression and atherosclerosis.
Atherosclerosis
The oral spleen tyrosine kinase inhibitor fostamatinib attenuates inflammation and atherogenesis in low-density lipoprotein receptor-deficient mice.
Atherosclerosis
Therapeutic implications of endothelin and thrombin G-protein-coupled receptor transactivation of tyrosine and serine/threonine kinase cell surface receptors.
Atherosclerosis
Tofacitinib improves atherosclerosis despite up-regulating serum cholesterol in patients with active rheumatoid arthritis: a cohort study.
Atherosclerosis
Urantide alleviates the symptoms of atherosclerotic rats in vivo and in vitro models through the JAK2/STAT3 signaling pathway.
Atherosclerosis
Vascular transcellular signaling.
Atrial Fibrillation
Bruton's tyrosine kinase Inhibitors and Cardiotoxicity: More Than Just Atrial Fibrillation.
Atrial Fibrillation
Cardiotoxicity of Novel Targeted Hematological Therapies.
Atrial Fibrillation
Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials.
Atrial Fibrillation
Focal adhesion kinase mediates atrial fibrosis via the AKT/S6K signaling pathway in chronic atrial fibrillation patients with rheumatic mitral valve disease.
Atrial Fibrillation
Genome-wide linkage scan identifies a novel genetic locus on chromosome 5p13 for neonatal atrial fibrillation associated with sudden death and variable cardiomyopathy.
Atrial Fibrillation
Ibrutinib Displays Atrial-Specific Toxicity in Human Stem Cell-Derived Cardiomyocytes.
Atrial Fibrillation
Ibrutinib-Mediated Atrial Fibrillation Attributable to Inhibition of C-Terminal Src Kinase.
Atrial Fibrillation
Increased Susceptibility for Atrial and Ventricular Cardiac Arrhythmias in Mice Treated With a Single High Dose of Ibrutinib.
Atrial Fibrillation
Pharmacological evidence for altered src kinase regulation of I (Ca,L) in patients with chronic atrial fibrillation.
Atrial Fibrillation
[Involvement of Src kinase in the down-regulation of ultra-rapid delayed rectifier K(+)current induced by tumor necrosis factor-? in cardiomyocytes].
Autoimmune Diseases
A hypomorphic allele of ZAP-70 reveals a distinct thymic threshold for autoimmune disease versus autoimmune reactivity.
Autoimmune Diseases
A novel human autoimmune syndrome caused by combined hypomorphic and activating mutations in ZAP-70.
Autoimmune Diseases
A Novel Triazolopyridine-Based Spleen Tyrosine Kinase Inhibitor That Arrests Joint Inflammation.
Autoimmune Diseases
A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single-Dose and Multiple-Rising-Dose Study of the BTK Inhibitor TAK-020 in Healthy Subjects.
Autoimmune Diseases
A Supratherapeutic Dose of the Janus Kinase Inhibitor Tasocitinib (CP-690,550) Does Not Prolong QTc Interval in Healthy Participants.
Autoimmune Diseases
B cell-specific loss of Lyn kinase leads to autoimmunity.
Autoimmune Diseases
Bayesian Machine Learning to Discover Bruton's Tyrosine Kinase (BTK) Inhibitors.
Autoimmune Diseases
Bleeding by Bruton Tyrosine Kinase-Inhibitors: Dependency on Drug Type and Disease.
Autoimmune Diseases
Bruton's Tyrosine Kinase Inhibitors for the Treatment of Autoimmune Diseases and Cancers.
Autoimmune Diseases
Bruton's Tyrosine Kinase Is Not Essential for B Cell Survival beyond Early Developmental Stages.
Autoimmune Diseases
Btk inhibition treats TLR7/IFN driven murine lupus.
Autoimmune Diseases
Characterization of the Effect of Hepatic Impairment on Upadacitinib Pharmacokinetics.
Autoimmune Diseases
Characterization of the Effect of Renal Impairment on Upadacitinib Pharmacokinetics.
Autoimmune Diseases
Curcumin modulation of the activation of PYK2 in peripheral blood mononuclear cells from patients with lupus nephritis.
Autoimmune Diseases
Current Status in the Discovery of Covalent Janus Kinase 3 (JAK3) inhibitors.
Autoimmune Diseases
Design and synthesis of boron-containing diphenylpyrimidines as potent BTK and JAK3 dual inhibitors.
Autoimmune Diseases
Design, synthesis and biological evaluation of 7H-pyrrolo[2,3-d]pyrimidin-4-amine derivatives as selective Btk inhibitors with improved pharmacokinetic properties for the treatment of rheumatoid arthritis.
Autoimmune Diseases
Design, synthesis and biological evaluation of novel dithiocarbamate-substituted diphenylaminopyrimidine derivatives as BTK inhibitors.
Autoimmune Diseases
Differences in gene expression and alterations in cell cycle of acute myeloid leukemia cell lines after treatment with JAK inhibitors.
Autoimmune Diseases
Discovery of a potent, selective, and covalent ZAP-70 kinase inhibitor.
Autoimmune Diseases
Discovery of Affinity-Based Probes for Btk Occupancy Assays.
Autoimmune Diseases
Discovery of BIIB068: A Selective, Potent, Reversible Bruton's Tyrosine Kinase Inhibitor as an Orally Efficacious Agent for Autoimmune Diseases.
Autoimmune Diseases
Discovery of CP-690,550: a potent and selective Janus kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejection.
Autoimmune Diseases
Discovery of dual ZAP70 and Syk kinases inhibitors by docking into a rare C-helix-out conformation of Syk.
Autoimmune Diseases
Discovery of Lanraplenib (GS-9876): A Once-Daily Spleen Tyrosine Kinase Inhibitor for Autoimmune Diseases.
Autoimmune Diseases
Discovery of LOU064 (Remibrutinib), a Potent and Highly Selective Covalent Inhibitor of Bruton's Tyrosine Kinase.
Autoimmune Diseases
Discovery of Novel Bruton's Tyrosine Kinase Inhibitors Using a Hybrid Protocol of Virtual Screening Approaches Based on SVM Model, Pharmacophore and Molecular Docking.
Autoimmune Diseases
Discovery of Tricyclic Pyranochromenone as Novel Bruton's Tyrosine Kinase Inhibitors with in Vivo Antirheumatic Activity.
Autoimmune Diseases
Discovery of Tyrosine Kinase 2 (TYK2) Inhibitor (PF-06826647) for the Treatment of Autoimmune Diseases.
Autoimmune Diseases
Discovery of VX-509 (Decernotinib): A Potent and Selective Janus Kinase 3 Inhibitor for the Treatment of Autoimmune Diseases.
Autoimmune Diseases
Effect of CP-690,550, an orally active janus kinase inhibitor, on renal function in healthy adult volunteers.
Autoimmune Diseases
Efficacy and Pharmacodynamic Modeling of the BTK Inhibitor Evobrutinib in Autoimmune Disease Models.
Autoimmune Diseases
Enhanced Bruton's tyrosine kinase activity in peripheral blood B lymphocytes of autoimmune disease patients.
Autoimmune Diseases
Essential Kinases and Transcriptional Regulators and Their Roles in Autoimmunity.
Autoimmune Diseases
Exposure-Response Analyses for Upadacitinib Efficacy in Subjects With Atopic Dermatitis-Analyses of Phase 2b Study to Support Selection of Phase 3 Doses.
Autoimmune Diseases
Fate of lymphocytes after withdrawal of tofacitinib treatment.
Autoimmune Diseases
Fostamatinib, a Syk inhibitor prodrug for the treatment of inflammatory diseases.
Autoimmune Diseases
Garden of therapeutic delights: new targets in rheumatic diseases.
Autoimmune Diseases
Genetic interdependence of lyn and negative regulators of B cell receptor signaling in autoimmune disease development.
Autoimmune Diseases
GLIS3 and TYK2 Single Nucleotide Polymorphisms Are Not Associated with Dermatomyositis/Polymyositis in Chinese Han Population.
Autoimmune Diseases
Highly Selective Inhibition of Tyrosine Kinase 2 (TYK2) for the Treatment of Autoimmune Diseases: Discovery of the Allosteric Inhibitor BMS-986165.
Autoimmune Diseases
Human spleen tyrosine kinase (Syk) recombinant expression systems for high-throughput assays.
Autoimmune Diseases
Identification of a novel series of azabenzimidazole-derived inhibitors of spleen tyrosine kinase.
Autoimmune Diseases
Identification of Inhibitors of the Association of ZAP-70 with the T Cell Receptor by High-Throughput Screen.
Autoimmune Diseases
Identification of metabolites of evobrutinib in rat and human hepatocytes by using ultra-high performance liquid chromatography coupled with diode array detector and Q Exactive Orbitrap tandem mass spectrometry.
Autoimmune Diseases
Identification of Type-II Inhibitors Using Kinase Structures.
Autoimmune Diseases
Immunomodulating role of the JAKs inhibitor tofacitinib in a mouse model of bleomycin-induced scleroderma.
Autoimmune Diseases
Impaired T cell receptor signaling and development of T cell-mediated autoimmune arthritis.
Autoimmune Diseases
Induction of autoimmune disease in CTLA-4-/- mice depends on a specific CD28 motif that is required for in vivo costimulation.
Autoimmune Diseases
Interleukin-23: A New Atherosclerosis Target.
Autoimmune Diseases
Interleukin-6 Trans-Signaling Exacerbates Inflammation and Renal Pathology in Lupus-Prone Mice.
Autoimmune Diseases
JAK-inhibitor tofacitinib suppresses interferon alfa production by plasmacytoid dendritic cells and inhibits arthrogenic and antiviral effects of interferon alfa.
Autoimmune Diseases
JAK-STAT inhibitors for the treatment of immunomediated diseases.
Autoimmune Diseases
JAK1, but not JAK2 and STAT3, confers susceptibility to Vogt-Koyanagi-Harada (VKH) syndrome in a Han Chinese population.
Autoimmune Diseases
JAK2 and STAT3 polymorphisms in a Han Chinese population with Behçet's disease.
Autoimmune Diseases
Janus kinase inhibitors in autoimmune diseases.
Autoimmune Diseases
Janus kinase inhibitors: A therapeutic strategy for cancer and autoimmune diseases.
Autoimmune Diseases
JTE-852, a novel spleen tyrosine kinase inhibitor, blocks immunoglobulin G-mediated cellular responses and autoimmune reactions in vivo.
Autoimmune Diseases
Kinase inhibitors in the treatment of immune-mediated disease.
Autoimmune Diseases
Kinetic assay for characterization of spleen tyrosine kinase activity and inhibition with recombinant kinase and crude cell lysates.
Autoimmune Diseases
Measuring atropisomers of BMS-986142 using 2DLC as an enabling technology.
Autoimmune Diseases
Modification by covalent reaction or oxidation of cysteine residues in the tandem-SH2 domains of ZAP-70 and Syk can block phosphopeptide binding.
Autoimmune Diseases
Multifocal motor neuropathy is not associated with genetic variation in PTPN22, BANK1, Blk, FCGR2B, CD1A/E, and TAG-1 genes.
Autoimmune Diseases
Network pharmacology of JAK inhibitors.
Autoimmune Diseases
Novel concepts and treatments for autoimmune disease: ten focal points.
Autoimmune Diseases
Oral Janus kinase inhibitors for maintenance of remission in ulcerative colitis.
Autoimmune Diseases
Orelabrutinib: First Approval.
Autoimmune Diseases
Pancreatic Effects of a Bruton's Tyrosine Kinase Small-molecule Inhibitor in Rats Are Strain-dependent.
Autoimmune Diseases
Performance of Janus kinase inhibitors in psoriatic arthritis with axial involvement in indirect comparison with ankylosing spondylitis: a retrospective analysis from pooled data.
Autoimmune Diseases
Pharmacophore modeling and virtual screening in search of novel Bruton's tyrosine kinase inhibitors.
Autoimmune Diseases
Pharmacophore modeling of JAK1: A target infested with activity-cliffs.
Autoimmune Diseases
Population Pharmacokinetic Analysis of Mycophenolic Acid Coadministered With Either Tasocitinib (CP-690,550) or Tacrolimus in Adult Renal Allograft Recipients.
Autoimmune Diseases
Proof of concept for the clinical effects of oral rilzabrutinib, the first Bruton tyrosine kinase inhibitor for pemphigus vulgaris: the phase II BELIEVE study.
Autoimmune Diseases
PTPN22 phosphorylation acts as a molecular rheostat for the inhibition of TCR signaling.
Autoimmune Diseases
Pulmonary adverse events of small molecule JAK inhibitors in autoimmune disease: systematic review and meta-analysis.
Autoimmune Diseases
Purine derivatives as potent Bruton's tyrosine kinase (BTK) inhibitors for autoimmune diseases.
Autoimmune Diseases
Quantitative structure-activity relationship study on BTK inhibitors by modified multivariate adaptive regression spline and CoMSIA methods.
Autoimmune Diseases
Rational design of highly selective spleen tyrosine kinase inhibitors.
Autoimmune Diseases
Resolving TYK2 locus genotype-to-phenotype differences in autoimmunity.
Autoimmune Diseases
Role of Tyk-2 in Th9 and Th17 cells in allergic asthma.
Autoimmune Diseases
Safety, Tolerability, Pharmacokinetics, Target Occupancy, and Concentration-QT Analysis of the Novel BTK Inhibitor Evobrutinib in Healthy Volunteers.
Autoimmune Diseases
Selective functional inhibition of JAK-3 is sufficient for efficacy in collagen-induced arthritis in mice.
Autoimmune Diseases
Selective inhibition of spleen tyrosine kinase (SYK) with a novel orally bioavailable small molecule inhibitor, RO9021, impinges on various innate and adaptive immune responses: implications for SYK inhibitors in autoimmune disease therapy.
Autoimmune Diseases
Separation of Bruton's tyrosine kinase inhibitor atropisomers by supercritical fluid chromatography.
Autoimmune Diseases
Small Molecule Reversible Inhibitors of Bruton's Tyrosine Kinase (BTK): Structure-Activity Relationships Leading to the Identification of 7-(2-Hydroxypropan-2-yl)-4-[2-methyl-3-(4-oxo-3,4-dihydroquinazolin-3-yl)phenyl]-9H-carbazole-1-carboxamide (BMS-935177).
Autoimmune Diseases
Spleen tyrosine kinases: biology, therapeutic targets and drugs.
Autoimmune Diseases
ST6Gal-I restrains CD22-dependent antigen receptor endocytosis and Shp-1 recruitment in normal and pathogenic immune signaling.
Autoimmune Diseases
Structural insights for design of potent spleen tyrosine kinase inhibitors from crystallographic analysis of three inhibitor complexes.
Autoimmune Diseases
Structure-activity relationship studies of 5-benzylaminoimidazo[1,2-c]pyrimidine-8-carboxamide derivatives as potent, highly selective ZAP-70 kinase inhibitors.
Autoimmune Diseases
Suppression of autoimmune disease and of massive lymphadenopathy in MRL/Mp-lpr/lpr mice lacking tyrosine kinase Fyn (p59fyn).
Autoimmune Diseases
SVM Model for Virtual Screening of Lck Inhibitors.
Autoimmune Diseases
Syk kinase as a treatment target for therapy in autoimmune diseases.
Autoimmune Diseases
Syk mediates IL-17-induced CCL20 expression by targeting Act1-dependent K63-linked ubiquitination of TRAF6.
Autoimmune Diseases
Synthesis and biological activity of thieno[3,2-d]pyrimidines as potent JAK3 inhibitors for the treatment of idiopathic pulmonary fibrosis.
Autoimmune Diseases
Targeting Bruton's tyrosine kinase for the treatment of B cell associated malignancies and autoimmune diseases: Preclinical and clinical developments of small molecule inhibitors.
Autoimmune Diseases
The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy.
Autoimmune Diseases
The development of Bruton's tyrosine kinase (BTK) inhibitors from 2012 to 2017: A mini-review.
Autoimmune Diseases
The Role of STAT Signaling Pathways in the Pathogenesis of Systemic Lupus Erythematosus.
Autoimmune Diseases
The tyrosine kinase Lyn limits the cytokine responsiveness of plasma cells to restrict their accumulation in mice.
Autoimmune Diseases
Trichostatin A down-regulates ZAP-70, LAT and SLP-76 content in Jurkat T cells.
Autoimmune Diseases
Tyrosine Kinase 2 (TYK2) Allosteric Inhibitors To Treat Autoimmune Diseases.
Autoimmune Diseases
Tyrosine kinase 2 variant influences T lymphocyte polarization and multiple sclerosis susceptibility.
Autoimmune Diseases
Tyrosine Kinase Inhibitor Tyrphostin AG490 Retards Chronic Joint Inflammation in Mice.
Autoimmune Diseases
Tyrosine kinase inhibitors as potential drugs for B-cell lymphoid malignancies and autoimmune disorders.
Autoimmune Diseases
Using ovality to predict nonmutagenic, orally efficacious pyridazine amides as cell specific spleen tyrosine kinase inhibitors.
Autoimmune Diseases
VX-509 is a potent and selective Janus kinase 3 (JAK3) inhibitor that attenuates inflammation in animal models of autoimmune disease.
Autoimmune Diseases
[Everything you ever wanted to know about ZAP-70]
Autoimmune Lymphoproliferative Syndrome
Janus Kinase Inhibitor Tofacitinib Shows Potent Efficacy in a Mouse Model of Autoimmune Lymphoproliferative Syndrome (ALPS).
Avian Leukosis
Identification of Avian leukosis virus subgroup J associated acutely transforming viruses carrying the v-src oncogene in layer chickens.
Avian Leukosis
Karyotype analysis of the acute fibrosarcoma from chickens infected with subgroup J avian leukosis virus associated with v-src oncogene.
Avian Leukosis
Rescue of avian leukosis subgroup-J-associated acutely transforming viruses carrying different lengths of the v-fps oncogene and analysis of their tumorigenicity.
Axial Spondyloarthritis
Axial spondyloarthritis: emerging drug targets.
Axial Spondyloarthritis
Beyond the TNF-? Inhibitors: New and Emerging Targeted Therapies for Patients with Axial Spondyloarthritis and their Relation to Pathophysiology.
Axial Spondyloarthritis
Emerging Immunomodulatory Therapies and New Treatment Paradigms for Axial Spondyloarthritis.
Axial Spondyloarthritis
Novel Therapeutic Targets in Axial Spondyloarthritis.
Axial Spondyloarthritis
Promising Treatment Options for Axial Spondyloarthritis: An Overview of Experimental Pharmacological Agents.
Axial Spondyloarthritis
Treatment of Axial Spondyloarthritis: What Does the Future Hold?
Azoospermia
The expression of microRNAs and exposure to environmental contaminants related to human health: a review.
Babesiosis
Urinary proteome of dogs with kidney injury during babesiosis.
Bacteremia
MyD88- and Bruton's tyrosine kinase-mediated signals are essential for T cell-independent pathogen-specific IgM responses.
Bacterial Infections
A case report of disseminated histoplasmosis and concurrent cryptococcal meningitis in a patient treated with ruxolitinib.
Bacterial Infections
Abelson tyrosine kinase facilitates Salmonella enterica serovar Typhimurium entry into epithelial cells.
Bacterial Infections
Chlamydial Infection of Monocytes Stimulates IL-1beta Secretion Through Activation of the NLRP3 Inflammasome.
Bacterial Infections
Functional analysis of the porcine USP18 and its role during porcine arterivirus replication.
Bacterial Infections
Identification of mutations of Bruton's tyrosine kinase gene (BTK) in Brazilian patients with X-linked agammaglobulinemia.
Bacterial Infections
Inositol polyphosphates promote T cell-independent humoral immunity via the regulation of Bruton's tyrosine kinase.
Bacterial Infections
Lyn prevents aberrant inflammatory responses to
Bacterial Infections
Mutations of Bruton's tyrosine kinase gene in Brazilian patients with X-linked agammaglobulinemia.
Bacterial Infections
Neutrophil specific deletion of Syk kinase results in reduced host defense to bacterial infection.
Bacterial Infections
Novel Mutation of ZAP-70-related Combined Immunodeficiency: First Case from the National Iranian Registry and Review of the Literature.
Bacterial Infections
Spleen tyrosine kinase from Nile tilapia (Oreochromis niloticus): Molecular characterization, expression pattern upon bacterial infection and the potential role in BCR signaling and inflammatory response.
Bacterial Infections
Study of cytokine signaling: the quest for immunomodulatory drugs interacting with cytokine production and activity.
Bacterial Infections
Sustained correction of B-cell development and function in a murine model of X-linked agammaglobulinemia (XLA) using retroviral-mediated gene transfer.
Bacterial Infections
Transcriptional regulatory defects in the first intron of Bruton's tyrosine kinase.
Bacterial Infections
Wingless homolog Wnt11 suppresses bacterial invasion and inflammation in intestinal epithelial cells.
Bacterial Infections
[Gene diagnosis of X-linked agammaglobulinemia]
Barrett Esophagus
Dasatinib, a small molecule inhibitor of the Src kinase, reduces the growth and activates apoptosis in pre-neoplastic Barrett's esophagus cell lines: evidence for a noninvasive treatment of high-grade dysplasia.
Barrett Esophagus
Differential protein expression and oncogenic gene network link tyrosine kinase ephrin B4 receptor to aggressive gastric and gastroesophageal junction cancers.
Behcet Syndrome
Janus kinase 2 V617F mutation and thrombotic events in Behcet's disease: The Alexandria experience.
Bicuspid Aortic Valve Disease
Absence of TGFBR1 and TGFBR2 mutations in patients with bicuspid aortic valve and aortic dilation.
Bicuspid Aortic Valve Disease
Sequencing of NOTCH1, GATA5, TGFBR1 and TGFBR2 genes in familial cases of bicuspid aortic valve.
Biliary Tract Neoplasms
Restoration of RUNX3 enhances transforming growth factor-beta-dependent p21 expression in a biliary tract cancer cell line.
Biliary Tract Neoplasms
Src as a Therapeutic Target in Biliary Tract Cancer.
Blast Crisis
A case of biphenotypic blast crisis of unclassified myeloproliferative disorder.
Blast Crisis
A causal Bayesian network model of disease progression mechanisms in chronic myeloid leukemia.
Blast Crisis
A Convenient Cell Culture Model for CML Acquired Resistance Through BCR-ABL Mutations.
Blast Crisis
A novel HDAC inhibitor chidamide combined with imatinib synergistically targets tyrosine kinase inhibitor resistant chronic myeloid leukemia cells.
Blast Crisis
A novel insertion mutation of K294RGG within BCR-ABL kinase domain confers imatinib resistance: sequential analysis of the clonal evolution in a patient with chronic myeloid leukemia in blast crisis.
Blast Crisis
A novel pyridopyrimidine inhibitor of abl kinase is a picomolar inhibitor of Bcr-abl-driven K562 cells and is effective against STI571-resistant Bcr-abl mutants.
Blast Crisis
A pharmacodynamic model of Bcr-Abl signalling in chronic myeloid leukaemia.
Blast Crisis
A phase 2 study of MK-0457 in patients with BCR-ABL T315I mutant chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
Blast Crisis
ABL1 methylation is a distinct molecular event associated with clonal evolution of chronic myeloid leukemia.
Blast Crisis
Absence of alternative splicing in bcr-abl mRNA in chronic myeloid leukemia cell lines.
Blast Crisis
Acquired homozygosity of the rearranged bcr allele during the acute leukemic phase of a patient with Ph-negative chronic myeloid leukemia.
Blast Crisis
Activation of EVI1 transcription by the LEF1/?-catenin complex with p53-alteration in myeloid blast crisis of chronic myeloid leukemia.
Blast Crisis
Activation of Jak2 in patients with blast crisis chronic myelogenous leukemia: inhibition of Jak2 inactivates Lyn kinase.
Blast Crisis
Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.
Blast Crisis
Acute lymphoid leukemia molecular phenotype in a patient with benign-phase chronic myelogenous leukemia.
Blast Crisis
ADAR1 promotes malignant progenitor reprogramming in chronic myeloid leukemia.
Blast Crisis
Additive antileukemia effects by GFI1B- and BCR-ABL-specific siRNA in advanced phase chronic myeloid leukemic cells.
Blast Crisis
Aggressive myeloid leukemia formation is directed by the Musashi 2/Numb pathway.
Blast Crisis
Allogeneic hematopoietic stem cell transplantation for patients with chronic myeloid leukemia in second chronic phase attained by imatinib after onset of blast crisis.
Blast Crisis
Amplification of BCR-ABL and t(3;21) in a patient with blast crisis of chronic myelogenous leukemia.
Blast Crisis
An acute myeloid leukemia M6b blast crisis with giant proerythroblasts in chronic myeloid leukemia.
Blast Crisis
Analysis of P210bcr-abl tyrosine protein kinase activity in various subtypes of Philadelphia chromosome-positive cells from chronic myelogenous leukemia patients.
Blast Crisis
Anthelmintic drug niclosamide enhances the sensitivity of chronic myeloid leukemia cells to dasatinib through inhibiting Erk/Mnk1/eIF4E pathway.
Blast Crisis
Antibiotic anisomycin selectively targets leukemia cell lines and patient samples through suppressing Wnt/?-catenin signaling.
Blast Crisis
Antisense inhibition of Bcr-Abl/c-Abl synthesis promotes telomerase activity and upregulates tankyrase in human leukemia cells.
Blast Crisis
Arsenic induces apoptosis of multidrug-resistant human myeloid leukemia cells that express Bcr-Abl or overexpress MDR, MRP, Bcl-2, or Bcl-x(L).
Blast Crisis
Association of XRCC1 gene polymorphisms with chronic myeloid leukemia in the population of Andhra Pradesh, India.
Blast Crisis
Bcr-Abl activates AURKA and AURKB in chronic myeloid leukemia cells via AKT signaling.
Blast Crisis
BCR-ABL alternative splicing as a common mechanism for imatinib resistance: evidence from molecular dynamics simulations.
Blast Crisis
BCR-ABL down-regulates the DNA repair protein DNA-PKcs.
Blast Crisis
Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia.
Blast Crisis
BCR-ABL Mutation-Guided Therapy for CML Blast Crisis: A Case Report.
Blast Crisis
Bcr-abl positive blast crisis of chronic myeloid leukemia emerging in a case of metastatic colorectal cancer 3 months after completion of an 8-month course of cetuximab and irinotecan.
Blast Crisis
Bcr-Abl reduces endoplasmic reticulum releasable calcium levels by a Bcl-2-independent mechanism and inhibits calcium-dependent apoptotic signaling.
Blast Crisis
BCR-ABL with an e6a2 fusion in a CML patient diagnosed in blast crisis.
Blast Crisis
BCR-ABL-expressing cells transduced with the HSV-tk gene die by apoptosis upon treatment with ganciclovir.
Blast Crisis
BCR-ABL: a multi-faceted promoter of DNA mutation in chronic myelogeneous leukemia.
Blast Crisis
BCR/ABL and other kinases from chronic myeloproliferative disorders stimulate single-strand annealing, an unfaithful DNA double-strand break repair.
Blast Crisis
Bilineal T lymphoblastic and myeloid blast transformation in chronic myeloid leukemia with TP53 mutation-an uncommon presentation in adults.
Blast Crisis
Blockade of the Bcr-Abl kinase activity induces apoptosis of chronic myelogenous leukemia cells by suppressing signal transducer and activator of transcription 5-dependent expression of Bcl-xL.
Blast Crisis
BMS-214662 potently induces apoptosis of chronic myeloid leukemia stem and progenitor cells and synergizes with tyrosine kinase inhibitors.
Blast Crisis
Breakpoints on chromosomes 9 and 22 in Philadelphia chromosome-positive chronic myelogenous leukemia (CML). Amplification of rearranged c-abl oncogenes in CML blast crisis.
Blast Crisis
CGP57148B (STI-571) induces differentiation and apoptosis and sensitizes Bcr-Abl-positive human leukemia cells to apoptosis due to antileukemic drugs.
Blast Crisis
Chronic myelogenous leukemia: amplification of a rearranged c-abl oncogene in both chronic phase and blast crisis.
Blast Crisis
Chronic myelogenous leukemia: mechanisms underlying disease progression.
Blast Crisis
Chronic myeloid leukemia blast crisis arises from progenitors.
Blast Crisis
Chronic myeloid leukemia stem cells.
Blast Crisis
Chronic myeloid leukemia with an e1a3 BCR-ABL fusion protein: transformation to lymphoid blast crisis.
Blast Crisis
Clinico-hematological profile in biphenotypic acute leukemia.
Blast Crisis
Clonal Evolution and Blast Crisis Correlate with Enhanced Proteolytic Activity of Separase in BCR-ABL b3a2 Fusion Type CML under Imatinib Therapy.
Blast Crisis
Clonal evolution of AML1-ETO coexisting with BCR-ABL and additional chromosome abnormalities in a blastic transformation of chronic myeloid leukemia.
Blast Crisis
Coexistence of p190 BCR/ABL Transcript and CALR 52-bp Deletion in Chronic Myeloid Leukemia Blast Crisis: A Case Report.
Blast Crisis
Combined effects of doxorubicin and STI571 on growth, differentiation and apoptosis of CML cell line K562.
Blast Crisis
Combined inhibition of ?-catenin and Bcr-Abl synergistically targets tyrosine kinase inhibitor-resistant blast crisis chronic myeloid leukemia blasts and progenitors in vitro and in vivo.
Blast Crisis
Combined Therapy of ATRA and Imatinib Mesylate Decreases BCR-ABL and ABCB1/MDR1 Expression Through Cellular Differentiation in a Chronic Myeloid Leukemia Model.
Blast Crisis
Cooperation of BCR-ABL and AML1/MDS1/EVI1 in blocking myeloid differentiation and rapid induction of an acute myelogenous leukemia.
Blast Crisis
Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl-positive human acute leukemia cells.
Blast Crisis
Cross-talk between Bcr-Abl tyrosine kinase, protein kinase C and telomerase-a potential reason for resistance to Glivec in chronic myelogenous leukaemia.
Blast Crisis
Curcumin affects components of the chromosomal passenger complex and induces mitotic catastrophe in apoptosis-resistant Bcr-Abl-expressing cells.
Blast Crisis
Decreased expression level of SH2 domain-containing protein tyrosine phosphatase-1 (Shp1) is associated with progression of chronic myeloid leukaemia.
Blast Crisis
Dendritic-cell-peptide immunization provides immunoprotection against bcr-abl-positive leukemia in mice.
Blast Crisis
Description of a new BCR-ABL point mutation in a CML patient with evolution to lymphoid blast crisis.
Blast Crisis
Destabilization of Bcr-Abl/Jak2 Network by a Jak2/Abl Kinase Inhibitor ON044580 Overcomes Drug Resistance in Blast Crisis Chronic Myelogenous Leukemia (CML).
Blast Crisis
Detection of BCR-ABL proteins in blood cells of benign phase chronic myelogenous leukemia patients.
Blast Crisis
Differences and similarities in kinetics of BCR-ABL transcript levels in CML patients treated with imatinib mesylate for chronic or accelerated disease phase.
Blast Crisis
Differential display analysis of mRNAs in chronic myelogenous leukaemia.
Blast Crisis
Dose-dependent effects of Bcr-Abl in cell line models of different stages of chronic myeloid leukemia.
Blast Crisis
Durable Molecular Remission in a Lymphoid BP-CML Patient Harboring T315I Mutation Treated with Anti-CD19 CAR-T Therapy.
Blast Crisis
Ecotropic viral integration site I regulates alpha1, 6-fucosyl transferase expression and blocks erythropoiesis in chronic myeloid leukemia.
Blast Crisis
Effect of herbimycin A, an antagonist of tyrosine kinase, on bcr/abl oncoprotein-associated cell proliferations: abrogative effect on the transformation of murine hematopoietic cells by transfection of a retroviral vector expressing oncoprotein P210bcr/abl and preferential inhibition on Ph1-positive leukemia cell growth.
Blast Crisis
Effects of the IMP-dehydrogenase inhibitor, Tiazofurin, in bcr-abl positive acute myelogenous leukemia. Part I. In vivo studies.
Blast Crisis
Elevated Bcr-Abl expression levels are sufficient for a haematopoietic cell line to acquire a drug-resistant phenotype.
Blast Crisis
EphB4/ephrinB2 Contributes to Imatinib Resistance in Chronic Myeloid Leukemia Involved in Cytoskeletal Proteins.
Blast Crisis
Evi1 defines leukemia-initiating capacity and tyrosine kinase inhibitor resistance in chronic myeloid leukemia.
Blast Crisis
Evolutionary Dynamics of Chronic Myeloid Leukemia Progression: the Progression-Inhibitory Effect of Imatinib.
Blast Crisis
Expression and activity of Fyn mediate proliferation and blastic features of chronic myelogenous leukemia.
Blast Crisis
Expression of p210 and p190 BCR-ABL due to alternative splicing in chronic myelogenous leukaemia.
Blast Crisis
Extramedullary Blast Crisis in a Patient with T315I BCR-ABL Mutated Chronic Myeloid Leukemia.
Blast Crisis
Fluorescence in situ hybridization for the BCR-ABL fusion gene in a patient with imatinib mesylate-resistant chronic myelogenous leukaemia in extramedullary blast crisis.
Blast Crisis
FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia.
Blast Crisis
Functional features of RUNX1 mutants in acute transformation of chronic myeloid leukemia and their contribution to inducing murine full-blown leukemia.
Blast Crisis
Functionally Deregulated AML1/RUNX1 Cooperates with BCR-ABL to Induce a Blastic Phase-Like Phenotype of Chronic Myelogenous Leukemia in Mice.
Blast Crisis
Further evidence of the involvement of the c-abl oncogene in chronic myelogenous leukemia and acute lymphocytic leukemia.
Blast Crisis
Fyn is not essential for Bcr-Abl-induced leukemogenesis in mouse bone marrow transplantation models.
Blast Crisis
Glycogen synthase kinase 3beta missplicing contributes to leukemia stem cell generation.
Blast Crisis
Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML.
Blast Crisis
Hes1 immortalizes committed progenitors and plays a role in blast crisis transition in chronic myelogenous leukemia.
Blast Crisis
Heterogeneity in expression of the bcr-abl fusion transcript in CML blast crisis.
Blast Crisis
Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells.
Blast Crisis
Histone demethylase RBP2 mediates the blast crisis of chronic myeloid leukemia through an RBP2/PTEN/BCR-ABL cascade.
Blast Crisis
Imatinib failure and response to dasatinib in a patient with chronic myeloid leukemia in blast crisis and a novel, nine-nucleotide BCR-ABL insertion mutation.
Blast Crisis
Imatinib induces a cytogenetic response in blast crisis or interferon failure chronic myeloid leukemia patients with e19a2 BCR-ABL transcripts.
Blast Crisis
Imatinib resistance associated with BCR-ABL upregulation is dependent on HIF-1alpha-induced metabolic reprograming.
Blast Crisis
Imatinib: new preparation. For Chronic myeloid leukaemia: further assessment required.
Blast Crisis
Impact of additional chromosomal aberrations and BCR-ABL kinase domain mutations on the response to nilotinib in Philadelphia chromosome-positive chronic myeloid leukemia.
Blast Crisis
Increase of bcr-abl chimeric mRNA expression in tumor cells of patients with chronic myeloid leukemia precedes disease progression.
Blast Crisis
Inhibition of mitochondrial metabolism by methyl-2-cyano-3,12-dioxooleana-1,9-diene-28-oate induces apoptotic or autophagic cell death in chronic myeloid leukemia cells.
Blast Crisis
inv(16)(p13q22) in chronic myelogenous leukemia in blast phase: a clinicopathologic, cytogenetic, and molecular study of five cases.
Blast Crisis
Involvement of Akt kinase in the action of STI571 on chronic myelogenous leukemia cells.
Blast Crisis
Jak2 is involved in c-Myc induction by Bcr-Abl.
Blast Crisis
Last findings on dual inhibitors of abl and SRC tyrosine-kinases.
Blast Crisis
Low concentrations of STI571 in the cerebrospinal fluid: a case report.
Blast Crisis
Maintaining low BCR-ABL signaling output to restrict CML progression and enable persistence.
Blast Crisis
Management of chronic myeloid leukemia in blast crisis.
Blast Crisis
Methylation of the major breakpoint cluster region (M-bcr) in Philadelphia-positive CML.
Blast Crisis
Molecular biology of chronic myeloid leukemia.
Blast Crisis
Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia.
Blast Crisis
Near haploid blast phase in a chronic myeloid leukemia detected by fluorescence in situ hybridization using a BCR-ABL probe.
Blast Crisis
New Mouse Models to Investigate the Efficacy of Drug Combinations in Human Chronic Myeloid Leukemia.
Blast Crisis
Overcoming imatinib resistance using Src inhibitor CGP76030, Abl inhibitor nilotinib and Abl/Lyn inhibitor INNO-406 in newly established K562 variants with BCR-ABL gene amplification.
Blast Crisis
p190 BCR-ABL mRNA is expressed at low levels in p210-positive chronic myeloid and acute lymphoblastic leukemias.
Blast Crisis
p53 modulates the effect of ribosomal protein S6 kinase1 (S6K1) on cisplatin toxicity in chronic myeloid leukemia cells.
Blast Crisis
p53 stabilization induces apoptosis in chronic myeloid leukemia blast crisis cells.
Blast Crisis
Pathobiology of lymphoid and myeloid blast crisis and management issues.
Blast Crisis
Predominantly BCR-ABL negative myeloid precursors in interferon-alpha treated chronic myelogenous leukemia: a follow-up study of peripheral blood colony-forming cells with fluorescence in situ hybridization.
Blast Crisis
Protein tyrosine phosphatase PTP1B suppresses p210 bcr-abl-induced transformation of rat-1 fibroblasts and promotes differentiation of K562 cells.
Blast Crisis
Quantitative real-time reverse-transcription polymerase chain reaction for diagnosis of BCR-ABL positive leukemias and molecular monitoring following allogeneic stem cell transplantation.
Blast Crisis
Regulation and Targeting of Eg5, a Mitotic Motor Protein in Blast Crisis CML: Overcoming Imatinib Resistance.
Blast Crisis
Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia.
Blast Crisis
Role of DNA Damage Response in Suppressing Malignant Progression of Chronic Myeloid Leukemia and Polycythemia Vera: Impact of Different Oncogenes.
Blast Crisis
Stable molecular remission induced by imatinib mesylate (STI571) in a patient with CML lymphoid blast crisis relapsing after allogeneic stem cell transplantation.
Blast Crisis
Subcellular localization of Bcr, Abl, and Bcr-Abl proteins in normal and leukemic cells and correlation of expression with myeloid differentiation.
Blast Crisis
Successful treatment of T315I BCR-ABL mutated lymphoid blast phase chronic myeloid leukemia with chimeric antigen receptor T cell therapy followed by dasatinib.
Blast Crisis
Synergistic effects of p53 activation via MDM2 inhibition in combination with inhibition of Bcl-2 or Bcr-Abl in CD34+ proliferating and quiescent chronic myeloid leukemia blast crisis cells.
Blast Crisis
T-cell blast crisis of chronic myelogenous leukemia presented with coexisting p210 and p190 BCR-ABL transcripts and t(10;11)(q11;p15).
Blast Crisis
T315I-mutated Bcr-Abl in chronic myeloid leukemia and imatinib: insights from a computational study.
Blast Crisis
Targeting of the Alox12-12-HETE in Blast Crisis Chronic Myeloid Leukemia Inhibits Leukemia Stem/Progenitor Cell Function.
Blast Crisis
The amount of BCR-ABL fusion transcripts detected by the real-time quantitative polymerase chain reaction method in patients with Philadelphia chromosome positive chronic myeloid leukemia correlates with the disease stage.
Blast Crisis
The biology of chronic myelogenous leukemia progression: who, what, where, and why?
Blast Crisis
The CML stem cell: evolution of the progenitor.
Blast Crisis
The molecular mechanism of chronic myelogenous leukemia and its therapeutic implications: studies in a murine model.
Blast Crisis
The role of methylation in CML.
Blast Crisis
The sensitivity of chronic myeloid leukemia CD34 cells to Bcr-Abl tyrosine kinase inhibitors is modulated by ceramide levels.
Blast Crisis
The TGF-beta type II receptor in chronic myeloid leukemia: analysis of microsatellite regions and gene expression.
Blast Crisis
Transcriptional suppression of BACH2 by the Bcr-Abl oncoprotein is mediated by PAX5.
Blast Crisis
Triptolide induces cell death independent of cellular responses to imatinib in blast crisis chronic myelogenous leukemia cells including quiescent CD34+ primitive progenitor cells.
Blast Crisis
Where are we going with CML research?
Blast Crisis
[Analysis of Clinical Characteristics in De novo Chronic Myelogenous Leukemia Patients with Extramedullary T-Lymphoblastic Blast Crisis].
Blast Crisis
[Erythroleukemic blast crisis of chronic myeloid leukemia.]
Blast Crisis
[Molecular analysis of bcr-abl mRNA during long-term follow-up of cases of chronic myelogenous leukemia]
Blast Crisis
[Monitoring bcr-abl mRNA levels by real-time quantitative RT-PCR in chronic myeloid leukemia patients after hematopoietic stem cell transplantation]
Blast Crisis
[STI571: a new dimension in the treatment of chronic myeloid leukemia]
Blast Crisis
[The prognostic significance of derivative chromosome 9 deletions in chronic myeloid leukemia]
Blindness
An Anti-inflammatory Role of VEGFR2/Src Kinase Inhibitor in HSV-1 Induced Immunopathology.
Blister
Caspase-mediated cleavage of focal adhesion kinase pp125FAK and disassembly of focal adhesions in human endothelial cell apoptosis.
Blister
Functional screening of Alzheimer risk loci identifies PTK2B as an in vivo modulator and early marker of Tau pathology.
Blister
GnRH Induces ERK-Dependent Bleb Formation in Gonadotrope Cells, Involving Recruitment of Members of a GnRH Receptor-Associated Signalosome to the Blebs.
Blister
LIM-kinase 2 induces formation of stress fibres, focal adhesions and membrane blebs, dependent on its activation by Rho-associated kinase-catalysed phosphorylation at threonine-505.
Blister
Localization of TGF-beta type II receptor and ED-A fibronectin in normal conjunctiva and failed filtering blebs.
Blister
SH4-domain-induced plasma membrane dynamization promotes bleb-associated cell motility.
Blister
Zyxin and vinculin distribution at the cell-extracellular matrix attachment complex (CMAX) in corneal epithelial tissue are actin dependent.
Bloom Syndrome
Identification of proteins in the hamster DNA end-binding complex.
Bloom Syndrome
Novel immunodeficiency data servers.
Bone Diseases
Bone-targeted 2,6,9-trisubstituted purines: novel inhibitors of Src tyrosine kinase for the treatment of bone diseases.
Bone Diseases
Bone-targeted Src kinase inhibitors: novel pyrrolo- and pyrazolopyrimidine analogues.
Bone Diseases
Novel bone-targeted Src tyrosine kinase inhibitor drug discovery.
Bone Diseases
Prevention of Bone Destruction by Mechanical Loading Is Not Enhanced by the Bruton's Tyrosine Kinase Inhibitor CC-292 in Myeloma Bone Disease.
Bone Diseases
Role of Bruton's tyrosine kinase in myeloma cell migration and induction of bone disease.
Bone Diseases
SRC kinase inhibition with saracatinib limits the development of osteolytic bone disease in multiple myeloma.
Bone Diseases
Targeting protein kinases for bone disease: discovery and development of Src inhibitors.
Bone Diseases
Three-dimensional quantitative structure-activity relationship studies on c-Src inhibitors based on different docking methods.
Bone Diseases, Metabolic
Imatinib Promotes Osteoblast Differentiation by Inhibiting PDGFR Signaling and Inhibits Osteoclastogenesis by Both Direct and Stromal Cell-Dependent Mechanisms.
Bone Marrow Diseases
Ruxolitinib for the treatment of myelofibrosis: its clinical potential.
Bone Marrow Failure Disorders
Mdm2 phosphorylation by Akt regulates the p53 response to oxidative stress to promote cell proliferation and tumorigenesis.
Bone Marrow Failure Disorders
Phosphorylation of the Mdm2 oncoprotein by the c-Abl tyrosine kinase regulates p53 tumor suppression and the radiosensitivity of mice.
Bone Marrow Failure Disorders
The thrombopoietin receptor: revisiting the master regulator of platelet production.
Bone Neoplasms
Blockade of spinal dopamine D1/D2 receptor suppresses activation of NMDA receptor through G?q and Src kinase to attenuate chronic bone cancer pain.
Bone Neoplasms
Interleukin-6-mediated functional upregulation of TRPV1 receptors in dorsal root ganglion neurons through the activation of JAK/PI3K signaling pathway: roles in the development of bone cancer pain in a rat model.
Bone Neoplasms
JAK1/STAT3 regulatory effect of ?-caryophyllene on MG-63 osteosarcoma cells via ROS-induced apoptotic mitochondrial pathway by DNA fragmentation.
Bone Neoplasms
MicroRNA profiling reveals dysregulated microRNAs and their target gene regulatory networks in cemento-ossifying fibroma.
Bone Neoplasms
Vascular Endothelial Growth Factor A Signaling Promotes Spinal Central Sensitization and Pain-related Behaviors in Female Rats with Bone Cancer.
Bone Resorption
A novel Bruton's tyrosine kinase inhibitor acalabrutinib suppresses osteoclast differentiation and P. gingivalis lipopolysaccharide-induced alveolar bone resorption.
Bone Resorption
A novel inhibitor of the tyrosine kinase Src suppresses phosphorylation of its major cellular substrates and reduces bone resorption in vitro and in rodent models in vivo.
Bone Resorption
ACP5, a direct transcriptional target of FoxM1, promotes tumor metastasis and indicates poor prognosis in hepatocellular carcinoma.
Bone Resorption
Activation of the receptor EphB4 by its specific ligand ephrin B2 in human osteoarthritic subchondral bone osteoblasts.
Bone Resorption
Activin Receptor Signaling: A Potential Therapeutic Target for Osteoporosis.
Bone Resorption
Bidirectional signaling through ephrinA2-EphA2 enhances osteoclastogenesis and suppresses osteoblastogenesis.
Bone Resorption
BMPRIA is required for osteogenic differentiation and RANKL expression in adult bone marrow mesenchymal stromal cells.
Bone Resorption
Bone cell interactions through Eph/ephrin: Bone modeling, remodeling and associated diseases.
Bone Resorption
Bone morphogenetic protein type IA receptor signaling regulates postnatal osteoblast function and bone remodeling.
Bone Resorption
Bruton's tyrosine kinase (Btk) inhibitor tirabrutinib suppresses osteoclastic bone resorption.
Bone Resorption
c-Src control of chloride channel support for osteoclast HCl transport and bone resorption.
Bone Resorption
Cbp Recruitment of Csk Into Lipid Rafts is Critical to c-Src Kinase Activity and Bone Resorption in Osteoclasts.
Bone Resorption
Compressive force regulates ephrinB2 and EphB4 in osteoblasts and osteoclasts contributing to alveolar bone resorption during experimental tooth movement.
Bone Resorption
Critical role of cortactin in actin ring formation and osteoclastic bone resorption.
Bone Resorption
Cytokines and growth factors in the regulation of bone remodeling.
Bone Resorption
Development and characterization of a porcine model to study osteoclast differentiation and activity.
Bone Resorption
Effects of Porphyromonas gingivalis lipopolysaccharide on osteoblast-osteoclast bidirectional EphB4-EphrinB2 signaling.
Bone Resorption
Effects of Src kinase inhibition by saracatinib (AZD0530) on bone turnover in advanced malignancy in a Phase I study.
Bone Resorption
Effects of the Src Kinase Inhibitor Saracatinib (AZD0530) on Bone Turnover in Healthy Men: A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Phase I Trial.
Bone Resorption
Emerging and potential therapies for osteoporosis.
Bone Resorption
Emerging pharmacologic therapies for osteoporosis.
Bone Resorption
EphB4 enhances the process of endochondral ossification and inhibits remodeling during bone fracture repair.
Bone Resorption
Future anti-catabolic therapeutic targets in bone disease.
Bone Resorption
Fyn positively regulates the activation of DAP12 and FcR?-mediated costimulatory signals by RANKL during osteoclastogenesis.
Bone Resorption
Herbal formulation, Yukmi-jihang-tang-Jahage, regulates bone resorption by inhibition of phosphorylation mediated by tyrosine kinase Src and cyclooxygenase expression.
Bone Resorption
Histone deacetylase 3 supports endochondral bone formation by controlling cytokine signaling and matrix remodeling.
Bone Resorption
In vitro and in vivo suppression of osteoclast function by adenovirus vector-induced csk gene.
Bone Resorption
Inhibition of protein kinase c-Src as a therapeutic approach for cancer and bone metastases.
Bone Resorption
Inhibition of the classical NF-kappaB pathway prevents osteoclast bone-resorbing activity.
Bone Resorption
Inhibitory Effect of Adenovirus-Mediated siRNA-Targeting BMPR-IB on UHMWPE-Induced Bone Destruction in the Murine Air Pouch Model.
Bone Resorption
Intracellular signal transduction pathways: good therapeutic targets for joint destruction in rheumatoid arthritis.
Bone Resorption
Lipoic acid increases the expression of genes involved in bone formation in mice fed a high-fat diet.
Bone Resorption
Loss of BMP signaling mediated by BMPR1A in osteoblasts leads to differential bone phenotypes in mice depending on anatomical location of the bones.
Bone Resorption
Macrophage-stimulating protein activates STK receptor tyrosine kinase on osteoclasts and facilitates bone resorption by osteoclast-like cells.
Bone Resorption
Pharmacologic Calcitriol Inhibits Osteoclast Lineage Commitment via the BMP-Smad1- I?B-NF-?B Pathway.
Bone Resorption
Plectin stabilizes microtubules during osteoclastic bone resorption by acting as a scaffold for Src and Pyk2.
Bone Resorption
Possible involvement of focal adhesion kinase, p125FAK, in osteoclastic bone resorption.
Bone Resorption
Prevalent and Emerging Therapies for Osteoporosis.
Bone Resorption
Prognostic significance of ACP5 expression in patients with lung adenocarcinoma.
Bone Resorption
PTH battles TGF-beta in bone.
Bone Resorption
Pyk2 cytonuclear localization: mechanisms and regulation by serine dephosphorylation.
Bone Resorption
Selective inhibition of Src family kinases by SU6656 increases bone mass by uncoupling bone formation from resorption in mice.
Bone Resorption
Spleen tyrosine kinase (SYK) inhibitor PRT062607 protects against ovariectomy-induced bone loss and breast cancer-induced bone destruction.
Bone Resorption
SRC inhibitors in metastatic bone disease.
Bone Resorption
Src kinase activity is essential for osteoclast function.
Bone Resorption
SRC kinase inhibition: targeting bone metastases and tumor growth in prostate and breast cancer.
Bone Resorption
TBCRC-010: Phase I/II Study of Dasatinib in Combination with Zoledronic Acid for the Treatment of Breast Cancer Bone Metastasis.
Bone Resorption
The potential effect of Bruton's tyrosine kinase in refractory periapical periodontitis.
Bone Resorption
The role of c-Src kinase in the regulation of osteoclast function.
Bone Resorption
Tyrosine kinases Btk and Tec regulate osteoclast differentiation by linking RANK and ITAM signals.
Bone Resorption
UCS15A, a non-kinase inhibitor of Src signal transduction.
Boutonneuse Fever
Endothelial Cell Proteomic Response to Rickettsia conorii Infection Reveals Activation of the Janus Kinase (JAK)-Signal Transducer and Activator of Transcription (STAT)-Inferferon Stimulated Gene (ISG)15 Pathway and Reprogramming Plasma Membrane Integrin/Cadherin Signaling.
Brain Diseases
A Src family kinase inhibitor improves survival in experimental acute liver failure associated with elevated cerebral and circulating vascular endothelial growth factor levels.
Brain Diseases
EphB4 Regulates Self-Renewal, Proliferation and Neuronal Differentiation of Human Embryonic Neural Stem Cells in Vitro.
Brain Diseases
Fyn kinase in brain diseases and cancer: the search for inhibitors.
Brain Diseases
Highly selective inhibition of Bruton's tyrosine kinase attenuates skin and brain disease in murine lupus.
Brain Edema
Blood-brain barrier breakdown and repair by Src after thrombin-induced injury.
Brain Edema
Hydrogen Inhalation Ameliorated Mast Cell-Mediated Brain Injury After Intracerebral Hemorrhage in Mice.
Brain Edema
Levo-tetrahydropalmatine attenuates mouse blood-brain barrier injury induced by focal cerebral ischemia and reperfusion: Involvement of Src kinase.
Brain Edema
PGE2 receptor agonist misoprostol protects brain against intracerebral hemorrhage in mice.
Brain Edema
Postischemic gene transfer of soluble Flt-1 protects against brain ischemia with marked attenuation of blood-brain barrier permeability.
Brain Infarction
Neuroprotective Profile of Novel Src Kinase Inhibitors in Rodent Models of Cerebral Ischemia.
Brain Injuries
Bruton's tyrosine kinase is essential for NLRP3 inflammasome activation and contributes to ischaemic brain injury.
Brain Injuries
c-Abl Tyrosine Kinase-Mediated Neuronal Apoptosis in Subarachnoid Hemorrhage by Modulating the LRP-1-Dependent Akt/GSK3? Survival Pathway.
Brain Injuries
Dectin-1/Syk signaling triggers neuroinflammation after ischemic stroke in mice.
Brain Injuries
Dexmedetomidine Exerts Brain-Protective Effects Under Cardiopulmonary Bypass Through Inhibiting the Janus Kinase 2/Signal Transducers and Activators of Transcription 3 Pathway.
Brain Injuries
Distribution of bone morphogenetic protein and bone morphogenetic protein receptor transcripts in the rodent nervous system and up-regulation of bone morphogenetic protein receptor type II in hippocampal dentate gyrus in a rat model of global cerebral ischemia.
Brain Injuries
Experimental treatment for focal hyperglycemic ischemic brain injury in the rat.
Brain Injuries
Inhibition of Src tyrosine kinase and effect on outcomes in a new in vivo model of surgically induced brain injury.
Brain Injuries
Macrophage-Inducible C-Type Lectin/Spleen Tyrosine Kinase Signaling Pathway Contributes to Neuroinflammation After Subarachnoid Hemorrhage in Rats.
Brain Injuries
Neuroprotection of GluR5-containing Kainate Receptor Activation against Ischemic Brain Injury through Decreasing Tyrosine Phosphorylation of N-Methyl-D-aspartate Receptors Mediated by Src Kinase.
Brain Injuries
Pyk2 inhibition attenuates hypoxic-ischemic brain injury in neonatal mice.
Brain Injuries
Src deficiency or blockade of Src activity in mice provides cerebral protection following stroke.
Brain Injuries
Src kinase inhibition decreases thrombin-induced injury and cell cycle re-entry in striatal neurons.
Brain Injuries
Suppression of etk/bmx protects against ischemic brain injury.
Brain Injuries, Traumatic
Downregulation of Src-kinase and glutamate-receptor phosphorylation after traumatic brain injury.
Brain Injuries, Traumatic
Neuroprotective Profile of Novel Src Kinase Inhibitors in Rodent Models of Cerebral Ischemia.
Brain Ischemia
A transforming growth factor-beta antagonist unmasks the neuroprotective role of this endogenous cytokine in excitotoxic and ischemic brain injury.
Brain Ischemia
c-Abl Tyrosine Kinase-Mediated Neuronal Apoptosis in Subarachnoid Hemorrhage by Modulating the LRP-1-Dependent Akt/GSK3? Survival Pathway.
Brain Ischemia
Delayed phosphorylation of p38 mitogen-activated protein kinase in the AT1a knock-out mouse striatal neurons during middle cerebral artery occlusion and reperfusion.
Brain Ischemia
Distribution of bone morphogenetic protein and bone morphogenetic protein receptor transcripts in the rodent nervous system and up-regulation of bone morphogenetic protein receptor type II in hippocampal dentate gyrus in a rat model of global cerebral ischemia.
Brain Ischemia
Electroacupuncture effect on neurological behavior and tyrosine kinase-JAK 2 in rats with focal cerebral ischemia.
Brain Ischemia
Electroacupuncture effects on cortical neurons, as well as Janus kinase 2-signal transducer and activator of transcription 3 signal transduction pathway, in a rat model of cerebral ischemia.
Brain Ischemia
Levo-tetrahydropalmatine attenuates mouse blood-brain barrier injury induced by focal cerebral ischemia and reperfusion: Involvement of Src kinase.
Brain Ischemia
N-methyl-D-aspartate receptor and L-type voltage-gated Ca2+ channel activation mediate proline-rich tyrosine kinase 2 phosphorylation during cerebral ischemia in rats.
Brain Ischemia
Neuroprotective Profile of Novel Src Kinase Inhibitors in Rodent Models of Cerebral Ischemia.
Brain Ischemia
Non-receptor tyrosine kinase Src is required for ischemia-stimulated neuronal cell proliferation via Raf/ERK/CREB activation in the dentate gyrus.
Brain Ischemia
Postischemic gene transfer of soluble Flt-1 protects against brain ischemia with marked attenuation of blood-brain barrier permeability.
Brain Ischemia
S-Nitrosylation of proline-rich tyrosine kinase 2 involves its activation induced by oxygen-glucose deprivation.
Brain Ischemia
Spry2-mediated inhibition of the Ras/ERK pathway through interaction with Src kinase following cerebral ischemia.
Brain Ischemia
Src family kinase-inhibitor PP2 reduces focal ischemic brain injury.
Brain Ischemia
Src kinase up-regulates the ERK cascade through inactivation of protein phosphatase 2A following cerebral ischemia.
Brain Ischemia
STAT3 signaling after traumatic brain injury.
Brain Ischemia
Study on the mechanism of JAK2/STAT3 signaling pathway-mediated inflammatory reaction after cerebral ischemia.
Brain Ischemia
The role of non-receptor protein tyrosine kinases in the excitotoxicity induced by the overactivation of NMDA receptors.
Brain Ischemia
Two types of calcium channels regulating activation of proline-rich tyrosine kinase 2 induced by transient brain ischemia in rat hippocampus.
Brain Neoplasms
Chondroitin Sulphate Proteoglycans in the Tumour Microenvironment.
Brain Neoplasms
Differential expression of Csk homologous kinase (CHK) in normal brain and brain tumors.
Brain Neoplasms
EphB4 controls blood vascular morphogenesis during postnatal angiogenesis.
Brain Neoplasms
Genome Medicine for Brain Tumors: Current Status and Future Perspectives.
Brain Neoplasms
Kinome profiling in pediatric brain tumors as a new approach for target discovery.
Brain Neoplasms
PTEN-independent induction of caspase-mediated cell death and reduced invasion by the focal adhesion targeting domain (FAT) in human astrocytic brain tumors which highly express focal adhesion kinase (FAK).
Brain Neoplasms
Src Inhibitors Pyrazolo[3,4-d]pyrimidines, Si306 and Pro-Si306, Inhibit Focal Adhesion Kinase and Suppress Human Glioblastoma Invasion In Vitro and In Vivo.
Brain Neoplasms
SYK Inhibition Blocks Proliferation and Migration of Glioma Cells, and Modifies the Tumor Microenvironment.
Brain Neoplasms
Up-Regulation of Hsa-miR-11181 in Glioblastoma Multiforme as A Regulator of AKT2 and TGFBR1 Signalling.
Breast Neoplasms
(-)-Oleocanthal Combined with Lapatinib Treatment Synergized against HER-2 Positive Breast Cancer In Vitro and In Vivo.
Breast Neoplasms
4-Aryl-4H-naphthopyrans derivatives: one-pot synthesis, evaluation of Src kinase inhibitory and anti-proliferative activities.
Breast Neoplasms
?-Catenin haploinsufficiency promotes mammary tumorigenesis in an ErbB2-positive basal breast cancer model.
Breast Neoplasms
A comprehensive, multi-scale dynamical model of ErbB receptor signal transduction in human mammary epithelial cells.
Breast Neoplasms
A highly conserved NTRK3 C-terminal sequence in the ETV6-NTRK3 oncoprotein binds the phosphotyrosine binding domain of insulin receptor substrate-1: an essential interaction for transformation.
Breast Neoplasms
A molecular mechanism for stress-induced alterations in susceptibility to disease.
Breast Neoplasms
A novel adaptor-like protein which is a substrate for the non-receptor tyrosine kinase, BRK.
Breast Neoplasms
A phase I study of the SRC kinase inhibitor dasatinib with trastuzumab and paclitaxel as first line therapy for patients with HER2-overexpressing advanced breast cancer. GEICAM/2010-04 study.
Breast Neoplasms
A Phase II Study of Trastuzumab Emtansine in HER2-Positive Non-Small Cell Lung Cancer.
Breast Neoplasms
A phosphotyrosine switch determines the antitumor activity of ER?.
Breast Neoplasms
A rapid and sensitive method for EphB4 identification as a diagnostic and therapeutic biomarker in invasive breast cancer.
Breast Neoplasms
A rationally designed photo-chemo core-shell nanomedicine for inhibiting the migration of metastatic breast cancer cells followed by photodynamic killing.
Breast Neoplasms
A role for the epithelial-cell-specific tyrosine kinase Sik during keratinocyte differentiation.
Breast Neoplasms
A silent mutation made possible efficient production of active human Frk tyrosine kinase in Escherichia coli.
Breast Neoplasms
Aberrant expression of novel and previously described cell membrane markers in human breast cancer cell lines and tumors.
Breast Neoplasms
Aberration hubs in protein interaction networks highlight actionable targets in cancer.
Breast Neoplasms
ABL tyrosine kinase inhibition variable effects on the invasive properties of different triple negative breast cancer cell lines.
Breast Neoplasms
Activated Src increases adhesion, survival and alpha2-integrin expression in human breast cancer cells.
Breast Neoplasms
Activation of Abl tyrosine kinases promotes invasion of aggressive breast cancer cells.
Breast Neoplasms
Activation of c-Src/HER1/STAT5b and HER1/ERK1/2 Signaling Pathways and Cell Migration by Hexachlorobenzene in MDA-MB-231 Human Breast Cancer Cell Line.
Breast Neoplasms
Activation of JAK2/STAT3 signaling by osteopontin promotes tumor growth in human breast cancer cells.
Breast Neoplasms
Activation of Src in human breast tumor cell lines: elevated levels of phosphotyrosine phosphatase activity that preferentially recognizes the Src carboxy terminal negative regulatory tyrosine 530.
Breast Neoplasms
Activation of the integrin effector kinase focal adhesion kinase in cancer cells is regulated by crosstalk between protein kinase Calpha and the PDZ adapter protein mda-9/Syntenin.
Breast Neoplasms
Adaptation to TKI treatment reactivates ERK signaling in tyrosine kinase-driven leukemias and other malignancies.
Breast Neoplasms
Adipocyte activation of cancer stem cell signaling in breast cancer.
Breast Neoplasms
Aggressive breast cancer cells are dependent on activated Abl kinases for proliferation, anchorage-independent growth and survival.
Breast Neoplasms
AKT1 and AKT2 isoforms play distinct roles during breast cancer progression through the regulation of specific downstream proteins.
Breast Neoplasms
Altered localization and activity of the intracellular tyrosine kinase BRK/Sik in prostate tumor cells.
Breast Neoplasms
Alternative splicing disrupts a nuclear localization signal in spleen tyrosine kinase that is required for invasion suppression in breast cancer.
Breast Neoplasms
An aberrant spliced transcript of focal adhesion kinase is exclusively expressed in human breast cancer.
Breast Neoplasms
An enzyme-linked immunosorbent assay for the determination of src-family tyrosine kinase activity in breast cancer.
Breast Neoplasms
An ErbB2/c-Src axis links bioenergetics with PRC2 translation to drive epigenetic reprogramming and mammary tumorigenesis.
Breast Neoplasms
An essential role for Src kinase in ErbB receptor signaling through the MAPK pathway.
Breast Neoplasms
An evaluation of focal adhesion kinase in breast cancer by tissue microarrays.
Breast Neoplasms
An oncogenic isoform of HER2 associated with locally disseminated breast cancer and trastuzumab resistance.
Breast Neoplasms
Analysis of multiple physical parameters for mechanical phenotyping of living cells.
Breast Neoplasms
Anti-metastatic effect of jolkinolide B and the mechanism of activity in breast cancer MDA-MB-231 cells.
Breast Neoplasms
Anti-oestrogens but not oestrogen deprivation promote cellular invasion in intercellular adhesion-deficient breast cancer cells.
Breast Neoplasms
Anti-tumour effects of antibodies targeting the extracellular cysteine-rich region of the receptor tyrosine kinase EphB4.
Breast Neoplasms
Anticancer Activity of Tubulosine through Suppression of Interleukin-6-Induced Janus Kinase 2/Signal Transducer and Activation of Transcription 3 Signaling.
Breast Neoplasms
Arg/Abl2 promotes invasion and attenuates proliferation of breast cancer in vivo.
Breast Neoplasms
Association of csk-homologous kinase (CHK) (formerly MATK) with HER-2/ErbB-2 in breast cancer cells.
Breast Neoplasms
Association of estrogen receptor alpha and histone deacetylase 6 causes rapid deacetylation of tubulin in breast cancer cells.
Breast Neoplasms
Association of SYK Genetic Variations with Breast Cancer Pathogenesis.
Breast Neoplasms
Atezolizumab potentiates Tcell-mediated cytotoxicity and coordinates with FAK to suppress cell invasion and motility in PD-L1+ triple negative breast cancer cells.
Breast Neoplasms
Atomic force microscopy and graph analysis to study the P-cadherin/SFK mechanotransduction signalling in breast cancer cells.
Breast Neoplasms
ATP7A delivers copper to the lysyl oxidase family of enzymes and promotes tumorigenesis and metastasis.
Breast Neoplasms
BCAR3 regulates Src/p130 Cas association, Src kinase activity, and breast cancer adhesion signaling.
Breast Neoplasms
Benzo-[a]-pyrene induces FAK activation and cell migration in MDA-MB-231 breast cancer cells.
Breast Neoplasms
Beyond genomics.
Breast Neoplasms
Binding of MMP-9-degraded fibronectin to ?6 integrin promotes invasion via the FAK-Src-related Erk1/2 and PI3K/Akt/Smad-1/5/8 pathways in breast cancer.
Breast Neoplasms
Bioinformatics analysis of microarray profiling identifies the mechanism of focal adhesion kinase signalling pathway in proliferation and apoptosis of breast cancer cells modulated by green tea polyphenol epigallocatechin 3-gallate.
Breast Neoplasms
Bosutinib: A review of preclinical studies in chronic myelogenous leukaemia.
Breast Neoplasms
Breast cancer cell line proliferation blocked by the Src-related Rak tyrosine kinase.
Breast Neoplasms
Breast Cancer Malignant Processes are Regulated by Pax-5 Through the Disruption of FAK Signaling Pathways.
Breast Neoplasms
Breast cancer patients' clinical outcome measures are associated with Src kinase family member expression.
Breast Neoplasms
Breast Cancer Special Feature: Mammary epithelial-specific disruption of c-Src impairs cell cycle progression and tumorigenesis.
Breast Neoplasms
Breast Cancer Stem Cells with Tumor- versus Metastasis-Initiating Capacities Are Modulated by TGFBR1 Inhibition.
Breast Neoplasms
Breast cancer vaccines delivered by dendritic cell-targeted lentivectors induce potent antitumor immune responses and protect mice from mammary tumor growth.
Breast Neoplasms
Breast cancer: the menacing face of Janus kinase.
Breast Neoplasms
Breast Tumor Kinase (Brk/PTK6) Is a Mediator of Hypoxia-Associated Breast Cancer Progression.
Breast Neoplasms
Breast Tumor Kinase (Brk/PTK6) Is Induced by HIF, Glucocorticoid Receptor, and PELP1-Mediated Stress Signaling in Triple-Negative Breast Cancer.
Breast Neoplasms
Breast Tumor Kinase (Brk/PTK6) Mediates Advanced Cancer Phenotypes via SH2-Domain Dependent Activation of RhoA and Aryl Hydrocarbon Receptor (AhR) Signaling.
Breast Neoplasms
Breast tumor kinase (Brk/PTK6) plays a role in the differentiation of primary keratinocytes.
Breast Neoplasms
Breast tumor kinase (protein tyrosine kinase 6) regulates heregulin-induced activation of ERK5 and p38 MAP kinases in breast cancer cells.
Breast Neoplasms
Breast tumor kinase and extracellular signal-regulated kinase 5 mediate Met receptor signaling to cell migration in breast cancer cells.
Breast Neoplasms
Breast tumor kinase BRK requires kinesin-2 subunit KAP3A in modulation of cell migration.
Breast Neoplasms
Breast tumor kinase phosphorylates p190RhoGAP to regulate rho and ras and promote breast carcinoma growth, migration, and invasion.
Breast Neoplasms
Breast tumor kinase/protein tyrosine kinase 6 (Brk/PTK6) activity in normal and neoplastic biliary epithelia.
Breast Neoplasms
Brk activates rac1 and promotes cell migration and invasion by phosphorylating paxillin.
Breast Neoplasms
BRK phosphorylates PSF promoting its cytoplasmic localization and cell cycle arrest.
Breast Neoplasms
BRK phosphorylates SMAD4 for proteasomal degradation and inhibits tumor suppressor FRK to control SNAIL, SLUG, and metastatic potential.
Breast Neoplasms
BRK targets Dok1 for ubiquitin-mediated proteasomal degradation to promote cell proliferation and migration.
Breast Neoplasms
Brk/PTK6 cooperates with HER2 and Src in regulating breast cancer cell survival and epithelial-to-mesenchymal transition.
Breast Neoplasms
Brk/PTK6 signaling in normal and cancer cell models.
Breast Neoplasms
Brk/PTK6 sustains activated EGFR signaling through inhibiting EGFR degradation and transactivating EGFR.
Breast Neoplasms
BRK/Sik expression in the gastrointestinal tract and in colon tumors.
Breast Neoplasms
Bruton's Tyrosine Kinase Inhibitors Prevent Therapeutic Escape in Breast Cancer Cells.
Breast Neoplasms
Building a better understanding of the intracellular tyrosine kinase PTK6 - BRK by BRK.
Breast Neoplasms
c-Abl inhibits breast cancer tumorigenesis through reactivation of p53-mediated p21 expression.
Breast Neoplasms
c-Abl regulates estrogen receptor alpha transcription activity through its stabilization by phosphorylation.
Breast Neoplasms
C-SRC tyrosine kinase activity is associated with tumor colonization in bone and lung in an animal model of human breast cancer metastasis.
Breast Neoplasms
cAMP Elevation Down-Regulates ?3 Integrin and Focal Adhesion Kinase and Inhibits Leptin-Induced Migration of MDA-MB-231 Breast Cancer Cells.
Breast Neoplasms
Carboxyl-terminal Src kinase homologous kinase negatively regulates the chemokine receptor CXCR4 through YY1 and impairs CXCR4/CXCL12 (SDF-1alpha)-mediated breast cancer cell migration.
Breast Neoplasms
CD44-mediated oncogenic signaling and cytoskeleton activation during mammary tumor progression.
Breast Neoplasms
CEP-33779 antagonizes ATP-binding cassette subfamily B member 1 mediated multidrug resistance by inhibiting its transport function.
Breast Neoplasms
Characteristics of trials and regulatory pathways leading to US approval of innovative vs. non-innovative oncology drugs.
Breast Neoplasms
Circulating extracellular vesicles from patients with breast cancer enhance migration and invasion via a Src?dependent pathway in MDA?MB?231 breast cancer cells.
Breast Neoplasms
Clinical Evolution of Epithelial-Mesenchymal Transition in Human Carcinomas.
Breast Neoplasms
Clinical significance of high focal adhesion kinase gene copy number and overexpression in invasive breast cancer.
Breast Neoplasms
Cloning and characterisation of cDNAs encoding a novel non-receptor tyrosine kinase, brk, expressed in human breast tumours.
Breast Neoplasms
Clustering of monosialyl-Gb5 initiates downstream signalling events leading to invasion of MCF-7 breast cancer cells.
Breast Neoplasms
Co-crystal structures of PTK6: With Dasatinib at 2.24 ?, with novel imidazo[1,2-a]pyrazin-8-amine derivative inhibitor at 1.70 ? resolution.
Breast Neoplasms
Co-operative effect of c-Src tyrosine kinase and Stat3 in activation of hepatocyte growth factor expression in mammary carcinoma cells.
Breast Neoplasms
Co-overexpression of Janus kinase 2 and signal transducer and activator of transcription 5a promotes differentiation of mammary cancer cells through reversal of epithelial-mesenchymal transition.
Breast Neoplasms
Combined inhibition of EGFR and c-ABL suppresses the growth of fulvestrant-resistant breast cancer cells through miR-375-autophagy axis.
Breast Neoplasms
Combining Src inhibitors and aromatase inhibitors: a novel strategy for overcoming endocrine resistance and bone loss.
Breast Neoplasms
Compensatory function of Pyk2 in the promotion of FAK-null mammary cancer stem cell tumorigenicity and metastatic activity.
Breast Neoplasms
Constitutive activation of breast tumor kinase accelerates cell migration and tumor growth in vivo.
Breast Neoplasms
Constitutive activation of pp125fak in newly isolated human breast cancer cell lines.
Breast Neoplasms
Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells.
Breast Neoplasms
Constitutive tyrosine phosphorylation of ErbB-2 via Jak2 by autocrine secretion of prolactin in human breast cancer.
Breast Neoplasms
Cooperative action of tamoxifen and c-Src inhibition in preventing the growth of estrogen receptor-positive human breast cancer cells.
Breast Neoplasms
Copine-III interacts with ErbB2 and promotes tumor cell migration.
Breast Neoplasms
Copy number variation in ACHE/EPHB4 (7q22) and in BCHE/MME (3q26) genes in sporadic breast cancer.
Breast Neoplasms
Correction: Breast Tumor Kinase Phosphorylates p190RhoGAP to Regulate Rho and Ras and Promote Breast Carcinoma Growth, Migration, and Invasion.
Breast Neoplasms
Corrigendum: RUNX2 Phosphorylation by Tyrosine Kinase ABL Promotes Breast Cancer Invasion.
Breast Neoplasms
Coupling of RAFTK/Pyk2 kinase with c-Abl and their role in the migration of breast cancer cells.
Breast Neoplasms
Crystal structure of the kinase domain of human protein tyrosine kinase 6 (PTK6) at 2.33 ? resolution.
Breast Neoplasms
Csk homologous kinase (CHK) and ErbB-2 interactions are directly coupled with CHK negative growth regulatory function in breast cancer.
Breast Neoplasms
Csk homologous kinase associates with RAFTK/Pyk2 in breast cancer cells and negatively regulates its activation and breast cancer cell migration.
Breast Neoplasms
Csk homologous kinase, a novel signaling molecule, directly associates with the activated ErbB-2 receptor in breast cancer cells and inhibits their proliferation.
Breast Neoplasms
Cucurbitacin B suppresses metastasis mediated by reactive oxygen species (ROS) via focal adhesion kinase (FAK) in breast cancer MDA-MB-231 cells.
Breast Neoplasms
Curbing the focal adhesion kinase and its associated signaling events by pentoxifylline in MDA-MB-231 human breast cancer cells.
Breast Neoplasms
CXCL-12/stromal cell-derived factor-1alpha transactivates HER2-neu in breast cancer cells by a novel pathway involving Src kinase activation.
Breast Neoplasms
Dasatinib inhibits mammary tumour development in a genetically engineered mouse model.
Breast Neoplasms
Dasatinib plus Capecitabine for Advanced Breast Cancer: Safety and Efficacy in Phase I Study CA180004.
Breast Neoplasms
Dasatinib prevents skeletal metastasis of osteotropic MDA-MB-231 cells in a xenograft mouse model.
Breast Neoplasms
DDR2 upregulation confers ferroptosis susceptibility of recurrent breast tumors through the Hippo pathway.
Breast Neoplasms
Decreased tyrosine phosphorylation of focal adhesion kinase after estradiol treatment of MCF-7 human breast carcinoma cells.
Breast Neoplasms
Defining central themes in breast cancer biology by differential proteomics: conserved regulation of cell spreading and focal adhesion kinase.
Breast Neoplasms
Deletion of the BMP receptor BMPR1a impairs mammary tumor formation and metastasis.
Breast Neoplasms
Denbinobin suppresses breast cancer metastasis through the inhibition of Src-mediated signaling pathways.
Breast Neoplasms
Deregulation of the cell cycle by breast tumor kinase (Brk).
Breast Neoplasms
Design, synthesis, and cocrystal structure of a nonpeptide Src SH2 domain ligand.
Breast Neoplasms
Detection of Brk expression in non-small cell lung cancer: clinicopathological relevance.
Breast Neoplasms
Development of radicicol analogues.
Breast Neoplasms
Differential Gene Expression in Ductal Carcinoma In Situ of the Breast Based on ERBB2 Status.
Breast Neoplasms
Discordant ERBB2 Status and Genome Wide DNA Copy Number Alterations in Breast Cancer and Synchronous Lymph Node Metastasis: A Case Report and Literature Review.
Breast Neoplasms
Discovery of 4-anilino ?-carbolines as novel Brk inhibitors.
Breast Neoplasms
Discovery of novel imidazo[1,2-a]pyrazin-8-amines as Brk/PTK6 inhibitors.
Breast Neoplasms
Disruption of focal adhesion kinase slows transendothelial migration of AU-565 breast cancer cells.
Breast Neoplasms
Down-regulation of cathepsin S and matrix metalloproteinase-9 via Src, a non-receptor tyrosine kinase, suppresses triple-negative breast cancer growth and metastasis.
Breast Neoplasms
Doxorubicin induces atypical NF-?B activation through c-Abl kinase activity in breast cancer cells.
Breast Neoplasms
Dual inhibition of focal adhesion kinase and epidermal growth factor receptor pathways cooperatively induces death receptor-mediated apoptosis in human breast cancer cells.
Breast Neoplasms
Dual Mechanisms of LYN Kinase Dysregulation Drive Aggressive Behavior in Breast Cancer Cells.
Breast Neoplasms
Dual Src Kinase/Pretubulin Inhibitor KX-01, Sensitizes ER?-negative Breast Cancers to Tamoxifen through ER? Reexpression.
Breast Neoplasms
Dual targeting of Src and ER prevents acquired antihormone resistance in breast cancer cells.
Breast Neoplasms
Effect of RAD51C expression on the chemosensitivity of E?-Myc p19Arf-/- cells and its clinical significance in breast cancer.
Breast Neoplasms
Effect of triptolide on focal adhesion kinase and survival in MCF-7 breast cancer cells.
Breast Neoplasms
Effects of hyperactive Janus kinase 2 signaling in mammary epithelial cells.
Breast Neoplasms
Effects of simultaneous knockdown of HER2 and PTK6 on malignancy and tumor progression in human breast cancer cells.
Breast Neoplasms
EGFR-c-Src-Mediated HDAC3 Phosphorylation Exacerbates Invasion of Breast Cancer Cells.
Breast Neoplasms
Elevated Levels of StAR-Related Lipid Transfer Protein 3 Alter Cholesterol Balance and Adhesiveness of Breast Cancer Cells: Potential Mechanisms Contributing to Progression of HER2-Positive Breast Cancers.
Breast Neoplasms
Emerging therapeutic targets in breast cancer bone metastasis.
Breast Neoplasms
Endogenous control of cell cycle progression by autocrine transforming growth factor beta in breast cancer cells.
Breast Neoplasms
ENHANCED AND SELECTIVE KILLING OF CHRONIC MYELOGENOUS LEUKEMIA CELLS WITH AN ENGINEERED BCR-ABL BINDING PROTEIN AND IMATINIB.
Breast Neoplasms
Enhanced resistance to tamoxifen by the c-ABL proto-oncogene in breast cancer.
Breast Neoplasms
Enzymatic and immunohistochemical evaluation of tyrosine phosphorylation in breast cancer specimens.
Breast Neoplasms
EphB4 promotes or suppresses Ras/MEK/ERK pathway in a context-dependent manner: Implications for EphB4 as a cancer target.
Breast Neoplasms
EphB4 tyrosine kinase stimulation inhibits growth of MDA-MB-231 breast cancer cells in a dose and time dependent manner.
Breast Neoplasms
Ephrin?B2 inhibits cell proliferation and motility in vitro and predicts longer metastasis?free survival in breast cancer.
Breast Neoplasms
Epidermal growth factor stimulation can substitute for c-Src overexpression in promoting breast carcinoma invasion.
Breast Neoplasms
Epidermal growth factor-receptor activation modulates Src-dependent resistance to lapatinib in breast cancer models.
Breast Neoplasms
Erb-b2 Receptor Tyrosine Kinase 2 (ERBB2) Promotes ATG12-Dependent Autophagy Contributing to Treatment Resistance of Breast Cancer Cells.
Breast Neoplasms
ErbB-inhibitory protein: a modified ectodomain of epidermal growth factor receptor synergizes with dasatinib to inhibit growth of breast cancer cells.
Breast Neoplasms
Erythropoietin Stimulates Tumor Growth via EphB4.
Breast Neoplasms
Estrogen and pure antiestrogen fulvestrant (ICI 182 780) augment cell-matrigel adhesion of MCF-7 breast cancer cells through a novel G protein coupled estrogen receptor (GPR30)-to-calpain signaling axis.
Breast Neoplasms
Estrogen promotes reversible epithelial-to-mesenchymal-like transition and collective motility in MCF-7 breast cancer cells.
Breast Neoplasms
Estrogen receptor alpha phosphorylation and its functional impact in human breast cancer.
Breast Neoplasms
Estrogen receptor signaling regulates the expression of the breast tumor kinase in breast cancer cells.
Breast Neoplasms
Estrogen receptor-{alpha} promotes breast cancer cell motility and invasion via focal adhesion kinase and N-WASP.
Breast Neoplasms
Estrogens and PTP1B Function in a Novel Pathway to Regulate Aromatase Enzymatic Activity in Breast Cancer Cells.
Breast Neoplasms
Etk/Bmx regulates proteinase-activated-receptor1 (PAR1) in breast cancer invasion: signaling partners, hierarchy and physiological significance.
Breast Neoplasms
Etk/Bmx tyrosine kinase activates Pak1 and regulates tumorigenicity of breast cancer cells.
Breast Neoplasms
Evaluation of EphB4 as Target for Image-Guided Surgery of Breast Cancer.
Breast Neoplasms
Evolution of breast cancer therapeutics: Breast tumour kinase's role in breast cancer and hope for breast tumour kinase targeted therapy.
Breast Neoplasms
Exon 16-Skipping HER2 as a Novel Mechanism of Osimertinib Resistance in EGFR L858R/T790M-Positive Non-Small Cell Lung Cancer.
Breast Neoplasms
Exploring Rak tyrosine kinase function in breast cancer.
Breast Neoplasms
Expression of a phosphorylated substrate domain of p130Cas promotes PyMT-induced c-Src-dependent murine breast cancer progression.
Breast Neoplasms
Expression of Ephb2 and Ephb4 in breast carcinoma.
Breast Neoplasms
Expression of GST-fused kinase domain of human Csk homologous kinase from Pichia pastoris facilitates easy purification.
Breast Neoplasms
Expression of MLN64 influences cellular matrix adhesion of breast cancer cells, the role for focal adhesion kinase.
Breast Neoplasms
Expression of Syk in invasive breast cancer: correlation to proliferation and invasiveness.
Breast Neoplasms
Expression of tyrosine kinases in human malignancies as potential targets for kinase-specific inhibitors.
Breast Neoplasms
Expression profile of tyrosine kinases in breast cancer.
Breast Neoplasms
Extracellular AGR3 regulates breast cancer cells migration via Src signaling.
Breast Neoplasms
Extracellular vesicles from young women's breast cancer patients drive increased invasion of non-malignant cells via the Focal Adhesion Kinase pathway: a proteomic approach.
Breast Neoplasms
Extracellular Visfatin-Promoted Malignant Behavior in Breast Cancer Is Mediated Through c-Abl and STAT3 Activation.
Breast Neoplasms
FAK activates AKT-mTOR signaling to promote the growth and progression of MMTV-Wnt1-driven basal-like mammary tumors.
Breast Neoplasms
FAK alters invadopodia and focal adhesion composition and dynamics to regulate breast cancer invasion.
Breast Neoplasms
FAK overexpression and p53 mutations are highly correlated in human breast cancer.
Breast Neoplasms
FAK signaling in cancer-associated fibroblasts promotes breast cancer cell migration and metastasis by exosomal miRNAs-mediated intercellular communication.
Breast Neoplasms
FAK-Copy-Gain Is a Predictive Marker for Sensitivity to FAK Inhibition in Breast Cancer.
Breast Neoplasms
Fascin Activates ?-Catenin Signaling and Promotes Breast Cancer Stem Cell Function Mainly Through Focal Adhesion Kinase (FAK): Relation With Disease Progression.
Breast Neoplasms
Flavonoid effects relevant to cancer.
Breast Neoplasms
Focal adhesion kinase (FAK) deficiency in mononuclear phagocytes alters murine breast tumor progression.
Breast Neoplasms
Focal adhesion kinase and protein kinase B cooperate to suppress Doxorubicin-induced apoptosis of breast tumor cells.
Breast Neoplasms
Focal adhesion kinase contributes to proliferative potential of ErbB2 mammary tumour cells but is dispensable for ErbB2 mammary tumour induction in vivo.
Breast Neoplasms
Focal Adhesion Kinase Fine Tunes Multifaced Signals toward Breast Cancer Progression.
Breast Neoplasms
Focal adhesion kinase N-terminus in breast carcinoma cells induces rounding, detachment and apoptosis.
Breast Neoplasms
Focal adhesion kinase regulates the phosphorylation protein tyrosine phosphatase-? at Tyr789 in breast cancer cells.
Breast Neoplasms
Focal adhesion kinase-related proline-rich tyrosine kinase 2 and focal adhesion kinase are co-overexpressed in early-stage and invasive ErbB-2-positive breast cancer and cooperate for breast cancer cell tumorigenesis and invasiveness.
Breast Neoplasms
Focal adhesion kinase: A prominent determinant in breast cancer initiation, progression and metastasis.
Breast Neoplasms
FRK inhibits breast cancer cell migration and invasion by suppressing epithelial-mesenchymal transition.
Breast Neoplasms
From single- to multi-target drugs in cancer therapy: when aspecificity becomes an advantage.
Breast Neoplasms
Function of focal adhesion kinase scaffolding to mediate endophilin A2 phosphorylation promotes epithelial-mesenchymal transition and mammary cancer stem cell activities in vivo.
Breast Neoplasms
Functional analysis of Csk and CHK kinases in breast cancer cells.
Breast Neoplasms
Functional interaction between the epidermal growth factor receptor and c-Src kinase activity.
Breast Neoplasms
Functional involvement of src and focal adhesion kinase in a CD99 splice variant-induced motility of human breast cancer cells.
Breast Neoplasms
Ganoderic acid A exerts antitumor activity against MDA-MB-231 human breast cancer cells by inhibiting the Janus kinase 2/signal transducer and activator of transcription 3 signaling pathway.
Breast Neoplasms
Geminin overexpression promotes imatinib sensitive breast cancer: a novel treatment approach for aggressive breast cancers, including a subset of triple negative.
Breast Neoplasms
Gene expression profile by inhibiting Raf-1 protein kinase in breast cancer cells.
Breast Neoplasms
Genetic Variability in the microRNA Binding Sites of BMPR1B, TGFBR1, IQGAP1, KRAS, SETD8 and RYR3 and Risk of Breast Cancer in Colombian Women.
Breast Neoplasms
Genetic variation in the JAK/STAT/SOCS signaling pathway influences breast cancer-specific mortality through interaction with cigarette smoking and use of aspirin/NSAIDs: the Breast Cancer Health Disparities Study.
Breast Neoplasms
Growth-related oncogene produced in human breast cancer cells and regulated by Syk protein-tyrosine kinase.
Breast Neoplasms
Heat shock protein 90? stabilizes focal adhesion kinase and enhances cell migration and invasion in breast cancer cells.
Breast Neoplasms
HER2 reduces breast cancer radiosensitivity by activating focal adhesion kinase in vitro and in vivo.
Breast Neoplasms
HER2 regulates Brk/PTK6 stability via upregulating calpastatin, an inhibitor of calpain.
Breast Neoplasms
Heregulin and HER2 signaling selectively activates c-Src phosphorylation at tyrosine 215.
Breast Neoplasms
High expression of focal adhesion kinase (p125FAK) in node-negative breast cancer is related to overexpression of HER-2/neu and activated Akt kinase but does not predict outcome.
Breast Neoplasms
High focal adhesion kinase expression in breast carcinoma is associated with lymphovascular invasion and triple-negative phenotype.
Breast Neoplasms
High focal adhesion kinase expression in invasive breast carcinomas is associated with an aggressive phenotype.
Breast Neoplasms
High-throughput RNAi screening for novel modulators of vimentin expression identifies MTHFD2 as a regulator of breast cancer cell migration and invasion.
Breast Neoplasms
Histochemical staining of protein-tyrosine phosphatase activity in primary human mammary carcinoma: relationship with established prognostic indicators.
Breast Neoplasms
Hsp90 rescues PTK6 from proteasomal degradation in breast cancer cells.
Breast Neoplasms
Human breast cancer cell metastasis is attenuated by lysyl oxidase inhibitors through down-regulation of focal adhesion kinase and the paxillin-signaling pathway.
Breast Neoplasms
Hyaluronan-CD44 interaction promotes c-Src-mediated twist signaling, MicroRNA-10b expression and RhoA/RhoC upregulation leading to Rho-kinase-associated Cytoskeleton Activation and Breast Tumor Cell Invasion.
Breast Neoplasms
Hyperphosphorylated cortactin in cancer cells plays an inhibitory role in cell motility.
Breast Neoplasms
Hypoglycemia-induced c-Jun phosphorylation is mediated by c-Jun N-terminal kinase 1 and Lyn kinase in drug-resistant human breast carcinoma MCF-7/ADR cells.
Breast Neoplasms
Hypoxia-inducible factor-dependent ADAM12 expression mediates breast cancer invasion and metastasis.
Breast Neoplasms
Identification of circulating tumour cells in early stage breast cancer patients using multi marker immunobead RT-PCR.
Breast Neoplasms
Identification of novel SNPs in SYK gene of breast cancer patients: computational analysis of SNPs in the 5'UTR.
Breast Neoplasms
Identification of protein-tyrosine phosphatase 1B as the major tyrosine phosphatase activity capable of dephosphorylating and activating c-Src in several human breast cancer cell lines.
Breast Neoplasms
Identification of STAT3 as a specific substrate of breast tumor kinase.
Breast Neoplasms
Identification of TENM4 as a Novel Cancer Stem Cell-Associated Molecule and Potential Target in Triple Negative Breast Cancer.
Breast Neoplasms
Imatinib mesylate enhances the malignant behavior of human breast carcinoma cells.
Breast Neoplasms
Imatinib reverses doxorubicin resistance by affecting activation of STAT3-dependent NF-?B and HSP27/p38/AKT pathways and by inhibiting ABCB1.
Breast Neoplasms
Immunohistochemically demonstrable pp60(c-SRC) in human breast-cancer.
Breast Neoplasms
Impact of fedratinib on the pharmacokinetics of transporter probe substrates using a cocktail approach.
Breast Neoplasms
Impact of protein tyrosine kinase 6 (PTK6) on human epidermal growth factor receptor (HER) signalling in breast cancer.
Breast Neoplasms
In situ quantification of HER2-protein tyrosine kinase 6 (PTK6) protein-protein complexes in paraffin sections from breast cancer tissues.
Breast Neoplasms
In vitro cytotoxic effect of Trastuzumab in combination with Pertuzumab in breast cancer cells is improved by interleukin-2 activated NK cells.
Breast Neoplasms
In-depth analyses of kinase-dependent tyrosine phosphoproteomes based on metal ion-functionalized soluble nanopolymers.
Breast Neoplasms
Increased expression of miR-551a by c-Fos reduces Focal Adhesion Kinase (FAK) levels and blocks tumorigenesis.
Breast Neoplasms
Induction of transforming growth factor-beta receptor type II expression in estrogen receptor-positive breast cancer cells through SP1 activation by 5-aza-2'-deoxycytidine.
Breast Neoplasms
Inhibition of a specific N-glycosylation activity results in attenuation of breast carcinoma cell invasiveness-related phenotypes: inhibition of epidermal growth factor-induced dephosphorylation of focal adhesion kinase.
Breast Neoplasms
Inhibition of c-ABL sensitizes breast cancer cells to the dual ErbB receptor tyrosine kinase inhibitor lapatinib (GW572016).
Breast Neoplasms
Inhibition of focal adhesion kinase by antisense oligonucleotides enhances the sensitivity of breast cancer cells to camptothecins.
Breast Neoplasms
Inhibition of focal adhesion kinase suppresses the adverse phenotype of endocrine-resistant breast cancer cells and improves endocrine response in endocrine-sensitive cells.
Breast Neoplasms
Inhibition of Ras and STAT3 activity of 4-(tert-butyl)-N-carbamoylbenzamide as antiproliferative agent in HER2-expressing breast cancer cells.
Breast Neoplasms
Inhibition of Src kinases by a selective tyrosine kinase inhibitor causes mitotic arrest.
Breast Neoplasms
Inhibition of SYK kinase does not confer a pro-proliferative or pro-invasive phenotype in breast epithelium or breast cancer cells.
Breast Neoplasms
Inhibition of transforming growth factor beta signaling in MCF-7 cells results in resistance to tumor necrosis factor alpha: a role for Bcl-2.
Breast Neoplasms
Inhibitors of growth factor signalling.
Breast Neoplasms
Integrative genomic analyses of WNT11: transcriptional mechanisms based on canonical WNT signals and GATA transcription factors signaling.
Breast Neoplasms
Integrin-uPAR signaling leads to FRA-1 phosphorylation and enhanced breast cancer invasion.
Breast Neoplasms
Interaction between Brk kinase and insulin receptor substrate-4.
Breast Neoplasms
Interaction of proliferation cell nuclear antigen (PCNA) with c-Abl in cell proliferation and response to DNA damages in breast cancer.
Breast Neoplasms
Interaction of the non-phosphorylated peptide G7-18NATE with Grb7-SH2 domain requires phosphate for enhanced affinity and specificity.
Breast Neoplasms
Interactions of STAP-2 with Brk and STAT3 participate in cell growth of human breast cancer cells.
Breast Neoplasms
Interleukin-1? activates focal adhesion kinase and Src to induce matrix metalloproteinase-9 production and invasion of MCF-7 breast cancer cells.
Breast Neoplasms
Interplay between EphB4 on tumor cells and vascular ephrin-B2 regulates tumor growth.
Breast Neoplasms
Intestinal breast cancer resistance protein (BCRP) requires Janus kinase 3 activity for drug efflux and barrier functions in obesity.
Breast Neoplasms
Intracellular modifiers of integrin alpha 6p production in aggressive prostate and breast cancer cell lines.
Breast Neoplasms
Intramitochondrial Src kinase links mitochondrial dysfunctions and aggressiveness of breast cancer cells.
Breast Neoplasms
Intrinsic focal adhesion kinase activity controls orthotopic breast carcinoma metastasis via the regulation of urokinase plasminogen activator expression in a syngeneic tumor model.
Breast Neoplasms
Involvement of focal adhesion kinase in inhibition of motility of human breast cancer cells by sphingosine 1-phosphate.
Breast Neoplasms
Involvement of Lyn and the Atypical Kinase SgK269/PEAK1 in a Basal Breast Cancer Signaling Pathway.
Breast Neoplasms
Involvement of STAP-2 in Brk-mediated phosphorylation and activation of STAT5 in breast cancer cells.
Breast Neoplasms
Involvement of the chemokine receptor CXCR4 and its ligand stromal cell-derived factor 1alpha in breast cancer cell migration through human brain microvascular endothelial cells.
Breast Neoplasms
Is expression or activation of Src kinase associated with cancer-specific survival in ER-, PR- and HER2-negative breast cancer patients?
Breast Neoplasms
Is telomerase reactivation associated with the down-regulation of TGF beta receptor-II expression in human breast cancer?
Breast Neoplasms
Is there an association with phosphorylation and dephosphorylation of Src kinase at tyrosine 530 and breast cancer patient disease-specific survival.
Breast Neoplasms
JAK2, STAT3 and SOCS3 gene expression in women with and without breast cancer.
Breast Neoplasms
Janus Kinase 1 Plays a Critical Role in Mammary Cancer Progression.
Breast Neoplasms
Janus kinase 2 is required for the initiation but not maintenance of prolactin-induced mammary cancer.
Breast Neoplasms
Knockdown of Bone Morphogenetic Proteins Type 1a Receptor (BMPR1a) in Breast Cancer Cells Protects Bone from Breast Cancer-Induced Osteolysis by Suppressing RANKL Expression.
Breast Neoplasms
KX-01, a novel Src kinase inhibitor directed toward the peptide substrate site, synergizes with tamoxifen in estrogen receptor ? positive breast cancer.
Breast Neoplasms
Lack of interaction between ErbB2 and insulin receptor substrate signaling in breast cancer.
Breast Neoplasms
Leptin induces upregulation of sphingosine kinase 1 in oestrogen receptor-negative breast cancer via Src family kinase-mediated, janus kinase 2-independent pathway.
Breast Neoplasms
LINC00520 is induced by Src, STAT3, and PI3K and plays a functional role in breast cancer.
Breast Neoplasms
Lipid raft specific knockdown of SRC family kinase activity inhibits cell adhesion and cell cycle progression of breast cancer cells.
Breast Neoplasms
Logic-based analysis of gene expression data predicts association between TNF, TGFB1 and EGF pathways in basal-like breast cancer.
Breast Neoplasms
Long non-coding RNA (lncRNA) transcriptional landscape in breast cancer identifies LINC01614 as non-favorable prognostic biomarker regulated by TGF? and focal adhesion kinase (FAK) signaling.
Breast Neoplasms
Loss of EphB4 receptor tyrosine kinase protein expression during carcinogenesis of the human breast.
Breast Neoplasms
Low expression of BMPRIB indicates poor prognosis of breast cancer and is insensitive to taxane-anthracycline chemotherapy.
Breast Neoplasms
Low expression of PTK6/Brk predicts poor prognosis in patients with laryngeal squamous cell carcinoma.
Breast Neoplasms
Lyn modulates Claudin-2 expression and is a therapeutic target for breast cancer liver metastasis.
Breast Neoplasms
Lysyl oxidase regulates breast cancer cell migration and adhesion through a hydrogen peroxide-mediated mechanism.
Breast Neoplasms
Mammary epithelial-specific ablation of the focal adhesion kinase suppresses mammary tumorigenesis by affecting mammary cancer stem/progenitor cells.
Breast Neoplasms
Mammary epithelial-specific disruption of focal adhesion kinase retards tumor formation and metastasis in a transgenic mouse model of human breast cancer.
Breast Neoplasms
Mammary gland specific expression of Brk/PTK6 promotes delayed involution and tumor formation associated with activation of p38 MAPK.
Breast Neoplasms
Mammary gland-specific ablation of focal adhesion kinase reduces the incidence of p53-mediated mammary tumour formation.
Breast Neoplasms
Mechanisms of HGF/Met signaling to Brk and Sam68 in breast cancer progression.
Breast Neoplasms
Metabolic oxidative stress activates signal transduction and gene expression during glucose deprivation in human tumor cells.
Breast Neoplasms
Microparticles Mediate the Intercellular Regulation of microRNA-503 and Proline-Rich Tyrosine Kinase 2 to Alter the Migration and Invasion Capacity of Breast Cancer Cells.
Breast Neoplasms
MicroRNA-204 targets JAK2 in breast cancer and induces cell apoptosis through the STAT3/BCl-2/survivin pathway.
Breast Neoplasms
MicroRNA-7 inhibits multiple oncogenic pathways to suppress HER2?16 mediated breast tumorigenesis and reverse trastuzumab resistance.
Breast Neoplasms
miR-101 promotes breast cancer cell apoptosis by targeting Janus kinase 2.
Breast Neoplasms
miR-146a-5p targets interleukin-1 receptor-associated kinase 1 to inhibit the growth, migration, and invasion of breast cancer cells.
Breast Neoplasms
Mislocalization of cell-cell adhesion complexes in tamoxifen-resistant breast cancer cells with elevated c-Src tyrosine kinase activity.
Breast Neoplasms
Modulating therapeutic effects of the c-Src inhibitor via oestrogen receptor and human epidermal growth factor receptor 2 in breast cancer cell lines.
Breast Neoplasms
Molecular analysis of V617F mutation in Janus kinase 2 gene of breast cancer patients.
Breast Neoplasms
Molecular characterization as a target for cancer therapy in relation to orphan status disorders (Review).
Breast Neoplasms
Molecular characterization of human breast tumor vascular cells.
Breast Neoplasms
Molecular oncology: current trends in diagnostics.
Breast Neoplasms
Monitoring Src status after dasatinib treatment in HER2+ breast cancer with 89Zr-trastuzumab PET imaging.
Breast Neoplasms
MUC16 induced rapid G2/M transition via interactions with JAK2 for increased proliferation and anti-apoptosis in breast cancer cells.
Breast Neoplasms
Mullerian inhibiting substance inhibits breast cancer cell growth through an NFkappa B-mediated pathway.
Breast Neoplasms
Mutant p53 dictates the oncogenic activity of c-Abl in triple-negative breast cancers.
Breast Neoplasms
Myoferlin Depletion Elevates Focal Adhesion Kinase and Paxillin Phosphorylation and Enhances Cell-Matrix Adhesion in Breast Cancer Cells.
Breast Neoplasms
N-(4-hydroxyphenyl)retinamide activation of transforming growth factor-beta and induction of apoptosis in human breast cancer cells.
Breast Neoplasms
N-cadherin mediates the migration of bone marrow-derived mesenchymal stem cells toward breast tumor cells.
Breast Neoplasms
Non-receptor tyrosine kinase 2 reaches its lowest expression levels in human breast cancer during regional nodal metastasis.
Breast Neoplasms
Novel endocrine therapies in breast cancer.
Breast Neoplasms
Novel estrogen receptor-alpha binding sites and estradiol target genes identified by chromatin immunoprecipitation cloning in breast cancer.
Breast Neoplasms
Nuclear p120-catenin contributes to anoikis resistance of Lobular Breast Cancer through Kaiso-dependent Wnt11 expression.
Breast Neoplasms
NVP-BEZ235 or JAKi Treatment leads to decreased survival of examined GBM and BBC cells.
Breast Neoplasms
Oleic acid induces ERK1/2 activation and AP-1 DNA binding activity through a mechanism involving Src kinase and EGFR transactivation in breast cancer cells.
Breast Neoplasms
Oleic acid promotes migration on MDA-MB-231 breast cancer cells through an arachidonic acid-dependent pathway.
Breast Neoplasms
Oncogenic transformation of human mammary epithelial cells by autocrine human growth hormone.
Breast Neoplasms
Optimisation of the RT-PCR detection of immunomagnetically enriched carcinoma cells.
Breast Neoplasms
Optimization, pharmacophore modeling and 3D-QSAR studies of sipholanes as breast cancer migration and proliferation inhibitors.
Breast Neoplasms
Orally bioavailable small-molecule inhibitor of transcription factor Stat3 regresses human breast and lung cancer xenografts.
Breast Neoplasms
Osteopontin increases breast cancer cell sensitivity to specific signaling pathway inhibitors in preclinical models.
Breast Neoplasms
Osteopontin induces AP-1-mediated secretion of urokinase-type plasminogen activator through c-Src-dependent epidermal growth factor receptor transactivation in breast cancer cells.
Breast Neoplasms
Osteopontin promotes vascular endothelial growth factor-dependent breast tumor growth and angiogenesis via autocrine and paracrine mechanisms.
Breast Neoplasms
Over-expression of ERT(ESX/ESE-1/ELF3), an ets-related transcription factor, induces endogenous TGF-beta type II receptor expression and restores the TGF-beta signaling pathway in Hs578t human breast cancer cells.
Breast Neoplasms
Overcoming resistance to fulvestrant (ICI182,780) by Downregulating the c-ABL Proto-Oncogene in breast cancer.
Breast Neoplasms
Overcoming Resistance to Targeted Therapies in Cancer.
Breast Neoplasms
Overexpression of PTK6 (breast tumor kinase) protein--a prognostic factor for long-term breast cancer survival--is not due to gene amplification.
Breast Neoplasms
Overexpression of RhoA-GTP induces activation of the Epidermal Growth Factor Receptor, dephosphorylation of focal adhesion kinase and increased motility in breast cancer cells.
Breast Neoplasms
p130Cas interacts with estrogen receptor alpha and modulates non-genomic estrogen signaling in breast cancer cells.
Breast Neoplasms
p130Cas substrate domain signaling promotes migration, invasion, and survival of estrogen receptor-negative breast cancer cells.
Breast Neoplasms
p185neu is phosphorylated on tyrosine in human primary breast tumors which overexpress neu/erbB-2.
Breast Neoplasms
p53-Dependent repression of focal adhesion kinase in response to estradiol in breast cancer cell-lines.
Breast Neoplasms
PAI-1 induces Src inhibitor resistance via CCL5 in HER2-positive breast cancer cells.
Breast Neoplasms
Paradoxes of the EphB4 receptor in cancer.
Breast Neoplasms
PARP regulates TGF-beta receptor type II expression in estrogen receptor-positive breast cancer cell lines.
Breast Neoplasms
Parthenolide Covalently Targets and Inhibits Focal Adhesion Kinase in Breast Cancer Cells.
Breast Neoplasms
Partial agonistic effect of cetuximab on epidermal growth factor receptor and Src kinase activation in triple?negative breast cancer cell lines.
Breast Neoplasms
PDLIM4/RIL-mediated regulation of Src and malignant properties of breast cancer cells.
Breast Neoplasms
PEAK1 Acts as a Molecular Switch to Regulate Context-Dependent TGF? Responses in Breast Cancer.
Breast Neoplasms
Peptidomimetic Src/Pretubulin Inhibitor KX-01 Alone and in Combination with Paclitaxel Suppresses Growth, Metastasis in Human ER/PR/HER2-Negative Tumor Xenografts.
Breast Neoplasms
Peripheral T lymphocytes from women with breast cancer exhibit abnormal protein expression of several signaling molecules.
Breast Neoplasms
Personalized medicine and pharmacogenetic biomarkers: progress in molecular oncology testing.
Breast Neoplasms
PET imaging of colorectal and breast cancer by targeting EphB4 receptor with 64Cu-labeled hAb47 and hAb131 antibodies.
Breast Neoplasms
PH006, a novel and selective Src kinase inhibitor, suppresses human breast cancer growth and metastasis in vitro and in vivo.
Breast Neoplasms
Pharmacological profiling of a dual FAK/IGF-1R kinase inhibitor TAE226 in cellular and in vivo tumor models.
Breast Neoplasms
Phosphoproteomic Analysis Identifies Focal Adhesion Kinase 2 (FAK2) as a Potential Therapeutic Target for Tamoxifen Resistance in Breast Cancer.
Breast Neoplasms
Phosphorylation of focal adhesion kinase promotes extravasation of breast cancer cells.
Breast Neoplasms
Physical Intimacy of Breast Cancer Cells with Mesenchymal Stem Cells Elicits Trastuzumab Resistance through Src Activation.
Breast Neoplasms
Platelets are associated with xenograft tumor growth and the clinical malignancy of ovarian cancer through an angiogenesis-dependent mechanism.
Breast Neoplasms
Polymorphisms associated with oral clefts as potential susceptibility markers for oral and breast cancer.
Breast Neoplasms
Polymorphisms in the Janus kinase 2 (JAK)/signal transducer and activator of transcription (STAT) genes: putative association of the STAT gene region with familial breast cancer.
Breast Neoplasms
Polyubiquitination and proteasomal degradation of the p185c-erbB-2 receptor protein-tyrosine kinase induced by geldanamycin.
Breast Neoplasms
Post-transcriptional regulation of ERBB2 by miR26a/b and HuR confers resistance to tamoxifen in estrogen receptor-positive breast cancer cells.
Breast Neoplasms
Pressure stimulates breast cancer cell adhesion independently of cell cycle and apoptosis regulatory protein (CARP)-1 regulation of focal adhesion kinase.
Breast Neoplasms
Processing of integrin alpha(v) subunit by membrane type 1 matrix metalloproteinase stimulates migration of breast carcinoma cells on vitronectin and enhances tyrosine phosphorylation of focal adhesion kinase.
Breast Neoplasms
Progesterone receptor enhances breast cancer cell motility and invasion via extranuclear activation of focal adhesion kinase.
Breast Neoplasms
Progesterone receptor isoforms PRA and PRB differentially contribute to breast cancer cell migration through interaction with focal adhesion kinase complexes.
Breast Neoplasms
Prognostic and clinical significance of focal adhesion kinase expression in breast cancer: A systematic review and meta-analysis.
Breast Neoplasms
Prognostic Significance of Focal Adhesion Kinase in Node-Negative Breast Cancer.
Breast Neoplasms
Prognostic value of ephrin B receptors in breast cancer: An online survival analysis using the microarray data of 3,554 patients.
Breast Neoplasms
Prognostic value of periostin in early-stage breast cancer treated with conserving surgery and radiotherapy.
Breast Neoplasms
Prognostic value of protein tyrosine kinase 6 (PTK6) for long-term survival of breast cancer patients.
Breast Neoplasms
Prognostic versus predictive value of biomarkers in oncology.
Breast Neoplasms
Prolactin stimulates the JAK2 and focal adhesion kinase pathways in human breast carcinoma T47-D cells.
Breast Neoplasms
Protein kinases in human breast cancer.
Breast Neoplasms
Protein tyrosine kinase 6 mediates TNF?-induced endothelial barrier dysfunction.
Breast Neoplasms
Protein tyrosine kinase 6 negatively regulates growth and promotes enterocyte differentiation in the small intestine.
Breast Neoplasms
Protein tyrosine kinase 6 promotes ERBB2-induced mammary gland tumorigenesis in the mouse.
Breast Neoplasms
Protein tyrosine kinase 6 regulates mammary gland tumorigenesis in mouse models.
Breast Neoplasms
Protein Tyrosine Kinase 6 Regulates UVB-Induced Signaling and Tumorigenesis in Mouse Skin.
Breast Neoplasms
Protein-tyrosine Phosphatase and Kinase Specificity in Regulation of SRC and Breast Tumor Kinase.
Breast Neoplasms
PTK6/BRK is expressed in the normal mammary gland and activated at the plasma membrane in breast tumors.
Breast Neoplasms
PTPL1/PTPN13 regulates breast cancer cell aggressiveness through direct inactivation of Src kinase.
Breast Neoplasms
Putting the BRK on breast cancer: From molecular target to therapeutics.
Breast Neoplasms
Pyk2 and FAK differentially regulate invadopodia formation and function in breast cancer cells.
Breast Neoplasms
PYK2 integrates growth factor and cytokine receptors signaling and potentiates breast cancer invasion via a positive feedback loop.
Breast Neoplasms
PYK2 promotes HER2-positive breast cancer invasion.
Breast Neoplasms
Pyrazolopyrimidine Derivatives as Antineoplastic Agents: with a Special Focus on Thyroid Cancer.
Breast Neoplasms
Quantitative proteomics and transcriptomics addressing the estrogen receptor subtype-mediated effects in T47D breast cancer cells exposed to the phytoestrogen genistein.
Breast Neoplasms
Radiation promotes malignant phenotypes through SRC in breast cancer cells.
Breast Neoplasms
RAFTK/Pyk2 tyrosine kinase mediates the association of p190 RhoGAP with RasGAP and is involved in breast cancer cell invasion.
Breast Neoplasms
Randomized phase-II evaluation of letrozole plus dasatinib in hormone receptor positive metastatic breast cancer patients.
Breast Neoplasms
Rapid Discovery and Structure-Activity Relationships of Pyrazolopyrimidines That Potently Suppress Breast Cancer Cell Growth via SRC Kinase Inhibition with Exceptional Selectivity over ABL Kinase.
Breast Neoplasms
Reactivation of SYK expression by inhibition of DNA methylation suppresses breast cancer cell invasiveness.
Breast Neoplasms
Reactivation of Syk gene by AZA suppresses metastasis but not proliferation of breast cancer cells.
Breast Neoplasms
Receptor tyrosine kinase EphB4 is a survival factor in breast cancer.
Breast Neoplasms
Reciprocal regulation of Abl and receptor tyrosine kinases.
Breast Neoplasms
Reconstruction of Different Modes of WNT Dependent Protein Networks from Time Series Protein Quantification.
Breast Neoplasms
Reduced expression of BMPR-IB correlates with poor prognosis and increased proliferation of breast cancer cells.
Breast Neoplasms
Reduced expression of the murine HLA-G homolog Qa-2 is associated with malignancy, epithelial-mesenchymal transition and stemness in breast cancer cells.
Breast Neoplasms
Regulated association of protein kinase B/Akt with breast tumor kinase.
Breast Neoplasms
Regulation of focal adhesion kinase activation, breast cancer cell motility, and amoeboid invasion by the RhoA guanine nucleotide exchange factor Net1.
Breast Neoplasms
Relative levels of let-7a, miR-17, miR-27b, miR-125a, miR-125b and miR-206 as potential molecular markers to evaluate grade, receptor status and molecular type in breast cancer.
Breast Neoplasms
Repression of Fyn-related kinase in breast cancer cells is associated with promoter site-specific CpG methylation.
Breast Neoplasms
Repression of transforming growth factor-beta receptor type I promoter expression by Sp1 deficiency.
Breast Neoplasms
Requirement of ER? and basal activities of EGFR and Src kinase in Cd-induced activation of MAPK/ERK pathway in human breast cancer MCF-7 cells.
Breast Neoplasms
Responsiveness to transforming growth factor-beta (TGF-beta)-mediated growth inhibition is a function of membrane-bound TGF-beta type II receptor in human breast cancer cells.
Breast Neoplasms
Retinoic acid increases tyrosine phosphorylation of focal adhesion kinase and paxillin in MCF-7 human breast cancer cells.
Breast Neoplasms
Role of breast tumour kinase in the in vitro differentiation of HaCaT cells.
Breast Neoplasms
Role of c-Myb during prolactin-induced signal transducer and activator of transcription 5a signaling in breast cancer cells.
Breast Neoplasms
Role of c-Src and focal adhesion kinase in progression and metastasis of estrogen receptor-positive breast cancer.
Breast Neoplasms
Role of LOXs and COX-2 on FAK activation and cell migration induced by linoleic acid in MDA-MB-231 breast cancer cells.
Breast Neoplasms
Role of microRNA-150-5p/SRCIN1 axis in the progression of breast cancer.
Breast Neoplasms
Role of Src in breast cancer cell migration and invasion in a breast cell/bone-derived cell microenvironment.
Breast Neoplasms
Role of the Brk SH3 domain in substrate recognition.
Breast Neoplasms
RRR-alpha-tocopheryl succinate enhances TGF-beta 1, -beta 2, and -beta 3 and TGF-beta R-II expression by human MDA-MB-435 breast cancer cells.
Breast Neoplasms
RUNX2 Phosphorylation by Tyrosine Kinase ABL Promotes Breast Cancer Invasion.
Breast Neoplasms
S100P and HYAL2 as prognostic markers for patients with triple-negative breast cancer.
Breast Neoplasms
Sanguinarine combats hypoxia-induced activation of EphB4 and HIF-1? pathways in breast cancer.
Breast Neoplasms
Selective targeting of c-Abl via a cryptic mitochondrial targeting signal activated by cellular redox status in leukemic and breast cancer cells.
Breast Neoplasms
Shorter disease-specific survival of ER-positive breast cancer patients with high cytoplasmic Src kinase expression after tamoxifen treatment.
Breast Neoplasms
SHPS-1: a budding molecule against cancer dissemination.
Breast Neoplasms
Signal transducer and activator of transcription 5b: a new target of breast tumor kinase/protein tyrosine kinase 6.
Breast Neoplasms
Signaling pathway of globo-series glycosphingolipids and ?1,3-galactosyltransferase V (?3GalT5) in breast cancer.
Breast Neoplasms
SKI-606 (bosutinib), a novel Src kinase inhibitor, suppresses migration and invasion of human breast cancer cells.
Breast Neoplasms
Small molecule chloropyramine hydrochloride (C4) targets the binding site of focal adhesion kinase and vascular endothelial growth factor receptor 3 and suppresses breast cancer growth in vivo.
Breast Neoplasms
Small Non-Coding RNA Profiling Identifies miR-181a-5p as a Mediator of Estrogen Receptor Beta-Induced Inhibition of Cholesterol Biosynthesis in Triple-Negative Breast Cancer.
Breast Neoplasms
Solution structure and backbone dynamics of the non-receptor protein-tyrosine kinase-6 Src homology 2 domain.
Breast Neoplasms
Somatic acquisition and signaling of TGFBR1*6A in cancer.
Breast Neoplasms
Sortilin is associated with breast cancer aggressiveness and contributes to tumor cell adhesion and invasion.
Breast Neoplasms
Sp1-mediated epigenetic dysregulation dictates HDAC inhibitor susceptibility of HER2-overexpressing breast cancer.
Breast Neoplasms
Specific induction of pp125 focal adhesion kinase in human breast cancer.
Breast Neoplasms
Spleen tyrosine kinase (SYK) inhibitor PRT062607 protects against ovariectomy-induced bone loss and breast cancer-induced bone destruction.
Breast Neoplasms
Splicing imbalances in basal-like breast cancer underpin perturbation of cell surface and oncogenic pathways and are associated with patients' survival.
Breast Neoplasms
Sporadic mutations and expression analysis of spleen tyrosine kinase gene in breast cancer: a preliminary report.
Breast Neoplasms
SRC as a therapeutic target in breast cancer.
Breast Neoplasms
Src family kinases mediate epidermal growth factor receptor signaling from lipid rafts in breast cancer cells.
Breast Neoplasms
Src Inhibition Blocks c-Myc Translation and Glucose Metabolism to Prevent the Development of Breast Cancer.
Breast Neoplasms
Src inhibitors in breast cancer therapy.
Breast Neoplasms
SRC kinase inhibition: targeting bone metastases and tumor growth in prostate and breast cancer.
Breast Neoplasms
Src kinase promotes adhesion-independent activation of FAK and enhances cellular migration in tamoxifen-resistant breast cancer cells.
Breast Neoplasms
Src kinase regulates metalloproteinase-9 secretion induced by type IV collagen in MCF-7 human breast cancer cells.
Breast Neoplasms
Src kinase: a therapeutic opportunity in endocrine-responsive and resistant breast cancer.
Breast Neoplasms
Src phosphorylates Tyr284 in TGF-beta type II receptor and regulates TGF-beta stimulation of p38 MAPK during breast cancer cell proliferation and invasion.
Breast Neoplasms
SRC promotes lipogenesis: implications for obesity and breast cancer.
Breast Neoplasms
SRC tyrosine kinase activates the YAP/TAZ axis and thereby drives tumor growth and metastasis.
Breast Neoplasms
STAP-2 is phosphorylated at tyrosine-250 by Brk and modulates Brk-mediated STAT3 activation.
Breast Neoplasms
Star-related lipid transfer protein 10 (STARD10): a novel key player in alcohol-induced breast cancer progression.
Breast Neoplasms
Stat3 is tyrosine-phosphorylated through the interleukin-6/glycoprotein 130/Janus kinase pathway in breast cancer.
Breast Neoplasms
STI571 sensitizes breast cancer cells to 5-fluorouracil, cisplatin and camptothecin in a cell type-specific manner.
Breast Neoplasms
Subcellular localization of total and activated Src kinase in African American and Caucasian breast cancer.
Breast Neoplasms
Suppressor of cytokine signaling 3 inhibits breast tumor kinase activation of STAT3.
Breast Neoplasms
SWIM domain protein ZSWIM4 is required for JAK2 inhibition resistance in breast cancer.
Breast Neoplasms
Syk, a protein-tyrosine kinase, suppresses the cell motility and nuclear factor kappa B-mediated secretion of urokinase type plasminogen activator by inhibiting the phosphatidylinositol 3'-kinase activity in breast cancer cells.
Breast Neoplasms
Syndecan-1 modulates ?-integrin-dependent and interleukin-6-dependent functions in breast cancer cell adhesion, migration, and resistance to irradiation.
Breast Neoplasms
Synergistic anticancer effects of ruxolitinib and calcitriol in estrogen receptor?positive, human epidermal growth factor receptor 2?positive breast cancer cells.
Breast Neoplasms
Synthesis of 3-phenylpyrazolopyrimidine-1,2,3-triazole conjugates and evaluation of their Src kinase inhibitory and anticancer activities.
Breast Neoplasms
Synthesis, Src Kinase Inhibitory and Anticancer Activities of 1-Substituted 3-(N-Alkyl-N-phenylamino)propane-2-ols.
Breast Neoplasms
TAD1822-7 induces ROS-mediated apoptosis of HER2 positive breast cancer by decreasing E-cadherin in an EphB4 dependent manner.
Breast Neoplasms
TAE226-induced apoptosis in breast cancer cells with overexpressed Src or EGFR.
Breast Neoplasms
Targeting BRK-Positive Breast Cancers with Small-Molecule Kinase Inhibitors.
Breast Neoplasms
Targeting c-Src kinase enhances tamoxifen's inhibitory effect on cell growth by modulating expression of cell cycle and survival proteins.
Breast Neoplasms
Targeting focal adhesion kinase in ER+/HER2+ breast cancer improves trastuzumab response.
Breast Neoplasms
Targeting invadopodia-mediated breast cancer metastasis by using ABL kinase inhibitors.
Breast Neoplasms
Targeting janus kinase 2 in Her2/neu-expressing mammary cancer: Implications for cancer prevention and therapy.
Breast Neoplasms
Targeting on glycosylation of mutant FLT3 in acute myeloid leukemia.
Breast Neoplasms
Targeting p70S6K Prevented Lung Metastasis in a Breast Cancer Xenograft Model.
Breast Neoplasms
Targeting the EphB4 receptor tyrosine kinase sensitizes HER2-positive breast cancer cells to Lapatinib.
Breast Neoplasms
Taxol Induces Brk-dependent Prosurvival Phenotypes in TNBC Cells through an AhR/GR/HIF-driven Signaling Axis.
Breast Neoplasms
TBCRC-010: Phase I/II Study of Dasatinib in Combination with Zoledronic Acid for the Treatment of Breast Cancer Bone Metastasis.
Breast Neoplasms
Tenascin C induces epithelial-mesenchymal transition-like change accompanied by SRC activation and focal adhesion kinase phosphorylation in human breast cancer cells.
Breast Neoplasms
TGF-? stimulates Pyk2 expression as part of an epithelial-mesenchymal transition program required for metastatic outgrowth of breast cancer.
Breast Neoplasms
TGF-beta induces formation of F-actin cores and matrix degradation in human breast cancer cells via distinct signaling pathways.
Breast Neoplasms
TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development.
Breast Neoplasms
TGF? isoforms and receptors mRNA expression in breast tumours: prognostic value and clinical implications.
Breast Neoplasms
TGFB1 and TGFBR1 polymorphisms and breast cancer risk in the Nurses' Health Study.
Breast Neoplasms
TGFBR1 polymorphism and risk of breast cancer in Iranian women.
Breast Neoplasms
TGFBR1 Signaling and Breast Cancer.
Breast Neoplasms
TGFBR1(*)6A and Int7G24A variants of transforming growth factor-beta receptor 1 in Swedish familial and sporadic breast cancer.
Breast Neoplasms
The Alternative Splice Variant of Protein Tyrosine Kinase 6 Negatively Regulates Growth and Enhances PTK6-Mediated Inhibition of ?-Catenin.
Breast Neoplasms
The associated pyrazolopyrimidines PP1 and PP2 inhibit protein tyrosine kinase 6 activity and suppress breast cancer cell proliferation.
Breast Neoplasms
The c-Yes 3'-UTR contains adenine/uridine-rich elements that bind AUF1 and HuR involved in mRNA decay in breast cancer cells.
Breast Neoplasms
The Cain and Abl of epithelial-mesenchymal transition and transforming growth factor-? in mammary epithelial cells.
Breast Neoplasms
The coexpression of EphB4 and EphrinB2 is associated with poor prognosis in HER2-positive breast cancer [Retraction].
Breast Neoplasms
The coexpression of EphB4 and EphrinB2 is associated with poor prognosis in HER2-positive breast cancer.
Breast Neoplasms
The Concentration of Microvesicles Isolated from Peripheral Blood in Breast Cancer Patients is Elevated.
Breast Neoplasms
The direct effect of focal adhesion kinase (FAK), dominant-negative FAK, FAK-CD and FAK siRNA on gene expression and human MCF-7 breast cancer cell tumorigenesis.
Breast Neoplasms
The EphB4 receptor suppresses breast cancer cell tumorigenicity through an Abl-Crk pathway.
Breast Neoplasms
The focal adhesion kinase suppresses transformation-associated, anchorage-independent apoptosis in human breast cancer cells. Involvement of death receptor-related signaling pathways.
Breast Neoplasms
The impact of Thr91 mutation on c-Src resistance to UM-164: molecular dynamics study revealed a new opportunity for drug design.
Breast Neoplasms
The intensification of anticancer activity of LFM-A13 by erythropoietin as a possible option for inhibition of breast cancer.
Breast Neoplasms
The lysyl oxidase pro-peptide attenuates fibronectin-mediated activation of focal adhesion kinase and p130Cas in breast cancer cells.
Breast Neoplasms
The non-receptor tyrosine kinase TNK2/ACK1 is a novel therapeutic target in triple negative breast cancer.
Breast Neoplasms
The prognostic value of Stathmin-1, S100A2, and SYK proteins in ER-positive primary breast cancer patients treated with adjuvant tamoxifen monotherapy: an immunohistochemical study.
Breast Neoplasms
The protein-tyrosine kinase Syk interacts with TRAF-interacting protein TRIP in breast epithelial cells.
Breast Neoplasms
The relation between anti-TGBFR1 immunohistochemical reaction and low Ki67, small tumor size and high estrogen receptor expression in invasive breast cancer.
Breast Neoplasms
The relationship between phosphorylation status of focal adhesion kinases, molecular subtypes, tumour microenvironment and survival in patients with primary operable ductal breast cancer.
Breast Neoplasms
The RNA binding protein Sam68 is acetylated in tumor cell lines, and its acetylation correlates with enhanced RNA binding activity.
Breast Neoplasms
The role of EphB4 and IGF-IR expression in breast cancer cells.
Breast Neoplasms
The role of insulin receptor substrate-1 in transformation by v-src.
Breast Neoplasms
The role of tyrosine kinase Etk/Bmx in EGF-induced apoptosis of MDA-MB-468 breast cancer cells.
Breast Neoplasms
The Ron receptor tyrosine kinase activates c-Abl to promote cell proliferation through tyrosine phosphorylation of PCNA in breast cancer.
Breast Neoplasms
The Src kinase pathway promotes tamoxifen agonist action in Ishikawa endometrial cells through phosphorylation-dependent stabilization of estrogen receptor (alpha) promoter interaction and elevated steroid receptor coactivator 1 activity.
Breast Neoplasms
The Syk Kinase Promotes Mammary Epithelial Integrity and Inhibits Breast Cancer Invasion by Stabilizing the E-Cadherin/Catenin Complex.
Breast Neoplasms
The Syk tyrosine kinase localizes to the centrosomes and negatively affects mitotic progression.
Breast Neoplasms
The tyrosine kinase Abl is required for Src-transforming activity in mouse fibroblasts and human breast cancer cells.
Breast Neoplasms
The unique N-terminal region of SRMS regulates enzymatic activity and phosphorylation of its novel substrate docking protein 1.
Breast Neoplasms
The von Hippel-Lindau Tumor Suppressor Protein Is Destabilized by Src: Implications for Tumor Angiogenesis and Progression.
Breast Neoplasms
Time Trends in Receipt of Germline Genetic Testing and Results for Women Diagnosed With Breast Cancer or Ovarian Cancer, 2012-2019.
Breast Neoplasms
TNF?/IFN? Mediated Intestinal Epithelial Barrier Dysfunction Is Attenuated by MicroRNA-93 Downregulation of PTK6 in Mouse Colonic Epithelial Cells.
Breast Neoplasms
Tracing the footprints of the breast cancer oncogene BRK - Past till present.
Breast Neoplasms
TRAF3 in T Cells Restrains Negative Regulators of LAT to Promote TCR/CD28 Signaling.
Breast Neoplasms
Transcription repressor activity of spleen tyrosine kinase mediates breast tumor suppression.
Breast Neoplasms
Translational evidence on the role of Src kinase and activated Src kinase in invasive breast cancer.
Breast Neoplasms
Trastuzumab-induced recruitment of Csk-homologous kinase (CHK) to ErbB2 receptor is associated with ErbB2-Y1248 phosphorylation and ErbB2 degradation to mediate cell growth inhibition.
Breast Neoplasms
TrkB Inhibits the BMP Signaling-Mediated Growth Inhibition of Cancer Cells.
Breast Neoplasms
Tyrosine kinase p56lck regulates cell motility and nuclear factor kappaB-mediated secretion of urokinase type plasminogen activator through tyrosine phosphorylation of IkappaBalpha following hypoxia/reoxygenation.
Breast Neoplasms
Tyrosine kinase, p56lck-induced cell motility, and urokinase-type plasminogen activator secretion involve activation of epidermal growth factor receptor/extracellular signal regulated kinase pathways.
Breast Neoplasms
Tyrosine phosphorylation of HDAC3 by Src kinase mediates proliferation of HER2-positive breast cancer cells.
Breast Neoplasms
Tyrosine phosphorylation of sam68 by breast tumor kinase regulates intranuclear localization and cell cycle progression.
Breast Neoplasms
Tyrosine Phosphorylation Profiling Reveals the Signaling Network Characteristics of Basal Breast Cancer Cells.
Breast Neoplasms
Use of RNA interference to validate Brk as a novel therapeutic target in breast cancer: Brk promotes breast carcinoma cell proliferation.
Breast Neoplasms
Vascular endothelial growth factor receptor-3 and focal adhesion kinase bind and suppress apoptosis in breast cancer cells.
Breast Neoplasms
Viewing the Eph receptors with a focus on breast cancer heterogeneity.
Breast Neoplasms
Wilms' tumor 1 protein and focal adhesion kinase mediate keratinocyte growth factor signaling in breast cancer cells.
Breast Neoplasms
WNT11 is a direct target of early growth response protein 1.
Breast Neoplasms
[Biological mechanism of full-length form of spleen tyrosine kinase regulating gene transcription in breast cancer cells]
Breast Neoplasms
[Construction of the eukaryotic expression vector of human syk and its effect on MHC-I expression of human breast cancer cells.]
Breast Neoplasms
[Current management and future prospect of HER-2 mutant non-small cell lung cancer].
Breast Neoplasms
[Effect of Janus kinase inhibitor AG490 on invasion and metastasis of human breast cancer cells]
Breast Neoplasms
[Effect of SRC Kinase on Adriamycin Resistance and Invasion and Metastasis in Human Breast Cancer Cells].
Breast Neoplasms
[Expression of deleted in liver cancer 1 and phosphorelated focal adhesion kinase in breast cancer].
Breast Neoplasms
[Focal adhesion kinase expression and angiogenesis in breast carcinoma]
Breast Neoplasms
[Hereditary breast carcinomas pathologist's perspective].
Breast Neoplasms
[Janus kinase 3 facilitates the migration of breast cancer cells by store-operated calcium channel].
Breast Neoplasms
[Molecular Targeted Therapy and Laboratory Tests].
Breast Neoplasms
[PP2 enhances intercellular communication of gap junction in breast cancer Hs578T cells].
Breast Neoplasms
[Spleen tyrosine kinase (L) suppresses breast cancer development by downregulating the expression of cyclin D1, ID1, B-myb and Fra1]
Brucellosis
Activation of bovine neutrophils by Brucella spp.
Budd-Chiari Syndrome
Association of factor V Leiden, Janus kinase 2, prothrombin, and MTHFR mutations with primary Budd-Chiari syndrome in Egyptian patients.
Budd-Chiari Syndrome
Budd-Chiari syndrome.
Budd-Chiari Syndrome
Janus Kinase 2 Mutation-Associated Budd-Chiari Syndrome Presenting as a Tumor.
Budd-Chiari Syndrome
Prevalence and clinical outcomes of the 46/1 haplotype, Janus kinase 2 mutations, and ten-eleven translocation 2 mutations in Budd-Chiari syndrome and their impact on thrombotic complications post liver transplantation.
Budd-Chiari Syndrome
Prevalence of the activating JAK2 tyrosine kinase mutation V617F in the Budd-Chiari syndrome.
Budd-Chiari Syndrome
Pseudocirrhosis in Chronic Budd Chiari Syndrome With Janus Tyrosine Kinase 2 (JAK2) Mutation.
Burkitt Lymphoma
A novel STAT inhibitor, OPB-31121, has a significant antitumor effect on leukemia with STAT-addictive oncokinases.
Burkitt Lymphoma
Antitumor activity of new pyrazolo[3,4-d]pyrimidine SRC kinase inhibitors in Burkitt lymphoma cell lines and its enhancement by WEE1 inhibition.
Burkitt Lymphoma
c-Ha-ras1 is not deleted in aniridia-Wilms' tumour association.
Burkitt Lymphoma
Calpain inhibitor II induces caspase-dependent apoptosis in human acute lymphoblastic leukemia and non-Hodgkin's lymphoma cells as well as some solid tumor cells.
Burkitt Lymphoma
Cell cycle-dependent modulation of alpha-interferon-inducible gene expression and activation of signaling components in Daudi cells.
Burkitt Lymphoma
Expression of p56lck in B-cell neoplasias.
Burkitt Lymphoma
Ibrutinib significantly inhibited Bruton's tyrosine kinase (BTK) phosphorylation,in-vitro proliferation and enhanced overall survival in a preclinical Burkitt lymphoma (BL) model.
Burkitt Lymphoma
Immunohistochemical analysis of ZAP-70 expression in B-cell lymphoid neoplasms.
Burkitt Lymphoma
Immunohistochemical detection of ZAP-70 in 341 cases of non-Hodgkin and Hodgkin lymphoma.
Burkitt Lymphoma
In defense of the somatic mutation theory of cancer.
Burkitt Lymphoma
Purification and characterization of proteins with associated tyrosine protein kinase activity from human B lymphocytes.
Burkitt Lymphoma
Rearrangements of c-myc and c-abl genes in tumour cells in Burkitt's lymphoma.
Burkitt Lymphoma
Resistance to TGF-beta1 correlates with a reduction of TGF-beta type II receptor expression in Burkitt's lymphoma and Epstein-Barr virus-transformed B lymphoblastoid cell lines.
Burkitt Lymphoma
Some questions on the significance of chromosome alterations in leukemias and lymphomas: a review.
Burkitt Lymphoma
ZAP-70 expression in normal pro/pre B cells, mature B cells, and in B-cell acute lymphoblastic leukemia.
Bursitis
Genetic variants involved in extracellular matrix homeostasis play a role in the susceptibility to frozen shoulder: a case-control study.
Candidiasis
Mendelian traits causing susceptibility to mucocutaneous fungal infections in human subjects.
Candidiasis, Chronic Mucocutaneous
Mendelian traits causing susceptibility to mucocutaneous fungal infections in human subjects.
Carcinogenesis
"Masked" Ph1-chromosome in chronic myelogenous leukaemia (CML).
Carcinogenesis
17-hydroxy-jolkinolide B inhibits signal transducers and activators of transcription 3 signaling by covalently cross-linking Janus kinases and induces apoptosis of human cancer cells.
Carcinogenesis
A common phosphotyrosine signature for the Bcr-Abl kinase.
Carcinogenesis
A common polymorphism in pre-microRNA-146a is associated with lung cancer risk in a Korean population.
Carcinogenesis
A haplotype of TGFBR1 is predominantly found in non-small cell lung cancer patients displaying TGFBR1 allelic-specific expression.
Carcinogenesis
A mutation at the major phosphotyrosine in pp60v-src alters oncogenic potential.
Carcinogenesis
A novel Src kinase inhibitor reduces tumour formation in a skin carcinogenesis model.
Carcinogenesis
A requirement for SOCS-1 and SOCS-3 phosphorylation in Bcr-Abl-induced tumorigenesis.
Carcinogenesis
A Swiss 3T3 variant cell line resistant to the effects of tumor promoters cannot be transformed by src.
Carcinogenesis
Ab initio modeling and experimental assessment of Janus Kinase 2 (JAK2) kinase-pseudokinase complex structure.
Carcinogenesis
Abelson kinase's intrinsically disordered region plays essential roles in protein function and protein stability.
Carcinogenesis
Aberrant SYK Kinase Signaling Is Essential for Tumorigenesis Induced by TSC2 Inactivation.
Carcinogenesis
ABL Genomic Editing Sufficiently Abolishes Oncogenesis of Human Chronic Myeloid Leukemia Cells In Vitro and In Vivo.
Carcinogenesis
Abl interconnects oncogenic Met and p53 core pathways in cancer cells.
Carcinogenesis
Acacetin and pinostrobin as a promising inhibitor of cancer-associated protein kinases.
Carcinogenesis
Activated Abl kinase inhibits oncogenic transforming growth factor-{beta} signaling and tumorigenesis in mammary tumors.
Carcinogenesis
Activation of abl family kinases in solid tumors.
Carcinogenesis
Activation of beta-catenin-TCF-mediated transcription by non-receptor tyrosine kinase v-Src.
Carcinogenesis
Activation of the c-Src tyrosine kinase is required for the induction of mammary tumors in transgenic mice.
Carcinogenesis
Activation of the receptor protein tyrosine kinase EphB4 in endometrial hyperplasia and endometrial carcinoma.
Carcinogenesis
ADAM9 as a potential target molecule in cancer.
Carcinogenesis
Adaptors for disorders of the brain? The cancer signaling proteins NEDD9, CASS4, and PTK2B in Alzheimer's disease.
Carcinogenesis
AGO2 phosphorylation by c-Src kinase promotes tumorigenesis.
Carcinogenesis
Alteration of cell growth and morphology by overexpression of transforming growth factor beta type II receptor in human lung adenocarcinoma cells.
Carcinogenesis
Alterations of the transforming growth factor-beta signaling pathway in hepatocellular carcinomas induced endogenously and exogenously in rats.
Carcinogenesis
An ultrasensitive high-throughput electrochemiluminescence immunoassay for the Cdc42-associated protein tyrosine kinase ACK1.
Carcinogenesis
Analysis of microsatellite instability and loss of heterozygosity in uterine endometrial adenocarcinoma.
Carcinogenesis
Antitumor activity of saracatinib (AZD0530), a c-Src/Abl kinase inhibitor, alone or in combination with chemotherapeutic agents in gastric cancer.
Carcinogenesis
BCR-ABL oncogenic transformation of NIH 3T3 fibroblasts requires the IL-3 receptor.
Carcinogenesis
Bone morphogenetic protein signaling suppresses tumorigenesis at gastric epithelial transition zones in mice.
Carcinogenesis
Breakpoint cluster region-c-abl oncogene 1, non-receptor tyrosine kinase signaling: current patterns of the versatile regulator revisited.
Carcinogenesis
Breast Cancer Special Feature: Mammary epithelial-specific disruption of c-Src impairs cell cycle progression and tumorigenesis.
Carcinogenesis
c-Abl in oxidative stress, aging and cancer.
Carcinogenesis
c-Abl inhibits breast cancer tumorigenesis through reactivation of p53-mediated p21 expression.
Carcinogenesis
c-Abl: activation and nuclear targets.
Carcinogenesis
C-Src and c-Yes are two unlikely partners of spermatogenesis and their roles in blood-testis barrier dynamics.
Carcinogenesis
Caffeic acid, a phenolic phytochemical in coffee, directly inhibits Fyn kinase activity and UVB-induced COX-2 expression.
Carcinogenesis
Cancer prevention and therapy through the modulation of the tumor microenvironment.
Carcinogenesis
Cancer-associated mutations activate the nonreceptor tyrosine kinase Ack1.
Carcinogenesis
Cantharidin treatment inhibits hepatocellular carcinoma development by regulating the JAK2/STAT3 and PI3K/Akt pathways in an EphB4-dependent manner.
Carcinogenesis
Chemopreventive and Chemotherapeutic Actions of mTOR Inhibitor in Genetically Defined Head and Neck Squamous Cell Carcinoma Mouse Model.
Carcinogenesis
Co-overexpression of AXL and c-ABL predicts a poor prognosis in esophageal adenocarcinoma and promotes cancer cell survival.
Carcinogenesis
Comparative genomics on Wnt5a and Wnt5b genes.
Carcinogenesis
Constitutional activation of IL-6-mediated JAK/STAT pathway through hypermethylation of SOCS-1 in human gastric cancer cell line.
Carcinogenesis
Constitutive activation of the Janus kinase-STAT pathway in T lymphoma overexpressing the Lck protein tyrosine kinase.
Carcinogenesis
Constitutive expression of mature transforming growth factor beta1 in the liver accelerates hepatocarcinogenesis in transgenic mice.
Carcinogenesis
Copy number variation in ACHE/EPHB4 (7q22) and in BCHE/MME (3q26) genes in sporadic breast cancer.
Carcinogenesis
Cortactin and focal adhesion kinase as predictors of cancer risk in patients with laryngeal premalignancy.
Carcinogenesis
Csk-binding protein (Cbp) negatively regulates epidermal growth factor-induced cell transformation by controlling Src activation.
Carcinogenesis
Cucurbitacin B inhibits cell proliferation and induces apoptosis in human osteosarcoma cells via modulation of the JAK2/STAT3 and MAPK pathways.
Carcinogenesis
CXCR7 promotes melanoma tumorigenesis via Src kinase signaling.
Carcinogenesis
Cyclin-dependent kinase 1-mediated phosphorylation of YES links mitotic arrest and apoptosis during antitubulin chemotherapy.
Carcinogenesis
Dasatinib enhances cisplatin sensitivity in human esophageal squamous cell carcinoma (ESCC) cells via suppression of PI3K/AKT and Stat3 pathways.
Carcinogenesis
Dasatinib-induced autophagy is enhanced in combination with temozolomide in glioma.
Carcinogenesis
Decreased expression of JAK1 associated with immune infiltration and poor prognosis in lung adenocarcinoma.
Carcinogenesis
Decreased focal adhesion kinase suppresses papilloma formation during experimental mouse skin carcinogenesis.
Carcinogenesis
Dehydrocrenatidine is a novel janus kinase inhibitor.
Carcinogenesis
Development of TGF-beta resistance during malignant progression.
Carcinogenesis
Development of transgenic mice that inducibly express an active form of c-Src in the epidermis.
Carcinogenesis
Differential gene expression in colon carcinoma cells and tissues detected with a cDNA array.
Carcinogenesis
Differential protein expression and oncogenic gene network link tyrosine kinase ephrin B4 receptor to aggressive gastric and gastroesophageal junction cancers.
Carcinogenesis
Differential regulation of cell motility and invasion by FAK.
Carcinogenesis
Differential roles of Src in transforming growth factor-ß regulation of growth arrest, epithelial-to-mesenchymal transition and cell migration in pancreatic ductal adenocarcinoma cells.
Carcinogenesis
Discovery and evaluation of triple inhibitors of VEGFR-2, TIE-2 and EphB4 as anti-angiogenic and anti-cancer agents.
Carcinogenesis
Discovery of novel anti-angiogenesis agents. Part 10: Multi-target inhibitors of VEGFR-2, Tie-2 and EphB4 incorporated with 1,2,3-triazol.
Carcinogenesis
Discovery of novel anti-angiogenesis agents. Part 8: Diaryl thiourea bearing 1H-indazole-3-amine as multi-target RTKs inhibitors.
Carcinogenesis
Disruption of postnatal folliculogenesis and development of ovarian tumor in a mouse model with aberrant transforming growth factor beta signaling.
Carcinogenesis
Distinct and opposite roles for SH2 and SH3 domains of v-src in embryo survival and hemangiosarcoma formation.
Carcinogenesis
DNA methylation-mediated downregulation of PTPN3 attenuates to boost TGF-? signaling in osteosarcoma cells.
Carcinogenesis
Dominant effects of the bcr-abl oncogene on Drosophila morphogenesis.
Carcinogenesis
Down-regulation of EphB4 phosphorylation is necessary for esophageal squamous cell carcinoma tumorigenecity.
Carcinogenesis
Down-regulation of the tumor suppressor gene C-terminal Src kinase: an early event during premalignant colonic epithelial hyperproliferation.
Carcinogenesis
Downregulation of spleen tyrosine kinase in hepatocellular carcinoma by promoter CpG island hypermethylation and its potential role in carcinogenesis.
Carcinogenesis
Downregulation of transforming growth factor beta type II receptor in laryngeal carcinogenesis.
Carcinogenesis
Downregulation of uPAR inhibits migration, invasion, proliferation, FAK/PI3K/Akt signaling and induces senescence in papillary thyroid carcinoma cells.
Carcinogenesis
Dual Drug Targeting of Mutant Bcr-Abl Induces Inactive Conformation: New Strategy for the Treatment of Chronic Myeloid Leukemia and Overcoming Monotherapy Resistance.
Carcinogenesis
Effect of chemopreventive agents on intermediate biomarkers during different stages of azoxymethane-induced colon carcinogenesis.
Carcinogenesis
Effect of ets-related transcription factor (ERT) on transforming growth factor (TGF)-beta type II receptor gene expression in human cancer cell lines.
Carcinogenesis
Efficient disruption of bcr-abl gene by CRISPR RNA-guided FokI nucleases depresses the oncogenesis of chronic myeloid leukemia cells.
Carcinogenesis
Emerging Roles of Wnt Ligands in Human Colorectal Cancer.
Carcinogenesis
Enforced SOCS1 and SOCS3 expression attenuates Lck-mediated cellular transformation.
Carcinogenesis
Enhanced tumorigenesis and reduced transforming growth factor-beta type II receptor in lung tumors from mice with reduced gene dosage of transforming growth factor-beta1.
Carcinogenesis
Enhancement of tyrosyl phosphorylation and protein expression of eps8 by v-Src.
Carcinogenesis
EphB4 is overexpressed in gliomas and promotes the growth of glioma cells.
Carcinogenesis
EphB4 is overexpressed in papillary thyroid carcinoma and promotes the migration of papillary thyroid cancer cells.
Carcinogenesis
EPHB4 tyrosine-kinase receptor expression and biological significance in soft tissue sarcoma.
Carcinogenesis
Ergosterol peroxide inhibits ovarian cancer cell growth through multiple pathways.
Carcinogenesis
Essential roles of BMPR-IA signaling in differentiation and growth of hair follicles and in skin tumorigenesis.
Carcinogenesis
Evolution of somatic mutations in mammary tumors in transgenic mice is influenced by the inherited genotype.
Carcinogenesis
Examination of the role of CSF-1 independence in myc retrovirus induced monocyte tumorigenesis.
Carcinogenesis
Expression levels of EPHB4, EFNB2 and caspase-8 are associated with clinicopathological features and progression of esophageal squamous cell cancer.
Carcinogenesis
Expression of c-Ki-ras, c-Ha-ras, and c-myc in specific cell types during hepatocarcinogenesis.
Carcinogenesis
Expression of receptor tyrosine kinase EphB4 and its ligand ephrin-B2 is associated with malignant potential in endometrial cancer.
Carcinogenesis
Expression of STAT3 and Bcl-6 oncoprotein in sodium arsenite-treated SV-40 immortalized human uroepithelial cells.
Carcinogenesis
Expression of the signal transducer and activator of transcription factor 3 and Janus kinase 3 in colorectal carcinomas, colonic adenomas and ulcerative colitis.
Carcinogenesis
Flavonoids as Protein Kinase Inhibitors for Cancer Chemoprevention: Direct Binding and Molecular Modeling.
Carcinogenesis
Focal adhesion kinase (FAK) inhibitor-defactinib suppresses the malignant progression of human esophageal squamous cell carcinoma (ESCC) cells via effective blockade of PI3K/AKT axis and downstream molecular network.
Carcinogenesis
Focal Adhesion Kinase Expression in Ameloblastoma: A Preliminary Observational Study.
Carcinogenesis
Focal Adhesion Kinase Fine Tunes Multifaced Signals toward Breast Cancer Progression.
Carcinogenesis
Focal adhesion kinase is required for intestinal regeneration and tumorigenesis downstream of Wnt/c-Myc signaling.
Carcinogenesis
Focal adhesion kinase overexpression and its impact on human osteosarcoma.
Carcinogenesis
Focal adhesion kinase-related proline-rich tyrosine kinase 2 and focal adhesion kinase are co-overexpressed in early-stage and invasive ErbB-2-positive breast cancer and cooperate for breast cancer cell tumorigenesis and invasiveness.
Carcinogenesis
From tumorigenesis to microenvironment and immunoregulation: the many faces of focal adhesion kinase and challenges associated with targeting this elusive protein.
Carcinogenesis
From xeroderma pigmentosum to the biological clock contributions of Dirk Bootsma to human genetics.
Carcinogenesis
Genetic changes in the transforming growth factor beta (TGF-beta) type II receptor gene in human gastric cancer cells: correlation with sensitivity to growth inhibition by TGF-beta.
Carcinogenesis
Genetic engineering to study testicular tumorigenesis.
Carcinogenesis
Genomic amplification upregulates estrogen-related receptor alpha and its depletion inhibits oral squamous cell carcinoma tumors in vivo.
Carcinogenesis
Granulosa Cell-Expressed BMPR1A and BMPR1B Have Unique Functions in Regulating Fertility but Act Redundantly to Suppress Ovarian Tumor Development.
Carcinogenesis
Helicobacter pylori infection and lung cancer: a review of an emerging hypothesis.
Carcinogenesis
Hepatitis C virus NS5A protein interacts with and negatively regulates the non-receptor protein tyrosine kinase Syk.
Carcinogenesis
High expression of FER tyrosine kinase predicts poor prognosis in clear cell renal cell carcinoma.
Carcinogenesis
High expression of long non-coding RNA H19 is required for efficient tumorigenesis induced by Bcr-Abl oncogene.
Carcinogenesis
Histone deacetylases inhibitor sodium butyrate inhibits JAK2/STAT signaling through upregulation of SOCS1 and SOCS3 mediated by HDAC8 inhibition in myeloproliferative neoplasms.
Carcinogenesis
HMGB1 promotes HCC progression partly by downregulating p21 via ERK/c-Myc pathway and upregulating MMP-2.
Carcinogenesis
Ibrutinib exerts potent antifibrotic and antitumor activities in mouse models of pancreatic adenocarcinoma.
Carcinogenesis
Idelalisib induces G1 arrest and apoptosis in chronic myeloid leukemia K562 cells.
Carcinogenesis
Identification of new MHC-restriction elements for presentation of the p210(BCR-ABL) fusion region to human cytotoxic T lymphocytes.
Carcinogenesis
Imaging focal adhesion kinase activation in breast cancer-promoting cell proliferation and carcinogenesis, but not migration, invasion, or metastatic predilection.
Carcinogenesis
Imatinib mesylate in chronic myeloid leukemia: a prospective, single arm, non-randomized study.
Carcinogenesis
Imatinib restores VASP activity and its interaction with Zyxin in BCR-ABL leukemic cells.
Carcinogenesis
Immunogenicity of a p210(BCR-ABL) fusion domain candidate DNA vaccine targeted to dendritic cells by a recombinant adeno-associated virus vector in vitro.
Carcinogenesis
Important players in carcinogenesis as potential targets in cancer therapy: an update.
Carcinogenesis
In vitro phosphorylation of caveolin-rich membrane domains: identification of an associated serine kinase activity as a casein kinase II-like enzyme.
Carcinogenesis
In vivo tumor surveillance by NK cells requires TYK2 but not TYK2 kinase activity.
Carcinogenesis
INCB018424 induces apoptotic cell death through the suppression of pJAK1 in human colon cancer cells.
Carcinogenesis
Increased expression of focal adhesion kinase correlates with cellular proliferation and apoptosis during 4-nitroquinoline-1-oxide-induced rat tongue carcinogenesis.
Carcinogenesis
Increased expression of miR-551a by c-Fos reduces Focal Adhesion Kinase (FAK) levels and blocks tumorigenesis.
Carcinogenesis
Increased immunoreactivity and protein tyrosine kinase activity of the protooncogene pp60c-src in preneoplastic lesions in rat pancreas.
Carcinogenesis
Increases in c-Yes expression level and activity promote motility but not proliferation of human colorectal carcinoma cells.
Carcinogenesis
Interaction of Abl Tyrosine Kinases with SOCS3 Impairs Its Suppressor Function in Tumorigenesis.
Carcinogenesis
Interplay between EphB4 on tumor cells and vascular ephrin-B2 regulates tumor growth.
Carcinogenesis
JAK2V617F promotes replication fork stalling with disease-restricted impairment of the intra-S checkpoint response.
Carcinogenesis
Janus Kinase 2 Inhibitor AG490 Inhibits the STAT3 Signaling Pathway by Suppressing Protein Translation of gp130.
Carcinogenesis
Kit and PDGFR-alpha activities are necessary for Notch4/Int3-induced tumorigenesis.
Carcinogenesis
Knockout of LASP1 in CXCR4 expressing CML cells promotes cell persistence, proliferation and TKI resistance.
Carcinogenesis
Liver tyrosine kinase activation during early stages of chemical hepatocarcinogenesis.
Carcinogenesis
Liver-specific expressions of HBx and src in the p53 mutant trigger hepatocarcinogenesis in zebrafish.
Carcinogenesis
Loss of EphB4 receptor tyrosine kinase protein expression during carcinogenesis of the human breast.
Carcinogenesis
Loss of TGF-beta type II receptor in fibroblasts promotes mammary carcinoma growth and invasion through upregulation of TGF-alpha-, MSP- and HGF-mediated signaling networks.
Carcinogenesis
Lymph node metastasis is mediated by suppressor of cytokine signaling-3 in gastric cancer.
Carcinogenesis
Malignant transformation of an epithelial cell by v-Src via tv-a-mediated retroviral infection: a new cell model for studying carcinogenesis.
Carcinogenesis
Mammary epithelial-specific ablation of the focal adhesion kinase suppresses mammary tumorigenesis by affecting mammary cancer stem/progenitor cells.
Carcinogenesis
Mammary tumors expressing the neu proto-oncogene possess elevated c-Src tyrosine kinase activity.
Carcinogenesis
Mapping of hereditary mixed polyposis syndrome (HMPS) to chromosome 10q23 by genomewide high-density single nucleotide polymorphism (SNP) scan and identification of BMPR1A loss of function.
Carcinogenesis
mDia1 targets v-Src to the cell periphery and facilitates cell transformation, tumorigenesis, and invasion.
Carcinogenesis
Mdm2 phosphorylation by Akt regulates the p53 response to oxidative stress to promote cell proliferation and tumorigenesis.
Carcinogenesis
Mechanisms in the chemoprevention of colon cancer: modulation of protein kinase C, tyrosine protein kinase and diacylglycerol kinase activities by 1,4-phenylenebis-(methylene)selenocyanate and impact of low-fat diet.
Carcinogenesis
Microsatellite alteration at chromosome 11 in primary human nasopharyngeal carcinoma in Taiwan.
Carcinogenesis
Microsatellite instability and mutated type II transforming growth factor-beta receptor gene in gliomas.
Carcinogenesis
Microsatellite instability(MSI) in non-small cell lung cancer(NSCLC) is highly associated with transforming growth factor-beta type II receptor(TGF-beta RII) frameshift mutation.
Carcinogenesis
miR-140-5p alleviates the aggressive progression of Wilms' tumor through directly targeting TGFBR1 gene.
Carcinogenesis
MiR-203 regulates JAK-STAT pathway in affecting pancreatic cancer cells proliferation and apoptosis by targeting SOCS3.
Carcinogenesis
MiR-221 inhibits proliferation of pancreatic cancer cells via down regulation of SOCS3.
Carcinogenesis
MiR-340 affects gastric cancer cell proliferation, cycle, and apoptosis through regulating SOCS3/JAK-STAT signaling pathway.
Carcinogenesis
miR-656 inhibits glioma tumorigenesis through repression of BMPR1A.
Carcinogenesis
MLKL inhibits intestinal tumorigenesis by suppressing STAT3 signaling pathway.
Carcinogenesis
Modulating effect of amount and types of dietary fat on ornithine decarboxylase, tyrosine protein kinase and prostaglandins production during colon carcinogenesis in male F344 rats.
Carcinogenesis
Molecular cloning and characterization of human WNT11.
Carcinogenesis
Molecular dimensions of gastrointestinal tumors: some thoughts for digestion.
Carcinogenesis
Morphologic and molecular analysis of estrogen-induced pituitary tumorigenesis in targeted disruption of transforming growth factor-beta receptor type II and/or p27 mice.
Carcinogenesis
Muc1 affects c-Src signaling in PyV MT-induced mammary tumorigenesis.
Carcinogenesis
Mutational analysis of the transforming growth factor beta receptor type II gene in hereditary nonpolyposis colorectal cancer and early-onset colorectal cancer patients.
Carcinogenesis
Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas.
Carcinogenesis
Mutations of the transforming growth factor-beta type II receptor gene and genomic instability in hereditary nonpolyposis colorectal cancer.
Carcinogenesis
Mutations of the transforming growth factor-beta type II receptor gene are strongly related to sporadic proximal colon carcinomas with microsatellite instability.
Carcinogenesis
Myristoylation of Src kinase mediates Src induced and high fat diet accelerated prostate tumor progression in mice.
Carcinogenesis
New and emerging Bruton tyrosine kinase inhibitors for treating mantle cell lymphoma - where do they fit in?
Carcinogenesis
Noncanonical Wnt11 inhibits hepatocellular carcinoma cell proliferation and migration.
Carcinogenesis
Novel insights into c-Src.
Carcinogenesis
Over-Expression of Ephb4 Is Associated with Carcinogenesis of Gastric Cancer.
Carcinogenesis
Overexpression and significance of focal adhesion kinase in hepatocellular carcinoma and its relationship with HBV infection.
Carcinogenesis
Overexpression of cellular Src in fibroblasts enhances endocytic internalization of epidermal growth factor receptor.
Carcinogenesis
p53 regulates FAK expression in human tumor cells.
Carcinogenesis
Paracrine Fibroblast Growth Factor Initiates Oncogenic Synergy with Epithelial FGFR/Src Transformation in Prostate Tumor Progression.
Carcinogenesis
Paradoxes of the EphB4 receptor in cancer.
Carcinogenesis
Pathological significance and prognostic significance of FES expression in bladder cancer vary according to tumor grade.
Carcinogenesis
Phase II Study of Paclitaxel and Dasatinib in Metastatic Breast Cancer.
Carcinogenesis
Phosphoinositide-3-Kinase Enhancers, PIKEs: Their Biological Functions and Roles in Cancer.
Carcinogenesis
Phosphorylation of dedicator of cytokinesis 1 (Dock180) at tyrosine residue Y722 by Src family kinases mediates EGFRvIII-driven glioblastoma tumorigenesis.
Carcinogenesis
Phosphorylation of Dok1 by Abl family kinases inhibits CrkI transforming activity.
Carcinogenesis
Phosphorylation of focal adhesion kinase at Tyr397 in gastric carcinomas and its clinical significance.
Carcinogenesis
Preclinical efficacy for a novel tyrosine kinase inhibitor, ArQule 531 against acute myeloid leukemia.
Carcinogenesis
Prognostic significance and correlation with survival of bcl-2 and TGF-beta RII in colon cancer.
Carcinogenesis
Prognostic value of protein tyrosine kinase 6 (PTK6) for long-term survival of breast cancer patients.
Carcinogenesis
Protein tyrosine kinase 6 promotes ERBB2-induced mammary gland tumorigenesis in the mouse.
Carcinogenesis
Protein tyrosine kinase 6 regulates mammary gland tumorigenesis in mouse models.
Carcinogenesis
Protein Tyrosine Kinase 6 Regulates UVB-Induced Signaling and Tumorigenesis in Mouse Skin.
Carcinogenesis
Proteomics Analysis of Cellular Imatinib Targets and their Candidate Downstream Effectors.
Carcinogenesis
Pterostilbene exerts antitumor activity against human osteosarcoma cells by inhibiting the JAK2/STAT3 signaling pathway.
Carcinogenesis
Quantitative modeling of chronic myeloid leukemia: insights from radiobiology.
Carcinogenesis
RalA mediates v-Src, v-Ras, and v-Raf regulation of CD44 and fibronectin expression in NIH3T3 fibroblasts.
Carcinogenesis
Ras- and PI3K-dependent breast tumorigenesis in mice and humans requires focal adhesion kinase signaling.
Carcinogenesis
Redox Circuitries Driving Src Regulation.
Carcinogenesis
Reduced transforming growth factor-beta type II receptor (TGF-beta RII) expression in adenocarcinoma of the lung.
Carcinogenesis
Reduction in transforming growth factor-beta type II receptor in mouse lung carcinogenesis.
Carcinogenesis
Retroviral expression screening of oncogenes in pancreatic ductal carcinoma.
Carcinogenesis
Role of cyclooxygenase 2 in protein kinase C beta II-mediated colon carcinogenesis.
Carcinogenesis
Role of erbB3 receptors in cancer therapeutic resistance.
Carcinogenesis
Role of Focal Adhesion Kinase in Head and Neck Squamous Cell Carcinoma and Its Therapeutic Prospect.
Carcinogenesis
Role of Pyk2 in Human Cancers.
Carcinogenesis
Role of SRC kinases in Neu-induced tumorigenesis: challenging the paradigm using Csk homologous kinase transgenic mice.
Carcinogenesis
Roles of Src family kinase, Ras, and mTOR signaling in intestinal epithelial homeostasis and tumorigenesis.
Carcinogenesis
Selective elimination of cancer cells by the adenovirus E4orf4 protein in a Drosophila cancer model: a new paradigm for cancer therapy.
Carcinogenesis
Selective pyrrolo-pyrimidine inhibitors reveal a necessary role for Src family kinases in Bcr-Abl signal transduction and oncogenesis.
Carcinogenesis
SP2509, an inhibitor of LSD1, exerts potential antitumor effects by targeting the JAK/STAT3 signaling.
Carcinogenesis
Specific Expression of a New Bruton Tyrosine Kinase Isoform (p65BTK) in the Glioblastoma Gemistocytic Histotype.
Carcinogenesis
Src family kinases phosphorylate protein kinase C delta on tyrosine residues and modify the neoplastic phenotype of skin keratinocytes.
Carcinogenesis
Src SUMOylation Inhibits Tumor Growth Via Decreasing FAK Y925 Phosphorylation.
Carcinogenesis
SSeCKS/Gravin/AKAP12 attenuates expression of proliferative and angiogenic genes during suppression of v-Src-induced oncogenesis.
Carcinogenesis
STAT5b, a Mediator of Synergism between c-Src and the Epidermal Growth Factor Receptor.
Carcinogenesis
Structural and biophysical characterization of the EphB4*ephrinB2 protein-protein interaction and receptor specificity.
Carcinogenesis
Structure and chromosomal localization of the human gene of the phosphotyrosyl phosphatase activator (PTPA) of protein phosphatase 2A.
Carcinogenesis
Structure and regulation of the c-Fes protein-tyrosine kinase.
Carcinogenesis
Structure, regulation, signaling, and targeting of abl kinases in cancer.
Carcinogenesis
Study of cytokine signaling: the quest for immunomodulatory drugs interacting with cytokine production and activity.
Carcinogenesis
Suppression of malignant growth potentials of v-Src-transformed human gallbladder epithelial cells by adenovirus-mediated dominant negative H-Ras.
Carcinogenesis
Suppression of protein tyrosine phosphatase N23 predisposes to breast tumorigenesis via activation of FYN kinase.
Carcinogenesis
Targeted inhibition of SRC kinase signaling attenuates pancreatic tumorigenesis.
Carcinogenesis
Targeting Focal Adhesion Kinase Suppresses the Malignant Phenotype in Rhabdomyosarcoma Cells.
Carcinogenesis
Targeting receptor tyrosine kinase EphB4 in cancer therapy.
Carcinogenesis
Targeting Small Molecule Tyrosine Kinases by Polyphenols: New Move Towards Anti-tumor Drug Discovery.
Carcinogenesis
Targeting the JAK/STAT Signaling Pathway Using Phytocompounds for Cancer Prevention and Therapy.
Carcinogenesis
TFAP2C-mediated upregulation of TGFBR1 promotes lung tumorigenesis and epithelial-mesenchymal transition.
Carcinogenesis
TGF-beta signaling is disrupted in endometrioid-type endometrial carcinomas.
Carcinogenesis
The Activation of MEK/ERK Signaling Pathway by Bone Morphogenetic Protein 4 to Increase Hepatocellular Carcinoma Cell Proliferation and Migration.
Carcinogenesis
The Cain and Abl of epithelial-mesenchymal transition and transforming growth factor-? in mammary epithelial cells.
Carcinogenesis
The calpain system and cancer.
Carcinogenesis
The contrasting oncogenic and tumor suppressor roles of FES.
Carcinogenesis
The Crosstalk between FAK and Wnt Signaling Pathways in Cancer and Its Therapeutic Implication.
Carcinogenesis
The Crosstalk between Src and Hippo/YAP Signaling Pathways in Non-Small Cell Lung Cancer (NSCLC).
Carcinogenesis
The direct effect of focal adhesion kinase (FAK), dominant-negative FAK, FAK-CD and FAK siRNA on gene expression and human MCF-7 breast cancer cell tumorigenesis.
Carcinogenesis
The embryonic environment strongly attenuates v-src oncogenesis in mesenchymal and epithelial tissues, but not in endothelia.
Carcinogenesis
The expression and tyrosine phosphorylation of E-cadherin/catenin adhesion complex, and focal adhesion kinase in invasive cervical carcinomas.
Carcinogenesis
The genomic structure of the gene encoding the human transforming growth factor beta type II receptor (TGF-beta RII).
Carcinogenesis
The N-terminal domain of the non-receptor tyrosine kinase ABL confers protein instability and suppresses tumorigenesis.
Carcinogenesis
The nonreceptor tyrosine kinase c-Src attenuates SCF(?-TrCP) E3-ligase activity abrogating Taz proteasomal degradation.
Carcinogenesis
The nuclear factor kappa-B signaling pathway as a therapeutic target against thyroid cancers.
Carcinogenesis
The receptor tyrosine kinase EPHB4 has tumor suppressor activities in intestinal tumorigenesis.
Carcinogenesis
The receptor-like protein tyrosine phosphatase alpha: a role in cell proliferation and oncogenesis.
Carcinogenesis
The Role of Focal Adhesion Kinase in Lung Cancer.
Carcinogenesis
The Role of STAT3 in Thyroid Cancer.
Carcinogenesis
The Src Family Kinase Inhibitors PP2 and PP1 block TGF-beta1-Mediated Cellular Responses by Direct and Differential Inhibition of Type I and Type II TGF-beta Receptors.
Carcinogenesis
The SRC-family tyrosine kinase HCK shapes the landscape of SKAP2 interactome.
Carcinogenesis
Therapeutic approaches in myelofibrosis and myelodysplastic/myeloproliferative overlap syndromes.
Carcinogenesis
Therapeutic targeting of the focal adhesion complex prevents oncogenic TGF-beta signaling and metastasis.
Carcinogenesis
Therapy-related chronic myeloid leukemia: an epidemiological, clinical and pathogenetic appraisal.
Carcinogenesis
Three Tyrosine Residues in the Erythropoietin Receptor Are Essential for Janus Kinase 2 V617F Mutant-induced Tumorigenesis.
Carcinogenesis
Thymic tumorigenesis induced by overexpression of p56lck.
Carcinogenesis
Transcriptome profiling reveals target in primary myelofibrosis together with structural biology study on novel natural inhibitors regarding JAK2.
Carcinogenesis
Transforming growth factor beta type II receptor gene mutations in adenomas from hereditary nonpolyposis colorectal cancer.
Carcinogenesis
Transforming growth factor-beta 1 and its receptors in human lung cancer and mouse lung carcinogenesis.
Carcinogenesis
Transforming growth factor-beta receptor type 2 mutations and microsatellite instability in sporadic colorectal adenomas and carcinomas.
Carcinogenesis
Transforming Growth Factor-beta Receptors: Role in Physiology and Disease.
Carcinogenesis
Transforming growth factor-beta, transforming growth factor-beta receptor II, and p27Kip1 expression in nontumorous and neoplastic human pituitaries.
Carcinogenesis
Transgenic mice and host cell mutants resistant to transformation as model systems for identifying multiple components in oncogenesis.
Carcinogenesis
Translational Control of C-terminal Src Kinase (Csk) Expression by PRL3 Phosphatase.
Carcinogenesis
Tumour induction by activated abl involves tyrosine phosphorylation of the product of the cbl oncogene.
Carcinogenesis
Tumour susceptibility and spontaneous mutation in mice deficient in Mlh1, Pms1 and Pms2 DNA mismatch repair.
Carcinogenesis
Tyrosine phosphorylation of growth factor receptor-bound protein-7 by focal adhesion kinase in the regulation of cell migration, proliferation, and tumorigenesis.
Carcinogenesis
Upregulation of focal adhesion kinase (FAK) expression in ductal carcinoma in situ (DCIS) is an early event in breast tumorigenesis.
Carcinogenesis
Vitamin D Receptor Protects Against Dysbiosis and Tumorigenesis via the JAK/STAT Pathway in Intestine.
Carcinogenesis
While at Rome miRNA and TRAIL do whatever BCR-ABL commands to do.
Carcinogenesis
Wnt11 alters integrin and cadherin expression by ovarian cancer spheroids and inhibits tumorigenesis and metastasis.
Carcinogenesis
[Damage to the transforming growth factor TGF-beta type II receptor gene and microsatellite instability in carcinoma cells of the gastrointestinal tract]
Carcinogenesis
[Detecting protein expression of EphrinB2 ligand and its receptor EphB4 in astrocytoma using confocal laser scanning microscopy]
Carcinogenesis
[Effect of spleen tyrosine kinase expression re-activation by inhibition of DNA methylation on oncogenesis growth of gastric cancer]
Carcinogenesis
[Expression of deleted in liver cancer 1 and phosphorelated focal adhesion kinase in breast cancer].
Carcinogenesis
[Expressions of EphB4 and HIF-1? in human lung cancer and their significances.]
Carcinogenesis
[Human mismatch repair genes and HNPCC]
Carcinogenesis
[Mechanism underlying tumorigenesis induced by Bcr-Abl oncogene and A-MuLV virus].
Carcinogenesis
[The characteristics of focal adhesion kinase (FAK) and its role in carcinogenesis]
Carcinoid Tumor
Focal Adhesion Kinase, a Downstream Mediator of Raf-1 Signaling, Suppresses Cellular Adhesion, Migration, and Neuroendocrine Markers in BON Carcinoid Cells.
Carcinoid Tumor
GHRH antagonist inhibits focal adhesion kinase (FAK) and decreases expression of vascular endothelial growth factor (VEGF) in human lung cancer cells in vitro.
Carcinoma
15-Deoxy-?12,14-prostaglandin J2 Inhibits Cell Migration on Renal Cell Carcinoma via Down-Regulation of Focal Adhesion Kinase Signaling.
Carcinoma
3-substitued indoles: one-pot synthesis and evaluation of anticancer and Src kinase inhibitory activities.
Carcinoma
3D cell cultures of human head and neck squamous cell carcinoma cells are radiosensitized by the focal adhesion kinase inhibitor TAE226.
Carcinoma
A case of aggressive squamous cell carcinoma with lymphovascular invasion during treatment with the Janus kinase inhibitor tofacitinib.
Carcinoma
A case of chronic myeloid leukemia with minor bcr-abl transcript following fluorouracil therapy for esophageal carcinoma.
Carcinoma
A case of Merkel cell carcinoma development under treatment with a Janus kinase inhibitor.
Carcinoma
A CD44 survival pathway triggers chemoresistance via lyn kinase and phosphoinositide 3-kinase/Akt in colon carcinoma cells.
Carcinoma
A differential effect of the Walker 256 carcinoma on the tyrosine protein kinase activity of liver plasma membrane domains.
Carcinoma
A dominant negative mutation of transforming growth factor-beta receptor type II gene in microsatellite stable oesophageal carcinoma.
Carcinoma
A Luminacin D Analog HL142 Inhibits Ovarian Tumor Growth and Metastasis by Reversing EMT and Attenuating the TGF? and FAK Pathways.
Carcinoma
A phase II trial of the Src kinase inhibitor saracatinib (AZD0530) in patients with metastatic or locally advanced gastric or gastro esophageal junction (GEJ) adenocarcinoma: a trial of the PMH phase II consortium.
Carcinoma
A role for epidermal growth factor receptor, c-Src and focal adhesion kinase in an in vitro model for the progression of colon cancer.
Carcinoma
A role for focal adhesion kinase in hyluronan-dependent MMP-2 secretion in a human small-cell lung carcinoma cell line, QG90.
Carcinoma
A transmembrane-anchored chimeric focal adhesion kinase is constitutively activated and phosphorylated at tyrosine residues identical to pp125FAK.
Carcinoma
A tyrosine protein kinase activated by bombesin in normal fibroblasts and small cell carcinomas.
Carcinoma
Abl kinases are required for invadopodia formation and chemokine-induced invasion.
Carcinoma
Actin cytoskeletal mediators of motility and invasion amplified and overexpressed in head and neck cancer.
Carcinoma
Actin disruption inhibits bombesin stimulation of focal adhesion kinase (pp125FAK) in prostate carcinoma.
Carcinoma
Activated spleen tyrosine kinase promotes malignant progression of oral squamous cell carcinoma via mTOR/S6 signaling pathway in an ERK1/2-independent manner.
Carcinoma
Activation of pp60c-src protein kinase activity in human colon carcinoma.
Carcinoma
Activation of Src mediates acquired cisplatin resistance in human lung carcinoma cells.
Carcinoma
Activation of Src tyrosine kinase in esophageal carcinoma cells in different regulatory environments and corresponding occurrence mechanism.
Carcinoma
Activation of the focal adhesion kinase signal transduction pathway in cervical carcinoma cell lines and human genital epithelial cells immortalized with human papillomavirus type 18.
Carcinoma
Activation of the pp60c-src protein kinase is an early event in colonic carcinogenesis.
Carcinoma
Activation of the protein-tyrosine kinase associated with the bombesin receptor complex in small cell lung carcinomas.
Carcinoma
Activation of the receptor protein tyrosine kinase EphB4 in endometrial hyperplasia and endometrial carcinoma.
Carcinoma
Adhesion systems in normal breast and in invasive breast carcinoma.
Carcinoma
Aggressive Merkel Cell Carcinoma After Janus Kinase Inhibitor Ruxolitinib for Polycythemia Vera.
Carcinoma
Aggressive squamous cell carcinoma in a patient on the Janus kinase inhibitor ruxolitinib.
Carcinoma
Alterations in the expression of pp60c-src and p56lck associated with butyrate-induced differentiation of human colon carcinoma cells.
Carcinoma
Alterations in the focal adhesion kinase/Src signal transduction pathway correlate with increased migratory capacity of prostate carcinoma cells.
Carcinoma
Alterations of the cytoskeletal organization in tumor cell lines by a cardiotonic drug, vesnarinone, through protein tyrosine phosphorylation.
Carcinoma
Altered localization and activity of the intracellular tyrosine kinase BRK/Sik in prostate tumor cells.
Carcinoma
Alternate RASSF1 Transcripts Control SRC Activity, E-Cadherin Contacts, and YAP-Mediated Invasion.
Carcinoma
Amplification of N-myc oncogene in human melanoma cells.
Carcinoma
An altered fibronectin matrix induces anoikis of human squamous cell carcinoma cells by suppressing integrin alpha v levels and phosphorylation of FAK and ERK.
Carcinoma
An alternative pathway for expression of p56lck from type I promoter transcripts in colon carcinoma.
Carcinoma
An intronic variant of the TGFBR1 gene is associated with carcinomas of the kidney and bladder.
Carcinoma
Androgen deprivation modulates gene expression profile along prostate cancer progression.
Carcinoma
Anti-prostate cancer activity of a nanoformulation of the spleen tyrosine kinase (SYK) inhibitor C61.
Carcinoma
Anti-tumor effect of a novel FAK inhibitor TAE226 against human oral squamous cell carcinoma.
Carcinoma
Antiangiogenic and antitumor effects of SRC inhibition in ovarian carcinoma.
Carcinoma
Ascl1-induced Wnt11 regulates neuroendocrine differentiation, cell proliferation, and E-cadherin expression in small-cell lung cancer and Wnt11 regulates small-cell lung cancer biology.
Carcinoma
Ascorbate up-regulates MLH1 (Mut L homologue-1) and p73: implications for the cellular response to DNA damage.
Carcinoma
Association of BDNF and BMPR1A with clinicopathologic parameters in benign and malignant gallbladder lesions.
Carcinoma
ATP7A delivers copper to the lysyl oxidase family of enzymes and promotes tumorigenesis and metastasis.
Carcinoma
B lymphocytes repress hepatic tumorigenesis but not development in Hras12V transgenic mice.
Carcinoma
Barium promotes anchorage-independent growth and invasion of human HaCaT keratinocytes via activation of c-SRC kinase.
Carcinoma
BET, SRC, and BCL2 family inhibitors are synergistic drug combinations with PARP inhibitors in ovarian cancer.
Carcinoma
Bone morphogenetic protein-2/4 and bone morphogenetic protein receptor type IA expression in metastatic and nonmetastatic oral squamous cell carcinoma.
Carcinoma
Bruton's tyrosine kinase (BTK) mediates resistance to EGFR inhibition in non-small-cell lung carcinoma.
Carcinoma
c-Abl expression in oral squamous cell carcinomas.
Carcinoma
c-Abl modulates tumor cell sensitivity to antibody-dependent cellular cytotoxicity.
Carcinoma
c-Abl Tyrosine Kinase Is Regulated Downstream of the Cytoskeletal Protein Synemin in Head and Neck Squamous Cell Carcinoma Radioresistance and DNA Repair.
Carcinoma
c-Ski overexpression promotes tumor growth and angiogenesis through inhibition of transforming growth factor-beta signaling in diffuse-type gastric carcinoma.
Carcinoma
c-Src kinase activity is required for hepatocyte growth factor-induced motility and anchorage-independent growth of mammary carcinoma cells.
Carcinoma
c-Yes tyrosine kinase activity in human colon carcinoma.
Carcinoma
Carbon Ion Irradiation Enhances the Anti-tumor Efficiency in Tongue Squamous Cell Carcinoma via Modulating the FAK Signaling.
Carcinoma
Carbon Ion Therapy Inhibits Esophageal Squamous Cell Carcinoma Metastasis by Upregulating STAT3 Through the JAK2/STAT3 Signaling Pathway.
Carcinoma
Caveolin-1 phosphorylation in human squamous and epidermoid carcinoma cells: dependence on ErbB1 expression and Src activation.
Carcinoma
Cell directional migration and oriented division on three-dimensional laser-induced periodic surface structures on polystyrene.
Carcinoma
Cervical Cancer Growth Is Regulated by a c-ABL-PLK1 Signaling Axis.
Carcinoma
Chemokine receptor 7 via proline-rich tyrosine kinase-2 upregulates the chemotaxis and migration ability of squamous cell carcinoma of the head and neck.
Carcinoma
Chemopreventive and Chemotherapeutic Actions of mTOR Inhibitor in Genetically Defined Head and Neck Squamous Cell Carcinoma Mouse Model.
Carcinoma
Chrysin serves as a novel inhibitor of DGK?/FAK interaction to suppress the malignancy of esophageal squamous cell carcinoma (ESCC).
Carcinoma
Circ_0015756 promotes proliferation, invasion and migration by microRNA-7-dependent inhibition of FAK in hepatocellular carcinoma.
Carcinoma
Cirsiliol targets tyrosine kinase 2 to inhibit esophageal squamous cell carcinoma growth in vitro and in vivo.
Carcinoma
Class I and III HDACs and loss of active chromatin features contribute to epigenetic silencing of CDX1 and EPHB tumor suppressor genes in colorectal cancer.
Carcinoma
Clinical Evolution of Epithelial-Mesenchymal Transition in Human Carcinomas.
Carcinoma
Clinical significance of focal adhesion kinase in resectable pancreatic cancer.
Carcinoma
Cloning and biochemical characterization of LIMK-2, a protein kinase containing two LIM domains.
Carcinoma
Co-operative effect of c-Src tyrosine kinase and Stat3 in activation of hepatocyte growth factor expression in mammary carcinoma cells.
Carcinoma
Coexpression of ephrin-Bs and their receptors in colon carcinoma.
Carcinoma
Comparative analysis of a panel of biomarkers related to protein phosphatase 2A between laryngeal squamous cell carcinoma tissues and adjacent normal tissues.
Carcinoma
Concordant Promoter Methylation of Transforming Growth Factor-Beta Receptor Types I and II Occurs Early in Esophageal Squamous Cell Carcinoma.
Carcinoma
Correction: Focal Adhesion Kinase Targeting Using In vivo Short Interfering RNA Delivery in Neutral Liposomes for Ovarian Carcinoma Therapy.
Carcinoma
Correction: Therapeutic Efficacy of a Novel Focal Adhesion Kinase Inhibitor TAE226 in Ovarian Carcinoma.
Carcinoma
Correction: Zheng, L., et al. PBN11-8, a Cytotoxic Polypeptide Purified from Marine Bacillus, Suppresses Invasion and Migration of Human Hepatocellular Carcinoma Cells by Targeting Focal Adhesion Kinase Pathways. Polymers 2018, 10, 1043.
Carcinoma
Correlation of focal adhesion kinase expression with nodal metastasis in patients with head and neck cutaneous squamous cell carcinoma.
Carcinoma
Cross talk of signals between EGFR and IL-6R through JAK2/STAT3 mediate epithelial-mesenchymal transition in ovarian carcinomas.
Carcinoma
Cytomegalovirus Proctitis in a Patient with Chronic Lymphocytic Leukemia on Ibrutinib Therapy: A Case Report.
Carcinoma
Cytoplasmic c-Abl provides a molecular 'Rheostat' controlling carcinoma cell survival and invasion.
Carcinoma
DDR2 overexpression in oral squamous cell carcinoma is associated to lymph node metastasis.
Carcinoma
Decreased expression of focal adhesion kinase is associated with a poor prognosis in extrahepatic bile duct carcinoma.
Carcinoma
Decreased expression of protein tyrosine kinase 6 contributes to tumor progression and metastasis in laryngeal squamous cell carcinoma.
Carcinoma
Decreased Stability of Transforming Growth Factor beta Type II Receptor mRNA in RER+ Human Colon Carcinoma Cells
Carcinoma
Decreased stability of transforming growth factor beta type II receptor mRNA in RER+ human colon carcinoma cells.
Carcinoma
Defective transforming growth factor beta signaling pathway in head and neck squamous cell carcinoma as evidenced by the lack of expression of activated Smad2.
Carcinoma
Development of a metastatic fluorescent Lewis Lung carcinoma mouse model: identification of mRNAs and microRNAs involved in tumor invasion.
Carcinoma
Diabetes may increase risk for oral cancer through the insulin receptor substrate-1 and focal adhesion kinase pathway.
Carcinoma
Differential effects of ketoconazole and primaquine on the pharmacokinetics and tissue distribution of imatinib in mice.
Carcinoma
Differential expression of the non-receptor tyrosine kinase BRK in oral squamous cell carcinoma and normal oral epithelium.
Carcinoma
Differential gene expression in colon carcinoma cells and tissues detected with a cDNA array.
Carcinoma
Differential pp60c-src activity in well and poorly differentiated human colon carcinomas and cell lines.
Carcinoma
Differentiation of normal and cancer cells induced by sulfhydryl reduction: biochemical and molecular mechanisms.
Carcinoma
Diffuse-type gastric carcinoma: progression, angiogenesis, and transforming growth factor beta signaling.
Carcinoma
Digenic/multilocus aetiology of multiple self-healing squamous epithelioma (Ferguson-Smith disease): TGFBR1 and a second linked locus.
Carcinoma
Direct tumorigenic conversion of human gallbladder carcinoma cells by v-src but not by activated c-H-ras oncogene.
Carcinoma
Disruption of Ca2+-dependent cell-matrix adhesion enhances c-Src kinase activity, but causes dissociation of the c-Src/FAK complex and dephosphorylation of tyrosine-577 of FAK in carcinoma cells.
Carcinoma
Disruption of transforming growth factor beta-Smad signaling pathway in head and neck squamous cell carcinoma as evidenced by mutations of SMAD2 and SMAD4.
Carcinoma
Distinct variants affecting differential splicing of TGFBR1 exon 5 cause either Loeys-Dietz syndrome or multiple self-healing squamous epithelioma.
Carcinoma
Down-regulation of EphB4 phosphorylation is necessary for esophageal squamous cell carcinoma tumorigenecity.
Carcinoma
Down-Regulation of miR-2053 Inhibits the Development and Progression of Esophageal Carcinoma by Targeting Fyn-Related Kinase (FRK).
Carcinoma
Downregulated expression of PTK6 is correlated with poor survival in esophageal squamous cell carcinoma.
Carcinoma
Downregulation of the c-Fes protein-tyrosine kinase inhibits the proliferation of human renal carcinoma cells.
Carcinoma
Downregulation of transforming growth factor beta type II receptor in laryngeal carcinogenesis.
Carcinoma
Dual regulation of Myc by Abl.
Carcinoma
Dual targeting of EGFR and focal adhesion kinase in 3D grown HNSCC cell cultures.
Carcinoma
Early events in the antiproliferative action of tumor necrosis factor are similar to the early events in epidermal growth factor growth stimulation.
Carcinoma
Effect of Src kinase inhibition on metastasis and tumor angiogenesis in human pancreatic cancer.
Carcinoma
EGF-R signaling through Fyn kinase disrupts the function of integrin alpha6beta4 at hemidesmosomes: role in epithelial cell migration and carcinoma invasion.
Carcinoma
EGFR-dependent tyrosine phosphorylation of integrin ?4 is not required for downstream signaling events in cancer cell lines.
Carcinoma
Elevated c-Src and c-Yes expression in malignant skin cancers.
Carcinoma
Elevated expression of pp60c-src in low grade human bladder carcinoma.
Carcinoma
Elevated protein-tyrosine-phosphatase activity in human colon-carcinoma.
Carcinoma
Elevated Src family kinase activity stabilizes E-cadherin-based junctions and collective movement of head and neck squamous cell carcinomas.
Carcinoma
Enhanced constitutive invasion activity in human nontumorigenic keratinocytes exposed to a low level of barium for a long time.
Carcinoma
Enhanced expression of c-myc and epidermal growth factor receptor (C-erbB-1) genes in primary human renal cancer.
Carcinoma
Enhanced tumorigenesis and reduced transforming growth factor-beta type II receptor in lung tumors from mice with reduced gene dosage of transforming growth factor-beta1.
Carcinoma
Enhancing radiosensitization in EphB4 receptor-expressing Head and Neck Squamous Cell Carcinomas.
Carcinoma
EphB4 as a Novel Target for the EGFR-Independent Suppressive Effects of Osimertinib on Cell Cycle Progression in Non-Small Cell Lung Cancer.
Carcinoma
EphB4 provides survival advantage to squamous cell carcinoma of the head and neck.
Carcinoma
EPHB4 Regulates the Proliferation and Metastasis of Oral Squamous Cell Carcinoma through the HMGB1/NF-?B Signalling Pathway.
Carcinoma
Epidermal growth factor-induced tumor cell invasion and metastasis initiated by dephosphorylation and downregulation of focal adhesion kinase.
Carcinoma
Eps8 controls Src- and FAK-dependent phenotypes in squamous carcinoma cells.
Carcinoma
Etk/Bmx, a PH-domain containing tyrosine kinase, protects prostate cancer cells from apoptosis induced by photodynamic therapy or thapsigargin.
Carcinoma
Expression and clinical significance of FAK, ILK, and PTEN in salivary adenoid cystic carcinoma.
Carcinoma
Expression and prognostic significance of EFNB2 and EphB4 genes in patients with oesophageal squamous cell carcinoma.
Carcinoma
Expression and secretion of inhibin and activin in normal and neoplastic uterine tissues. High levels of serum activin A in women with endometrial and cervical carcinoma.
Carcinoma
Expression levels of EPHB4, EFNB2 and caspase-8 are associated with clinicopathological features and progression of esophageal squamous cell cancer.
Carcinoma
Expression of activin and inhibin subunits, receptors and binding proteins in human adrenocortical neoplasms.
Carcinoma
Expression of c-ABL, c-KIT, and platelet-derived growth factor receptor-beta in ovarian serous carcinoma and normal ovarian surface epithelium.
Carcinoma
Expression of c-src in cultured human neuroblastoma and small-cell lung carcinoma cell lines correlates with neurocrine differentiation.
Carcinoma
Expression of EphB4 in head and neck squamous cell carcinoma.
Carcinoma
Expression of focal adhesion kinase and alpha5 and beta1 integrins in carcinomas and its clinical significance.
Carcinoma
Expression of focal adhesion kinase and phosphorylated focal adhesion kinase in squamous cell carcinoma of the larynx.
Carcinoma
Expression of focal adhesion kinase in small-cell lung carcinoma.
Carcinoma
Expression of Müllerian inhibiting substance type II receptor and antiproliferative effects of MIS on human cervical cancer.
Carcinoma
Expression of p73 and c-Abl proteins in human ovarian carcinomas.
Carcinoma
Expression of paxillin and FAK mRNA and the related clinical significance in esophageal carcinoma.
Carcinoma
Expression of putative tumor suppressor gene spleen tyrosine kinase in esophageal squamous cell carcinoma.
Carcinoma
Expression of the EPHB4 receptor tyrosine kinase in head and neck and renal malignancies--implications for solid tumors and potential for therapeutic inhibition.
Carcinoma
Expression of the gene coding for the light chain of calpactin I (annexin II) in cell lines DiFi, HT-29, and WI-38.
Carcinoma
Expression of the lck tyrosine kinase gene in human colon carcinoma and other non-lymphoid human tumor cell lines.
Carcinoma
Expression of Wnt pathway molecules is associated with disease outcome in metastatic high-grade serous carcinoma.
Carcinoma
Expression of Wnt11 and Rock2 in esophageal squamous cell carcinoma by activation of the WNT/PCP pathway and its clinical significance.
Carcinoma
Expression of Wnt11 and Rock2 protein with clinical characteristics of esophageal squamous cell carcinoma in Kazakh and Han patients.
Carcinoma
Extensive alteration in the expression profiles of TGFB pathway signaling components and TP53 is observed along the gastric dysplasia-carcinoma sequence.
Carcinoma
Extracellular engagement of ADAM12 induces clusters of invadopodia with localized ectodomain shedding activity.
Carcinoma
Features of multiple self-healing squamous epithelioma and Loeys-Dietz syndrome in a patient with a novel TGFBR1 variant.
Carcinoma
First evidence supporting a potential role for the BMP/SMAD pathway in the progression of oestrogen receptor-positive breast cancer.
Carcinoma
Focal adhesion kinase (FAK) immunocytochemical expression in breast ductal invasive carcinoma (DIC): correlation with clinicopathological parameters and tumor proliferative capacity.
Carcinoma
Focal adhesion kinase (FAK) inhibitor-defactinib suppresses the malignant progression of human esophageal squamous cell carcinoma (ESCC) cells via effective blockade of PI3K/AKT axis and downstream molecular network.
Carcinoma
Focal adhesion kinase (FAK) is associated with poor prognosis in urinary bladder carcinoma.
Carcinoma
Focal Adhesion Kinase (FAK) Overexpression and Phosphorylation in Oral Squamous Cell Carcinoma and their Clinicopathological Significance.
Carcinoma
Focal adhesion kinase (pp125FAK) expression, activation and association with paxillin and p50CSK in human metastatic prostate carcinoma.
Carcinoma
Focal adhesion kinase and E-cadherin as markers for nodal metastasis in laryngeal cancer.
Carcinoma
Focal adhesion kinase as a marker of malignant phenotype in breast and cervical carcinomas.
Carcinoma
Focal adhesion kinase inhibitor PF573228 and death receptor 5 agonist lexatumumab synergistically induce apoptosis in pancreatic carcinoma.
Carcinoma
Focal adhesion kinase interacts with the transcriptional coactivator FHL2 and both are overexpressed in epithelial ovarian cancer.
Carcinoma
Focal adhesion kinase is required for bombesin-induced prostate cancer cell motility.
Carcinoma
Focal adhesion kinase knockdown in carcinoma-associated fibroblasts inhibits oral squamous cell carcinoma metastasis via downregulating MCP-1/CCL2 expression.
Carcinoma
Focal adhesion kinase overexpression: Correlation with lymph node metastasis and shorter survival in oral squamous cell carcinoma.
Carcinoma
Focal adhesion kinase regulates metastatic adhesion of carcinoma cells within liver sinusoids.
Carcinoma
Focal adhesion kinase targeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy.
Carcinoma
Full-length spleen tyrosine kinase inhibits the invasion and metastasis of human laryngeal squamous cell carcinoma.
Carcinoma
Fusobacteria modulate oral carcinogenesis and promote cancer progression.
Carcinoma
Gastric carcinomas with microsatellite instability: clinical features and mutations to the TGF-beta type II receptor, IGFII receptor, and BAX genes.
Carcinoma
Gastrin-stimulated G?13 Activation of Rgnef Protein (ArhGEF28) in DLD-1 Colon Carcinoma Cells.
Carcinoma
Genetic alterations involved in the development of gallbladder carcinomas from Greek patients.
Carcinoma
Genome-wide analysis of oral squamous cell carcinomas revealed over expression of ISG15, Nestin and WNT11.
Carcinoma
Glucose Drives Growth Factor-Independent Esophageal Cancer Proliferation via Phosphohistidine-Focal Adhesion Kinase Signaling.
Carcinoma
Green tea epigallocatechin gallate exhibits anticancer effect in human pancreatic carcinoma cells via the inhibition of both focal adhesion kinase and insulin-like growth factor-I receptor.
Carcinoma
Growth factor regulation of integrin-mediated cell motility.
Carcinoma
GTPase Regulator Associated with Focal Adhesion Kinase 1 (GRAF1) Immunoglobulin-Associated Ataxia and Neuropathy.
Carcinoma
Hepatic silicosis, cirrhosis, and liver tumors in mice and hamsters: studies of transforming growth factor beta expression.
Carcinoma
Hepatocyte growth factor/scatter factor induces tyrosine phosphorylation of focal adhesion kinase (p125FAK) and promotes migration and invasion by oral squamous cell carcinoma cells.
Carcinoma
HER2 Status in Molecular Subtypes of Urothelial Carcinoma of the Renal Pelvis and Ureter.
Carcinoma
High expression of FER tyrosine kinase predicts poor prognosis in clear cell renal cell carcinoma.
Carcinoma
Histochemical staining of protein-tyrosine phosphatase activity in primary human mammary carcinoma: relationship with established prognostic indicators.
Carcinoma
HO-3867, a synthetic compound, inhibits the migration and invasion of ovarian carcinoma cells through downregulation of fatty acid synthase and focal adhesion kinase.
Carcinoma
Human pancreatic tumor cells are sensitized to ionizing radiation by knockdown of caveolin-1.
Carcinoma
Identification of spleen tyrosine kinase as a potential therapeutic target for esophageal squamous cell carcinoma using reverse phase protein arrays.
Carcinoma
IL-13 induces phosphorylation and activation of JAK2 Janus kinase in human colon carcinoma cell lines: similarities between IL-4 and IL-13 signaling.
Carcinoma
IL6 is associated with response to dasatinib and cetuximab: Phase II clinical trial with mechanistic correlatives in cetuximab-resistant head and neck cancer.
Carcinoma
Immunohistochemical assessment of Eph/ephrin expression in oral squamous cell carcinoma and precursor lesions.
Carcinoma
Immunohistochemical expression of TGF beta (TGF-?), TGF beta receptor 1 (TGFBR1), and Ki67 in intestinal variant of gastric adenocarcinomas.
Carcinoma
In oral squamous cell carcinoma, high FAK expression is correlated with low P53 expression.
Carcinoma
In situ analysis of transforming growth factors-beta (TGF-beta 1, TGF-beta 2, TGF-beta 3) and TGF-beta type II receptor expression in basal cell carcinomas.
Carcinoma
Increased dosage and amplification of the focal adhesion kinase gene in human cancer cells.
Carcinoma
Induction of apoptosis of detached oral squamous cell carcinoma cells by safingol. Possible role of Bim, focal adhesion kinase and endonuclease G.
Carcinoma
Inhibition of Bruton's tyrosine kinase as a therapeutic strategy for chemoresistant oral squamous cell carcinoma and potential suppression of cancer stemness.
Carcinoma
Inhibition of cell growth and upregulation of MAD2 in human oesophageal squamous cell carcinoma after treatment with the SRC/ABL inhibitor dasatinib.
Carcinoma
Inhibition of focal adhesion kinase (FAK) activity prevents anchorage-independent ovarian carcinoma cell growth and tumor progression.
Carcinoma
Inhibition of focal adhesion kinase expression or activity disrupts epidermal growth factor-stimulated signaling promoting the migration of invasive human carcinoma cells.
Carcinoma
Inhibition of focal adhesion kinase induces apoptosis in human gastric carcinoma cells (SGC-7901).
Carcinoma
Inhibition of IKK?/NF-?B signaling pathway to improve Dasatinib efficacy in suppression of cisplatin-resistant head and neck squamous cell carcinoma.
Carcinoma
Inhibition of protein FAK enhances 5-FU chemosensitivity to gastric carcinoma via p53 signaling pathways.
Carcinoma
Inhibition of Spleen Tyrosine Kinase Potentiates Paclitaxel-Induced Cytotoxicity in Ovarian Cancer Cells by Stabilizing Microtubules.
Carcinoma
Inhibition of Src kinase activity by Ad-mda7 suppresses vascular endothelial growth factor expression in prostate carcinoma cells.
Carcinoma
Inhibition of SRC tyrosine kinase as treatment for human pancreatic cancer growing orthotopically in nude mice.
Carcinoma
Inhibition of Src tyrosine kinase reverts chemoresistance toward 5-fluorouracil in human pancreatic carcinoma cells: an involvement of epidermal growth factor receptor signaling.
Carcinoma
Inhibition of tumor growth and angiogenesis by soluble EphB4.
Carcinoma
Integrin alpha2-mediated ERK and calpain activation play a critical role in cell adhesion and motility via focal adhesion kinase signaling: identification of a novel signaling pathway.
Carcinoma
Interleukin-6 upregulates SOX18 expression in osteosarcoma.
Carcinoma
Interleukin4R? (IL4R?) and IL13R?1 Are Associated with the Progress of Renal Cell Carcinoma through Janus Kinase 2 (JAK2)/Forkhead Box O3 (FOXO3) Pathways.
Carcinoma
Investigation of the expression of the EphB4 receptor tyrosine kinase in prostate carcinoma.
Carcinoma
Involvement of c-Src in carcinoma cell motility and metastasis.
Carcinoma
Involvement of focal adhesion kinase in cellular invasion of head and neck squamous cell carcinomas via regulation of MMP-2 expression.
Carcinoma
Involvement of focal adhesion kinase in cellular proliferation, apoptosis and prognosis of laryngeal squamous cell carcinoma.
Carcinoma
Ionizing radiation modules of the expression and tyrosine phosphorylation of the focal adhesion-associated proteins focal adhesion kinase (FAK) and its substrates p130cas and paxillin in A549 human lung carcinoma cells in vitro.
Carcinoma
Isolation of v-fms and its human cellular homolog.
Carcinoma
JAK kinase inhibition abrogates STAT3 activation and head and neck squamous cell carcinoma tumor growth.
Carcinoma
JAK2/STAT3 signaling pathway activation mediates tumor angiogenesis by upregulation of VEGF and bFGF in non-small-cell lung cancer.
Carcinoma
Janus kinase 2 inhibition by Licochalcone B suppresses esophageal squamous cell carcinoma growth.
Carcinoma
Kinomic profiling identifies focal adhesion kinase 1 as a therapeutic target in advanced clear cell renal cell carcinoma.
Carcinoma
Knockdown of focal adhesion kinase reverses colon carcinoma multicellular resistance.
Carcinoma
Lack of correlation between growth inhibition by TGF-beta and the percentage of cells expressing type II TGF-beta receptor in human non-small cell lung carcinoma cell lines.
Carcinoma
Localization of transforming growth factor-beta1 and type II receptor in developing normal human prostate and carcinoma tissues.
Carcinoma
Loss of desmoglein-2 promotes gallbladder carcinoma progression and resistance to EGFR-targeted therapy through Src kinase activation.
Carcinoma
Loss of EphB4 receptor tyrosine kinase protein expression during carcinogenesis of the human breast.
Carcinoma
Loss of T-cell receptor zeta chain and p56lck in T-cells infiltrating human renal cell carcinoma.
Carcinoma
Loss of TGF-beta type II receptor in fibroblasts promotes mammary carcinoma growth and invasion through upregulation of TGF-alpha-, MSP- and HGF-mediated signaling networks.
Carcinoma
Mechanisms responsible for signaling and functional defects.
Carcinoma
Microsatellite instability in the adenoma-carcinoma sequence of the stomach.
Carcinoma
Microsatellite instability-associated mutations associate preferentially with the intestinal type of primary gastric carcinomas in a high-risk population.
Carcinoma
Migration of renal carcinoma cells is dependent on protein kinase Cdelta via beta1 integrin and focal adhesion kinase.
Carcinoma
miR-769-5p suppressed cell proliferation, migration and invasion by targeting TGFBR1 in non-small cell lung carcinoma.
Carcinoma
miRNA- and cytokine-associated extracellular vesicles mediate squamous cell carcinomas.
Carcinoma
MLLT11/AF1q boosts oncogenic STAT3 activity through Src-PDGFR tyrosine kinase signaling.
Carcinoma
Molecular cloning and characterization of human WNT11.
Carcinoma
Morphology of ras-transformed cells becomes apparently normal again with tyrosine kinase inhibitors without a decrease in the ras-GTP complex.
Carcinoma
Mouse platelet-derived growth factor alpha receptor: sequence, tissue-specific expression and correlation with metastatic phenotype.
Carcinoma
MUC1 oncoprotein blocks nuclear targeting of c-Abl in the apoptotic response to DNA damage.
Carcinoma
Multiple mechanisms for Wnt11-mediated repression of the canonical Wnt signaling pathway.
Carcinoma
Multiple Self-Healing Squamous Epithelioma (MSSE): A Digenic Trait Associated with Loss of Function Mutations in TGFBR1 and Variants at a Second Linked Locus on the Long Arm of Chromosome 9.
Carcinoma
Multiple Self-Healing Squamous Epithelioma (MSSE): Rare Variants in an Adjacent Region of Chromosome 9q22.3 to Known TGFBR1 Mutations Suggest a Digenic or Multilocus Etiology.
Carcinoma
Multiple self-healing squamous epithelioma is caused by a disease-specific spectrum of mutations in TGFBR1.
Carcinoma
Mutation of the transforming growth factor-beta type II receptor gene is a rare event in human sporadic gastric carcinomas.
Carcinoma
Mutations of the transforming growth factor-beta type II receptor gene are strongly related to sporadic proximal colon carcinomas with microsatellite instability.
Carcinoma
N- and C-terminal isoforms of Arg quantified by real-time PCR are specifically expressed in human normal and neoplastic cells, in neoplastic cell lines, and in HL-60 cell differentiation.
Carcinoma
New drugs in thyroid cancer.
Carcinoma
Next-generation sequencing implicates oncogenic roles for p53 and JAK/STAT signaling in microcystic adnexal carcinomas.
Carcinoma
Non-coding RNA 886 promotes renal cell carcinoma growth and metastasis through the Janus kinase 2/signal transducer and activator of transcription 3 signaling pathway.
Carcinoma
Novel biomarker candidates for the diagnosis of ovarian clear cell carcinoma.
Carcinoma
Oncogenic transformation of human mammary epithelial cells by autocrine human growth hormone.
Carcinoma
One-pot regioselective synthesis of tetrahydroindazolones and evaluation of their antiproliferative and Src kinase inhibitory activities.
Carcinoma
Over-expression of mir-124 inhibits MMP-9 expression and decreases invasion of renal cell carcinoma cells.
Carcinoma
Overexpression and activation of the tyrosine kinase Src in human pancreatic carcinoma.
Carcinoma
Overexpression of focal adhesion kinase in head and neck squamous cell carcinoma is independent of fak gene copy number.
Carcinoma
Overexpression of focal adhesion kinase, a protein tyrosine kinase, in ovarian carcinoma.
Carcinoma
p190RhoGEF (Rgnef) promotes colon carcinoma tumor progression via interaction with focal adhesion kinase.
Carcinoma
p70S6K is regulated by focal adhesion kinase and is required for Src-selective autophagy.
Carcinoma
Phase 3 Trials of Tirbanibulin Ointment for Actinic Keratosis.
Carcinoma
Phosphorylated Signal Transducer and Activator of Transcription 1 is a potential predictor of interferon response in patients with advanced renal cell carcinoma.
Carcinoma
Phosphorylation of focal adhesion kinase at Tyr397 in gastric carcinomas and its clinical significance.
Carcinoma
Pilot study: alteration of deleted in liver cancer1 and phosphorylated focal adhesion kinase y397 cytoplasmic expression and the prognostic value in advanced epithelial ovarian carcinoma.
Carcinoma
Platelets are associated with xenograft tumor growth and the clinical malignancy of ovarian cancer through an angiogenesis-dependent mechanism.
Carcinoma
Pleiotrophin exerts its migration and invasion effect through the neuropilin-1 pathway.
Carcinoma
Ponicidin induces apoptosis via JAK2 and STAT3 signaling pathways in gastric carcinoma.
Carcinoma
pp60c-src activation in human colon carcinoma.
Carcinoma
Precise localization of the human gene encoding cell adhesion kinase beta (CAK beta/PYK2) to chromosome 8 at p21.1 by fluorescence in situ hybridization.
Carcinoma
Prevalence of Mutations in Discoidin Domain-Containing Receptor Tyrosine Kinase 2 (DDR2) in Squamous Cell Lung Cancers in Korean Patients.
Carcinoma
Prognostic Value of Focal Adhesion Kinase (FAK) in Human Solid Carcinomas: A Meta-Analysis.
Carcinoma
Proline-Rich Tyrosine Kinase 2 (Pyk2) Regulates IGF-I-Induced Cell Motility and Invasion of Urothelial Carcinoma Cells.
Carcinoma
Prostatic carcinoma cell migration via alpha(v)beta3 integrin is modulated by a focal adhesion kinase pathway.
Carcinoma
Rapamycin inhibits F-actin reorganization and phosphorylation of focal adhesion proteins.
Carcinoma
RB1CC1 functions as a tumor-suppressing gene in renal cell carcinoma via suppression of PYK2 activity and disruption of TAZ-mediated PDL1 transcription activation.
Carcinoma
Receptors for interleukin (IL)-4 do not associate with the common gamma chain, and IL-4 induces the phosphorylation of JAK2 tyrosine kinase in human colon carcinoma cells.
Carcinoma
Reduced C-terminal Src kinase activity is correlated inversely with pp60(c-src) activity in colorectal carcinoma.
Carcinoma
Regulation of the PH-domain-containing tyrosine kinase Etk by focal adhesion kinase through the FERM domain.
Carcinoma
Regulation of the Src tyrosine kinase and Syp tyrosine phosphatase by their cellular association.
Carcinoma
Regulation of vascular endothelial growth factor expression in human colon carcinoma cells by activity of src kinase.
Carcinoma
Relationship between grade of microsatellite instability and target genes of mismatch repair pathways in sporadic colorectal carcinoma.
Carcinoma
Repression of transforming growth factor-beta receptor type I promoter expression by Sp1 deficiency.
Carcinoma
Response of renal cell carcinoma to ibrutinib, a bruton tyrosine kinase inhibitor, in a patient treated for chronic lymphocytic leukemia.
Carcinoma
Restoration of bone morphogenetic protein receptor type II expression leads to a decreased rate of tumor growth in bladder transitional cell carcinoma cell line TSU-Pr1.
Carcinoma
Restoration of expression of signal-transduction molecules in lymphocytes from patients with metastatic renal cell cancer after combination immunotherapy.
Carcinoma
Restoration of expression of transforming growth factor-beta type II receptor in murine renal cell carcinoma (renca) cells by 5-Aza-2'-deoxycytidine.
Carcinoma
Retraction: Proline-Rich Tyrosine Kinase 2 (Pyk2) Regulates IGF-I-Induced Cell Motility and Invasion of Urothelial Carcinoma Cells.
Carcinoma
Reverse signaling through membrane-bound interleukin-15.
Carcinoma
RNA interference-mediated silencing of focal adhesion kinase inhibits growth of human colon carcinoma xenograft in nude mice.
Carcinoma
Role of Focal Adhesion Kinase in Head and Neck Squamous Cell Carcinoma and Its Therapeutic Prospect.
Carcinoma
Saracatinib Impairs Head and Neck Squamous Cell Carcinoma Invasion by Disrupting Invadopodia Function.
Carcinoma
Serum spleen tyrosine kinase and vascular endothelial growth factor-C levels predict lymph node metastasis of oesophageal squamous cell carcinoma.
Carcinoma
Shikonin induces apoptosis and inhibits migration of ovarian carcinoma cells by inhibiting the phosphorylation of Src and FAK.
Carcinoma
Signal transduction through extracellular signal-regulated kinase-like pp57 blocked in differentiated colon carcinoma cells having low levels of c-src kinase.
Carcinoma
Simultaneous targeting of src kinase and receptor tyrosine kinase results in synergistic inhibition of renal cell carcinoma proliferation and migration.
Carcinoma
SNAI1 expression and the mesenchymal phenotype: an immunohistochemical study performed on 46 cases of oral squamous cell carcinoma.
Carcinoma
SNU cell lines and their application for cancer research.
Carcinoma
Soluble form of ephrinB2 inhibits xenograft growth of squamous cell carcinoma of the head and neck.
Carcinoma
Specific Oncogenic Activity of the Src-Family Tyrosine Kinase c-Yes in Colon Carcinoma Cells.
Carcinoma
Spleen tyrosine kinase activity regulates epidermal growth factor receptor signaling pathway in ovarian cancer.
Carcinoma
Spleen tyrosine kinase as a novel candidate tumor suppressor gene for human oral squamous cell carcinoma.
Carcinoma
Squamous cell carcinoma cell aggregates escape suspension-induced, p53-mediated anoikis: fibronectin and integrin alphav mediate survival signals through focal adhesion kinase.
Carcinoma
Src inhibitors are promising therapy molecules for human cervical carcinomas.
Carcinoma
SRC is dephosphorylated at tyrosine 530 in human colon carcinomas.
Carcinoma
Src kinase contributes to the metastatic spread of carcinoma cells.
Carcinoma
Src kinase potentiates androgen receptor transactivation function and invasion of androgen-independent prostate cancer C4-2 cells.
Carcinoma
Src Plays a Key Role in ADAM28 Expression in v-src-Transformed Epithelial Cells and Human Carcinoma Cells.
Carcinoma
Subsets of salivary duct carcinoma defined by morphologic evidence of pleomorphic adenoma, PLAG1 or HMGA2 rearrangements, and common genetic alterations.
Carcinoma
Synergistic activity of the SRC family kinase inhibitor dasatinib and oxaliplatin in colon carcinoma cells is mediated by oxidative stress.
Carcinoma
Synergistic cooperation between the beta-catenin signaling pathway and steroidogenic factor 1 in the activation of the Mullerian inhibiting substance type II receptor.
Carcinoma
Taiwan cobra cardiotoxin III inhibits Src kinase leading to apoptosis and cell cycle arrest of oral squamous cell carcinoma Ca9-22 cells.
Carcinoma
Targeting CXCR4 and FAK reverses doxorubicin resistance and suppresses invasion in non-small cell lung carcinoma.
Carcinoma
Targeting FAK radiosensitizes 3-dimensional grown human HNSCC cells through reduced Akt1 and MEK1/2 signaling.
Carcinoma
Targeting glutamine metabolism and the focal adhesion kinase additively inhibits the mammalian target of the rapamycin pathway in spheroid cancer stem-like properties of ovarian clear cell carcinoma in vitro.
Carcinoma
Targeting of focal adhesion kinase by flavonoids and small-interfering RNAs reduces tumor cell migration ability.
Carcinoma
Targeting Src in Mucinous Ovarian Carcinoma.
Carcinoma
TGF-? Signal Transduction in Pancreatic Carcinoma Cells is Sensitive to Inhibition by the Src Tyrosine Kinase Inhibitor AZM475271.
Carcinoma
TGFB1 and TGFBR1 polymorphic variants in relationship to bladder cancer risk and prognosis.
Carcinoma
The association between elevated EphB4 expression, smoking status, and advanced-stage disease in patients with head and neck squamous cell carcinoma.
Carcinoma
The COOH-terminal Src kinase Csk is a tumor antigen in human carcinoma.
Carcinoma
The differential expression of EphB2 and EphB4 receptor kinases in normal bladder and in transitional cell carcinoma of the bladder.
Carcinoma
The differential expression of EPHB4 and ephrin B2 in cutaneous squamous cell carcinoma according to the grade of tumor differentiation: a clinicopathological study.
Carcinoma
The expression and role of tyrosine kinase ETK/BMX in renal cell carcinoma.
Carcinoma
The expression and tyrosine phosphorylation of E-cadherin/catenin adhesion complex, and focal adhesion kinase in invasive cervical carcinomas.
Carcinoma
The pro-apoptotic protein Prostate Apoptosis Response Protein-4 (Par-4) can be activated in colon cancer cells by treatment with Src inhibitor and 5-FU.
Carcinoma
The product of the EMS1 gene, amplified and overexpressed in human carcinomas, is homologous to a v-src substrate and is located in cell-substratum contact sites.
Carcinoma
The prognostic impact of EphB2/B4 expression on patients with advanced ovarian carcinoma.
Carcinoma
The receptor tyrosine kinase EphB4 is overexpressed in ovarian cancer, provides survival signals and predicts poor outcome.
Carcinoma
The relation between anti-TGBFR1 immunohistochemical reaction and low Ki67, small tumor size and high estrogen receptor expression in invasive breast cancer.
Carcinoma
The RNA-binding protein Sam68 contributes to proliferation and survival of human prostate cancer cells.
Carcinoma
The role of protein tyrosine phosphorylation in integrin-mediated gene induction in monocytes.
Carcinoma
The significance of EphB4 and EphrinB2 expression and survival in head and neck squamous cell carcinoma.
Carcinoma
The Src family kinase inhibitors PP2 and PP1 effectively block TGF-beta1-induced cell migration and invasion in both established and primary carcinoma cells.
Carcinoma
The stem cell gene "inhibitor of differentiation 1" (ID1) is frequently expressed in non-small cell lung cancer.
Carcinoma
Therapeutic efficacy of a novel focal adhesion kinase inhibitor TAE226 in ovarian carcinoma.
Carcinoma
Three-Dimensional Interactions Analysis of the Anticancer Target c-Src Kinase with Its Inhibitors.
Carcinoma
Transforming growth factor beta regulates cell-cell adhesion through extracellular matrix remodeling and activation of focal adhesion kinase in human colon carcinoma Moser cells.
Carcinoma
Transforming growth factor-beta 1 and its receptors in human lung cancer and mouse lung carcinogenesis.
Carcinoma
Transforming growth factor-beta, transforming growth factor-beta receptor II, and p27Kip1 expression in nontumorous and neoplastic human pituitaries.
Carcinoma
Transinactivation of the epidermal growth factor receptor tyrosine kinase and focal adhesion kinase phosphorylation by dietary flavonoids: effect on invasive potential of human carcinoma cells.
Carcinoma
TYK2 in Cancer Metastases: Genomic and Proteomic Discovery.
Carcinoma
Tyrosine nitration of c-SRC tyrosine kinase in human pancreatic ductal adenocarcinoma.
Carcinoma
Tyrosine protein kinase activity of human hyperplastic prostate and carcinoma cell lines PC3 and DU145.
Carcinoma
Unique Mechanism by Which TGFBR1 Variants Cause 2 Distinct System Diseases?- Loeys-Dietz Syndrome and Multiple Self-Healing Squamous Epithelioma.
Carcinoma
Vascular endothelial growth factor C enhances cervical cancer migration and invasion via activation of focal adhesion kinase.
Carcinoma
Vessels' morphology in SMAD4 and BMPR1A-related juvenile polyposis.
Carcinoma
Wnt/?-catenin signalling induces MLL to create epigenetic changes in salivary gland tumours.
Carcinoma
Zeylenone inhibits proliferation and promotes apoptosis in ovarian carcinoma cells via Janus kinase 2 / signal transducers and activators of transcription 3 pathways.
Carcinoma
[Anti-proliferation effect of genistein on salivary adenoid cystic carcinoma cell line SACC-83 in vitro]
Carcinoma
[BMP7 Signaling via BMPR1A, BMPR1B Inhibits the Proliferation of Lung Large Carcinoma NCI-H460 Cell.]
Carcinoma
[Damage to the transforming growth factor TGF-beta type II receptor gene and microsatellite instability in carcinoma cells of the gastrointestinal tract]
Carcinoma
[Effect of focal adhesion kinase on biological characteristics of Tca8113 tongue squamous cell carcinoma]
Carcinoma
[Effect of genistein on proliferation of renal cell carcinoma cell line GRC-1 and its influence to p27 expression]
Carcinoma
[Effect of the focal adhesion kinase inhibitor TAE226 on the epithelial-mesenchymal transition in human oral squamous cell carcinoma cell line].
Carcinoma
[Effects of genistein on the expressions of cell apoptosis-related proteins in salivary adenoid cystic carcinoma cell line SACC-83]
Carcinoma
[Effects of genistein on the expressions of cell cycle proteins in salivary adenoid cystic carcinoma cell line SACC-83.]
Carcinoma
[Effects of Genistein on the proliferation and expression of survivin in salivary adenoid cystic carcinoma cell line SACC-83]
Carcinoma
[Expression and clinical significance of focal adhesion kinase in oral squamous cell carcinoma]
Carcinoma
[Expression and clinical significance of proline-rich tyrosine kinase 2 and phospho-protein kinase B in tongue squamous cell carcinoma].
Carcinoma
[Expression of focal adhesion kinase in laryngeal carcinoma]
Carcinoma
[Expression of full-length spleen tyrosine kinase in the oral squamous cell carcinoma and its relationship with tumor invasion and metastasis].
Carcinoma
[Expression of proline-rich tyrosine kinase-2 (Pyk2) in gastric carcinoma and its significance]
Carcinoma
[Functional properties of the WNT11 new isoform, expressed in colon carcinoma cell line HT29].
Carcinoma
[Gene expression profiles of protein kinases and phosphatases obtained by hybridization with cDNA arrays: molecular portrait of human prostate carcinoma]
Carcinoma
[Hereditary breast carcinomas pathologist's perspective].
Carcinoma
[Knockdown of Fez family zinc finger protein 1 antisense ribonucleic acid 1 (FEZF1-AS1) inhibits invasion and migration of esophageal squamous cell carcinoma cells by blocking JAK2/STAT3 pathway].
Carcinoma
[Molecular portrait of human kidney carcinomas: the gene expression profiling of protein-tyrosine kinases and tyrosine phosphatases which controlled regulatory signals in the cells]
Carcinoma
[Proteomic identification and comparison of differentiation-related proteins in gastric carcinoma cell lines]
Carcinoma
[The endothelial podosome]
Carcinoma
[The expression and significance of integrin beta1 and focal adhesion kinase and its clinical value in laryngeal carcinoma]
Carcinoma
[The expression of tumor suppressor gene PTEN protein and focal adhesion kinase in salivary adenoid cystic carcinoma and its significance.]
Carcinoma
[Tyrosine kinases of the Src family, enzymes with multiple functions: from the growth of fibroblasts to the migration of epithelial cells]
Carcinoma in Situ
The differential expression of EphB2 and EphB4 receptor kinases in normal bladder and in transitional cell carcinoma of the bladder.
Carcinoma, Adenoid Cystic
Expression and clinical significance of FAK, ILK, and PTEN in salivary adenoid cystic carcinoma.
Carcinoma, Adenoid Cystic
[Anti-proliferation effect of genistein on salivary adenoid cystic carcinoma cell line SACC-83 in vitro]
Carcinoma, Adenoid Cystic
[Effects of genistein on the expressions of cell apoptosis-related proteins in salivary adenoid cystic carcinoma cell line SACC-83]
Carcinoma, Adenoid Cystic
[Effects of genistein on the expressions of cell cycle proteins in salivary adenoid cystic carcinoma cell line SACC-83.]
Carcinoma, Adenoid Cystic
[Effects of Genistein on the proliferation and expression of survivin in salivary adenoid cystic carcinoma cell line SACC-83]
Carcinoma, Adenoid Cystic
[The expression of tumor suppressor gene PTEN protein and focal adhesion kinase in salivary adenoid cystic carcinoma and its significance.]
Carcinoma, Basal Cell
Elevated c-Src and c-Yes expression in malignant skin cancers.
Carcinoma, Basal Cell
In situ analysis of transforming growth factors-beta (TGF-beta 1, TGF-beta 2, TGF-beta 3) and TGF-beta type II receptor expression in basal cell carcinomas.
Carcinoma, Basal Cell
miRNA- and cytokine-associated extracellular vesicles mediate squamous cell carcinomas.
Carcinoma, Ductal
Activated c-SRC in ductal carcinoma in situ correlates with high tumour grade, high proliferation and HER2 positivity.
Carcinoma, Ductal
Focal adhesion kinase and Wnt signaling regulate human ductal carcinoma in situ stem cell activity and response to radiotherapy.
Carcinoma, Ductal
Upregulation of focal adhesion kinase (FAK) expression in ductal carcinoma in situ (DCIS) is an early event in breast tumorigenesis.
Carcinoma, Ehrlich Tumor
A tyrosine-specific protein kinase from Ehrlich ascites tumor cells.
Carcinoma, Embryonal
Changes in c-onc expression during embryonal carcinoma cell differentiation.
Carcinoma, Embryonal
Cloning and biochemical characterization of LIMK-2, a protein kinase containing two LIM domains.
Carcinoma, Embryonal
Complexes of gamma-tubulin with nonreceptor protein tyrosine kinases Src and Fyn in differentiating P19 embryonal carcinoma cells.
Carcinoma, Embryonal
Differential expression of BMP receptors in early mouse development.
Carcinoma, Embryonal
Differential expression of inhibin subunits and follistatin, but not of activin receptor type II, during early murine embryonic development.
Carcinoma, Embryonal
Expression of c-src and c-abl in embryonal carcinoma cells and adult mouse tissues.
Carcinoma, Embryonal
Regulation of microtubule nucleation from membranes by complexes of membrane-bound gamma-tubulin with Fyn kinase and phosphoinositide 3-kinase.
Carcinoma, Embryonal
Syk protein-tyrosine kinase is involved in neuron-like differentiation of embryonal carcinoma P19 cells.
Carcinoma, Embryonal
The effects of v-src expression on the differentiation of embryonal carcinoma cells.
Carcinoma, Endometrioid
Activation of the receptor protein tyrosine kinase EphB4 in endometrial hyperplasia and endometrial carcinoma.
Carcinoma, Hepatocellular
ABL1, Overexpressed in Hepatocellular Carcinomas, Regulates Expression of NOTCH1 and Promotes Development of Liver Tumors in Mice.
Carcinoma, Hepatocellular
Abrogation of constitutive STAT3 activity sensitizes human hepatoma cells to TRAIL-mediated apoptosis.
Carcinoma, Hepatocellular
Activation of c-Yes in hepatocellular carcinoma: A preliminary study.
Carcinoma, Hepatocellular
Alterations of the transforming growth factor-beta signaling pathway in hepatocellular carcinomas induced endogenously and exogenously in rats.
Carcinoma, Hepatocellular
Altered regulation of Src tyrosine kinase by transforming growth factor beta1 in a human hepatoma cell line.
Carcinoma, Hepatocellular
An indel polymorphism in the 3' untranslated region of JAK1 confers risk for hepatocellular carcinoma possibly by regulating JAK1 transcriptional activity in a Chinese population.
Carcinoma, Hepatocellular
Auranofin blocks interleukin-6 signalling by inhibiting phosphorylation of JAK1 and STAT3.
Carcinoma, Hepatocellular
c-src tyrosine kinase is associated with the asialoglycoprotein receptor in human hepatoma cells.
Carcinoma, Hepatocellular
Changes in cell ultrastructure and inhibition of JAK1/STAT3 signaling pathway in CBRH-7919 cells with astaxanthin.
Carcinoma, Hepatocellular
CHK1 targets spleen tyrosine kinase (L) for proteolysis in hepatocellular carcinoma.
Carcinoma, Hepatocellular
Circ_0015756 promotes proliferation, invasion and migration by microRNA-7-dependent inhibition of FAK in hepatocellular carcinoma.
Carcinoma, Hepatocellular
Cloning, mapping, and characterization of the human sorbin and SH3 domain containing 1 (SORBS1) gene: a protein associated with c-Abl during insulin signaling in the hepatoma cell line Hep3B.
Carcinoma, Hepatocellular
Correction: Zheng, L., et al. PBN11-8, a Cytotoxic Polypeptide Purified from Marine Bacillus, Suppresses Invasion and Migration of Human Hepatocellular Carcinoma Cells by Targeting Focal Adhesion Kinase Pathways. Polymers 2018, 10, 1043.
Carcinoma, Hepatocellular
Corrigendum to: miR-4458 inhibits the epithelial-mesenchymal transition of hepatocellular carcinoma cells by suppressing the TGF-? signaling pathway via targeting TGFBR1.
Carcinoma, Hepatocellular
Cross talk between the TM4SF5/focal adhesion kinase and the interleukin-6/STAT3 pathways promotes immune escape of human liver cancer cells.
Carcinoma, Hepatocellular
Current understanding of tyrosine kinase BMX in inflammation and its inhibitors.
Carcinoma, Hepatocellular
Cyclic phosphatidic acid inhibits RhoA-mediated autophosphorylation of FAK at Tyr-397 and subsequent tumor-cell invasion.
Carcinoma, Hepatocellular
Dihydrotanshinone I inhibits the growth of hepatoma cells by direct inhibition of Src.
Carcinoma, Hepatocellular
Distinct pathways of genomic progression to benign and malignant tumors of the liver.
Carcinoma, Hepatocellular
Downregulation of spleen tyrosine kinase in hepatocellular carcinoma by promoter CpG island hypermethylation and its potential role in carcinogenesis.
Carcinoma, Hepatocellular
Enhanced expression of the protein kinase substrate p36 in human hepatocellular carcinoma.
Carcinoma, Hepatocellular
Expression and prognostic significance of focal adhesion kinase in hepatocellular carcinoma.
Carcinoma, Hepatocellular
Expression of Src and FAK in Hepatocellular Carcinoma and the Effect of Src Inhibitors on Hepatocellular Carcinoma In Vitro.
Carcinoma, Hepatocellular
Expression of tyrosine kinase Etk/Bmx and its relationship with AP-1- and NF-kappaB-associated proteins in hepatocellular carcinoma.
Carcinoma, Hepatocellular
Expression of Variant Isoforms of the Tyrosine Kinase SYK Determines the Prognosis of Hepatocellular Carcinoma.
Carcinoma, Hepatocellular
Focal Adhesion Kinase (FAK) Over-Expression and Prognostic Implication in Pediatric Hepatocellular Carcinoma.
Carcinoma, Hepatocellular
Focal adhesion kinase activation limits efficacy of Dasatinib in c-Myc driven hepatocellular carcinoma.
Carcinoma, Hepatocellular
Focal adhesion kinase affects the sensitivity of human hepatocellular carcinoma cell line SMMC-7721 to tumor necrosis factor-alpha/cycloheximide-induced apoptosis by regulating protein kinase B levels.
Carcinoma, Hepatocellular
Focal Adhesion Kinase and ?-Catenin Cooperate to Induce Hepatocellular Carcinoma.
Carcinoma, Hepatocellular
Focal adhesion kinase depletion reduces human hepatocellular carcinoma growth by repressing enhancer of zeste homolog 2.
Carcinoma, Hepatocellular
Focal adhesion kinase is overexpressed in hepatocellular carcinoma and can be served as an independent prognostic factor.
Carcinoma, Hepatocellular
Focal adhesion kinase: important to prostaglandin E2-mediated adhesion, migration and invasion in hepatocellular carcinoma cells.
Carcinoma, Hepatocellular
Focal Adhesion Kinase: Insight into Molecular Roles and Functions in Hepatocellular Carcinoma.
Carcinoma, Hepatocellular
Frequent epigenetic inactivation of spleen tyrosine kinase gene in human hepatocellular carcinoma.
Carcinoma, Hepatocellular
Fructose 2,6-bisphosphate and the control of glycolysis by growth factors, tumor promoters and oncogenes.
Carcinoma, Hepatocellular
Functions and therapeutic value of focal adhesion kinase signaling during hepatocellular carcinoma development and progression.
Carcinoma, Hepatocellular
Gene therapy targeting hepatocellular carcinoma by a dual-regulated oncolytic adenovirus harboring the focal adhesion kinase shRNA.
Carcinoma, Hepatocellular
Glycosaminoglycans and their synthetic mimetics inhibit RANTES-induced migration and invasion of human hepatoma cells.
Carcinoma, Hepatocellular
Growth inhibition by transforming growth factor beta (TGF-beta) type I is restored in TGF-beta-resistant hepatoma cells after expression of TGF-beta receptor type II cDNA.
Carcinoma, Hepatocellular
Hepatitis B virus large surface antigen promotes liver carcinogenesis by activating the Src/PI3K/Akt pathway.
Carcinoma, Hepatocellular
Hepatitis B virus-related insertional mutagenesis occurs frequently in human liver cancers and recurrently targets human telomerase gene.
Carcinoma, Hepatocellular
High expression of Janus kinase 2 in background normal liver tissue of resected hepatocellular carcinoma is associated with worse prognosis.
Carcinoma, Hepatocellular
Human and mouse hepatocellular adenoma and carcinoma display similar tumorigenesis pathway alterations.
Carcinoma, Hepatocellular
Identification of a human cDNA encoding a novel protein kinase with two repeats of the LIM/double zinc finger motif.
Carcinoma, Hepatocellular
Identification of c-Yes expression in the nuclei of hepatocellular carcinoma cells: involvement in the early stages of hepatocarcinogenesis.
Carcinoma, Hepatocellular
Identification of p62, a phosphotyrosine independent ligand of p56lck kinase, as a major component of intracytoplasmic hyaline bodies in hepatocellular carcinoma.
Carcinoma, Hepatocellular
Immunohistochemical assessment of Eph/ephrin expression in oral squamous cell carcinoma and precursor lesions.
Carcinoma, Hepatocellular
In silico identification of oncogenic potential of fyn-related kinase in hepatocellular carcinoma.
Carcinoma, Hepatocellular
Jak inhibitor induces S phase cell-cycle arrest and augments TRAIL-induced apoptosis in human hepatocellular carcinoma cells.
Carcinoma, Hepatocellular
Janus Kinase 2 (JAK2) Dissociates Hepatosteatosis from Hepatocellular Carcinoma in Mice.
Carcinoma, Hepatocellular
Jianpijiedu fang improves survival of hepatocarcinoma mice by affecting phosphatase and tensin homolog, phosphoinositide 3-kinase, and focal adhesion kinase.
Carcinoma, Hepatocellular
Krüppel?like factor expression and correlation with FAK, MMP?9 and E?cadherin expression in hepatocellular carcinoma.
Carcinoma, Hepatocellular
MicroRNA-140-5p suppresses tumor growth and metastasis by targeting TGFBR1 and FGF9 in hepatocellular carcinoma.
Carcinoma, Hepatocellular
MicroRNA-590-5p regulates proliferation and invasion in human hepatocellular carcinoma cells by targeting TGF-? RII.
Carcinoma, Hepatocellular
Microsatellite instability and mutations of E2F-4 in hepatocellular carcinoma from Korea.
Carcinoma, Hepatocellular
miR-130-3p Promotes MTX-Induced Immune Killing of Hepatocellular Carcinoma Cells by Targeting EPHB4.
Carcinoma, Hepatocellular
miR-4458 inhibits the epithelial-mesenchymal transition of hepatocellular carcinoma cells by suppressing the TGF-? signaling pathway via targeting TGFBR1.
Carcinoma, Hepatocellular
MR-1 modulates proliferation and migration of human hepatoma HepG2 cells through myosin light chains-2 (MLC2)/focal adhesion kinase (FAK)/Akt signaling pathway.
Carcinoma, Hepatocellular
Noncanonical Wnt11 inhibits hepatocellular carcinoma cell proliferation and migration.
Carcinoma, Hepatocellular
Overexpressed focal adhesion kinase predicts a higher incidence of extrahepatic metastasis and worse survival in hepatocellular carcinoma.
Carcinoma, Hepatocellular
Overexpression and significance of focal adhesion kinase in hepatocellular carcinoma and its relationship with HBV infection.
Carcinoma, Hepatocellular
Overexpression of Abl2 predicts poor prognosis in hepatocellular carcinomas and is associated with cancer cell migration and invasion.
Carcinoma, Hepatocellular
Overexpression of HAb18G/CD147 promotes invasion and metastasis via alpha3beta1 integrin mediated FAK-paxillin and FAK-PI3K-Ca(2+) pathways.
Carcinoma, Hepatocellular
PBN11-8, a Cytotoxic Polypeptide Purified from Marine Bacillus, Suppresses Invasion and Migration of Human Hepatocellular Carcinoma Cells by Targeting Focal Adhesion Kinase Pathways.
Carcinoma, Hepatocellular
Pharmacological activation of AMPK suppresses inflammatory response evoked by IL-6 signalling in mouse liver and in human hepatocytes.
Carcinoma, Hepatocellular
Prolactin Promotes Hepatocellular Carcinoma through Janus Kinase 2.
Carcinoma, Hepatocellular
Proline-rich tyrosine kinase 2 (Pyk2) promotes cell motility of hepatocellular carcinoma through induction of epithelial to mesenchymal transition.
Carcinoma, Hepatocellular
Proline-rich tyrosine kinase 2 (Pyk2) promotes proliferation and invasiveness of hepatocellular carcinoma cells through c-Src/ERK activation.
Carcinoma, Hepatocellular
Prostaglandin E2 receptor EP1-mediated phosphorylation of focal adhesion kinase enhances cell adhesion and migration in hepatocellular carcinoma cells.
Carcinoma, Hepatocellular
Protein kinase C-mediated tyrosine phosphorylation of paxillin and focal adhesion kinase requires cytoskeletal integrity and is uncoupled to mitogen-activated protein kinase activation in human hepatoma cells.
Carcinoma, Hepatocellular
Reduced C-terminal Src kinase (Csk) activities in hepatocellular carcinoma.
Carcinoma, Hepatocellular
Regulation of JAK2 protein expression by chronic, pulsatile GH administration in vivo: a possible mechanism for ligand enhancement of signal transduction.
Carcinoma, Hepatocellular
Role of expression of focal adhesion kinase in progression of hepatocellular carcinoma.
Carcinoma, Hepatocellular
Silencing of lemur tyrosine kinase 2 restricts the proliferation and invasion of hepatocellular carcinoma through modulation of GSK-3?/Wnt/?-catenin signaling.
Carcinoma, Hepatocellular
Staurosporine inhibits a tyrosine protein kinase in human hepatoma cell membranes.
Carcinoma, Hepatocellular
Suppression of in vivo tumorigenicity of rat hepatoma cell line KDH-8 cells by soluble TGF-beta receptor type II.
Carcinoma, Hepatocellular
Targeting interleukin-1 receptor-associated kinase 1 for human hepatocellular carcinoma.
Carcinoma, Hepatocellular
The ectodomain of matriptase-2 plays an important nonproteolytic role in suppressing hepcidin expression in mice.
Carcinoma, Hepatocellular
The effect of Bruton's tyrosine kinase (BTK) inhibitors on collagen-induced platelet aggregation, BTK, and tyrosine kinase expressed in hepatocellular carcinoma (TEC).
Carcinoma, Hepatocellular
The long noncoding RNA AK002107 negatively modulates miR-140-5p and targets TGFBR1 to induce epithelial-mesenchymal transition in hepatocellular carcinoma.
Carcinoma, Hepatocellular
The role of proline rich tyrosine kinase 2 (Pyk2) on cisplatin resistance in hepatocellular carcinoma.
Carcinoma, Hepatocellular
Transforming growth factor beta 1 selectively increases gene expression of the serine/threonine kinase receptor 1 (SKR1) in human hepatoma cell lines.
Carcinoma, Hepatocellular
Transforming growth factor-beta1 stimulated protein kinase B serine-473 and focal adhesion kinase tyrosine phosphorylation dependent on cell adhesion in human hepatocellular carcinoma SMMC-7721 cells.
Carcinoma, Hepatocellular
Transient knockdown-mediated deficiency in plectin alters hepatocellular motility in association with activated FAK and Rac1-GTPase.
Carcinoma, Hepatocellular
Tumor prone phenotype of mice deficient in a novel apoptosis-inducing gene, drs.
Carcinoma, Hepatocellular
Tyrosine Kinase SYK is a Potential Therapeutic Target for Liver Fibrosis.
Carcinoma, Hepatocellular
Tyrosine protein kinase in preneoplastic and neoplastic rat liver.
Carcinoma, Hepatocellular
Upregulation of Focal Adhesion Kinase by 14-3-3? via NF?B Activation in Hepatocellular Carcinoma.
Carcinoma, Hepatocellular
[Focal adhesion kinase mRNA overexpression in hepatocellular carcinoma HCC) and correlation thereof with prognosis of HCC]
Carcinoma, Hepatocellular
[Influence of focal adhesion kinase (FAK) on the biological behaviors of human hepatocellular carcinoma cells]
Carcinoma, Hepatocellular
[Inhibitory effects of antisense focal adhesion kinase oligodeoxynucleotides on the invasion of Bel 7402 hepatocellular carcinoma cells]
Carcinoma, Hepatocellular
[Liver phosphotyrosine protein phosphatase and tyrosine protein kinase in chemical hepatocarcinogenesis]
Carcinoma, Hepatocellular
[RNA interference targeting focal adhesion kinase inhibited the growth of human hepatocellular carcinoma sk-hep-1].
Carcinoma, Intraductal, Noninfiltrating
Activated c-SRC in ductal carcinoma in situ correlates with high tumour grade, high proliferation and HER2 positivity.
Carcinoma, Intraductal, Noninfiltrating
Differential Gene Expression in Ductal Carcinoma In Situ of the Breast Based on ERBB2 Status.
Carcinoma, Intraductal, Noninfiltrating
Focal adhesion kinase and Wnt signaling regulate human ductal carcinoma in situ stem cell activity and response to radiotherapy.
Carcinoma, Intraductal, Noninfiltrating
The relation between anti-TGBFR1 immunohistochemical reaction and low Ki67, small tumor size and high estrogen receptor expression in invasive breast cancer.
Carcinoma, Intraductal, Noninfiltrating
Upregulation of focal adhesion kinase (FAK) expression in ductal carcinoma in situ (DCIS) is an early event in breast tumorigenesis.
Carcinoma, Lewis Lung
Development of a metastatic fluorescent Lewis Lung carcinoma mouse model: identification of mRNAs and microRNAs involved in tumor invasion.
Carcinoma, Medullary
Renal medullary carcinoma and ABL gene amplification.
Carcinoma, Merkel Cell
A case of Merkel cell carcinoma development under treatment with a Janus kinase inhibitor.
Carcinoma, Merkel Cell
Aggressive Merkel Cell Carcinoma After Janus Kinase Inhibitor Ruxolitinib for Polycythemia Vera.
Carcinoma, Non-Small-Cell Lung
A haplotype of TGFBR1 is predominantly found in non-small cell lung cancer patients displaying TGFBR1 allelic-specific expression.
Carcinoma, Non-Small-Cell Lung
Activation of Janus kinase 1 confers poor prognosis in patients with non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Bombesin and gastrin releasing peptide increase tyrosine phosphorylation of focal adhesion kinase and paxillin in non-small cell lung cancer cells.
Carcinoma, Non-Small-Cell Lung
Bruton's tyrosine kinase (BTK) mediates resistance to EGFR inhibition in non-small-cell lung carcinoma.
Carcinoma, Non-Small-Cell Lung
Combination of heat shock protein 90 and focal adhesion kinase inhibitors synergistically inhibits the growth of non-small cell lung cancer cells.
Carcinoma, Non-Small-Cell Lung
Detection of novel paraja ring finger 2-fer tyrosine kinase mRNA chimeras is associated with poor postoperative prognosis in non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Early Candidate Biomarkers of Non-Small Cell Lung Cancer Are Screened and Identified in Premalignant Lung Lesions.
Carcinoma, Non-Small-Cell Lung
Effect of spleen tyrosine kinase on nonsmall cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Effects of Src kinase inhibition induced by dasatinib in non-small cell lung cancer cell lines treated with cisplatin.
Carcinoma, Non-Small-Cell Lung
Efficacy of focal adhesion kinase inhibition in non-small cell lung cancer with oncogenically activated MAPK pathways.
Carcinoma, Non-Small-Cell Lung
EphB4 as a Novel Target for the EGFR-Independent Suppressive Effects of Osimertinib on Cell Cycle Progression in Non-Small Cell Lung Cancer.
Carcinoma, Non-Small-Cell Lung
Expression and pharmacological inhibition of thymidylate synthase and Src kinase in nonsmall cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Expression of c-src in cultured human neuroblastoma and small-cell lung carcinoma cell lines correlates with neurocrine differentiation.
Carcinoma, Non-Small-Cell Lung
Expression of protein tyrosine kinase 6 (PTK6) in nonsmall cell lung cancer and their clinical and prognostic significance.
Carcinoma, Non-Small-Cell Lung
FER overexpression is associated with poor postoperative prognosis and cancer-cell survival in non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Focal Adhesion Kinase Inhibitors in Combination with Erlotinib Demonstrate Enhanced Anti-Tumor Activity in Non-Small Cell Lung Cancer.
Carcinoma, Non-Small-Cell Lung
FOXD3-AS1 suppresses the progression of non-small cell lung cancer by regulating miR-150/SRCIN1axis.
Carcinoma, Non-Small-Cell Lung
G9a Promotes Invasion and Metastasis of Non-Small Cell Lung Cancer through Enhancing Focal Adhesion Kinase Activation via NF-?B Signaling Pathway.
Carcinoma, Non-Small-Cell Lung
Identification of novel allosteric binding sites and multi-targeted allosteric inhibitors of receptor and non-receptor tyrosine kinases using a computational approach.
Carcinoma, Non-Small-Cell Lung
JAK2 inhibition sensitizes resistant EGFR-mutant lung adenocarcinoma to tyrosine kinase inhibitors.
Carcinoma, Non-Small-Cell Lung
JAK2/STAT3 signaling pathway activation mediates tumor angiogenesis by upregulation of VEGF and bFGF in non-small-cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Lack of correlation between growth inhibition by TGF-beta and the percentage of cells expressing type II TGF-beta receptor in human non-small cell lung carcinoma cell lines.
Carcinoma, Non-Small-Cell Lung
LncRNA TMPO-AS1 facilitates the proliferation and metastasis of NSCLC cells by up-regulating ERBB2 via sponging miR-204-3p.
Carcinoma, Non-Small-Cell Lung
Long non-coding RNA DANCR promoted non-small cell lung cancer cells metastasis via modulating of miR-1225-3p/ErbB2 signal.
Carcinoma, Non-Small-Cell Lung
MicroRNA-510 Plays Oncogenic Roles in Non-Small Cell Lung Cancer by Directly Targeting SRC Kinase Signaling Inhibitor 1.
Carcinoma, Non-Small-Cell Lung
MicroRNA-98-5p inhibits proliferation and metastasis in non-small cell lung cancer by targeting TGFBR1.
Carcinoma, Non-Small-Cell Lung
miR-140-3p inhibits progression of non-small cell lung cancer by targeting Janus kinase 1.
Carcinoma, Non-Small-Cell Lung
miR-3607-3p suppresses non-small cell lung cancer (NSCLC) by targeting TGFBR1 and CCNE2.
Carcinoma, Non-Small-Cell Lung
MiR-410 affects the proliferation and apoptosis of lung cancer A549 cells through regulation of SOCS3/JAK-STAT signaling pathway.
Carcinoma, Non-Small-Cell Lung
miR-769-5p suppressed cell proliferation, migration and invasion by targeting TGFBR1 in non-small cell lung carcinoma.
Carcinoma, Non-Small-Cell Lung
New drugs in thyroid cancer.
Carcinoma, Non-Small-Cell Lung
Non-small-cell lung cancer with ERBB2 mutation in non-tyrosine kinase domain benefits from pyrotinib: A case report.
Carcinoma, Non-Small-Cell Lung
Oncogenic activation of c-Abl in non-small cell lung cancer cells lacking FUS1 expression: inhibition of c-Abl by the tumor suppressor gene product Fus1.
Carcinoma, Non-Small-Cell Lung
p65BTK is a novel potential actionable target in KRAS-mutated/EGFR-wild type lung adenocarcinoma.
Carcinoma, Non-Small-Cell Lung
Phase 2 study of the focal adhesion kinase inhibitor defactinib (VS-6063) in previously treated advanced KRAS mutant non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Plumbagin reduces osteopontin-induced invasion through inhibiting the Rho-associated kinase signaling pathway in A549 cells and suppresses osteopontin-induced lung metastasis in BalB/c mice.
Carcinoma, Non-Small-Cell Lung
Prognostic significance of expression of nm23-H1 and focal adhesion kinase in non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Protein tyrosine kinase 2: a novel therapeutic target to overcome acquired EGFR-TKI resistance in non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Selective antitumor activity of ibrutinib in EGFR-mutant non-small cell lung cancer cells.
Carcinoma, Non-Small-Cell Lung
Simultaneous Identification of EGFR,KRAS,ERBB2, and TP53 Mutations in Patients with Non-Small Cell Lung Cancer by Machine Learning-Derived Three-Dimensional Radiomics.
Carcinoma, Non-Small-Cell Lung
SOCS3 expression is inversely correlated with Pyk2 in non-small cell lung cancer and exogenous SOCS3 inhibits proliferation and invasion of A549 cells.
Carcinoma, Non-Small-Cell Lung
Somatic Mutations and Splicing Variants of Focal Adhesion Kinase in Non-Small Cell Lung Cancer.
Carcinoma, Non-Small-Cell Lung
Targeting CXCR4 and FAK reverses doxorubicin resistance and suppresses invasion in non-small cell lung carcinoma.
Carcinoma, Non-Small-Cell Lung
Transforming growth factor-beta 1 and its receptors in human lung cancer and mouse lung carcinogenesis.
Carcinoma, Non-Small-Cell Lung
Treatment-related toxicities in a phase II trial of dasatinib in patients with squamous cell carcinoma of the lung.
Carcinoma, Non-Small-Cell Lung
Up-regulation of focal adhesion kinase in non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Up-regulation of proline-rich tyrosine kinase 2 in non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
[Association between Ephb4 gene polymorphism and non-small cell lung cancer]
Carcinoma, Non-Small-Cell Lung
[Effect of Src tyrosine kinase inhibition on secretion of MMP-2 and MMP-9 by non-small cell lung cancer cells].
Carcinoma, Non-Small-Cell Lung
[Molecular Targeted Therapy and Laboratory Tests].
Carcinoma, Non-Small-Cell Lung
[Relationship between multi-slice spiral CT pulmonary perfusion imaging and the expression of EphB4 and ephrinB2 in non-small cell lung cancer].
Carcinoma, Ovarian Epithelial
AKT2, a member of the protein kinase B family, is activated by growth factors, v-Ha-ras, and v-src through phosphatidylinositol 3-kinase in human ovarian epithelial cancer cells.
Carcinoma, Ovarian Epithelial
Ambivalent role of pFAK-Y397 in serous ovarian cancer--a study of the OVCAD consortium.
Carcinoma, Ovarian Epithelial
c-Yes enhances tumor migration and invasion via PI3K/AKT pathway in epithelial ovarian cancer.
Carcinoma, Ovarian Epithelial
Caspase 3-mediated focal adhesion kinase processing in human ovarian cancer cells: possible regulation by X-linked inhibitor of apoptosis protein.
Carcinoma, Ovarian Epithelial
Characterization of inhibin/activin subunit, follistatin, and activin type II receptors in human ovarian cancer cell lines: a potential role in autocrine growth regulation.
Carcinoma, Ovarian Epithelial
Clinical investigation of receptor and non-receptor tyrosine kinase inhibitors for the treatment of epithelial ovarian cancer.
Carcinoma, Ovarian Epithelial
Correlation between SNPs of PIK3CA, ERBB2 3'UTR, and their interactions with environmental factors and the risk of epithelial ovarian cancer.
Carcinoma, Ovarian Epithelial
Expression and clinical significance of focal adhesion kinase and adrenomedullin in epithelial ovarian cancer.
Carcinoma, Ovarian Epithelial
Focal adhesion kinase interacts with the transcriptional coactivator FHL2 and both are overexpressed in epithelial ovarian cancer.
Carcinoma, Ovarian Epithelial
Focal adhesion kinase: an alternative focus for anti-angiogenesis therapy in ovarian cancer.
Carcinoma, Ovarian Epithelial
Overexpression of c-Abl predicts unfavorable outcome in epithelial ovarian cancer.
Carcinoma, Ovarian Epithelial
Pilot study: alteration of deleted in liver cancer1 and phosphorylated focal adhesion kinase y397 cytoplasmic expression and the prognostic value in advanced epithelial ovarian carcinoma.
Carcinoma, Ovarian Epithelial
Sex-determining region Y-box3 (SOX3) functions as an oncogene in promoting epithelial ovarian cancer by targeting Src kinase.
Carcinoma, Pancreatic Ductal
High expression of AMAP1, an ARF6 effector, is associated with elevated levels of PD-L1 and fibrosis of pancreatic cancer.
Carcinoma, Papillary
Clinical Significance of EphB4 and EphB6 Expression in Human Malignant and Benign Thyroid Lesions.
Carcinoma, Papillary
Continued expression of a tissue specific activated oncogene in the early steps of radiation-induced human thyroid carcinogenesis.
Carcinoma, Papillary
The trk family of oncogenes and neurotrophin receptors.
Carcinoma, Renal Cell
15-Deoxy-?12,14-prostaglandin J2 Inhibits Cell Migration on Renal Cell Carcinoma via Down-Regulation of Focal Adhesion Kinase Signaling.
Carcinoma, Renal Cell
Aberration hubs in protein interaction networks highlight actionable targets in cancer.
Carcinoma, Renal Cell
Circ_0015756 promotes proliferation, invasion and migration by microRNA-7-dependent inhibition of FAK in hepatocellular carcinoma.
Carcinoma, Renal Cell
Differential effects of ketoconazole and primaquine on the pharmacokinetics and tissue distribution of imatinib in mice.
Carcinoma, Renal Cell
Downregulation of the c-Fes protein-tyrosine kinase inhibits the proliferation of human renal carcinoma cells.
Carcinoma, Renal Cell
Enhanced expression of c-myc and epidermal growth factor receptor (C-erbB-1) genes in primary human renal cancer.
Carcinoma, Renal Cell
Expression of the EPHB4 receptor tyrosine kinase in head and neck and renal malignancies--implications for solid tumors and potential for therapeutic inhibition.
Carcinoma, Renal Cell
High expression of FER tyrosine kinase predicts poor prognosis in clear cell renal cell carcinoma.
Carcinoma, Renal Cell
Interleukin4R? (IL4R?) and IL13R?1 Are Associated with the Progress of Renal Cell Carcinoma through Janus Kinase 2 (JAK2)/Forkhead Box O3 (FOXO3) Pathways.
Carcinoma, Renal Cell
Kinomic profiling identifies focal adhesion kinase 1 as a therapeutic target in advanced clear cell renal cell carcinoma.
Carcinoma, Renal Cell
Loss of T-cell receptor zeta chain and p56lck in T-cells infiltrating human renal cell carcinoma.
Carcinoma, Renal Cell
Migration of renal carcinoma cells is dependent on protein kinase Cdelta via beta1 integrin and focal adhesion kinase.
Carcinoma, Renal Cell
Molecular cloning and characterization of human WNT11.
Carcinoma, Renal Cell
Non-coding RNA 886 promotes renal cell carcinoma growth and metastasis through the Janus kinase 2/signal transducer and activator of transcription 3 signaling pathway.
Carcinoma, Renal Cell
Over-expression of mir-124 inhibits MMP-9 expression and decreases invasion of renal cell carcinoma cells.
Carcinoma, Renal Cell
Phosphorylated Signal Transducer and Activator of Transcription 1 is a potential predictor of interferon response in patients with advanced renal cell carcinoma.
Carcinoma, Renal Cell
RB1CC1 functions as a tumor-suppressing gene in renal cell carcinoma via suppression of PYK2 activity and disruption of TAZ-mediated PDL1 transcription activation.
Carcinoma, Renal Cell
Response of renal cell carcinoma to ibrutinib, a bruton tyrosine kinase inhibitor, in a patient treated for chronic lymphocytic leukemia.
Carcinoma, Renal Cell
Restoration of expression of signal-transduction molecules in lymphocytes from patients with metastatic renal cell cancer after combination immunotherapy.
Carcinoma, Renal Cell
Restoration of expression of transforming growth factor-beta type II receptor in murine renal cell carcinoma (renca) cells by 5-Aza-2'-deoxycytidine.
Carcinoma, Renal Cell
Simultaneous targeting of src kinase and receptor tyrosine kinase results in synergistic inhibition of renal cell carcinoma proliferation and migration.
Carcinoma, Renal Cell
The expression and role of tyrosine kinase ETK/BMX in renal cell carcinoma.
Carcinoma, Renal Cell
[Effect of genistein on proliferation of renal cell carcinoma cell line GRC-1 and its influence to p27 expression]
Carcinoma, Small Cell
A tyrosine protein kinase activated by bombesin in normal fibroblasts and small cell carcinomas.
Carcinoma, Squamous Cell
3D cell cultures of human head and neck squamous cell carcinoma cells are radiosensitized by the focal adhesion kinase inhibitor TAE226.
Carcinoma, Squamous Cell
A case of aggressive squamous cell carcinoma with lymphovascular invasion during treatment with the Janus kinase inhibitor tofacitinib.
Carcinoma, Squamous Cell
Aggressive squamous cell carcinoma in a patient on the Janus kinase inhibitor ruxolitinib.
Carcinoma, Squamous Cell
An altered fibronectin matrix induces anoikis of human squamous cell carcinoma cells by suppressing integrin alpha v levels and phosphorylation of FAK and ERK.
Carcinoma, Squamous Cell
Ascl1-induced Wnt11 regulates neuroendocrine differentiation, cell proliferation, and E-cadherin expression in small-cell lung cancer and Wnt11 regulates small-cell lung cancer biology.
Carcinoma, Squamous Cell
Barium promotes anchorage-independent growth and invasion of human HaCaT keratinocytes via activation of c-SRC kinase.
Carcinoma, Squamous Cell
c-Abl modulates tumor cell sensitivity to antibody-dependent cellular cytotoxicity.
Carcinoma, Squamous Cell
c-Abl Tyrosine Kinase Is Regulated Downstream of the Cytoskeletal Protein Synemin in Head and Neck Squamous Cell Carcinoma Radioresistance and DNA Repair.
Carcinoma, Squamous Cell
Carbon Ion Irradiation Enhances the Anti-tumor Efficiency in Tongue Squamous Cell Carcinoma via Modulating the FAK Signaling.
Carcinoma, Squamous Cell
Chemokine receptor 7 via proline-rich tyrosine kinase-2 upregulates the chemotaxis and migration ability of squamous cell carcinoma of the head and neck.
Carcinoma, Squamous Cell
Chemopreventive and Chemotherapeutic Actions of mTOR Inhibitor in Genetically Defined Head and Neck Squamous Cell Carcinoma Mouse Model.
Carcinoma, Squamous Cell
Correlation of constitutive activation of raf-1 with morphological transformation and abrogation of tyrosine phosphorylation of distinct sets of proteins in human squamous carcinoma cells.
Carcinoma, Squamous Cell
Correlation of focal adhesion kinase expression with nodal metastasis in patients with head and neck cutaneous squamous cell carcinoma.
Carcinoma, Squamous Cell
Defective transforming growth factor beta signaling pathway in head and neck squamous cell carcinoma as evidenced by the lack of expression of activated Smad2.
Carcinoma, Squamous Cell
Disruption of transforming growth factor beta-Smad signaling pathway in head and neck squamous cell carcinoma as evidenced by mutations of SMAD2 and SMAD4.
Carcinoma, Squamous Cell
Downregulation of transforming growth factor beta type II receptor in laryngeal carcinogenesis.
Carcinoma, Squamous Cell
Dual targeting of EGFR and focal adhesion kinase in 3D grown HNSCC cell cultures.
Carcinoma, Squamous Cell
Elevated c-Src and c-Yes expression in malignant skin cancers.
Carcinoma, Squamous Cell
Elevated Src family kinase activity stabilizes E-cadherin-based junctions and collective movement of head and neck squamous cell carcinomas.
Carcinoma, Squamous Cell
Enhanced constitutive invasion activity in human nontumorigenic keratinocytes exposed to a low level of barium for a long time.
Carcinoma, Squamous Cell
Enhancing radiosensitization in EphB4 receptor-expressing Head and Neck Squamous Cell Carcinomas.
Carcinoma, Squamous Cell
EphB4 provides survival advantage to squamous cell carcinoma of the head and neck.
Carcinoma, Squamous Cell
Expression of EphB4 in head and neck squamous cell carcinoma.
Carcinoma, Squamous Cell
Expression of focal adhesion kinase and phosphorylated focal adhesion kinase in squamous cell carcinoma of the larynx.
Carcinoma, Squamous Cell
Expression of the EPHB4 receptor tyrosine kinase in head and neck and renal malignancies--implications for solid tumors and potential for therapeutic inhibition.
Carcinoma, Squamous Cell
Expression of Wnt11 and Rock2 protein with clinical characteristics of esophageal squamous cell carcinoma in Kazakh and Han patients.
Carcinoma, Squamous Cell
Focal adhesion kinase and E-cadherin as markers for nodal metastasis in laryngeal cancer.
Carcinoma, Squamous Cell
GTPase Regulator Associated with Focal Adhesion Kinase 1 (GRAF1) Immunoglobulin-Associated Ataxia and Neuropathy.
Carcinoma, Squamous Cell
IL6 is associated with response to dasatinib and cetuximab: Phase II clinical trial with mechanistic correlatives in cetuximab-resistant head and neck cancer.
Carcinoma, Squamous Cell
Increased dosage and amplification of the focal adhesion kinase gene in human cancer cells.
Carcinoma, Squamous Cell
Inhibition of IKK?/NF-?B signaling pathway to improve Dasatinib efficacy in suppression of cisplatin-resistant head and neck squamous cell carcinoma.
Carcinoma, Squamous Cell
Inhibition of Raf-1 protein kinase by antisense phosphorothioate oligodeoxyribonucleotide is associated with sensitization of human laryngeal squamous carcinoma cells to gamma radiation.
Carcinoma, Squamous Cell
Involvement of focal adhesion kinase in cellular invasion of head and neck squamous cell carcinomas via regulation of MMP-2 expression.
Carcinoma, Squamous Cell
JAK kinase inhibition abrogates STAT3 activation and head and neck squamous cell carcinoma tumor growth.
Carcinoma, Squamous Cell
miRNA- and cytokine-associated extracellular vesicles mediate squamous cell carcinomas.
Carcinoma, Squamous Cell
Modulation of epidermal growth factor receptor interaction with the detergent-insoluble cytoskeleton and its effects on receptor tyrosine kinase activity.
Carcinoma, Squamous Cell
Overexpression of focal adhesion kinase in head and neck squamous cell carcinoma is independent of fak gene copy number.
Carcinoma, Squamous Cell
p70S6K is regulated by focal adhesion kinase and is required for Src-selective autophagy.
Carcinoma, Squamous Cell
Prevalence of Mutations in Discoidin Domain-Containing Receptor Tyrosine Kinase 2 (DDR2) in Squamous Cell Lung Cancers in Korean Patients.
Carcinoma, Squamous Cell
Protein kinase C inhibition of the epidermal growth factor receptor tyrosine protein kinase activity is independent of the oligomeric state of the receptor.
Carcinoma, Squamous Cell
Role of epidermal growth factor-stimulated protein kinase in control of proliferation of A431 cells.
Carcinoma, Squamous Cell
Role of Focal Adhesion Kinase in Head and Neck Squamous Cell Carcinoma and Its Therapeutic Prospect.
Carcinoma, Squamous Cell
Saracatinib Impairs Head and Neck Squamous Cell Carcinoma Invasion by Disrupting Invadopodia Function.
Carcinoma, Squamous Cell
Soluble form of ephrinB2 inhibits xenograft growth of squamous cell carcinoma of the head and neck.
Carcinoma, Squamous Cell
Squamous cell carcinoma cell aggregates escape suspension-induced, p53-mediated anoikis: fibronectin and integrin alphav mediate survival signals through focal adhesion kinase.
Carcinoma, Squamous Cell
Targeting FAK radiosensitizes 3-dimensional grown human HNSCC cells through reduced Akt1 and MEK1/2 signaling.
Carcinoma, Squamous Cell
The association between elevated EphB4 expression, smoking status, and advanced-stage disease in patients with head and neck squamous cell carcinoma.
Carcinoma, Squamous Cell
The differential expression of EPHB4 and ephrin B2 in cutaneous squamous cell carcinoma according to the grade of tumor differentiation: a clinicopathological study.
Carcinoma, Squamous Cell
The significance of EphB4 and EphrinB2 expression and survival in head and neck squamous cell carcinoma.
Carcinoma, Squamous Cell
Transforming growth factor-beta 1 and its receptors in human lung cancer and mouse lung carcinogenesis.
Carcinoma, Squamous Cell
Wnt/?-catenin signalling induces MLL to create epigenetic changes in salivary gland tumours.
Carcinoma, Squamous Cell
[Effect of focal adhesion kinase on biological characteristics of Tca8113 tongue squamous cell carcinoma]
Carcinoma, Squamous Cell
[Expression and clinical significance of proline-rich tyrosine kinase 2 and phospho-protein kinase B in tongue squamous cell carcinoma].
Carcinoma, Transitional Cell
Restoration of bone morphogenetic protein receptor type II expression leads to a decreased rate of tumor growth in bladder transitional cell carcinoma cell line TSU-Pr1.
Carcinoma, Transitional Cell
The differential expression of EphB2 and EphB4 receptor kinases in normal bladder and in transitional cell carcinoma of the bladder.
Carcinosarcoma
Expression of TGF-beta type I and II receptors in normal and cancerous human endometrium.
Cardiac Tamponade
Impending Cardiac Tamponade as the Initial Manifestation of BCR-ABL Positive Chronic Myeloid Leukemia.
Cardiomegaly
Cardiotoxicity of Novel Targeted Hematological Therapies.
Cardiomegaly
Chrysophanol attenuated isoproterenol-induced cardiac hypertrophy by inhibiting Janus kinase 2/signal transducer and activator of transcription 3 signaling pathway.
Cardiomegaly
Endothelial Bmx tyrosine kinase activity is essential for myocardial hypertrophy and remodeling.
Cardiomegaly
Expression and distribution of Src in the nucleus of myocytes in cardiac hypertrophy.
Cardiomegaly
Focal adhesion kinase signaling in cardiac hypertrophy and failure.
Cardiomegaly
Inactivation of focal adhesion kinase in cardiomyocytes promotes eccentric cardiac hypertrophy and fibrosis in mice.
Cardiomegaly
Inhibitory molecules in signal transduction pathways of cardiac hypertrophy.
Cardiomegaly
Loss of Bmx nonreceptor tyrosine kinase prevents pressure overload-induced cardiac hypertrophy.
Cardiomegaly
Mechanisms of blood pressure variability-induced cardiac hypertrophy and dysfunction in mice with impaired baroreflex.
Cardiomegaly
Multifarious molecular signaling cascades of cardiac hypertrophy: can the muddy waters be cleared?
Cardiomegaly
Pressure overload-induced cardiac hypertrophy response requires janus kinase 2-histone deacetylase 2 signaling.
Cardiomegaly
Signal transducer and activator of transcription 3 in the heart transduces not only a hypertrophic signal but a protective signal against doxorubicin-induced cardiomyopathy.
Cardiomegaly
Significance of ERK cascade compared with JAK/STAT and PI3-K pathway in gp130-mediated cardiac hypertrophy.
Cardiomegaly
Structure of focal adhesion kinase in healthy heart versus pathological cardiac hypertrophy: A modeling and simulation study.
Cardiomegaly
Targeting focal adhesion kinase with small interfering RNA prevents and reverses load-induced cardiac hypertrophy in mice.
Cardiomegaly
[Expression of focal adhesion kinase in cardiac myocytes of hypertrophic ventricle]
Cardiomegaly
[Phosphorylation and nuclear translocation of serine 722 and serine 910 of focal adhesion kinase in hypertrophic cardiac myocytes of left ventricle of spontaneously hypertensive rats]
Cardiomyopathies
Elevated expression of C3G protein in the peri-infarct myocardium of rats.
Cardiomyopathies
Impaired angiotensin II-extracellular signal-regulated kinase signaling in failing human ventricular myocytes.
Cardiomyopathies
Increased expression of Dock180 protein in the noninfarcted myocardium in rats.
Cardiomyopathies
Unsolved medical issues and new targets for further research in viral myocarditis and dilated cardiomyopathy.
Cardiomyopathy, Dilated
Alterations in Janus kinase (JAK)-signal transducers and activators of transcription (STAT) signaling in patients with end-stage dilated cardiomyopathy.
Cardiomyopathy, Dilated
Inhibition of osteopontin reduce the cardiac myofibrosis in dilated cardiomyopathy via focal adhesion kinase mediated signaling pathway.
Cardiomyopathy, Dilated
The tyrosine kinase p56lck is essential in coxsackievirus B3-mediated heart disease.
Cardiomyopathy, Dilated
[Content of myosin-activating protein kinases in myocardium of patients with dilated cardiomyopathy and in the animal heart]
Cardiomyopathy, Hypertrophic
Individualized interactomes for network-based precision medicine in hypertrophic cardiomyopathy with implications for other clinical pathophenotypes.
Cardiotoxicity
An anticancer C-Kit kinase inhibitor is reengineered to make it more active and less cardiotoxic.
Cardiotoxicity
Bruton's tyrosine kinase Inhibitors and Cardiotoxicity: More Than Just Atrial Fibrillation.
Cardiotoxicity
Cardioprotective Strategies to Prevent Cancer Treatment-Related Cardiovascular Toxicity: a Review.
Cardiotoxicity
Cardiotoxicity of the cancer therapeutic agent imatinib mesylate.
Cardiotoxicity
Focal adhesion kinase antagonizes doxorubicin cardiotoxicity via p21(Cip1.).
Cardiotoxicity
Mechanistic Investigation of Imatinib-Induced Cardiac Toxicity and the Involvement of c-Abl Kinase.
Cardiotoxicity
MiR-15b-5p is Involved in Doxorubicin-Induced Cardiotoxicity via Inhibiting Bmpr1a Signal in H9c2 Cardiomyocyte.
Cardiotoxicity
Preclinical development of a novel BCR-ABL T315I inhibitor against chronic myeloid leukemia.
Cardiotoxicity
Structural reengineering of imatinib to decrease cardiac risk in cancer therapy.
Cardiovascular Diseases
(-)-Epigallocatechin Gallate Regulates CD3-mediated T Cell Receptor Signaling in Leukemia through the Inhibition of ZAP-70 Kinase.
Cardiovascular Diseases
A familial congenital heart disease with a possible multigenic origin involving a mutation in BMPR1A.
Cardiovascular Diseases
Multiple Facial Milia in Patients With Loeys-Dietz Syndrome.
Cardiovascular Diseases
Pathophysiology of the chronic kidney disease-mineral bone disorder.
Cardiovascular Diseases
The activin receptor is stimulated in the skeleton, vasculature, heart, and kidney during chronic kidney disease.
Cardiovascular Diseases
The expression of microRNAs and exposure to environmental contaminants related to human health: a review.
Cardiovascular Diseases
Vaccinia virus-mediated high level expression and single step purification of recombinant Jak2 protein.
Carotid Artery Diseases
Activation of the Non-receptor Tyrosine Kinase cSrc in Macrophage-rich Atherosclerotic Plaques of Human Carotid Arteries.
Cataract
Coordinate signaling by Src and p38 kinases in the induction of cortical cataracts.
Cataract
Extracellular matrix and integrin signaling in lens development and cataract.
Cataract
Mechanism of Src kinase induction of cortical cataract following exposure to stress: destabilization of cell-cell junctions.
Cataract
Role of transforming growth factor-beta in transdifferentiation and fibrosis of lens epithelial cells.
Celiac Disease
Food Processing, Dysbiosis, Gastrointestinal Inflammatory Diseases, and Antiangiogenic Functional Foods or Beverages.
Celiac Disease
Interleukin 15-Dependent T Cell-like Innate Intraepithelial Lymphocytes Develop in the Intestine and Transform into Lymphomas in Celiac Disease.
Celiac Disease
Tofacitinib, a Janus Kinase Inhibitor Demonstrates Efficacy in an IL-15 Transgenic Mouse Model that Recapitulates Pathologic Manifestations of Celiac Disease.
Cell Transformation, Neoplastic
The lack of v-src involvement in tumorigenicity of marmoset cells transformed in vitro with Rous sarcoma virus.
Cerebellar Ataxia
The c-Abl inhibitor, nilotinib, as a potential therapeutic agent for chronic cerebellar ataxia.
Cerebellar Ataxia
Two new cases of anti-Ca (anti-ARHGAP26/GRAF) autoantibody-associated cerebellar ataxia.
Cerebral Hemorrhage
Hydrogen Inhalation Ameliorated Mast Cell-Mediated Brain Injury After Intracerebral Hemorrhage in Mice.
Cerebral Hemorrhage
Levetiracetam Reduces Early Inflammatory Response After Experimental Intracerebral Hemorrhage by Regulating the Janus Kinase 2 (JAK2)-Signal Transducer and Activator of Transcription 3 (STAT3) Signaling Pathway.
Cerebral Hemorrhage
Src kinase inhibition decreases thrombin-induced injury and cell cycle re-entry in striatal neurons.
Cerebral Hemorrhage
SRC kinase inhibition improves acute outcomes after experimental intracerebral hemorrhage.
Cerebral Hemorrhage
The dual role of SRC kinases in intracerebral hemorrhage.
Cerebral Hemorrhage
Tyrosine kinase Fyn promotes apoptosis after intracerebral hemorrhage in rats by activating Drp1 signaling.
Cerebral Infarction
Activation of the Non-receptor Tyrosine Kinase cSrc in Macrophage-rich Atherosclerotic Plaques of Human Carotid Arteries.
CHARGE Syndrome
Targeted next?generation sequencing for research and diagnostics in congenital heart disease, and cleft lip and/or palate.
Chemical and Drug Induced Liver Injury
Protective effect of Chushizi (Fructus Broussonetiae) on acetaminophen-induced rat hepatitis by inhibiting the Toll-like receptor 3/c-Jun N-terminal kinase/c-jun/c-fos/janus protein tyrosine kinase/activators of transcription 3 pathway.
Cherubism
Second-Generation SYK Inhibitor Entospletinib Ameliorates Fully Established Inflammation and Bone Destruction in the Cherubism Mouse Model.
Cherubism
[Molecular and Cellular Pathogenesis of Cherubism].
Cholangiocarcinoma
A role for focal adhesion kinase signaling in tumor necrosis factor-alpha-dependent matrix metalloproteinase-9 production in a cholangiocarcinoma cell line, CCKS1.
Cholangiocarcinoma
Cucurbitacin B Diminishes Metastatic Behavior of Cholangiocarcinoma Cells by Suppressing Focal Adhesion Kinase.
Cholangiocarcinoma
Cucurbitacin B induces mitochondrial-mediated apoptosis pathway in cholangiocarcinoma cells via suppressing focal adhesion kinase signaling.
Cholangiocarcinoma
Expression of etk/bmx tyrosine kinase in intrahepatic cholangiocarcinoma.
Cholangiocarcinoma
Focal adhesion kinase (FAK) promotes cholangiocarcinoma development and progression via YAP activation.
Cholangiocarcinoma
Focal adhesion kinase and Src phosphorylations in HGF-induced proliferation and invasion of human cholangiocarcinoma cell line, HuCCA-1.
Cholangiocarcinoma
Imatinib mesylate induces apoptosis in human cholangiocarcinoma cells.
Cholangiocarcinoma
Reduced expression of focal adhesion kinase in intrahepatic cholangiocarcinoma is associated with poor tumor differentiation.
Cholecystitis
Association of BDNF and BMPR1A with clinicopathologic parameters in benign and malignant gallbladder lesions.
Cholera
Evidence that v-Src-induced phospholipase D activity is mediated by a G protein.
Cholera
Induction of B(1)-kinin receptors in vascular smooth muscle cells: cellular mechanisms of map kinase activation.
Cholera
Signal transducing molecules and glycosyl-phosphatidylinositol-linked proteins form a caveolin-rich insoluble complex in MDCK cells.
Cholera
[Synthesis, Cloning and Expression of a Multiple Epitope Antigen of BCR-ABL Fusion Gene]
Choline Deficiency
Dietary choline deficiency and excess induced intestinal inflammation and alteration of intestinal tight junction protein transcription potentially by modulating NF-?B, STAT and p38 MAPK signaling molecules in juvenile Jian carp.
Choline Deficiency
Intestinal immune responses of Jian carp against Aeromonas hydrophila depressed by choline deficiency: Varied change patterns of mRNA levels of cytokines, tight junction proteins and related signaling molecules among three intestinal segments.
Chondrosarcoma
Cell density-dependent proliferative effects of transforming growth factor (TGF)-beta 1, beta 2, and beta 3 in human chondrosarcoma cells HCS-2/8 are associated with changes in the expression of TGF-beta receptor type I.
Chondrosarcoma
Inhibition of Src by microRNA-23b increases the cisplatin sensitivity of chondrosarcoma cells.
Chondrosarcoma
Src kinases in chondrosarcoma chemoresistance and migration: dasatinib sensitises to doxorubicin in TP53 mutant cells.
Chondrosarcoma
Suppressed invasive and migratory behaviors of SW1353 chondrosarcoma cells through the regulation of Src, Rac1 GTPase, and MMP13.
Chondrosarcoma
The C-terminal domain of focal adhesion kinase reduces the tumor cell invasiveness in chondrosarcoma cell lines.
Chorea
Chorea, Pruritus and Polycythemia: Looking for Clues.
Chorioamnionitis
Differential expression of transforming growth factor-beta 1 and transforming growth factor-beta receptors in myometrium of women with failed induction of labor, no labor, and preterm labor.
Choriocarcinoma
Expression of a fms-related oncogene in carcinogen-induced neoplastic epithelial cells.
Choriocarcinoma
Expression of TGF-beta signaling proteins in normal placenta and gestational trophoblastic disease.
Choriocarcinoma
Gal-1 silenced trophoblast tumor cells (BeWo) show decreased syncytium formation and different miRNA production compared to non-target silenced BeWo cells.
Choriocarcinoma
Is galectin-1 a trigger for trophoblast cell fusion?: the MAP-Kinase pathway and syncytium formation in trophoblast tumor cells BeWo.
Choriocarcinoma
Optimized logic rules reveal interferon-?-induced modes regulated by histone deacetylases and protein tyrosine phosphatases.
Choroidal Neovascularization
Antiangiogenic effect of dasatinib in murine models of oxygen-induced retinopathy and laser-induced choroidal neovascularization.
Choroidal Neovascularization
Focal adhesion kinase signaling pathway participates in the formation of choroidal neovascularization and regulates the proliferation and migration of choroidal microvascular endothelial cells by acting through HIF-1 and VEGF expression in RPE cells.
Choroidal Neovascularization
Inhibition of choroidal neovascularization by anti-EphB4 monoclonal antibody.
Choroidal Neovascularization
Soluble EphB4 regulates choroidal endothelial cell function and inhibits laser-induced choroidal neovascularization.
Chronic Kidney Disease-Mineral and Bone Disorder
Ligand trap for the activin type IIA receptor protects against vascular disease and renal fibrosis in mice with chronic kidney disease.
Chronic Kidney Disease-Mineral and Bone Disorder
Pathophysiology of the chronic kidney disease-mineral bone disorder.
Chronic Kidney Disease-Mineral and Bone Disorder
The activin receptor is stimulated in the skeleton, vasculature, heart, and kidney during chronic kidney disease.
Chronic Periodontitis
CD24 activates the NLRP3 inflammasome through c-Src kinase activity in a model of the lining epithelium of inflamed periodontal tissues.
Chronic Urticaria
Effects of a topical treatment with spleen tyrosine kinase inhibitor in healthy subjects and patients with cold urticaria or chronic spontaneous urticaria: Results of a phase 1a/b randomised double-blind placebo-controlled study.
Cleft Lip
Ectodermal Wnt controls nasal pit morphogenesis through modulation of the BMP/FGF/JNK signaling axis.
Cleft Palate
ACTIVIN SUBUNIT AND RECEPTOR EXPRESSION IN NORMAL AND CLEFT HUMAN FETAL PALATE TISSUES.
Cleft Palate
Activin subunit and receptor expression in normal and cleft human fetal palate tissues.
Cleft Palate
Altered BMP-Smad4 signaling causes complete cleft palate by disturbing osteogenesis in palatal mesenchyme.
Cleft Palate
Ectodermal Wnt controls nasal pit morphogenesis through modulation of the BMP/FGF/JNK signaling axis.
Cleft Palate
Progressive aortic root and pulmonary artery aneurysms in a neonate with Loeys-Dietz syndrome type 1B.
Clubfoot
Progressive aortic root and pulmonary artery aneurysms in a neonate with Loeys-Dietz syndrome type 1B.
Cockayne Syndrome
Cockayne syndrome protein B interacts with and is phosphorylated by c-Abl tyrosine kinase.
Colitis
Bruton tyrosine kinase deficiency augments NLRP3 inflammasome activation and causes IL-1?-mediated colitis.
Colitis
Butyric Acid Increases the Therapeutic Effect of EHLJ7 on Ulcerative Colitis by Inhibiting JAK2/STAT3/SOCS1 Signaling Pathway.
Colitis
E3 ligase c-Cbl regulates intestinal inflammation through suppressing fungi-induced noncanonical NF-?B activation.
Colitis
Estrogen receptor ? alleviates inflammatory lesions in a rat model of inflammatory bowel disease via down-regulating P2X7R expression in macrophages.
Colitis
Intestinal Epithelial Cell Tyrosine Kinase 2 Transduces IL-22 Signals To Protect from Acute Colitis.
Colitis
MFG-E8 attenuates intestinal inflammation in murine experimental colitis by modulating osteopontin-dependent alphavbeta3 integrin signaling.
Colitis
New treatment options for inflammatory bowel diseases.
Colitis
Nitrotyrosylation of Ca2+ channels prevents c-Src kinase regulation of colonic smooth muscle contractility in experimental colitis.
Colitis
Novel Pentapeptide Derived from Chicken by-Product Ameliorates DSS-Induced Colitis by Enhancing Intestinal Barrier Function via AhR-Induced Src Inactivation.
Colitis
Oxazolone-induced over-expression of focal adhesion kinase in colonic epithelial cells of colitis mouse model.
Colitis
P014. Selective Janus Kinase 1 inhibitor targets monocytes and tissue macrophages during DSS colitis.
Colitis
Role of Csk in intestinal epithelial barrier function and protection against colitis.
Colitis
Role of Janus kinase 3 in mucosal differentiation and predisposition to colitis.
Colitis
T cells that cannot respond to TGF-beta escape control by CD4(+)CD25(+) regulatory T cells.
Colitis
Targeting of the Tec Kinase ITK Drives Resolution of T Cell-Mediated Colitis and Emerges as Potential Therapeutic Option in Ulcerative Colitis.
Colitis
Targeting the Eph/Ephrin System as Anti-Inflammatory Strategy in IBD.
Colitis
The Src kinase Fyn is protective in acute chemical-induced colitis and promotes recovery from disease.
Colitis
The Syk Inhibitor Fostamatinib Decreases the Severity of Colonic Mucosal Damage in a Rodent Model of Colitis.
Colitis
Tyrosine kinase 2 signalling drives pathogenic T-cells in colitis.
Colitis
Ulcerative Colitis.
Colitis
[Mechanism of sophocarpine in treating experimental colitis in mice].
Colitis, Ulcerative
A Macromolecular Janus Kinase (JAK) Inhibitor Prodrug Effectively Ameliorates Dextran Sulfate Sodium-Induced Ulcerative Colitis in Mice.
Colitis, Ulcerative
Application of Physiologically Based Pharmacokinetic Modeling to Predict Drug Exposure and Support Dosing Recommendations for Potential Drug-Drug Interactions or in Special Populations: An Example Using Tofacitinib.
Colitis, Ulcerative
c-src tyrosine kinase activity: a marker of dysplasia in ulcerative colitis.
Colitis, Ulcerative
Clinical Pharmacology of Janus Kinase Inhibitors in Inflammatory Bowel Disease.
Colitis, Ulcerative
Combination Therapy With Tofacitinib Plus Intensive Granulocyte and Monocyte Adsorptive Apheresis as Induction Therapy for Refractory Ulcerative Colitis.
Colitis, Ulcerative
Contribution of a European-Prevalent Variant near CD83 and an East Asian-Prevalent Variant near IL17RB to Herpes Zoster Risk in Tofacitinib Treatment: Results of Genome-Wide Association Study Meta-Analyses.
Colitis, Ulcerative
Cost-Effectiveness of Different Strategies for the Treatment of Moderate-to-Severe Ulcerative Colitis.
Colitis, Ulcerative
Cost-effectiveness of tofacitinib compared with infliximab, adalimumab, golimumab, vedolizumab and ustekinumab for the treatment of moderate to severe ulcerative colitis in Germany.
Colitis, Ulcerative
Direct and Indirect Effects of Tofacitinib on Treatment Satisfaction in Patients with Ulcerative Colitis.
Colitis, Ulcerative
Efficacy and Safety of Extended Induction With Tofacitinib for the Treatment of Ulcerative Colitis.
Colitis, Ulcerative
Efficacy and Safety of Tofacitinib in Ulcerative Colitis Based on Prior Tumor Necrosis Factor Inhibitor Failure Status.
Colitis, Ulcerative
Efficacy and Safety of Tofacitinib Retreatment for Ulcerative Colitis After Treatment Interruption: Results From the OCTAVE Clinical Trials.
Colitis, Ulcerative
Efficacy of Upadacitinib in a Randomized Trial of Patients With Active Ulcerative Colitis.
Colitis, Ulcerative
Elevated c-Src tyrosine kinase activity in premalignant epithelia of ulcerative colitis.
Colitis, Ulcerative
Expression of receptor interacting protein 3 and mixed lineage kinase domain-like protein-key proteins in necroptosis is upregulated in ulcerative colitis.
Colitis, Ulcerative
Expression of the signal transducer and activator of transcription factor 3 and Janus kinase 3 in colorectal carcinomas, colonic adenomas and ulcerative colitis.
Colitis, Ulcerative
Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial.
Colitis, Ulcerative
GSK2586184, a JAK1 selective inhibitor, in two patients with ulcerative colitis.
Colitis, Ulcerative
Herpes Zoster Infection in Patients With Ulcerative Colitis Receiving Tofacitinib.
Colitis, Ulcerative
Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data.
Colitis, Ulcerative
Intestinally-restricted Janus Kinase inhibition: a potential approach to maximize the therapeutic index in inflammatory bowel disease therapy.
Colitis, Ulcerative
JAK inhibition in inflammatory bowel disease.
Colitis, Ulcerative
JAK inhibitors: Novel developments in management of ulcerative colitis.
Colitis, Ulcerative
JAK-STAT pathway targeting for the treatment of inflammatory bowel disease.
Colitis, Ulcerative
JAK2 rs10758669 Polymorphisms and Susceptibility to Ulcerative Colitis and Crohn's Disease: A Meta-analysis.
Colitis, Ulcerative
Maintenance of Remission With Tofacitinib Therapy in Patients With Ulcerative Colitis.
Colitis, Ulcerative
Medical therapy versus surgery in moderate-to-severe ulcerative colitis.
Colitis, Ulcerative
New drug therapies on the horizon for IBD.
Colitis, Ulcerative
Novel Therapeutic Options for People with Ulcerative Colitis: An Update on Recent Developments with Janus Kinase (JAK) Inhibitors.
Colitis, Ulcerative
Off-label studies on tofacitinib in dermatology: a review.
Colitis, Ulcerative
Oral Janus kinase inhibitors for maintenance of remission in ulcerative colitis.
Colitis, Ulcerative
Outcomes of Pregnancies With Maternal/Paternal Exposure in the Tofacitinib Safety Databases for Ulcerative Colitis.
Colitis, Ulcerative
Outcomes of Tofacitinib Dose Reduction in Patients with Ulcerative Colitis in Stable Remission from the Randomised RIVETING Trial.
Colitis, Ulcerative
Peficitinib, an Oral Janus Kinase Inhibitor, in Moderate-to-severe Ulcerative Colitis: Results From a Randomised, Phase 2 Study.
Colitis, Ulcerative
Phase 1 Dose-Escalation Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Tofacitinib in Japanese Healthy Volunteers.
Colitis, Ulcerative
Pneumocystis Jirovecii Pneumonia after Initiation of Tofacitinib Therapy in Rheumatoid Arthritis: Case-Based Review.
Colitis, Ulcerative
Population Pharmacokinetics of Tofacitinib in Patients With Moderate to Severe Ulcerative Colitis.
Colitis, Ulcerative
Randomized trial of tofacitinib in active ulcerative colitis: analysis of efficacy based on patient-reported outcomes.
Colitis, Ulcerative
Real-world clinical and endoscopic outcomes after one year tofacitinib treatment in ulcerative colitis.
Colitis, Ulcerative
Real-World Effectiveness of Tofacitinib for Moderate to Severe Ulcerative Colitis: A Multi-Centre UK Experience.
Colitis, Ulcerative
Real-world evidence of tofacitinib effectiveness and safety in patients with refractory ulcerative colitis.
Colitis, Ulcerative
Real-World Experience with Tofacitinib in IBD at a Tertiary Center.
Colitis, Ulcerative
Refractory case of ulcerative colitis with idiopathic thrombocytopenic purpura successfully treated by Janus kinase inhibitor tofacitinib: A case report.
Colitis, Ulcerative
Schisandrin B prevents ulcerative colitis and colitis-associated-cancer by activating focal adhesion kinase and influence on gut microbiota in an in vivo and in vitro model.
Colitis, Ulcerative
Targeting of the Tec Kinase ITK Drives Resolution of T Cell-Mediated Colitis and Emerges as Potential Therapeutic Option in Ulcerative Colitis.
Colitis, Ulcerative
The JAK inhibitor tofacitinib ameliorates immune?mediated liver injury in mice.
Colitis, Ulcerative
Tofacitinib ameliorates atherosclerosis and reduces foam cell formation in apoE deficient mice.
Colitis, Ulcerative
Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis.
Colitis, Ulcerative
Tofacitinib as Induction and Maintenance Therapy in Japanese Patients with Active Ulcerative Colitis.
Colitis, Ulcerative
Tofacitinib downregulates antiviral immune defence in keratinocytes and reduces T cell activation.
Colitis, Ulcerative
Tofacitinib for Biologic-Experienced Hospitalized Patients With Acute Severe Ulcerative Colitis: A Retrospective Case-Control Study.
Colitis, Ulcerative
Tofacitinib for the treatment of tumor necrosis factor-? inhibitor refractory esophageal Crohn's disease: a case report.
Colitis, Ulcerative
Tofacitinib for the Treatment of Ulcerative Colitis: Analysis of Nonmelanoma Skin Cancer Rates From the Ulcerative Colitis Clinical Program.
Colitis, Ulcerative
Tofacitinib for ulcerative colitis: results of the prospective Dutch Initiative on Crohn and Colitis (ICC) registry.
Colitis, Ulcerative
Tofacitinib in Patients with Ulcerative Colitis: Health-Related Quality of Life in Phase 3 Randomised Controlled Induction and Maintenance Studies.
Colitis, Ulcerative
Tofacitinib in Patients with Ulcerative Colitis: Inflammatory Bowel Disease Questionnaire Items in Phase 3 Randomized Controlled Induction Studies.
Colitis, Ulcerative
Tofacitinib induction and maintenance therapy in East Asian patients with active ulcerative colitis: subgroup analyses from three phase 3 multinational studies.
Colitis, Ulcerative
Tofacitinib Treatment Is Associated With Modest and Reversible Increases in Serum Lipids in Patients With Ulcerative Colitis.
Colitis, Ulcerative
Tofacitinib Treatment Safety in Moderate to Severe Ulcerative Colitis: Comparison of Observational Population Cohort Data From the IBM MarketScan® Administrative Claims Database With Tofacitinib Trial Data.
Colitis, Ulcerative
Tofacitinib Use in Adults with Chronic Inflammatory Disease During the Severe Acute Respiratory Syndrome Coronavirus 2 Pandemic: What Is Known So Far?
Colitis, Ulcerative
Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis.
Colitis, Ulcerative
Tofacitinib, an Oral Janus Kinase Inhibitor: Analysis of Malignancy (Excluding Nonmelanoma Skin Cancer) Events Across the Ulcerative Colitis Clinical Program.
Colitis, Ulcerative
Tofacitinib, the First Oral Janus Kinase Inhibitor Approved for Adult Ulcerative Colitis.
Colitis, Ulcerative
Tofacitinib-Associated Cerebral Venous Sinus Thrombosis.
Colitis, Ulcerative
Update on Janus kinase antagonists in inflammatory bowel disease.
Colitis, Ulcerative
Use of Tofacitinib for the Treatment of Arthritis Associated With Ulcerative Colitis.
Colitis, Ulcerative
Vaccinations in Adult Patients with Inflammatory Bowel Diseases in the West.
Colitis, Ulcerative
[Granulomatous rosacea-like dermatitis under therapy with tofacitinib].
Colitis, Ulcerative
[JAK inhibitors: Perspectives in internal medicine].
Colonic Neoplasms
4-Aryl-4H-Chromene-3-Carbonitrile Derivatives: Evaluation of Src Kinase Inhibitory and Anticancer Activities.
Colonic Neoplasms
A family with two consecutive nonsense mutations in BMPR1A causing juvenile polyposis.
Colonic Neoplasms
A role for epidermal growth factor receptor, c-Src and focal adhesion kinase in an in vitro model for the progression of colon cancer.
Colonic Neoplasms
Acquisition of cell adhesion and induction of focal adhesion kinase of human colon cancer Colo 201 cells by retinoic acid-induced differentiation.
Colonic Neoplasms
Activating SRC mutation in a subset of advanced human colon cancers.
Colonic Neoplasms
Activation of focal adhesion kinase through an interaction with ?4 integrin contributes to tumorigenicity of colon cancer.
Colonic Neoplasms
Activation of the FAK-src molecular scaffolds and p130Cas-JNK signaling cascades by alpha1-integrins during colon cancer cell invasion.
Colonic Neoplasms
Adhesion, actin cytoskeleton organisation and the spreading of colon adenocarcinoma cells induced by EGF are mediated by alpha2beta1 integrin low clustering through focal adhesion kinase.
Colonic Neoplasms
Akt directly regulates focal adhesion kinase through association and serine phosphorylation: implication for pressure-induced colon cancer metastasis.
Colonic Neoplasms
Allele-specific expression of TGFBR1 in colon cancer patients.
Colonic Neoplasms
Alpha-actinin-1 phosphorylation modulates pressure-induced colon cancer cell adhesion through regulation of focal adhesion kinase-Src interaction.
Colonic Neoplasms
Analysis of signaling protein kinases in human colon or colorectal carcinomas.
Colonic Neoplasms
Bone morphogenetic protein signaling and growth suppression in colon cancer.
Colonic Neoplasms
Butyrate regulates the expression of c-Src and focal adhesion kinase and inhibits cell invasion of human colon cancer cells.
Colonic Neoplasms
CD44 regulates cell migration in human colon cancer cells via Lyn kinase and AKT phosphorylation.
Colonic Neoplasms
Clinical and molecular characterization of individuals with recurrent genomic disorder at 10q22.3q23.2.
Colonic Neoplasms
Colon cancer cell adhesion in response to Src kinase activation and actin-cytoskeleton by non-laminar shear stress.
Colonic Neoplasms
Combination of an SRC kinase inhibitor with a novel pharmacological antagonist of the urokinase receptor diminishes in vitro colon cancer invasiveness.
Colonic Neoplasms
Constitutive activation of JAK3/STAT3 in colon carcinoma tumors and cell lines: inhibition of JAK3/STAT3 signaling induces apoptosis and cell cycle arrest of colon carcinoma cells.
Colonic Neoplasms
Cross talk between receptor guanylyl cyclase C and c-src tyrosine kinase regulates colon cancer cell cytostasis.
Colonic Neoplasms
Dasatinib reduces 5-Fu-triggered apoptosis in colon carcinoma by directly modulating Src-dependent caspase-9 phosphorylation.
Colonic Neoplasms
Decreased CHK protein levels are associated with Src activation in colon cancer cells.
Colonic Neoplasms
Decreased transforming growth factor beta type II receptor expression in intestinal adenomas from Min/+ mice is associated with increased cyclin D1 and cyclin-dependent kinase 4 expression.
Colonic Neoplasms
Development of a Rapid-Onset, Acid-Labile Linkage Polyplex-Mixed Micellar System for Anticancer Therapy.
Colonic Neoplasms
Dihydroartemisinin increases apoptosis of colon cancer cells through targeting Janus kinase 2/signal transducer and activator of transcription 3 signaling.
Colonic Neoplasms
Dual inhibition of MET and SRC kinase activity as a combined targeting strategy for colon cancer.
Colonic Neoplasms
Early adhesion induces interaction of FAK and Fyn in lipid domains and activates raft-dependent Akt signaling in SW480 colon cancer cells.
Colonic Neoplasms
Effect of chemopreventive agents on intermediate biomarkers during different stages of azoxymethane-induced colon carcinogenesis.
Colonic Neoplasms
Effect of ets-related transcription factor (ERT) on transforming growth factor (TGF)-beta type II receptor gene expression in human cancer cell lines.
Colonic Neoplasms
Effectiveness of Scutellaria barbata water extract on inhibiting colon tumor growth and metastasis in tumor-bearing mice.
Colonic Neoplasms
Enhanced expression of cholecystokinin-2 receptor promotes the progression of colon cancer through activation of focal adhesion kinase.
Colonic Neoplasms
EphB4 promotes the proliferation, invasion, and angiogenesis of human colorectal cancer.
Colonic Neoplasms
Epithelial-mesenchymal transition and metastasis of colon cancer cells induced by the FAK pathway in cancer-associated fibroblasts.
Colonic Neoplasms
Eps8 facilitates cellular growth and motility of colon cancer cells by increasing the expression and activity of focal adhesion kinase.
Colonic Neoplasms
Evaluation of EphA2 and EphB4 as Targets for Image-Guided Colorectal Cancer Surgery.
Colonic Neoplasms
Expression of GRP and its receptor in well-differentiated colon cancer cells correlates with the presence of focal adhesion kinase phosphorylated at tyrosines 397 and 407.
Colonic Neoplasms
Expression of kinase-defective mutants of c-Src in human metastatic colon cancer cells decreases Bcl-xL and increases oxaliplatin- and Fas-induced apoptosis.
Colonic Neoplasms
Expression of matrix macromolecules and functional properties of EGF-responsive colon cancer cells are inhibited by panitumumab.
Colonic Neoplasms
Expression of protooncogene-encoded mRNA by colonic epithelial cells in inflammatory bowel disease.
Colonic Neoplasms
Expression of tyrosine kinases in human malignancies as potential targets for kinase-specific inhibitors.
Colonic Neoplasms
Fibronectin promotes invasiveness and focal adhesion kinase tyrosine phosphorylation of human colon cancer cell.
Colonic Neoplasms
Focal adhesion kinase autophosphorylation inhibition decreases colon cancer cell growth and enhances the efficacy of chemotherapy.
Colonic Neoplasms
Focal adhesion kinase expression is not a prognostic predictor in colon adenocarcinoma patients.
Colonic Neoplasms
Focal adhesion kinase is not required for Src-induced formation of invadopodia in KM12C colon cancer cells and can interfere with their assembly.
Colonic Neoplasms
Focal adhesion kinase mediates defects in the force-dependent reinforcement of initial integrin-cytoskeleton linkages in metastatic colon cancer cell lines.
Colonic Neoplasms
Fraxetin inhibits the growth of colon adenocarcinoma cells via the Janus kinase 2/signal transducer and activator of transcription 3 signalling pathway.
Colonic Neoplasms
Gastrin-releasing peptide mediates its morphogenic properties in human colon cancer by upregulating intracellular adhesion protein-1 (ICAM-1) via focal adhesion kinase.
Colonic Neoplasms
Genetic variation in bone morphogenetic protein (BMP) and colon and rectal cancer.
Colonic Neoplasms
Identification of concurrent germ-line mutations in hMSH2 and/or hMLH1 in Japanese hereditary nonpolyposis colorectal cancer kindreds.
Colonic Neoplasms
Identification of potential biomarkers for measuring inhibition of Src kinase activity in colon cancer cells following treatment with dasatinib.
Colonic Neoplasms
Identification of Src-specific phosphorylation site on focal adhesion kinase: dissection of the role of Src SH2 and catalytic functions and their consequences for tumor cell behavior.
Colonic Neoplasms
Increased dosage and amplification of the focal adhesion kinase gene in human cancer cells.
Colonic Neoplasms
Induction of colonic epithelial cell apoptosis by p47-dependent oxidants.
Colonic Neoplasms
Induction of the differentiated phenotype in human colon cancer cell is associated with the attenuation of subcellular tyrosine phosphorylation.
Colonic Neoplasms
Infrequent detection of germline allele-specific expression of TGFBR1 in lymphoblasts and tissues of colon cancer patients.
Colonic Neoplasms
Inhibition of c-Yes induces differentiation of HT-29 human colon cancer stem cells through midbody elongation.
Colonic Neoplasms
Inhibition of Src kinases by a selective tyrosine kinase inhibitor causes mitotic arrest.
Colonic Neoplasms
Lack of activating c-SRC mutations at codon 531 in rectal cancer.
Colonic Neoplasms
Lemur tyrosine kinase 2 acts as a positive regulator of NF-?B activation and colon cancer cell proliferation.
Colonic Neoplasms
Leptin promotes motility and invasiveness in human colon cancer cells by activating multiple signal-transduction pathways.
Colonic Neoplasms
Lunasin potentiates the effect of oxaliplatin preventing outgrowth of colon cancer metastasis, binds to ?5?1 integrin and suppresses FAK/ERK/NF-?B signaling.
Colonic Neoplasms
Mechanisms in the chemoprevention of colon cancer: modulation of protein kinase C, tyrosine protein kinase and diacylglycerol kinase activities by 1,4-phenylenebis-(methylene)selenocyanate and impact of low-fat diet.
Colonic Neoplasms
MicroRNA-27b suppresses tumor progression by regulating ARFGEF1 and focal adhesion signaling.
Colonic Neoplasms
MicroRNA-885-3p inhibits the growth of HT-29 colon cancer cell xenografts by disrupting angiogenesis via targeting BMPR1A and blocking BMP/Smad/Id1 signaling.
Colonic Neoplasms
MicroRNA?7 suppresses human colon cancer invasion and proliferation by targeting the expression of focal adhesion kinase.
Colonic Neoplasms
miR-424-5p reduces 5-fluorouracil resistance possibly by inhibiting Src/focal adhesion kinase signalling-mediated epithelial-mesenchymal transition in colon cancer cells.
Colonic Neoplasms
Overexpression of the csk gene suppresses tumor metastasis in vivo.
Colonic Neoplasms
p140Cap dual regulation of E-cadherin/EGFR cross-talk and Ras signalling in tumour cell scatter and proliferation.
Colonic Neoplasms
Possible involvement of Wnt11 in colorectal cancer progression.
Colonic Neoplasms
Pressure stimulates breast cancer cell adhesion independently of cell cycle and apoptosis regulatory protein (CARP)-1 regulation of focal adhesion kinase.
Colonic Neoplasms
Prognostic significance and correlation with survival of bcl-2 and TGF-beta RII in colon cancer.
Colonic Neoplasms
Progression of familial adenomatous polyposis (FAP) colonic cells after transfer of the src or polyoma middle T oncogenes: cooperation between src and HGF/Met in invasion.
Colonic Neoplasms
PTP1B Contributes to the Oncogenic Properties of Colon Cancer Cells through Src Activation.
Colonic Neoplasms
Rapid tyrosine phosphorylation of focal adhesion kinase, paxillin, and p130Cas by gastrin in human colon cancer cells.
Colonic Neoplasms
Receptor protein tyrosine kinase EphB4 is up-regulated in colon cancer.
Colonic Neoplasms
RNA interference-mediated silencing of focal adhesion kinase inhibits growth of human colon carcinoma xenograft in nude mice.
Colonic Neoplasms
Signal Transducers and Activators of Transcription 3 Activation Is Involved in Nuclear Accumulation of {beta}-Catenin in Colorectal Cancer.
Colonic Neoplasms
Simultaneous inhibition of focal adhesion kinase and SRC enhances detachment and apoptosis in colon cancer cell lines.
Colonic Neoplasms
Specific Oncogenic Activity of the Src-Family Tyrosine Kinase c-Yes in Colon Carcinoma Cells.
Colonic Neoplasms
Sphingosine kinase 1 promotes tumor progression and confers malignancy phenotypes of colon cancer by regulating the focal adhesion kinase pathway and adhesion molecules.
Colonic Neoplasms
Src activity alters alpha3 integrin expression in colon tumor cells.
Colonic Neoplasms
Src family kinase members have a common response to histone deacetylase inhibitors in human colon cancer cells.
Colonic Neoplasms
Src kinase pathway is involved in NFAT5-mediated S100A4 induction by hyperosmotic stress in colon cancer cells.
Colonic Neoplasms
SRC transcriptional activation in a subset of human colon cancer cell lines.
Colonic Neoplasms
Src transformation of colonic epithelial cells: enhanced anchorage-independent growth in an Apc(+/min) background.
Colonic Neoplasms
Src tyrosine kinase phosphorylation of nuclear receptor HNF4? correlates with isoform-specific loss of HNF4? in human colon cancer.
Colonic Neoplasms
STI571 reduces TRAIL-induced apoptosis in colon cancer cells: c-Abl activation by the death receptor leads to stress kinase-dependent cell death.
Colonic Neoplasms
Syndecan-1-Dependent Regulation of Heparanase Affects Invasiveness, Stem Cell Properties, and Therapeutic Resistance of Caco2 Colon Cancer Cells.
Colonic Neoplasms
Syndecan-2 cytoplasmic domain upregulates Matrix Metalloproteinase-7 expression via Protein KinaseC? mediated FAK/ERK signaling pathway in colon cancer.
Colonic Neoplasms
Synthesis of 3-phenylpyrazolopyrimidine-1,2,3-triazole conjugates and evaluation of their Src kinase inhibitory and anticancer activities.
Colonic Neoplasms
Targeting Protein Tyrosine Kinase 6 Enhances Apoptosis of Colon Cancer Cells Following DNA Damage.
Colonic Neoplasms
The cytosolic domain of protein-tyrosine kinase 7 (PTK7), generated from sequential cleavage by a disintegrin and metalloprotease 17 (ADAM17) and ?-secretase, enhances cell proliferation and migration in colon cancer cells.
Colonic Neoplasms
The EPH receptor Bs (EPHBs) promoters are unmethylated in colon and ovarian cancers.
Colonic Neoplasms
The pro-apoptotic protein Prostate Apoptosis Response Protein-4 (Par-4) can be activated in colon cancer cells by treatment with Src inhibitor and 5-FU.
Colonic Neoplasms
The receptor tyrosine kinase EPHB4 has tumor suppressor activities in intestinal tumorigenesis.
Colonic Neoplasms
The role of Src family kinases in the normal and neoplastic gastrointestinal tract.
Colonic Neoplasms
The role of the cytoskeleton in differentially regulating pressure-mediated effects on malignant colonocyte focal adhesion signaling and cell adhesion.
Colonic Neoplasms
Thrombin-dependent modulation of ?1-integrin-mediated signaling up-regulates prolidase and HIF-1? through p-FAK in colorectal cancer cells.
Colonic Neoplasms
TP53-dependence on the effect of doxorubicin and Src inhibitor combination therapy.
Colonic Neoplasms
Transcriptional signature induced by a C-terminal c-Src mutant in a human breast cell line.
Colonic Neoplasms
Ubiquitin-dependent degradation of active Src.
Colonic Neoplasms
[A study of gastrin-focal adhesion kinase signal pathway in human colon cancer cells.]
Colonic Neoplasms
[Effect of JAK2/STAT3/vimentin signaling pathway on proliferation and migration of human colon cancer cells.]
Colonic Neoplasms
[Influence of Pyk2 on hepatic metastasis and ultrastructure of human colonic cancer cells].
Colorectal Neoplasms
A cell-based screen for inhibitors of protein folding and degradation.
Colorectal Neoplasms
A genetic variant located in the miR-532-5p-binding site of TGFBR1 is associated with the colorectal cancer risk.
Colorectal Neoplasms
A growth-suppressive function for the c-fes protein-tyrosine kinase in colorectal cancer.
Colorectal Neoplasms
A novel genetic score model of UGT1A1 and TGFB pathway as predictor of severe irinotecan-related diarrhea in metastatic colorectal cancer patients.
Colorectal Neoplasms
A Novel Netrin-1-Derived Peptide Enhances Protection against Neuronal Death and Mitigates of Intracerebral Hemorrhage in Mice.
Colorectal Neoplasms
aCGH local copy number aberrations associated with overall copy number genomic instability in colorectal cancer: coordinate involvement of the regions including BCR and ABL.
Colorectal Neoplasms
Activation of Src by c-Met overexpression mediates metastatic properties of colorectal carcinoma cells.
Colorectal Neoplasms
Activation of Src kinase in primary colorectal carcinoma: an indicator of poor clinical prognosis.
Colorectal Neoplasms
Alternative splicing of spleen tyrosine kinase differentially regulates colorectal cancer progression.
Colorectal Neoplasms
Analyses of the APC and TGF-beta type II receptor genes, and microsatellite instability in mucosal colorectal carcinomas.
Colorectal Neoplasms
Analysis of SRC oncogenic signaling in colorectal cancer by stable isotope labeling with heavy amino acids in mouse xenografts.
Colorectal Neoplasms
Antiproliferative effect of sulindac in colonic neoplasia prevention: role of COOH-terminal Src kinase.
Colorectal Neoplasms
Association of a let-7 miRNA binding region of TGFBR1 with hereditary mismatch repair proficient colorectal cancer (MSS HNPCC).
Colorectal Neoplasms
Associations between polymorphisms in the SYK promoter and susceptibility to sporadic colorectal cancer in a Southern Han Chinese population - a short report.
Colorectal Neoplasms
AZD1480, a JAK inhibitor, inhibits cell growth and survival of colorectal cancer via modulating the JAK2/STAT3 signaling pathway.
Colorectal Neoplasms
Bcr-abl positive blast crisis of chronic myeloid leukemia emerging in a case of metastatic colorectal cancer 3 months after completion of an 8-month course of cetuximab and irinotecan.
Colorectal Neoplasms
Bimolecular Fluorescence Complementation Demonstrates That the c-Fes Protein-Tyrosine Kinase Forms Constitutive Oligomers in Living Cells.
Colorectal Neoplasms
BMPR1A mutations in early-onset colorectal cancer with mismatch repair proficiency.
Colorectal Neoplasms
BMPR1A mutations in hereditary nonpolyposis colorectal cancer without mismatch repair deficiency.
Colorectal Neoplasms
Both STAT1 and STAT3 are favourable prognostic determinants in colorectal carcinoma.
Colorectal Neoplasms
Chemoprevention of colorectal cancer by targeting Janus kinase 3 with a rationally designed small molecule inhibitor.
Colorectal Neoplasms
Co-occurrence of Lynch syndrome and juvenile polyposis syndrome confirmed by multigene panel testing.
Colorectal Neoplasms
Colorectal Cancer Metastases Settle in the Hepatic Microenvironment Through ?5?1 Integrin.
Colorectal Neoplasms
Colorectal cancers in patients with the (9A/6A) polymorphism of TGFBR1 exhibit lesser inter-(simple sequence repeat) PCR genomic instability and present clinically at greater age.
Colorectal Neoplasms
Combination Antitumor Effect of Sorafenib via Calcium-Dependent Deactivation of Focal Adhesion Kinase Targeting Colorectal Cancer Cells.
Colorectal Neoplasms
Constitutively decreased TGFBR1 allelic expression is a common finding in colorectal cancer and is associated with three TGFBR1 SNPs.
Colorectal Neoplasms
Cotargeting BET proteins overcomes resistance arising from PI3K/mTOR blockade-induced protumorigenic senescence in colorectal cancer.
Colorectal Neoplasms
CSK-homologous kinase (CHK/MATK) is a potential colorectal cancer tumour suppressor gene epigenetically silenced by promoter methylation.
Colorectal Neoplasms
Dasatinib, a Src inhibitor, sensitizes liver metastatic colorectal carcinoma to oxaliplatin in tumors with high levels of phospho-Src.
Colorectal Neoplasms
Debate about TGFBR1 and the susceptibility to colorectal cancer.
Colorectal Neoplasms
Demonstration that mutation of the type II transforming growth factor beta receptor inactivates its tumor suppressor activity in replication error-positive colon carcinoma cells.
Colorectal Neoplasms
Detection of Deregulated Pathways to Lymphatic Metastasis in Oral Squamous Cell Carcinoma.
Colorectal Neoplasms
Differential expression of Janus kinase 3 (JAK3), matrix metalloproteinase 13 (MMP13), heat shock protein 60 (HSP60), and mouse double minute 2 (MDM2) in human colorectal cancer progression using human cancer cDNA microarrays.
Colorectal Neoplasms
Dual inhibition of ?V integrins and Src kinase activity as a combination therapy strategy for colorectal cancer.
Colorectal Neoplasms
Dual Inhibition of EGFR and c-Src by Cetuximab and Dasatinib Combined with FOLFOX Chemotherapy in Patients with Metastatic Colorectal Cancer.
Colorectal Neoplasms
Effects of EphB4 receptor expression on colorectal cancer cells, tumor growth, vascularization and composition.
Colorectal Neoplasms
EPHB4 and Survival of Colorectal Cancer Patients.
Colorectal Neoplasms
EphB4 promotes the proliferation, invasion, and angiogenesis of human colorectal cancer.
Colorectal Neoplasms
EPHB4 tyrosine-kinase receptor expression and biological significance in soft tissue sarcoma.
Colorectal Neoplasms
Evaluation of EphA2 and EphB4 as Targets for Image-Guided Colorectal Cancer Surgery.
Colorectal Neoplasms
Exposing oncogenic dependencies for cancer drug target discovery and validation using RNAi.
Colorectal Neoplasms
Expression and Y435-phosphorylation of Abelson interactor 1 (Abi1) promotes tumour cell adhesion, extracellular matrix degradation and invasion by colorectal carcinoma cells.
Colorectal Neoplasms
Expression of C-terminal src kinase in human colorectal cancer cell lines.
Colorectal Neoplasms
Expression of the signal transducer and activator of transcription factor 3 and Janus kinase 3 in colorectal carcinomas, colonic adenomas and ulcerative colitis.
Colorectal Neoplasms
Focal adhesion kinase functions as an akt downstream target in migration of colorectal cancer cells.
Colorectal Neoplasms
FOXQ1 promotes cancer metastasis by PI3K/AKT signaling regulation in colorectal carcinoma.
Colorectal Neoplasms
Geldanamycin-induced cytotoxicity in human colon-cancer cell lines: evidence against the involvement of c-Src or DT-diaphorase.
Colorectal Neoplasms
Gene expression profiling identifies EPHB4 as a potential predictive biomarker in colorectal cancer patients treated with bevacizumab.
Colorectal Neoplasms
Genetic variants in IL-6/JAK/STAT3 pathway and the risk of CRC.
Colorectal Neoplasms
Genetic variants in the TGF?-signaling pathway influence expression of miRNAs in colon and rectal normal mucosa and tumor tissue.
Colorectal Neoplasms
Germline allele-specific expression of TGFBR1 confers an increased risk of colorectal cancer.
Colorectal Neoplasms
Growth inhibition due to complementation of transforming growth factor-beta receptor type II-defect by human chromosome 3 transfer in human colorectal carcinoma cells.
Colorectal Neoplasms
Hamartomatous polyposis in a middle-aged female with rare colonic adenomatous spread.
Colorectal Neoplasms
Identification of concurrent germ-line mutations in hMSH2 and/or hMLH1 in Japanese hereditary nonpolyposis colorectal cancer kindreds.
Colorectal Neoplasms
Identification of novel allosteric binding sites and multi-targeted allosteric inhibitors of receptor and non-receptor tyrosine kinases using a computational approach.
Colorectal Neoplasms
Increased Bcl-xL expression mediates v-Src-induced resistance to anoikis in intestinal epithelial cells.
Colorectal Neoplasms
Increases in c-Yes expression level and activity promote motility but not proliferation of human colorectal carcinoma cells.
Colorectal Neoplasms
Infrequent detection of germline allele-specific expression of TGFBR1 in lymphoblasts and tissues of colon cancer patients.
Colorectal Neoplasms
Inhibiting focal adhesion kinase: A potential target for enhancing therapeutic efficacy in colorectal cancer therapy.
Colorectal Neoplasms
Integrative genomic analyses of WNT11: transcriptional mechanisms based on canonical WNT signals and GATA transcription factors signaling.
Colorectal Neoplasms
Investigation into Enhancing Capecitabine Efficacy in Colorectal Cancer by Inhibiting Focal Adhesion Kinase Signaling.
Colorectal Neoplasms
Iterative microarray and RNA interference-based interrogation of the SRC-induced invasive phenotype.
Colorectal Neoplasms
KSR1 and EPHB4 Regulate Myc and PGC1? To Promote Survival of Human Colon Tumors.
Colorectal Neoplasms
Lack of activating c-SRC mutations at codon 531 in rectal cancer.
Colorectal Neoplasms
Lack of an association between the TGFBR1*6A variant and colorectal cancer risk.
Colorectal Neoplasms
Lack of mutation at codon 531 of SRC in advanced colorectal cancers from Italian patients.
Colorectal Neoplasms
Molecular dimensions of gastrointestinal tumors: some thoughts for digestion.
Colorectal Neoplasms
Mucin 16 Promotes Colorectal Cancer Development and Progression Through Activation of Janus Kinase 2.
Colorectal Neoplasms
Mutational analysis of TGF-beta type II receptor, Smad2, Smad3, Smad4, Smad6 and Smad7 genes in colorectal cancer.
Colorectal Neoplasms
Mutational analysis of the transforming growth factor beta receptor type II gene in hereditary nonpolyposis colorectal cancer and early-onset colorectal cancer patients.
Colorectal Neoplasms
Mutations in hMSH6 alone are not sufficient to cause the microsatellite instability in colorectal cancer cell lines.
Colorectal Neoplasms
Mutations of the transforming growth factor-beta type II receptor gene and genomic instability in hereditary nonpolyposis colorectal cancer.
Colorectal Neoplasms
Mutations of the transforming growth factor-beta type II receptor gene are strongly related to sporadic proximal colon carcinomas with microsatellite instability.
Colorectal Neoplasms
Netrin-1 Preserves Blood-Brain Barrier Integrity Through Deleted in Colorectal Cancer/Focal Adhesion Kinase/RhoA Signaling Pathway Following Subarachnoid Hemorrhage in Rats.
Colorectal Neoplasms
No association between germline allele-specific expression of TGFBR1 and colorectal cancer risk in Caucasian and Ashkenazi populations.
Colorectal Neoplasms
Noncanonical TGF? Pathway Relieves the Blockade of IL1?/TGF?-Mediated Crosstalk between Tumor and Stroma: TGFBR1 and TAK1 Inhibition in Colorectal Cancer.
Colorectal Neoplasms
Notch signaling promotes serrated neoplasia pathway in colorectal cancer through epigenetic modification of EPHB2 and EPHB4.
Colorectal Neoplasms
Nuclear expression of phosphorylated focal adhesion kinase is associated with poor prognosis in human colorectal cancer.
Colorectal Neoplasms
Nuclear localization of Dpc4 (Madh4, Smad4) in colorectal carcinomas and relation to mismatch repair/transforming growth factor-beta receptor defects.
Colorectal Neoplasms
Odin (ANKS1A) is a Src family kinase target in colorectal cancer cells.
Colorectal Neoplasms
Oncogenic signaling by tyrosine kinases of the SRC family in advanced colorectal cancer.
Colorectal Neoplasms
Optimization of the diagnosis of inherited colorectal cancer using NGS and capture of exonic and intronic sequences of panel genes.
Colorectal Neoplasms
Overcoming Resistance to Targeted Therapies in Cancer.
Colorectal Neoplasms
Overexpression of focal adhesion kinase (p125FAK) in human colorectal carcinoma liver metastases: independence from c-src or c-yes activation.
Colorectal Neoplasms
Overexpression of focal adhesion kinase in primary colorectal carcinomas and colorectal liver metastases: immunohistochemistry and real-time PCR analyses.
Colorectal Neoplasms
Personalized medicine and pharmacogenetic biomarkers: progress in molecular oncology testing.
Colorectal Neoplasms
Phase II study of saracatinib (AZD0530) in patients with previously treated metastatic colorectal cancer.
Colorectal Neoplasms
Possible involvement of Wnt11 in colorectal cancer progression.
Colorectal Neoplasms
Precise localization of the human gene encoding cell adhesion kinase beta (CAK beta/PYK2) to chromosome 8 at p21.1 by fluorescence in situ hybridization.
Colorectal Neoplasms
Preferential induction of EphB4 over EphB2 and its implication in colorectal cancer progression.
Colorectal Neoplasms
Promoter methylation blocks FES protein-tyrosine kinase gene expression in colorectal cancer.
Colorectal Neoplasms
Quantitative phosphoproteomics reveals a cluster of tyrosine kinases that mediates SRC invasive activity in advanced colon carcinoma cells.
Colorectal Neoplasms
Rapid tyrosine phosphorylation of focal adhesion kinase, paxillin, and p130Cas by gastrin in human colon cancer cells.
Colorectal Neoplasms
Reduced C-terminal Src kinase activity is correlated inversely with pp60(c-src) activity in colorectal carcinoma.
Colorectal Neoplasms
Regulation of paxillin-p130-PI3K-AKT signaling axis by Src and PTPRT impacts colon tumorigenesis.
Colorectal Neoplasms
Role of Bruton's Tyrosine Kinase in Stage III Colorectal Cancer.
Colorectal Neoplasms
Ropivacaine inhibits the proliferation and migration of colorectal cancer cells through ITGB1.
Colorectal Neoplasms
Ruxolitinib induces apoptosis of human colorectal cancer cells by downregulating the JAK1/2-STAT1-Mcl-1 axis.
Colorectal Neoplasms
Screening of BMPR1a for pathogenic mutations in familial colorectal cancer type X families from Newfoundland.
Colorectal Neoplasms
Should a single nucleotide variant in TGFBR1 modify colorectal cancer screening recommendations?
Colorectal Neoplasms
SKI-606 decreases growth and motility of colorectal cancer cells by preventing pp60(c-Src)-dependent tyrosine phosphorylation of beta-catenin and its nuclear signaling.
Colorectal Neoplasms
SNX10 (sorting nexin 10) inhibits colorectal cancer initiation and progression by controlling autophagic degradation of SRC.
Colorectal Neoplasms
Somatic acquisition and signaling of TGFBR1*6A in cancer.
Colorectal Neoplasms
SRC activates TAZ for intestinal tumorigenesis and regeneration.
Colorectal Neoplasms
Src activity is modulated by oxaliplatin and correlates with outcomes after hepatectomy for metastatic colorectal cancer.
Colorectal Neoplasms
Src family kinase inhibitor Saracatinib (AZD0530) impairs oxaliplatin uptake in colorectal cancer cells and blocks organic cation transporters.
Colorectal Neoplasms
Synergistically Anti-metastatic Effect of 5-Flourouracil on Colorectal Cancer Cells via Calcium-mediated Focal Adhesion Kinase Proteolysis.
Colorectal Neoplasms
Tgf-beta signaling alterations and colon cancer.
Colorectal Neoplasms
TGFBR1 and cancer susceptibility.
Colorectal Neoplasms
Tgfbr1 haploinsufficiency is a potent modifier of colorectal cancer development.
Colorectal Neoplasms
TGFBR1 intralocus epistatic interaction as a risk factor for colorectal cancer.
Colorectal Neoplasms
TGFBR1 variants TGFBR1(*)6A and Int7G24A are not associated with an increased familial colorectal cancer risk.
Colorectal Neoplasms
TGFBR1*6A is a potential modifier of migration and invasion in colorectal cancer cells.
Colorectal Neoplasms
The association of polymorphisms on TGFBR1 and colorectal cancer risk: a meta-analysis.
Colorectal Neoplasms
The effect of focal adhesion kinase gene silencing on 5-fluorouracil chemosensitivity involves an Akt/NF-kappaB signaling pathway in colorectal carcinomas.
Colorectal Neoplasms
The EPH receptor Bs (EPHBs) promoters are unmethylated in colon and ovarian cancers.
Colorectal Neoplasms
Treatment with cucurbitacin B alone and in combination with gefitinib induces cell cycle inhibition and apoptosis via EGFR and JAK/STAT pathway in human colorectal cancer cell lines.
Colorectal Neoplasms
Two divergent signaling pathways for TGF-beta separated by a mutation of its type II receptor gene.
Colorectal Neoplasms
Ursolic Acid Induces Apoptosis in Colorectal Cancer Cells Partially via Upregulation of MicroRNA-4500 and Inhibition of JAK2/STAT3 Phosphorylation.
Colorectal Neoplasms
Vascular endothelial growth factor receptors 1,3 and caveolin-1 are implicated in colorectal cancer aggressiveness and prognosis--correlations with epidermal growth factor receptor, CD44v6, focal adhesion kinase, and c-Met.
Colorectal Neoplasms
Wnt-11 as a Potential Prognostic Biomarker and Therapeutic Target in Colorectal Cancer.
Colorectal Neoplasms
[Expression of proline-rich tyrosine kinase-2 in human primary colorectal carcinoma and its prognostic implication]
Colorectal Neoplasms
[Mutations of hMSH2 gene and hMLH1 gene in human colovectal carcinomas]
Colorectal Neoplasms
[Spleen tyrosine kinase inhibits proliferation and promotes apoptosis of colorectal cancer cells in vitro via regulating Fra-1].
Colorectal Neoplasms, Hereditary Nonpolyposis
BMPR1A mutations in hereditary nonpolyposis colorectal cancer without mismatch repair deficiency.
Colorectal Neoplasms, Hereditary Nonpolyposis
Co-occurrence of Lynch syndrome and juvenile polyposis syndrome confirmed by multigene panel testing.
Colorectal Neoplasms, Hereditary Nonpolyposis
Genetic testing by cancer site: stomach.
Colorectal Neoplasms, Hereditary Nonpolyposis
Identification of concurrent germ-line mutations in hMSH2 and/or hMLH1 in Japanese hereditary nonpolyposis colorectal cancer kindreds.
Colorectal Neoplasms, Hereditary Nonpolyposis
Molecular dimensions of gastrointestinal tumors: some thoughts for digestion.
Colorectal Neoplasms, Hereditary Nonpolyposis
Mutational analysis of the transforming growth factor beta receptor type II gene in hereditary nonpolyposis colorectal cancer and early-onset colorectal cancer patients.
Colorectal Neoplasms, Hereditary Nonpolyposis
Mutations of the transforming growth factor-beta type II receptor gene and genomic instability in hereditary nonpolyposis colorectal cancer.
Colorectal Neoplasms, Hereditary Nonpolyposis
Nuclear localization of Dpc4 (Madh4, Smad4) in colorectal carcinomas and relation to mismatch repair/transforming growth factor-beta receptor defects.
Colorectal Neoplasms, Hereditary Nonpolyposis
Two divergent signaling pathways for TGF-beta separated by a mutation of its type II receptor gene.
Common Variable Immunodeficiency
Analysis of genetic defects in patients with the common variable immunodeficiency phenotype in a single Taiwanese tertiary care hospital.
Common Variable Immunodeficiency
Defective recruitment and activation of ZAP-70 in common variable immunodeficiency patients with T cell defects.
Common Variable Immunodeficiency
Detection of Bruton's tyrosine kinase mutations in hypogammaglobulinaemic males registered as common variable immunodeficiency (CVID) in the Japanese Immunodeficiency Registry.
Common Variable Immunodeficiency
Primary immunodeficiency diseases associated with increased susceptibility to viral infections and malignancies.
Communicable Diseases
Successful treatment with imatinib mesylate in a case of minor BCR-ABL-positive acute myelogenous leukemia.
Confusion
Disruption of anchoring junctions in the testes of experimental varicocele rats.
Congenital Abnormalities
Compound mutations in Bmpr1a and Tak1 synergize facial deformities via increased cell death.
Congenital Abnormalities
Ectodermal Wnt controls nasal pit morphogenesis through modulation of the BMP/FGF/JNK signaling axis.
Congenital Abnormalities
Integration of comprehensive 3D microCT and signaling analysis reveals differential regulatory mechanisms of craniofacial bone development.
Congenital Abnormalities
Modulation of noncanonical TGF-? signaling prevents cleft palate in Tgfbr2 mutant mice.
Conjunctivitis, Allergic
Quercetin as a Lyn kinase inhibitor inhibits IgE-mediated allergic conjunctivitis.
Connective Tissue Diseases
Mutations of bone morphogenetic protein receptor type II are not found in patients with pulmonary hypertension and underlying connective tissue diseases.
Connective Tissue Diseases
Pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: pathophysiology.
Contracture
Apelin-induced cardioprotection against ischaemia/reperfusion injury: roles of epidermal growth factor and Src.
Contracture
Reversal of TET-mediated 5-hmC loss in hypoxic fibroblasts by ascorbic acid.
Coronary Disease
The Expression and Clinical Significance of Spleen Tyrosine Kinase in Patients with Coronary Heart Disease.
Coronary Occlusion
Demonstration of selective protein kinase C-dependent activation of Src and Lck tyrosine kinases during ischemic preconditioning in conscious rabbits.
Coronavirus Infections
Coronavirus S protein-induced fusion is blocked prior to hemifusion by Abl kinase inhibitors.
COVID-19
Additional baricitinib loading dose improves clinical outcome in COVID-19.
COVID-19
Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry.
COVID-19
Balancing Potential Benefits and Risks of Bruton Tyrosine Kinase Inhibitor Therapies in Multiple Sclerosis During the COVID-19 Pandemic.
COVID-19
Baricitinib and dexamethasone for hospitalized patients with COVID-19.
COVID-19
Bleeding by Bruton Tyrosine Kinase-Inhibitors: Dependency on Drug Type and Disease.
COVID-19
Bruton tyrosine kinase inhibitors as potential therapeutic agents for COVID-19: A review.
COVID-19
Bruton's Tyrosine Kinase: A Promising Target for the Treatment of COVID-19.
COVID-19
BTK/ITK dual inhibitors: Modulating immunopathology and lymphopenia for COVID-19 therapy.
COVID-19
Can emapalumab be life saving for refractory, recurrent, and progressive cytokine storm caused by COVID-19, which is resistant to anakinra, tocilizumab, and Janus kinase inhibitors.
COVID-19
Clinical efficacy and safety of Janus kinase inhibitors for COVID-19: A systematic review and meta-analysis of randomized controlled trials.
COVID-19
Complement activation and increased expression of Syk, mucin-1 and CaMK4 in kidneys of patients with COVID-19.
COVID-19
Covid-19 and diabetes mellitus: unveiling the interaction of two pandemics.
COVID-19
COVID-19 revisiting inflammatory pathways of arthritis.
COVID-19
Immunosuppressive drugs for patients with psoriasis during the COVID-19 pandemic era. A review.
COVID-19
Inhibition of Bruton tyrosine kinase in patients with severe COVID-19.
COVID-19
JAK inhibitors dampen activation of interferon-activated transcriptomes and the SARS-CoV-2 receptor ACE2 in human renal proximal tubules.
COVID-19
JAK out of the Box; The Rationale behind Janus Kinase Inhibitors in the COVID-19 setting, and their potential in obese and diabetic populations.
COVID-19
Janus kinase (JAK)-inhibitors and coronavirus disease 2019 (Covid-19) outcomes: a systematic review and meta-analysis.
COVID-19
Janus kinase inhibitor baricitinib is not an ideal option for management of COVID-19.
COVID-19
Janus Kinase Inhibitors and Coronavirus Disease (COVID)-19: Rationale, Clinical Evidence and Safety Issues.
COVID-19
Janus kinase inhibitors and major COVID-19 outcomes: time to forget the two faces of Janus! A meta-analysis of randomized controlled trials.
COVID-19
Janus Kinase inhibitors for the treatment of hospitalized patients with COVID-19.
COVID-19
Janus kinase signaling as risk factor and therapeutic target for severe SARS-CoV-2 infection.
COVID-19
Kinase inhibitors developed for treatment of hematologic malignancies: implications for immune modulation in COVID-19.
COVID-19
Management of patients with chronic lymphocytic leukemia during the SARS-CoV-2 pandemic.
COVID-19
Mechanism of baricitinib supports artificial intelligence-predicted testing in COVID-19 patients.
COVID-19
Multi-omics data integration and network-based analysis drives a multiplex drug repurposing approach to a shortlist of candidate drugs against COVID-19.
COVID-19
Multimodal single-cell omics analysis identifies epithelium-immune cell interactions and immune vulnerability associated with sex differences in COVID-19.
COVID-19
Novel Development of Predictive Feature Fingerprints to Identify Chemistry-Based Features for the Effective Drug Design of SARS-CoV-2 Target Antagonists and Inhibitors Using Machine Learning.
COVID-19
Outcomes of COVID-19 in patients with CLL: a multicenter international experience.
COVID-19
Perceptions and Behaviors of Patients with Inflammatory Bowel Disease during the COVID-19 Crisis.
COVID-19
Pharmacological and non-pharmacological efforts at prevention, mitigation, and treatment for COVID-19.
COVID-19
Protective role of Bruton tyrosine kinase inhibitors in patients with chronic lymphocytic leukaemia and COVID-19.
COVID-19
Regulation of the ACE2 locus in human airways cells.
COVID-19
Relevance of the Bruton Tyrosine Kinase as a Target for COVID-19 Therapy.
COVID-19
Reply: Calm before the storm: Understanding the role of Janus kinase inhibitors in COVID-19.
COVID-19
Reply: Potential role of Janus kinase inhibitors in COVID-19.
COVID-19
Role of monoclonal antibody drugs in the treatment of COVID-19.
COVID-19
Selective targeting of the inactive state of hematopoietic cell kinase (Hck) with a stable curcumin derivative.
COVID-19
Single-Cell Transcriptome Analysis Highlights a Role for Neutrophils and Inflammatory Macrophages in the Pathogenesis of Severe COVID-19.
COVID-19
Social Distancing, Health Care Disruptions, Telemedicine Use, and Treatment Interruption During the COVID-19 Pandemic in Patients With or Without Autoimmune Rheumatic Disease.
COVID-19
Structure-Based Virtual Screening Reveals Ibrutinib and Zanubrutinib as Potential Repurposed Drugs against COVID-19.
COVID-19
The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation.
COVID-19
The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19.
COVID-19
The use of Janus Kinase inhibitors in hospitalized patients with COVID-19: Systematic review and meta-analysis.
COVID-19
Tofacitinib in Patients Hospitalized with Covid-19 Pneumonia.
COVID-19
Treating Leukemia in the Time of COVID-19.
COVID-19
Use of Janus kinase inhibitors in COVID-19: a prospective observational series in 522 individuals.
COVID-19
Why Do Immunosuppressed Patients with Inflammatory Bowel Disease Not Seem to Be at a Higher Risk of COVID-19?
COVID-19
[Potential therapeutic drugs for novel coronavirus pneumonia].
Craniosynostoses
BmpR1A is a major type 1 BMP receptor for BMP-Smad signaling during skull development.
Craniosynostoses
BMPR1A maintains skeletal stem cell properties in craniofacial development and craniosynostosis.
Craniosynostoses
Genetics of craniosynostosis: genes, syndromes, mutations and genotype-phenotype correlations.
Crohn Disease
A Phase 2 Study of Tofacitinib, an Oral Janus Kinase Inhibitor, in Patients With Crohn's Disease.
Crohn Disease
Clinical Confirmation that the Selective JAK1 Inhibitor Filgotinib (GLPG0634) has a Low Liability for Drug-drug Interactions.
Crohn Disease
Cross-disorder analysis of schizophrenia and 19 immune-mediated diseases identifies shared genetic risk.
Crohn Disease
Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohn's Disease.
Crohn Disease
Influence of age and renal impairment on the steady state pharmacokinetics of filgotinib, a selective JAK1 inhibitor.
Crohn Disease
JAK-STAT pathway targeting for the treatment of inflammatory bowel disease.
Crohn Disease
JAK2 rs10758669 Polymorphisms and Susceptibility to Ulcerative Colitis and Crohn's Disease: A Meta-analysis.
Crohn Disease
Janus Kinase Antagonists and Other Novel Small Molecules for the Treatment of Crohn's Disease.
Crohn Disease
Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Modeling of Filgotinib (GLPG0634), a Selective JAK1 Inhibitor, in Support of Phase IIB Dose Selection.
Crohn Disease
Quality of Life and Work Productivity Improvements with Upadacitinib: Phase 2b Evidence from Patients with Moderate to Severe Crohn's Disease.
Crohn Disease
Randomized Controlled Trial Substudy of Cell-specific Mechanisms of Janus Kinase 1 Inhibition With Upadacitinib in the Crohn's Disease Intestinal Mucosa: Analysis From the CELEST Study.
Crohn Disease
Strong Evidence of a Combination Polymorphism of the Tyrosine Kinase 2 Gene and the Signal Transducer and Activator of Transcription 3 Gene as a DNA-Based Biomarker for Susceptibility to Crohn's Disease in the Japanese Population.
Crohn Disease
Tofacitinib for the treatment of tumor necrosis factor-? inhibitor refractory esophageal Crohn's disease: a case report.
Crohn Disease
UniPR1331: Small Eph/Ephrin Antagonist Beneficial in Intestinal Inflammation by Interfering with Type-B Signaling.
Crohn Disease
Update on Janus kinase antagonists in inflammatory bowel disease.
Crohn Disease
Vaccinations in Adult Patients with Inflammatory Bowel Diseases in the West.
Cryptococcosis
Ibrutinib, a Bruton's tyrosine kinase inhibitor, a new risk factor for cryptococcosis.
Cryptococcosis
X-linked immunodeficient mice exhibit enhanced susceptibility to Cryptococcus neoformans Infection.
Cryptorchidism
Genetic studies of MIS signalling in sexual development.
Cystadenoma
Platelets are associated with xenograft tumor growth and the clinical malignancy of ovarian cancer through an angiogenesis-dependent mechanism.
Cystic Fibrosis
In silico prediction and validation of potential therapeutic genes in pancreatic ?-cells associated with type 2 diabetes.
Cystic Fibrosis
PhenCode: connecting ENCODE data with mutations and phenotype.
Cystic Fibrosis
The tyrosine kinase p60c-src regulates the fast gate of the cystic fibrosis transmembrane conductance regulator chloride channel.
Cystic Fibrosis
Tyrosine kinase c-Src constitutes a bridge between cystic fibrosis transmembrane regulator channel failure and MUC1 overexpression in cystic fibrosis.
Cystitis
Infections in patients on BCR-ABL tyrosine kinase inhibitor therapy: cases and review of the literature.
Cysts
Csk differentially regulates Src64 during distinct morphological events in Drosophila germ cells.
Cysts
Effects of src kinase and TGFbeta1 on the differentiation and morphogenesis of MDCK cells grown in three-dimensional collagen and Matrigel environments.
Cysts
Expression of TGFBR1, TGFBR2, TGFBR3, ACVR1B and ACVR2B is altered in ovaries of cows with cystic ovarian disease.
Cysts
Impairment of Wnt11 function leads to kidney tubular abnormalities and secondary glomerular cystogenesis.
Cysts
Inhibiting Focal Adhesion Kinase Ameliorates Cyst Development in Polycystin-1-Deficient Polycystic Kidney Disease in Animal Model.
Cysts
JAK signaling regulates germline cyst breakdown and primordial follicle formation in mice.
Cysts
Kif3a controls murine nephron number via GLI3 repressor, cell survival, and gene expression in a lineage-specific manner.
Cysts
Properties of Transport Mediated by the Human Organic Cation Transporter 2 Studied in a Polarized Three-Dimensional Epithelial Cell Culture Model.
Cysts
Requirement of focal adhesion kinase in branching tubulogenesis.
Cysts
Src64 controls a novel actin network required for proper ring canal formation in the Drosophila male germline.
Cysts
Yield and Clinical Utility of Next-Generation Sequencing in Selected Patients With Lung Adenocarcinoma.
Darier Disease
Focal adhesion kinase is expressed in acantholytic keratinocytes associated with pemphigus vulgaris and pemphigus foliaceus.
Death, Sudden, Cardiac
Inhibition of c-Src tyrosine kinase prevents angiotensin II-mediated connexin-43 remodeling and sudden cardiac death.
Deficiency Diseases
Bruton's tyrosine kinase is required for activation of IkappaB kinase and nuclear factor kappaB in response to B cell receptor engagement.
Deficiency Diseases
Disturbed Transcription of TLRs' Negative Regulators and Cytokines Secretion among TLR4- and 9-Activated PBMCs of Agammaglobulinemic Patients.
Dehydration
A role for c-Abl in c-myc regulation.
Dementia
Genome-wide association meta-analysis of neuropathologic features of Alzheimer's disease and related dementias.
Dementia
Nilotinib Fails to Prevent Synucleinopathy and Cell Loss in a Mouse Model of Multiple System Atrophy.
Dementia
The Src kinase Lyn is required for CCR5 signaling in response to MIP-1beta and R5 HIV-1 gp120 in human macrophages.
Dementia, Vascular
Association of intronic sequence variant in the gene encoding spleen tyrosine kinase with susceptibility to vascular dementia.
Demyelinating Diseases
Can rheumatologists stop causing demyelinating disease?
Demyelinating Diseases
Expression of Bone Morphogenetic Proteins in Multiple Sclerosis Lesions.
Demyelinating Diseases
Inhibition of Bruton's tyrosine kinase interferes with pathogenic B-cell development in inflammatory CNS demyelinating disease.
Dengue
An evolutionary conserved function of the JAK-STAT pathway in anti-dengue defense.
Dengue
Bruton's tyrosine kinase phosphorylates Toll-like receptor 3 to initiate antiviral response.
Dengue
GNF-2 Inhibits Dengue Virus by Targeting Abl Kinases and the Viral E Protein.
Dengue
Identification and characterization of the role of c-terminal Src kinase in dengue virus replication.
Dengue
Spleen Tyrosine Kinase (Syk) Mediates IL-1? Induction by Primary Human Monocytes during Antibody-enhanced Dengue Virus Infection.
Dengue
The small molecules AZD0530 and dasatinib inhibit dengue virus RNA replication via Fyn kinase.
Dermatitis
A pharmacokinetic study of oclacitinib maleate in six cats.
Dermatitis
Effects of the Janus Kinase Inhibitor CP-690550 (Tofacitinib) in a Rat Model of Oxazolone-Induced Chronic Dermatitis.
Dermatitis
Focal adhesion kinase is expressed in acantholytic keratinocytes associated with pemphigus vulgaris and pemphigus foliaceus.
Dermatitis
Remission of Severe Eyelid Dermatitis With a Topical Janus Kinase Inhibitor.
Dermatitis
Topically Administered Janus-Kinase Inhibitors Tofacitinib and Oclacitinib Display Impressive Antipruritic and Anti-Inflammatory Responses in a Model of Allergic Dermatitis.
Dermatitis
[Granulomatous rosacea-like dermatitis under therapy with tofacitinib].
Dermatitis, Atopic
A blinded, randomized, placebo-controlled trial of the efficacy and safety of the Janus kinase inhibitor oclacitinib (Apoquel®) in client-owned dogs with atopic dermatitis.
Dermatitis, Atopic
Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis.
Dermatitis, Atopic
Application of Janus Kinase Inhibitors in Atopic Dermatitis: An Updated Systematic Review and Meta-Analysis of Clinical Trials.
Dermatitis, Atopic
Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials.
Dermatitis, Atopic
Baricitinib in patients with moderate-to-severe atopic dermatitis: Results from a randomized monotherapy phase 3 trial in the United States and Canada (BREEZE-AD5).
Dermatitis, Atopic
Baricitinib: therapeutic potential for moderate to severe atopic dermatitis.
Dermatitis, Atopic
Bridging to a selective Janus kinase 1 inhibitor in severe atopic dermatitis: An instructive case with upadacitinib.
Dermatitis, Atopic
Comparing quality of life outcomes of JAK inhibitors and biological treatments for atopic dermatitis: a systematic review and network meta-analysis.
Dermatitis, Atopic
Comparison of topical tofacitinib and 0.1% hypochlorous acid in a murine atopic dermatitis model.
Dermatitis, Atopic
Delgocitinib ointment in pediatric patients with atopic dermatitis: A phase 3, randomized, double-blind, vehicle-controlled study and a subsequent open-label, long-term study.
Dermatitis, Atopic
Delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with moderate to severe atopic dermatitis: A phase 3, randomized, double-blind, vehicle-controlled study and an open-label, long-term extension study.
Dermatitis, Atopic
Discovery of a Janus Kinase Inhibitor Bearing a Highly Three-Dimensional Spiro Scaffold: JTE-052 (Delgocitinib) as a New Dermatological Agent to Treat Inflammatory Skin Disorders.
Dermatitis, Atopic
Drugs targeting the JAK/STAT pathway for the treatment of immune-mediated inflammatory skin diseases: protocol for a scoping review.
Dermatitis, Atopic
Effects of Delgocitinib Ointment 0.5% on the Normal Mouse Skin and Epidermal Tight Junction Proteins in Comparison With Topical Corticosteroids.
Dermatitis, Atopic
Effects of Hepatic Impairment on the Pharmacokinetics of Abrocitinib and Its Metabolites.
Dermatitis, Atopic
Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.
Dermatitis, Atopic
Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial.
Dermatitis, Atopic
Efficacy and Safety of Baricitinib Combined With Topical Corticosteroids for Treatment of Moderate to Severe Atopic Dermatitis: A Randomized Clinical Trial.
Dermatitis, Atopic
Efficacy and Safety of Janus Kinase Inhibitors for the Treatment of Atopic Dermatitis: A Systematic Review and Meta-Analysis.
Dermatitis, Atopic
Efficacy and Safety of Oral Janus Kinase 1 Inhibitor Abrocitinib for Patients With Atopic Dermatitis: A Phase 2 Randomized Clinical Trial.
Dermatitis, Atopic
Efficacy and Safety of SHR0302, a Highly Selective Janus Kinase 1 Inhibitor, in Patients with Moderate to Severe Atopic Dermatitis: A Phase II Randomized Clinical Trial.
Dermatitis, Atopic
Efficacy and safety of topical Janus kinase and phosphodiesterase inhibitor-4 inhibitors for the treatment of atopic dermatitis: A network meta-analysis.
Dermatitis, Atopic
Efficacy and safety of topical JTE-052, a Janus kinase inhibitor, in Japanese adult patients with moderate-to-severe atopic dermatitis: a phase II, multicentre, randomized, vehicle-controlled clinical study.
Dermatitis, Atopic
Emerging Role of Janus Kinase Inhibitors for the Treatment of Atopic Dermatitis.
Dermatitis, Atopic
Emerging systemic therapies for atopic dermatitis: oral small molecules and targeted topical agents.
Dermatitis, Atopic
Exposure-Response Analyses for Upadacitinib Efficacy in Subjects With Atopic Dermatitis-Analyses of Phase 2b Study to Support Selection of Phase 3 Doses.
Dermatitis, Atopic
Extended Safety Analysis of Baricitinib 2 mg in Adult Patients with Atopic Dermatitis: An Integrated Analysis from Eight Randomized Clinical Trials.
Dermatitis, Atopic
Hand eczema: treatment.
Dermatitis, Atopic
IgE hyperproduction through enhanced tyrosine phosphorylation of Janus kinase 3 in NC/Nga mice, a model for human atopic dermatitis.
Dermatitis, Atopic
Impact of baricitinib in combination with topical steroids on atopic dermatitis symptoms, quality of life and functioning in adult patients with moderate-to-severe atopic dermatitis from the BREEZE-AD7 Phase 3 randomized trial.
Dermatitis, Atopic
JAK inhibitors and infections risk: focus on herpes zoster.
Dermatitis, Atopic
Janus kinase inhibitor delgocitinib suppresses pruritus and nerve elongation in an atopic dermatitis murine model.
Dermatitis, Atopic
Janus kinase inhibitors for atopic dermatitis: a promising treatment modality.
Dermatitis, Atopic
Janus kinase inhibitors for the therapy of atopic dermatitis.
Dermatitis, Atopic
Janus Kinase Inhibitors in Dermatology: Part 2: Applications in Psoriasis, Atopic Dermatitis, and Other Dermatoses.
Dermatitis, Atopic
Janus Kinase Inhibitors: A Review of Their Emerging Applications in Dermatology
Dermatitis, Atopic
Kinetic-Pharmacodynamic Model of Platelet Time Course in Patients With Moderate-to-Severe Atopic Dermatitis Treated With Oral Janus Kinase 1 Inhibitor Abrocitinib.
Dermatitis, Atopic
Leveraging the nice face of Janus kinase inhibition-ruxolitinib cream in atopic dermatitis.
Dermatitis, Atopic
Long-term Efficacy of Baricitinib in Adults With Moderate to Severe Atopic Dermatitis Who Were Treatment Responders or Partial Responders: An Extension Study of 2 Randomized Clinical Trials.
Dermatitis, Atopic
Long-term safety and efficacy of delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with atopic dermatitis.
Dermatitis, Atopic
Pharmacokinetics of Ruxolitinib in Patients with Atopic Dermatitis Treated With Ruxolitinib Cream: Data from Phase II and III Studies.
Dermatitis, Atopic
Phase 1 studies to assess the safety, tolerability and pharmacokinetics of JTE-052 (a novel Janus kinase inhibitor) ointment in Japanese healthy volunteers and patients with atopic dermatitis.
Dermatitis, Atopic
Phase 2 clinical study of delgocitinib ointment in pediatric patients with atopic dermatitis.
Dermatitis, Atopic
Pooled safety analysis of baricitinib in adult patients with atopic dermatitis from 8 randomized clinical trials.
Dermatitis, Atopic
Rapid Improvement of Itch Associated With Atopic Dermatitis With Abrocitinib Is Partially Independent of Overall Disease Improvement: Results From Pooled Phase 2b and 3 Monotherapy Studies.
Dermatitis, Atopic
Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial.
Dermatitis, Atopic
Safety and toxicity of combined oclacitinib and carboplatin or doxorubicin in dogs with solid tumors: a pilot study.
Dermatitis, Atopic
Safety considerations of systemic Janus kinase inhibitors in atopic dermatitis applications.
Dermatitis, Atopic
Safety of Janus kinase (JAK) inhibitors in the short-term treatment of atopic dermatitis.
Dermatitis, Atopic
Systematic Review on the Efficacy and Safety of Oral Janus Kinase Inhibitors for the Treatment of Atopic Dermatitis.
Dermatitis, Atopic
The effectiveness of Janus kinase inhibitors in treating atopic dermatitis: A systematic review and meta-analysis.
Dermatitis, Atopic
The efficacy of Janus kinase inhibitors in patients with atopic dermatitis: A systematic review and network meta-analysis.
Dermatitis, Atopic
The frequency of urinary tract infection and subclinical bacteriuria in dogs with allergic dermatitis treated with oclacitinib: a prospective study.
Dermatitis, Atopic
The oral Janus kinase/spleen tyrosine kinase inhibitor ASN002 demonstrates efficacy and improves associated systemic inflammation in patients with moderate-to-severe atopic dermatitis: results from a randomized double-blind placebo-controlled study.
Dermatitis, Atopic
Topical treatment with mastic (resin from Pistacia lentiscus) elicits anti-inflammatory and anti-pruritic responses by modulating keratinocyte activation in a mouse model of allergic dermatitis.
Dermatitis, Atopic
Treatment of atopic dermatitis with biologics and Janus kinase inhibitors.
Dermatitis, Atopic
Treatment of recalcitrant atopic dermatitis with the oral Janus kinase inhibitor tofacitinib citrate.
Dermatitis, Atopic
Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial.
Dermatitis, Atopic
[Topical therapy for atopic eczema].
Dermatitis, Contact
Effects of the novel and potent lymphocyte-specific protein tyrosine kinase inhibitor TKM0150 on mixed lymphocyte reaction and contact hypersensitivity in mice.
Dermatofibrosarcoma
Complex t(5;8) involving the CSPG2 and PTK2B genes in a case of dermatofibrosarcoma protuberans without the COL1A1-PDGFB fusion.
Dermatomyositis
Iacta Alea Est: The Inexorable Advance of Tofacitinib in the Treatment of Dermatomyositis-Associated Rapidly Progressive Interstitial Lung Disease. A Case Report.
Dermatomyositis
Janus kinase (JAK) inhibition with baricitinib in refractory juvenile dermatomyositis.
Dermatomyositis
Janus kinase 1/2 inhibition with baricitinib in the treatment of juvenile dermatomyositis.
Dermatomyositis
Janus kinase inhibitor significantly improved rash and muscle strength in juvenile dermatomyositis.
Dermatomyositis
Janus Kinase Inhibitors: A Review of Their Emerging Applications in Dermatology
Dermatomyositis
Management of refractory cutaneous dermatomyositis: potential role of Janus kinase inhibition with tofacitinib.
Dermatomyositis
Reply: Janus kinase 1/2 inhibition with baricitinib in the treatment of juvenile dermatomyositis.
Dermatomyositis
Successful management with Janus kinase inhibitor tofacitinib in refractory juvenile dermatomyositis: a pilot study and literature review.
Dermatomyositis
Unexpected Hair Regrowth in a Patient with Longstanding Alopecia Universalis During Treatment of Recalcitrant Dermatomyositis with the Janus Kinase Inhibitor Ruxolitinib.
Dermatomyositis
[Response of dermatomyositis with lung involvement to Janus kinase inhibitor treatment].
Diabetes Complications
Identification of cross-species shared transcriptional networks of diabetic nephropathy in human and mouse glomeruli.
Diabetes Mellitus
A Link Between Alzheimer's and Type II Diabetes Mellitus? Ca+2 -Mediated Signal Control and Protein Localization.
Diabetes Mellitus
Diabetes may increase risk for oral cancer through the insulin receptor substrate-1 and focal adhesion kinase pathway.
Diabetes Mellitus
Effects of diabetes and hypertension on glomerular transforming growth factor-beta receptor expression.
Diabetes Mellitus
Effects of Diabetes Mellitus on the Disposition of Tofacitinib, a Janus Kinase Inhibitor, in Rats.
Diabetes Mellitus
Effects of sevoflurane pretreatment on renal Src and FAK expression in diabetic rats after renal ischemia/reperfusion injury.
Diabetes Mellitus
Infection risk in patients undergoing treatment for inflammatory arthritis: non-biologics versus biologics.
Diabetes Mellitus
Targeting JAK3 with JANEX-1 for prevention of autoimmune type 1 diabetes in NOD mice.
Diabetes Mellitus
The rs2304256 Polymorphism in TYK2 Gene Is Associated with Protection for Type 1 Diabetes Mellitus.
Diabetes Mellitus, Experimental
Diabetic nephropathy and transforming growth factor-beta: transforming our view of glomerulosclerosis and fibrosis build-up.
Diabetes Mellitus, Type 1
Association analysis of the lymphocyte-specific protein tyrosine kinase (LCK) gene in type 1 diabetes.
Diabetes Mellitus, Type 1
Contribution of PTPN22, CD28, CTLA-4 and ZAP-70 variants to the risk of type 1 diabetes in Tunisians.
Diabetes Mellitus, Type 1
LCK rs10914542-G allele associates with type 1 diabetes in children via T cell hyporesponsiveness.
Diabetes Mellitus, Type 1
MicroRNAs and histone deacetylase inhibition-mediated protection against inflammatory ?-cell damage.
Diabetes Mellitus, Type 1
Preclinical evaluation of tyrosine kinase 2 inhibitors for human beta-cell protection in type 1 diabetes.
Diabetes Mellitus, Type 1
Subtyping of Type 1 Diabetes as Classified by Anti-GAD Antibody, IgE Levels, and Tyrosine kinase 2 (TYK2) Promoter Variant in the Japanese.
Diabetes Mellitus, Type 1
The rs2304256 Polymorphism in TYK2 Gene Is Associated with Protection for Type 1 Diabetes Mellitus.
Diabetes Mellitus, Type 1
TYK2 Promoter Variant Is Associated with Impaired Insulin Secretion and Lower Insulin Resistance in Japanese Type 2 Diabetes Patients.
Diabetes Mellitus, Type 2
Baricitinib counteracts metaflammation, thus protecting against diet-induced metabolic abnormalities in mice.
Diabetes Mellitus, Type 2
Effects of imatinib on vascular insulin sensitivity and free fatty acid transport in early weight gain.
Diabetes Mellitus, Type 2
Enhancement of mesenteric artery contraction to 5-HT depends on Rho kinase and Src kinase pathways in the ob/ob mouse model of type 2 diabetes.
Diabetes Mellitus, Type 2
Glucosylpolyphenols as inhibitors of A?-induced Fyn kinase activation and Tau phosphorylation: synthesis, membrane permeability, and exploratory target assessment within the scope of type 2 diabetes and Alzheimer's disease.
Diabetes Mellitus, Type 2
Imatinib and type 2 diabetes.
Diabetes Mellitus, Type 2
Increased glomerular and tubular expression of transforming growth factor-beta1, its type II receptor, and activation of the Smad signaling pathway in the db/db mouse.
Diabetes Mellitus, Type 2
Insulin-receptor kinase activity of adipose tissue from morbidly obese humans with and without NIDDM.
Diabetes Mellitus, Type 2
MLR-1023 is a potent and selective allosteric activator of Lyn kinase in vitro that improves glucose tolerance in vivo.
Diabetes Mellitus, Type 2
Solution structure of the zinc finger HIT domain in protein FON.
Diabetes Mellitus, Type 2
The Lyn kinase activator MLR-1023 is a novel insulin receptor potentiator that elicits a rapid-onset and durable improvement in glucose homeostasis in animal models of type 2 diabetes.
Diabetes Mellitus, Type 2
Vascular proliferation and transforming growth factor-beta expression in pre- and early stage of diabetes mellitus in Otsuka Long-Evans Tokushima fatty rats.
Diabetes Mellitus, Type 2
[Effects of aerobic exercise and resveratrol on the expressions of JAK2 and TGF-?1 in renal tissue of type 2 diabetes rats].
Diabetic Angiopathies
Key role of Src kinase in S100B-induced activation of the receptor for advanced glycation end products in vascular smooth muscle cells.
Diabetic Cardiomyopathies
Melatonin therapy for diabetic cardiomyopathy: A mechanism involving Syk-mitochondrial complex I-SERCA pathway.
Diabetic Foot
Effect and Mechanism of the Bruton Tyrosine Kinase (Btk) Inhibitor Ibrutinib on Rat Model of Diabetic Foot Ulcers.
Diabetic Nephropathies
Evidence for a role of transforming growth factor (TGF)-beta1 in the induction of postglomerular albuminuria in diabetic nephropathy: amelioration by soluble TGF-beta type II receptor.
Diabetic Nephropathies
Expression-based network biology identifies alteration in key regulatory pathways of type 2 diabetes and associated risk/complications.
Diabetic Nephropathies
Increased glomerular and tubular expression of transforming growth factor-beta1, its type II receptor, and activation of the Smad signaling pathway in the db/db mouse.
Diabetic Nephropathies
Inhibition of Src Kinase Blocks High Glucose-Induced EGFR Transactivation and Collagen Synthesis in Mesangial Cells and Prevents Diabetic Nephropathy in Mice.
Diabetic Nephropathies
JAK-STAT Activity in Peripheral Blood Cells and Kidney Tissue in IgA Nephropathy.
Diabetic Nephropathies
miR-136 improves renal fibrosis in diabetic rats by targeting down-regulation of tyrosine kinase SYK and inhibition of TGF-?1/Smad3 signaling pathway.
Diabetic Nephropathies
Resequencing of genes for transforming growth factor beta1 (TGFB1) type 1 and 2 receptors (TGFBR1, TGFBR2), and association analysis of variants with diabetic nephropathy.
Diabetic Nephropathies
Serum amyloid A and Janus kinase 2 in a mouse model of diabetic kidney disease.
Diabetic Nephropathies
SMAD3 promotes autophagy dysregulation by triggering lysosome depletion in tubular epithelial cells in diabetic nephropathy.
Diabetic Nephropathies
Spleen tyrosine kinase promotes NLR family pyrin domain containing 3 inflammasome?mediated IL?1? secretion via c?Jun N?terminal kinase activation and cell apoptosis during diabetic nephropathy.
Diabetic Nephropathies
Suppressor of Cytokine Signaling-1 Ameliorates Expression of MCP-1 in Diabetic Nephropathy.
Diabetic Nephropathies
Suppressor of Cytokine Signaling-1 Peptidomimetic Limits Progression of Diabetic Nephropathy.
Diabetic Nephropathies
Suppressor of cytokine signaling-1 reduces high glucose-induced TGF-beta1 and fibronectin synthesis in human mesangial cells.
Diabetic Neuropathies
Role of Fyn-mediated NMDA receptor function in prediabetic neuropathy in mice.
Diabetic Retinopathy
Silver nanoparticles inhibit VEGF-and IL-1beta-induced vascular permeability via Src dependent pathway in porcine retinal endothelial cells.
Diabetic Retinopathy
Spleen Tyrosine Kinase Mediates Microglial Activation in Mice With Diabetic Retinopathy.
Diabetic Retinopathy
The effect of spleen tyrosine kinase inhibitor R406 on diabetic retinopathy in experimental diabetic rats.
Diabetic Retinopathy
The retinal tyrosine kinome of diabetic Akimba mice highlights potential for specific Src family kinase inhibition in retinal vascular disease.
Diffuse Intrinsic Pontine Glioma
Effects of FKBP12 and type II BMP receptors on signal transduction by ALK2 activating mutations associated with genetic disorders.
Disorders of Sex Development
Synergistic cooperation between the beta-catenin signaling pathway and steroidogenic factor 1 in the activation of the Mullerian inhibiting substance type II receptor.
Diverticulum
Transforming growth factor ? receptor type 1 is essential for female reproductive tract integrity and function.
DNA Repair-Deficiency Disorders
BCR-ABL down-regulates the DNA repair protein DNA-PKcs.
Down Syndrome
Janus kinase inhibition in Down syndrome: 2 cases of therapeutic benefit for alopecia areata.
Down Syndrome
Janus kinase mutations in the development of acute megakaryoblastic leukemia in children with and without Down's syndrome.
Down Syndrome
Loss-of-function JAK3 mutations in TMD and AMKL of Down syndrome.
Down Syndrome
Poor prognosis for P2RY8-CRLF2 fusion but not for CRLF2 over-expression in children with intermediate risk B-cell precursor acute lymphoblastic leukemia.
Drug-Related Side Effects and Adverse Reactions
Immunosuppressive agents in organ transplantation: past, present, and future.
Drug-Related Side Effects and Adverse Reactions
Management of Chronic Myeloid Leukemia in Childhood.
Drug-Related Side Effects and Adverse Reactions
Pharmacovigilance evaluation of the relationship between impaired glucose metabolism and BCR-ABL inhibitor use by using an adverse drug event reporting database.
Drug-Related Side Effects and Adverse Reactions
RAD 001 (everolimus) prevents mTOR and Akt late re-activation in response to imatinib in chronic myeloid leukemia.
Drug-Related Side Effects and Adverse Reactions
The treatment of pediatric chronic myelogenous leukemia in the imatinib era.
Drug-Related Side Effects and Adverse Reactions
Thromboembolic Adverse Drug Reactions in Janus Kinase (JAK) Inhibitors: Does the Inhibitor Specificity Play a Role?
Dry Eye Syndromes
Immunomodulatory effect of the topical ophthalmic Janus kinase inhibitor tofacitinib (CP-690,550) in patients with dry eye disease.
Dry Eye Syndromes
Tofacitinib (CP-690,550), a Janus kinase inhibitor for dry eye disease: results from a phase 1/2 trial.
Dwarfism
Correlation Analysis Between Expression Levels of Hepatic Growth Hormone Receptor, Janus Kinase 2, Insulin-Like Growth Factor-I Genes and Dwarfism Phenotype in Bama Minipig.
Dwarfism, Pituitary
Update on X-linked hypogammaglobulinemia with isolated growth hormone deficiency.
Dysentery, Bacillary
Cortactin and Crk cooperate to trigger actin polymerization during Shigella invasion of epithelial cells.
Dyskinesias
NR2B antagonist CP-101,606 inhibits NR2B phosphorylation at tyrosine-1472 and its interactions with Fyn in levodopa-induced dyskinesia rat model.
Dyskinesias
Pivotal Role of Fyn Kinase in Parkinson's Disease and Levodopa-Induced Dyskinesia: a Novel Therapeutic Target?
Dyskinesias
Tat-Src reduced NR2B tyrosine phosphorylation and its interaction with NR2B in levodopa-induced dyskinetic rats model.
Dyslipidemias
Actein ameliorates hepatic steatosis and fibrosis in high fat diet-induced NAFLD by regulation of insulin and leptin resistant.
Dyslipidemias
Inhibition of JAK2 Suppresses Myelopoiesis and Atherosclerosis in Apoe-/- Mice.
Dyspnea
Structure-Based Virtual Screening Reveals Ibrutinib and Zanubrutinib as Potential Repurposed Drugs against COVID-19.
Ebstein Anomaly
A case of capillary malformation-arteriovenous malformation and Ebstein's anomaly in a child with EphB4 mutation.
Ecthyma
Pseudomonas aeruginosa sepsis presenting as oral ecthyma gangrenosum in identical twins with Bruton tyrosine kinase gene mutation: Two case reports and review of the literature.
Eczema
Hand eczema: treatment.
Eczema
Severe eczema and Hyper-IgE in Loeys-Dietz-syndrome - contribution to new findings of immune dysregulation in connective tissue disorders.
Eczema
TGF? receptor mutations impose a strong predisposition for human allergic disease.
Eczema
What's new in atopic eczema? An analysis of systematic reviews published in 2018. Part 1: prevention and topical therapies.
Ehlers-Danlos Syndrome
Aneurysm syndromes caused by mutations in the TGF-beta receptor.
Ehlers-Danlos Syndrome
Identification of a novel TGFBR1 mutation in a Loeys-Dietz syndrome type II patient with vascular Ehlers-Danlos syndrome phenotype.
Ehlers-Danlos Syndrome
Mutation of ACTA2 gene as an important cause of familial and nonfamilial nonsyndromatic thoracic aortic aneurysm and/or dissection (TAAD).
Embolic Stroke
Implications of Janus Kinase 2 Mutation in Embolic Stroke of Unknown Source.
Encephalitis
Expression of platelet-derived growth factor receptor-?/ß, vascular endothelial growth factor receptor-2, c-Abl, and c-Kit in canine granulomatous meningoencephalitis and necrotizing encephalitis.
Encephalitis
The Janus kinase inhibitor ruxolitinib reduces HIV replication in human macrophages and ameliorates HIV encephalitis in a murine model.
Encephalitis
Translocation-generated ITK-FER and ITK-SYK fusions induce STAT3 phosphorylation and CD69 expression.
Encephalitis, Japanese
Blocking of interferon-induced Jak-Stat signaling by Japanese encephalitis virus NS5 through a protein tyrosine phosphatase-mediated mechanism.
Encephalitis, Japanese
Japanese encephalitis virus infection stimulates Src tyrosine kinase in neuron/glia.
Encephalitis, Japanese
Pathogenicity and virulence of Japanese encephalitis virus: Neuroinflammation and neuronal cell damage.
Encephalomyelitis
C-type lectins and extracellular vesicles in virus-induced NETosis.
Encephalomyelitis
Exogenous IL-9 Ameliorates Experimental Autoimmune Myasthenia Gravis Symptoms in Rats.
Encephalomyelitis
IL-1 receptor-associated kinase 1 regulates susceptibility to organ-specific autoimmunity.
Encephalomyelitis
Inhibition of the BMP Signaling Pathway Ameliorated Established Clinical Symptoms of Experimental Autoimmune Encephalomyelitis.
Encephalomyelitis
Tofacitinib ameliorates atherosclerosis and reduces foam cell formation in apoE deficient mice.
Encephalomyelitis
Tyrosine kinase 2 plays critical roles in the pathogenic CD4 T cell responses for the development of experimental autoimmune encephalomyelitis.
Encephalomyelitis, Autoimmune, Experimental
Exogenous IL-9 Ameliorates Experimental Autoimmune Myasthenia Gravis Symptoms in Rats.
Encephalomyelitis, Autoimmune, Experimental
IL-1 receptor-associated kinase 1 regulates susceptibility to organ-specific autoimmunity.
Encephalomyelitis, Autoimmune, Experimental
Inhibition of the BMP Signaling Pathway Ameliorated Established Clinical Symptoms of Experimental Autoimmune Encephalomyelitis.
Encephalomyelitis, Autoimmune, Experimental
Tyrosine kinase 2 plays critical roles in the pathogenic CD4 T cell responses for the development of experimental autoimmune encephalomyelitis.
Endometrial Hyperplasia
Activation of the receptor protein tyrosine kinase EphB4 in endometrial hyperplasia and endometrial carcinoma.
Endometrial Hyperplasia
Autophagy in the physiological endometrium and cancer.
Endometrial Hyperplasia
Overexpression of erythropoietin-producing hepatocyte receptor B4 and ephrin-B2 is associated with estrogen receptor expression in endometrial adenocarcinoma.
Endometrial Neoplasms
A window-of-opportunity clinical trial of dasatinib in women with newly diagnosed endometrial cancer.
Endometrial Neoplasms
Aberrant expression and mutations of TGF-beta receptor type II gene in endometrial cancer.
Endometrial Neoplasms
Activation of the receptor protein tyrosine kinase EphB4 in endometrial hyperplasia and endometrial carcinoma.
Endometrial Neoplasms
Analysis of candidate target genes for mononucleotide repeat mutation in microsatellite instability-high (MSI-H) endometrial cancer.
Endometrial Neoplasms
Autophagy in the physiological endometrium and cancer.
Endometrial Neoplasms
Collagen triple helix repeat containing 1 promotes endometrial cancer cell migration by activating the focal adhesion kinase signaling pathway.
Endometrial Neoplasms
Conditional abrogation of transforming growth factor-? receptor 1 in PTEN-inactivated endometrium promotes endometrial cancer progression in mice.
Endometrial Neoplasms
Endometrial cancer invasion depends on cancer-derived tumor necrosis factor-alpha and stromal derived hepatocyte growth factor.
Endometrial Neoplasms
Endometrial cancer is a receptor-mediated target for Mullerian Inhibiting Substance.
Endometrial Neoplasms
Epithelial membrane protein-2 promotes endometrial tumor formation through activation of FAK and Src.
Endometrial Neoplasms
Estradiol and Tamoxifen Induce Cell Migration through GPR30 and Activation of Focal Adhesion Kinase (FAK) in Endometrial Cancers with Low or without Nuclear Estrogen Receptor ? (ER?).
Endometrial Neoplasms
Expression of focal adhesion kinase in patients with endometrial cancer: a clinicopathologic study.
Endometrial Neoplasms
Expression of receptor tyrosine kinase EphB4 and its ligand ephrin-B2 is associated with malignant potential in endometrial cancer.
Endometrial Neoplasms
Expression of TGF-beta type I and II receptors in normal and cancerous human endometrium.
Endometrial Neoplasms
Genetic Polymorphisms of TGFB1, TGFBR1, SNAI1 and TWIST1 Are Associated with Endometrial Cancer Susceptibility in Chinese Han Women.
Endometrial Neoplasms
Gonadotropin-releasing hormone (GnRH)-I and GnRH-II induce cell growth inhibition in human endometrial cancer cells: involvement of integrin beta3 and focal adhesion kinase.
Endometrial Neoplasms
Insights into endometrial serous carcinogenesis and progression.
Endometrial Neoplasms
Interleukin-1 receptor-associated kinase 1 correlates with metastasis and invasion in endometrial carcinoma.
Endometrial Neoplasms
LEFTY2 Controls Migration of Human Endometrial Cancer Cells via Focal Adhesion Kinase Activity (FAK) and miRNA-200a.
Endometrial Neoplasms
Leptin induces functional activation of cyclooxygenase-2 through JAK2/STAT3, MAPK/ERK, and PI3K/AKT pathways in human endometrial cancer cells.
Endometrial Neoplasms
miR-20a-5p inhibits endometrial cancer progression by targeting janus kinase 1.
Endometrial Neoplasms
MLH1 enhances the sensitivity of human endometrial carcinoma cells to cisplatin by activating the MLH1/c-Abl apoptosis signaling pathway.
Endometrial Neoplasms
Molecular differences between RER+ and RER- sporadic endometrial carcinomas in a large population-based series.
Endometrial Neoplasms
Mutations of the transforming growth factor-beta type II receptor gene and genomic instability in hereditary nonpolyposis colorectal cancer.
Endometrial Neoplasms
Overexpression of enhancer of zeste homolog 2 (EZH2) and focal adhesion kinase (FAK) in high grade endometrial carcinoma.
Endometrial Neoplasms
Overexpression of ephrinB2 and EphB4 in tumor advancement of uterine endometrial cancers.
Endometrial Neoplasms
Stress-induced phosphoprotein-1 maintains the stability of JAK2 in cancer cells.
Endometrial Neoplasms
The expression and action of granulocyte macrophage-colony stimulating factor and its interaction with TGF-beta in endometrial carcinoma.
Endometrial Neoplasms
The Src kinase pathway promotes tamoxifen agonist action in Ishikawa endometrial cells through phosphorylation-dependent stabilization of estrogen receptor (alpha) promoter interaction and elevated steroid receptor coactivator 1 activity.
Endometriosis
Activin A, Activin Receptor Type II, Nodal, and Cripto mRNA Are Expressed by Eutopic and Ectopic Endometrium in Women With Ovarian Endometriosis.
Endometriosis
Alteration of focal adhesion kinase expression in eutopic endometrium of women with endometriosis.
Endometriosis
B lymphocytes inactivation by Ibrutinib limits endometriosis progression in mice.
Endometriosis
Comprehensive study of angiogenic factors in women with endometriosis compared to women without endometriosis.
Endometriosis
Differential expression of genes in eutopic and ectopic endometrium from patients with ovarian endometriosis.
Endometriosis
DNA microarray analysis of gene expression profiles in deep endometriosis using laser capture microdissection.
Endometriosis
Enhanced cyclooxygenase-2 expression levels and metalloproteinase 2 and 9 activation by Hexachlorobenzene in human endometrial stromal cells.
Endometriosis
Expression of focal adhesion kinase in endometrial stromal cells of women with endometriosis was adjusted by ovarian steroid hormones.
Endometriosis
Focal adhesion kinase expression in ovarian endometriosis.
Endometriosis
Healthy women and patients with endometriosis show high concentrations of inhibin A, inhibin B, and activin A in peritoneal fluid throughout the menstrual cycle.
Endometriosis
Inhibition of erythropoietin-producing hepatoma receptor B4 (EphB4) signaling suppresses the vascularization and growth of endometriotic lesions.
Endometriosis
miR-96-5p regulated TGF-?/SMAD signaling pathway and suppressed endometrial cell viability and migration via targeting TGFBR1.
Endometriosis
Mullerian inhibiting substance induces apoptosis of human endometrial stromal cells in endometriosis.
Endometriosis
Specific Photothermal Ablation Therapy of Endometriosis by Targeting Delivery of Gold Nanospheres.
Endometriosis
Targeting mast cells in endometriosis with janus kinase 3 inhibitor, JANEX-1.
Endotoxemia
A direct binding site for Grb2 contributes to transformation and leukemogenesis by the Tel-Abl (ETV6-Abl) tyrosine kinase.
Endotoxemia
Fyn kinase mediates pro-inflammatory response in a mouse model of endotoxemia: Relevance to translational research.
Endotoxemia
In vivo lipopolysaccharide exposure of human blood leukocytes induces cross-tolerance to multiple TLR ligands.
Endotoxemia
Roles of MMP-2/-9 in cardiac dysfunction during early multiple organ failure in an ovine animal model.
Endotoxemia
Small interfering RNA targeting focal adhesion kinase prevents cardiac dysfunction in endotoxemia.
Eosinophilia
Hypereosinophilic syndrome-a rare adverse event of anti-cytokine treatment in rheumatoid arthritis resolved after Janus kinase inhibitor therapy.
Epidermodysplasia Verruciformis
Primary immunodeficiency diseases associated with increased susceptibility to viral infections and malignancies.
Epilepsy
A non-mitotic role for aurora kinase A as a direct activator of cell migration upon interaction with PLD, FAK and Src.
Epilepsy
Altered expression of c-Abl in patients with epilepsy and in a rat model.
Epilepsy
Aurora A Kinase Inhibitor AKI603 Induces Cellular Senescence in Chronic Myeloid Leukemia Cells Harboring T315I Mutation.
Epilepsy
BDNF selectively regulates GABAA receptor transcription by activation of the JAK/STAT pathway.
Epilepsy
Gain control of N-methyl-D-aspartate receptor activity by receptor-like protein tyrosine phosphatase alpha.
Epilepsy
Genetic Interaction of H19 and TGFBR1 Polymorphisms with Risk of Epilepsy in a Chinese Population.
Epilepsy
Increased expression of TGF-beta type I receptor in brain tissues of patients with temporal lobe epilepsy.
Epilepsy
Increased NRG1-ErbB4 signaling in human symptomatic epilepsy.
Epilepsy
Recombinant Human Erythropoietin Protects Myocardial Cells from Apoptosis via the Janus-Activated Kinase 2/Signal Transducer and Activator of Transcription 5 Pathway in Rats with Epilepsy.
Epilepsy, Temporal Lobe
Altered expression of c-Abl in patients with epilepsy and in a rat model.
Epilepsy, Temporal Lobe
Increased expression of TGF-beta type I receptor in brain tissues of patients with temporal lobe epilepsy.
Epstein-Barr Virus Infections
Chronic active Epstein-Barr virus infection as the initial symptom in a Janus kinase 3 deficiency child: Case report and literature review.
Epstein-Barr Virus Infections
IL-2-inducible T-cell kinase deficiency with pulmonary manifestations due to disseminated Epstein-Barr virus infection.
Erectile Dysfunction
The effects of single versus combined therapy using LIM-kinase 2 inhibitor and type 5 phosphodiesterase inhibitor on erectile function in a rat model of cavernous nerve injury-induced erectile dysfunction.
Erythema
Erythema Nodosum-like Septal Panniculitis Secondary to Lenalidomide Therapy in a Patient With Janus Kinase 2-Positive Myelofibrosis.
Erythema
Unilateral and segmental distribution of facial erythema: is it a real port-wine stain?
Escherichia coli Infections
Src kinase inhibition with dasatinib impairs neutrophil function and clearance of Escherichia coli infection in a murine model of acute lung injury.
Esophageal Achalasia
c-Abl regulates gastrointestinal muscularis propria homeostasis via ERKs.
Esophageal Neoplasms
Connective tissue growth factor gene expression alters tumor progression in esophageal cancer.
Esophageal Neoplasms
Critical role for the receptor tyrosine kinase EPHB4 in esophageal cancers.
Esophageal Neoplasms
Integrative genomic analyses of WNT11: transcriptional mechanisms based on canonical WNT signals and GATA transcription factors signaling.
Esophageal Neoplasms
miR-1 suppresses the proliferation and promotes the apoptosis of esophageal carcinoma cells by targeting Src.
Esophageal Squamous Cell Carcinoma
Activation of Src tyrosine kinase in esophageal carcinoma cells in different regulatory environments and corresponding occurrence mechanism.
Esophageal Squamous Cell Carcinoma
Carbon Ion Therapy Inhibits Esophageal Squamous Cell Carcinoma Metastasis by Upregulating STAT3 Through the JAK2/STAT3 Signaling Pathway.
Esophageal Squamous Cell Carcinoma
Chrysin serves as a novel inhibitor of DGK?/FAK interaction to suppress the malignancy of esophageal squamous cell carcinoma (ESCC).
Esophageal Squamous Cell Carcinoma
Cirsiliol targets tyrosine kinase 2 to inhibit esophageal squamous cell carcinoma growth in vitro and in vivo.
Esophageal Squamous Cell Carcinoma
Concordant Promoter Methylation of Transforming Growth Factor-Beta Receptor Types I and II Occurs Early in Esophageal Squamous Cell Carcinoma.
Esophageal Squamous Cell Carcinoma
Down-regulation of EphB4 phosphorylation is necessary for esophageal squamous cell carcinoma tumorigenecity.
Esophageal Squamous Cell Carcinoma
Downregulated expression of PTK6 is correlated with poor survival in esophageal squamous cell carcinoma.
Esophageal Squamous Cell Carcinoma
Expression and prognostic significance of EFNB2 and EphB4 genes in patients with oesophageal squamous cell carcinoma.
Esophageal Squamous Cell Carcinoma
Expression levels of EPHB4, EFNB2 and caspase-8 are associated with clinicopathological features and progression of esophageal squamous cell cancer.
Esophageal Squamous Cell Carcinoma
Expression of putative tumor suppressor gene spleen tyrosine kinase in esophageal squamous cell carcinoma.
Esophageal Squamous Cell Carcinoma
Expression of Wnt11 and Rock2 in esophageal squamous cell carcinoma by activation of the WNT/PCP pathway and its clinical significance.
Esophageal Squamous Cell Carcinoma
Expression of Wnt11 and Rock2 protein with clinical characteristics of esophageal squamous cell carcinoma in Kazakh and Han patients.
Esophageal Squamous Cell Carcinoma
Focal adhesion kinase (FAK) inhibitor-defactinib suppresses the malignant progression of human esophageal squamous cell carcinoma (ESCC) cells via effective blockade of PI3K/AKT axis and downstream molecular network.
Esophageal Squamous Cell Carcinoma
Glucose Drives Growth Factor-Independent Esophageal Cancer Proliferation via Phosphohistidine-Focal Adhesion Kinase Signaling.
Esophageal Squamous Cell Carcinoma
Identification of spleen tyrosine kinase as a potential therapeutic target for esophageal squamous cell carcinoma using reverse phase protein arrays.
Esophageal Squamous Cell Carcinoma
Inhibition of cell growth and upregulation of MAD2 in human oesophageal squamous cell carcinoma after treatment with the SRC/ABL inhibitor dasatinib.
Esophageal Squamous Cell Carcinoma
Janus kinase 2 inhibition by Licochalcone B suppresses esophageal squamous cell carcinoma growth.
Esophageal Squamous Cell Carcinoma
Serum spleen tyrosine kinase and vascular endothelial growth factor-C levels predict lymph node metastasis of oesophageal squamous cell carcinoma.
Esophageal Squamous Cell Carcinoma
[Knockdown of Fez family zinc finger protein 1 antisense ribonucleic acid 1 (FEZF1-AS1) inhibits invasion and migration of esophageal squamous cell carcinoma cells by blocking JAK2/STAT3 pathway].
Essential Hypertension
Protein tyrosine kinase 2beta as a candidate gene for hypertension.
Exanthema
Expression of proto-oncogenes in mouse eggs and preimplantation embryos.
Exanthema
Hyperkeratotic Skin Adverse Events Induced by Anticancer Treatments: A Comprehensive Review.
Exanthema
Janus kinase inhibitor significantly improved rash and muscle strength in juvenile dermatomyositis.
Exanthema
Vascular tumors produced by NIH/3T3 cells transfected with human AIDS Kaposi's sarcoma DNA.
Exostoses, Multiple Hereditary
DNA polymorphism analysis of hereditary multiple exostoses in horses.
Eye Abnormalities
Distinct developmental programs require different levels of Bmp signaling during mouse retinal development.
Fabry Disease
Sixty-nine kilobases of contiguous human genomic sequence containing the alpha-galactosidase A and Bruton's tyrosine kinase loci.
Familial Primary Pulmonary Hypertension
A novel BMPR2 mutation with widely disparate heritable pulmonary arterial hypertension clinical phenotype.
Familial Primary Pulmonary Hypertension
Bone morphogenetic protein (BMP) type II receptor is required for BMP-mediated growth arrest and differentiation in pulmonary artery smooth muscle cells.
Familial Primary Pulmonary Hypertension
Bone morphogenetic protein receptor type II C-terminus interacts with c-Src: implication for a role in pulmonary arterial hypertension.
Familial Primary Pulmonary Hypertension
Bone morphogenetic protein receptor type II deficiency and increased inflammatory cytokine production. A gateway to pulmonary arterial hypertension.
Familial Primary Pulmonary Hypertension
Characteristics of pulmonary arterial hypertension in affected carriers of a mutation located in the cytoplasmic tail of BMPRII.
Familial Primary Pulmonary Hypertension
Genetics of pulmonary hypertension: from bench to bedside.
Familial Primary Pulmonary Hypertension
Novel insertional mutation in the bone morphogenetic protein receptor type II associated with sporadic primary pulmonary hypertension.
Familial Primary Pulmonary Hypertension
Plasma levels of apelin are reduced in patients with liver fibrosis and cirrhosis but are not correlated with circulating levels of bone morphogenetic protein 9 and 10.
Familial Primary Pulmonary Hypertension
Primary pulmonary hypertension after amfepramone (diethylpropion) with BMPR2 mutation.
Familial Primary Pulmonary Hypertension
Sex Differences in Pulmonary Hypertension.
Familial Primary Pulmonary Hypertension
[Pulmonary arterial hypertension and BMP system abnormality]
Fasciculation
Genetic analysis of the role of Eph receptors in the development of the mammalian nervous system.
Fasciitis
Janus kinase inhibitor tofacitinib is a potential therapeutic option for refractory eosinophilic fasciitis.
Fasciitis
Treatment of generalized deep morphea and eosinophilic fasciitis with the Janus kinase inhibitor tofacitinib.
Fatty Liver
CircScd1 Promotes Fatty Liver Disease via the Janus Kinase 2/Signal Transducer and Activator of Transcription 5 Pathway.
Fatty Liver
Hepatocyte-specific deletion of Janus kinase 2 (JAK2) protects against diet-induced steatohepatitis and glucose intolerance.
Fatty Liver
Hepatocyte-Specific Disruption of CD36 Attenuates Fatty Liver and Improves Insulin Sensitivity in HFD-Fed Mice.
Fatty Liver
MiR-130a-3p attenuates activation and induces apoptosis of hepatic stellate cells in nonalcoholic fibrosing steatohepatitis by directly targeting TGFBR1 and TGFBR2.
Fatty Liver
SYK-3BP2 Pathway Activity in Parenchymal and Myeloid Cells Is a Key Pathogenic Factor in Metabolic Steatohepatitis.
Fatty Liver
Therapeutic inhibition of spleen tyrosine kinase in inflammatory macrophages using PLGA nanoparticles for the treatment of non-alcoholic steatohepatitis.
Fatty Liver
[Effects of puerarin on expressions of leptin receptor mRNA, phosphorylated Janus kinase 2/phosphorylated signal transducers and activators of transcription 3 proteins in the liver of rats with non-alcoholic fatty liver]
Fetal Alcohol Spectrum Disorders
Effect of pre- and postnatal ethanol exposure on protein tyrosine kinase activity and its endogenous substrates in rat cerebral cortex.
Fibroadenoma
Constitutive activation of breast tumor kinase accelerates cell migration and tumor growth in vivo.
Fibroadenoma
Mullerian inhibiting substance inhibits breast cancer cell growth through an NFkappa B-mediated pathway.
Fibromatosis, Aggressive
Signal transduction pathway analysis in fibromatosis: receptor and nonreceptor tyrosine kinases.
Fibrosarcoma
A conformationally sensitive GHR [growth hormone (GH) receptor] antibody: impact on GH signaling and GHR proteolysis.
Fibrosarcoma
Activation of the protein tyrosine phosphatase SHP2 via the interleukin-6 signal transducing receptor protein gp130 requires tyrosine kinase Jak1 and limits acute-phase protein expression.
Fibrosarcoma
Alopecia in patients treated with molecularly targeted anticancer therapies.
Fibrosarcoma
Alpinia officinarum Stimulates Osteoblast Mineralization and Inhibits Osteoclast Differentiation.
Fibrosarcoma
Continuous requirement for pp60-Src and phospho-paxillin during fibronectin matrix assembly by transformed cells.
Fibrosarcoma
Down-regulation of collagen XII in transformed mesenchymal cells.
Fibrosarcoma
EPHB4 tyrosine-kinase receptor expression and biological significance in soft tissue sarcoma.
Fibrosarcoma
Focal adhesion kinase is activated in invading fibrosarcoma cells and regulates metastasis.
Fibrosarcoma
Focal adhesion kinase regulates syndecan-2-mediated tumorigenic activity of HT1080 fibrosarcoma cells.
Fibrosarcoma
Interferon gamma activation of Raf-1 is Jak1-dependent and p21ras-independent.
Fibrosarcoma
Janus kinase 2 enhances the stability of the mature growth hormone receptor.
Fibrosarcoma
Karyotype analysis of the acute fibrosarcoma from chickens infected with subgroup J avian leukosis virus associated with v-src oncogene.
Fibrosarcoma
Lamivudine Inhibits the Replication of ALV-J Associated Acutely Transforming Virus and its Helper Virus and Tumor Growth In vitro and In vivo.
Fibrosarcoma
LIM kinase-2 targeting as a possible anti-metastasis therapy.
Fibrosarcoma
Localization of viral transforming sequences within marker chromosomes associated with tumor formation and progression in a murine fibrosarcoma.
Fibrosarcoma
Nucleic acid sequence and oncogenic properties of the HZ2 feline sarcoma virus v-abl insert.
Fibrosarcoma
Rescue of avian leukosis subgroup-J-associated acutely transforming viruses carrying different lengths of the v-fps oncogene and analysis of their tumorigenicity.
Fibrosarcoma
Stimulation of mouse osteopontin promoter by v-Src is mediated by a CCAAT box-binding factor.
Fibrosarcoma
Suppression in transformed avian fibroblasts of a gene (crp) encoding a cysteine-rich protein containing LIM domains.
Fibrosarcoma
Syndecan-1 suppresses cell growth and migration via blocking JAK1/STAT3 and Ras/Raf/MEK/ERK pathways in human colorectal carcinoma cells.
Fibrosarcoma
Taishan Pinus Massoniana pollen polysaccharide inhibits the replication of acute tumorigenic ALV-J and its associated tumor growth.
Food Hypersensitivity
Remission of food allergy by the Janus kinase inhibitor ruxolitinib in mice.
Food Hypersensitivity
TGF? receptor mutations impose a strong predisposition for human allergic disease.
Foot Ulcer
Effect and Mechanism of the Bruton Tyrosine Kinase (Btk) Inhibitor Ibrutinib on Rat Model of Diabetic Foot Ulcers.
Foot-and-Mouth Disease
Foot-and-mouth disease virus structural protein VP3 degrades Janus kinase 1 to inhibit IFN-? signal transduction pathways.
Fragile X Syndrome
Augmented noncanonical BMP type II receptor signaling mediates the synaptic abnormality of fragile X syndrome.
Fragile X Syndrome
JAKMIP1, a Novel Regulator of Neuronal Translation, Modulates Synaptic Function and Autistic-like Behaviors in Mouse.
Frontotemporal Lobar Degeneration
PTK2/FAK regulates UPS impairment via SQSTM1/p62 phosphorylation in TARDBP/TDP-43 proteinopathies.
Gallbladder Neoplasms
JAK2 tyrosine kinase inhibitor AG490 suppresses cell growth and invasion of gallbladder cancer cells via inhibition of JAK2/STAT3 signaling.
Gallbladder Neoplasms
The Novel Selective Pan-TRK Inhibitor ONO-7579 Exhibits Antitumor Efficacy Against Human Gallbladder Cancer
Gastritis
Antral atrophy, intestinal metaplasia, and preneoplastic markers in Mexican children with Helicobacter pylori-positive and Helicobacter pylori-negative gastritis.
Gastritis
Helicobacter pylori-controlled c-Abl localization promotes cell migration and limits apoptosis.
Gastroenteritis
Eosinophilic gastroenteritis in a patient with Bruton's tyrosine kinase deficiency.
Gastroesophageal Reflux
Helicobacter pylori infection and lung cancer: a review of an emerging hypothesis.
Gastroesophageal Reflux
Proinflammatory cytokines and bile acids upregulate ?Np73 protein, an inhibitor of p53 and p73 tumor suppressors.
Gastrointestinal Diseases
TGF? receptor mutations impose a strong predisposition for human allergic disease.
Gastrointestinal Neoplasms
A novel germline BMPR1A variant (c.72_73delGA) in a Japanese family with hereditary mixed polyposis syndrome.
Gastrointestinal Neoplasms
Disruption of transforming growth factor-beta signaling through beta-spectrin ELF leads to hepatocellular cancer through cyclin D1 activation.
Gastrointestinal Neoplasms
Molecular dimensions of gastrointestinal tumors: some thoughts for digestion.
Gastrointestinal Neoplasms
Molecular mutation characteristics of mismatch and homologous recombination repair genes in gastrointestinal cancer.
Gastrointestinal Neoplasms
Phenotypic Differences in Juvenile Polyposis Syndrome With or Without a Disease-causing SMAD4/BMPR1A Variant.
Gastrointestinal Neoplasms
Translational Research in Pancreatic Cancer. Highlights from the "2011 ASCO Gastrointestinal Cancers Symposium". San Francisco, CA, USA. January 20-22, 2011.
Gastrointestinal Neoplasms
[Damage to the transforming growth factor TGF-beta type II receptor gene and microsatellite instability in carcinoma cells of the gastrointestinal tract]
Gastrointestinal Stromal Tumors
A benefit-risk assessment of imatinib in chronic myeloid leukaemia and gastrointestinal stromal tumours.
Gastrointestinal Stromal Tumors
A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient.
Gastrointestinal Stromal Tumors
An anticancer C-Kit kinase inhibitor is reengineered to make it more active and less cardiotoxic.
Gastrointestinal Stromal Tumors
Basic science going clinical: molecularly targeted therapy of chronic myelogenous leukemia.
Gastrointestinal Stromal Tumors
C-kit expression in pediatric solid tumors: a comparative immunohistochemical study.
Gastrointestinal Stromal Tumors
Detection of resistance to imatinib by metabolic profiling: clinical and drug development implications.
Gastrointestinal Stromal Tumors
Differential effects of ketoconazole and primaquine on the pharmacokinetics and tissue distribution of imatinib in mice.
Gastrointestinal Stromal Tumors
Discovery of a small molecule type II inhibitor of wild-type and gatekeeper mutants of BCR-ABL, PDGFR{alpha}, Kit, and Src kinases.
Gastrointestinal Stromal Tumors
Effect of St John's wort on imatinib mesylate pharmacokinetics.
Gastrointestinal Stromal Tumors
FMS receptor for M-CSF (CSF-1) is sensitive to the kinase inhibitor imatinib and mutation of Asp-802 to Val confers resistance.
Gastrointestinal Stromal Tumors
Imatinib as a novel antifibrotic agent in bleomycin-induced pulmonary fibrosis in mice.
Gastrointestinal Stromal Tumors
Imatinib mesylate (gleevec; STI571) monotherapy is ineffective in suppressing human anaplastic thyroid carcinoma cell growth in vitro.
Gastrointestinal Stromal Tumors
Imatinib mesylate enhances the malignant behavior of human breast carcinoma cells.
Gastrointestinal Stromal Tumors
Imatinib mesylate radiosensitizes human glioblastoma cells through inhibition of platelet-derived growth factor receptor.
Gastrointestinal Stromal Tumors
Imatinib-induced hyperbilirubinemia with UGT1A1 (*28) promoter polymorphism: first case series in patients with gastrointestinal stromal tumor.
Gastrointestinal Stromal Tumors
Imatinib: as adjuvant therapy for gastrointestinal stromal tumour.
Gastrointestinal Stromal Tumors
Impact of Chromosomal Rearrangement upon DNA Methylation Patterns in Leukemia.
Gastrointestinal Stromal Tumors
In vivo imaging of bcr-abl overexpressing tumors with a radiolabeled imatinib analog as an imaging surrogate for imatinib.
Gastrointestinal Stromal Tumors
Inhibition of focal adhesion kinase as a potential therapeutic strategy for imatinib-resistant gastrointestinal stromal tumor.
Gastrointestinal Stromal Tumors
Involvement of focal adhesion kinase in the progression and prognosis of gastrointestinal stromal tumors.
Gastrointestinal Stromal Tumors
Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinib.
Gastrointestinal Stromal Tumors
Molecular dimensions of gastrointestinal tumors: some thoughts for digestion.
Gastrointestinal Stromal Tumors
Molecular interactions in imatinib-DPPC liposomes.
Gastrointestinal Stromal Tumors
Molecular targeted therapy of gastrointestinal stromal tumors.
Gastrointestinal Stromal Tumors
Molecularly targeted therapy for gastrointestinal cancer.
Gastrointestinal Stromal Tumors
Multicentric sporadic gastrointestinal stromal tumors (GISTs) of the stomach with distinct clonal origin: differential diagnosis to familial and syndromal GIST variants and peritoneal metastasis.
Gastrointestinal Stromal Tumors
Persistent cutaneous hyperpigmentation after tyrosine kinase inhibition with imatinib for GIST.
Gastrointestinal Stromal Tumors
Pityriasis rosea-like Drug Eruption Induced by Imatinib Mesylate (Gleevec).
Gastrointestinal Stromal Tumors
Possible Role of Interleukin-31/33 Axis in Imatinib Mesylate-Associated Skin Toxicity.
Gastrointestinal Stromal Tumors
Pulmonary toxicities of tyrosine kinase inhibitors.
Gastrointestinal Stromal Tumors
Rational therapeutic intervention in cancer: kinases as drug targets.
Gastrointestinal Stromal Tumors
Reactivation of chronic hepatitis B infection related to imatinib mesylate therapy.
Gastrointestinal Stromal Tumors
Reduced exposure of imatinib after coadministration with acetaminophen in mice.
Gastrointestinal Stromal Tumors
Report of the fifteenth international symposium of the foundation for promotion of cancer research: new horizons in the diagnosis and treatment of hematological malignancies based on molecular genetic features.
Gastrointestinal Stromal Tumors
Rhabdomyosarcomatous differentiation in gastrointestinal stromal tumors after imatinib resistance: a potential diagnostic pitfall.
Gastrointestinal Stromal Tumors
Role of protein tyrosine kinase inhibitors in cancer therapeutics.
Gastrointestinal Stromal Tumors
STI571 (Glivec) induces cell death in the gastrointestinal stromal tumor cell line, GIST-T1, via endoplasmic reticulum stress response.
Gastrointestinal Stromal Tumors
Successful rechallenge with imatinib in a patient with chronic myeloid leukemia who previously experienced imatinib mesylate induced pneumonitis.
Gastrointestinal Stromal Tumors
Surgery and imatinib in the management of GIST: emerging approaches to adjuvant and neoadjuvant therapy.
Gastrointestinal Stromal Tumors
T670X KIT mutations in gastrointestinal stromal tumors: making sense of missense.
Gastrointestinal Stromal Tumors
Targeting PDGF receptors in cancer--rationales and proof of concept clinical trials.
Gastrointestinal Stromal Tumors
The c-kit tyrosine kinase inhibitor STI571 for colorectal cancer therapy.
Gastrointestinal Stromal Tumors
The development and application of imatinib.
Gastrointestinal Stromal Tumors
The safety profile of imatinib in CML and GIST: long-term considerations.
Gastrointestinal Stromal Tumors
Tyrosine kinase inhibitor imatinib mesylate as anticancer agent for advanced ocular melanoma expressing immunoistochemical C-KIT (CD 117): preliminary results of a compassionate use clinical trial.
Gastrointestinal Stromal Tumors
Tyrosine Kinase Inhibitors for the Treatment of Chronic Myeloid Leukemia.
Gastrointestinal Stromal Tumors
[Imatinib--a new perspective in the treatment of tumors]
Gaucher Disease
An unusual case of T-cell acute lymphoblastic leukemia in a patient with BCR-ABL positive chronic myeloid leukemia and Gaucher disease.
Gaucher Disease
c-Abl activates RIPK3 signaling in Gaucher disease.
gelatinase b deficiency
Hes1 promotes blast crisis in chronic myelogenous leukemia through MMP-9 upregulation in leukemic cells.
Genetic Diseases, Inborn
A novel Bruton's tyrosine kinase gene (BTK) invariant splice site mutation in a Malaysian family with X-linked agammaglobulinemia.
Genetic Diseases, Inborn
Effects of FKBP12 and type II BMP receptors on signal transduction by ALK2 activating mutations associated with genetic disorders.
Genetic Diseases, Inborn
Presentation of a case of Bruton type primary agammaglobulinemia in Guinea.
Gestational Trophoblastic Disease
Expression of TGF-beta signaling proteins in normal placenta and gestational trophoblastic disease.
Glaucoma
Discovery and Development of LX7101, a Dual LIM-Kinase and ROCK Inhibitor for the Treatment of Glaucoma.
Glaucoma
Modeling of LIM-Kinase 2 Inhibitory Activity of Pyrrolopyrimidine Analogues: Useful in Treatment of Ocular Hypertension and Glaucoma.
Glaucoma
Novel Class of LIM-Kinase 2 Inhibitors for the Treatment of Ocular Hypertension and Associated Glaucoma.
Glioblastoma
A novel low-molecular weight inhibitor of focal adhesion kinase, TAE226, inhibits glioma growth.
Glioblastoma
A Study of the Focal Adhesion Kinase Inhibitor GSK2256098 in Patients with Recurrent Glioblastoma with Evaluation of Tumor Penetration of [11C]GSK2256098.
Glioblastoma
Activation and translocation of c-Src to the cytoskeleton by both platelet-derived growth factor and epidermal growth factor.
Glioblastoma
Alphavbeta3/alphavbeta5 integrins-FAK-RhoB: a novel pathway for hypoxia regulation in glioblastoma.
Glioblastoma
Analysis of the c-src gene product structure, abundance, and protein kinase activity in human neuroblastoma and glioblastoma cells.
Glioblastoma
ARHGAP21 modulates FAK activity and impairs glioblastoma cell migration.
Glioblastoma
Autophagy inhibition by TSSC4 (tumor suppressing subtransferable candidate 4) contributes to sustainable cancer cell growth.
Glioblastoma
Cloning and biochemical characterization of LIMK-2, a protein kinase containing two LIM domains.
Glioblastoma
Constitutive phosphorylation of Janus kinase 2 in the GL15 glioblastoma derived human cell line.
Glioblastoma
Danthron inhibits the migration and invasion of human brain glioblastoma multiforme cells through the inhibition of mRNA expression of focal adhesion kinase, Rho kinases-1 and metalloproteinase-9.
Glioblastoma
Design, Synthesis, and Biological Evaluation of Covalent Inhibitors of Focal Adhesion Kinase (FAK) against Human Malignant Glioblastoma.
Glioblastoma
Differential effects of ketoconazole and primaquine on the pharmacokinetics and tissue distribution of imatinib in mice.
Glioblastoma
Differential role of proline-rich tyrosine kinase 2 and focal adhesion kinase in determining glioblastoma migration and proliferation.
Glioblastoma
Downregulation of Focal Adhesion Kinase (FAK) by cord blood stem cells inhibits angiogenesis in glioblastoma.
Glioblastoma
Downregulation of microRNA-431 by human interferon-? inhibits viability of medulloblastoma and glioblastoma cells via upregulation of SOCS6.
Glioblastoma
Dual-Modality Micro-Positron Emission Tomography/Computed Tomography and Near-Infrared Fluorescence Imaging of EphB4 in Orthotopic Glioblastoma Xenograft Models.
Glioblastoma
EphB2 receptor controls proliferation/migration dichotomy of glioblastoma by interacting with focal adhesion kinase.
Glioblastoma
Expression and functional roles of Smad1 and BMPR-IB in glioma development.
Glioblastoma
Expression of EphrinB2 and EphB4 in glioma tissues correlated to the progression of glioma and the prognosis of glioblastoma patients.
Glioblastoma
FAK signaling in anaplastic astrocytoma and glioblastoma tumors.
Glioblastoma
Geldanamycin inhibits migration of glioma cells in vitro: a potential role for hypoxia-inducible factor (HIF-1alpha) in glioma cell invasion.
Glioblastoma
Girdin, an actin-binding protein, is critical for migration, adhesion, and invasion of human glioblastoma cells.
Glioblastoma
Gliomatosis cerebri: no evidence for a separate brain tumor entity.
Glioblastoma
Glycogen Synthase Kinase 3? Sustains Invasion of Glioblastoma via the Focal Adhesion Kinase, Rac1, and c-Jun N-Terminal Kinase-Mediated Pathway.
Glioblastoma
HEF1 is a necessary and specific downstream effector of FAK that promotes the migration of glioblastoma cells.
Glioblastoma
Ibrutinib, a Bruton's tyrosine kinase inhibitor, exhibits antitumoral activity and induces autophagy in glioblastoma.
Glioblastoma
Identification of imidazo[4,5-c]pyridin-2-one derivatives as novel Src family kinase inhibitors against glioblastoma.
Glioblastoma
Identification of new pyrrolo[2,3-d]pyrimidines as Src tyrosine kinase inhibitors in vitro active against Glioblastoma.
Glioblastoma
Imatinib and Nilotinib increase glioblastoma cell invasion via Abl-independent stimulation of p130Cas and FAK signalling.
Glioblastoma
Imatinib reverses doxorubicin resistance by affecting activation of STAT3-dependent NF-?B and HSP27/p38/AKT pathways and by inhibiting ABCB1.
Glioblastoma
Immunohistochemical Analysis of Platelet-derived Growth Factor Receptor-alpha, -beta, c-kit, c-abl, and Arg Proteins in Glioblastoma: Possible Implications for Patient Selection for Imatinib Mesylate Therapy.
Glioblastoma
In situ analysis of integrin and growth factor receptor signaling pathways in human glioblastomas suggests overlapping relationships with focal adhesion kinase activation.
Glioblastoma
Inhibition of migration of human glioblastoma cells by cerivastatin in association with focal adhesion kinase (FAK).
Glioblastoma
Inhibition of the JAK-2/STAT3 signaling pathway impedes the migratory and invasive potential of human glioblastoma cells.
Glioblastoma
Integrin ?v?3 Engagement Regulates Glucose Metabolism and Migration through Focal Adhesion Kinase (FAK) and Protein Arginine Methyltransferase 5 (PRMT5) in Glioblastoma Cells.
Glioblastoma
L-Thyroxine vs. 3,5,3'-triiodo-L-thyronine and cell proliferation: activation of mitogen-activated protein kinase and phosphatidylinositol 3-kinase.
Glioblastoma
LKB1 deficiency promotes proliferation and invasion of glioblastoma through activation of mTOR and focal adhesion kinase signaling pathways.
Glioblastoma
Loss of focal adhesion kinase (FAK) inhibits epidermal growth factor receptor-dependent migration and induces aggregation of nh(2)-terminal FAK in the nuclei of apoptotic glioblastoma cells.
Glioblastoma
Lyn kinase activity is the predominant cellular SRC kinase activity in glioblastoma tumor cells.
Glioblastoma
Microglia-derived TGF-beta as an important regulator of glioblastoma invasion--an inhibition of TGF-beta-dependent effects by shRNA against human TGF-beta type II receptor.
Glioblastoma
MicroRNA-7 regulates glioblastoma cell invasion via targeting focal adhesion kinase expression.
Glioblastoma
Molecular genetics of human glioma.
Glioblastoma
Nonreceptor tyrosine kinase BMX maintains self-renewal and tumorigenic potential of glioblastoma stem cells by activating STAT3.
Glioblastoma
NVP-BEZ235 or JAKi Treatment leads to decreased survival of examined GBM and BBC cells.
Glioblastoma
Over-expression of BMPR-IB reduces the malignancy of glioblastoma cells by upregulation of p21 and p27Kip1.
Glioblastoma
p27Kip1 and cyclin D1 are necessary for focal adhesion kinase regulation of cell cycle progression in glioblastoma cells propagated in vitro and in vivo in the scid mouse brain.
Glioblastoma
Pathway alterations during glioma progression revealed by reverse phase protein lysate arrays.
Glioblastoma
PDCD10-Deficiency Promotes Malignant Behaviors and Tumor Growth via Triggering EphB4 Kinase Activity in Glioblastoma.
Glioblastoma
PHIP drives glioblastoma motility and invasion by regulating the focal adhesion complex.
Glioblastoma
Phosphorylation of dedicator of cytokinesis 1 (Dock180) at tyrosine residue Y722 by Src family kinases mediates EGFRvIII-driven glioblastoma tumorigenesis.
Glioblastoma
Polyphenolic Compounds of Crataegus Berry, Leaf, and Flower Extracts Affect Viability and Invasive Potential of Human Glioblastoma Cells.
Glioblastoma
Proton Therapy and Src Family Kinase Inhibitor Combined Treatments on U87 Human Glioblastoma Multiforme Cell Line.
Glioblastoma
PTEN suppresses hyaluronic acid-induced matrix metalloproteinase-9 expression in U87MG glioblastoma cells through focal adhesion kinase dephosphorylation.
Glioblastoma
PTEN-independent induction of caspase-mediated cell death and reduced invasion by the focal adhesion targeting domain (FAT) in human astrocytic brain tumors which highly express focal adhesion kinase (FAK).
Glioblastoma
Pyrazolo[3,4-d]pyrimidine Tyrosine Kinase Inhibitors Induce Oxidative Stress in Patient-Derived Glioblastoma Cells.
Glioblastoma
Rapamycin inhibits F-actin reorganization and phosphorylation of focal adhesion proteins.
Glioblastoma
Reciprocal regulation of Abl and receptor tyrosine kinases.
Glioblastoma
Reciprocal regulation of Abl kinase by Crk Y251 and Abi1 controls invasive phenotypes in glioblastoma.
Glioblastoma
Rosmarinic acid inhibits cell proliferation, migration, and invasion and induces apoptosis in human glioma cells.
Glioblastoma
Silencing microRNA-221/222 cluster suppresses glioblastoma angiogenesis by suppressor of cytokine signaling-3-dependent JAK/STAT pathway.
Glioblastoma
Small-molecule inhibitors of FGFR, integrins and FAK selectively decrease L1CAM-stimulated glioblastoma cell motility and proliferation.
Glioblastoma
Specific Expression of a New Bruton Tyrosine Kinase Isoform (p65BTK) in the Glioblastoma Gemistocytic Histotype.
Glioblastoma
SRC Family Kinase Inhibition Through a New Pyrazolo[3,4-d]Pyrimidine Derivative as a Feasible Approach for Glioblastoma Treatment.
Glioblastoma
Src Inhibitors Pyrazolo[3,4-d]pyrimidines, Si306 and Pro-Si306, Inhibit Focal Adhesion Kinase and Suppress Human Glioblastoma Invasion In Vitro and In Vivo.
Glioblastoma
SRC Kinase in Glioblastoma News from an Old Acquaintance.
Glioblastoma
SRC Tyrosine Kinase Inhibitor and X-rays Combined Effect on Glioblastoma Cell Lines.
Glioblastoma
The nuclear localization of 3'-phosphoinositide-dependent kinase-1 is dependent on its association with the protein tyrosine phosphatase SHP-1.
Glioblastoma
The pattern of enhancement of Src kinase activity on platelet-derived growth factor stimulation of glioblastoma cells is affected by the integrin engaged.
Glioblastoma
The Radiosensitizing Effect of AZD0530 in Glioblastoma and Glioblastoma Stem-Like Cells.
Glioblastoma
The Role of Hypoxia and SRC Tyrosine Kinase in Glioblastoma Invasiveness and Radioresistance.
Glioblastoma
The significance of microRNA-184 on JAK2/STAT3 signaling pathway in the formation mechanism of glioblastoma.
Glioblastoma
Therapeutic potential of AZD1480 for the treatment of human glioblastoma.
Glioblastoma
Thymoquinone reduces migration and invasion of human glioblastoma cells associated with FAK, MMP-2 and MMP-9 down-regulation.
Glioblastoma
Up-Regulation of Hsa-miR-11181 in Glioblastoma Multiforme as A Regulator of AKT2 and TGFBR1 Signalling.
Glioma
A novel low-molecular weight inhibitor of focal adhesion kinase, TAE226, inhibits glioma growth.
Glioma
A phase 1 and randomized, placebo-controlled phase 2 trial of bevacizumab plus dasatinib in patients with recurrent glioblastoma: Alliance/North Central Cancer Treatment Group N0872.
Glioma
A role for activated Cdc42 in glioblastoma multiforme invasion.
Glioma
A Short Region of Connexin43 Reduces Human Glioma Stem Cell Migration, Invasion, and Survival through Src, PTEN, and FAK.
Glioma
ABL2/ARG tyrosine kinase mediates SEMA3F-induced RhoA inactivation and cytoskeleton collapse in human glioma cells.
Glioma
Angiopoietin 2 induces glioma cell invasion by stimulating matrix metalloprotease 2 expression through the alphavbeta1 integrin and focal adhesion kinase signaling pathway.
Glioma
Antisense oligonucleodes targeting the focal adhesion kinase inhibit proliferation, induce apoptosis and cooperate with cytotoxic drugs in human glioma cells.
Glioma
Arg kinase mediates CXCL12/CXCR4-induced invadopodia formation and invasion of glioma cells.
Glioma
Bone morphogenetic protein type IB receptor is progressively expressed in malignant glioma tumours.
Glioma
c-Src Phosphorylates and Inhibits the Function of the CIC Tumor Suppressor Protein.
Glioma
Characterization and response of newly developed high-grade glioma cultures to the tyrosine kinase inhibitors, erlotinib, gefitinib and imatinib.
Glioma
Characterization of Tu-2449, a glioma cell line derived from a spontaneous tumor in GFAP-v-src-transgenic mice: comparison with established murine glioma cell lines.
Glioma
CircRNA EPHB4 modulates stem properties and proliferation of gliomas via sponging miR-637 and up-regulating SOX10.
Glioma
Co-expression modules of NF1, PTEN and sprouty enable distinction of adult diffuse gliomas according to pathway activities of receptor tyrosine kinases.
Glioma
Conditional deletion of the focal adhesion kinase FAK alters remodeling of the blood-brain barrier in glioma.
Glioma
Connexin43 recruits PTEN and Csk to inhibit c-Src activity in glioma cells and astrocytes.
Glioma
Differential effect of imatinib and synergism of combination treatment with chemotherapeutic agents in malignant glioma cells.
Glioma
Differential effects of ketoconazole and primaquine on the pharmacokinetics and tissue distribution of imatinib in mice.
Glioma
Effects of FKBP12 and type II BMP receptors on signal transduction by ALK2 activating mutations associated with genetic disorders.
Glioma
Effects of nonselective cation channels and PI3K on endothelin-1-induced PYK2 tyrosine phosphorylation in C6 glioma cells.
Glioma
EGFRvIII-mediated transactivation of receptor tyrosine kinases in glioma: mechanism and therapeutic implications.
Glioma
Emodin suppresses hyaluronic acid-induced MMP-9 secretion and invasion of glioma cells.
Glioma
EphB4 is overexpressed in gliomas and promotes the growth of glioma cells.
Glioma
EphB4 mediates resistance to antiangiogenic therapy in experimental glioma.
Glioma
Expression and functional roles of Smad1 and BMPR-IB in glioma development.
Glioma
Expression of c-src in cultured human neuroblastoma and small-cell lung carcinoma cell lines correlates with neurocrine differentiation.
Glioma
Expression of EphrinB2 and EphB4 in glioma tissues correlated to the progression of glioma and the prognosis of glioblastoma patients.
Glioma
Expression of focal adhesion kinase and phosphorylated focal adhesion kinase in human gliomas is associated with unfavorable overall survival.
Glioma
Expression of tyrosine kinases FAK and Pyk2 in 331 human astrocytomas.
Glioma
Fusicoccin a, a phytotoxic carbotricyclic diterpene glucoside of fungal origin, reduces proliferation and invasion of glioblastoma cells by targeting multiple tyrosine kinases.
Glioma
Ganglioside GD3 Enhances Invasiveness of Gliomas by Forming a Complex with Platelet-derived Growth Factor Receptor ? and Yes Kinase.
Glioma
Geldanamycin induces mitotic catastrophe and subsequent apoptosis in human glioma cells.
Glioma
Gene expression profile of glioblastoma multiforme invasive phenotype points to new therapeutic targets.
Glioma
High expression of Bruton's tyrosine kinase (BTK) is required for EGFR-induced NF-?B activation and predicts poor prognosis in human glioma.
Glioma
Hyaluronate activates tyrosine phosphorylation of cellular proteins including focal adhesion kinase via CD44 in human glioma cells.
Glioma
Induction of cell-cycle arrest and apoptosis in glioblastoma stem-like cells by WP1193, a novel small molecule inhibitor of the JAK2/STAT3 pathway.
Glioma
Induction of proline-rich tyrosine kinase 2 activation-mediated C6 glioma cell invasion after anti-vascular endothelial growth factor therapy.
Glioma
Induction of WNT11 by hypoxia and hypoxia-inducible factor-1? regulates cell proliferation, migration and invasion.
Glioma
Inhibition of both focal adhesion kinase and insulin-like growth factor-I receptor kinase suppresses glioma proliferation in vitro and in vivo.
Glioma
Intratumoral concentrations of imatinib after oral administration in patients with glioblastoma multiforme.
Glioma
L1CAM stimulates glioma cell motility and proliferation through the fibroblast growth factor receptor.
Glioma
Leucine-rich glioma inactivated 3 induces neurite outgrowth through Akt and focal adhesion kinase.
Glioma
Ligand-dependent EphB4 activation serves as an anchoring signal in glioma cells.
Glioma
Mda-9/syntenin Promotes Human Brain Glioma Migration through Focal Adhesion Kinase (FAK)-JNK and FAK-AKT Signaling.
Glioma
Microglia Activate Migration of Glioma Cells through a Pyk2 Intracellular Pathway.
Glioma
Microsatellite instability and mutated type II transforming growth factor-beta receptor gene in gliomas.
Glioma
miR-656 inhibits glioma tumorigenesis through repression of BMPR1A.
Glioma
Mutated focal adhesion kinase induces apoptosis in a human glioma cell line, T98G.
Glioma
Nanofiber-mediated inhibition of focal adhesion kinase sensitizes glioma stemlike cells to epidermal growth factor receptor inhibition.
Glioma
Neurotrophic Receptor Tyrosine Kinase 2 (NTRK2) Alterations in Low-Grade Gliomas: Report of a Novel Gene Fusion Partner in a Pilocytic Astrocytoma and Review of the Literature.
Glioma
Over-expression of tetraspanin 8 in malignant glioma regulates tumor cell progression.
Glioma
Pathway alterations during glioma progression revealed by reverse phase protein lysate arrays.
Glioma
Patupilone (epothilone B, EPO906) and imatinib (STI571, Glivec) in combination display enhanced antitumour activity in vivo against experimental rat C6 glioma.
Glioma
Pharmacologic blockade of FAK autophosphorylation decreases human glioblastoma tumor growth and synergizes with temozolomide.
Glioma
Phase 1 trial of dasatinib plus erlotinib in adults with recurrent malignant glioma.
Glioma
Platelet-derived growth factor-mediated gliomagenesis and brain tumor recruitment.
Glioma
Prevention of irradiation-induced glioma cell invasion by temozolomide involves caspase 3 activity and cleavage of focal adhesion kinase.
Glioma
PTEN gene transfer suppresses the invasive potential of human malignant gliomas by regulating cell invasion-related molecules.
Glioma
PTEN regulates tumor cell adhesion of colon carcinoma cells under dynamic conditions of fluid flow.
Glioma
Pyr3 Induces Apoptosis and Inhibits Migration in Human Glioblastoma Cells.
Glioma
Repression of Fyn-related kinase in breast cancer cells is associated with promoter site-specific CpG methylation.
Glioma
RNA interference-mediated silencing of focal adhesion kinase inhibits growth of human malignant glioma xenograft in nude mice.
Glioma
Safety and pharmacokinetics of dose-intensive imatinib mesylate plus temozolomide: phase 1 trial in adults with malignant glioma.
Glioma
Serine protease inhibitor (SERPIN) B1 suppresses cell migration and invasion in glioma cells.
Glioma
Specific Expression of a New Bruton Tyrosine Kinase Isoform (p65BTK) in the Glioblastoma Gemistocytic Histotype.
Glioma
Specific inhibition of SRC kinase impairs malignant glioma growth in vitro and in vivo.
Glioma
Store-operated Ca 2+ entry regulates glioma cell migration and invasion via modulation of Pyk2 phosphorylation.
Glioma
Targeting neuronal activity-regulated neuroligin-3 dependency in high-grade glioma.
Glioma
Tenascin-C promotes microvascular cell migration and phosphorylation of focal adhesion kinase.
Glioma
The Effect of Chemoradiotherapy with SRC Tyrosine Kinase Inhibitor, PP2 and Temozolomide on Malignant Glioma Cells In Vitro and In Vivo.
Glioma
The effect of epidermal growth factor receptor variant III on glioma cell migration by stimulating ERK phosphorylation through the focal adhesion kinase signaling pathway.
Glioma
The inflammatory cytokine IL-22 promotes murine gliomas via proliferation.
Glioma
The protein phosphatase activity of PTEN regulates SRC family kinases and controls glioma migration.
Glioma
The tyrosine kinase pyk2 promotes migration and invasion of glioma cells.
Glioma
Tumor necrosis factor-like weak inducer of apoptosis (TWEAK) promotes glioblastoma cell chemotaxis via Lyn activation.
Glioma
Tyrosine 311 is phosphorylated by c-Abl and promotes the apoptotic effect of PKCdelta in glioma cells.
Glioma
Up-Regulation of Hsa-miR-11181 in Glioblastoma Multiforme as A Regulator of AKT2 and TGFBR1 Signalling.
Glomerulonephritis
A spleen tyrosine kinase inhibitor reduces the severity of established glomerulonephritis.
Glomerulonephritis
An inhibitor of spleen tyrosine kinase suppresses experimental crescentic glomerulonephritis.
Glomerulonephritis
Correlation of disease activity in proliferative glomerulonephritis with glomerular spleen tyrosine kinase expression.
Glomerulonephritis
Cutting Edge: Deletion of Ezrin in B Cells of Lyn-Deficient Mice Downregulates Lupus Pathology.
Glomerulonephritis
Gene transfer and kidney disease.
Glomerulonephritis
Increased expression of cell adhesion kinase beta in human and rat crescentic glomerulonephritis.
Glomerulonephritis
Myeloid cell-mediated renal injury in rapidly progressive glomerulonephritis depends upon spleen tyrosine kinase.
Glomerulonephritis
Suppression of Glomerulonephritis in Lupus-Prone NZB × NZW Mice by RN486, a Selective Inhibitor of Bruton's Tyrosine Kinase.
Glomerulonephritis
TGF-beta type II receptor deficiency prevents renal injury via decrease in ERK activity in crescentic glomerulonephritis.
Glomerulonephritis
Therapeutic Blockade of Immune Complex-Mediated Glomerulonephritis by Highly Selective Inhibition of Bruton's Tyrosine Kinase.
Glomerulonephritis, IGA
Enhanced Bruton's tyrosine kinase activity in the kidney of patients with IgA nephropathy.
Glomerulonephritis, IGA
Fostamatinib: First Global Approval.
Glomerulonephritis, IGA
JAK-STAT Activity in Peripheral Blood Cells and Kidney Tissue in IgA Nephropathy.
Glomerulonephritis, IGA
Role of the Spleen Tyrosine Kinase Pathway in Driving Inflammation in IgA Nephropathy.
Glomerulonephritis, IGA
Spleen Tyrosine Kinase Inhibition Ameliorates Tubular Inflammation in IgA Nephropathy.
Glomerulonephritis, IGA
Spleen Tyrosine Kinase Is Important in the Production of Proinflammatory Cytokines and Cell Proliferation in Human Mesangial Cells following Stimulation with IgA1 Isolated from IgA Nephropathy Patients.
Glomerulonephritis, Membranous
Crk1/2-dependent signaling is necessary for podocyte foot process spreading in mouse models of glomerular disease.
Glomerulosclerosis, Focal Segmental
Crk1/2-dependent signaling is necessary for podocyte foot process spreading in mouse models of glomerular disease.
Glomerulosclerosis, Focal Segmental
Janus kinase 2/signal transducer and activator of transcription 3 inhibitors attenuate the effect of cardiotrophin-like cytokine factor 1 and human focal segmental glomerulosclerosis serum on glomerular filtration barrier.
Glucose Intolerance
Absence of Shb impairs insulin secretion by elevated FAK activity in pancreatic islets.
Glucose Intolerance
Adipocyte-Specific Deletion of Janus Kinase 2 (JAK2) Leads to Increased Adiposity and Age-Related Glucose Intolerance.
Glucose Intolerance
Hepatocyte-specific deletion of Janus kinase 2 (JAK2) protects against diet-induced steatohepatitis and glucose intolerance.
Glucose Metabolism Disorders
[Relationship between glucose metabolic disorders and expression of insulin receptor in posthepatitic cirrhosis hepatocyte and HBV DNA in pancreatic cells]
Glycogen Storage Disease Type VI
A Philadelphia chromosome positive acute lymphoblastic leukemia of donor origin after allogeneic bone marrow transplantation for chronic myelogenous leukemia in chronic phase.
Glycogen Storage Disease Type VI
Heterogenous expression of bcr-abl fusion mRNA in a patient with Philadelphia-chromosome-positive acute lymphoblastic leukaemia.
Goiter
Clinical utility of TGFB1 and its receptors (TGFBR1 and TGFBR2) in thyroid nodules: evaluation based on single nucleotide polymorphisms and mRNA analysis.
Graft vs Host Disease
Association with the presence of naive T cells in chronic myeloid leukemia patients after allogeneic human stem cell transplantation and the lower incidence of chronic graft-versus host disease and relapse.
Graft vs Host Disease
Azole antifungals and new targeted therapies for hematological malignancy.
Graft vs Host Disease
Bruton Tyrosine Kinase Inhibitors: Present and Future.
Graft vs Host Disease
Colon and liver tissue damage detection using methylated SESN3 and PTK2B genes in circulating cell-free DNA in patients with acute graft-versus-host disease.
Graft vs Host Disease
Combined Inhibition of c-Abl and PDGF Receptors for Prevention and Treatment of Murine Sclerodermatous Chronic Graft-versus-Host Disease.
Graft vs Host Disease
Correction: Colon and liver tissue damage detection using methylated SESN3 and PTK2B genes in circulating cell-free DNA in patients with acute graft-versus-host disease.
Graft vs Host Disease
CP-690550, a Janus kinase inhibitor, suppresses CD4+ T-cell-mediated acute graft-versus-host disease by inhibiting the interferon-? pathway.
Graft vs Host Disease
Dual targeting of Bruton's tyrosine kinase and Janus kinase 3 with rationally designed inhibitors prevents graft-versus-host disease (GVHD) in a murine allogeneic bone marrow transplantation model.
Graft vs Host Disease
Efficacy and tolerance of ruxolitinib in refractory sclerodermatous chronic Graft-Versus-Host Disease.
Graft vs Host Disease
Frequent detection of BCR-ABL specific mRNA in patients with chronic myeloid leukemia (CML) following allogeneic and syngeneic bone marrow transplantation (BMT).
Graft vs Host Disease
Itacitinib prevents xenogeneic GVHD in humanized mice.
Graft vs Host Disease
Janus kinase 3 inhibitor WHI-P131/JANEX-1 prevents graft-versus-host disease but spares the graft-versus-leukemia function of the bone marrow allografts in a murine bone marrow transplantation model.
Graft vs Host Disease
Janus Kinase Inhibition for Graft-Versus-Host Disease: Current Status and Future Prospects.
Graft vs Host Disease
Janus Kinase Inhibitors: A Review of Their Emerging Applications in Dermatology
Graft vs Host Disease
Kinetics of the graft-versus-leukemia response after donor leukocyte infusions for relapsed chronic myeloid leukemia after allogeneic bone marrow transplantation.
Graft vs Host Disease
Off-label studies on ruxolitinib in dermatology: a review.
Graft vs Host Disease
Preclinical evaluation of JAK1/2 inhibition by ruxolitinib in a murine model of chronic graft-versus-host disease.
Graft vs Host Disease
Predicting relapse of chronic myelogenous leukemia after allogeneic bone marrow transplantation by bcr-abl mRNA and DNA fingerprinting.
Graft vs Host Disease
Recipient and donor JAK2 46/1 haplotypes are associated with acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation.
Graft vs Host Disease
Ruxolitinib for steroid-refractory graft versus host disease in pediatric HSCT: high response rate and manageable toxicity.
Graft vs Host Disease
Stable molecular remission induced by imatinib mesylate (STI571) in a patient with CML lymphoid blast crisis relapsing after allogeneic stem cell transplantation.
Graft vs Host Disease
Syk and tired of current chronic GVHD therapies.
Graft vs Host Disease
Targeting Janus kinase 3 to attenuate the severity of acute graft-versus-host disease across the major histocompatibility barrier in mice.
Graft vs Host Disease
The Effect of Renal Impairment on the Pharmacokinetics and Safety of Itacitinib.
Graft vs Host Disease
The role of ibrutinib in COVID-19 hyperinflammation: A case report.
Graft vs Host Disease
The Role of Janus Kinase Signaling in Graft-Versus-Host Disease and Graft Versus Leukemia.
Graft vs Host Disease
The significance of bcr-abl molecular detection in chronic myeloid leukemia patients "late," 18 months or more after transplantation.
Graft vs Host Disease
[Clinical factors that affect the detection of BCR-ABL transcripts after allogenic bone marrow transplantation for chronic myeloid leukemia]
Granuloma
Expression of Tie-2, angiopoietin-1, angiopoietin-2, ephrinB2 and EphB4 in pyogenic granuloma of human gingiva implicates their roles in inflammatory angiogenesis.
Granuloma Annulare
Granuloma annulare skin profile shows activation of T-helper cell type 1, T-helper cell type 2, and Janus kinase pathways.
Granuloma Annulare
Janus kinase inhibition induces disease remission in cutaneous sarcoidosis and granuloma annulare.
Granulomatosis with Polyangiitis
Evidence for enhanced Bruton's tyrosine kinase activity in transitional and naïve B cells of patients with granulomatosis with polyangiitis.
Granulomatous Disease, Chronic
Novel immunodeficiency data servers.
Granulosa Cell Tumor
Constitutively active transforming growth factor ? receptor 1 in the mouse ovary promotes tumorigenesis.
Granulosa Cell Tumor
Granulosa Cell-Expressed BMPR1A and BMPR1B Have Unique Functions in Regulating Fertility but Act Redundantly to Suppress Ovarian Tumor Development.
Graves Disease
Tear film proteome in age-related macular degeneration.
Hamartoma
Association of autoimmune thyroiditis and celiac disease with Juvenile Polyposis due to 10q23.1q23.31 deletion: Potential role of PI3K/Akt pathway dysregulation.
Hamartoma
Mutation analysis of related genes in hamartoma polyp tissue of Peutz-Jeghers syndrome.
Hamartoma Syndrome, Multiple
A new case with 10q23 interstitial deletion encompassing both PTEN and BMPR1A narrows the genetic region deleted in juvenile polyposis syndrome.
Hamartoma Syndrome, Multiple
An unexpected Cowden syndrome case found among members of a large familial adenomatous polyposis kindred.
Hamartoma Syndrome, Multiple
Association of autoimmune thyroiditis and celiac disease with Juvenile Polyposis due to 10q23.1q23.31 deletion: Potential role of PI3K/Akt pathway dysregulation.
Hamartoma Syndrome, Multiple
BMP signaling inhibits intestinal stem cell self-renewal through suppression of Wnt-beta-catenin signaling.
Hamartoma Syndrome, Multiple
BMP2 exposure results in decreased PTEN protein degradation and increased PTEN levels.
Hamartoma Syndrome, Multiple
Looking for the hidden mutation: Bannayan-Riley-Ruvalcaba syndrome caused by constitutional and mosaic 10q23 microdeletions involving PTEN and BMPR1A.
Hamartoma Syndrome, Multiple
Overlap of juvenile polyposis syndrome and cowden syndrome due to de novo chromosome 10 deletion involving BMPR1A and PTEN: implications for treatment and surveillance.
Head and Neck Neoplasms
AXL Mediates Cetuximab and Radiation Resistance Through Tyrosine 821 and the c-ABL Kinase Pathway in Head and Neck Cancer.
Head and Neck Neoplasms
EphB4: A promising target for upper aerodigestive malignancies.
Head and Neck Neoplasms
Head and neck cancer cell radiosensitization upon dual targeting of c-Abl and beta1-integrin.
Head and Neck Neoplasms
Lyn kinase mediates cell motility and tumor growth in EGFRvIII-expressing head and neck cancer.
Head and Neck Neoplasms
Overcoming cancer cell resistance to VSV oncolysis with JAK1/2 inhibitors.
Head and Neck Neoplasms
Screening and Validation of Molecular Targeted Radiosensitizers.
Head and Neck Neoplasms
Spleen tyrosine kinase expression is correlated with human papillomavirus in head and neck cancer.
Hearing Loss
JAK2/STAT3 inhibition attenuates noise-induced hearing loss.
Heart Arrest
Effects of NaHS and hydroxylamine on the expressions of brain-derived neurotrophic factor and its receptors in rats after cardiac arrest and cardiopulmonary resuscitation.
Heart Arrest
Regulation of tyrosine protein kinase receptor Trk-B and motor function in rats following cardiac arrest.
Heart Arrest
[Effects of brain necroptosis and cytokines expression array on brain injury in rats with cardiac arrest].
Heart Defects, Congenital
A familial congenital heart disease with a possible multigenic origin involving a mutation in BMPR1A.
Heart Defects, Congenital
Absence of TGFBR1 and TGFBR2 mutations in patients with bicuspid aortic valve and aortic dilation.
Heart Defects, Congenital
AcvR1-mediated BMP signaling in second heart field is required for arterial pole development: Implications for myocardial differentiation and regional identity.
Heart Defects, Congenital
BMPR1A is a candidate gene for congenital heart defects associated with the recurrent 10q22q23 deletion syndrome.
Heart Defects, Congenital
Duplication of 10q22.3-q23.3 encompassing BMPR1A and NGR3 associated with congenital heart disease, microcephaly, and mild intellectual disability.
Heart Defects, Congenital
Pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: pathophysiology.
Heart Defects, Congenital
Wnt11 regulates cardiac chamber development and disease during perinatal maturation.
Heart Diseases
Comparative genomics on Wnt11 gene.
Heart Diseases
Mutant activin-like kinase 2 in fibrodysplasia ossificans progressiva are activated via T203 by BMP type II receptors.
Heart Diseases
The tyrosine kinase p56lck is essential in coxsackievirus B3-mediated heart disease.
Heart Failure
Cardiomyocyte apoptosis triggered by RAFTK/pyk2 via Src kinase is antagonized by paxillin.
Heart Failure
CRNK gene transfer improves function and reverses the myosin heavy chain isoenzyme switch during post-myocardial infarction left ventricular remodeling.
Heart Failure
Elevated expression of C3G protein in the peri-infarct myocardium of rats.
Heart Failure
Expression of bone morphogenetic protein 4 and its receptors in the remodeling heart.
Heart Failure
Increased expression of Dock180 protein in the noninfarcted myocardium in rats.
Heart Failure
Outflow tract cushions perform a critical valve-like function in the early embryonic heart requiring BMPRIA-mediated signaling in cardiac neural crest.
Heart Failure
Paxillin and Focal Adhesion Kinase (FAK) Regulate Cardiac Contractility in the Zebrafish Heart.
Heart Failure
PYK2 regulates SERCA2 gene expression in neonatal rat ventricular myocytes.
Heart Failure
Src and multiple MAP kinase activation in cardiac hypertrophy and congestive heart failure under chronic pressure-overload: comparison with acute mechanical stretch.
Heart Failure
Statin rosuvastatin inhibits apoptosis of human coronary artery endothelial cells through upregulation of the JAK2/STAT3 signaling pathway.
Heart Failure
The role of Pyk2 in cardiac arrhythmogenesis.
Heart Septal Defects, Atrial
BMPR1A mutation-positive juvenile polyposis syndrome and atrial septal defect: coincidence or association?
Heart Septal Defects, Atrial
Homozygous missense variant in BMPR1A resulting in BMPR signaling disruption and syndromic features.
Hemangioma, Cavernous, Central Nervous System
Assessing the association of common genetic variants in EPHB4 and RASA1 with phenotype severity in familial cerebral cavernous malformation.
Hemangiosarcoma
Distinct and opposite roles for SH2 and SH3 domains of v-src in embryo survival and hemangiosarcoma formation.
Hemangiosarcoma
Generation of recombinant murine retroviral genomes containing the v-src oncogene: isolation of a virus inducing hemangiosarcomas in the brain.
Hemangiosarcoma
Phosphotyrosine enrichment identifies focal adhesion kinase and other tyrosine kinases for targeting in canine hemangiosarcoma.
Hematologic Diseases
Assessment of azithromycin as an anticancer agent for treatment of imatinib sensitive and resistant CML cells.
Hematologic Diseases
Benzoquinone, a leukemogenic metabolite of benzene, catalytically inhibits the protein tyrosine phosphatase PTPN2 and alters STAT1 signaling.
Hematologic Diseases
Hematologic disease induced in BALB/c mice by a bcr-abl retrovirus is influenced by the infection conditions.
Hematologic Diseases
Mutations in myeloproliferative neoplasms - their significance and clinical use.
Hematologic Diseases
Optimizing therapy for patients with chronic myelogenous leukemia in chronic phase.
Hematologic Diseases
[Oral molecular targeting agents in hematological malignancy]
Hematologic Diseases
[Pathogenesis of thrombosis in JAK2V617F myeloproliferative neoplasms].
Hematologic Diseases
[Research advances in the role of JAK2 mutations in acute leukemia].
Hematologic Neoplasms
A case of chronic myelogenous leukemia with e8a2 fusion transcript.
Hematologic Neoplasms
A Case of Hypophosphatemia with Increased Urinary Excretion of Phosphorus Associated with Ibrutinib.
Hematologic Neoplasms
A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single-Dose and Multiple-Rising-Dose Study of the BTK Inhibitor TAK-020 in Healthy Subjects.
Hematologic Neoplasms
A Pyrazolo[3,4-d]pyrimidine compound inhibits Fyn phosphorylation and induces apoptosis in natural killer cell leukemia.
Hematologic Neoplasms
A small molecule inhibitor of Pim protein kinases blocks the growth of precursor T-cell lymphoblastic leukemia/lymphoma.
Hematologic Neoplasms
Activated c-Abl tyrosine kinase in malignant solid tumors.
Hematologic Neoplasms
Altered splicing in hematological malignancies reveals a tissue-specific translational block of the Src-family tyrosine kinase fyn brain isoform expression.
Hematologic Neoplasms
Azole antifungals and new targeted therapies for hematological malignancy.
Hematologic Neoplasms
BCR-ABL in chronic myelogenous leukemia--how does it work?
Hematologic Neoplasms
Bruton's tyrosine kinase (BTK) mediates resistance to EGFR inhibition in non-small-cell lung carcinoma.
Hematologic Neoplasms
C-sis and C-abl expression in chronic myelogenous leukemia and other hematologic malignancies.
Hematologic Neoplasms
CBL family E3 ubiquitin ligases control JAK2 ubiquitination and stability in hematopoietic stem cells and myeloid malignancies.
Hematologic Neoplasms
Characterization of imatinib-resistant K562 cell line displaying resistance mechanisms.
Hematologic Neoplasms
Combination of simvastatin and imatinib sensitizes the CD34+ cells in K562 to cell death.
Hematologic Neoplasms
Comparative analysis of interphase FISH and RT-PCR to detect bcr-abl translocation in chronic myelogenous leukemia and related disorders.
Hematologic Neoplasms
Constitutive activation of STAT5A and STAT5B regulates IgM secretion in Waldenstrom's macroglobulinemia.
Hematologic Neoplasms
Cytotoxic effect of 6-Shogaol in Imatinib sensitive and resistant K562 cells.
Hematologic Neoplasms
Defining the role of the JAK-STAT pathway in head and neck and thoracic malignancies: implications for future therapeutic approaches.
Hematologic Neoplasms
Depletion of STAT5 blocks TEL-SYK-induced APMF-type leukemia with myelofibrosis and myelodysplasia in mice.
Hematologic Neoplasms
Design and synthesis of boron-containing diphenylpyrimidines as potent BTK and JAK3 dual inhibitors.
Hematologic Neoplasms
Design, synthesis and biological evaluation of novel dithiocarbamate-substituted diphenylaminopyrimidine derivatives as BTK inhibitors.
Hematologic Neoplasms
Detection of BCR-ABL in Hematological Malignancies by RT-PCR.
Hematologic Neoplasms
Differences in gene expression and alterations in cell cycle of acute myeloid leukemia cell lines after treatment with JAK inhibitors.
Hematologic Neoplasms
Discovery of Novel Janus Kinase (JAK) and Histone Deacetylase (HDAC) Dual Inhibitors for the Treatment of Hematological Malignancies.
Hematologic Neoplasms
Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton's Tyrosine Kinase.
Hematologic Neoplasms
Early events in leukemogenesis in P190Bcr-abl transgenic mice.
Hematologic Neoplasms
EPHB4 is a therapeutic target in AML and promotes leukemia cell survival via AKT.
Hematologic Neoplasms
Focal adhesion kinase as a target in the treatment of hematological malignancies.
Hematologic Neoplasms
Functional aspects of apoptosis in hematopoiesis and consequences of failure.
Hematologic Neoplasms
Functional interplay of SP family members and nuclear factor Y is essential for transcriptional activation of the human Calreticulin gene.
Hematologic Neoplasms
Glucosylceramide synthase inhibitor PDMP sensitizes chronic myeloid leukemia T315I mutant to Bcr-Abl inhibitor and cooperatively induces glycogen synthase kinase-3-regulated apoptosis.
Hematologic Neoplasms
GTPase regulator associated with the focal adhesion kinase (GRAF) transcript was down-regulated in patients with myeloid malignancies.
Hematologic Neoplasms
Hematopoietic cell kinase (HCK) is a potential therapeutic target for dysplastic and leukemic cells due to integration of erythropoietin/PI3K pathway and regulation of erythropoiesis: HCK in erythropoietin/PI3K pathway.
Hematologic Neoplasms
Ibrutinib in CLL/SLL: From bench to bedside (Review).
Hematologic Neoplasms
Ibrutinib, a Bruton's tyrosine kinase inhibitor, a new risk factor for cryptococcosis.
Hematologic Neoplasms
Ibrutinib-associated sever skin toxicity: A case of multiple inflamed skin lesions and cellulitis in a 68-year-old male patient with relapsed chronic lymphocytic leukemia - Case report and literature review.
Hematologic Neoplasms
Ibrutinib-Induced Vasculitis in a Patient with Metastatic Colon Cancer Treated in Combination with Cetuximab.
Hematologic Neoplasms
Id1 is a common downstream target of oncogenic tyrosine kinases in leukemic cells.
Hematologic Neoplasms
Identification of a novel inhibitor of JAK2 tyrosine kinase by structure-based virtual screening.
Hematologic Neoplasms
Implications of Janus Kinase 2 Mutation in Embolic Stroke of Unknown Source.
Hematologic Neoplasms
Increased expression of a novel c-abl-related RNA in K562 cells.
Hematologic Neoplasms
Inhibition of Hematopoietic Cell Kinase Activity Suppresses Myeloid Cell-Mediated Colon Cancer Progression.
Hematologic Neoplasms
Inhibition of Src family kinases with dasatinib blocks migration and invasion of human melanoma cells.
Hematologic Neoplasms
JAK1/2 Inhibitors AZD1480 and CYT387 Inhibit Canine B-Cell Lymphoma Growth by Increasing Apoptosis and Disrupting Cell Proliferation.
Hematologic Neoplasms
JAK2 V617F Mutation in Adult T Cell Leukemia-Lymphoma.
Hematologic Neoplasms
Janus kinase deregulation in leukemia and lymphoma.
Hematologic Neoplasms
Kinase inhibitors developed for treatment of hematologic malignancies: implications for immune modulation in COVID-19.
Hematologic Neoplasms
Kinases as drug discovery targets in hematologic malignancies.
Hematologic Neoplasms
MK-0457, an Aurora kinase and BCR-ABL inhibitor, is active in patients with BCR-ABL T315I leukemia.
Hematologic Neoplasms
MPT0B002, a novel microtubule inhibitor, downregulates T315I mutant Bcr-Abl and induces apoptosis of imatinib-resistant chronic myeloid leukemia cells.
Hematologic Neoplasms
MUC1 in hematological malignancies.
Hematologic Neoplasms
NKG2A Down-Regulation by Dasatinib Enhances Natural Killer Cytotoxicity and Accelerates Effective Treatment Responses in Patients With Chronic Myeloid Leukemia.
Hematologic Neoplasms
Noncovalent inhibition of C481S Bruton tyrosine kinase by GDC-0853: a new treatment strategy for ibrutinib-resistant CLL.
Hematologic Neoplasms
Novel agents and regimens for hematological malignancies: recent updates from 2020 ASH annual meeting.
Hematologic Neoplasms
Novel Association of a Familial TGFBR1 Mutation in Loeys-Dietz Syndrome with Concomitant Hematologic Malignancy.
Hematologic Neoplasms
Novel dual Src/Abl inhibitors for hematologic and solid malignancies.
Hematologic Neoplasms
Novel Indications for Bruton's Tyrosine Kinase Inhibitors, beyond Hematological Malignancies.
Hematologic Neoplasms
Novel lncRNA-IUR suppresses Bcr-Abl-induced tumorigenesis through regulation of STAT5-CD71 pathway.
Hematologic Neoplasms
PAK-dependent STAT5 serine phosphorylation is required for BCR-ABL-induced leukemogenesis.
Hematologic Neoplasms
Peripheral T cell lymphoma: new model + new insight.
Hematologic Neoplasms
Phase I Study of a Novel Oral Janus Kinase 2 Inhibitor, SB1518, in Patients With Relapsed Lymphoma: Evidence of Clinical and Biologic Activity in Multiple Lymphoma Subtypes.
Hematologic Neoplasms
Preclinical Studies of PROTACs in Hematological Malignancies.
Hematologic Neoplasms
Pregnancy and Accelerated Phase of Myeloid Chronic Leukemia Treated with Imatinib: A Case Report from a Developing Country.
Hematologic Neoplasms
Profile of pacritinib and its potential in the treatment of hematologic disorders.
Hematologic Neoplasms
Rearrangement of PDGFR? gene in a patient with Ph-negative chronic myeloid leukemia t(5;12)(q33;p13) in imatinib mesylate treatment-free remission: a case report.
Hematologic Neoplasms
Recurrent numerical aberrations of JAK2 and deregulation of the JAK2-STAT cascade in lymphomas.
Hematologic Neoplasms
Role of Bruton's tyrosine kinase (BTK) in growth and metastasis of INA6 myeloma cells.
Hematologic Neoplasms
Src tyrosine kinase preactivation is associated with platelet hypersensitivity in essential thrombocythemia and polycythemia vera.
Hematologic Neoplasms
STAT3 Inhibitors: Finding a Home in Lymphoma and Leukemia.
Hematologic Neoplasms
Stat5 Exerts Distinct, Vital Functions in the Cytoplasm and Nucleus of Bcr-Abl+ K562 and Jak2(V617F)+ HEL Leukemia Cells.
Hematologic Neoplasms
SYK is a critical regulator of FLT3 in acute myeloid leukemia.
Hematologic Neoplasms
Synergistic Interactions between DMAG and Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitors in Bcr/abl+ Leukemia Cells Sensitive and Resistant to Imatinib Mesylate.
Hematologic Neoplasms
Systematic review of infectious events with the Bruton tyrosine kinase inhibitor ibrutinib in the treatment of hematologic malignancies.
Hematologic Neoplasms
Targeted therapies in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia.
Hematologic Neoplasms
TAT-CC fusion protein depresses the oncogenicity of BCR-ABL in vitro and in vivo through interrupting its oligomerization.
Hematologic Neoplasms
Taxodione induces apoptosis in BCR-ABL-positive cells through ROS generation.
Hematologic Neoplasms
The Bruton's tyrosine kinase inhibitor ibrutinib exerts immunomodulatory effects through regulation of tumor-infiltrating macrophages.
Hematologic Neoplasms
The BTK Inhibitor ARQ 531 Targets Ibrutinib-Resistant CLL and Richter Transformation.
Hematologic Neoplasms
The Janus Kinase 2 (JAK2) V617F mutation in hematological malignancies in México.
Hematologic Neoplasms
The promise of Janus kinase inhibitors in the treatment of hematological malignancies.
Hematologic Neoplasms
Therapeutic effect and mechanism of ibrutinib combined with dexamethasone on multiple myeloma.
Hematologic Neoplasms
Use of the «BCR/ABL - multitest» kit in the algorithm of laboratory diagnostics of oncohematological diseases: economic aspects.
Hematologic Neoplasms
ZAP-70 expression in B-cell hematologic malignancy is not limited to CLL/SLL.
Hematologic Neoplasms
[Advancement of peptide vaccines for hematologic malignancies].
Hematologic Neoplasms
[Quality assurance of the molecular diagnostic tests in hematological malignancies]
Hematoma, Subdural, Chronic
Inhibitory Mechanism of the Outer Membrane Growth of Chronic Subdural Hematomas.
Hemoglobinuria
Paroxysmal nocturnal hemoglobinuria induced by the occurrence of BCR-ABL in a PIGA mutant hematopoietic progenitor cell.
Hemoglobinuria
Somatic mutations and the hierarchy of hematopoiesis.
Hemoglobinuria, Paroxysmal
Paroxysmal nocturnal hemoglobinuria induced by the occurrence of BCR-ABL in a PIGA mutant hematopoietic progenitor cell.
Hemoglobinuria, Paroxysmal
Somatic mutations and the hierarchy of hematopoiesis.
Hemophilia A
Prevention of the anti-factor VIII memory B-cell response by inhibition of the Bruton's tyrosine kinase in experimental hemophilia A.
Hepatitis
Expression of oncogenes in human liver disease.
Hepatitis
The tyrosine kinase p56lck is essential in coxsackievirus B3-mediated heart disease.
Hepatitis A
SMAD3 promotes autophagy dysregulation by triggering lysosome depletion in tubular epithelial cells in diabetic nephropathy.
Hepatitis B
Activation of c-myc expression by c-Abl is independent of both the DNA binding function of c-Abl and the c-myc EP site.
Hepatitis B
Activation of Focal Adhesion Kinase by Hepatitis B Virus HBx Protein: Multiple Functions in Viral Replication.
Hepatitis B
Association of Bcr-Abl Tyrosine Kinase Inhibitors With Hepatitis B Virus Reactivation Requiring Antiviral Treatment in Taiwan.
Hepatitis B
Effect of Bruton tyrosine kinase inhibitor on efficacy of adjuvanted recombinant hepatitis B and zoster vaccines.
Hepatitis B
ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an Infectious Diseases perspective (Intracellular signaling pathways: tyrosine kinase and mTOR inhibitors).
Hepatitis B
HBx protein induces EMT through c-Src activation in SMMC-7721 hepatoma cell line.
Hepatitis B
Hepatitis B virus e antigen physically associates with receptor-interacting serine/threonine protein kinase 2 and regulates IL-6 gene expression.
Hepatitis B
Hepatitis B virus HBx protein activation of cyclin A-cyclin-dependent kinase 2 complexes and G1 transit via a Src kinase pathway.
Hepatitis B
Hepatitis B virus promotes ?-catenin-signalling and disassembly of adherens junctions in a Src kinase dependent fashion.
Hepatitis B
Infection risk in patients undergoing treatment for inflammatory arthritis: non-biologics versus biologics.
Hepatitis B
Infections in patients on BCR-ABL tyrosine kinase inhibitor therapy: cases and review of the literature.
Hepatitis B
Involvement of endoplasmic reticulum in hepatitis B virus replication.
Hepatitis B
SNU cell lines and their application for cancer research.
Hepatitis B, Chronic
A deficient translocation of CD3?, ZAP-70 and Grb2 to lipid raft, as a hallmark of defective adaptive immune response during chronic hepatitis B infection.
Hepatitis C
Abl Tyrosine Kinase Regulates Hepatitis C Virus Entry.
Hepatitis C
Association of 49245A>G (rs868) polymorphism in the 3'UTR of donor TGFBR1 gene with course of hepatitis C following orthotopic liver transplantation.
Hepatitis C
Focal Adhesion Kinase (FAK) Mediates the Induction of Pro-Oncogenic and Fibrogenic Phenotypes in Hepatitis C Virus (HCV)-Infected Cells.
Hepatitis C
Hepatitis C virus core protein differently regulates the JAK-STAT signaling pathway under interleukin-6 and interferon-gamma stimuli.
Hepatitis C
Hepatitis C virus infection inhibits a Src-kinase regulatory phosphatase and reduces T cell activation in vivo.
Hepatitis C
Hepatitis C virus NS5A mediated STAT3 activation requires co-operation of Jak1 kinase.
Hepatitis C
Hepatitis C virus NS5A protein binds the SH3 domain of the Fyn tyrosine kinase with high affinity: mutagenic analysis of residues within the SH3 domain that contribute to the interaction.
Hepatitis C
Hepatitis C Virus Particle Assembly Involves Phosphorylation of NS5A by the c-Abl Tyrosine Kinase.
Hepatitis C
Infection risk in patients undergoing treatment for inflammatory arthritis: non-biologics versus biologics.
Hepatitis C
Interaction of Hepatitis C Virus Core Protein with Janus Kinase Is Required for Efficient Production of Infectious Viruses.
Hepatitis C
Optimization of the Isolation and Amplification of RNA From Formalin-fixed, Paraffin-embedded Tissue: The Armed Forces Institute of Pathology Experience and Literature Review.
Hepatitis C
Phosphorylated Ezrin (Thr567) Regulates Hippo Pathway and Yes-Associated Protein (Yap) in Liver.
Hepatitis C
Reduced expression of Jak-1 and Tyk-2 proteins leads to interferon resistance in Hepatitis C virus replicon.
Hepatitis C
Structure of the c-Src-SH3 domain in complex with a proline-rich motif of NS5A protein from the hepatitis C virus.
Hepatitis C
Yeast Endoplasmic Reticulum Sequestration Screening for the Engineering of Proteases from Libraries Expressed in Yeast.
Hepatitis E
[Severe Hepatitis E virus infection in a patient with rheumatoid arthritis treated with baricitinib].
Hepatitis, Alcoholic
The role of Tec kinase signaling pathways in the development of Mallory Denk Bodies in balloon cells in alcoholic hepatitis.
Hepatitis, Autoimmune
Serum level of transforming growth factor-beta1 (TGF-beta1) and the expression of TGF-beta receptor type II in peripheral blood mononuclear cells in patients with autoimmune hepatitis.
Hepatitis, Chronic
Identification of c-Yes expression in the nuclei of hepatocellular carcinoma cells: involvement in the early stages of hepatocarcinogenesis.
Hepatoblastoma
Inhibition of cell migration by focal adhesion kinase: Time-dependent difference in integrin-induced signaling between endothelial and hepatoblastoma cells.
Hepatoblastoma
Nuclear accumulations of p53 and Mdm2 are accompanied by reductions in c-Abl and p300 in zinc-depleted human hepatoblastoma cells.
Hepatomegaly
Massive hepatomegaly and involvement by Janus Kinase 2-positive myeloproliferative neoplasm.
Hepatomegaly
ZAP-70 as a possible prognostic factor in childhood acute lymphoblastic leukemia.
Hepatopulmonary Syndrome
[Splenic tyrosine kinase promotes pulmonary angiogenesis in rats with hepatopulmonary syndrome].
Hereditary Breast and Ovarian Cancer Syndrome
Genetic testing by cancer site: stomach.
Hernia, Umbilical
BMPR1A-mediated BMP1 signalling is disrupted in the cadmium-induced omphalocele in the chick model.
Hernias, Diaphragmatic, Congenital
Upregulated EFNB2 and EPHB4 promotes lung development in a nitrofen-induced congenital diaphragmatic hernia rat model.
Herpes Simplex
Developing RNase P ribozymes for gene-targeting and antiviral therapy.
Herpes Simplex
Engineering of RNase P ribozyme for gene-targeting applications.
Herpes Simplex
Focal adhesion kinase plays a pivotal role in herpes simplex virus entry.
Herpes Simplex
Herpes simplex virus requires VP11/12 to activate Src family kinase-phosphoinositide 3-kinase-Akt signaling.
Herpes Simplex
Herpes Simplex Virus Type 1 Neuronal Infection Perturbs Golgi Apparatus Integrity through Activation of Src Tyrosine Kinase and Dyn-2 GTPase.
Herpes Simplex
Inhibition of herpes simplex virus replication by genistein, an inhibitor of protein-tyrosine kinase.
Herpes Simplex
Inhibitory effect of tyrphostin on the replication of herpes simplex virus type 1.
Herpes Simplex
Microarray analysis of genes with differential expression of m6A methylation in lung cancer.
Herpes Simplex
New erythroxane-type diterpenoids from Fagonia boveana (Hadidi) Hadidi & Graf.
Herpes Simplex
Role of Herpes Simplex Virus VP11/12 Tyrosine-Based Motifs in Binding and Activation of the Src Family Kinase Lck and Recruitment of p85, Grb2, and Shc.
Herpes Simplex
The location of v-src in a retrovirus vector determines whether the virus is toxic or transforming.
Herpes Simplex
Variations in transcription-repair coupling in mouse cells.
Herpes Zoster
A Patient with Tyrosine Kinase 2 Deficiency without Hyper-IgE Syndrome.
Herpes Zoster
Angiopoietin-like protein 2 promotes the progression of diabetic kidney disease.
Herpes Zoster
Effect of Bruton tyrosine kinase inhibitor on efficacy of adjuvanted recombinant hepatitis B and zoster vaccines.
Herpes Zoster
Herpes Zoster in Tofacitinib: Risk is Further Increased with Glucocorticoids but not Methotrexate.
Herpes Zoster
Suspected Herpes Zoster-associated Encephalitis during Treatment with Oral Tofacitinib in Alopecia Universalis.
Herpes Zoster
Tofacitinib modulates the VZV-specific CD4+ T cell immune response in vitro in lymphocytes of patients with rheumatoid arthritis.
Herpes Zoster
Update on the Safety Profile of Tofacitinib in Rheumatoid Arthritis from Clinical Trials to Real-World Studies: A Narrative Review.
Herpes Zoster
[Risk profile of disease-modifying antirheumatic drugs: an update from the RABBIT register].
Hidradenitis Suppurativa
A case paradoxical hidradenitis suppurativa with janus kinase inhibitor, literature review and pooled analysis of biological agent-induced HS.
Hidradenitis Suppurativa
In silico Analysis of Gamma-Secretase-Complex Mutations in Hidradenitis Suppurativa Demonstrates Disease-Specific Substrate Recognition and Cleavage Alterations.
HIV Infections
HIV infection in vitro enhances the activity of src-family protein tyrosine kinases.
HIV Infections
HIV infection--induced posttranslational modification of T cell signaling molecules associated with disease progression.
HIV Infections
HIV-1 infection is facilitated in T cells by decreasing p56lck protein tyrosine kinase activity.
HIV Infections
Pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: pathophysiology.
Hodgkin Disease
A novel PTPN1 splice variant upregulates JAK/STAT activity in classical Hodgkin lymphoma cells.
Hodgkin Disease
Classical Hodgkin's Lymphoma in the Era of Immune Checkpoint Inhibition.
Hodgkin Disease
Engraftment of HLA-matched sibling hematopoietic stem cells after immunosuppressive conditioning regimen in patients with hematologic neoplasias.
Hodgkin Disease
Hodgkin lymphoma in a mutated ZAP-70 negative B-cell Chronic Lymphocytic Leukemia patient.
Hodgkin Disease
Hodgkin's disease associated with chronic myeloid leukemia. Determination of bcr-abl rearrangement in paraffin-embedded tumors using the polymerase chain reaction.
Hodgkin Disease
Hodgkin's disease variant of Richter's syndrome clonally related to chronic lymphocytic leukemia arises in ZAP-70 negative mutated CLL.
Hodgkin Disease
Immunohistochemical detection of ZAP-70 in 341 cases of non-Hodgkin and Hodgkin lymphoma.
Hodgkin Disease
PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma.
Hodgkin Disease
Pre-clinical anti-tumor activity of Bruton's Tyrosine Kinase inhibitor in Hodgkin's Lymphoma cellular and subcutaneous tumor model.
Hodgkin Disease
Prevalence of PDL1 Amplification and Preliminary Response to Immune Checkpoint Blockade in Solid Tumors.
Hodgkin Disease
Recurrent mutations of the STAT6 DNA binding domain in primary mediastinal B-cell lymphoma.
Hodgkin Disease
Richter transformation to Hodgkin lymphoma on Bruton's tyrosine kinase inhibitor therapy.
Hodgkin Disease
Searching for evidence of disease and malignant cell contamination in ovarian tissue stored from hematologic cancer patients.
Hodgkin Disease
Sophoraflavanone G induces apoptosis of human cancer cells by targeting upstream signals of STATs.
Hodgkin Disease
The JAK inhibitor AZD1480 regulates proliferation and immunity in Hodgkin lymphoma.
Hodgkin Disease
The PTP1B mutant PTP1B?2-4 is a positive regulator of the JAK/STAT signalling pathway in Hodgkin lymphoma.
Hodgkin Disease
ZAP-70 expression in B-cell hematologic malignancy is not limited to CLL/SLL.
Huntington Disease
A chemical genomics-aggrephagy integrated method studying functional analysis of autophagy inducers.
Hydatidiform Mole
Expression of TGF-beta signaling proteins in normal placenta and gestational trophoblastic disease.
Hydrocephalus
Expression of TGF-betas and TGF-beta type II receptor in cerebrospinal fluid of patients with idiopathic normal pressure hydrocephalus.
Hydrocephalus
Loss of Fyn tyrosine kinase on the C57BL/6 genetic background causes hydrocephalus with defects in oligodendrocyte development.
Hydrocephalus
Toxic non-resorptive internal hydrocephalus as a result of haemorrhagic ventriculitis during induction chemotherapy of Bcr-Abl positive acute lymphoblastic leukaemia.
Hydrocephalus, Normal Pressure
Expression of TGF-betas and TGF-beta type II receptor in cerebrospinal fluid of patients with idiopathic normal pressure hydrocephalus.
Hydronephrosis
The significance of the nongenomic pathway in mediating inflammatory signaling of the dioxin-activated Ah receptor to cause toxic effects.
Hydrops Fetalis
EPHB4 kinase-inactivating mutations cause autosomal dominant lymphatic-related hydrops fetalis.
Hydrops Fetalis
Janus-faced EPHB4-associated disorders: novel pathogenic variants and unreported intrafamilial overlapping phenotypes.
Hydrops Fetalis
Loss of function mutations in EPHB4 are responsible for vein of Galen aneurysmal malformation.
Hyper-IgM Immunodeficiency Syndrome
Absence of memory B cells in patients with common variable immunodeficiency.
Hyper-IgM Immunodeficiency Syndrome
Novel immunodeficiency data servers.
Hyperalgesia
Can Src protein tyrosine kinase inhibitors be combined with opioid analgesics? Src and opioid-induced tolerance, hyperalgesia and addiction.
Hyperalgesia
CXCL13/CXCR5 signaling contributes to diabetes-induced tactile allodynia via activating pERK, pSTAT3, pAKT pathways and pro-inflammatory cytokines production in the spinal cord of male mice.
Hyperalgesia
EphrinB2 induces tyrosine phosphorylation of NR2B via Src-family kinases during inflammatory hyperalgesia.
Hyperalgesia
GDNF hyperalgesia is mediated by PLCgamma, MAPK/ERK, PI3K, CDK5 and Src family kinase signaling and dependent on the IB4-binding protein versican.
Hyperalgesia
Interaction of transient receptor potential vanilloid 4, integrin, and SRC tyrosine kinase in mechanical hyperalgesia.
Hyperalgesia
Involvement of a spinal brain-derived neurotrophic factor/full-length TrkB pathway in the development of nerve injury-induced thermal hyperalgesia in mice.
Hyperalgesia
JAK/STAT3 pathway is activated in spinal cord microglia after peripheral nerve injury and contributes to neuropathic pain development in rat.
Hyperalgesia
Janus kinase 2 activation participates in prostaglandin E2-induced hyperalgesia.
Hyperalgesia
Prooxidant-induced c-Src/nuclear factor kappa B-coupled signalling in sensory ganglia mediates cutaneous hyperalgesia.
Hyperalgesia
Role of GPCR (mu-opioid)-receptor tyrosine kinase (epidermal growth factor) crosstalk in opioid-induced hyperalgesic priming (type II).
Hyperalgesia
Transient decrease in nociceptor GRK2 expression produces long-term enhancement in inflammatory pain.
Hypereosinophilic Syndrome
Cyclin-dependent kinase 7/9 inhibitor SNS-032 abrogates FIP1-like-1 platelet-derived growth factor receptor ? and bcr-abl oncogene addiction in malignant hematologic cells.
Hypereosinophilic Syndrome
Discovery of a small molecule type II inhibitor of wild-type and gatekeeper mutants of BCR-ABL, PDGFR{alpha}, Kit, and Src kinases.
Hypereosinophilic Syndrome
Imatinib and tyrosine kinase inhibition, in the management of BCR-ABL negative myeloproliferative disorders.
Hypereosinophilic Syndrome
Ponatinib efficiently kills imatinib-resistant chronic eosinophilic leukemia cells harboring gatekeeper mutant T674I FIP1L1-PDGFR?: roles of Mcl-1 and ?-catenin.
Hypereosinophilic Syndrome
Ruxolitinib found to cause eyelash growth: a case report.
Hypereosinophilic Syndrome
T670X KIT mutations in gastrointestinal stromal tumors: making sense of missense.
Hypereosinophilic Syndrome
The chronic myeloproliferative disorders and mutation of JAK2: Dameshek's 54 year old speculation comes of age.
Hypergammaglobulinemia
[Juvenile myelomonocytic leukemia: A three-case series].
Hyperglycemia
Angiotensin II blockade prevents hyperglycemia-induced activation of JAK and STAT proteins in diabetic rat kidney glomeruli.
Hyperglycemia
Effects of diabetes and hypertension on glomerular transforming growth factor-beta receptor expression.
Hyperglycemia
Hyperglycemia and reactive oxygen species mediate apoptosis in aortic endothelial cells through Janus kinase 2.
Hyperglycemia
Hyperglycemia-induced p66shc inhibits insulin-like growth factor I-dependent cell survival via impairment of Src kinase-mediated phosphoinositide-3 kinase/AKT activation in vascular smooth muscle cells.
Hyperglycemia
The Abnormal Architecture of Healed Diabetic Ulcers Is the Result of FAK Degradation by Calpain 1.
Hyperglycemia
The renal TGF-beta system in the db/db mouse model of diabetic nephropathy.
Hyperhomocysteinemia
Evaluation of The Presence of Hereditary And Acquired Thrombophilias In Brazilian Children And Adolescents With Diagnoses of Portal Vein Thrombosis.
Hyperinsulinism
Actein ameliorates hepatic steatosis and fibrosis in high fat diet-induced NAFLD by regulation of insulin and leptin resistant.
Hyperinsulinism
Decreased erythrocyte insulin binding in hypertensive subjects with hyperinsulinemia.
Hyperinsulinism
The renal TGF-beta system in the db/db mouse model of diabetic nephropathy.
Hyperlipidemias
Cardiovascular Risk Assessment and Impact of Medications on Cardiovascular Disease in Inflammatory Bowel Disease.
Hyperostosis
Rapid remission of refractory synovitis, acne, pustulosis, hyperostosis, and osteitis syndrome in response to the Janus kinase inhibitor tofacitinib: A case report.
Hypersensitivity
(-)-Asarinin inhibits mast cells activation as a Src family kinase inhibitor.
Hypersensitivity
A Bcr-Abl Inhibitor GNF-2 Attenuates Inflammatory Activation of Glia and Chronic Pain.
Hypersensitivity
A novel druglike spleen tyrosine kinase binder prevents anaphylactic shock when administered orally.
Hypersensitivity
Acute stress induces visceral hypersensitivity via glucocorticoid receptor-mediated membrane insertion of TRPM8: Involvement of a non-receptor tyrosine kinase Pyk2.
Hypersensitivity
Application of a pharmacogenetic test adoption model to six oncology biomarkers.
Hypersensitivity
BDNF Contributes to Spinal Long-Term Potentiation and Mechanical Hypersensitivity Via Fyn-Mediated Phosphorylation of NMDA Receptor GluN2B Subunit at Tyrosine 1472 in Rats Following Spinal Nerve Ligation.
Hypersensitivity
Delgocitinib: First Approval.
Hypersensitivity
Discovery of a Natural Syk Inhibitor from Chinese Medicine through a Docking-Based Virtual Screening and Biological Assay Study.
Hypersensitivity
Discovery of dual ZAP70 and Syk kinases inhibitors by docking into a rare C-helix-out conformation of Syk.
Hypersensitivity
Effect of reduced EPHB4 expression in thymic epithelial cells on thymocyte development and peripheral T cell function.
Hypersensitivity
Effects of Src-kinase inhibition in cancer-induced bone pain.
Hypersensitivity
Electroacupuncture ameliorates mechanical hypersensitivity by down-regulating spinal Janus kinase 2/signal transducer and activation of transcription 3 and interleukin 6 in rats with spared nerve injury.
Hypersensitivity
Eosinophilic gastroenteritis in a patient with Bruton's tyrosine kinase deficiency.
Hypersensitivity
Genetic and biochemical evidence for a critical role of Janus kinase (JAK)-3 in mast cell-mediated type I hypersensitivity reactions.
Hypersensitivity
Identification of Type-II Inhibitors Using Kinase Structures.
Hypersensitivity
JTE-852, a novel spleen tyrosine kinase inhibitor, blocks antigen-induced allergic reactions in rats.
Hypersensitivity
Microglial Janus kinase/signal transduction and activator of transcription 3 pathway activity directly impacts astrocyte and spinal neuron characteristics.
Hypersensitivity
Morin inhibits Fyn kinase in mast cells and IgE-mediated type I hypersensitivity response in vivo.
Hypersensitivity
Negative regulation of immunoglobulin E-dependent allergic responses by Lyn kinase.
Hypersensitivity
Oclacitinib (APOQUEL(®) ) is a novel Janus kinase inhibitor with activity against cytokines involved in allergy.
Hypersensitivity
Potential applications of Bruton's tyrosine kinase inhibitors for the prevention of allergic reactions.
Hypersensitivity
Progressive multifocal leukoencephalopathy in a patient with common variable immunodeficiency and abnormal CD8+ T-cell subset distribution.
Hypersensitivity
RN486, a Selective Bruton's Tyrosine Kinase Inhibitor, Abrogates Immune Hypersensitivity Responses and Arthritis in Rodents.
Hypersensitivity
SFT Thijsen et al. Hypersensitivity of bcr-abl progenitors to hyperthermia in patients with chronic myeloid leukemia. Leukemia 1997; 11: 1762-1768.
Hypersensitivity
Src tyrosine kinase preactivation is associated with platelet hypersensitivity in essential thrombocythemia and polycythemia vera.
Hypersensitivity
TAS05567, a Novel Potent and Selective Spleen Tyrosine Kinase Inhibitor, Abrogates Immunoglobulin-Mediated Autoimmune and Allergic Reactions in Rodent Models.
Hypersensitivity
The Possible Importance of ?3 Integrins for Leukemogenesis and Chemoresistance in Acute Myeloid Leukemia.
Hypersensitivity
The role of the tyrosine kinase Lyn in allergy and cancer.
Hypersensitivity
Topical treatment with mastic (resin from Pistacia lentiscus) elicits anti-inflammatory and anti-pruritic responses by modulating keratinocyte activation in a mouse model of allergic dermatitis.
Hypersensitivity
Treatment of inflammatory and neuropathic pain by uncoupling Src from the NMDA receptor complex.
Hypersensitivity
Vascular Endothelial Growth Factor A Signaling Promotes Spinal Central Sensitization and Pain-related Behaviors in Female Rats with Bone Cancer.
Hypersensitivity, Immediate
A novel druglike spleen tyrosine kinase binder prevents anaphylactic shock when administered orally.
Hypersensitivity, Immediate
Genetic and biochemical evidence for a critical role of Janus kinase (JAK)-3 in mast cell-mediated type I hypersensitivity reactions.
Hypersensitivity, Immediate
Morin inhibits Fyn kinase in mast cells and IgE-mediated type I hypersensitivity response in vivo.
Hypersensitivity, Immediate
Targeting Janus kinase 3 in mast cells prevents immediate hypersensitivity reactions and anaphylaxis.
Hypertelorism
International Registry of Patients Carrying TGFBR1 or TGFBR2 Mutations: Results of the MAC (Montalcino Aortic Consortium).
Hypertension
'There and Back Again'-Forward Genetics and Reverse Phenotyping in Pulmonary Arterial Hypertension.
Hypertension
A novel BMPR2 mutation with widely disparate heritable pulmonary arterial hypertension clinical phenotype.
Hypertension
Angiotensin II utilizes JANUS KINASE 2 in hypertension, but not in the physiologic control of blood pressure during low salt intake.
Hypertension
Angiotensin-converting enzyme 2 alleviates pulmonary artery hypertension through inhibition of focal adhesion kinase expression.
Hypertension
Blockade of JAK2 protects mice against hypoxia-induced pulmonary arterial hypertension by repressing pulmonary arterial smooth muscle cell proliferation.
Hypertension
BMP signaling in vascular diseases.
Hypertension
BMP type II receptor as a therapeutic target in pulmonary arterial hypertension.
Hypertension
BMPR2 mutations and survival in pulmonary arterial hypertension: an individual participant data meta-analysis.
Hypertension
Bone morphogenetic protein (BMP) type II receptor is required for BMP-mediated growth arrest and differentiation in pulmonary artery smooth muscle cells.
Hypertension
Bone morphogenetic protein receptor type II and inflammation are bringing old concepts into the new pulmonary arterial hypertension world.
Hypertension
Bone morphogenetic protein receptor type II C-terminus interacts with c-Src: implication for a role in pulmonary arterial hypertension.
Hypertension
Bone morphogenetic protein receptor type II deficiency and increased inflammatory cytokine production. A gateway to pulmonary arterial hypertension.
Hypertension
C-src tyrosine kinase gene rs1378942 polymorphism and hypertension in Asians: Review and meta-analysis.
Hypertension
Cardioprotective Strategies to Prevent Cancer Treatment-Related Cardiovascular Toxicity: a Review.
Hypertension
Characteristics of pulmonary arterial hypertension in affected carriers of a mutation located in the cytoplasmic tail of BMPRII.
Hypertension
Clinical characteristics and survival of Chinese patients diagnosed with pulmonary arterial hypertension who carry BMPR2 or EIF2KAK4 variants.
Hypertension
Clinical features of pulmonary arterial hypertension in patients receiving dasatinib.
Hypertension
Dasatinib induces lung vascular toxicity and predisposes to pulmonary hypertension.
Hypertension
Dasatinib-induced pulmonary arterial hypertension complicated with scleroderma: a case report.
Hypertension
Defective cellular trafficking of the bone morphogenetic protein receptor type II by mutations underlying familial pulmonary arterial hypertension.
Hypertension
Duvelisib (Copiktra) in relapsed or refractory chronic lymphocytic leukemia: safety and efficacy.
Hypertension
Effects of diabetes and hypertension on glomerular transforming growth factor-beta receptor expression.
Hypertension
Erratum to: BMP type II receptor as a therapeutic target in pulmonary arterial hypertension.
Hypertension
Expression and distribution of Src in the nucleus of myocytes in cardiac hypertrophy.
Hypertension
Genetics of pulmonary arterial hypertension: current and future implications.
Hypertension
Hypertension promotes phosphorylation of focal adhesion kinase and proline-rich tyrosine kinase 2 in rats: implication for the pathogenesis of hypertensive vascular disease.
Hypertension
In silico investigation of potential SRC kinase ligands from traditional Chinese medicine.
Hypertension
Interleukin 6 knockout prevents angiotensin II hypertension: role of renal vasoconstriction and janus kinase 2/signal transducer and activator of transcription 3 activation.
Hypertension
miR-181b-5p inhibits endothelial-mesenchymal transition in monocrotaline-induced pulmonary arterial hypertension by targeting endocan and TGFBR1.
Hypertension
Mutations of the TGF-beta type II receptor BMPR2 in pulmonary arterial hypertension.
Hypertension
Novel crosstalk to BMP signalling: cGMP-dependent kinase I modulates BMP receptor and Smad activity.
Hypertension
Plasma levels of apelin are reduced in patients with liver fibrosis and cirrhosis but are not correlated with circulating levels of bone morphogenetic protein 9 and 10.
Hypertension
Protein tyrosine kinase 2beta as a candidate gene for hypertension.
Hypertension
Pulmonary arterial hypertension in interferonophaties: a case report and a review of the literature.
Hypertension
Pulmonary vascular remodeling patterns and expression of general control nonderepressible 2 (GCN2) in pulmonary veno-occlusive disease.
Hypertension
Smad signaling in the rat model of monocrotaline pulmonary hypertension.
Hypertension
Smooth muscle protein 22alpha-mediated patchy deletion of Bmpr1a impairs cardiac contractility but protects against pulmonary vascular remodeling.
Hypertension
Soluble form of vascular cell adhesion molecule 1 induces migration and proliferation of vascular smooth muscle cells.
Hypertension
Src Kinases Regulate Glutamatergic Input to Hypothalamic Presympathetic Neurons and Sympathetic Outflow in Hypertension.
Hypertension
Subcellular redistribution of focal adhesion kinase and its related nonkinase in hypertrophic myocardium.
Hypertension
The BMP Receptor 2 in Pulmonary Arterial Hypertension: When and Where the Animal Model Matches the Patient.
Hypertension
The Dynamic Actin Cytoskeleton in Smooth Muscle.
Hypertension
Three novel BMPR2 mutations associated with advanced pulmonary arterial hypertension.
Hypertension
[Expression of focal adhesion kinase in cardiac myocytes of hypertrophic ventricle]
Hypertension
[NF-?B inhibitor improves pulmonary vascular remodeling by reversing LPS-induced down-regulation of BMPRII].
Hypertension
[Phosphorylation and nuclear translocation of serine 722 and serine 910 of focal adhesion kinase in hypertrophic cardiac myocytes of left ventricle of spontaneously hypertensive rats]
Hypertension
[Pulmonary arterial hypertension and BMP system abnormality]
Hypertension, Portal
Screening strategies for pulmonary arterial hypertension.
Hypertension, Pulmonary
Activation of signaling molecules and matrix metalloproteinases in right ventricular myocardium of rats with pulmonary hypertension.
Hypertension, Pulmonary
Augmented pulmonary vasoconstrictor reactivity following chronic hypoxia requires Src kinase and EGFR signaling.
Hypertension, Pulmonary
Critical Role of the Axonal Guidance Cue EphrinB2 in Lung Growth, Angiogenesis, and Repair.
Hypertension, Pulmonary
Dasatinib induces lung vascular toxicity and predisposes to pulmonary hypertension.
Hypertension, Pulmonary
Eicosapentaenoic acid ameliorates pulmonary hypertension via inhibition of tyrosine kinase Fyn.
Hypertension, Pulmonary
Heme Biosynthesis Modulation via ?-Aminolevulinic Acid Administration Attenuates Chronic Hypoxia-induced Pulmonary Hypertension.
Hypertension, Pulmonary
Interleukin-6 Modulates the Expression of the Bone Morphogenic Protein Receptor Type II Through a Novel STAT3-microRNA Cluster 17/92 Pathway.
Hypertension, Pulmonary
Long-term Effects of the Janus Kinase 1/2 Inhibitor Ruxolitinib on Pulmonary Hypertension and the Cardiac Function in a Patient with Myelofibrosis.
Hypertension, Pulmonary
Loss of immune homeostasis in patients with idiopathic pulmonary arterial hypertension.
Hypertension, Pulmonary
Mutations of bone morphogenetic protein receptor type II are not found in patients with pulmonary hypertension and underlying connective tissue diseases.
Hypertension, Pulmonary
Patchy deletion of Bmpr1a potentiates proximal pulmonary artery remodeling in mice exposed to chronic hypoxia.
Hypertension, Pulmonary
Pathobiology of pulmonary arterial hypertension.
Hypertension, Pulmonary
Pulmonary extra-medullary hematopoiesis and pulmonary hypertension from underlying polycythemia vera: a case series.
Hypertension, Pulmonary
Pulmonary vascular remodeling patterns and expression of general control nonderepressible 2 (GCN2) in pulmonary veno-occlusive disease.
Hypertension, Pulmonary
Pyk2 aggravates hypoxia-induced pulmonary hypertension by activating HIF-1?
Hypertension, Pulmonary
RELM-? promotes human pulmonary artery smooth muscle cell proliferation via FAK-stimulated surviving.
Hypertension, Pulmonary
Signaling molecules in nonfamilial pulmonary hypertension.
Hypertension, Pulmonary
[Biomarker screening of rat pulmonary hypertension model by transcriptome sequencing].
Hypertension, Pulmonary
[Pulmonary Hypertension: microRNAs in Pathogenesis, Diagnosis and Therapy.]
Hypertension, Renovascular
Possible interesting link between Janus kinase 2 mutation and renovascular hypertension.
Hypertension, Renovascular
Renovascular hypertension from the BCR-ABL tyrosine kinase inhibitor ponatinib.
Hypertrophy, Left Ventricular
CRNK gene transfer improves function and reverses the myosin heavy chain isoenzyme switch during post-myocardial infarction left ventricular remodeling.
Hypertrophy, Left Ventricular
PYK2 regulates SERCA2 gene expression in neonatal rat ventricular myocytes.
Hypertrophy, Right Ventricular
Cardiac developmental defects and eccentric right ventricular hypertrophy in cardiomyocyte focal adhesion kinase (FAK) conditional knockout mice.
Hypopharyngeal Neoplasms
Association of the upregulated expression of focal adhesion kinase with poor prognosis and tumor dissemination in hypopharyngeal cancer.
Hypophosphatemia
[Cancer and electrolytes imbalance]
Hypospadias
Associations of TGFBR1 and TGFBR2 gene polymorphisms with the risk of hypospadias: a case-control study in a Chinese population.
Hypotension
EPHB4 Protein Expression in Vascular Smooth Muscle Cells Regulates Their Contractility, and EPHB4 Deletion Leads to Hypotension in Mice.
Hypotension
NF-?B activation mediates LPS-or zymosan-induced hypotension and inflammation reversed by BAY61-3606, a selective Syk inhibitor, in rat models of septic and non-septic shock.
Hypothyroidism
Nilotinib-induced hypothyroidism in a patient with chronic myeloid leukemia.
Hypoxia, Brain
Effects of Src kinase inhibition on expression of pro-caspase-2 after brain hypoxia in a piglet animal model.
Hypoxia, Brain
Effects of Src Kinase Inhibition on Expression of Protein Tyrosine Phosphatase 1B after Brain Hypoxia in a Piglet Animal Model.
Hypoxia, Brain
Temporal Changes in Caspase-1 and Caspase-8 Activities Following Brain Hypoxia With and Without Src kinase Inhibition in a Piglet Animal Model.
Hypoxia-Ischemia, Brain
Effect of Src Kinase inhibition on Cytochrome c, Smac/DIABLO and Apoptosis Inducing Factor (AIF) Following Cerebral Hypoxia-Ischemia in Newborn Piglets.
Hypoxia-Ischemia, Brain
Neonatal cerebral hypoxia-ischemia: involvement of FAK-dependent pathway.
Idiopathic Pulmonary Fibrosis
Downregulation of FAK-related non-kinase mediates the migratory phenotype of human fibrotic lung fibroblasts.
Idiopathic Pulmonary Fibrosis
Enhanced Bruton's tyrosine kinase in B-cells and autoreactive IgA in patients with idiopathic pulmonary fibrosis.
Idiopathic Pulmonary Fibrosis
Nintedanib, a triple tyrosine kinase inhibitor, attenuates renal fibrosis in chronic kidney disease.
Ileitis
ZAP-70 genotype disrupts the relationship between microbiota and host, leading to spondyloarthritis and ileitis in SKG mice.
Ileus
Inhibition of JAK1 mitigates postoperative ileus in mice.
Ileus
Inhibition of spleen tyrosine kinase as treatment of postoperative ileus.
Immune System Diseases
Discovery of Evobrutinib: An Oral, Potent, and Highly Selective, Covalent Bruton's Tyrosine Kinase (BTK) Inhibitor for the Treatment of Immunological Diseases.
Immune System Diseases
Effective, safe, and sustained correction of murine XLA using a UCOE-BTK promoter-based lentiviral vector.
Immune System Diseases
Impaired T cell receptor signaling and development of T cell-mediated autoimmune arthritis.
Immune System Diseases
Small-molecule inhibitors of spleen tyrosine kinase as therapeutic agents for immune disorders: will promise meet expectations?
Immune System Diseases
Stereochemical Differences in Fluorocyclopropyl Amides Enable Tuning of Btk Inhibition and Off-Target Activity.
Immune System Diseases
Tubulosine selectively inhibits JAK3 signalling by binding to the ATP-binding site of the kinase of JAK3.
Immune System Diseases
[The next step in the treatment of immune diseases: jakinibs, inhibitors of the intracellular Janus kinase].
Infarction, Middle Cerebral Artery
Delayed phosphorylation of p38 mitogen-activated protein kinase in the AT1a knock-out mouse striatal neurons during middle cerebral artery occlusion and reperfusion.
Infections
A case of Fabry's disease with congenital agammaglobulinemia.
Infections
A de novo transcriptome analysis shows that modulation of the JAK-STAT signaling pathway by salmonid alphavirus subtype 3 favors virus replication in macrophage/dendritic-like TO-cells.
Infections
A deficient translocation of CD3?, ZAP-70 and Grb2 to lipid raft, as a hallmark of defective adaptive immune response during chronic hepatitis B infection.
Infections
A Dual Role for the Nonreceptor Tyrosine Kinase Pyk2 during the Intracellular Trafficking of Human Papillomavirus 16.
Infections
A new retroviral vector, CA1, to identify and select for cells expressing an inserted gene in vitro and in vivo.
Infections
A novel focal adhesion kinase from Marsupenaeus japonicus and its response to WSSV infection.
Infections
A Patient with Tyrosine Kinase 2 Deficiency without Hyper-IgE Syndrome.
Infections
A role for c-Abl in c-myc regulation.
Infections
Abelson tyrosine kinase facilitates Salmonella enterica serovar Typhimurium entry into epithelial cells.
Infections
Abl Tyrosine Kinase Regulates Hepatitis C Virus Entry.
Infections
Abnormal peripheral lymphocyte function in c-abl mutant mice.
Infections
Abrogation of factor-dependence in two IL-3-dependent cell lines can occur by two distinct mechanisms.
Infections
Abrogation of IL-3 dependent growth requires a functional v-src gene product: evidence for an autocrine growth cycle.
Infections
Access to nectin favors herpes simplex virus infection at the apical surface of polarized human epithelial cells.
Infections
Activated lck tyrosine protein kinase stimulates antigen-independent interleukin-2 production in T cells.
Infections
Activation of Abl by Helicobacter pylori: a novel kinase for CagA and crucial mediator of host cell scattering.
Infections
Activation of the MAPK, ERK, following Leishmania amazonensis infection of macrophages.
Infections
Altered stem cell (CFU-S) function following infection of hematopoietic cells with a virus carrying V-src.
Infections
An immediate-early protein of white spot syndrome virus modulates the phosphorylation of focal adhesion kinase of shrimp.
Infections
Angiopoietin/Tie2 signaling transforms capillaries into venules primed for leukocyte trafficking in airway inflammation.
Infections
ATP1A1-mediated Src signaling inhibits coronavirus entry into host cells.
Infections
Avian influenza viruses inhibit the major cellular signalling integrator c-Abl.
Infections
Beta Interferon-Mediated Activation of Signal Transducer and Activator of Transcription Protein 1 Interferes with Rickettsia conorii Replication in Human Endothelial Cells.
Infections
Bone marrow B lymphocyte development in c-abl-deficient mice.
Infections
c-SRC protein tyrosine kinase regulates early HIV-1 infection post-entry.
Infections
Caveolin-1 associated adenovirus entry into human corneal cells.
Infections
CD36 and Fyn Kinase Mediate Malaria-Induced Lung Endothelial Barrier Dysfunction in Mice Infected with Plasmodium berghei.
Infections
CD46 is phosphorylated at tyrosine 354 upon infection of epithelial cells by Neisseria gonorrhoeae.
Infections
Cerebral aspergillosis in a patient on ibrutinib therapy-A predisposition not to overlook.
Infections
Changes in the level of apoptosis-related proteins in Jurkat cells infected with HIV-1 versus HIV-2.
Infections
Characteristics of Chikungunya virus infection in patients with established rheumatoid arthritis.
Infections
Chicken myeloid stem cells infected by retroviruses carrying the v-fps oncogene do not require exogenous growth factors to differentiate in vitro.
Infections
Chlamydial Infection of Monocytes Stimulates IL-1beta Secretion Through Activation of the NLRP3 Inflammasome.
Infections
Conditional ablation of TYK2 in immunity to viral infection and tumor surveillance.
Infections
Considerations for safety in the use of systemic medications for psoriasis and atopic dermatitis during the COVID-19 pandemic.
Infections
Correlation Between PAI-1 Gene 4G/5G Polymorphism and the Risk of Thrombosis in Ph Chromosome-Negative Myeloproliferative Neoplasms.
Infections
Debilitating progressive encephalitis in a patient with BTK deficiency.
Infections
Decoding Susceptibility to Respiratory Viral Infections and Asthma Inception in Children.
Infections
Dectin-1 Activation during Leishmania amazonensis Phagocytosis Prompts Syk-Dependent Reactive Oxygen Species Production To Trigger Inflammasome Assembly and Restriction of Parasite Replication.
Infections
Defects in Jak-STAT-mediated cytokine signals cause hyper-IgE syndrome: lessons from a primary immunodeficiency.
Infections
Delayed diagnosis of X-linked agammaglobulinaemia in a boy with recurrent meningitis.
Infections
Diffuse-type gastric carcinoma: progression, angiogenesis, and transforming growth factor beta signaling.
Infections
Discovery of Janus Kinase 2 (JAK2) and Histone Deacetylase (HDAC) Dual Inhibitors as a Novel Strategy for the Combinational Treatment of Leukemia and Invasive Fungal Infections.
Infections
Dissection of signaling pathways and cloning of new signal transducers in tyrosine kinase-induced pathways by genetic selection.
Infections
Disseminated Bacille Calmette-Guérin infection in a patient with severe combined immunodeficiency caused by JAK3 gene mutation.
Infections
Disseminated Cryptococcal Disease in a Patient with Chronic Lymphocytic Leukemia on Ibrutinib.
Infections
Down regulation by p60v-src of genes specifically expressed and developmentally regulated in postmitotic quail neuroretina cells.
Infections
Down-modulation of the ZAP-70 protein tyrosine kinase in macaque T lymphocytes infected with SIVsmmPBj14.
Infections
Dual microRNA Screens Reveal That the Immune-Responsive miR-181 Promotes Henipavirus Entry and Cell-Cell Fusion.
Infections
Dysregulation of focal adhesion kinase upon Toxoplasma gondii infection facilitates parasite translocation across polarised primary brain endothelial cell monolayers.
Infections
Effect of Bruton tyrosine kinase inhibitor on efficacy of adjuvanted recombinant hepatitis B and zoster vaccines.
Infections
Effect of infection with murine recombinant retroviruses containing the v-src oncogene on interleukin 2- and interleukin 3-dependent growth states.
Infections
Effect of the mutation of tyrosine 713 in p93c-fes on its catalytic activity and ability to promote myeloid differentiation in K562 cells.
Infections
Effects of colony-stimulating factors on leukemia progenitor cells and oncogene expression.
Infections
Endothelial Cell Proteomic Response to Rickettsia conorii Infection Reveals Activation of the Janus Kinase (JAK)-Signal Transducer and Activator of Transcription (STAT)-Inferferon Stimulated Gene (ISG)15 Pathway and Reprogramming Plasma Membrane Integrin/Cadherin Signaling.
Infections
Enteropathogenic Escherichia coli induces modification of the focal adhesions of infected host cells.
Infections
Ephrin B2 expression in Kaposi sarcoma is induced by human herpesvirus type 8: phenotype switch from venous to arterial endothelium.
Infections
Epstein-Barr virus latent membrane protein 2A blocks calcium mobilization in B lymphocytes.
Infections
ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an Infectious Diseases perspective (Intracellular signaling pathways: tyrosine kinase and mTOR inhibitors).
Infections
EVALUATION OF EXPERIMENTAL INFECTION WITH L. (L.) AMAZONENSIS IN X-LINKED IMMUNODEFICIENT MICE.
Infections
Express path analysis identifies a tyrosine kinase Src-centric network regulating divergent host responses to Mycobacterium tuberculosis infection.
Infections
Expression of a novel gene encoding a 51.5 kD precursor protein is induced by different retroviral oncogenes in quail neuroretinal cells.
Infections
Expression of etk/bmx tyrosine kinase in intrahepatic cholangiocarcinoma.
Infections
Expression of Etk/Bmx tyrosine kinase in the tumorigenicity of nasopharyngeal epithelium and its relation with EB virus infection and the apoptosis-related protein Bcl-2.
Infections
Expression of p56lck in B-cell neoplasias.
Infections
Expression of transforming growth factor beta type II receptor reduces tumorigenicity in human gastric cancer cells.
Infections
Expression of tyrosine kinase Etk/Bmx and its relationship with AP-1- and NF-kappaB-associated proteins in hepatocellular carcinoma.
Infections
Expression of v-src in embryonic neural retina alters cell adhesion, inhibits histogenesis, and prevents induction of glutamine synthetase.
Infections
Extracellular pressure stimulates macrophage phagocytosis by inhibiting a pathway involving FAK and ERK.
Infections
Fatal disseminated mouse adenovirus type 1 infection in mice lacking B cells or Bruton's tyrosine kinase.
Infections
Focal adhesion kinase activation is required for TNF-?-induced production of matrix metalloproteinase-2 and proinflammatory cytokines in cultured human periodontal ligament fibroblasts.
Infections
Focal adhesion kinase is critical for entry of Kaposi's sarcoma-associated herpesvirus into target cells.
Infections
Focal adhesion kinase plays a pivotal role in herpes simplex virus entry.
Infections
Gamma interferon-induced interferon regulatory factor 1-dependent antiviral response inhibits vaccinia virus replication in mouse but not human fibroblasts.
Infections
Gene expression profiling in AGS cells stimulated with Helicobacter pylori isogenic strains (cagA positive or cagA negative).
Infections
Genetics in community-acquired pneumonia.
Infections
Genome-Wide Gene Expression Analysis Identifies the Proto-oncogene Tyrosine-Protein Kinase Src as a Crucial Virulence Determinant of Infectious Laryngotracheitis Virus in Chicken Cells.
Infections
HECT E3 Ubiquitin Ligase Nedd4 Is Required for Antifungal Innate Immunity.
Infections
Helicobacter canis bacteraemia in a rheumatoid arthritis patient treated with tofacitinib: case report and literature review.
Infections
Helicobacter pylori CagA Induces Cortactin Y-470 Phosphorylation-Dependent Gastric Epithelial Cell Scattering via Abl, Vav2 and Rac1 Activation.
Infections
Helicobacter pylori infection and lung cancer: a review of an emerging hypothesis.
Infections
Helicobacter pylori infection interferes with epithelial Stat6-mediated interleukin-4 signal transduction independent of cagA, cagE, or VacA.
Infections
Hematologic disease induced in BALB/c mice by a bcr-abl retrovirus is influenced by the infection conditions.
Infections
Herpes simplex virus requires VP11/12 to activate Src family kinase-phosphoinositide 3-kinase-Akt signaling.
Infections
Herpes simplex virus triggers activation of calcium-signaling pathways.
Infections
Herpes Simplex Virus Type 1 Neuronal Infection Perturbs Golgi Apparatus Integrity through Activation of Src Tyrosine Kinase and Dyn-2 GTPase.
Infections
HIV-1 down-regulates CD4 costimulation of TCR/CD3-directed tyrosine phosphorylation through CD4/p56lck dissociation.
Infections
HIV-1 infection is facilitated in T cells by decreasing p56lck protein tyrosine kinase activity.
Infections
Host Src controls gallid alpha herpesvirus 1 intercellular spread in a cellular fatty acid metabolism-dependent manner.
Infections
Human cytomegalovirus induces cellular tyrosine kinase signaling and promotes glioma cell invasiveness.
Infections
Human herpesvirus 7 induces the down-regulation of CD4 antigen in lymphoid T cells without affecting p56lck levels.
Infections
Human metapneumovirus inhibits IFN-? signaling by downregulating Jak1 and Tyk2 cellular levels.
Infections
Hydroquinone regulates hemeoxygenase-1 expression via modulation of Src kinase activity through thiolation of cysteine residues.
Infections
Hyper-IgE syndrome.
Infections
Hypoxia Decreases Invasin-Mediated Yersinia enterocolitica Internalization into Caco-2 Cells.
Infections
Ibrutinib in PCNSL: The Curious Cases of Clinical Responses and Aspergillosis.
Infections
Ibrutinib, a Bruton's tyrosine kinase inhibitor, a new risk factor for cryptococcosis.
Infections
IFN-alpha beta secreted during infection is necessary but not sufficient for negative feedback regulation of IFN-alpha beta signaling by Mycobacterium tuberculosis.
Infections
IL-2-inducible T-cell kinase deficiency with pulmonary manifestations due to disseminated Epstein-Barr virus infection.
Infections
Immunosuppressive drugs for patients with psoriasis during the COVID-19 pandemic era. A review.
Infections
In vivo administration of a JAK3 inhibitor to chronically siv infected rhesus macaques leads to NK cell depletion associated with transient modest increase in viral loads.
Infections
In vivo tumor surveillance by NK cells requires TYK2 but not TYK2 kinase activity.
Infections
Incipient Diabetes Mellitus and Nascent Thyroid Disease Presenting as Beard Alopecia Areata: Case Report and Treatment Review of Alopecia Areata of the Beard.
Infections
Increased Src kinase level results in increased protein tyrosine phosphorylation in scrapie-infected neuronal cell lines.
Infections
Induction of cyclophilin A by influenza A virus infection facilitates group A Streptococcus coinfection.
Infections
Infection of terminally differentiated myotubes with Rous sarcoma virus: reduced synthesis of env and v-src proteins.
Infections
Infection risk in patients undergoing treatment for inflammatory arthritis: non-biologics versus biologics.
Infections
Infections in baricitinib clinical trials for patients with active rheumatoid arthritis.
Infections
Infections in Dupilumab Clinical Trials in Atopic Dermatitis: A Comprehensive Pooled Analysis.
Infections
Infections in patients on BCR-ABL tyrosine kinase inhibitor therapy: cases and review of the literature.
Infections
Infiltration of tumor-reactive transforming growth factor-beta insensitive CD8+ T cells into the tumor parenchyma is associated with apoptosis and rejection of tumor cells.
Infections
Integrin alpha3beta1 (CD 49c/29) is a cellular receptor for Kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8) entry into the target cells.
Infections
Intracellular invasion by Orientia tsutsugamushi is mediated by integrin signaling and actin cytoskeleton rearrangements.
Infections
Ixodes scapularis JAK-STAT Pathway Regulates Tick Antimicrobial Peptides, Thereby Controlling the Agent of Human Granulocytic Anaplasmosis.
Infections
JAK3 restrains inflammatory responses and protects against periodontal disease through Wnt3a signaling.
Infections
Janus kinase inhibitors prevent migration of rheumatoid arthritis neutrophils towards interleukin-8, but do not inhibit priming of the respiratory burst or reactive oxygen species production.
Infections
JNK regulates MCP-1 expression in adenovirus type 19-infected human corneal fibroblasts.
Infections
Kaposi's sarcoma-associated herpesvirus induces the phosphatidylinositol 3-kinase-PKC-zeta-MEK-ERK signaling pathway in target cells early during infection: implications for infectivity.
Infections
Kinase activity profiling of Gram-negative pneumonia.
Infections
Laminin acts via focal adhesion kinase/phosphatidylinositol-3' kinase/protein kinase B to down-regulate beta1-adrenergic receptor signalling in cat atrial myocytes.
Infections
Leishmania donovani amastigotes impair gamma interferon-induced STAT1alpha nuclear translocation by blocking the interaction between STAT1alpha and importin-alpha5.
Infections
Leishmania donovani Exploits Tollip, a Multitasking Protein, To Impair TLR/IL-1R Signaling for Its Survival in the Host.
Infections
lncRNA AK085865 Promotes Macrophage M2 Polarization in CVB3-Induced VM by Regulating ILF2-ILF3 Complex-Mediated miRNA-192 Biogenesis.
Infections
Malignant transformation of an epithelial cell by v-Src via tv-a-mediated retroviral infection: a new cell model for studying carcinogenesis.
Infections
Management of patients with chronic lymphocytic leukemia during the SARS-CoV-2 pandemic.
Infections
Mechanism of baricitinib supports artificial intelligence-predicted testing in COVID-19 patients.
Infections
Mice lacking protein tyrosine kinase fyn develop a T helper-type 1 response and resistLeishmania major infection.
Infections
Microarray analysis of genes with differential expression of m6A methylation in lung cancer.
Infections
Modulation of enzymatic activity of Src-family kinases in bovine T cells transformed by Theileria parva.
Infections
Morpholino-based correction of hypomorphic ZAP70 mutation in an adult with combined immunodeficiency.
Infections
Morphological transformation, tumorigenicity and src-specific cytotoxic T-lymphocyte-mediated tumor immunity induced by murine 3T3 cells expressing src oncogenes encoding novel non-myristylated N-terminal domains.
Infections
Mutation of a site of tyrosine phosphorylation in the lymphocyte-specific tyrosine protein kinase, p56lck, reveals its oncogenic potential in fibroblasts.
Infections
Myeloid-derived tissue-type plasminogen activator promotes macrophage motility through FAK, Rac1, and NF-?B pathways.
Infections
MYO1F regulates antifungal immunity by regulating acetylation of microtubules.
Infections
Myxoma virus selectively disrupts type I interferon signaling in primary human fibroblasts by blocking the activation of the Janus kinase Tyk2.
Infections
Nef stimulates proliferation of glomerular podocytes through activation of Src-dependent Stat3 and MAPK1,2 pathways.
Infections
Negative Correlation Between Hepatitis C Virus (HCV) and Let-7 MicroRNA Family in Transplanted Livers: The Role of rs868 Single-Nucleotide Polymorphism.
Infections
Network pharmacology of JAK inhibitors.
Infections
NLRP3 inflammasome activation by Paracoccidioides brasiliensis.
Infections
Nonmuscle Myosin Heavy Chain IIA Recognizes Sialic Acids on Sialylated RNA Viruses To Suppress Proinflammatory Responses via the DAP12-Syk Pathway.
Infections
Nonreceptor Tyrosine Kinase c-Abl- and Arg-Mediated IRF3 Phosphorylation Regulates Innate Immune Responses by Promoting Type I IFN Production.
Infections
Novel Roles of Focal Adhesion Kinase in Cytoplasmic Entry and Replication of Influenza A Viruses.
Infections
Oncogene-dependent engraftment of human myeloid leukemia cells in immunosuppressed mice.
Infections
Overexpression and significance of focal adhesion kinase in hepatocellular carcinoma and its relationship with HBV infection.
Infections
Pathogenic prions deviate PrP(C) signaling in neuronal cells and impair A-beta clearance.
Infections
Phosphorylation of Helicobacter pylori CagA by c-Abl leads to cell motility.
Infections
PID in Disguise: Molecular Diagnosis of IRAK-4 Deficiency in an Adult Previously Misdiagnosed With Autosomal Dominant Hyper IgE Syndrome.
Infections
Population context determines cell-to-cell variability in endocytosis and virus infection.
Infections
Potent activity of a nucleoside reverse transcriptase inhibitor, 4'-ethynyl-2-fluoro-2'-deoxyadenosine, against human immunodeficiency virus type 1 infection in a model using human peripheral blood mononuclear cell-transplanted NOD/SCID Janus kinase 3 knockout mice.
Infections
Primary immunodeficiency diseases associated with increased susceptibility to viral infections and malignancies.
Infections
Profound differences in potassium current properties of normal and Rous sarcoma virus-transformed chicken embryo fibroblasts.
Infections
Protein kinase A-mediated inhibition of gamma interferon-induced tyrosine phosphorylation of Janus kinases and latent cytoplasmic transcription factors in human monocytes by Ehrlichia chaffeensis.
Infections
Quercetin Prevents Escherichia coli O157:H7 Adhesion to Epithelial Cells via Suppressing Focal Adhesions.
Infections
Reconstitution of humoral immunity and decreased risk of infections in patients with chronic lymphocytic leukemia treated with Bruton tyrosine kinase inhibitors.
Infections
Reduced c-Met expression by an adenovirus expressing a c-Met ribozyme inhibits tumorigenic growth and lymph node metastases of PC3-LN4 prostate tumor cells in an orthotopic nude mouse model.
Infections
Regulation of Constitutive Interferon-Stimulated Genes (Isgs) in Tumor Cells Contributes to Enhanced Antitumor Response of Newcastle Disease Virus-Infected Tumor Vaccines.
Infections
Regulation of type I interferon signaling in immunity and inflammation: A comprehensive review.
Infections
Requirement for Abl kinases in T cell receptor signaling.
Infections
Retroviral insertional mutagenesis identifies RUNX genes involved in chronic myeloid leukemia disease persistence under imatinib treatment.
Infections
Risk for infections with glucocorticoids and DMARDs in patients with rheumatoid arthritis.
Infections
Risk of infection associated with Janus Kinase (JAK) inhibitors and biological therapies in inflammatory intestinal disease and rheumatoid arthritis. Prevention strategies.
Infections
Risk of infection associated with targeted therapies for solid organ and hematological malignancies.
Infections
Role of Abl kinase and the Wave2 signaling complex in HIV-1 entry at a post-hemifusion step.
Infections
Role of B cells in host defense against primary Coxiella burnetii infection.
Infections
Role of Herpes Simplex Virus VP11/12 Tyrosine-Based Motifs in Binding and Activation of the Src Family Kinase Lck and Recruitment of p85, Grb2, and Shc.
Infections
Schistosoma mansoni FES Tyrosine Kinase Involvement in the Mammalian Schistosomiasis Outcome and Miracidia Infection Capability in Biomphalaria glabrata.
Infections
Selective immortalization of murine macrophages from fresh bone marrow by a raf/myc recombinant murine retrovirus.
Infections
Serine phosphorylation of cortactin controls focal adhesion kinase activity and cell scattering induced by Helicobacter pylori.
Infections
Short-term treatment with gamma interferon induces stable reversion of ras-transformed mouse fibroblasts.
Infections
Some findings of FADD knockdown in inhibition of HIV-1 replication in Jurkat cells and PBMCs.
Infections
Spleen Tyrosine Kinase as a Target Therapy for Pseudomonas aeruginosa Infection.
Infections
Spleen tyrosine kinase from Nile tilapia (Oreochromis niloticus): Molecular characterization, expression pattern upon bacterial infection and the potential role in BCR signaling and inflammatory response.
Infections
Src kinase inhibition with dasatinib impairs neutrophil function and clearance of Escherichia coli infection in a murine model of acute lung injury.
Infections
Src-dependent Tyrosine Phosphorylation of Non-muscle Myosin Heavy Chain-IIA Restricts Listeria monocytogenes Cellular Infection.
Infections
State and role of SRC family kinases in replication of herpes simplex virus 1.
Infections
Suspected Herpes Zoster-associated Encephalitis during Treatment with Oral Tofacitinib in Alopecia Universalis.
Infections
Taohong siwu decoction attenuates myocardial fibrosis by inhibiting fibrosis proliferation and collagen deposition via TGFBR1 signaling pathway.
Infections
Testosterone-induced persistent susceptibility to Plasmodium chabaudi malaria: long-term changes of lincRNA and mRNA expression in the spleen.
Infections
TGF-beta 1 signaling controls retinal pericyte contractile protein expression.
Infections
The Amino-Terminal Part of the Needle-Tip Translocator LcrV of Yersinia pseudotuberculosis Is Required for Early Targeting of YopH and In vivo Virulence.
Infections
The c-Src and Pyk2 protein tyrosine kinases play protective roles in early HIV-1 infection of CD4+ T cell lines.
Infections
The gammac-cytokine regulated transcription factor, STAT5, increases HIV-1 production in primary CD4 T cells.
Infections
The integrin-triggered rescue of T lymphocyte apoptosis is blocked in HIV-1-infected individuals.
Infections
The Interplay of Notch Signaling and STAT3 in TLR-Activated Human Primary Monocytes.
Infections
The non-receptor tyrosine kinase Tec controls assembly and activity of the noncanonical caspase-8 inflammasome.
Infections
The pathogenic E. coli type III effector EspZ interacts with host CD98 and facilitates host cell prosurvival signalling.
Infections
The product of the v-src-inducible gene nr-13 is a potent anti-apoptotic factor.
Infections
The relationship of modulation of major histocompatibility complex class I antigens to retrovirus transformation in rat cell lines.
Infections
The role of p56lck in the development of gamma delta T cells and their function during an infection by Listeria monocytogenes.
Infections
The tyrosine kinase p56lck is essential in coxsackievirus B3-mediated heart disease.
Infections
The v-src oncogene may not be responsible for the increased radioresistance of hematopoietic progenitor cells expressing v-src.
Infections
TLR2/CXCR4 coassociation facilitates Chlamydia pneumoniae infection-induced atherosclerosis.
Infections
Toxoplasma gondii inhibits mast cell degranulation by suppressing phospholipase C?-mediated Ca(2+) mobilization.
Infections
Transcriptional downregulation of the retina-specific QR1 gene by pp60v-src and identification of a novel v-src-responsive unit.
Infections
Transcriptional stimulation of the retina-specific QR1 gene upon growth arrest involves a Maf-related protein.
Infections
Transgenes encoding both type I and type IV c-abl proteins rescue the lethality of c-abl mutant mice.
Infections
Transient myelodysplastic syndrome in X-linked agammaglobulinemia with a novel Btk mutation.
Infections
Tuberculosis, hepatitis B and herpes zoster in tofacitinib-treated patients with rheumatoid arthritis.
Infections
Tumor Suppressor Analysis in CML.
Infections
Two sequential layers of antibody-mediated control of Legionella pneumophila infection.
Infections
Type II interferon signaling in the brain during a viral infection with age-dependent pathogenesis.
Infections
Usage of heparan sulfate, integrins, and FAK in HPV16 infection.
Infections
X-linked agammaglobulinemia - first case with Bruton tyrosine kinase mutation from Pakistan.
Infections
Yellow Fever Virus, but Not Zika Virus or Dengue Virus, Inhibits T-Cell Receptor-Mediated T-Cell Function by an RNA-Based Mechanism.
Infections
ZAP-70 positive cells in treated and untreated HIV-1 infected patients.
Infections
ZAP-70, CTLA-4 and proximal T cell receptor signaling in cows infected with Mycobacterium avium subsp. paratuberculosis.
Infections
[Clinical significance of ZAP-70 protein expression in chronic lymphocytic leukemia/small lymphocytic lymphoma]
Infections
[Risk Factors of Leukemia-free Survival in Ph
Infections
[Severe Hepatitis E virus infection in a patient with rheumatoid arthritis treated with baricitinib].
Infertility
BMPR1A and BMPR1B Missense Mutations Cause Primary Ovarian Insufficiency.
Infertility
Determination of c-Abl tyrosine kinase and mTERT catalytic subunit of telomerase expression level during prenatal-postnatal mouse ovary-testis development.
Infertility
Genetic studies of MIS signalling in sexual development.
Infertility
Ptk2b deletion improves mice folliculogenesis and fecundity via inhibiting follicle loss mediated by Erk pathway.
Infertility
Successful Planned Pregnancy through Vitrified-Warmed Embryo Transfer in a Woman with Chronic Myeloid Leukemia: Case Report and Literature Review.
Infertility, Male
Transcriptional alterations of genes related to fertility decline in male rats induced by chronic sleep restriction.
Inflammatory Bowel Diseases
Advances in the Development of Janus Kinase Inhibitors in Inflammatory Bowel Disease: Future Prospects.
Inflammatory Bowel Diseases
Association between single nucleotide polymorphisms in prospective genes and susceptibility to ankylosing spondylitis and inflammatory bowel disease in a single centre in Turkey.
Inflammatory Bowel Diseases
CCL4-mediated targeting of spleen tyrosine kinase (Syk) inhibitor using nanoparticles alleviates inflammatory bowel disease.
Inflammatory Bowel Diseases
Clinical Pharmacology of Janus Kinase Inhibitors in Inflammatory Bowel Disease.
Inflammatory Bowel Diseases
Corrigendum: The Future of Janus Kinase Inhibitors in Inflammatory Bowel Disease.
Inflammatory Bowel Diseases
Enhancer of zeste homolog 2 contributes to apoptosis by inactivating janus kinase 2/ signal transducer and activator of transcription signaling in inflammatory bowel disease.
Inflammatory Bowel Diseases
Food Processing, Dysbiosis, Gastrointestinal Inflammatory Diseases, and Antiangiogenic Functional Foods or Beverages.
Inflammatory Bowel Diseases
Genetic and Pharmacological Dissection of the Role of Spleen Tyrosine Kinase (Syk) in Intestinal Inflammation and Immune Dysfunction in Inflammatory Bowel Diseases.
Inflammatory Bowel Diseases
Intestinally-restricted Janus Kinase inhibition: a potential approach to maximize the therapeutic index in inflammatory bowel disease therapy.
Inflammatory Bowel Diseases
JAK inhibitors and infections risk: focus on herpes zoster.
Inflammatory Bowel Diseases
JAK-STAT inhibitors for the treatment of immunomediated diseases.
Inflammatory Bowel Diseases
Janus Kinase Inhibition With Tofacitinib: Changing the Face of Inflammatory Bowel Disease Treatment.
Inflammatory Bowel Diseases
Janus kinase inhibitors for the treatment of inflammatory bowel diseases: developments from phase I and phase II clinical trials.
Inflammatory Bowel Diseases
Kinase inhibitors in the treatment of immune-mediated disease.
Inflammatory Bowel Diseases
Long-term safety and tolerability of oral tofacitinib in patients with Crohn's disease: results from a phase 2, open-label, 48-week extension study.
Inflammatory Bowel Diseases
Optimizing Immunization Strategies in Patients with IBD.
Inflammatory Bowel Diseases
PF-06651600, a Dual JAK3/TEC Family Kinase Inhibitor.
Inflammatory Bowel Diseases
Reduced migration of fibroblasts in inflammatory bowel disease: role of inflammatory mediators and focal adhesion kinase.
Inflammatory Bowel Diseases
Regulation of Janus Kinase 2 by an Inflammatory Bowel Disease Causal Non-coding Single Nucleotide Polymorphism.
Inflammatory Bowel Diseases
Role of Csk in intestinal epithelial barrier function and protection against colitis.
Inflammatory Bowel Diseases
Safety and potential interaction of immunosuppressive drugs for the treatment of inflammatory bowel disease in elderly patients.
Inflammatory Bowel Diseases
Safety of Janus Kinase Inhibitors in Patients with Inflammatory Bowel Diseases or Other Immune-mediated Diseases: a Systematic Review and Meta-Analysis.
Inflammatory Bowel Diseases
Selective Tyrosine Kinase 2 Inhibition for Treatment of Inflammatory Bowel Disease: New Hope on the Rise.
Inflammatory Bowel Diseases
Spondyloarthritis: new insights into clinical aspects, translational immunology and therapeutics.
Inflammatory Bowel Diseases
Strong Evidence of a Combination Polymorphism of the Tyrosine Kinase 2 Gene and the Signal Transducer and Activator of Transcription 3 Gene as a DNA-Based Biomarker for Susceptibility to Crohn's Disease in the Japanese Population.
Inflammatory Bowel Diseases
Systematic review with meta-analysis: efficacy and safety of oral Janus kinase inhibitors for inflammatory bowel disease.
Inflammatory Bowel Diseases
The Future of Janus Kinase Inhibitors in Inflammatory Bowel Disease.
Inflammatory Bowel Diseases
Tofacitinib Therapy in Children and Young Adults With Pediatric-onset Medically Refractory Inflammatory Bowel Disease.
Inflammatory Bowel Diseases
Tyrosine kinase 2 signalling drives pathogenic T-cells in colitis.
Inflammatory Bowel Diseases
Update on Janus kinase antagonists in inflammatory bowel disease.
Inflammatory Bowel Diseases
Vaccination in Patients with Inflammatory Bowel Diseases.
Inflammatory Bowel Diseases
Vaccinations in Adult Patients with Inflammatory Bowel Diseases in the West.
Inflammatory Bowel Diseases
Why Do Immunosuppressed Patients with Inflammatory Bowel Disease Not Seem to Be at a Higher Risk of COVID-19?
Inflammatory Bowel Diseases
[Biologics and Janus kinase inhibitor for inflammatory bowel disease -understanding the clinical guideline for IBD].
Inflammatory Breast Neoplasms
The effects of CEP-37440, an inhibitor of focal adhesion kinase, in vitro and in vivo on inflammatory breast cancer cells.
Influenza in Birds
Avian influenza viruses inhibit the major cellular signalling integrator c-Abl.
Influenza in Birds
Hemagglutinin from the H5N1 Virus Activates Janus Kinase 3 to Dysregulate Innate Immunity.
Influenza in Birds
Nonstructural Protein 1 (NS1)-Mediated Inhibition of c-Abl Results in Acute Lung Injury and Priming for Bacterial Coninfections: Insights Into 1918 H1N1 Pandemic?
Influenza in Birds
The PDZ-ligand and Src-homology type 3 domains of epidemic avian influenza virus NS1 protein modulate human Src kinase activity during viral infection.
Influenza, Human
CLEC5A-Mediated Enhancement of the Inflammatory Response in Myeloid Cells Contributes to Influenza Virus Pathogenicity In Vivo.
Influenza, Human
Entropy Hotspots for the Binding of Intrinsically Disordered Ligands to a Receptor Domain.
Influenza, Human
Focal adhesion kinase (FAK) regulates polymerase activity of multiple influenza A virus subtypes.
Influenza, Human
In Vitro and In Vivo Antiviral Activity of Gingerenone A on Influenza A Virus Is Mediated by Targeting Janus Kinase 2.
Influenza, Human
Inhibiting Bruton's Tyrosine Kinase Rescues Mice from Lethal Influenza Induced Acute Lung Injury.
Influenza, Human
Novel Roles of Focal Adhesion Kinase in Cytoplasmic Entry and Replication of Influenza A Viruses.
Influenza, Human
Optimization of the Isolation and Amplification of RNA From Formalin-fixed, Paraffin-embedded Tissue: The Armed Forces Institute of Pathology Experience and Literature Review.
Influenza, Human
Quantitative subcellular proteome and secretome profiling of influenza A virus-infected human primary macrophages.
Influenza, Human
Sphingosine 1-phosphate-metabolizing enzymes control influenza virus propagation and viral cytopathogenicity.
Influenza, Human
Structure and Dynamics of Membrane Proteins and Membrane Associated Proteins with Native Bicelles from Eukaryotic Tissues.
Insulin Resistance
Adipocyte-specific deficiency of Janus kinase (JAK) 2 in mice impairs lipolysis and increases body weight, and leads to insulin resistance with ageing.
Insulin Resistance
c-Abl inhibition mitigates diet-induced obesity through improving insulin sensitivity of subcutaneous fat in mice.
Insulin Resistance
Decreased erythrocyte insulin binding in hypertensive subjects with hyperinsulinemia.
Insulin Resistance
Effects of imatinib on vascular insulin sensitivity and free fatty acid transport in early weight gain.
Insulin Resistance
Focal Adhesion Kinase contributes to insulin-induced actin reorganization into a mesh harboring Glucose transporter-4 in insulin resistant skeletal muscle cells.
Insulin Resistance
Focal adhesion kinase negatively regulates neuronal insulin resistance.
Insulin Resistance
Focal adhesion kinase regulates insulin resistance in skeletal muscle.
Insulin Resistance
Immunofluorescent visualisation of focal adhesion kinase in human skeletal muscle and its associated microvasculature.
Insulin Resistance
Impact of fasting on growth hormone signaling and action in muscle and fat.
Insulin Resistance
In vivo inhibition of focal adhesion kinase causes insulin resistance.
Insulin Resistance
Insulin-Like Growth Factor Binding Protein 1 Could Improve Glucose Regulation and Insulin Sensitivity Through Its RGD Domain.
Insulin Resistance
Leptin down-regulates insulin action through phosphorylation of serine-318 in insulin receptor substrate 1.
Insulin Resistance
Loss of BMP receptor type 1A in murine adipose tissue attenuates age-related onset of insulin resistance.
Insulin Resistance
Novel phosphorylation of PPAR? ameliorates obesity-induced adipose tissue inflammation and improves insulin sensitivity.
Insulin Resistance
Tumor necrosis factor-alpha induces hepatic insulin resistance in obese Zucker (fa/fa) rats via interaction of leukocyte antigen-related tyrosine phosphatase with focal adhesion kinase.
Insulin Resistance
Tyrosine Kinase Inhibitors and Diabetes: A Novel Treatment Paradigm?
Insulin Resistance
Upregulation of IL-4 signaling contributes to aerobic exercise-induced insulin sensitivity.
Insulinoma
C-Abl inhibitor imatinib enhances insulin production by ? cells: c-Abl negatively regulates insulin production via interfering with the expression of NKx2.2 and GLUT-2.
Intellectual Disability
Abl2/Arg controls dendritic spine and dendrite arbor stability via distinct cytoskeletal control pathways.
Intellectual Disability
Duplication of 10q22.3-q23.3 encompassing BMPR1A and NGR3 associated with congenital heart disease, microcephaly, and mild intellectual disability.
Intellectual Disability
[Genetic testing and prenatal diagnosis for a family with 10q22.3q23.2 microdeletion].
Intervertebral Disc Degeneration
Wnt11 overexpression promote adipose-derived stem cells differentiating to the nucleus pulposus-like phenotype.
Intervertebral Disc Displacement
Impact of Wnt signals on human intervertebral disc cell regeneration.
Intestinal Diseases
Risk of infection associated with Janus Kinase (JAK) inhibitors and biological therapies in inflammatory intestinal disease and rheumatoid arthritis. Prevention strategies.
Intestinal Polyposis
BMP signaling inhibits intestinal stem cell self-renewal through suppression of Wnt-beta-catenin signaling.
Intracranial Aneurysm
The transforming growth factor-? receptor genes and the risk of intracranial aneurysms.
Intracranial Arteriovenous Malformations
Ephrin B2 and EphB4 selectively mark arterial and venous vessels in cerebral arteriovenous malformation.
Intracranial Hemorrhages
Assessing the association of common genetic variants in EPHB4 and RASA1 with phenotype severity in familial cerebral cavernous malformation.
Intracranial Hemorrhages
EPHB4 gene polymorphisms and risk of intracranial hemorrhage in patients with brain arteriovenous malformations.
Invasive Fungal Infections
Call for Action: Invasive Fungal Infections Associated With Ibrutinib and Other Small Molecule Kinase Inhibitors Targeting Immune Signaling Pathways.
Invasive Fungal Infections
Cryptococcus neoformans empyema in a patient receiving ibrutinib for diffuse large B-cell lymphoma and a review of the literature.
Invasive Fungal Infections
Discovery of Janus Kinase 2 (JAK2) and Histone Deacetylase (HDAC) Dual Inhibitors as a Novel Strategy for the Combinational Treatment of Leukemia and Invasive Fungal Infections.
Invasive Fungal Infections
Invasive fungal infections in patients treated with Bruton's tyrosine kinase inhibitors.
Invasive Fungal Infections
Risk of infection associated with targeted therapies for solid organ and hematological malignancies.
Invasive Pulmonary Aspergillosis
Invasive aspergillosis related to ibrutinib therapy for chronic lymphocytic leukemia.
Iron Deficiencies
The Role of Advanced Practitioners in Optimizing Clinical Management and Support of Patients With Polycythemia Vera.
Ischemic Stroke
A Truncated Fragment of Src Protein Kinase Generated by Calpain-Mediated Cleavage is A Mediator of Neuronal Death in Excitotoxicity.
Ischemic Stroke
Activin A improves the neurological outcome after ischemic stroke in mice by promoting oligodendroglial ACVR1B-mediated white matter remyelination.
Ischemic Stroke
Correction to: Pyruvate Kinase M2 Increases Angiogenesis, Neurogenesis, and Functional Recovery Mediated by Upregulation of STAT3 and Focal Adhesion Kinase Activities after Ischemic Stroke in Adult Mice.
Ischemic Stroke
Dectin-1/Syk signaling triggers neuroinflammation after ischemic stroke in mice.
Ischemic Stroke
Discovery of novel 2-anilinopyrazolo[1,5-a]pyrimidine derivatives as c-Src kinase inhibitors for the treatment of acute ischemic stroke.
Ischemic Stroke
Janus Kinase Inhibition Ameliorates Ischemic Stroke Injury and Neuroinflammation Through Reducing NLRP3 Inflammasome Activation via JAK2/STAT3 Pathway Inhibition.
Ischemic Stroke
Levo-tetrahydropalmatine Attenuates Neuron Apoptosis Induced by Cerebral Ischemia-Reperfusion Injury: Involvement of c-Abl Activation.
Ischemic Stroke
miR-129-2-3p directly targets SYK gene and associates with the risk of ischaemic stroke in a Chinese population.
Ischemic Stroke
Overexpression of EphB4 promotes neurogenesis, but inhibits neuroinflammation in mice with acute ischemic stroke.
Ischemic Stroke
Perlecan, a modular instructive proteoglycan with diverse functional properties.
Ischemic Stroke
Protective effects of angiopoietin-like 4 on cerebrovascular and functional damages in ischaemic stroke.
Ischemic Stroke
Pyruvate Kinase M2 Increases Angiogenesis, Neurogenesis, and Functional Recovery Mediated by Upregulation of STAT3 and Focal Adhesion Kinase Activities After Ischemic Stroke in Adult Mice.
Ischemic Stroke
Selective Inhibition of Janus Kinase 3 Has No Impact on Infarct Size or Neurobehavioral Outcomes in Permanent Ischemic Stroke in Mice.
Jacobsen Distal 11q Deletion Syndrome
Janus kinase 3 missense mutation in a child with Jacobsen syndrome.
Job Syndrome
A Patient with Tyrosine Kinase 2 Deficiency without Hyper-IgE Syndrome.
Job Syndrome
Hyper-IgE syndrome, 2021 update.
Job Syndrome
Hyper-IgE syndrome.
Job Syndrome
Primary immunodeficiency diseases associated with increased susceptibility to viral infections and malignancies.
Job Syndrome
Severe eczema and Hyper-IgE in Loeys-Dietz-syndrome - contribution to new findings of immune dysregulation in connective tissue disorders.
Job Syndrome
The Hyper-IgE Syndromes: Lessons in Nature, From Bench to Bedside.
Job Syndrome
The hyperimmunoglobulin E syndrome--clinical manifestation diversity in primary immune deficiency.
Joint Diseases
Impact of Janus Kinase Inhibition on the Treatment of Axial Spondyloarthropathies.
Joint Diseases
The osteoclast: a potential therapeutic target of bone and joint destruction in rheumatoid arthritis.
Keloid
A Role for Neuregulin-1 in Promoting Keloid Fibroblast Migration via ErbB2-mediated Signaling.
Keloid
Increased transcriptional response to mechanical strain in keloid fibroblasts due to increased focal adhesion complex formation.
Keloid
Mechanical coupling of cytoskeletal elasticity and force generation is crucial for understanding the migrating nature of keloid fibroblasts.
Keloid
Upregulated periostin promotes angiogenesis in keloids through activation of the ERK 1/2 and focal adhesion kinase pathways, as well as the upregulated expression of VEGF and angiopoietin?1.
Keratitis
Correlation between matrix metalloproteinase expression and activation of the focal adhesion kinase signaling pathway in herpes stromal keratitis.
Keratosis
Hyperkeratotic Skin Adverse Events Induced by Anticancer Treatments: A Comprehensive Review.
Keratosis, Actinic
Phase 3 Trials of Tirbanibulin Ointment for Actinic Keratosis.
Keratosis, Actinic
Reversible binding of the anticancer drug KXO1 (tirbanibulin) to the colchicine-binding site of ?-tubulin explains KXO1's low clinical toxicity.
Keratosis, Actinic
Tirbanibulin Ointment 1% as a Novel Treatment for Actinic Keratosis: Phase 1 and 2 Results.
Keratosis, Actinic
Tirbanibulin: First Approval.
Kidney Diseases
Inhibition of spleen tyrosine kinase suppresses skin and kidney disease in lupus prone mice.
Kidney Diseases
MicroRNA-140-5p Mediates Renal Fibrosis Through TGF-?1/Smad Signaling Pathway by Directly Targeting TGFBR1.
Kidney Failure, Chronic
Pharmacokinetics of tofacitinib, a Janus Kinase inhibitor, in PATIENTS with impaired renal function and end stage renal disease.
Kidney Failure, Chronic
Prevalence of the Janus Kinase 2 V617F Mutation in Patients with End-Stage Renal Disease.
Kidney Neoplasms
Aberration hubs in protein interaction networks highlight actionable targets in cancer.
Kidney Neoplasms
Expression and prognostic significance of Src family members in renal clear cell carcinoma.
Kidney Neoplasms
Expression of bone morphogenetic protein-7, its receptors and Smad1/5/8 in normal human kidney and renal cell cancer.
Kidney Neoplasms
Mechanistically distinct cancer-associated mTOR activation clusters predict sensitivity to rapamycin.
Kidney Neoplasms
Nuclear expression of Lyn, a Src family kinase member, is associated with poor prognosis in renal cancer patients.
Klinefelter Syndrome
Chronic myeloid leukemia in patient with the Klinefelter syndrome.
Laryngeal Neoplasms
Basement membrane protein ladinin-1 and the MIF-CD44-?1 integrin signaling axis are implicated in laryngeal cancer metastasis.
Laryngeal Neoplasms
Curcumin, a potential inhibitor of MMP-2 in human laryngeal squamous carcinoma cells HEp2.
Laryngeal Neoplasms
Focal adhesion kinase and E-cadherin as markers for nodal metastasis in laryngeal cancer.
Laryngeal Neoplasms
Immunohistochemical Expression of Cortactin and Focal Adhesion Kinase Predicts Recurrence Risk and Laryngeal Cancer Risk Beyond Histologic Grading.
Laryngeal Neoplasms
Involvement of focal adhesion kinase in cellular proliferation, apoptosis and prognosis of laryngeal squamous cell carcinoma.
Laryngomalacia
Homozygous missense variant in BMPR1A resulting in BMPR signaling disruption and syndromic features.
Latent Tuberculosis
Infection risk in patients undergoing treatment for inflammatory arthritis: non-biologics versus biologics.
Leiomyoma
Gene expression profiling of leiomyoma and myometrial smooth muscle cells in response to transforming growth factor-beta.
Leiomyoma
Gonadotropin releasing hormone analogue therapy alters signal transduction pathways involving mitogen-activated protein and focal adhesion kinases in leiomyoma.
Leiomyoma
Literature Review on the Role of Uterine Fibroids in Endometrial Function.
Leiomyoma
microRNA 21: response to hormonal therapies and regulatory function in leiomyoma, transformed leiomyoma and leiomyosarcoma cells.
Leiomyoma
Paracrine activation of WNT/?-catenin pathway in uterine leiomyoma stem cells promotes tumor growth.
Leiomyoma
Wnt/?-catenin signaling pathway in uterine leiomyoma: role in tumor biology and targeting opportunities.
Lens Diseases
The effects of c-Src kinase on EMT signaling pathway in human lens epithelial cells associated with lens diseases.
Lentivirus Infections
IGHG1 functions as an oncogene in tongue squamous cell carcinoma via JAK1/STAT5 signaling.
Leprosy
Disruption of HLA-DR raft, deregulations of Lck-ZAP-70-Cbl-b cross-talk and miR181a towards T cell hyporesponsiveness in leprosy.
Leukemia
(-)-Epigallocatechin Gallate Regulates CD3-mediated T Cell Receptor Signaling in Leukemia through the Inhibition of ZAP-70 Kinase.
Leukemia
3rd generation ABL kinase inhibitor and Philadelphia chromosome positive leukemia.
Leukemia
4-Aryl-4H-Chromene-3-Carbonitrile Derivatives: Evaluation of Src Kinase Inhibitory and Anticancer Activities.
Leukemia
9;22 translocation and bcr rearrangements in chronic myelocytic leukemia patients among atomic bomb survivors.
Leukemia
A 77-kDa protein associates with pp125FAK in mast cells and becomes tyrosine-phosphorylated by high affinity IgE receptor aggregation.
Leukemia
A BCR-ABL mutant lacking direct binding sites for the GRB2, CBL and CRKL adapter proteins fails to induce leukemia in mice.
Leukemia
A cascade screening approach for the identification of Bcr-Abl myristate pocket binders active against wild type and T315I mutant.
Leukemia
A case of acute myeloid leukemia with e6a2 BCR-ABL fusion transcript acquired after progressing from chronic myelomonocytic leukemia.
Leukemia
A cell-based screen for resistance of Bcr-Abl-positive leukemia identifies the mutation pattern for PD166326, an alternative Abl kinase inhibitor.
Leukemia
A coiled-coil oligomerization domain of Bcr is essential for the transforming function of Bcr-Abl oncoproteins.
Leukemia
A coiled-coil tetramerization domain of BCR-ABL is essential for the interactions of SH2-containing signal transduction molecules.
Leukemia
A comparative analysis of FISH, RT-PCR, and cytogenetics for the diagnosis of bcr-abl-positive leukemias.
Leukemia
A direct binding site for Grb2 contributes to transformation and leukemogenesis by the Tel-Abl (ETV6-Abl) tyrosine kinase.
Leukemia
A myristoyl/phosphotyrosine switch regulates c-Abl.
Leukemia
A Nimbolide-Based Kinase Degrader Preferentially Degrades Oncogenic BCR-ABL.
Leukemia
A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance.
Leukemia
A novel STAT inhibitor, OPB-31121, has a significant antitumor effect on leukemia with STAT-addictive oncokinases.
Leukemia
A Philadelphia chromosome positive acute lymphoblastic leukemia of donor origin after allogeneic bone marrow transplantation for chronic myelogenous leukemia in chronic phase.
Leukemia
A requirement for NF-kappaB activation in Bcr-Abl-mediated transformation.
Leukemia
A Screening-Based Approach to Circumvent Tumor Microenvironment-Driven Intrinsic Resistance to BCR-ABL+ Inhibitors in Ph+ Acute Lymphoblastic Leukemia.
Leukemia
A Study on the Expression of BCR-ABL Transcript in Mixed Phenotype Acute Leukemia (MPAL) Cases Using the Reverse Transcriptase Polymerase Reaction Assay (RT-PCR) and its Correlation with Hematological Remission Status Post Initial Induction Therapy.
Leukemia
A transgenic mouse model of human T cell leukemia virus type 1-associated diseases.
Leukemia
Abelson kinase regulates epithelial morphogenesis in Drosophila.
Leukemia
Abelson murine leukemia virus induces platelet-derived growth factor-independent fibroblast growth: correlation with kinase activity and dissociation from full morphologic transformation.
Leukemia
Abelson virus transformation prevents TRAIL expression by inhibiting FoxO3a and NF-kappaB.
Leukemia
Aberrant DNA methylation of the Src kinase Hck, but not of Lyn, in Philadelphia chromosome negative acute lymphocytic leukemia.
Leukemia
ABL Genomic Editing Sufficiently Abolishes Oncogenesis of Human Chronic Myeloid Leukemia Cells In Vitro and In Vivo.
Leukemia
Abl interconnects oncogenic Met and p53 core pathways in cancer cells.
Leukemia
ABL kinase inhibitory and antiproliferative activity of novel picolinamide based benzothiazoles.
Leukemia
ABL oncogenes and phosphoinositide 3-kinase: mechanism of activation and downstream effectors.
Leukemia
Abl tyrosine protein kinase.
Leukemia
Abl-interactor-1, a novel SH3 protein binding to the carboxy-terminal portion of the Abl protein, suppresses v-abl transforming activity.
Leukemia
ABL1 methylation in Ph-positive ALL is exclusively associated with the P210 form of BCR-ABL.
Leukemia
Abl: the prototype of oncogenic fusion proteins.
Leukemia
Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL+ leukemia cells.
Leukemia
Absence of BCR-ABL rearrangement (with m-bcr breakpoint) in chronic myelomonocytic leukemia.
Leukemia
Acceleration of chronic myeloproliferation by enforced expression of Meis1 or Meis3 in Icsbp-deficient bone marrow cells.
Leukemia
Accumulation of p60lck in HTLV-I-transformed T cell lines detected by an anti-lck monoclonal antibody, MOL 171.
Leukemia
Acetylshikonin induces apoptosis of human leukemia cell line K562 by inducing S phase cell cycle arrest, modulating ROS accumulation, depleting Bcr-Abl and blocking NF-?B signaling.
Leukemia
Acquisition of the Ph chromosome and BCR-ABL fusion product in AML-M2 and t(8;21) leukemia: cytogenetic and FISH evidence for a late event.
Leukemia
Activated abl oncogenes and apoptosis: differing responses of transformed myeloid progenitor cell lines.
Leukemia
Activation of abl family kinases in solid tumors.
Leukemia
Activation of c-Abl kinase activity and transformation by a chemical inducer of dimerization.
Leukemia
Activation of c-Abl tyrosine kinase requires caspase activation and is not involved in JNK/SAPK activation during apoptosis of human monocytic leukemia U937 cells.
Leukemia
Activation of murine c-abl protooncogene: effect of a point mutation on oncogenic activation.
Leukemia
Activation of p53 by SIRT1 Inhibition Enhances Elimination of CML Leukemia Stem Cells in Combination with Imatinib.
Leukemia
Activation of phosphatidylinositol 3-kinase through glycoprotein 130 induces protein kinase B and p70 S6 kinase phosphorylation in cardiac myocytes.
Leukemia
Activation of phosphatidylinositol-3-kinase in Jurkat T cells depends on the presence of the p56lck tyrosine kinase.
Leukemia
Activation of the c-abl oncogene by viral transduction or chromosomal translocation generates altered c-abl proteins with similar in vitro kinase properties.
Leukemia
Activation of tyrosine kinases in cancer.
Leukemia
Activity of a novel Aurora kinase inhibitor against the T315I mutant form of BCR-ABL: in vitro and in vivo studies.
Leukemia
Activity of histone deacetylase inhibitors and an Aurora kinase inhibitor in BCR-ABL-expressing leukemia cells: Combination of HDAC and Aurora inhibitors in BCR-ABL-expressing cells.
Leukemia
Activity of the farnesyl protein transferase inhibitor SCH66336 against BCR/ABL-induced murine leukemia and primary cells from patients with chronic myeloid leukemia.
Leukemia
Activity of the multitargeted kinase inhibitor, AT9283, in imatinib-resistant BCR-ABL-positive leukemic cells.
Leukemia
Acute lymphoblastic leukemia in children.
Leukemia
Acute lymphoid leukemia molecular phenotype in a patient with benign-phase chronic myelogenous leukemia.
Leukemia
Acute myeloblastic leukemia with active tyrosine protein kinase.
Leukemia
Acute myeloblastic leukemia with associated BCR-ABL translocation in a dog.
Leukemia
Adaptation to TKI treatment reactivates ERK signaling in tyrosine kinase-driven leukemias and other malignancies.
Leukemia
Additional member of the protein-tyrosine kinase family: the src- and lck-related protooncogene c-tkl.
Leukemia
Additive antileukemia effects by GFI1B- and BCR-ABL-specific siRNA in advanced phase chronic myeloid leukemic cells.
Leukemia
Adhesion structures in leukemia cells and their regulation by Src family kinases.
Leukemia
Advances in Immunotherapy of Chronic Myeloid Leukemia CML.
Leukemia
Aggregation of the high-affinity IgE receptor and enhanced activity of p53/56lyn protein-tyrosine kinase.
Leukemia
Aggressive myeloid leukemia formation is directed by the Musashi 2/Numb pathway.
Leukemia
AHI-1 interacts with BCR-ABL and modulates BCR-ABL transforming activity and imatinib response of CML stem/progenitor cells.
Leukemia
Allium Roseum L. Extract Exerts Potent Suppressive Activities on Chronic Myeloid Leukemia K562 Cell Viability Through the Inhibition of BCR-ABL, PI3K/Akt, and ERK1/2 Pathways and the Abrogation of VEGF Secretion.
Leukemia
Allogeneic hematopoietic cell transplantation in children with relapsed acute lymphoblastic leukemia isolated to the central nervous system.
Leukemia
Allogeneic stem cell transplantation for patients harboring T315I BCR-ABL mutated leukemias.
Leukemia
Alterations in expression of p56lck during myeloid differentiation of LSTRA cells.
Leukemia
Alterations in Janus kinase (JAK)-signal transducers and activators of transcription (STAT) signaling in patients with end-stage dilated cardiomyopathy.
Leukemia
Altered protein kinase activities of lymphoid cells transformed by Abelson and Moloney leukemia viruses.
Leukemia
Ameliorating effect of Kalpaamruthaa on altered energy metabolism in BCR-ABL(+) cell line induced leukemic mouse model.
Leukemia
AMPK in BCR-ABL expressing leukemias. Regulatory effects and therapeutic implications.
Leukemia
Amplified C lambda and c-abl genes are on the same marker chromosome in K562 leukemia cells.
Leukemia
An accurate, simple prognostic model consisting of age, JAK2, CALR, and MPL mutation status for patients with primary myelofibrosis.
Leukemia
An actin-binding function contributes to transformation by the Bcr-Abl oncoprotein of Philadelphia chromosome-positive human leukemias.
Leukemia
An aging mouse model of human chronic myeloid leukemia.
Leukemia
An alteration of the human c-abl protein in K562 leukemia cells unmasks associated tyrosine kinase activity.
Leukemia
An imatinib-only window followed by imatinib and chemotherapy for Philadelphia chromosome-positive acute leukemia: long-term results of the CMLALL1 trial.
Leukemia
Analysis of the biologic properties of p230 Bcr-Abl reveals unique and overlapping properties with the oncogenic p185 and p210 Bcr-Abl tyrosine kinases.
Leukemia
Andrographolide downregulates the v-Src and Bcr-Abl oncoproteins and induces Hsp90 cleavage in the ROS-dependent suppression of cancer malignancy.
Leukemia
Anti-ganglioside monoclonal antibody AA4 selectively inhibits IgE-induced signal transduction pathways in rat basophilic leukemia cells.
Leukemia
Anti-leukemic activity of axitinib against cells harboring the BCR-ABL T315I point mutation.
Leukemia
Anti-leukemic effects of gallic acid on human leukemia K562 cells: Downregulation of COX-2, inhibition of BCR/ABL kinase and NF-?B inactivation.
Leukemia
Antiapoptotic effect of c-fes protooncogene during granulocytic differentiation.
Leukemia
Antibody recognition of the tumor-specific b3-a2 junction of bcr-abl chimeric proteins in Philadelphia-chromosome-positive leukemias.
Leukemia
Antileukemic Activity and Molecular Docking Study of a Polyphenolic Extract from Coriander Seeds.
Leukemia
Antisense oligodeoxynucleotide combination therapy of primary chronic myelogenous leukemia blast crisis in SCID mice.
Leukemia
Antitumor activity of erbstatin, a tyrosine protein kinase inhibitor.
Leukemia
Antitumor Effects of Blocking Protein Neddylation in T315I-BCR-ABL Leukemia Cells and Leukemia Stem Cells.
Leukemia
Apoptosis in blood diseases. Review new data.
Leukemia
Apoptosis-based dual molecular targeting by INNO-406, a second-generation Bcr-Abl inhibitor, and ABT-737, an inhibitor of antiapoptotic Bcl-2 proteins, against Bcr-Abl-positive leukemia.
Leukemia
Apoptotic effect of PP2 a Src tyrosine kinase inhibitor, in murine B cell leukemia.
Leukemia
Appearance of acute leukemia-associated P190BCR-ABL in chronic myelogenous leukemia may correlate with disease progression.
Leukemia
Application of flow cytometry in pediatric hematology-oncology.
Leukemia
Are there better Bcr-Abl kinase inhibitors for chronic myeloid leukaemia than imatinib? Evaluation of Saglio G, Kim D-W, Issaragrisil S, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010;362:2251-9, and Kantarjian H, Shah NP, Hochhaus A, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010;362:2260-70.
Leukemia
Arf gene loss enhances oncogenicity and limits imatinib response in mouse models of Bcr-Abl-induced acute lymphoblastic leukemia.
Leukemia
Arginine butyrate downregulates p210 bcr-abl expression and induces apoptosis in chronic myelogenous leukemia cells.
Leukemia
Arsenic trioxide inhibits translation of mRNA of bcr-abl, resulting in attenuation of Bcr-Abl levels and apoptosis of human leukemia cells.
Leukemia
As4S4 targets RING-type E3 ligase c-CBL to induce degradation of BCR-ABL in chronic myelogenous leukemia.
Leukemia
Ascorbate/menadione-induced oxidative stress kills cancer cells that express normal or mutated forms of the oncogenic protein Bcr-Abl. An in vitro and in vivo mechanistic study.
Leukemia
Assembling defenses against therapy-resistant leukemic stem cells: Bcl6 joins the ranks.
Leukemia
Assessing the thrombotic risk of patients with essential thrombocythemia in the genomic era.
Leukemia
Assessment of azithromycin as an anticancer agent for treatment of imatinib sensitive and resistant CML cells.
Leukemia
Association between imatinib-resistant BCR-ABL mutation-negative leukemia and persistent activation of LYN kinase.
Leukemia
Association of HLA antigens and BCR-ABL transcripts in leukemia patients with the Philadelphia chromosome.
Leukemia
Association of HLA Class I and Class II genes with bcr-abl transcripts in leukemia patients with t(9;22) (q34;q11).
Leukemia
Association of Janus kinase 2 (JAK2) polymorphisms with acute leukemia susceptibility.
Leukemia
Association of p93c-fes tyrosine protein kinase with granulocytic/monocytic differentiation and resistance to differentiating agents in HL-60 leukemia cells.
Leukemia
Association of the protein kinases c-Bcr and Bcr-Abl with proteins of the 14-3-3 family.
Leukemia
ASXL1 mutations in Chinese patients with essential thrombocythemia.
Leukemia
Augmentation of the antileukemia potency of total-body irradiation (TBI) by a novel P-site inhibitor of spleen tyrosine kinase (SYK).
Leukemia
Aurora A Kinase Inhibitor AKI603 Induces Cellular Senescence in Chronic Myeloid Leukemia Cells Harboring T315I Mutation.
Leukemia
Aurora kinases as anticancer drug targets.
Leukemia
Autoantibodies to Abl and Bcr proteins.
Leukemia
Automated analysis of lipid drug-response markers by combined fast and high-resolution whole cell MALDI mass spectrometry biotyping.
Leukemia
Autophagy: friend or foe in the treatment of fusion protein-associated leukemias?
Leukemia
Azole antifungals and new targeted therapies for hematological malignancy.
Leukemia
Bcr - Abl-mediated resistance to apoptosis is independent of PI 3-kinase activity.
Leukemia
BCR binds to the xeroderma pigmentosum group B protein.
Leukemia
bcr rearrangement and C-abl gene expression in Ph1-positive hybrid acute leukemia with simultaneous proliferation of lymphoid and myeloid blasts.
Leukemia
BCR sequences essential for transformation by the BCR-ABL oncogene bind to the ABL SH2 regulatory domain in a non-phosphotyrosine-dependent manner.
Leukemia
Bcr-Abl activates AURKA and AURKB in chronic myeloid leukemia cells via AKT signaling.
Leukemia
BCR-ABL and v-abl oncogenes induce distinct patterns of thymic lymphoma involving different lymphocyte subsets.
Leukemia
Bcr-Abl efficiently induces a myeloproliferative disease and production of excess interleukin-3 and granulocyte-macrophage colony-stimulating factor in mice: a novel model for chronic myelogenous leukemia.
Leukemia
BCR-ABL fusion regions as a source of multiple leukemia-specific CD8+ T-cell epitopes.
Leukemia
BCR-ABL fusion transcript types and levels and their interaction with secondary genetic changes in determining the phenotype of Philadelphia chromosome-positive leukemias.
Leukemia
BCR-ABL Independent Mechanisms of Resistance in Chronic Myeloid Leukemia.
Leukemia
BCR-ABL induces neurite-like structures and BCR lacking the SH2-binding domain induces cell rounding in PC12 cells.
Leukemia
BCR-ABL induces the expression of Skp2 through the PI3K pathway to promote p27Kip1 degradation and proliferation of chronic myelogenous leukemia cells.
Leukemia
bcr-abl mRNA lacking abl exon a2 detected by polymerase chain reaction in a chronic myelogeneous leukemia patient.
Leukemia
bcr-abl oncogene activation in Philadelphia chromosome-positive acute lymphoblastic leukemia.
Leukemia
Bcr-Abl oncogene stimulates Jab1 expression via cooperative interaction of ?-catenin and STAT1 in chronic myeloid leukemia cells.
Leukemia
BCR-ABL protein expression in peripheral blood cells of chronic myelogenous leukemia patients undergoing therapy.
Leukemia
BCR-ABL rearrangement and HLA antigens: a possible link to leukemia pathogenesis and immunotherapy.
Leukemia
BCR-ABL rearrangement frequencies in chronic myeloid leukemia and acute lymphoblastic leukemia in Ecuador, South America.
Leukemia
BCR-ABL regulates death receptor expression for TNF-related apoptosis-inducing ligand (TRAIL) in Philadelphia chromosome-positive leukemia.
Leukemia
Bcr-Abl regulates osteopontin transcription via Ras, PI-3K, aPKC, Raf-1, and MEK.
Leukemia
Bcr-Abl regulates protein kinase Ciota (PKCiota) transcription via an Elk1 site in the PKCiota promoter.
Leukemia
bcr-abl RNA in patients with chronic myelogenous leukemia.
Leukemia
BCR-ABL translocation in a dog with chronic monocytic leukemia.
Leukemia
BCR-ABL tyrosine kinase activity regulates the expression of multiple genes implicated in the pathogenesis of chronic myeloid leukemia.
Leukemia
bcr-abl-Induced cell lines can switch from mast cell to erythroid or myeloid differentiation in vitro.
Leukemia
BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein.
Leukemia
Bcr-Abl-mediated resistance to apoptosis is independent of constant tyrosine-kinase activity.
Leukemia
BCR-ABL-positive acute myeloid leukemia: a new entity? Analysis of clinical and molecular features.
Leukemia
BCR-ABL1- positive chronic myeloid leukemia with erythrocytosis presenting as polycythemia vera: a case report.
Leukemia
BCR-ABL: a multi-faceted promoter of DNA mutation in chronic myelogeneous leukemia.
Leukemia
Bcr: a negative regulator of the Bcr-Abl oncoprotein in leukemia.
Leukemia
Benzopyranones and benzothiopyranones: a class of tyrosine protein kinase inhibitors with selectivity for the v-abl kinase.
Leukemia
Betulin, a Newly Characterized Compound in Acacia auriculiformis Bark, Is a Multi-Target Protein Kinase Inhibitor.
Leukemia
Biological effects of T315I-mutated BCR-ABL in an embryonic stem cell-derived hematopoiesis model.
Leukemia
Biological therapy for pediatric malignancy: current perspectives.
Leukemia
Blockade of JAK2 activity suppressed accumulation of ?-catenin in leukemic cells.
Leukemia
BMI1 collaborates with BCR-ABL in leukemic transformation of human CD34+ cells.
Leukemia
Bmi1 reprograms CML B-lymphoid progenitors to become B-ALL-initiating cells.
Leukemia
Bone marrow mesenchymal stem cells from infants with MLL-AF4+ acute leukemia harbor and express the MLL-AF4 fusion gene.
Leukemia
Bosutinib : a review of preclinical and clinical studies in chronic myelogenous leukemia.
Leukemia
Breakpoint Cluster Region-Mediated Inflammation Is Dependent on Casein Kinase II.
Leukemia
Bruton's tyrosine kinase as a molecular target in treatment of leukemias and lymphomas as well as inflammatory disorders and autoimmunity.
Leukemia
Bruton's tyrosine kinase is not essential for Bcr-Abl-mediated transformation of lymphoid or myeloid cells.
Leukemia
BTK gatekeeper residue variation combined with cysteine 481 substitution causes super-resistance to irreversible inhibitors acalabrutinib, ibrutinib and zanubrutinib.
Leukemia
c-Abl antagonizes the YAP oncogenic function.
Leukemia
c-Abl Inhibitors Enable Insights into the Pathophysiology and Neuroprotection in Parkinson's Disease.
Leukemia
c-Abl mediates endothelial apoptosis induced by inhibition of integrins alphavbeta3 and alphavbeta5 and by disruption of actin.
Leukemia
c-Abl tyrosine kinase promotes adipocyte differentiation by targeting PPAR-gamma 2.
Leukemia
c-CBL is not required for leukemia induction by Bcr-Abl in mice.
Leukemia
C-JUN promotes BCR-ABL induced lymphoid leukemia by inhibiting methylation of the 5' region of Cdk6.
Leukemia
CALR-positive myeloproliferative disorder in a patient with Ph-positive chronic myeloid leukemia in durable treatment-free remission: a case report.
Leukemia
CaMKII ?, a critical regulator of CML stem/progenitor cells, is a target of the natural product berbamine.
Leukemia
Can kinomics and proteomics bridge the gap between pediatric cancers and newly designed kinase inhibitors?
Leukemia
CBL family E3 ubiquitin ligases control JAK2 ubiquitination and stability in hematopoietic stem cells and myeloid malignancies.
Leukemia
CD4(+) T Cells Contribute to the Remodeling of the Microenvironment Required for Sustained Tumor Regression upon Oncogene Inactivation.
Leukemia
cDNA array analysis identifies thymic LCK as upregulated in moderate murine zinc deficiency before T-lymphocyte population changes.
Leukemia
Cell Death Induced by the Jak2 Inhibitor, G6, Correlates with Cleavage of Vimentin Filaments.
Leukemia
Cellular expression of antiapoptotic BCL-2 oncoprotein in newly diagnosed childhood acute lymphoblastic leukemia: a Children's Cancer Group Study.
Leukemia
Cepharanthine activates caspases and induces apoptosis in Jurkat and K562 human leukemia cell lines.
Leukemia
Chaperone-rich cell lysate embedded with BCR-ABL peptide demonstrates enhanced anti-tumor activity against a murine BCR-ABL positive leukemia.
Leukemia
Characteristics and mutation analysis of Ph-positive leukemia patients with T315I mutation receiving tyrosine kinase inhibitors.
Leukemia
Characterization of midostaurin as a dual inhibitor of FLT3 and SYK and potentiation of FLT3 inhibition against FLT3-ITD-driven leukemia harboring activated SYK kinase.
Leukemia
Characterization of the Abelson murine leukemia virus-encoded tyrosine-specific protein kinase.
Leukemia
Characterization of two novel sublines established from a human megakaryoblastic leukemia cell line transfected with p210(BCR-ABL).
Leukemia
Chemokines as a Conductor of Bone Marrow Microenvironment in Chronic Myeloid Leukemia.
Leukemia
Childhood chronic myeloid leukemia with monocytosis.
Leukemia
Cholesterol esterification inhibition and imatinib treatment synergistically inhibit growth of BCR-ABL mutation-independent resistant chronic myelogenous leukemia.
Leukemia
Chromosomal localization and characterization of c-abl in the t(6;9) of acute nonlymphocytic leukemia.
Leukemia
Chromosomal localization of the human genes for lipocortin I and lipocortin II.
Leukemia
Chromosome marker and enhanced expression of c-Ha-ras in a DMBA-induced erythroleukemia cell line (D5A1).
Leukemia
Chronic lymphocytic leukemia modeled in mouse by targeted miR-29 expression.
Leukemia
Chronic Myeloid Leukemia (CML) Mouse Model in Translational Research.
Leukemia
Chronic myeloid leukemia as an immunological target.
Leukemia
Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival.
Leukemia
Chronic myeloid leukemia-from the Philadelphia chromosome to specific target drugs: A literature review.
Leukemia
Chronic myeloid leukemia-still a few questions.
Leukemia
Chronic myelomonocytic leukemia with p190 BCR-ABL rearrangement mimicking advanced liver disease at presentation.
Leukemia
Chronic neutrophilic leukemia with an associated V617F JAK2 tyrosine kinase mutation.
Leukemia
Chronic neutrophilic leukemia: case report documenting the absence of bcr-abl rearrangement.
Leukemia
Classical Philadelphia-negative myeloproliferative neoplasms: focus on mutations and JAK2 inhibitors.
Leukemia
Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling.
Leukemia
Clinical and molecular predictors of disease severity and survival in chronic lymphocytic leukemia.
Leukemia
Clinical applications of BCR-ABL molecular testing in acute leukemia.
Leukemia
Clinical characteristics and outcomes of mixed phenotype acute leukemia with Philadelphia chromosome positive and/or bcr-abl positive in adult.
Leukemia
Clinical features and prognostic implications of TCF3-PBX1 and ETV6-RUNX1 in adult acute lymphoblastic leukemia.
Leukemia
Clinical features of pulmonary arterial hypertension in patients receiving dasatinib.
Leukemia
Clinical peptide vaccination trials for leukemia patients.
Leukemia
Clinical Significance of BCR-ABL Fusion Gene in Chronic Myeloid Leukemia Patients.
Leukemia
Clinical significance of BCR-ABL fusion gene subtypes in chronic myelogenous and acute lymphoblastic leukemias.
Leukemia
Clinical significance of the BCR-ABL fusion gene in adult acute lymphoblastic leukemia: a Cancer and Leukemia Group B Study (8762).
Leukemia
Clonal evolution with +11q 13, t(1;7) and t(1;4) at relapse in a patient with Ph positive acute lymphocytic leukemia (ALL) treated with single agent front line imatinib followed by dasatinib.
Leukemia
Cloning and characterization of the human homolog of mouse Jak2.
Leukemia
Cloning of the cDNA for the deleted syk kinase homologous to ZAP-70 from human basophilic leukemia cell line (KU812).
Leukemia
CML mouse model in translational research.
Leukemia
Coadministration of UCN-01 with MEK1/2 inhibitors potently induces apoptosis in BCR/ABL+ leukemia cells sensitive and resistant to ST1571.
Leukemia
Coexistence of PML-RAR? and BCR-ABL in acute promyelocytic leukemia.
Leukemia
Collisionally induced fragmentation of [M-H](-) species of resveratrol and piceatannol investigated by deuterium labelling and accurate mass measurements.
Leukemia
Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3.
Leukemia
Combination therapy of BCR-ABL-positive B cell acute lymphoblastic leukemia by tyrosine kinase inhibitor dasatinib and c-JUN N-terminal kinase inhibition.
Leukemia
Combination therapy with copanlisib and ABL tyrosine kinase inhibitors against Philadelphia chromosome-positive resistant cells.
Leukemia
Combinatorial efficacy of entospletinib and chemotherapy in patient-derived xenograft models of infant acute lymphoblastic leukemia.
Leukemia
Comparison of a multiplex reverse transcriptase-polymerase chain reaction for BCR-ABL to fluorescence in situ hybridization, Southern blotting, and conventional cytogenetics in the monitoring of patients with Ph1-positive leukemias.
Leukemia
Comparison of bcr-abl protein expression and Philadelphia chromosome analyses in chronic myelogenous leukemia patients.
Leukemia
Comparison of mutated ABL1 and JAK2 as oncogenes and drug targets in myeloproliferative disorders.
Leukemia
Comparison of three recombinant murine leukemia viruses carrying the v-src oncogene of avian sarcoma virus: differences in in vitro transformation and in vivo pathogenicity.
Leukemia
Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development.
Leukemia
Complex chromosomal translocations in the Philadelphia chromosome leukemias. Serial translocations or a concerted genomic rearrangement?
Leukemia
Complex phosphorylation dynamics control the composition of the Syk interactome in B cells.
Leukemia
Conformational disturbance in Abl kinase upon mutation and deregulation.
Leukemia
Conformational flexibility, binding energy, role of salt bridge and alanine-mutagenesis for c-Abl kinase complex.
Leukemia
Conjugate DNAzymes.
Leukemia
Consistent involvement of the bcr gene by 9;22 breakpoints in pediatric acute leukemias.
Leukemia
Constitutive activation of Lyn kinase enhances BCR responsiveness, but not the development of CLL in Eµ-TCL1 mice.
Leukemia
Constitutive activation of the Janus kinase-STAT pathway in T lymphoma overexpressing the Lck protein tyrosine kinase.
Leukemia
Constitutive NF-kappab/Rel activation in philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL).
Leukemia
Contextualizing the Use of Moxetumomab Pasudotox in the Treatment of Relapsed or Refractory Hairy Cell Leukemia.
Leukemia
Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia.
Leukemia
Controlling subcellular localization to alter function: Sending oncogenic Bcr-Abl to the nucleus causes apoptosis.
Leukemia
Coordinate Modulation of Glycolytic Enzymes and OXPHOS by Imatinib in BCR-ABL Driven Chronic Myelogenous Leukemia Cells.
Leukemia
Correlation of ZAP-70 expression in B cell leukemias to the ex vivo response to a combination of fludarabine/genistein.
Leukemia
Cotreatment with apicidin overcomes TRAIL resistance via inhibition of Bcr-Abl signaling pathway in K562 leukemia cells.
Leukemia
Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl-positive human acute leukemia cells.
Leukemia
Critical role of Ser-520 phosphorylation for membrane recruitment and activation of the ZAP-70 tyrosine kinase in T cells.
Leukemia
CRKL regulates alternative splicing of cancer-related genes in cervical cancer samples and HeLa cell.
Leukemia
Crosstalk between BCR/ABL oncoprotein and CXCR4 signaling through a Src family kinase in human leukemia cells.
Leukemia
CTLs specific for bcr-abl joining region segment peptides fail to lyse leukemia cells expressing p210 bcr-abl protein.
Leukemia
Current CML therapy: progress and dilemma.
Leukemia
Current status of vaccination therapy for leukemias.
Leukemia
Cyclic AMP negatively controls c-myc transcription and G1 cell cycle progression in p210 BCR-ABL transformed cells: inhibitory activity exerted through cyclin D1 and cdk4.
Leukemia
Cytogenetic characterization of a BCR-ABL transduced mouse cell line.
Leukemia
Cytogenetic study of 75 erythroleukemias.
Leukemia
Cytoplasmic and nuclear localization of the 130 and 160 kDa Bcr proteins.
Leukemia
Danusertib (formerly PHA-739358)--a novel combined pan-Aurora kinases and third generation Bcr-Abl tyrosine kinase inhibitor.
Leukemia
Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia.
Leukemia
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.
Leukemia
Dasatinib induces autophagy in mice with Bcr-Abl-positive leukemia.
Leukemia
Declining lymphoid progenitor fitness promotes aging-associated leukemogenesis.
Leukemia
Deficiency of Bruton's tyrosine kinase in B cell precursor leukemia cells.
Leukemia
Deletion of the ABL SH3 domain reactivates de-oligomerized BCR-ABL for growth factor independence.
Leukemia
Denbinobin-mediated anticancer effect in human K562 leukemia cells: role in tubulin polymerization and Bcr-Abl activity.
Leukemia
Dendritic-cell-peptide immunization provides immunoprotection against bcr-abl-positive leukemia in mice.
Leukemia
Depletion of ?-catenin by Histone Deacetylase Inhibition Confers Elimination of CML Stem Cells in Combination with Imatinib.
Leukemia
Description of a novel Janus kinase 3 P132A mutation in acute megakaryoblastic leukemia and demonstration of previously reported Janus kinase 3 mutations in normal subjects.
Leukemia
Design and synthesis of 3-substituted benzamide derivatives as Bcr-Abl kinase inhibitors.
Leukemia
Design, synthesis and biological activities of Nilotinib derivates as antitumor agents.
Leukemia
Design, synthesis and biological evaluation of novel acrylamide analogues as inhibitors of BCR-ABL kinase.
Leukemia
Design, synthesis, and biological evaluations of novel 3-amino-4-ethynyl indazole derivatives as Bcr-Abl kinase inhibitors with potent cellular antileukemic activity.
Leukemia
Detection of bcr-abl fusion in chronic myelogeneous leukemia by in situ hybridization.
Leukemia
Detection of BCR-ABL fusion proteins in patients with leukemia using a cytometric bead array.
Leukemia
Detection of BCR-ABL gene mutations in Philadelphia chromosome positive leukemia patients resistant to STI-571 cancer therapy.
Leukemia
Detection of BCR-ABL proteins in blood cells of benign phase chronic myelogenous leukemia patients.
Leukemia
Detection of bcr-abl transcript in chronic myelogenous leukemia patients by reverse-transcription-polymerase chain reaction and capillary electrophoresis.
Leukemia
Detection of minimal residual disease in Philadelphia chromosome positive acute lymphoblastic leukemia: rationale for bone marrow transplantation from the polymerase chain reaction point of view.
Leukemia
Detection of molecular variants of BCR-ABL gene in bone marrow and blood of patients with chronic myeloid leukemia by reverse-transcriptase polymerase chain reaction (RT-PCR).
Leukemia
Detection of resistance to imatinib by metabolic profiling: clinical and drug development implications.
Leukemia
Detection of twelve nucleotides insertion in the BCR-ABL kinase domain in an imatinib-resistant but dasatinib-sensitive patient with bi-phenotypic acute leukemia.
Leukemia
Detection of tyrosine protein kinase substrates in fresh leukemia cells and normal blood cells using an immunoblotting technique.
Leukemia
Deubiquitylase USP25 prevents degradation of BCR-ABL protein and ensures proliferation of Ph-positive leukemia cells.
Leukemia
Development and application of a rapid molecular method for detection of fusion genes in pediatric leukemia.
Leukemia
Different molecular consequences of the 1;19 chromosomal translocation in childhood B-cell precursor acute lymphoblastic leukemia.
Leukemia
Differential effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway in acute lymphoblastic leukemia.
Leukemia
Differential impact of BTK active site inhibitors on the conformational state of full-length BTK.
Leukemia
Differential Impacts of Azole Antifungal Drugs on the Pharmacokinetic Profiles of Dasatinib in Rats by LC-MS-MS.
Leukemia
Differential signaling networks of Bcr-Abl p210 and p190 kinases in leukemia cells defined by functional proteomics.
Leukemia
Differentiation stage specificity of tyrosine phosphorylation in response to granulocyte macrophage colony stimulating factor (GM-CSF).
Leukemia
Direct interaction of Jak1 and v-Abl is required for v-Abl-induced activation of STATs and proliferation.
Leukemia
Direct relation between BCR-ABL tyrosine kinase activity and cyclin D2 expression in lymphoblasts.
Leukemia
Discovery and Protein Modeling Studies of Novel Compound Mutations Causing Resistance to Multiple Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia.
Leukemia
Discovery of allosteric BCR-ABL inhibitors from phenotypic screen to clinical candidate.
Leukemia
Discovery of Janus Kinase 2 (JAK2) and Histone Deacetylase (HDAC) Dual Inhibitors as a Novel Strategy for the Combinational Treatment of Leukemia and Invasive Fungal Infections.
Leukemia
Discovery of novel BCR-ABL PROTACs based on the cereblon E3 ligase design, synthesis, and biological evaluation.
Leukemia
Discovery of potent and highly selective covalent inhibitors of Bruton's tyrosine kinase bearing triazine scaffold.
Leukemia
Discovery of SIAIS178 as an effective BCR-ABL degrader by recruiting von Hippel-Lindau (VHL) E3 Ubiquitin Ligase.
Leukemia
Disease modifying agents of myeloproliferative neoplasms: a review.
Leukemia
Disruption of R867 and Y613 interaction plays key roles in JAK2 R867Q mutation caused acute leukemia.
Leukemia
Disruption of the Bcr-Abl/Hsp90 protein complex: a possible mechanism to inhibit Bcr-Abl-positive human leukemic blasts by novobiocin.
Leukemia
Distinct clinical characteristics of myeloproliferative neoplasms with calreticulin mutations.
Leukemia
Diverse underlying proliferation response to growth factors in imatinib-treated Philadelphia chromosome-positive leukemias.
Leukemia
DNA damage response as a prognostic indicator in metastatic breast cancer via mutational analysis.
Leukemia
Down-regulation of bcr-abl and bcl-x(L) expression in a leukemia cell line and its doxorubicin-resistant variant by topoisomerase II inhibitors.
Leukemia
Down-regulation of BRCA1 in BCR-ABL-expressing hematopoietic cells.
Leukemia
Downregulation of miR-217 correlates with resistance of ph(+) leukemia cells to ABL tyrosine kinase inhibitors.
Leukemia
Driver mutations in primary myelofibrosis and their implications.
Leukemia
Dual Inhibition of Bcr-Abl and Hsp90 by C086 Potently Inhibits the Proliferation of Imatinib-Resistant CML Cells.
Leukemia
Dual-specific Src and Abl kinase inhibitors, PP1 and CGP76030, inhibit growth and survival of cells expressing imatinib mesylate-resistant Bcr-Abl kinases.
Leukemia
Dynamic regulatory features of the protein tyrosine kinases.
Leukemia
E1A overcomes the apoptosis block in BCR-ABL+ leukemia cells and renders cells susceptible to induction of apoptosis by chemotherapeutic agents.
Leukemia
E2A-PBX1 Remodels Oncogenic Signaling Networks in B-cell Precursor Acute Lymphoid Leukemia.
Leukemia
Early events in leukemogenesis in P190Bcr-abl transgenic mice.
Leukemia
Effect of a selective Abl tyrosine kinase inhibitor, STI571, on in vitro growth of BCR-ABL-positive acute lymphoblastic leukemia cells.
Leukemia
Effect of Bcr sequences on the cellular function of the Bcr-Abl oncoprotein.
Leukemia
Effect of CALR and JAK2 mutations on the clinical and hematological phenotypes of the disease in patients with myelofibrosis - long-term experience from a single center.
Leukemia
Effect of EPH-ephrin signaling on the growth of human leukemia cells.
Leukemia
Effect of herbimycin A, an antagonist of tyrosine kinase, on bcr/abl oncoprotein-associated cell proliferations: abrogative effect on the transformation of murine hematopoietic cells by transfection of a retroviral vector expressing oncoprotein P210bcr/abl and preferential inhibition on Ph1-positive leukemia cell growth.
Leukemia
Effect of recombinant alpha-interferon on the expression of the bcr-abl fusion gene in human chronic myelogenous human leukemia cell lines.
Leukemia
Effective killing of Gleevec-resistant CML cells with T315I mutation by a natural compound PEITC through redox-mediated mechanism.
Leukemia
Effects of imatinib on bone marrow engraftment in syngeneic mice.
Leukemia
Effects of leukemia inhibitory receptor gene mutations on human hypothalamo-pituitary-adrenal function.
Leukemia
Effects of the IMP-dehydrogenase inhibitor, Tiazofurin, in bcr-abl positive acute myelogenous leukemia. Part II. In vitro studies.
Leukemia
Efficacy of imatinib mesylate as maintenance therapy in adults with acute lymphoblastic leukemia in first complete remission.
Leukemia
Efficacy of MK-0457 and in combination with vorinostat against Philadelphia chromosome positive acute lymphoblastic leukemia cells.
Leukemia
Efficacy of ponatinib against ABL tyrosine kinase inhibitor-resistant leukemia cells.
Leukemia
Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with nilotinib against BCR-ABL-positive leukemia cells involves the ABL kinase domain mutation.
Leukemia
Efficacy of the polo-like kinase inhibitor rigosertib, alone or in combination with Abelson tyrosine kinase inhibitors, against break point cluster region-c-Abelson-positive leukemia cells.
Leukemia
Electrochemical Branched-DNA Assay for Polymerase Chain Reaction-Free Detection and Quantification of Oncogenes in Messenger RNA.
Leukemia
Elevated expression of a subset of interferon inducible genes in primary bone marrow cells expressing p185 Bcr-Abl versus p210 Bcr-Abl by DNA microarray analysis.
Leukemia
Elevated expression of the c-fes proto-oncogene in adult human myeloid leukemia cells in the absence of gene amplification.
Leukemia
Elevation of c-abl-mRNA in human leukemic B lymphoblasts.
Leukemia
Emerging drugs for chronic myeloid leukemia.
Leukemia
Engagement of the CD19 receptor on human B-lineage leukemia cells activates LCK tyrosine kinase and facilitates radiation-induced apoptosis.
Leukemia
Engineering 3-alkyltriazenes to block bcr-abl kinase: a novel strategy for the therapy of advanced bcr-abl expressing leukemias.
Leukemia
Engineering a BCR-ABL-activated caspase for the selective elimination of leukemic cells.
Leukemia
Engineering the substrate specificity of the Abl tyrosine kinase.
Leukemia
ENHANCED AND SELECTIVE KILLING OF CHRONIC MYELOGENOUS LEUKEMIA CELLS WITH AN ENGINEERED BCR-ABL BINDING PROTEIN AND IMATINIB.
Leukemia
Enhanced Risk for Specific Somatic Myeloproliferative Neoplastic Mutations in Patients with Stroke.
Leukemia
EPHB4 is a therapeutic target in AML and promotes leukemia cell survival via AKT.
Leukemia
Epigenetic therapy in myeloproliferative neoplasms: evidence and perspectives.
Leukemia
Equally potent inhibition of c-Src and Abl by compounds that recognize inactive kinase conformations.
Leukemia
Erythropoietin promotes resistance against the Abl tyrosine kinase inhibitor imatinib (STI571) in K562 human leukemia cells.
Leukemia
Essential thrombocythemia with the Philadelphia chromosome and BCR-ABL gene rearrangement. An entity distinct from chronic myeloid leukemia and Philadelphia chromosome-negative essential thrombocythemia.
Leukemia
Evaluation of deoxyhypusine synthase inhibitors targeting BCR-ABL positive leukemias.
Leukemia
Evidence for involvement of two isoforms of Syk protein-tyrosine kinase in signal transduction through the high affinity IgE receptor on rat basophilic leukemia cells.
Leukemia
Evidence of a new chimeric bcr/c-abl mRNA in patients with chronic myelocytic leukemia and the Philadelphia chromosome.
Leukemia
Examination of Stability of Bone Marrow Blood RNA in the PAXgene Tube.
Leukemia
Expression analysis of Akirin-2, NF?B-p65 and ?-catenin proteins in imatinib resistance of chronic myeloid leukemia.
Leukemia
Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation.
Leukemia
Expression of BCR - ABL in M1 myeloid leukemia cells induces differentiation without arresting proliferation.
Leukemia
Expression of bcr-abl fusion transcripts following bone marrow transplantation for Philadelphia chromosome-positive leukemia.
Leukemia
Expression of cellular oncogenes in primary cells from human acute leukemias.
Leukemia
Expression of the ABL-BCR fusion gene in Philadelphia-positive acute lymphoblastic leukemia.
Leukemia
Expression of the c-fes proto-oncogene in granulocyte-macrophage colony-stimulating factor-dependent acute myelogenous leukemia cells grown autonomously.
Leukemia
Expression of the human T-cell-specific tyrosine kinase YT16 (lck) message in leukemic T-cell lines.
Leukemia
Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia.
Leukemia
Expression patterns of WT-1 and Bcr-Abl measured by TaqMan quantitative real-time RT-PCR during follow-up of leukemia patients with the Ph chromosome.
Leukemia
Fas signaling and blockade of Bcr-Abl kinase induce apoptotic Hrk protein via DREAM inhibition in human leukemia cells.
Leukemia
FGF2-FGFR1 signaling regulates release of Leukemia-Protective exosomes from bone marrow stromal cells.
Leukemia
Fibroblast and hematopoietic cell transformation by the fms oncogene (CSF-1 receptor).
Leukemia
Fine mapping of chromosome 22 breakpoints within the breakpoint cluster region (bcr) implies a role for bcr exon 3 in determining disease duration in chronic myeloid leukemia.
Leukemia
Flavopiridol potentiates STI571-induced mitochondrial damage and apoptosis in BCR-ABL-positive human leukemia cells.
Leukemia
Flotillin-1 regulates IgE receptor-mediated signaling in rat basophilic leukemia (RBL-2H3) cells.
Leukemia
Flow cytometric immunobead assay for the detection of BCR-ABL fusion proteins in leukemia patients.
Leukemia
Flt-1, a receptor for vascular endothelial growth factor, has transforming and morphogenic potentials.
Leukemia
FLT3 tyrosine kinase as a target molecule for selective antileukemia therapy.
Leukemia
Forced expression of cyclin-dependent kinase 6 confers resistance of pro-B acute lymphocytic leukemia to Gleevec treatment.
Leukemia
Frequent polymorphism in BCR exon b2 identified in BCR-ABL positive and negative individuals using fluorescent hybridization probes.
Leukemia
Friend Spleen Focus-Forming Virus Activates the Tyrosine Kinase sf-Stk and the Transcription Factor PU.1 to Cause a Multi-Stage Erythroleukemia in Mice.
Leukemia
From genes to therapy: the case of Philadelphia chromosome-positive leukemias.
Leukemia
FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia.
Leukemia
Functional uncoupling of the Janus kinase 3-Stat5 pathway in malignant growth of human T cell leukemia virus type 1-transformed human T cells.
Leukemia
Further evidence of the involvement of the c-abl oncogene in chronic myelogenous leukemia and acute lymphocytic leukemia.
Leukemia
Fyn is not essential for Bcr-Abl-induced leukemogenesis in mouse bone marrow transplantation models.
Leukemia
Gads (Grb2-related adaptor downstream of Shc) is required for BCR-ABL-mediated lymphoid leukemia.
Leukemia
Galangin increases the cytotoxic activity of imatinib mesylate in imatinib-sensitive and imatinib-resistant Bcr-Abl expressing leukemia cells.
Leukemia
Gene expression profiling of CD34(+) cells from patients with myeloproliferative neoplasms.
Leukemia
Generation and characterization of transforming variants of the lck tyrosine protein kinase.
Leukemia
Generation of a recombinant Moloney murine leukemia virus carrying the v-src gene of avian sarcoma virus: transformation in vitro and pathogenesis in vivo.
Leukemia
Generation of induced pluripotent stem cells from primary chronic myelogenous leukemia patient samples.
Leukemia
Generation of recombinant murine retroviral genomes containing the v-src oncogene: isolation of a virus inducing hemangiosarcomas in the brain.
Leukemia
Genetic abnormalities and drug resistance in acute lymphoblastic leukemia.
Leukemia
Genetic marking shows that Ph+ cells present in autologous transplants of chronic myelogenous leukemia (CML) contribute to relapse after autologous bone marrow in CML.
Leukemia
Genetic stability of human embryonic stem cells: A first-step toward the development of potential hESC-based systems for modeling childhood leukemia.
Leukemia
Genetic, phenotypic and clinical features of acute lymphoblastic leukemias expressing myeloperoxidase mRNA detected by RT-PCR.
Leukemia
Genome-wide screen reveals WNT11, a non-canonical WNT gene, as a direct target of ETS transcription factor ERG.
Leukemia
Glivec and CML: a lucky date.
Leukemia
Global phosphoproteomics reveals crosstalk between bcr-abl and negative feedback mechanisms controlling SRC signaling.
Leukemia
Growth hormone regulation of SIRP and SHP-2 tyrosyl phosphorylation and association.
Leukemia
Growth of chronic myeloid leukemia cells is inhibited by infection with Ad-SH2-HA adenovirus that disrupts Grb2-Bcr-Abl complexes.
Leukemia
Growth, differentiation, and malignant transformation of pre-B cells mediated by inducible activation of v-Abl oncogene.
Leukemia
HDAC Inhibitors potentiate the activity of the Bcr/Abl Kinase Inhibitor KW-2449 in imatinib-sensitive and -resistant Bcr/Abl+ leukemia cells in vitro and in vivo.
Leukemia
Heat shock protein 90: a potential therapeutic target in leukemic progenitor and stem cells harboring mutant BCR-ABL resistant to kinase inhibitors.
Leukemia
Helicobacter pylori-controlled c-Abl localization promotes cell migration and limits apoptosis.
Leukemia
Hemin reduces cellular sensitivity to imatinib and anthracyclins via Nrf2.
Leukemia
Hes1 immortalizes committed progenitors and plays a role in blast crisis transition in chronic myelogenous leukemia.
Leukemia
High CFTR expression in Philadelphia chromosome-positive acute leukemia protects and maintains continuous activation of BCR-ABL and related signaling pathways in combination with PP2A.
Leukemia
High level of tyrosine protein kinase in a murine lymphoma cell line induced by Moloney leukemia virus.
Leukemia
High-resolution melting analysis for a reliable and two-step scanning of mutations in the tyrosine kinase domain of the chimerical bcr-abl gene.
Leukemia
High-throughput liquid chromatography/electrospray ionization-tandem mass spectrometry method using in-source collision-induced dissociation for simultaneous quantification of imatinib, dasatinib, bosutinib, nilotinib, and ibrutinib in human plasma.
Leukemia
Highly efficient elimination of Philadelphia leukemic cells by exposure to bcr/abl antisense oligodeoxynucleotides combined with mafosfamide.
Leukemia
Highly specific characterization of tyrosine phosphoproteins in tumor cells based on monoclonal antibodies defined by conjugated phosphotyramine.
Leukemia
Histone deacetylase inhibitors promote STI571-mediated apoptosis in STI571-sensitive and -resistant Bcr/Abl+ human myeloid leukemia cells.
Leukemia
Histone deacetylases inhibitor sodium butyrate inhibits JAK2/STAT signaling through upregulation of SOCS1 and SOCS3 mediated by HDAC8 inhibition in myeloproliferative neoplasms.
Leukemia
Hodgkin's disease variant of Richter's syndrome clonally related to chronic lymphocytic leukemia arises in ZAP-70 negative mutated CLL.
Leukemia
Hsa-miR-520d-5p promotes survival in human dermal fibroblasts exposed to a lethal dose of UV irradiation.
Leukemia
Hsp90 cleavage by an oxidative stress leads to its client proteins degradation and cancer cell death.
Leukemia
HSP90 inhibitor AUY922 induces cell death by disruption of the Bcr-Abl, Jak2 and HSP90 signaling network complex in leukemia cells.
Leukemia
Hsp90 inhibitor, BIIB021, induces apoptosis and autophagy by regulating mTOR-Ulk1 pathway in imatinib-sensitive and -resistant chronic myeloid leukemia cells.
Leukemia
Huai Qi Huang-induced Apoptosis via Down-regulating PRKCH and Inhibiting RAF/MEK/ERK Pathway in Ph+ Leukemia Cells.
Leukemia
Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity.
Leukemia
Human leukemia K562 cells: relationship between hemin-mediated erythroid induction, cell proliferation and expression of c-abl and c-myc oncogenes.
Leukemia
Hybrid compounds as new Bcr/Abl inhibitors.
Leukemia
Hybridization protection assay: a rapid, sensitive, and specific method for detection of Philadelphia chromosome-positive leukemias.
Leukemia
Hyperactivation of Oncogenic JAK3 Mutants Depend on ATP Binding to the Pseudokinase Domain.
Leukemia
Hypothesis: upfront use of ABL kinase inhibitor combination, either simultaneously or sequentially, in high-risk Ph+ leukemias?
Leukemia
Ibrutinib Therapy Increases T Cell Repertoire Diversity in Patients with Chronic Lymphocytic Leukemia.
Leukemia
Identification and characterization of SET, a nuclear phosphoprotein encoded by the translocation break point in acute undifferentiated leukemia.
Leukemia
Identification of a 58,000 daltons phosphoprotein with tyrosine protein kinase activity in a murine lymphoma cell line.
Leukemia
Identification of a novel p190-derived breakpoint Peptide suitable for Peptide vaccine therapeutic approach in ph+ acute lymphoblastic leukemia patients.
Leukemia
Identification of a rare e6a2 BCR-ABL fusion gene during the disease progression of chronic myelomonocytic leukemia: a case report.
Leukemia
Identification of Bisindolylmaleimide IX as a potential agent to treat drug-resistant BCR-ABL positive leukemia.
Leukemia
Identification of drug combinations containing imatinib for treatment of BCR-ABL+ leukemias.
Leukemia
Identification of Natural inhibitors of Bcr-Abl for the treatment of Chronic Myeloid Leukemia.
Leukemia
Identification of Phosphate-Containing Compounds as New Inhibitors of 14-3-3/c-Abl Protein-Protein Interaction.
Leukemia
Identification of the differentiation-associated p93 tyrosine protein kinase of HL-60 leukemia cells as the product of the human c-fes locus and its expression in myelomonocytic cells.
Leukemia
Ikaros antagonizes DNA binding by STAT5 in pre-B cells.
Leukemia
Imatinib and leptomycin B are effective in overcoming imatinib-resistance due to Bcr-Abl amplification and clonal evolution but not due to Bcr-Abl kinase domain mutation.
Leukemia
Imatinib and tyrosine kinase inhibition, in the management of BCR-ABL negative myeloproliferative disorders.
Leukemia
Imatinib mesylate (STI-571) reduces Bcr-Abl-mediated vascular endothelial growth factor secretion in chronic myelogenous leukemia.
Leukemia
Imatinib mesylate (STI571) abrogates the resistance to doxorubicin in human K562 chronic myeloid leukemia cells by inhibition of BCR/ABL kinase-mediated DNA repair.
Leukemia
Imatinib resistant chronic myelogenous leukemia, BCR-ABL positive by chromosome and FISH analyses but negative by PCR, in a child progressing to acute basophilic leukemia: cytogenetic follow-up.
Leukemia
Imatinib-induced acute generalized exanthematous pustulosis (AGEP) in two patients with chronic myeloid leukemia.
Leukemia
Imatinib-resistant CML cells have low ENT activity but maintain sensitivity to gemcitabine.
Leukemia
Immune response to Philadelphia chromosome-positive acute lymphoblastic leukemia induced by expression of CD80, interleukin 2, and granulocyte-macrophage colony-stimulating factor.
Leukemia
Impact of Chromosomal Rearrangement upon DNA Methylation Patterns in Leukemia.
Leukemia
Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children's Research Hospital.
Leukemia
Improved Survival of Calreticulin-Mutated Patients Compared With Janus Kinase 2 in Primary Myelofibrosis: A Meta-Analysis.
Leukemia
In defense of the somatic mutation theory of cancer.
Leukemia
In vitro Anti-leukaemia Activity of Pyrrolo[1,2-b][1,2,5]benzothiadiazepines (PBTDs).
Leukemia
In vitro JAK kinase activity and inhibition assays.
Leukemia
In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor.
Leukemia
Increased tyrosine protein kinase activity in hairy cell and monocytic leukemias.
Leukemia
Induction of BCR-ABL-specific immunity following vaccination with chaperone-rich cell lysates derived from BCR-ABL+ tumor cells.
Leukemia
Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome.
Leukemia
Induction of Chronic Myeloid Leukemia in Mice.
Leukemia
Induction of differentiation of human leukemia cells with a structurally altered c-abl (bcr/abl) gene by herbimycin A, an inhibitor of tyrosine kinase activity.
Leukemia
Induction of heparin-binding EGF-like growth factor and activation of EGF receptor in imatinib mesylate-treated squamous carcinoma cells.
Leukemia
Induction of hyperphosphorylation and activation of the p56lck protein tyrosine kinase by phenylarsine oxide, a phosphotyrosine phosphatase inhibitor.
Leukemia
Inhibition of Bcr-Abl Phosphorylation and Induction of Apoptosis by Pyrazolo[3,4-d]pyrimidines in Human Leukemia Cells.
Leukemia
Inhibition of c-fes expression by an antisense oligomer causes apoptosis of HL60 cells induced to granulocytic differentiation.
Leukemia
Inhibition of c-Jun N-terminal kinase by SP600125: a cDNA microarray analysis.
Leukemia
Inhibition of heat shock protein 90 prolongs survival of mice with BCR-ABL-T315I-induced leukemia and suppresses leukemic stem cells.
Leukemia
Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors.
Leukemia
Inhibition of interleukin-1 signaling enhances elimination of tyrosine kinase inhibitor treated CML stem cells.
Leukemia
Inhibition of Oxidative Phosphorylation Reverses Bone Marrow Hypoxia Visualized in Imageable Syngeneic B-ALL Mouse Model.
Leukemia
Inhibition of Phosphotyrosine Phosphatase 1B Causes Resistance in BCR-ABL-Positive Leukemia Cells to the ABL Kinase Inhibitor STI571.
Leukemia
Inhibition of small GTPase RalA regulates growth and arsenic-induced apoptosis in chronic myeloid leukemia (CML) cells.
Leukemia
Inhibition of the rous sarcoma virus long terminal repeat-driven transcription by in vitro methylation: different sensitivity in permissive chicken cells versus mammalian cells.
Leukemia
Inhibitory effect of a nucleoside analog, acyclovir, on leukemia cells.
Leukemia
Integrated computational biology analysis to evaluate target genes for chronic myelogenous leukemia.
Leukemia
Integrated microfluidic and imaging platform for a kinase activity radioassay to analyze minute patient cancer samples.
Leukemia
Integrin VLA-5 and FAK are Good Targets to Improve Treatment Response in the Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia.
Leukemia
Interaction of BCR-ABL with the retinoblastoma protein in Philadelphia chromosome-positive cell lines.
Leukemia
Intracerebral hemorrhage as a rare complication of imatinib in a Philadelphia chromosome positive acute lymphoblastic leukemia pediatric patient.
Leukemia
Intramolecular interactions of the regulatory domains of the Bcr-Abl kinase reveal a novel control mechanism.
Leukemia
Introducing crucial protein panel of gastric adenocarcinoma disease.
Leukemia
Involvement of ROS in chlorogenic acid-induced apoptosis of Bcr-Abl+ CML cells.
Leukemia
Isolated central nervous system relapse in two patients with BCR-ABL-positive acute leukemia while receiving a next-generation tyrosine kinase inhibitor.
Leukemia
Isolation and characterization of flat revertant cell lines from A-MuLV-transformed fibroblasts.
Leukemia
JAK-STAT signaling pathway mediates astrogliosis in brains of scrapie-infected mice.
Leukemia
JAK2 mutants (e.g., JAK2V617F) and their importance as drug targets in myeloproliferative neoplasms.
Leukemia
JAK2, CALR, and MPL Mutations in Egyptian Patients With Classic Philadelphia-negative Myeloproliferative Neoplasms.
Leukemia
JAK2, MPL, and CALR mutations in Chinese Han patients with essential thrombocythemia.
Leukemia
JAK2V617F drives Mcl-1 expression and sensitizes hematologic cell lines to dual inhibition of JAK2 and Bcl-xL.
Leukemia
Janus kinase 2 activation mechanisms revealed by analysis of suppressing mutations.
Leukemia
Janus kinase 3 inhibitor WHI-P131/JANEX-1 prevents graft-versus-host disease but spares the graft-versus-leukemia function of the bone marrow allografts in a murine bone marrow transplantation model.
Leukemia
Janus kinase deregulation in leukemia and lymphoma.
Leukemia
Janus Kinase Mutations in Mice Lacking PU.1 and Spi-B Drive B Cell Leukemia through Reactive Oxygen Species-Induced DNA Damage.
Leukemia
Janus kinase mutations in the development of acute megakaryoblastic leukemia in children with and without Down's syndrome.
Leukemia
K562 leukemia cells transfected with the human c-fes gene acquire the ability to undergo myeloid differentiation.
Leukemia
Kinase domain mutants of Bcr-Abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib.
Leukemia
Kinase drug discovery approaches in chronic myeloproliferative disorders.
Leukemia
Kinase-Addiction and Bi-Phasic Sensitivity-Resistance of Bcr-Abl-and Raf-1-Expressing Cells to Imatinib and Geldanamycin.
Leukemia
Kinase-independent mechanisms of resistance of leukemia stem cells to tyrosine kinase inhibitors.
Leukemia
KLF4 suppresses transformation of pre-B cells by ABL oncogenes.
Leukemia
Leukemia inhibitory factor regulates trophoblast giant cell differentiation via Janus kinase 1-signal transducer and activator of transcription 3-suppressor of cytokine signaling 3 pathway.
Leukemia
Leukemia patient-derived lymphoblastoid cell lines exhibit increased induction of leukemia-associated transcripts following high-dose irradiation.
Leukemia
Leukemia Stem Cells in Chronic Myeloid Leukemia.
Leukemia
Leukemia stem cells: the root of chronic myeloid leukemia.
Leukemia
Leukemia treatment in severe combined immunodeficiency mice by antisense oligodeoxynucleotides targeting cooperating oncogenes.
Leukemia
Leukemia-associated fusion proteins, dek-can and bcr-abl, represent immunogenic HLA-DR-restricted epitopes recognized by fusion peptide-specific CD4+ T lymphocytes.
Leukemia
Light microscopic detection of BCR-ABL transcripts after in-cell RT-PCR: fusion gene expression might correlate with clinical evolution of chronic myeloid leukemia.
Leukemia
Limitin: An interferon-like cytokine that preferentially influences B-lymphocyte precursors.
Leukemia
Lipocalin 2 is required for BCR-ABL-induced tumorigenesis.
Leukemia
Liposomal Nanoparticles of a Spleen Tyrosine Kinase P-Site Inhibitor Amplify the Potency of Low Dose Total Body Irradiation Against Aggressive B-Precursor Leukemia and Yield Superior Survival Outcomes in Mice.
Leukemia
LLL-3, a STAT3 inhibitor, represses BCR-ABL-positive cell proliferation, activates apoptosis and improves the effects of Imatinib mesylate.
Leukemia
Long circulating lectin conjugated paclitaxel loaded magnetic nanoparticles: a new theranostic avenue for leukemia therapy.
Leukemia
Loss function of Bcr mutation causes gastrointestinal dysmotility and brain developmental defects.
Leukemia
Loss of c-abl facilitates anchorage-independent growth of p53- and RB- deficient primary mouse embryonic fibroblasts.
Leukemia
Loss of Egr1, a human del5q gene, accelerates BCR-ABL driven chronic myelogenous leukemia.
Leukemia
Loss of Gadd45b accelerates BCR-ABL-driven CML.
Leukemia
Loss of p53 impedes the antileukemic response to BCR-ABL inhibition.
Leukemia
Low expression of Abelson interactor-1 is linked to acquired drug resistance in Bcr-Abl-induced leukemia.
Leukemia
Lyn kinase and ZAP70 are substrates of PTPROt in B-cells: Lyn inactivation by PTPROt sensitizes leukemia cells to VEGF-R inhibitor pazopanib.
Leukemia
Mechanism of MK-0457 efficacy against BCR-ABL positive leukemia cells.
Leukemia
Mechanism of shortened bones in mucopolysaccharidosis VII.
Leukemia
Mechanisms of apoptosis by the tyrphostin AG957 in hematopoietic cells.
Leukemia
Mechanisms of resistance to BCR-ABL TKIs and the therapeutic strategies: A review.
Leukemia
Mechanisms of resistance to STI571 in Philadelphia chromosome-associated leukemias.
Leukemia
Mechanisms of Resistance to Targeted Therapies in Acute Myeloid Leukemia and Chronic Myeloid Leukemia.
Leukemia
MEK kinase 1 is essential for Bcr-Abl-induced STAT3 and self-renewal activity in embryonic stem cells.
Leukemia
Methylated alteration of SHP1 complements mutation of JAK2 tyrosine kinase in patients with myeloproliferative neoplasm.
Leukemia
Mice homozygous for the ablm1 mutation show poor viability and depletion of selected B and T cell populations.
Leukemia
MicroRNA miR-125b causes leukemia.
Leukemia
MicroRNA-34a-mediated death of acute myeloid leukemia stem cells through apoptosis induction and exosome shedding inhibition via histone deacetylase 2 targeting.
Leukemia
miR-451a induced apoptosis of Philadelphia chromosome-positive acute lymphoblastic leukemia cells by targeting IL-6R.
Leukemia
MK-0457, an Aurora kinase and BCR-ABL inhibitor, is active in patients with BCR-ABL T315I leukemia.
Leukemia
Modeling BCR-ABL and MLL-AF9 leukemia in a human bone marrow-like scaffold-based xenograft model.
Leukemia
Modeling Philadelphia chromosome positive leukemias.
Leukemia
Modulation of activation-loop phosphorylation by JAK inhibitors is binding mode dependent.
Leukemia
Modulation of p210(BCR-ABL) activity in transduced primary human hematopoietic cells controls lineage programming.
Leukemia
Molecular and cellular bases of chronic myeloid leukemia.
Leukemia
Molecular characterization and sensitivity of STI-571 (imatinib mesylate, Gleevec)-resistant, Bcr-Abl-positive, human acute leukemia cells to SRC kinase inhibitor PD180970 and 17-allylamino-17-demethoxygeldanamycin.
Leukemia
Molecular characterization as a target for cancer therapy in relation to orphan status disorders (Review).
Leukemia
Molecular consequences of the BCR-ABL translocation in chronic myelogenous leukemia.
Leukemia
Molecular diagnostics of hematologic malignancies.
Leukemia
Molecular monitoring of Tunisian patients with chronic myeloid leukemia.
Leukemia
Molecular pathogenesis of chronic myeloid leukemia: implications for new therapeutic strategies.
Leukemia
Molecular pathophysiology of chronic myelogenous leukemia.
Leukemia
Molecular requirements for rapid plasmacytoma and pre-B lymphoma induction by Abelson murine leukemia virus in myc-transgenic mice.
Leukemia
Molecular signatures of chronic myeloid leukemia stem cells.
Leukemia
Molecular studies in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors.
Leukemia
Molecularly targeted treatment of chronic myeloid leukemia: beyond the imatinib era.
Leukemia
Morin inhibits Fyn kinase in mast cells and IgE-mediated type I hypersensitivity response in vivo.
Leukemia
Multifunctional Abl kinases in health and disease.
Leukemia
Multiplex in-cell reverse transcription-polymerase chain reaction for the simultaneous detection of p210 and p190 BCR-ABL mRNAs in chronic myeloid leukemia and Philadelphia-positive acute lymphoblastic leukemia cell lines.
Leukemia
Mutant forms of growth factor-binding protein-2 reverse BCR-ABL-induced transformation.
Leukemia
Mutated BCR-ABL Generates Immunogenic T Cell Epitopes In CML Patients.
Leukemia
Mutation of a phenylalanine conserved in SH3-containing tyrosine kinases activates the transforming ability of c-Abl.
Leukemia
Mutation-specific control of BCR-ABL T315I positive leukemia with a recombinant yeast-based therapeutic vaccine in a murine model.
Leukemia
Mutations affecting the MA portion of the v-Abl protein reveal a conserved role of Gag in Abelson murine leukemia virus (MLV) and Moloney MLV.
Leukemia
Myeloid differentiation associated tyrosine protein kinase activity in WEHI-3B murine monomyelocytic leukemia cells.
Leukemia
Myeloproliferative Neoplasms: A Contemporary Review.
Leukemia
Myeloproliferative neoplasms: A decade of discoveries and treatment advances.
Leukemia
N- and C-terminal isoforms of Arg quantified by real-time PCR are specifically expressed in human normal and neoplastic cells, in neoplastic cell lines, and in HL-60 cell differentiation.
Leukemia
N-Benzyladriamycin-14-valerate (AD 198) cytotoxicty circumvents Bcr-Abl anti-apoptotic signaling in human leukemia cells and also potentiates imatinib cytotoxicity.
Leukemia
N-terminal mutations activate the leukemogenic potential of the myristoylated form of c-abl.
Leukemia
Natural and Semisynthetic Chalcones as Dual FLT3 and Microtubule Polymerization Inhibitors.
Leukemia
Neferine in the Lotus Plumule Potentiates the Antitumor Effect of Imatinib in Primary Chronic Myeloid Leukemia Cells In Vitro.
Leukemia
Negative regulation of c-abl tyrosine kinase by its variable N-terminal amino acids.
Leukemia
New 2,6,9-trisubstituted purine derivatives as Bcr-Abl and Btk inhibitors and as promising agents against leukemia.
Leukemia
New dosing schedules of dasatinib for CML and adverse event management.
Leukemia
New Mouse Models to Investigate the Efficacy of Drug Combinations in Human Chronic Myeloid Leukemia.
Leukemia
New mutations detected by denaturing high performance liquid chromatography during screening of exon 6 bcr-abl mutations in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.
Leukemia
New rapid method to detect BCR-ABL fusion genes with multiplex RT-qPCR in one-tube at a time.
Leukemia
New tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia.
Leukemia
Nilotinib hampers the proliferation and function of CD8+ T lymphocytes through inhibition of T cell receptor signalling.
Leukemia
Nilotinib is more potent than imatinib for treating plexiform neurofibroma in vitro and in vivo.
Leukemia
Nilotinib treatment in mouse models of P190 Bcr/Abl lymphoblastic leukemia.
Leukemia
Nilotinib: a novel Bcr-Abl tyrosine kinase inhibitor for the treatment of leukemias.
Leukemia
No Loose Ends: A Review of the Pharmacotherapy of Hairy Cell and Hairy Cell Leukemia Variant.
Leukemia
Noncovalent inhibitors reveal BTK gatekeeper and auto-inhibitory residues that control its transforming activity.
Leukemia
Normal ABL1 is a tumor suppressor and therapeutic target in human and mouse leukemias expressing oncogenic ABL1 kinases.
Leukemia
Novel activating JAK2 mutation in a patient with Down syndrome and B-cell precursor acute lymphoblastic leukemia.
Leukemia
Novel Combination Treatments Targeting Chronic Myeloid Leukemia Stem Cells.
Leukemia
Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1.
Leukemia
Novel pyrazolo[3,4-d]pyrimidines as dual Src-Abl inhibitors active against mutant form of Abl and the leukemia K-562 cell line.
Leukemia
Novel role of pleckstrin homology domain of the Bcr-Abl protein: analysis of protein-protein and protein-lipid interactions.
Leukemia
Novel targeted drug therapies for the treatment of childhood acute leukemia.
Leukemia
Novel targeted therapies for Bcr-Abl positive acute leukemias: beyond STI571.
Leukemia
Novel therapeutic agents against cancer stem cells of chronic myeloid leukemia.
Leukemia
Nuclear localization of lymphocyte-specific protein tyrosine kinase (Lck) and its role in regulating LIM domain only 2 (Lmo2) gene.
Leukemia
Nuclear lymphocyte-specific protein tyrosine kinase and its interaction with CR6-interacting factor 1 promote the survival of human leukemic T cells.
Leukemia
Nucleic acid sequence and oncogenic properties of the HZ2 feline sarcoma virus v-abl insert.
Leukemia
Oligomerization of the ABL tyrosine kinase by the Ets protein TEL in human leukemia.
Leukemia
Omacetaxine mepesuccinate in the treatment of intractable chronic myeloid leukemia.
Leukemia
On systems and control approaches to therapeutic gain.
Leukemia
On the cellular uptake and membrane effect of the multifunctional peptide, TatLK15.
Leukemia
Oncogene expression in Rauscher murine leukemia virus induced erythroid, myeloid and lymphoid cell lines.
Leukemia
Oncogenes and cancer: clinical applications.
Leukemia
Oncogenic heterogeneous nuclear ribonucleoprotein D-like modulates the growth and imatinib response of human chronic myeloid leukemia CD34+ cells via pre-B-cell leukemia homeobox 1.
Leukemia
Oncogenic interaction between BCR-ABL and NUP98-HOXA9 demonstrated by the use of an in vitro purging culture system.
Leukemia
Oncogenic signaling: new insights and controversies from chronic myeloid leukemia.
Leukemia
Optimal management of patients with newly diagnosed chronic phase chronic myeloid leukemia in 2007.
Leukemia
Oridonin in combination with imatinib exerts synergetic anti-leukemia effect in Ph+ acute lymphoblastic leukemia cells in vitro by inhibiting activation of LYN/mTOR signaling pathway.
Leukemia
Oridonin Triggers Chaperon-mediated Proteasomal Degradation of BCR-ABL in Leukemia.
Leukemia
Orientation and oligomerization specificity of the Bcr coiled-coil oligomerization domain.
Leukemia
Osteopontin is upregulated by BCR-ABL.
Leukemia
Overcoming Bcr-Abl T315I mutation by combination of GNF-2 and ATP competitors in an Abl-independent mechanism.
Leukemia
Overcoming imatinib resistance using Src inhibitor CGP76030, Abl inhibitor nilotinib and Abl/Lyn inhibitor INNO-406 in newly established K562 variants with BCR-ABL gene amplification.
Leukemia
Overexpressed pp60c-src can induce focus formation without complete transformation of NIH 3T3 cells.
Leukemia
p190 BCR-ABL mRNA is expressed at low levels in p210-positive chronic myeloid and acute lymphoblastic leukemias.
Leukemia
p190(BCR-ABL) rearrangement as a secondary change in a case of acute myelo-monocytic leukemia with inv(16)(p13q22).
Leukemia
p210(BCR-ABL) reprograms transformed and normal human megakaryocytic progenitor cells into erythroid cells and suppresses FLI-1 transcription.
Leukemia
p210BCR/ABL, p190BCR/ABL, and TEL/ABL activate similar signal transduction pathways in hematopoietic cell lines.
Leukemia
p90RSK2 is essential for FLT3-ITD- but dispensable for BCR-ABL-induced myeloid leukemia.
Leukemia
Pak1 gene functioned differentially in different BCR-ABL subtypes in leukemiagenesis and treatment response through STAT5 pathway.
Leukemia
Patients with Philadelphia-positive leukemia with BCR-ABL kinase mutations before allogeneic transplantation predominantly relapse with the same mutation.
Leukemia
Patients with Philadelphia-positive leukemia with Y253H or F359V mutation have a high risk of developing new mutations in the setting of dasatinib resistance.
Leukemia
Patterns of surveillance for late effects of BCR-ABL tyrosine kinase inhibitors in survivors of pediatric Philadelphia chromosome positive leukemias.
Leukemia
Pediatric acute lymphoblastic leukemia.
Leukemia
Personalized medicine and pharmacogenetic biomarkers: progress in molecular oncology testing.
Leukemia
PHA-680626 exhibits anti-proliferative and pro-apoptotic activity on Imatinib-resistant chronic myeloid leukemia cell lines and primary CD34+ cells by inhibition of both Bcr-Abl tyrosine kinase and Aurora kinases.
Leukemia
Phase 1 study of INNO-406, a dual Abl/Lyn kinase inhibitor, in Philadelphia chromosome-positive leukemias after imatinib resistance or intolerance.
Leukemia
Phase II pilot study of oral dasatinib in patients with higher-risk myelodysplastic syndrome (MDS) who failed conventional therapy.
Leukemia
Philadelphia chromosome-positive leukemias: from basic mechanisms to molecular therapeutics.
Leukemia
Phosphatidylinositol-3 kinase inhibitors enhance the anti-leukemia effect of STI571.
Leukemia
Phospho-CRKL monitoring for the assessment of BCR-ABL activity in imatinib-resistant chronic myeloid leukemia or Ph+ acute lymphoblastic leukemia patients treated with nilotinib.
Leukemia
Phosphoinositide 3-kinase signaling is essential for ABL oncogene-mediated transformation of B-lineage cells.
Leukemia
Phosphoinositides are not phosphorylated by the very active tyrosine protein kinase from the murine lymphoma LSTRA.
Leukemia
Phosphorylation of ribosomal protein S6 on serine after microinjection of the Abelson murine leukemia virus tyrosine-specific protein kinase into Xenopus oocytes.
Leukemia
Phosphorylation of synthetic peptides containing Tyr-Met-X-Met motifs by nonreceptor tyrosine kinases in vitro.
Leukemia
PKC-?/Alox5 axis activation promotes Bcr-Abl-independent TKI-resistance in chronic myeloid leukemia.
Leukemia
Polarized distribution of Bcr-Abl in migrating myeloid cells and co-localization of Bcr-Abl and its target proteins.
Leukemia
Polycythemia vera and essential thrombocythemia: algorithmic approach.
Leukemia
Polydatin-induced cell apoptosis and cell cycle arrest are potentiated by Janus kinase 2 inhibition in leukemia cells.
Leukemia
Polyphenol tri-vanillic ester 13c inhibits P-JAK2V617F and Bcr-Abl oncokinase expression in correlation with STAT3/STAT5 inactivation and apoptosis induction in human leukemia cells.
Leukemia
Positron emission tomography imaging analysis of G2A as a negative modifier of lymphoid leukemogenesis initiated by the BCR-ABL oncogene.
Leukemia
Potent antiproliferative effect of fatty-acid derivative AIC-47 on leukemic mice harboring BCR-ABL mutation.
Leukemia
Potential molecules implicated in downstream signaling pathways of p185BCR-ABL in Ph+ ALL involve GTPase-activating protein, phospholipase C-gamma 1, and phosphatidylinositol 3'-kinase.
Leukemia
Potential therapeutic applications of antisense oligodeoxynucleotides in the treatment of chronic myelogenous leukemia.
Leukemia
Preclinical and clinical experience with dasatinib in Philadelphia chromosome-negative leukemias and myeloid disorders.
Leukemia
Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions.
Leukemia
Presence of calreticulin mutations in JAK2-negative polycythemia vera.
Leukemia
Presence or the emergence of a F317L BCR-ABL mutation may be associated with resistance to dasatinib in Philadelphia chromosome-positive leukemia.
Leukemia
Prevalence of MPL (W515K/L) Mutations in Patients with Negative-JAK2 (V617F) Myeloproliferative Neoplasm in North-East of Iran.
Leukemia
Pro-survival role of protein kinase C epsilon in Philadelphia chromosome positive acute leukemia.
Leukemia
Proposed Algorithm for the Best Detection of Different bcr-abl Gene Fusion Transcripts in Molecular Diagnostics Laboratories: Experience of a Major Referral Center.
Leukemia
Prospective BCR-ABL analysis by polymerase chain reaction (RT-PCR) in adult acute B-lineage lymphoblastic leukemia: reliability of RT-nested-PCR and comparison to cytogenetic data.
Leukemia
Protein Kinase CK2: A Targetable BCR-ABL Partner in Philadelphia Positive Leukemias.
Leukemia
Protein kinases as targets for anticancer agents: from inhibitors to useful drugs.
Leukemia
Protein tyrosine phosphatase PTP1B suppresses p210 bcr-abl-induced transformation of rat-1 fibroblasts and promotes differentiation of K562 cells.
Leukemia
Proto-oncogene expression and dissection of the myeloid growth to differentiation developmental cascade.
Leukemia
Proto-oncogene expression in human normal bone marrow.
Leukemia
Protooncogene expression and the clinical characteristics of acute nonlymphocytic leukemia: A Leukemia Intergroup pilot study.
Leukemia
PTEN is a tumor suppressor in CML stem cells and BCR-ABL-induced leukemias in mice.
Leukemia
Pulmonary toxicities of tyrosine kinase inhibitors.
Leukemia
Pure curcumin increases the expression of SOCS1 and SOCS3 in myeloproliferative neoplasms through suppressing class I histone deacetylases.
Leukemia
Purification and characterization of a protein-tyrosine kinase encoded by the Abelson murine leukemia virus.
Leukemia
Purification and characterization of p93fes- and p60src-related tyrosine protein kinase activities in differentiated HL-60 leukemia cells.
Leukemia
Purinostat Mesylate is a uniquely potent and selective inhibitor of HDACs for the treatment of BCR-ABL-induced B-cell acute lymphoblastic leukemia.
Leukemia
Pyrazolopyrimidine Derivatives as Antineoplastic Agents: with a Special Focus on Thyroid Cancer.
Leukemia
Quantification of BCR-ABL mRNA in plasma/serum of patients with chronic myelogenous leukemia.
Leukemia
Quantitative detection of bcr-abl transcripts in chronic myeloid leukemia.
Leukemia
Quantitative evaluation of BCR-ABL amount of transcript post mobilization with G-CSF of peripheral blood stem cells from chronic myeloid leukemia patients in cytogenetic response.
Leukemia
Quantitative real time-polymerase chain reaction method in Bcr-Abl translocation diagnostics.
Leukemia
Quantitative real-time reverse-transcription polymerase chain reaction for diagnosis of BCR-ABL positive leukemias and molecular monitoring following allogeneic stem cell transplantation.
Leukemia
Quinacrine Depletes BCR-ABL and Suppresses Ph-Positive Leukemia Cells.
Leukemia
Rapid automated detection of ABL kinase domain mutations in imatinib-resistant patients.
Leukemia
Rapid quantitative detection of BCR-ABL transcripts in chronic myeloid leukemia patients by real-time reverse transcriptase polymerase-chain reaction using fluorescently labeled probes.
Leukemia
Rearrangement of bcr and c-abl sequences in Ph-positive acute leukemias and Ph-negative CML--an update.
Leukemia
Rearrangement of the c-abl and bcr genes in Ph-negative CML and Ph-positive acute leukemias.
Leukemia
Recombinant murine interleukin-12 elicits potent antileukemic immune responses in a murine model of Philadelphia chromosome-positive acute lymphoblastic leukemia.
Leukemia
Reconstitution of T cell receptor signaling in ZAP-70-deficient cells by retroviral transduction of the ZAP-70 gene.
Leukemia
Recurring proviral integration suggests a role for proto-oncogene activation in thymomas induced with Mo-MuLV-rescued BCR/ABL virus.
Leukemia
Regional localization and developmental expression of the BCR gene in rodent brain.
Leukemia
Regulated expression of P210 Bcr-Abl during embryonic stem cell differentiation stimulates multipotential progenitor expansion and myeloid cell fate.
Leukemia
Regulation of the oncogenic activity of BCR-ABL by a tightly bound substrate protein RIN1.
Leukemia
Regulatory Molecules and Corresponding Processes of BCR-ABL Protein Degradation.
Leukemia
Reproductive fitness advantage of BCR-ABL expressing leukemia cells.
Leukemia
Requirement for antiapoptotic MCL-1 in the survival of BCR-ABL B-lineage acute lymphoblastic leukemia.
Leukemia
Requirement for CD44 in homing and engraftment of BCR-ABL-expressing leukemic stem cells.
Leukemia
Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia.
Leukemia
Resistance in the land of molecular cancer therapeutics.
Leukemia
Resistance of Philadelphia-chromosome positive leukemia towards the kinase inhibitor imatinib (STI571, Glivec): a targeted oncoprotein strikes back.
Leukemia
Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain.
Leukemia
Retroviral transduction models of Ph+ leukemia: advantages and limitations for modeling human hematological malignancies in mice.
Leukemia
Ribavirin Inhibits the Activity of mTOR/eIF4E, ERK/Mnk1/eIF4E Signaling Pathway and Synergizes with Tyrosine Kinase Inhibitor Imatinib to Impair Bcr-Abl Mediated Proliferation and Apoptosis in Ph+ Leukemia.
Leukemia
Ribozyme-mediated inhibition of bcr-abl gene expression in a Philadelphia chromosome-positive cell line.
Leukemia
RNA interference targeting of Bcr-Abl increases chronic myeloid leukemia cell killing by 17-allylamino-17-demethoxygeldanamycin.
Leukemia
RNA interference--about the reality to be exploited in cancer therapy.
Leukemia
RNAi-mediated silencing of p190Bcr-Abl inactivates Stat5 and cooperates with imatinib mesylate and 17-allylamino-17-demetoxygeldanamycin in selective killing of p190Bcr-Abl-expressing leukemia cells.
Leukemia
Role of calcium-dependent protein kinases in chronic myeloid leukemia: combined effects of PKC and BCR-ABL signaling on cellular alterations during leukemia development.
Leukemia
Role of the BCR-ABL oncogene in human leukemia: fifteenth Richard and Hinda Rosenthal Foundation Award Lecture.
Leukemia
Role of Vitamins A and D in BCR-ABL Arf-/- Acute Lymphoblastic Leukemia.
Leukemia
Roles of C-terminal Src kinase in the initiation and the termination of the high affinity IgE receptor-mediated signaling.
Leukemia
Roots of imatinib resistance: A question of self-renewal?
Leukemia
Rt-PCR method for diagnosis and follow-up of hematological malignancies: first approach in Bangladesh.
Leukemia
S6K1 determines the metabolic requirements for BCR-ABL survival.
Leukemia
Secondary activation of c-abl may be related to translocation to the nucleolar organizer region in an in vitro cultured rat leukemia cell line (K3D).
Leukemia
Secondary mutations as mediators of resistance to targeted therapy in leukemia.
Leukemia
Selective and effective targeting of chronic myeloid leukemia stem cells by topoisomerase II inhibitor etoposide in combination with imatinib mesylate in vitro.
Leukemia
Selective induction of apoptosis in Philadelphia chromosome-positive chronic myelogenous leukemia cells by an inhibitor of BCR - ABL tyrosine kinase, CGP 57148.
Leukemia
Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148).
Leukemia
Selective inhibition of leukemia cell proliferation by BCR-ABL antisense oligodeoxynucleotides.
Leukemia
Selective interactions of transforming and normal abl proteins with ATP, tyrosine-copolymer substrates, and tyrphostins.
Leukemia
Selective sensitization of tumors to chemotherapy by marine-derived lipids: A review.
Leukemia
Self-renewal of embryonic stem cells through culture on nanopattern polydimethylsiloxane substrate.
Leukemia
Sequences within the first exon of BCR inhibit the activated tyrosine kinases of c-Abl and the Bcr-Abl oncoprotein.
Leukemia
Serum Inter-?-inhibitor activates the Yes tyrosine kinase and YAP/TEAD transcriptional complex in mouse embryonic stem cells.
Leukemia
Severe hyperlipemia-induced pseudoerythrocytosis - Implication for misdiagnosis and blood transfusion: A case report and literature review.
Leukemia
SFT Thijsen et al. Hypersensitivity of bcr-abl progenitors to hyperthermia in patients with chronic myeloid leukemia. Leukemia 1997; 11: 1762-1768.
Leukemia
SGX393 inhibits the CML mutant Bcr-AblT315I and preempts in vitro resistance when combined with nilotinib or dasatinib.
Leukemia
SH2-containing phosphotyrosine phosphatase SHP-1 is involved in BCR-ABL signal transduction pathways.
Leukemia
Short interfering RNA (siRNA) targeting the Lyn kinase induces apoptosis in primary, and drug-resistant, BCR-ABL1(+) leukemia cells.
Leukemia
Significance of the Philadelphia chromosome in acute leukemias: variable correlation with rearrangements involving the c-abl and bcr genes.
Leukemia
Silencing of miR-21 sensitizes CML CD34+ stem/progenitor cells to imatinib-induced apoptosis by blocking PI3K/AKT pathway.
Leukemia
Simple multiplex RT-PCR for identifying common fusion transcripts in childhood acute leukemia.
Leukemia
Simultaneous expression of RBTN-2 and BCR-ABL oncogenes in a T-ALL with a t(11;14)(p13;q11) and a late-appearing Philadelphia chromosome.
Leukemia
Simultaneous novel BCR-ABL gene mutation and increased expression of BCR-ABL mRNA caused clinical resistance to STI571 in double-Ph-positive acute biphenotypic leukemia.
Leukemia
Simultaneous occurrence of t(9;22)(q34;q11.2) and t(16;16)(p13;q22) in a patient with chronic myeloid leukemia in blastic phase.
Leukemia
siRNA Library Screening Identifies a Druggable Immune-Signature Driving Esophageal Adenocarcinoma Cell Growth.
Leukemia
siRNA/lipopolymer nanoparticles to arrest growth of chronic myeloid leukemia cells in vitro and in vivo.
Leukemia
SIRT1 regulates metabolism and leukemogenic potential in CML stem cells.
Leukemia
SOCS-mediated downregulation of mutant Jak2 (V617F, T875N and K539L) counteracts cytokine-independent signaling.
Leukemia
Some lymphoid cell lines transformed by Abelson murine leukemia virus lack a major 36,000-dalton tyrosine protein kinase substrate.
Leukemia
Sonic hedgehog signaling regulates Bcr-Abl expression in human chronic myeloid leukemia cells.
Leukemia
Specific binding of leukemia oncogene fusion protein peptides to HLA class I molecules.
Leukemia
Specificity of arachidonic acid-induced inhibition of growth and activation of c-jun kinases and p38 mitogen-activated protein kinase in hematopoietic cells.
Leukemia
Specificity of disease induced by M-MuLV chimeric retroviruses containing v-myc or v-src is not determined by the LTR.
Leukemia
Spleen tyrosine kinase as a molecular target for treatment of leukemias and lymphomas.
Leukemia
Spontaneous resolution of a single lesion of myeloid leukemia cutis in an infant: case report and discussion.
Leukemia
Spontaneous subdural hematoma in a patient with Philadelphia chromosome-positive acute lymphoblastic leukemia with normal platelet count after dasatinib treatment.
Leukemia
SPR Detection and Discrimination of the Oligonucleotides Related to the Normal and the Hybrid bcr-abl Genes by Two Stringency Control Strategies.
Leukemia
Src activation plays an important key role in lymphomagenesis induced by FGFR1 fusion kinases.
Leukemia
Src family kinase inhibitor bosutinib enhances retinoic acid-induced differentiation of HL-60 leukemia cells.
Leukemia
Src family kinase inhibitor PP2 enhances differentiation of acute promyelocytic leukemia cell line induced by combination of all-trans-retinoic acid and arsenic trioxide.
Leukemia
Src Family Kinase Inhibitor PP2 Has Different Effects on All-Trans-Retinoic Acid or Arsenic Trioxide-Induced Differentiation of an Acute Promyelocytic Leukemia Cell Line.
Leukemia
Src family tyrosine kinase Lyn binds several proteins including paxillin in rat basophilic leukemia cells.
Leukemia
Src-kinase inhibitors sensitize human cells of myeloid origin to Toll-like-receptor-induced interleukin 12 synthesis.
Leukemia
ST1926, an orally active synthetic retinoid, induces apoptosis in chronic myeloid leukemia cells and prolongs survival in a murine model.
Leukemia
STAT5 activation by BCR-Abl contributes to transformation of K562 leukemia cells.
Leukemia
Stat5 Exerts Distinct, Vital Functions in the Cytoplasm and Nucleus of Bcr-Abl+ K562 and Jak2(V617F)+ HEL Leukemia Cells.
Leukemia
Stem cell transplantation for patients with chronic myeloid leukemia resistant to tyrosine kinase inhibitors with BCR-ABL kinase domain mutation T315I.
Leukemia
STI571 reduces TRAIL-induced apoptosis in colon cancer cells: c-Abl activation by the death receptor leads to stress kinase-dependent cell death.
Leukemia
Stimulation of Bruton's tyrosine kinase (BTK) and inositol 1,4,5-trisphosphate production in leukemia and lymphoma cells exposed to low energy electromagnetic fields.
Leukemia
Strategies to overcome resistance mutations of Bruton's tyrosine kinase inhibitor ibrutinib.
Leukemia
Structural alterations in the carboxyl-terminal domain of the BCRABL gene product activate its fibroblastic transforming potential.
Leukemia
Structural and functional dissection of the DH and PH domains of oncogenic Bcr-Abl tyrosine kinase.
Leukemia
Structural and signaling requirements for BCR-ABL-mediated transformation and inhibition of apoptosis.
Leukemia
Structural basis for the cytoskeletal association of Bcr-Abl/c-Abl.
Leukemia
Structural modification of c-abl in lymphoma and leukemia.
Leukemia
Structural optimization of diphenylpyrimidine derivatives (DPPYs) as potent Bruton's tyrosine kinase (BTK) inhibitors with improved activity toward B leukemia cell lines.
Leukemia
Structure of the Bcr-Abl oncoprotein oligomerization domain.
Leukemia
Studies on the inhibitory effects of quercetin on the growth of HL-60 leukemia cells.
Leukemia
Studying the pathogenesis of BCR-ABL+ leukemia in mice.
Leukemia
Subcellular localization of Bcr, Abl, and Bcr-Abl proteins in normal and leukemic cells and correlation of expression with myeloid differentiation.
Leukemia
Suboptimal response to or failure of imatinib treatment for chronic myeloid leukemia: what is the optimal strategy?
Leukemia
Suppression of Philadelphia1 leukemia cell growth in mice by BCR-ABL antisense oligodeoxynucleotide.
Leukemia
Suppressor of cytokine signalling 4 (SOCS4): moderator of ovarian primordial follicle activation.
Leukemia
SWATH-Proteomics of Ibrutinib's Action in Myeloid Leukemia Initiating Mutated G-CSFR Signaling.
Leukemia
Synergistic cytotoxicity from combination of imatinib and platinum-based anticancer drugs specifically in Bcr-Abl positive leukemia cells.
Leukemia
Synthesis of imatinib, a tyrosine kinase inhibitor, labeled with carbon-14.
Leukemia
Synthesis, biological evaluation and docking studies of 4-amino substituted 1H-pyrazolo[3,4-d]pyrimidines.
Leukemia
Systemic dasatinib fails to prevent development of central nervous system progression in a patient with BCR-ABL unmutated Philadelphia chromosome-positive leukemia.
Leukemia
Targeted therapies for high-risk acute myeloid leukemia.
Leukemia
Targeting BCR-ABL+ stem/progenitor cells and BCR-ABL-T315I mutant cells by effective inhibition of the BCR-ABL-Tyr177-GRB2 complex.
Leukemia
Targeting Bruton's tyrosine kinase for the treatment of B cell associated malignancies and autoimmune diseases: Preclinical and clinical developments of small molecule inhibitors.
Leukemia
Targeting Janus kinase 3 in the treatment of leukemia and inflammatory diseases.
Leukemia
Targeting methyltransferase PRMT5 eliminates leukemia stem cells in chronic myelogenous leukemia.
Leukemia
Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice.
Leukemia
Targeting of the N-terminal coiled coil oligomerization interface of BCR interferes with the transformation potential of BCR-ABL and increases sensitivity to STI571.
Leukemia
Targeting PFKFB3 sensitizes chronic myelogenous leukemia cells to tyrosine kinase inhibitor.
Leukemia
Targeting Src in endometriosis-associated ovarian cancer.
Leukemia
Targeting the BCR-ABL signaling pathway in therapy-resistant Philadelphia chromosome-positive leukemia.
Leukemia
Targeting the kinase activity of the BCR-ABL fusion protein in patients with chronic myeloid leukemia.
Leukemia
TARGETS AND EFFECTORS OF THE CELLULAR RESPONSE TO AURORA KINASE INHIBITOR MK-0457 (VX-680) IN IMATINIB SENSITIVE AND RESISTANT CHRONIC MYELOGENOUS LEUKEMIA.
Leukemia
Taxodione induces apoptosis in BCR-ABL-positive cells through ROS generation.
Leukemia
The amphiphysin-like protein 1 (ALP1) interacts functionally with the cABL tyrosine kinase and may play a role in cytoskeletal regulation.
Leukemia
The anti-apoptotic role of the unfolded protein response in Bcr-Abl-positive leukemia cells.
Leukemia
The ARF tumor suppressor in acute leukemias: insights from mouse models of Bcr-Abl-induced acute lymphoblastic leukemia.
Leukemia
The Bcr-Abl kinase inhibitor INNO-406 induces autophagy and different modes of cell death execution in Bcr-Abl-positive leukemias.
Leukemia
The Bcr-Abl leukemia oncogene activates Jun kinase and requires Jun for transformation.
Leukemia
The BCR-ABL oncoprotein potentially interacts with the xeroderma pigmentosum group B protein.
Leukemia
The Bcr-Abl tyrosine kinase activates mitogenic signaling pathways and stimulates G1-to-S phase transition in hematopoietic cells.
Leukemia
The Bcr-Abl tyrosine kinase inhibitor imatinib and promising new agents against Philadelphia chromosome-positive leukemias.
Leukemia
The BCR-ABL tyrosine kinase inhibits apoptosis by activating a Ras-dependent signaling pathway.
Leukemia
The BCR-ABL1-negative myeloproliferative neoplasms: a review of JAK inhibitors in the therapeutic armamentarium.
Leukemia
The Capable ABL: What Is Its Biological Function?
Leukemia
The chronic myelogenous leukemia-specific P210 protein is the product of the bcr/abl hybrid gene.
Leukemia
The combination of Nutlin-3 and Tanshinone IIA promotes synergistic cytotoxicity in acute leukemic cells expressing wild-type p53 by co-regulating MDM2-P53 and the AKT/mTOR pathway.
Leukemia
The controversial role of the Hedgehog pathway in normal and malignant hematopoiesis.
Leukemia
The dimerization property of glutathione S-transferase partially reactivates Bcr-Abl lacking the oligomerization domain.
Leukemia
The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype.
Leukemia
The effects of c-Abl mutation on developing B cell differentiation and survival.
Leukemia
The emerging role of Bcr-Abl-induced cystoskeletal remodeling in systemic persistence of leukemic stem cells.
Leukemia
The Fab fragment of anti-IgE C?2 domain prevents allergic reactions through interacting with IgE-Fc?RI? complex on rat mast cells.
Leukemia
The fps/fes tyrosine kinase is expressed in myeloid, vascular endothelial, epithelial, and neuronal cells and is localized in the trans-golgi network.
Leukemia
The functional interplay between the t(9;22)-associated fusion proteins BCR/ABL and ABL/BCR in Philadelphia chromosome-positive acute lymphatic leukemia.
Leukemia
The growing arsenal of ATP-competitive and allosteric inhibitors of BCR-ABL.
Leukemia
The Hsp90 inhibitor geldanamycin selectively sensitizes Bcr-Abl-expressing leukemia cells to cytotoxic chemotherapy.
Leukemia
The human leukemia oncogene bcr-abl abrogates the anchorage requirement but not the growth factor requirement for proliferation.
Leukemia
The Implication of Cancer Progenitor Cells and the Role of Epigenetics in the Development of Novel Therapeutic Strategies for Chronic Myeloid Leukemia.
Leukemia
The in vivo evaluation of active-site TOR inhibitors in models of BCR-ABL+ leukemia.
Leukemia
The involvement of Bcr in leukemias with the Philadelphia chromosome.
Leukemia
The kinase inhibitor STI571 reverses the Bcr-Abl induced point mutation frequencies observed in pre-leukemic P190(Bcr-Abl) transgenic mice.
Leukemia
The mouse c-abl locus: molecular cloning and characterization.
Leukemia
The multi-tyrosine kinase inhibitor TKI258, alone or in combination with RAD001, is effective for treatment of human leukemia with BCR-ABL translocation in vitro.
Leukemia
The N-terminal domain of the non-receptor tyrosine kinase ABL confers protein instability and suppresses tumorigenesis.
Leukemia
The NEDD8-activating enzyme inhibitor MLN4924 induces DNA damage in Ph+ leukemia and sensitizes for ABL kinase inhibitors.
Leukemia
The NF-kappaB pathway blockade by the IKK inhibitor PS1145 can overcome imatinib resistance.
Leukemia
The Philadelphia (Ph) chromosome in leukemia. I. A new mechanism due to interstitial deletion and insertion in chronic myelocytic leukemia.
Leukemia
The presence of a BCR-ABL mutant allele in CML does not always explain clinical resistance to imatinib.
Leukemia
The Role of Janus Kinase Signaling in Graft-Versus-Host Disease and Graft Versus Leukemia.
Leukemia
The SH2-containing adapter protein GRB10 interacts with BCR-ABL.
Leukemia
The signaling axis atypical protein kinase C ?/?-Satb2 mediates leukemic transformation of B-cell progenitors.
Leukemia
The significance of detecting WT1 expression in childhood acute leukemias.
Leukemia
The SOCS box of SOCS-1 accelerates ubiquitin-dependent proteolysis of TEL-JAK2.
Leukemia
The spectrum of adult B-lymphoid leukemias with BCR-ABL: molecular diagnostic, cytogenetic, and clinical laboratory perspectives.
Leukemia
The Src homology-2 protein Shb modulates focal adhesion kinase signaling in a BCR-ABL myeloproliferative disorder causing accelerated progression of disease.
Leukemia
The Syk kinase as a therapeutic target in leukemia and lymphoma.
Leukemia
The targetable role of herpes virus-associated ubiquitin-specific protease (HAUSP) in p190 BCR-ABL leukemia.
Leukemia
The tetramerization domain-independent Ras activation by BCR-ABL oncoprotein in hematopoietic cells.
Leukemia
The TGF-beta type II receptor in chronic myeloid leukemia: analysis of microsatellite regions and gene expression.
Leukemia
The Tyrosine Kinase c-Abl Promotes Homeodomain-interacting Protein Kinase 2 (HIPK2) Accumulation and Activation in Response to DNA Damage.
Leukemia
The tyrosine kinase inhibitor CGP 57148 (ST1 571) induces apoptosis in BCR-ABL-positive cells by down-regulating BCL-X.
Leukemia
The tyrosine phosphatase TC48 interacts with and inactivates the oncogenic fusion protein BCR-Abl but not cellular Abl.
Leukemia
Therapeutic prospect of Syk inhibitors.
Leukemia
Therapeutic targeting of Src-kinase Lyn in myeloid leukemic cell growth.
Leukemia
Therapy-related Ph+ leukemia after both bone marrow and mesenchymal stem cell transplantation for hypophosphatasia.
Leukemia
Three newly approved drugs for chronic lymphocytic leukemia: incorporating ibrutinib, idelalisib, and obinutuzumab into clinical practice.
Leukemia
Thrombopoietin acts synergistically with LIF to maintain an undifferentiated state of embryonic stem cells homozygous for a Shp-2 deletion mutation.
Leukemia
Thy-1 glycoprotein and src-like protein-tyrosine kinase p53/p56lyn are associated in large detergent-resistant complexes in rat basophilic leukemia cells.
Leukemia
TNF? activates MAPK and Jak-Stat pathways to promote mouse Müller cell proliferation.
Leukemia
Tocotrienol-rich fraction from annatto ameliorates expression of lysyl oxidase in human osteoblastic MG-63 cells.
Leukemia
Transcription suppression of SARI (suppressor of AP-1, regulated by IFN) by BCR-ABL in human leukemia cells.
Leukemia
Transcriptional activation of lck by retrovirus promoter insertion between two lymphoid-specific promoters.
Leukemia
Transformation by v-Myb.
Leukemia
Transformation of T-lymphoid cells by Abelson murine leukemia virus.
Leukemia
Transforming activity and tissue tropism of hybrid retroviral genomes containing portions of the v-abl and v-src oncogenes.
Leukemia
Transforming properties of chimeric TEL-JAK proteins in Ba/F3 cells.
Leukemia
Transforming proteins of some feline and avian sarcoma viruses are related structurally and functionally.
Leukemia
Transient response to imatinib mesylate (STI571) in a patient with the ETV6-ABL t(9;12) translocation.
Leukemia
Transposition of duplicated chromosomal segment involving fused BCR-ABL gene or ABL oncogene alone in chronic myelocytic leukemia and Ph chromosome-positive acute leukemia with complex karyotypes.
Leukemia
Treating Leukemia in the Time of COVID-19.
Leukemia
Treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Leukemia
Treatment of Philadelphia-chromosome-positive human leukemia in SCID mouse model with herbimycin A, bcr-abl tyrosine kinase activity inhibitor.
Leukemia
Trichostatin A down-regulates ZAP-70, LAT and SLP-76 content in Jurkat T cells.
Leukemia
Tyrosine kinase activity and transformation potency of bcr-abl oncogene products.
Leukemia
Tyrosine kinase gene fusions in cancer: translating mechanisms into targeted therapies.
Leukemia
Tyrosine kinase inhibitor as a therapeutic drug for chronic myelogenous leukemia and gastrointestinal stromal tumor.
Leukemia
Tyrosine kinase inhibitor induced isolated pericardial effusion.
Leukemia
Tyrosine Kinase Inhibitor Treatment for Newly Diagnosed Chronic Myeloid Leukemia.
Leukemia
Tyrosine phosphorylation and activation of focal adhesion kinase (p125FAK) by BCR-ABL oncoprotein.
Leukemia
Tyrosine phosphorylation of P160 BCR by P210 BCR-ABL.
Leukemia
Tyrosine phosphorylation of the nuclear receptor coactivator AIB1/SRC-3 is enhanced by Abl kinase and is required for its activity in cancer cells.
Leukemia
U.S. Food and Drug Administration Benefit-Risk Assessment of Nilotinib Treatment Discontinuation in Patients with Chronic Phase Chronic Myeloid Leukemia in a Sustained Molecular Remission.
Leukemia
Unexpected heterogeneity of BCR-ABL fusion mRNA detected by polymerase chain reaction in Philadelphia chromosome-positive acute lymphoblastic leukemia.
Leukemia
Unperturbed immune function despite mutation of C-terminal tyrosines in Syk previously implicated in signaling and activity regulation.
Leukemia
Use of the «BCR/ABL - multitest» kit in the algorithm of laboratory diagnostics of oncohematological diseases: economic aspects.
Leukemia
Using Bcr-Abl to examine mechanisms by which abl kinase regulates morphogenesis in Drosophila.
Leukemia
v-abl causes hematopoietic disease distinct from that caused by bcr-abl.
Leukemia
Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses.
Leukemia
What is the contribution of molecular studies to the diagnosis of BCR-ABL-positive disease in adult acute leukemia?
Leukemia
Wnt/Ca2+/NFAT signaling maintains survival of Ph+ leukemia cells upon inhibition of Bcr-Abl.
Leukemia
YAP promotes myogenic differentiation via the MEK5-ERK5 pathway.
Leukemia
ZAP-70 expression in normal pro/pre B cells, mature B cells, and in B-cell acute lymphoblastic leukemia.
Leukemia
ZAP-70 expression is a prognostic factor in chronic lymphocytic leukemia.
Leukemia
ZAP-70 is a novel conditional heat shock protein 90 (Hsp90) client: inhibition of Hsp90 leads to ZAP-70 degradation, apoptosis, and impaired signaling in chronic lymphocytic leukemia.
Leukemia
[A Modified Protocol for Rapid Establishing Mouse Model with Ph+ Positive Acute Lymphoblastic Leukemia].
Leukemia
[Acute lymphoblastic leukemias with aberrations of BCR-ABL genes]
Leukemia
[Amplification and rearrangement of proto-oncogene c-abl in human leukemia cells]
Leukemia
[An alternative Abl-kinase inhibitor overcomes imatinib resistance mutations of Bcr-Abl oncogenes]
Leukemia
[An experimental study on bone marrow purging in vitro for patients with chronic myelogenous leukemia]
Leukemia
[Biphenotypic Acute Leukemia with BCR-ABL mRNA Transcript b3a2 Type: A Case Report with Review of the Literature.]
Leukemia
[c-abl gene and bcr-abl fused gene in Ph1-positive leukemias]
Leukemia
[Classical and molecular cytogenetic abnormalities in 124 pediatric patients with acute lymphoblastic leukemia]
Leukemia
[Clinical Analysis of 12 Cases of Acute Myeloid Leukemia with Ph Chromosome and BCR-ABL Positive].
Leukemia
[Clinical and laboratorial analysis for 15 adult cases of mixed phenotypic acute leukemia with Ph chromosome and/or positive BCR-ABL].
Leukemia
[Detection of BCR-ABL gene sequences using RT-PCR in patients with leukemia in the IX region. Chile]
Leukemia
[Detection of phosphotyrosine in bcr-abl-positive cells with PY20 antibody and its clinical applications]
Leukemia
[Detection on BCR-ABL fusion gene in Ph1 chromosome positive leukemia by "nested" retrotranscriptase/polymerase chain reaction]
Leukemia
[Effect of methylation inhibitor on EphB4 gene expression, proliferation and apoptosis in CEM cells].
Leukemia
[Effect of Stably Down-regulating FMI Expression of K562 Cells on Sensitivity of K562 cells to Imatinib Mesylate].
Leukemia
[Expression and Clinical Significance of Focal Adhesion Kinase in Patients with Acute Leukemia].
Leukemia
[Expression of c-fes gene in leukemia cells and its clinical significance]
Leukemia
[Expression of the Wilms' Tumor Gene WT1 and Detection of Minimal Residual Disease in Acute Leukemia]
Leukemia
[Hematological malignancies]
Leukemia
[Hematopoietic stem cells and hematopoietic neoplasias]
Leukemia
[Identification bcr-abl fusion gene in leukemia cells with oligonucleotide microarray]
Leukemia
[Juvenile myelomonocytic leukemia: A three-case series].
Leukemia
[Mechanism underlying tumorigenesis induced by Bcr-Abl oncogene and A-MuLV virus].
Leukemia
[Molecular detection of the BCR-ABL gen by RT-PCR in Costa Rican children with leukemia]
Leukemia
[Molecular diagnosis of leukemia and lymphoma]
Leukemia
[Pilot treatment for 13 BCR-ABL positive leukemia patients with T315I mutation].
Leukemia
[Quality assurance of the molecular diagnostic tests in hematological malignancies]
Leukemia
[Research on the molecular basis of neoplasms: malignant melanoma as an example]
Leukemia
[Resistance mechanism of ST1571 and its prevention research--review.]
Leukemia
[Results of clinical studies on a selective inhibitor of ABL tyrosine kinase (STI571) in patients with Ph(+) leukemia]
Leukemia
[Selective inhibition of tyrosine kinases - a new therapeutic principle in oncology]
Leukemia
[Standardization of quantitative detection of BCR-ABL gene expression by RQ-PCR in patients with chronic myeloid leukemia in cooperation with European Leukemia Net].
Leukemia
[Synergistic inhibitory effect of STI571 in combination with arsenic trioxide on a multidrug-resistant leukemia cell line expressing bcr-abl.]
Leukemia
[The characteristics of evaluation of expression of ZAP-70 in tumor cells under b-cell chronic lymphatic leukemia using the flow cytofluorometry technique].
Leukemia
[The mechanisms of taxodione-induced apoptosis in BCR-ABL-positive leukemia cells].
Leukemia
[The reverse effect on drug-resistance against tyrosine kinase inhibitor STI571 in mdr1 and bcr-abl positive leukemic cells]
Leukemia
[The role of EGF receptor-dependent e3B1/Abi1 protein as a tumor suppressor protein in malignant tumors]
Leukemia
[Therapeutic Effect of Focal Adhesion Kinase Gene Silence on Leukemia.]
Leukemia
[Using real-time polymerase chain reaction to quantitate bcr-abl mRNA]
Leukemia, B-Cell
Apoptotic effect of PP2 a Src tyrosine kinase inhibitor, in murine B cell leukemia.
Leukemia, B-Cell
Homogeneous BTK Occupancy Assay for Pharmacodynamic Assessment of Tirabrutinib (GS-4059/ONO-4059) Target Engagement.
Leukemia, B-Cell
Janus Kinase Mutations in Mice Lacking PU.1 and Spi-B Drive B Cell Leukemia through Reactive Oxygen Species-Induced DNA Damage.
Leukemia, B-Cell
ZAP-70 promotes the infiltration of malignant B-lymphocytes into the bone marrow by enhancing signaling and migration after CXCR4 stimulation.
Leukemia, Basophilic, Acute
Imatinib resistant chronic myelogenous leukemia, BCR-ABL positive by chromosome and FISH analyses but negative by PCR, in a child progressing to acute basophilic leukemia: cytogenetic follow-up.
Leukemia, Biphenotypic, Acute
bcr rearrangement and C-abl gene expression in Ph1-positive hybrid acute leukemia with simultaneous proliferation of lymphoid and myeloid blasts.
Leukemia, Biphenotypic, Acute
Simultaneous novel BCR-ABL gene mutation and increased expression of BCR-ABL mRNA caused clinical resistance to STI571 in double-Ph-positive acute biphenotypic leukemia.
Leukemia, Biphenotypic, Acute
[Biphenotypic Acute Leukemia with BCR-ABL mRNA Transcript b3a2 Type: A Case Report with Review of the Literature.]
Leukemia, Erythroblastic, Acute
?12-prostaglandin J3, an omega-3 fatty acid-derived metabolite, selectively ablates leukemia stem cells in mice.
Leukemia, Erythroblastic, Acute
A case of acute erythroleukemia with concurrence of BCR-ABL and FLT3-TKD (D835E) mutation.
Leukemia, Erythroblastic, Acute
A natural-like synthetic small molecule impairs bcr-abl signaling cascades and induces megakaryocyte differentiation in erythroleukemia cells.
Leukemia, Erythroblastic, Acute
BCR-ABL induces tyrosine phosphorylation of YAP leading to expression of Survivin and Cyclin D1 in chronic myeloid leukemia cells.
Leukemia, Erythroblastic, Acute
Blockade of JAK2 activity suppressed accumulation of ?-catenin in leukemic cells.
Leukemia, Erythroblastic, Acute
CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients.
Leukemia, Erythroblastic, Acute
Erythropoietin induces tyrosine phosphorylation and kinase activity of the c-fps/fes proto-oncogene product in human erythropoietin-responsive cells.
Leukemia, Erythroblastic, Acute
Friend Spleen Focus-Forming Virus Activates the Tyrosine Kinase sf-Stk and the Transcription Factor PU.1 to Cause a Multi-Stage Erythroleukemia in Mice.
Leukemia, Erythroblastic, Acute
Increased ERK phosphorylation and caveolin-1 expression on K562 human chronic myelogenous leukemia cells by jacalin, a dietary plant lectin.
Leukemia, Erythroblastic, Acute
Methylation status of RASSF1A in patients with chronic myeloid leukemia.
Leukemia, Erythroblastic, Acute
Mutation of the Lyn tyrosine kinase delays the progression of Friend virus induced erythroleukemia without affecting susceptibility.
Leukemia, Erythroblastic, Acute
NF-kappaB/RelA transactivation is required for atypical protein kinase C iota-mediated cell survival.
Leukemia, Erythroblastic, Acute
Protooncogene expression in normal, preleukemic, and leukemic murine erythroid cells and its relationship to differentiation and proliferation.
Leukemia, Erythroblastic, Acute
Sustained mitogenic effect on K562 human chronic myelogenous leukemia cells by dietary lectin, jacalin.
Leukemia, Erythroblastic, Acute
v-abl activates embryonic globin gene expression in mouse erythroleukemia cells.
Leukemia, Feline
Colony stimulating factor-1 induced growth stimulation of v-fms transformed fibroblasts.
Leukemia, Feline
Molecular cloning of the feline c-fes proto-oncogene and construction of a chimeric transforming gene.
Leukemia, Feline
Nucleic acid sequence and oncogenic properties of the HZ2 feline sarcoma virus v-abl insert.
Leukemia, Feline
Nucleotide sequence of the feline retroviral oncogene v-fms shows unexpected homology with oncogenes encoding tyrosine-specific protein kinases.
Leukemia, Feline
The amino-terminal domain of the v-fms oncogene product includes a functional signal peptide that directs synthesis of a transforming glycoprotein in the absence of feline leukemia virus gag sequences.
Leukemia, Hairy Cell
Contextualizing the Use of Moxetumomab Pasudotox in the Treatment of Relapsed or Refractory Hairy Cell Leukemia.
Leukemia, Hairy Cell
No Loose Ends: A Review of the Pharmacotherapy of Hairy Cell and Hairy Cell Leukemia Variant.
Leukemia, Large Granular Lymphocytic
Platelet-derived growth factor mediates survival of leukemic large granular lymphocytes via an autocrine regulatory pathway.
Leukemia, Lymphocytic, Chronic, B-Cell
A case of chronic lymphocytic leukemia complicated by autoimmune hemolytic anemia due to ibrutinib treatment.
Leukemia, Lymphocytic, Chronic, B-Cell
A case of new-onset cardiomyopathy and ventricular tachycardia in a patient receiving ibrutinib for relapsed mantle cell lymphoma.
Leukemia, Lymphocytic, Chronic, B-Cell
A CD19/CD3 bispecific antibody for effective immunotherapy of chronic lymphocytic leukemia in the ibrutinib era.
Leukemia, Lymphocytic, Chronic, B-Cell
A potential therapeutic strategy for chronic lymphocytic leukemia by combining Idelalisib and GS-9973, a novel spleen tyrosine kinase (Syk) inhibitor.
Leukemia, Lymphocytic, Chronic, B-Cell
A Review of the Bruton Tyrosine Kinase Inhibitors in B-Cell Malignancies.
Leukemia, Lymphocytic, Chronic, B-Cell
A robust ratio metric method for analysis of Zap-70 expression in chronic lymphocytic leukemia (CLL).
Leukemia, Lymphocytic, Chronic, B-Cell
A single tube, four-color flow cytometry assay for evaluation of ZAP-70 and CD38 expression in chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
A single-tube multiplex method for monitoring mutations in cysteine 481 of Bruton Tyrosine Kinase (BTK) gene in chronic lymphocytic leukemia patients treated with ibrutinib.
Leukemia, Lymphocytic, Chronic, B-Cell
A synthetic peptide targeting the BH4 domain of Bcl-2 induces apoptosis in multiple myeloma and follicular lymphoma cells alone or in combination with agents targeting the BH3-binding pocket of Bcl-2.
Leukemia, Lymphocytic, Chronic, B-Cell
abl oncogene expression in non-Hodgkin lymphomas: correlation to histological differentiation and clinical status.
Leukemia, Lymphocytic, Chronic, B-Cell
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor.
Leukemia, Lymphocytic, Chronic, B-Cell
Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib.
Leukemia, Lymphocytic, Chronic, B-Cell
Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results.
Leukemia, Lymphocytic, Chronic, B-Cell
Acalabrutinib: a highly selective, potent Bruton tyrosine kinase inhibitor for the treatment of chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Activation of the B-cell receptor successively activates NF-?B and STAT3 in chronic lymphocytic leukemia cells.
Leukemia, Lymphocytic, Chronic, B-Cell
Activation of the MAPK pathway mediates resistance to PI3K inhibitors in chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Activity of the janus kinase inhibitor Ruxolitinib in chronic lymphocytic leukemia: results of a phase II trial.
Leukemia, Lymphocytic, Chronic, B-Cell
Acute gout flare of bilateral first metatarsophalangeal joints due to ibrutinib use in chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Additional genetic high-risk features such as 11q deletion, 17p deletion, and V3-21 usage characterize discordance of ZAP-70 and VH mutation status in chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
An improved flow cytometric method using FACS Lysing Solution for measurement of ZAP-70 expression in B-cell chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
An optimized whole blood method for flow cytometric measurement of ZAP-70 protein expression in chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Analysis of the Effects of the Bruton's tyrosine kinase (Btk) Inhibitor Ibrutinib on Monocyte Fc? Receptor (Fc?R) Function.
Leukemia, Lymphocytic, Chronic, B-Cell
Anti-BAFF-R antibody VAY-736 demonstrates promising preclinical activity in CLL and enhances effectiveness of ibrutinib.
Leukemia, Lymphocytic, Chronic, B-Cell
Antihistamines are synergistic with Bruton's tyrosine kinase inhibiter ibrutinib mediated by lysosome disruption in chronic lymphocytic leukemia (CLL) cells.
Leukemia, Lymphocytic, Chronic, B-Cell
Approaches for relapsed CLL after chemotherapy-free frontline regimens.
Leukemia, Lymphocytic, Chronic, B-Cell
ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Aspartic Aminopeptidase Is a Novel Biomarker of Aggressive Chronic Lymphocytic Leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, R406.
Leukemia, Lymphocytic, Chronic, B-Cell
B-cell receptor signaling in chronic lymphocytic leukemia and other B-cell malignancies.
Leukemia, Lymphocytic, Chronic, B-Cell
Baff serum level predicts time to first treatment in early chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Bone marrow infiltration pattern in B-cell chronic lymphocytic leukemia is related to immunoglobulin heavy-chain variable region mutation status and expression of 70-kd zeta-associated protein (ZAP-70).
Leukemia, Lymphocytic, Chronic, B-Cell
Bortezomib enhances the anti-cancer effect of the novel Bruton's tyrosine kinase inhibitor (BGB-3111) in mantle cell lymphoma expressing BTK.
Leukemia, Lymphocytic, Chronic, B-Cell
Bruton tyrosine kinase inhibition in chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Bruton tyrosine kinase inhibitor ONO/GS-4059: from bench to bedside.
Leukemia, Lymphocytic, Chronic, B-Cell
Bruton tyrosine kinase inhibitors for the frontline treatment of chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Bruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: Beyond Ibrutinib.
Leukemia, Lymphocytic, Chronic, B-Cell
Bruton Tyrosine Kinase Inhibitors: Present and Future.
Leukemia, Lymphocytic, Chronic, B-Cell
Bruton's tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL).
Leukemia, Lymphocytic, Chronic, B-Cell
Bruton's tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Bruton's tyrosine kinase inhibitor restrains Wnt signaling in chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Bruton's tyrosine kinase inhibitors in chronic lymphocytic leukemia and lymphoma.
Leukemia, Lymphocytic, Chronic, B-Cell
Bruton's tyrosine kinase inhibitors: first and second generation agents for patients with Chronic Lymphocytic Leukemia (CLL).
Leukemia, Lymphocytic, Chronic, B-Cell
Bruton's tyrosine kinase mediated signaling enhances leukemogenesis in a mouse model for chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Bruton's tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765.
Leukemia, Lymphocytic, Chronic, B-Cell
BTK Inhibitors, Irrespective of ITK Inhibition, Increase Efficacy of a CD19/CD3 Bispecific Antibody in CLL.
Leukemia, Lymphocytic, Chronic, B-Cell
BTK(C481S)-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
c-Abl expression in chronic lymphocytic leukemia cells: clinical and therapeutic implications.
Leukemia, Lymphocytic, Chronic, B-Cell
c-Abl regulates Mcl-1 gene expression in chronic lymphocytic leukemia cells.
Leukemia, Lymphocytic, Chronic, B-Cell
Cardiac side effects of bruton tyrosine kinase (BTK) inhibitors.
Leukemia, Lymphocytic, Chronic, B-Cell
Case series of unique adverse events related to the use of ibrutinib in patients with B-cell malignancies-A single institution experience and a review of literature.
Leukemia, Lymphocytic, Chronic, B-Cell
Cerebral Invasive Aspergillosis in a Case of Chronic Lymphocytic Leukemia with Bruton Tyrosine Kinase Inhibitor.
Leukemia, Lymphocytic, Chronic, B-Cell
Changing landscape of frontline therapy in chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Characterizing the kinetics of lymphocytosis in patients with chronic lymphocytic leukemia treated with single-agent ibrutinib.
Leukemia, Lymphocytic, Chronic, B-Cell
Chromatin mapping and single-cell immune profiling define the temporal dynamics of ibrutinib response in CLL.
Leukemia, Lymphocytic, Chronic, B-Cell
Chronic lymphocytic leukemia B cells contain anomalous Lyn tyrosine kinase, a putative contribution to defective apoptosis.
Leukemia, Lymphocytic, Chronic, B-Cell
Chronic lymphocytic leukemia developing in a patient with Janus kinase 2 V617F mutation positive myeloproliferative neoplasm.
Leukemia, Lymphocytic, Chronic, B-Cell
Chronic lymphocytic leukemia modeled in mouse by targeted miR-29 expression.
Leukemia, Lymphocytic, Chronic, B-Cell
Clinical and biological implications of target occupancy in CLL treated with the BTK inhibitor acalabrutinib.
Leukemia, Lymphocytic, Chronic, B-Cell
Clinical implications of ZAP-70 expressionin chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Clinical prognostic biomarkers in chronic lymphocytic leukemia and diffuse large B-cell lymphoma.
Leukemia, Lymphocytic, Chronic, B-Cell
Clinical significance of ZAP-70 protein expression in B-cell chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Clinical utility of assessing ZAP-70 and CD38 in chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Clonal heterogeneity in chronic lymphocytic leukemia cells: superior response to surface IgM cross-linking in CD38, ZAP-70-positive cells.
Leukemia, Lymphocytic, Chronic, B-Cell
Combinations of ZAP-70, CD38 and IGHV mutational status as predictors of time to first treatment in CLL.
Leukemia, Lymphocytic, Chronic, B-Cell
Combined analysis of ZAP-70 and CD38 expression as a predictor of disease progression in B-cell chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Combined analysis of ZAP-70 and CD38 expression in sudanese patients with B-cell chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Combined BTK and PI3K? Inhibition with Acalabrutinib and ACP-319 Improves Survival and Tumor Control in CLL Mouse Model.
Leukemia, Lymphocytic, Chronic, B-Cell
Combined chemosensitivity and chromatin profiling prioritizes drug combinations in CLL.
Leukemia, Lymphocytic, Chronic, B-Cell
Combining ibrutinib and checkpoint blockade improves CD8+ T-cell function and control of chronic lymphocytic leukemia in Em-TCL1 mice.
Leukemia, Lymphocytic, Chronic, B-Cell
Comparative analysis of flow cytometric techniques in assessment of ZAP-70 expression in relation to IgVH mutational status in chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Comparative analysis of interphase FISH and RT-PCR to detect bcr-abl translocation in chronic myelogenous leukemia and related disorders.
Leukemia, Lymphocytic, Chronic, B-Cell
Comparative analysis of ZAP-70 expression and Ig VH mutational status in B-cell chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Comparison Between Venetoclax-based and Bruton Tyrosine Kinase Inhibitor-based Therapy as Upfront Treatment of Chronic Lymphocytic Leukemia (CLL): A Systematic Review and Network Meta-analysis.
Leukemia, Lymphocytic, Chronic, B-Cell
Comparison of Acalabrutinib, A Selective Bruton Tyrosine Kinase Inhibitor, with Ibrutinib in Chronic Lymphocytic Leukemia Cells.
Leukemia, Lymphocytic, Chronic, B-Cell
Comparison of Bcl-2, CD38 and ZAP-70 Expression in Chronic Lymphocytic Leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Comparison of bone marrow and peripheral blood ZAP-70 status examined by flow cytometric immunophenotyping in patients with chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Comparison of ZAP-70/Syk mRNA levels with immunoglobulin heavy-chain gene mutation status and disease progression in chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Correction: Bruton's tyrosine kinase inhibitors in chronic lymphocytic leukemia and lymphoma.
Leukemia, Lymphocytic, Chronic, B-Cell
Correlation between ZAP-70, phospho-ZAP-70, and phospho-Syk expression in leukemic cells from patients with CLL.
Leukemia, Lymphocytic, Chronic, B-Cell
Correlation of flow cytometrically determined expression of ZAP-70 using the SBZAP antibody with IgVH mutation status and cytogenetics in 1,229 patients with chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Cortactin, another player in the Lyn signaling pathway, is overexpressed and alternatively spliced in leukemic cells from patients with B-cell Chronic Lymphocytic Leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Current Treatment of Chronic Lymphocytic Leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
CXCL12-induced chemotaxis is impaired in T cells from patients with ZAP-70-negative chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
CXCR4- and BCR-triggered integrin activation in B-cell chronic lymphocytic leukemia cells depends on JAK2-activated Bruton's tyrosine kinase.
Leukemia, Lymphocytic, Chronic, B-Cell
Cytomegalovirus Proctitis in a Patient with Chronic Lymphocytic Leukemia on Ibrutinib Therapy: A Case Report.
Leukemia, Lymphocytic, Chronic, B-Cell
D cyclins in CD5+ B-cell lymphoproliferative disorders: cyclin D1 and cyclin D2 identify diagnostic groups and cyclin D1 correlates with ZAP-70 expression in chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Decrease in total protein level of Bruton's tyrosine kinase during ibrutinib therapy in chronic lymphocytic leukemia lymphocytes.
Leukemia, Lymphocytic, Chronic, B-Cell
Decreased NOTCH1 Activation Correlates with Response to Ibrutinib in Chronic Lymphocytic Leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Dermatological Toxicities of Bruton's Tyrosine Kinase Inhibitors.
Leukemia, Lymphocytic, Chronic, B-Cell
Detection methods of ZAP-70 in chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Detection of ZAP-70 in patients with chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Development and characterization of prototypes for in vitro and in vivo mouse models of ibrutinib-resistant CLL.
Leukemia, Lymphocytic, Chronic, B-Cell
Differential expression and function of CD27 in chronic lymphocytic leukemia cells expressing ZAP-70.
Leukemia, Lymphocytic, Chronic, B-Cell
Differential gene expression induction by TRAIL in B chronic lymphocytic leukemia (B-CLL) cells showing high versus low levels of Zap-70.
Leukemia, Lymphocytic, Chronic, B-Cell
Discordance of ZAP-70 in patients with chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Discordant results of flow cytometric ZAP-70 expression status in B-CLL samples if different gating strategies are applied.
Leukemia, Lymphocytic, Chronic, B-Cell
Dissection of subclonal evolution by temporal mutation profiling in chronic lymphocytic leukemia patients treated with ibrutinib.
Leukemia, Lymphocytic, Chronic, B-Cell
Distinctive patterns of naïve/memory subset distribution and cytokine expression in CD4 T lymphocytes in ZAP-70 B-chronic lymphocytic patients.
Leukemia, Lymphocytic, Chronic, B-Cell
Dual inhibition of PI3K signaling and histone deacetylation halts proliferation and induces lethality in mantle cell lymphoma.
Leukemia, Lymphocytic, Chronic, B-Cell
Effect of Bruton tyrosine kinase inhibitor on efficacy of adjuvanted recombinant hepatitis B and zoster vaccines.
Leukemia, Lymphocytic, Chronic, B-Cell
Effect of ibrutinib on humoral dysfunction in patients with chronic lymphocytic leukemia: A single-center experience.
Leukemia, Lymphocytic, Chronic, B-Cell
Effect of Ibrutinib on the IFN Response of Chronic Lymphocytic Leukemia Cells.
Leukemia, Lymphocytic, Chronic, B-Cell
Efficacy and Safety of Ibrutinib in Indian Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma: Cases from a Named Patient Program.
Leukemia, Lymphocytic, Chronic, B-Cell
Efficacy of Ibrutinib-Based Regimen in Chronic Lymphocytic Leukemia: A Systematic Review.
Leukemia, Lymphocytic, Chronic, B-Cell
Elevated IL-17A and IL-22 regulate expression of inducible CD38 and Zap-70 in chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Entospletinib monotherapy in patients with relapsed or refractory chronic lymphocytic leukemia previously treated with B-cell receptor inhibitors: results of a phase 2 study.
Leukemia, Lymphocytic, Chronic, B-Cell
Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Evaluation of ZAP-70 expression by flow cytometry in chronic lymphocytic leukemia: A multicentric international harmonization process.
Leukemia, Lymphocytic, Chronic, B-Cell
Evolution of ibrutinib resistance in chronic lymphocytic leukemia (CLL).
Leukemia, Lymphocytic, Chronic, B-Cell
Expression feature of CD3, Fc?RI?, and Zap-70 in patients with chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Expression of BTK/p-BTK is different between CD5+ and CD5- B lymphocytes from Autoimmune Hemolytic Anemia/Evans syndromes.
Leukemia, Lymphocytic, Chronic, B-Cell
Expression of Functional Sphingosine-1 Phosphate Receptor-1 Is Reduced by B Cell Receptor Signaling and Increased by Inhibition of PI3 Kinase ? but Not SYK or BTK in Chronic Lymphocytic Leukemia Cells.
Leukemia, Lymphocytic, Chronic, B-Cell
Expression of the T-cell-specific tyrosine kinase Lck in normal B-1 cells and in chronic lymphocytic leukemia B cells.
Leukemia, Lymphocytic, Chronic, B-Cell
Expression of ZAP-70 in patients with chronic lymphocytic leukemia may change significantly during the course of the disease.
Leukemia, Lymphocytic, Chronic, B-Cell
Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Expression of ZAP-70 protein correlates with disease stage in chronic lymphocytic leukemia and is associated with, but not generally restricted to, non-mutated Ig VH status.
Leukemia, Lymphocytic, Chronic, B-Cell
FCRL2 expression predicts IGHV mutation status and clinical progression in chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Feasibility of an easily applicable method of ZAP-70 measurement in chronic lymphocytic leukemia in the routine flow cytometry setting: a methodological approach.
Leukemia, Lymphocytic, Chronic, B-Cell
Final analysis from RESONATE: up to 6?years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma.
Leukemia, Lymphocytic, Chronic, B-Cell
First-Line Therapy for Chronic Lymphocytic Leukemia: Bruton Tyrosine Kinase or BCL2 or Both?
Leukemia, Lymphocytic, Chronic, B-Cell
Flow Cytometric Analysis of ZAP-70 Protein Expression for B-Cell Chronic Lymphocytic Leukemia Prognostication: Usefulness and Limitations.
Leukemia, Lymphocytic, Chronic, B-Cell
Flow cytometric detection of ZAP-70 in chronic lymphocytic leukemia: correlation with immunocytochemistry and Western blot analysis.
Leukemia, Lymphocytic, Chronic, B-Cell
Flow cytometry for ZAP-70: New colors for chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Functional and clinical relevance of VLA-4 (CD49d/CD29) in ibrutinib-treated chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Functional characterization of BTK(C481S) mutation that confers ibrutinib resistance: exploration of alternative kinase inhibitors.
Leukemia, Lymphocytic, Chronic, B-Cell
Gene expression profiling in malignant lymphomas.
Leukemia, Lymphocytic, Chronic, B-Cell
Generation of a poor prognostic chronic lymphocytic leukemia-like disease model: PKC? subversion induces an upregulation of PKC?II expression in B lymphocytes.
Leukemia, Lymphocytic, Chronic, B-Cell
Genetic Loss of LCK Kinase Leads to Acceleration of Chronic Lymphocytic Leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Hair and Nail Changes During Long-term Therapy With Ibrutinib for Chronic Lymphocytic Leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
HLA-G expression in B chronic lymphocytic leukemia: a new prognostic marker?
Leukemia, Lymphocytic, Chronic, B-Cell
Hodgkin lymphoma in a mutated ZAP-70 negative B-cell Chronic Lymphocytic Leukemia patient.
Leukemia, Lymphocytic, Chronic, B-Cell
Hodgkin's disease variant of Richter's syndrome clonally related to chronic lymphocytic leukemia arises in ZAP-70 negative mutated CLL.
Leukemia, Lymphocytic, Chronic, B-Cell
How I Manage CLL with Venetoclax-Based Treatments.
Leukemia, Lymphocytic, Chronic, B-Cell
How I manage ibrutinib-refractory chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Hydroa Vacciniforme-Like Lymphoproliferative Disorder in an Adult Patient With Chronic Lymphocytic Leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Ibrutinib and Venetoclax for First-Line Treatment of CLL.
Leukemia, Lymphocytic, Chronic, B-Cell
Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study.
Leukemia, Lymphocytic, Chronic, B-Cell
Ibrutinib does not prevent kidney fibrosis following acute and chronic injury.
Leukemia, Lymphocytic, Chronic, B-Cell
Ibrutinib dose modifications in the management of CLL.
Leukemia, Lymphocytic, Chronic, B-Cell
Ibrutinib efficacy and tolerability in patients with relapsed chronic lymphocytic leukemia following allogeneic HCT.
Leukemia, Lymphocytic, Chronic, B-Cell
Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study.
Leukemia, Lymphocytic, Chronic, B-Cell
Ibrutinib for treatment of chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Ibrutinib Has Time-dependent On- and Off-target Effects on Plasma Biomarkers and Immune Cells in Chronic Lymphocytic Leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Ibrutinib in chronic lymphocytic leukemia and B cell malignancies.
Leukemia, Lymphocytic, Chronic, B-Cell
Ibrutinib in Chronic Lymphocytic Leukemia: Clinical Applications, Drug Resistance, and Prospects.
Leukemia, Lymphocytic, Chronic, B-Cell
Ibrutinib in CLL: a focus on adverse events, resistance, and novel approaches beyond ibrutinib.
Leukemia, Lymphocytic, Chronic, B-Cell
Ibrutinib in the treatment of chronic lymphocytic leukemia: 5?years on.
Leukemia, Lymphocytic, Chronic, B-Cell
Ibrutinib increases the risk of hypertension and atrial fibrillation: Systematic review and meta-analysis.
Leukemia, Lymphocytic, Chronic, B-Cell
Ibrutinib Inhibits Platelet Integrin ?IIb?3 Outside-In Signaling and Thrombus Stability But Not Adhesion to Collagen.
Leukemia, Lymphocytic, Chronic, B-Cell
Ibrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: implications for combination therapy.
Leukemia, Lymphocytic, Chronic, B-Cell
Ibrutinib is not an effective drug in primografts of TCF3-PBX1.
Leukemia, Lymphocytic, Chronic, B-Cell
Ibrutinib modulates the immunosuppressive CLL microenvironment through STAT3-mediated suppression of regulatory B-cell function and inhibition of the PD-1/PD-L1 pathway.
Leukemia, Lymphocytic, Chronic, B-Cell
Ibrutinib promotes atrial fibrillation by inducing structural remodeling and calcium dysregulation in the atrium.
Leukemia, Lymphocytic, Chronic, B-Cell
Ibrutinib Therapy Increases T Cell Repertoire Diversity in Patients with Chronic Lymphocytic Leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study.
Leukemia, Lymphocytic, Chronic, B-Cell
Ibrutinib Treatment of Mantle Cell Lymphoma Relapsing at Central Nervous System: A Case Report and Literature Review.
Leukemia, Lymphocytic, Chronic, B-Cell
Ibrutinib treatment via alternative administration in a patient with chronic lymphocytic leukemia and dysphagia.
Leukemia, Lymphocytic, Chronic, B-Cell
Ibrutinib, but not zanubrutinib, induces platelet receptor shedding of GPIb-IX-V complex and integrin ?IIb?3 in mice and humans.
Leukemia, Lymphocytic, Chronic, B-Cell
Ibrutinib-associated Arthralgias/Myalgias in Patients With Chronic Lymphocytic Leukemia: Incidence and Impact on Clinical Outcomes.
Leukemia, Lymphocytic, Chronic, B-Cell
Ibrutinib-associated tumor lysis syndrome in chronic lymphocytic leukemia/small lymphocytic lymphoma and mantle cell lymphoma: A case series and review of the literature.
Leukemia, Lymphocytic, Chronic, B-Cell
Ibrutinib-induced acute kidney injury via interstitial nephritis.
Leukemia, Lymphocytic, Chronic, B-Cell
Ibrutinib-naïve chronic lymphocytic leukemia lacks Bruton tyrosine kinase mutations associated with treatment resistance.
Leukemia, Lymphocytic, Chronic, B-Cell
Ibrutinib: A New Frontier in the Treatment of Chronic Lymphocytic Leukemia by Bruton's Tyrosine Kinase Inhibition.
Leukemia, Lymphocytic, Chronic, B-Cell
Ibrutinib: a novel Bruton's tyrosine kinase inhibitor with outstanding responses in patients with chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Identification of a structurally novel BTK mutation that drives ibrutinib resistance in CLL.
Leukemia, Lymphocytic, Chronic, B-Cell
Imbruvica (Ibrutinib), First-in-Class Bruton's Tyrosine Kinase Inhibitor, Receives Expanded Indications for Patients with Relapsed Chronic Lymphocytic Leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Immune impacts of Bruton tyrosine kinase inhibitors in chronic lymphocytic leukemia patients: are we closer to a holy grail?
Leukemia, Lymphocytic, Chronic, B-Cell
Immune Therapy for Chronic Lymphocytic Leukemia: Allogeneic Transplant, Chimeric Antigen Receptor T-cell Therapy, and Beyond.
Leukemia, Lymphocytic, Chronic, B-Cell
Immunohistochemical analysis of ZAP-70 expression in chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Immunohistochemical detection of ZAP-70 in 341 cases of non-Hodgkin and Hodgkin lymphoma.
Leukemia, Lymphocytic, Chronic, B-Cell
Immunomodulatory effect of ibrutinib: Reducing the barrier against fungal infections.
Leukemia, Lymphocytic, Chronic, B-Cell
Improved flow cytometric detection of ZAP-70 in chronic lymphocytic leukemia using experimentally optimized isotypic control antibodies.
Leukemia, Lymphocytic, Chronic, B-Cell
In Human Visualization of Ibrutinib-Induced CLL Compartment Shift.
Leukemia, Lymphocytic, Chronic, B-Cell
In-tandem insight from basic science combined with clinical research: CD38 as both marker and key component of the pathogenetic network underlying chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Indirect Treatment Comparisons of Ibrutinib Versus Physician's Choice and Idelalisib Plus Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Infectious Complications of Tyrosine Kinase Inhibitors in Hematological Malignancies.
Leukemia, Lymphocytic, Chronic, B-Cell
Integrative prognostic models predict long-term survival after immunochemotherapy in chronic lymphocytic leukemia patients.
Leukemia, Lymphocytic, Chronic, B-Cell
Invasive aspergillosis related to ibrutinib therapy for chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Invasive Fungal Infection Complicating Treatment With Ibrutinib.
Leukemia, Lymphocytic, Chronic, B-Cell
JAK2 tyrosine kinase mediates integrin activation induced by CXCL12 in B-cell chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Kinetics of CLL cells in tissues and blood during therapy with the BTK inhibitor ibrutinib.
Leukemia, Lymphocytic, Chronic, B-Cell
Kolmogorov-Smirnov statistical test for analysis of ZAP-70 expression in B-CLL, compared with quantitative PCR and IgV(H) mutation status.
Leukemia, Lymphocytic, Chronic, B-Cell
Late onset left ventricular dysfunction and cardiomyopathy induced with ibrutinib.
Leukemia, Lymphocytic, Chronic, B-Cell
Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab.
Leukemia, Lymphocytic, Chronic, B-Cell
Long-term outcomes for patients with chronic lymphocytic leukemia who discontinue ibrutinib.
Leukemia, Lymphocytic, Chronic, B-Cell
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
Leukemia, Lymphocytic, Chronic, B-Cell
Longitudinal CITE-Seq profiling of chronic lymphocytic leukemia during ibrutinib treatment: evolution of leukemic and immune cells at relapse.
Leukemia, Lymphocytic, Chronic, B-Cell
Lycorine sensitizes CD40 ligand-protected chronic lymphocytic leukemia cells to bezafibrate- and medroxyprogesterone acetate-induced apoptosis but dasatanib does not overcome reported CD40-mediated drug resistance.
Leukemia, Lymphocytic, Chronic, B-Cell
LYN Kinase in the Tumor Microenvironment Is Essential for the Progression of Chronic Lymphocytic Leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Macrophage-Mediated Antibody Dependent Effector Function in Aggressive B-Cell Lymphoma Treatment is Enhanced by Ibrutinib via Inhibition of JAK2.
Leukemia, Lymphocytic, Chronic, B-Cell
Management of Atrial Fibrillation in Patients on Ibrutinib: A Cleveland Clinic Experience.
Leukemia, Lymphocytic, Chronic, B-Cell
Management of relapsed/refractory marginal zone lymphoma: focus on ibrutinib.
Leukemia, Lymphocytic, Chronic, B-Cell
Managing chronic lymphocytic leukemia in 2020: an update on recent clinical advances with a focus on BTK and BCL-2 inhibitors.
Leukemia, Lymphocytic, Chronic, B-Cell
Managing toxicities of Bruton tyrosine kinase inhibitors.
Leukemia, Lymphocytic, Chronic, B-Cell
MARCKS affects cell motility and response to BTK inhibitors in CLL.
Leukemia, Lymphocytic, Chronic, B-Cell
Markers of increased angiogenesis and their correlation with biological parameters identifying high-risk patients in early B-cell chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Microenvironment regulates the expression of miR-21 and tumor suppressor genes PTEN, PIAS3 and PDCD4 through ZAP-70 in chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
miRNA analysis in B-cell chronic lymphocytic leukaemia: proliferation centres characterized by low miR-150 and high BIC/miR-155 expression.
Leukemia, Lymphocytic, Chronic, B-Cell
Modification of immunocytochemical ZAP-70 assay for potential clinical application in B-cell chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Modulation of CD44 Activity by A6-Peptide.
Leukemia, Lymphocytic, Chronic, B-Cell
Molecular basis of aggressive disease in chronic lymphocytic leukemia patients with 11q deletion and trisomy 12 chromosomal abnormalities.
Leukemia, Lymphocytic, Chronic, B-Cell
Morphological, immunophenotypic, and genetic features of chronic lymphocytic leukemia with trisomy 12: a comprehensive review.
Leukemia, Lymphocytic, Chronic, B-Cell
Multi-drug resistance mediated by P-glycoprotein overexpression is not correlated with ZAP-70/CD38 expression in B-cell chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Multicenter study of ZAP-70 expression in patients with B-cell chronic lymphocytic leukemia using an optimized flow cytometry method.
Leukemia, Lymphocytic, Chronic, B-Cell
Non-catalytic Bruton's tyrosine kinase activates PLC?2 variants mediating ibrutinib resistance in human chronic lymphocytic leukemia cells.
Leukemia, Lymphocytic, Chronic, B-Cell
Noncovalent inhibition of C481S Bruton tyrosine kinase by GDC-0853: a new treatment strategy for ibrutinib-resistant CLL.
Leukemia, Lymphocytic, Chronic, B-Cell
Noncovalent inhibitors reveal BTK gatekeeper and auto-inhibitory residues that control its transforming activity.
Leukemia, Lymphocytic, Chronic, B-Cell
Novel Agents in Chronic Lymphocytic Leukemia: New Combination Therapies and Strategies to Overcome Resistance.
Leukemia, Lymphocytic, Chronic, B-Cell
Novel synthetic drugs currently in clinical development for chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Optimization of flow cytometric measurement of ZAP-70 in chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Oral Bruton tyrosine kinase inhibitors selectively block atherosclerotic plaque-triggered thrombus formation.
Leukemia, Lymphocytic, Chronic, B-Cell
Oral fludarabine and cyclophosphamide as front-line chemotherapy in patients with chronic lymphocytic leukemia. The impact of biological parameters in the response duration.
Leukemia, Lymphocytic, Chronic, B-Cell
Outcomes of patients with chronic lymphocytic leukemia (CLL) after discontinuing ibrutinib.
Leukemia, Lymphocytic, Chronic, B-Cell
Outcomes of patients with CLL sequentially resistant to both BCL2 and BTK inhibition.
Leukemia, Lymphocytic, Chronic, B-Cell
Outcomes of Reduced Frequency Dosing of Ibrutinib in Chronic Lymphocytic Leukemia Patients Following Complete or Partial Remission: A Pilot Study.
Leukemia, Lymphocytic, Chronic, B-Cell
Overcoming Ibrutinib Resistance in Chronic Lymphocytic Leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
p53 expression by immunohistochemistry is an important determinant of survival in patients with chronic lymphocytic leukemia receiving frontline chemo-immunotherapy.
Leukemia, Lymphocytic, Chronic, B-Cell
p65 activity and ZAP-70 status predict the sensitivity of chronic lymphocytic leukemia cells to the selective IkappaB kinase inhibitor BMS-345541.
Leukemia, Lymphocytic, Chronic, B-Cell
p66Shc deficiency in the E?-TCL1 mouse model of chronic lymphocytic leukemia enhances leukemogenesis by altering the chemokine receptor landscape.
Leukemia, Lymphocytic, Chronic, B-Cell
Paraneoplastic Pemphigus Associated with B-cell Chronic Lymphocytic Leukemia Treated with Ibrutinib and Rituximab.
Leukemia, Lymphocytic, Chronic, B-Cell
Pharmacodynamics and proteomic analysis of acalabrutinib therapy: similarity of on-target effects to ibrutinib and rationale for combination therapy.
Leukemia, Lymphocytic, Chronic, B-Cell
Pharmacokinetic and pharmacodynamic evaluation of ibrutinib for the treatment of chronic lymphocytic leukemia: rationale for lower doses.
Leukemia, Lymphocytic, Chronic, B-Cell
Phase 1b study of obinutuzumab, ibrutinib, and venetoclax in relapsed and refractory chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Phase 1b Study of Tirabrutinib in Combination With Idelalisib or Entospletinib in Previously Treated Chronic Lymphocytic Leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Phase I study of single-agent CC-292, a highly selective Bruton's tyrosine kinase inhibitor, in relapsed/refractory chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Phase I study of tirabrutinib (ONO-4059/GS-4059) in patients with relapsed or refractory B-cell malignancies in Japan.
Leukemia, Lymphocytic, Chronic, B-Cell
Phase II study of acalabrutinib in ibrutinib-intolerant patients with relapsed/refractory chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Pitfalls and limitations of ZAP-70 detection in chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Platelet function and bleeding in chronic lymphocytic leukemia and mantle cell lymphoma patients on ibrutinib.
Leukemia, Lymphocytic, Chronic, B-Cell
Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies.
Leukemia, Lymphocytic, Chronic, B-Cell
Prevalence of BTK and PLCG2 mutations in a real-life CLL cohort still on ibrutinib after 3 years: a FILO group study.
Leukemia, Lymphocytic, Chronic, B-Cell
Prevalence of ZAP-70 and CD 38 in Indian chronic lymphocytic leukemia patients.
Leukemia, Lymphocytic, Chronic, B-Cell
Profound Sinoatrial Arrest Associated with Ibrutinib.
Leukemia, Lymphocytic, Chronic, B-Cell
Prognostic Factors for Complete Response to Ibrutinib in Patients With Chronic Lymphocytic Leukemia: A Pooled Analysis of 2 Clinical Trials.
Leukemia, Lymphocytic, Chronic, B-Cell
Prognostic impact of ZAP-70 expression in chronic lymphocytic leukemia: mean fluorescence intensity T/B ratio versus percentage of positive cells.
Leukemia, Lymphocytic, Chronic, B-Cell
Prognostic significance of combined analysis of ZAP-70 and CD38 in chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Prognostic value of lipoprotein lipase expression among egyptian B-chronic lymphocytic leukemia patients.
Leukemia, Lymphocytic, Chronic, B-Cell
Progressive Multifocal Leukoencephalopathy after Ibrutinib Therapy for Chronic Lymphocytic Leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy.
Leukemia, Lymphocytic, Chronic, B-Cell
Proteolysis Targeting Chimeras for BTK Efficiently Inhibit B-Cell Receptor Signaling and Can Overcome Ibrutinib Resistance in CLL Cells.
Leukemia, Lymphocytic, Chronic, B-Cell
Quantification of ZAP-70 expression in chronic lymphocytic leukemia: T/B-cell ratio of mean fluorescence intensity provides stronger prognostic value than percentage of positive cells.
Leukemia, Lymphocytic, Chronic, B-Cell
Quantification of ZAP-70 mRNA by real-time PCR is a prognostic factor in chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Quantitative DNA methylation analysis identifies a single CpG dinucleotide important for ZAP-70 expression and predictive of prognosis in chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Quantitative flow cytometry of ZAP-70 levels in chronic lymphocytic leukemia using molecules of equivalent soluble fluorochrome.
Leukemia, Lymphocytic, Chronic, B-Cell
Real--world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: Data from 95 consecutive patients treated in a compassionate use program.
Leukemia, Lymphocytic, Chronic, B-Cell
Reconstitution of humoral immunity and decreased risk of infections in patients with chronic lymphocytic leukemia treated with Bruton tyrosine kinase inhibitors.
Leukemia, Lymphocytic, Chronic, B-Cell
Recruitment of PKC-betaII to lipid rafts mediates apoptosis-resistance in chronic lymphocytic leukemia expressing ZAP-70.
Leukemia, Lymphocytic, Chronic, B-Cell
Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib.
Leukemia, Lymphocytic, Chronic, B-Cell
Resistance to Bruton's Tyrosine Kinase Inhibitors: The Achilles Heel of Their Success Story in Lymphoid Malignancies.
Leukemia, Lymphocytic, Chronic, B-Cell
Resistance to BTK inhibition by ibrutinib can be overcome by preventing FOXO3a nuclear export and PI3K/AKT activation in B-cell lymphoid malignancies.
Leukemia, Lymphocytic, Chronic, B-Cell
Response of renal cell carcinoma to ibrutinib, a bruton tyrosine kinase inhibitor, in a patient treated for chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Risk of Bleeding Associated With Ibrutinib in Patients With B-Cell Malignancies: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Leukemia, Lymphocytic, Chronic, B-Cell
Role for ZAP-70 Signaling in the Differential Effector Functions of Rituximab and Obinutuzumab (GA101) in Chronic Lymphocytic Leukemia B Cells.
Leukemia, Lymphocytic, Chronic, B-Cell
Role of NFAT in Chronic Lymphocytic Leukemia and Other B-Cell Malignancies.
Leukemia, Lymphocytic, Chronic, B-Cell
Role of spleen tyrosine kinase in the pathogenesis of chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Secondary mutations as mediators of resistance to targeted therapy in leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Selective BTK inhibition improves bendamustine therapy response and normalizes immune effector functions in chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Selective, novel spleen tyrosine kinase (Syk) inhibitors suppress chronic lymphocytic leukemia B-cell activation and migration.
Leukemia, Lymphocytic, Chronic, B-Cell
Serious Infections in Patients Receiving Ibrutinib for Treatment of Lymphoid Malignancies.
Leukemia, Lymphocytic, Chronic, B-Cell
Serum thrombopoietin compared with ZAP-70 and immunoglobulin heavy-chain gene mutation status as a predictor of time to first treatment in early chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Severe Hepatotoxicity due to Ibrutinib with a Review of Published Cases.
Leukemia, Lymphocytic, Chronic, B-Cell
Significant change in ZAP-70 expression during the course of chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Simple determination of plasma ibrutinib concentration using high-performance liquid chromatography.
Leukemia, Lymphocytic, Chronic, B-Cell
SLP76 integrates into the B-Cell receptor signaling cascade in chronic lymphocytic leukemia cells and is associated with aggressive disease course.
Leukemia, Lymphocytic, Chronic, B-Cell
Smudge cell percentage as a surrogate marker for ZAP-70 expression in patients with chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Spleen tyrosine kinase inhibition prevents chemokine- and integrin-mediated stromal protective effects in chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Spleen tyrosine kinase inhibitors reduce CD40L-induced proliferation of chronic lymphocytic leukemia cells but not normal B cells.
Leukemia, Lymphocytic, Chronic, B-Cell
Spleen Tyrosine Kinase Is Involved in the CD38 Signal Transduction Pathway in Chronic Lymphocytic Leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Spleen tyrosine kinase is overexpressed and represents a potential therapeutic target in chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Spontaneous apoptosis and proliferation detected by BCL-2 and CD71 proteins are important progression indicators within ZAP-70 negative chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Steroid effects on ZAP-70 and SYK in relation to apoptosis in poor prognosis chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Surrogate molecular markers for IGHV mutational status in chronic lymphocytic leukemia for predicting time to first treatment.
Leukemia, Lymphocytic, Chronic, B-Cell
T-cell ZAP-70 overexpression in chronic lymphocytic leukemia (CLL) correlates with CLL cell ZAP-70 levels, clinical stage and disease progression.
Leukemia, Lymphocytic, Chronic, B-Cell
Tafasitamab combined with idelalisib or venetoclax in patients with CLL previously treated with a BTK inhibitor.
Leukemia, Lymphocytic, Chronic, B-Cell
Targeted drugs in concert with chemo: opposites attract.
Leukemia, Lymphocytic, Chronic, B-Cell
Targeted multigene deep sequencing of Bruton tyrosine kinase inhibitor-resistant chronic lymphocytic leukemia with disease progression and Richter transformation.
Leukemia, Lymphocytic, Chronic, B-Cell
Targeting BTK in CLL: Beyond Ibrutinib.
Leukemia, Lymphocytic, Chronic, B-Cell
Targeting neoplastic B cells and harnessing microenvironment: the "double face" of ibrutinib and idelalisib.
Leukemia, Lymphocytic, Chronic, B-Cell
Targeting the C481S Ibrutinib-Resistance Mutation in Bruton's Tyrosine Kinase Using PROTAC-Mediated Degradation.
Leukemia, Lymphocytic, Chronic, B-Cell
Telomerase expression in B-cell chronic lymphocytic leukemia predicts survival and delineates subgroups of patients with the same igVH mutation status and different outcome.
Leukemia, Lymphocytic, Chronic, B-Cell
TH2/TH1 Shift Under Ibrutinib Treatment in Chronic Lymphocytic Leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
The addition of rituximab to fludarabine improves clinical outcome in untreated patients with ZAP-70-negative chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
The B-cell receptor and ZAP-70 in chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
The BET inhibitor GS-5829 targets chronic lymphocytic leukemia cells and their supportive microenvironment.
Leukemia, Lymphocytic, Chronic, B-Cell
The Bruton Tyrosine Kinase (BTK) Inhibitor Acalabrutinib Demonstrates Potent On-Target Effects and Efficacy in Two Mouse Models of Chronic Lymphocytic Leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo.
Leukemia, Lymphocytic, Chronic, B-Cell
The Bruton's tyrosine kinase (BTK) inhibitor, ibrutinib, with chemoimmunotherapy in patients with chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
The BTK Inhibitor ARQ 531 Targets Ibrutinib-Resistant CLL and Richter Transformation.
Leukemia, Lymphocytic, Chronic, B-Cell
The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
The combination of venetoclax and rituximab for the treatment of patients with recurrent chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
The evolving role of Bruton's tyrosine kinase inhibitors in chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
The gene expression response of chronic lymphocytic leukemia cells to IL-4 is specific, depends on ZAP-70 status and is differentially affected by an NF?B inhibitor.
Leukemia, Lymphocytic, Chronic, B-Cell
The Ibr-7 derivative of ibrutinib exhibits enhanced cytotoxicity against non-small cell lung cancer cells via targeting of mTORC1/S6 signaling.
Leukemia, Lymphocytic, Chronic, B-Cell
The impacts of zanubrutinib on immune cells in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.
Leukemia, Lymphocytic, Chronic, B-Cell
The Phospholipase C-?2 Mutants R665W and L845F Identified in Ibrutinib-Resistant Chronic Lymphocytic Leukemia Patients are Hypersensitive to the Rho GTPase Rac2.
Leukemia, Lymphocytic, Chronic, B-Cell
THE PROGNOSTIC SIGNIFICANCE OF COMBAIND EXPRESSION OF ZAP-70 AND CD38 IN CHRONIC LYMPHOCYTIC LEUKEMIA.
Leukemia, Lymphocytic, Chronic, B-Cell
The Prognostic Significance of Combined Expression of ZAP-70 and CD38 in Chronic Lymphocytic Leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
The proliferation center microenvironment and prognostic markers in chronic lymphocytic leukemia/small lymphocytic lymphoma.
Leukemia, Lymphocytic, Chronic, B-Cell
The role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
The safety of Bruton's tyrosine kinase inhibitors for the treatment of chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
The Spleen Tyrosine Kinase Inhibitor, Entospletinib (GS-9973) Restores Chemosensitivity in Lung Cancer Cells by Modulating ABCG2-mediated Multidrug Resistance.
Leukemia, Lymphocytic, Chronic, B-Cell
The structure, regulation, and function of ZAP-70.
Leukemia, Lymphocytic, Chronic, B-Cell
The study of different chromosomal aberrations, CD38 and ZAP-70 in chronic lymphocytic leukemia patients.
Leukemia, Lymphocytic, Chronic, B-Cell
Three years of ibrutinib in CLL.
Leukemia, Lymphocytic, Chronic, B-Cell
Toll-like receptor-7 tolerizes malignant B cells and enhances killing by cytotoxic agents.
Leukemia, Lymphocytic, Chronic, B-Cell
Treating CLL with Bruton Tyrosine Kinase Inhibitors: The Role of the Outpatient Oncology Nurse.
Leukemia, Lymphocytic, Chronic, B-Cell
Treatment of Chronic Lymphocytic Leukemia After Discontinuation of Bruton's Tyrosine Kinase Inhibitors.
Leukemia, Lymphocytic, Chronic, B-Cell
Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with the BTK inhibitor zanubrutinib: phase 2, single-arm, multicenter study.
Leukemia, Lymphocytic, Chronic, B-Cell
US Food and Drug Administration approvals for Bruton tyrosine kinase inhibitors in patients with chronic lymphocytic leukemia: Potential inefficiencies in trial design and evidence generation.
Leukemia, Lymphocytic, Chronic, B-Cell
Using high-sensitivity sequencing for the detection of mutations in BTK and PLC?2 genes in cellular and cell-free DNA and correlation with progression in patients treated with BTK inhibitors.
Leukemia, Lymphocytic, Chronic, B-Cell
Using the geometric mean fluorescence intensity index method to measure ZAP-70 expression in patients with chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Vaccine responses in patients with chronic lymphocytic leukemia on treatment with Bruton Tyrosine Kinase Inhibitors: a focused review.
Leukemia, Lymphocytic, Chronic, B-Cell
Validation of ZAP-70 methylation and its relative significance in predicting outcome in chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Variations in the detection of ZAP-70 in chronic lymphocytic leukemia: Comparison with IgV(H) mutation analysis.
Leukemia, Lymphocytic, Chronic, B-Cell
Vecabrutinib inhibits B-cell receptor signal transduction in chronic lymphocytic leukemia cell types with wild-type or mutant Bruton's tyrosine kinase.
Leukemia, Lymphocytic, Chronic, B-Cell
Zanubrutinib (BGB-3111), a Second-Generation Selective Covalent Inhibitor of Bruton's Tyrosine Kinase and Its Utility in Treating Chronic Lymphocytic Leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
ZAP-70 and CD38 expression are independent prognostic factors in patients with B-cell chronic lymphocytic leukaemia and combined analysis improves their predictive value.
Leukemia, Lymphocytic, Chronic, B-Cell
ZAP-70 as a possible prognostic factor in childhood acute lymphoblastic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
ZAP-70 constitutively regulates gene expression and protein synthesis in chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
ZAP-70 directly enhances IgM signaling in chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
ZAP-70 enhances B-cell-receptor signaling despite absent or inefficient tyrosine kinase activation in chronic lymphocytic leukemia and lymphoma B cells.
Leukemia, Lymphocytic, Chronic, B-Cell
ZAP-70 enhances IgM signaling independent of its kinase activity in chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
ZAP-70 enhances migration of malignant B lymphocytes towards CCL21 by inducing CCR7 expression via IgM-ERK1/2 activation.
Leukemia, Lymphocytic, Chronic, B-Cell
ZAP-70 expression and proliferative activity in chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile.
Leukemia, Lymphocytic, Chronic, B-Cell
ZAP-70 expression in B-cell chronic lymphocytic leukemia: evaluation by external (isotypic) or internal (T/NK cells) controls and correlation with IgV(H) mutations.
Leukemia, Lymphocytic, Chronic, B-Cell
ZAP-70 expression in B-cell hematologic malignancy is not limited to CLL/SLL.
Leukemia, Lymphocytic, Chronic, B-Cell
ZAP-70 expression in normal pro/pre B cells, mature B cells, and in B-cell acute lymphoblastic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
ZAP-70 expression is a prognostic factor in chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
ZAP-70 expression is associated with enhanced ability to respond to migratory and survival signals in B-cell chronic lymphocytic leukemia (B-CLL).
Leukemia, Lymphocytic, Chronic, B-Cell
ZAP-70 expression is associated with increased CD4 central memory T cells in chronic lymphocytic leukemia: cross-sectional study.
Leukemia, Lymphocytic, Chronic, B-Cell
ZAP-70 immunoreactivity is a prognostic marker of disease progression in chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
ZAP-70 in B cell malignancies.
Leukemia, Lymphocytic, Chronic, B-Cell
ZAP-70 in chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
ZAP-70 in chronic lymphocytic leukemia: A meta-analysis.
Leukemia, Lymphocytic, Chronic, B-Cell
ZAP-70 intron1 DNA methylation status: determination by pyrosequencing in B chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
ZAP-70 is a novel conditional heat shock protein 90 (Hsp90) client: inhibition of Hsp90 leads to ZAP-70 degradation, apoptosis, and impaired signaling in chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
ZAP-70 is expressed by a subset of normal human B-lymphocytes displaying an activated phenotype.
Leukemia, Lymphocytic, Chronic, B-Cell
ZAP-70 is expressed by normal and malignant human B-cell subsets of different maturational stage.
Leukemia, Lymphocytic, Chronic, B-Cell
ZAP-70 is highly expressed in most cases of childhood pre-B cell acute lymphoblastic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
ZAP-70 methylation and expression status in chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
ZAP-70 methylation status is associated with ZAP-70 expression status in chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
ZAP-70 mRNA expression provides clinically valuable information in early-stage chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Zap-70 positive chronic lymphocytic leukemia co-existing with Jak 2 V671F positive essential thrombocythemia: A common defective stem cell?
Leukemia, Lymphocytic, Chronic, B-Cell
ZAP-70 promotes the infiltration of malignant B-lymphocytes into the bone marrow by enhancing signaling and migration after CXCR4 stimulation.
Leukemia, Lymphocytic, Chronic, B-Cell
ZAP-70 protein expression and CD38 positivity in B-cell chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
ZAP-70 Shapes the Immune Microenvironment in B Cell Malignancies.
Leukemia, Lymphocytic, Chronic, B-Cell
ZAP-70 staining in chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
ZAP-70 tyrosine kinase is constitutively expressed and phosphorylated in B-lineage acute lymphoblastic leukemia cells.
Leukemia, Lymphocytic, Chronic, B-Cell
ZAP-70, IgVh, and cytogenetics for assessing prognosis in chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
[Abnormality of serum immunoglobulin in peripheral blood of patients with chronic lymphocytic leukemia.]
Leukemia, Lymphocytic, Chronic, B-Cell
[Clinical significance of ZAP-70 protein expression in chronic lymphocytic leukemia/small lymphocytic lymphoma]
Leukemia, Lymphocytic, Chronic, B-Cell
[Immunohistochemical detection of ZAP-70 protein and its importance in the diagnostics of B-CLL]
Leukemia, Lymphocytic, Chronic, B-Cell
[Molecular diagnosis of and molecular targeting therapy for leukemia]
Leukemia, Lymphocytic, Chronic, B-Cell
[Prognostic significance of telomere length in patients with chronic lymphocytic leukemia]
Leukemia, Lymphocytic, Chronic, B-Cell
[The characteristics of evaluation of expression of ZAP-70 in tumor cells under b-cell chronic lymphatic leukemia using the flow cytofluorometry technique].
Leukemia, Lymphocytic, Chronic, B-Cell
[ZAP-70 expression in 24 patients with B cell chronic lymphocytic leukemia]
Leukemia, Lymphocytic, Chronic, B-Cell
[ZAP-70 in B-cell chronic lymphocytic leukemia: clinical significance and methods of detection]
Leukemia, Lymphoid
11q22.3 deletion in B-chronic lymphocytic leukemia is specifically associated with bulky lymphadenopathy and ZAP-70 expression but not reduced expression of adhesion/cell surface receptor molecules.
Leukemia, Lymphoid
ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development.
Leukemia, Lymphoid
An actin-binding function contributes to transformation by the Bcr-Abl oncoprotein of Philadelphia chromosome-positive human leukemias.
Leukemia, Lymphoid
BCR-ABL fusion transcript types and levels and their interaction with secondary genetic changes in determining the phenotype of Philadelphia chromosome-positive leukemias.
Leukemia, Lymphoid
C-JUN promotes BCR-ABL induced lymphoid leukemia by inhibiting methylation of the 5' region of Cdk6.
Leukemia, Lymphoid
Chronic myeloid leukemia may be associated with several bcr-abl transcripts including the acute lymphoid leukemia-type 7 kb transcript.
Leukemia, Lymphoid
Elevated expression of the c-fes proto-oncogene in adult human myeloid leukemia cells in the absence of gene amplification.
Leukemia, Lymphoid
Forced expression of cyclin-dependent kinase 6 confers resistance of pro-B acute lymphocytic leukemia to Gleevec treatment.
Leukemia, Lymphoid
HS1, a Lyn kinase substrate, is abnormally expressed in B-chronic lymphocytic leukemia and correlates with response to fludarabine-based regimen.
Leukemia, Lymphoid
Ibrutinib induces multiple functional defects in the neutrophil response against Aspergillus fumigatus.
Leukemia, Lymphoid
Kinases as drug discovery targets in hematologic malignancies.
Leukemia, Lymphoid
Loss of Zap-70 and low molecular weight phosphotyrosine phosphatase occurs after therapy in a patient with B-chronic lymphocytic leukemia.
Leukemia, Lymphoid
No evidence for genomic imprinting of the human BCR gene.
Leukemia, Lymphoid
Nuclear positioning of the BACH2 gene in BCR-ABL positive leukemic cells.
Leukemia, Lymphoid
Panniculitis in Patients Undergoing Treatment With the Bruton Tyrosine Kinase Inhibitor Ibrutinib for Lymphoid Leukemias.
Leukemia, Lymphoid
Quantitative measure of c-abl and p15 methylation in chronic myelogenous leukemia: biological implications.
Leukemia, Lymphoid
Risk of Bleeding Associated With Ibrutinib in Patients With B-Cell Malignancies: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Leukemia, Lymphoid
Specific Antileukemic Activity of PD0332991, a CDK4/6 Inhibitor, against Philadelphia Chromosome-Positive Lymphoid Leukemia.
Leukemia, Lymphoid
T-cell receptor-induced phosphorylation of the zeta chain is efficiently promoted by ZAP-70 but not Syk.
Leukemia, Lymphoid
Telomere length, molecular cytogenetic findings, and immunophenotypic features in previously untreated patients with B-chronic lymphocytic leukemia.
Leukemia, Lymphoid
ZAP-70 Protein Expression in B-cell Chronic Lymphoid Leukemia: a Single Center Experience from Pakistan.
Leukemia, Lymphoid
[Expression of c-fes gene in leukemia cells and its clinical significance]
Leukemia, Lymphoid
[Expression of CLLU1 in patients with chronic lymphocytic leukemia and its prognostic significance]
Leukemia, Lymphoid
[Large granular lymphocytic leukemia]
Leukemia, Lymphoid
[Molecular targeted therapy in lymphoid leukemias].
Leukemia, Megakaryoblastic, Acute
Association between Lyn protein tyrosine kinase (p53/56lyn) and the beta subunit of the granulocyte-macrophage colony-stimulating factor (GM-CSF) receptors in a GM-CSF-dependent human megakaryocytic leukemia cell line (M-07e).
Leukemia, Megakaryoblastic, Acute
Description of a novel Janus kinase 3 P132A mutation in acute megakaryoblastic leukemia and demonstration of previously reported Janus kinase 3 mutations in normal subjects.
Leukemia, Megakaryoblastic, Acute
Ectopic expression of protein-tyrosine kinase Bcr-Abl suppresses tumor necrosis factor (TNF)-induced NF-kappa B activation and IkappaBalpha phosphorylation. Relationship with down-regulation of TNF receptors.
Leukemia, Megakaryoblastic, Acute
Janus kinase mutations in the development of acute megakaryoblastic leukemia in children with and without Down's syndrome.
Leukemia, Monocytic, Acute
[Molecular diagnosis of leukemia and lymphoma]
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
"Home-brew" FISH assay shows higher efficiency than BCR-ABL dual color, dual fusion probe in detecting microdeletions and complex rearrangements associated with t(9;22) in chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
(-)Gossypol and its combination with imatinib induce apoptosis in human chronic myeloid leukemic cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
(124)I-iodopyridopyrimidinone for PET of Abl kinase-expressing tumors in vivo.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1,3-Butadiene metabolite 1,2,3,4 diepoxybutane induces DNA adducts and micronuclei but not t(9;22) translocations in human cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
14-3-3 LIGAND PREVENTS NUCLEAR IMPORT OF C-ABL PROTEIN IN CHRONIC MYELOID LEUKEMIA.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
3q26/EVI1 rearrangement in myelodysplastic/myeloproliferative neoplasms: An early event associated with a poor prognosis.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
5'-OH-5-nitro-Indirubin oxime (AGM130), an Indirubin derivative, induces apoptosis of Imatinib-resistant chronic myeloid leukemia cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
7-Ketocholesterol overcomes drug resistance in chronic myeloid leukemia cell lines beyond MDR1 mechanism.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
9-(Arenethenyl)purines as dual Src/Abl kinase inhibitors targeting the inactive conformation: design, synthesis, and biological evaluation.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
?12-prostaglandin J3, an omega-3 fatty acid-derived metabolite, selectively ablates leukemia stem cells in mice.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
A 41-kilodalton protein is a potential substrate for the p210bcr-abl protein-tyrosine kinase in chronic myelogenous leukemia cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
A 62-kilodalton tyrosine phosphoprotein constitutively present in primary chronic phase chronic myelogenous leukemia enriched lineage negative blast populations.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
A 76-kb duplicon maps close to the BCR gene on chromosome 22 and the ABL gene on chromosome 9: possible involvement in the genesis of the Philadelphia chromosome translocation.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
A BCR-ABL mutant lacking direct binding sites for the GRB2, CBL and CRKL adapter proteins fails to induce leukemia in mice.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
A bcr-v-abl oncogene induces lymphomas in transgenic mice.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
A Bcr/Abl kinase antagonist for chronic myelogenous leukemia: a promising path for progress emerges.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
A Bcr/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
A Bead-Based Activity Screen for Small-Molecule Inhibitors of Signal Transduction in Chronic Myelogenous Leukemia Cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
A cascade screening approach for the identification of Bcr-Abl myristate pocket binders active against wild type and T315I mutant.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
A Case of Childhood Blastic Phase Chronic Myeloid Leukemia With Minor BCR-ABL.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
A Case of Chronic Myelogenous Leukemia Occurring in a Patient Treated for Essential Thrombocythemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
A case of chronic myelogenous leukemia with e8a2 fusion transcript.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
A case of chronic myeloid leukemia with minor bcr-abl transcript following fluorouracil therapy for esophageal carcinoma.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
A case of inflammatory nonscarring alopecia associated with the tyrosine kinase inhibitor nilotinib.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
A case report of bosutinib-induced interstitial granulomatous drug reaction in a patient with chronic myelogenous leukemia: a case report.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
A causal Bayesian network model of disease progression mechanisms in chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
A CD4+ T cell clone selected from a CML patient after donor lymphocyte infusion recognizes BCR-ABL breakpoint peptides but not tumor cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
A chronic myeloid leukemia patient with atypical karyotype and BCR-ABL e13a3 transcript caused by complex chromosome rearrangement.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
A clinical study to examine the potential effect of lansoprazole on the pharmacokinetics of bosutinib when administered concomitantly to healthy subjects.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
A co-operative evaluation of different methods of detecting BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia on second-line dasatinib or nilotinib therapy after failure of imatinib.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
A common phosphotyrosine signature for the Bcr-Abl kinase.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
A comparison of normal and leukemic stem cell biology in Chronic Myeloid Leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
A complex three-way translocation with deletion of the TP53 gene in a blast crisis chronic myeloid leukemia patient.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
A comprehensive analysis of breakpoint cluster region-abelson fusion oncogene splice variants in chronic myeloid leukemia and their correlation with disease biology.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
A comprehensive target selectivity survey of the BCR-ABL kinase inhibitor INNO-406 by kinase profiling and chemical proteomics in chronic myeloid leukemia cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
A computational approach to analyze the mechanism of action of the kinase inhibitor bafetinib.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
A Critical Review of Trials of First-Line BCR-ABL Inhibitor Treatment in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
A direct binding site for Grb2 contributes to transformation and leukemogenesis by the Tel-Abl (ETV6-Abl) tyrosine kinase.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
A Drug Resistance Screen Using a Selective MET Inhibitor Reveals a Spectrum of Mutations That Partially Overlap with Activating Mutations Found in Cancer Patients.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
A Half-Log Increase in BCR-ABL RNA Predicts a Higher Risk of Relapse in Patients with Chronic Myeloid Leukemia with an Imatinib-Induced Complete Cytogenetic Response.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
A historical overview of protein kinases and their targeted small molecule inhibitors.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
A JAK2 mutation in myeloproliferative disorders: pathogenesis and therapeutic and scientific prospects.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
A modified DAW-22 compound F-B1 inhibits Bcr/Abl and induces apoptosis in chronic myelogenous leukemia cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
A Multiple Reaction Monitoring (MRM) Method to Detect Bcr-Abl Kinase Activity in CML Using a Peptide Biosensor.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
A multivalent bcr-abl fusion peptide vaccination trial in patients with chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
A new diagnostic kit, ODK-1201, for the quantitation of low major BCR-ABL mRNA level in chronic myeloid leukemia: correlation of quantitation with major BCR-ABL mRNA kits.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
A NEW NON-PEPTIDIC INHIBITOR OF THE 14-3-3 DOCKING SITE INDUCES APOPTOTIC CELL DEATH IN CHRONIC MYELOID LEUKEMIA SENSITIVE OR RESISTANT TO IMATINIB.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
A Non-ATP-Competitive Dual Inhibitor of JAK2 and BCR-ABL Kinases: Elucidation of a Novel Therapeutic Spectrum Based on Substrate Competitive Inhibition.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
A novel allosterically trans-activated ribozyme, the maxizyme, with exceptional specificity in vitro and in vivo.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
A novel BCR-ABL fusion gene (e6a2) in a patient with Philadelphia chromosome-negative chronic myelogenous leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
A novel BCR-ABL fusion transcript (e18a2) in a child with chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
A novel cytogenetic abnormality t(7;8)(p11.2:q11.2) and a four-way Philadelphia translocation in an imatinib mesylate-resistant chronic myeloid leukemia patient.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
A novel FRET-based biosensor for the measurement of BCR-ABL activity and its response to drugs in living cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
A novel fusion circular RNA F-circBA1 derived from the BCR-ABL fusion gene displayed an oncogenic role in chronic myeloid leukemia cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
A Novel Inhibitor of STAT5 Signaling Overcomes Chemotherapy Resistance in Myeloid Leukemia Cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
A novel insertion mutation of K294RGG within BCR-ABL kinase domain confers imatinib resistance: sequential analysis of the clonal evolution in a patient with chronic myeloid leukemia in blast crisis.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
A novel mechanism for Bcr-Abl action: Bcr-Abl-mediated induction of the eIF4F translation initiation complex and mRNA translation.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
A novel mechanism for BCR-ABL action: stimulated secretion of CCN3 is involved in growth and differentiation regulation.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
A novel pyridopyrimidine inhibitor of abl kinase is a picomolar inhibitor of Bcr-abl-driven K562 cells and is effective against STI571-resistant Bcr-abl mutants.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
A once-daily dasatinib dosing strategy for chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
A peptide biosensor for detecting intracellular Abl kinase activity using MALDI-TOF MS.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
A Ph-negative chronic myeloid leukemia patient with a non-classical BCR-ABL rearrangement characterized by fluorescence in situ hybridization.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
A phase 2 study of MK-0457 in patients with BCR-ABL T315I mutant chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
A phase I clinical trial of ruxolitinib in combination with nilotinib in chronic myeloid leukemia patients with molecular evidence of disease.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
A phase I study of danusertib (PHA-739358) in adult patients with accelerated or blastic phase chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant or intolerant to imatinib and/or other second generation c-ABL therapy.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
A Pipeline for Drug Target Identification and Validation.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
A possible correlation between the type of bcr-abl hybrid messenger RNA and platelet count in Philadelphia-positive chronic myelogenous leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
A Prognostic and Predictive Study of BCR-ABL Expression Based on Characterization of Fusion Transcripts.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
A Rare Case of p190 BCR-ABL Chronic Myeloid Leukemia With a Very Good Response to Tyrosine Kinase Inhibitors.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
A rare chronic myeloid leukemia case with Philadelphia chromosome, BCR-ABL e13a3 transcript and complex translocation involving four different chromosomes.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
A rare e14a3 (b3a3) BCR-ABL fusion transcript in chronic myeloid leukemia: diagnostic challenges in clinical laboratory practice.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
A report of early cytogenetic response to imatinib in two patients with chronic myeloid leukemia at accelerated phase and carrying the e19a2 BCR-ABL transcript.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
A requirement for NF-kappaB activation in Bcr-Abl-mediated transformation.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
A research-inspired laboratory sequence investigating acquired drug resistance.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
A role for c-Abl in cell senescence and spontaneous immortalization.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
A screen to identify drug resistant variants to target-directed anti-cancer agents.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
A Screening-Based Approach to Circumvent Tumor Microenvironment-Driven Intrinsic Resistance to BCR-ABL+ Inhibitors in Ph+ Acute Lymphoblastic Leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
A sequential blockade strategy for the design of combination therapies to overcome oncogene addiction in chronic myelogenous leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
A single-tube allele specific-polymerase chain reaction to detect T315I resistant mutation in chronic myeloid leukemia patients.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
A Small Molecule Inhibitor, OGP46, Is Effective against Imatinib-Resistant BCR-ABL Mutations via the BCR-ABL/JAK-STAT Pathway.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
A solid-phase Bcr-Abl kinase assay in 96-well hydrogel plates.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
A Src-like inactive conformation in the abl tyrosine kinase domain.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
A therapeutically targetable mechanism of BCR-ABL-independent imatinib resistance in chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
A two-color BCR-ABL probe that greatly reduces the false positive and false negative rates for fluorescence in situ hybridization in chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
A Unique Activating Mutation in JAK2 (V617F) Is at the Origin of Polycythemia Vera and Allows a New Classification of Myeloproliferative Diseases.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
ABC transporter A3 facilitates lysosomal sequestration of imatinib and modulates susceptibility of chronic myeloid leukemia cell lines to this drug.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Aberrant BCR-ABL transcript with intronic insertion in a patient with philadelphia chromosome-positive chronic myeloid leukemia: implications for disease progression.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Aberrant DNA Methylation of SOCS1 Gene is Not Associated with Resistance to Imatinib Mesylate among Chronic Myeloid Leukemia Patients.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
ABL Genomic Editing Sufficiently Abolishes Oncogenesis of Human Chronic Myeloid Leukemia Cells In Vitro and In Vivo.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
ABL Kinase Domain Mutations in Iranian Chronic Myeloid Leukemia Patients with Resistance to Tyrosine Kinase Inhibitors.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
ABL kinase domain mutations in patients with chronic myeloid leukemia in Jordan.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
ABL kinase inhibitor therapy for CML: baseline assessments and response monitoring.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
ABL oncogenes and phosphoinositide 3-kinase: mechanism of activation and downstream effectors.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
ABL single nucleotide polymorphisms may masquerade as BCR-ABL mutations associated with resistance to tyrosine kinase inhibitors in patients with chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
ABL tyrosine kinase inhibition variable effects on the invasive properties of different triple negative breast cancer cell lines.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
ABL tyrosine kinase inhibitor-induced pulmonary alveolar proteinosis in chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Abl tyrosine kinase inhibitors for overriding Bcr-Abl/T315I: from the second to third generation.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
ABL1 methylation in Ph-positive ALL is exclusively associated with the P210 form of BCR-ABL.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
ABL1 promoter methylation can exist independently of BCR-ABL transcription in chronic myeloid leukemia hematopoietic progenitors.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
ABL1 tyrosine kinase domain mutations in chronic myeloid leukemia treatment resistance.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
ABL1-Directed Inhibitors for CML: Efficacy, Resistance and Future Perspectives.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Abrogation of the cell death response to oxidative stress by the c-Abl tyrosine kinase inhibitor STI571.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Absence of alternative splicing in bcr-abl mRNA in chronic myeloid leukemia cell lines.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Absence of the hybrid bcr-abl mRNA in Ph1-positive B lymphoblastoid cell lines established from a patient with chronic myelogenous leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Absolute quantitative detection of ABL tyrosine kinase domain point mutations in chronic myeloid leukemia using a novel nanofluidic platform and mutation-specific PCR.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
ABT-737 increases tyrosine kinase inhibitor-induced apoptosis in chronic myeloid leukemia cells through XIAP downregulation and sensitizes CD34(+) CD38(-) population to imatinib.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Acceleration of tumor growth and peri-tumoral blood clotting by imatinib mesylate (Gleevec).
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Achieving early molecular response in chronic myeloid leukemia in chronic phase to reduce the risk of progression: clinical relevance of the 3- and 6-month time points.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Aclacinomycin A sensitizes K562 chronic myeloid leukemia cells to imatinib through p38MAPK-mediated erythroid differentiation.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Activated c-Abl tyrosine kinase in malignant solid tumors.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Activation of bcr-abl fusion gene and ras oncogenes in chronic myelogenous leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Activation of Jak2 in patients with blast crisis chronic myelogenous leukemia: inhibition of Jak2 inactivates Lyn kinase.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Activation of p53 by SIRT1 Inhibition Enhances Elimination of CML Leukemia Stem Cells in Combination with Imatinib.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Activation of the Abelson tyrosine kinase activity is associated with suppression of apoptosis in hemopoietic cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Activation of the c-abl oncogene by viral transduction or chromosomal translocation generates altered c-abl proteins with similar in vitro kinase properties.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Activation of tyrosinase kinase and microfilament-binding functions of c-abl by bcr sequences in bcr/abl fusion proteins.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Active FKHRL1 overcomes imatinib resistance in chronic myelogenous leukemia-derived cell lines via the production of tumor necrosis factor-related apoptosis-inducing ligand.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Activin A induction of erythroid differentiation sensitizes K562 chronic myeloid leukemia cells to a subtoxic concentration of imatinib.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Activity of dual SRC-ABL inhibitors highlights the role of BCR/ABL kinase dynamics in drug resistance.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Activity of Fgr protein-tyrosine kinase is reduced in neutrophils of patients with myelodysplastic syndromes and chronic myelogenous leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Activity of the Bcr-Abl kinase inhibitor PD180970 against clinically relevant Bcr-Abl isoforms that cause resistance to imatinib mesylate (Gleevec, STI571).
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Acute dasatinib exposure commits Bcr-Abl-dependent cells to apoptosis.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Acute monocytic leukemia with coexpression of minor BCR-ABL1 and PICALM-MLLT10 fusion genes along with overexpression of HOXA9.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Acute renal failure secondary to imatinib mesylate treatment in chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Adaphostin-induced oxidative stress overcomes BCR/ABL mutation-dependent and -independent imatinib resistance.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
ADAR1 promotes malignant progenitor reprogramming in chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Additional chromosome abnormalities, BCR-ABL tyrosine kinase domain mutations and clinical outcome in Hungarian tyrosine kinase inhibitor-resistant chronic myelogenous leukemia patients.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Additive antileukemia effects by GFI1B- and BCR-ABL-specific siRNA in advanced phase chronic myeloid leukemic cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Adherence to BCR-ABL Inhibitors: Issues for CML Therapy.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Advances in Immunotherapy of Chronic Myeloid Leukemia CML.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Advances in targeted therapy for chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Advances in treatment of chronic myeloid leukemia with tyrosine kinase inhibitors: the evolving role of Bcr-Abl mutations and mutational analysis.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
AHI-1: a novel signaling protein and potential therapeutic target in human leukemia and brain disorders.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Aleukemic bcr-abl positive granulocytic sarcoma.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Allium Roseum L. Extract Exerts Potent Suppressive Activities on Chronic Myeloid Leukemia K562 Cell Viability Through the Inhibition of BCR-ABL, PI3K/Akt, and ERK1/2 Pathways and the Abrogation of VEGF Secretion.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Allogeneic hematopoietic stem cell transplantation for patients with chronic myeloid leukemia in second chronic phase attained by imatinib after onset of blast crisis.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failure.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Allogeneic Stem Cell Transplantation for Patients with T315I BCR-ABL Mutated Chronic Myeloid Leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Allogeneic stem cell transplants in chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Allografting for Bosutinib, Imatinib, Nilotinib, Dasatinib, and Interferon Resistant Chronic Myeloid Leukemia without ABL Kinase Mutation.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Allosteric Inhibition of Bcr-Abl Kinase by High-Affinity Monobody Inhibitors Directed to the SH2-Kinase Interface.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Allosteric inhibition of BCR-ABL.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Allosteric inhibitors of Bcr-abl-dependent cell proliferation.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Allosterically controllable maxizyme-mediated suppression of progression of leukemia in mice.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Allosterically controlled single-chained maxizymes with extremely high and specific activity.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Altered transcription of the c-abl oncogene in K-562 and other chronic myelogenous leukemia cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Alternative 5' end of the bcr-abl transcript in chronic myelogenous leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Alternative expression of TCR? related genes in patients with chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Alternative forms of the BCR-ABL oncogene have quantitatively different potencies for stimulation of immature lymphoid cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Alu and translisin recognition site sequences flanking translocation sites in a novel type of chimeric bcr-abl transcript suggest a possible general mechanism for bcr-abl breakpoints.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
AMP-activated protein kinase activation primes cytoplasmic translocation and autophagic degradation of the BCR-ABL protein in CML cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Amplification of BCR-ABL and t(3;21) in a patient with blast crisis of chronic myelogenous leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Amplified C lambda and c-abl genes are on the same marker chromosome in K562 leukemia cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
An actin-binding function contributes to transformation by the Bcr-Abl oncoprotein of Philadelphia chromosome-positive human leukemias.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
An activating amino acid substitution in the c-abl oncogene protein fails to produce a local conformational change.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
An acute myeloid leukemia M6b blast crisis with giant proerythroblasts in chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
An anticancer C-Kit kinase inhibitor is reengineered to make it more active and less cardiotoxic.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
An ent-Kaurane Diterpenoid Isolated from Rabdosia excisa Suppresses Bcr-Abl Protein Expression in Vitro and in Vivo and Induces Apoptosis of CML Cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
An inhibitor-resistant mutant of Hck protects CML cells against the antiproliferative and apoptotic effects of the broad-spectrum Src family kinase inhibitor A-419259.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
An Integrative Informatics Approach to Explain the Mechanism of Action of Novel N1-(Anthraquinon-2-yl) Amidrazones as BCR/ABL Inhibitors.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
An intron promotes the anti-bcr-abl activities of a retrovirally expressed ribozyme in chronic myeloid leukemia cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
An intron-derived insertion/truncation mutation in the BCR-ABL kinase domain in chronic myeloid leukemia patients undergoing kinase inhibitor therapy.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
An inv(16) in Ph-negative cells of a chronic myelogenous leukemia patient after imatinib treatment.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
An ultra-long circulating nanoparticle for reviving a highly selective BCR-ABL inhibitor in long-term effective and safe treatment of chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
An Unprecedented Case of p190 BCR-ABL Chronic Myeloid Leukemia Diagnosed during Treatment for Multiple Myeloma: A Case Report and Review of the Literature.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
An unusual case of T-cell acute lymphoblastic leukemia in a patient with BCR-ABL positive chronic myeloid leukemia and Gaucher disease.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
An update on dual Src/Abl inhibitors.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Anagrelide and imatinib mesylate combination therapy in patients with chronic myeloproliferative disorders.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Analogs, formulations and derivatives of imatinib: a patent review.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Analysis of ABL kinase domain mutations conferring resistance to tyrosine kinase inhibitors in chronic myeloid leukemia cases from India.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Analysis of BCR-ABL mRNA in chronic myelogenous leukemia patients and identification of a new BCR-related sequence in human DNA.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Analysis of immunoglobulin, T cell receptor and bcr rearrangements in human malignant lymphoma and Hodgkin's disease.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Analysis of P210bcr-abl tyrosine protein kinase activity in various subtypes of Philadelphia chromosome-positive cells from chronic myelogenous leukemia patients.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Analysis of Philadelphia chromosome-negative BCR-ABL-positive chronic myelogenous leukemia by hypermetaphase fluorescence in situ hybridization.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Analysis of the structural basis of specificity of inhibition of the Abl kinase by STI571.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Analytical Validation of a Highly Sensitive, Multiplexed Chronic Myeloid Leukemia Monitoring System Targeting BCR-ABL1 RNA.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Andrographolide and its potent derivative exhibit anticancer effects against imatinib-resistant chronic myeloid leukemia cells by downregulating the Bcr-Abl oncoprotein.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Anthelmintic drug niclosamide enhances the sensitivity of chronic myeloid leukemia cells to dasatinib through inhibiting Erk/Mnk1/eIF4E pathway.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Anthelmintic niclosamide suppresses transcription of BCR-ABL fusion oncogene via disabling Sp1 and induces apoptosis in imatinib-resistant CML cells harboring T315I mutant.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Anti-cancer fatty-acid derivative induces autophagic cell death through modulation of PKM isoform expression profile mediated by bcr-abl in chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Anti-proliferative effect of the abl tyrosine kinase inhibitor STI571 on the P-glycoprotein positive K562/ADM cell line.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Antibiotic anisomycin selectively targets leukemia cell lines and patient samples through suppressing Wnt/?-catenin signaling.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Antibody recognition of the tumor-specific bcr-abl joining region in chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Antibody-based detection of protein phosphorylation status to track the efficacy of novel therapies using nanogram protein quantities from stem cells and cell lines.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Anticancer therapeutics: "Addictive" targets, multi-targeted drugs, new drug combinations.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Anticipated Impact of Generic Imatinib Market Entry on the Costs of Tyrosine Kinase Inhibitors.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Anticipating clinical resistance to target-directed agents : the BCR-ABL paradigm.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Antisense BCR-ABL oligomers cause non-specific inhibition of chronic myeloid leukemia cell lines.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Antisense BCR-ABL oligonucleotides induce apoptosis in the Philadelphia chromosome-positive cell line BV173.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Antisense inhibition of Bcr-Abl/c-Abl synthesis promotes telomerase activity and upregulates tankyrase in human leukemia cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Antisense inhibition of P210 bcr-abl in chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Antisense oligodeoxynucleotide combination therapy of primary chronic myelogenous leukemia blast crisis in SCID mice.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Anxiety and depression associated with tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Apoptosis and erythroid differentiation triggered by Bcr-Abl inhibitors in CML cell lines are fully distinguishable processes that exhibit different sensitivity to caspase inhibition.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Apoptosis in chronic myeloid leukemia cells transiently treated with imatinib or dasatinib is caused by residual BCR-ABL kinase inhibition.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Appearance of acute leukemia-associated P190BCR-ABL in chronic myelogenous leukemia may correlate with disease progression.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Application of a new protocol for nested PCR to the detection of minimal residual bcr/abl transcripts.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Application of chromosome microdissection probes for elucidation of BCR-ABL fusion and variant Philadelphia chromosome translocations in chronic myelogenous leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Application of FISH to complex chromosomal rearrangements associated with chronic myelogenous leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Application of multiplexed kinase inhibitor beads to study kinome adaptations in drug-resistant leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Applying the discovery of the Philadelphia chromosome.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Are there better Bcr-Abl kinase inhibitors for chronic myeloid leukaemia than imatinib? Evaluation of Saglio G, Kim D-W, Issaragrisil S, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010;362:2251-9, and Kantarjian H, Shah NP, Hochhaus A, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010;362:2260-70.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Arf gene loss enhances oncogenicity and limits imatinib response in mouse models of Bcr-Abl-induced acute lymphoblastic leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Arginine butyrate downregulates p210 bcr-abl expression and induces apoptosis in chronic myelogenous leukemia cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Arsenic induces apoptosis of multidrug-resistant human myeloid leukemia cells that express Bcr-Abl or overexpress MDR, MRP, Bcl-2, or Bcl-x(L).
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Arsenic sulfide nanoformulation induces erythroid differentiation in chronic myeloid leukemia cells through degradation of BCR-ABL.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Arsenic trioxide inhibits translation of mRNA of bcr-abl, resulting in attenuation of Bcr-Abl levels and apoptosis of human leukemia cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
As4S4 targets RING-type E3 ligase c-CBL to induce degradation of BCR-ABL in chronic myelogenous leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Ascorbate/menadione-induced oxidative stress kills cancer cells that express normal or mutated forms of the oncogenic protein Bcr-Abl. An in vitro and in vivo mechanistic study.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Assessment of azithromycin as an anticancer agent for treatment of imatinib sensitive and resistant CML cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Assessment of Oxidative Stress in Patients with Chronic Myeloid Leukemia Depending on Associated Comorbidities.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Association Between BCR-ABL Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia and Cardiovascular Events, Major Molecular Response, and Overall Survival: A Systematic Review and Meta-analysis.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Association between insurance status at diagnosis and overall survival in chronic myeloid leukemia: A population-based study.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Association between molecular monitoring and long-term outcomes in chronic myelogenous leukemia patients treated with first line imatinib.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Association between severe toxicity of nilotinib and UGT1A1 polymorphisms in Japanese patients with chronic myelogenous leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Association of BCR/ABL transcript variants with different blood parameters and demographic features in Iraqi chronic myeloid leukemia patients.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Association of promoter polymorphisms of Fas -FasL genes with development of Chronic Myeloid Leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Association of XRCC1 gene polymorphisms with chronic myeloid leukemia in the population of Andhra Pradesh, India.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
ASXL1 and JAK2V617F gene mutation screening in Iranian patients with chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
ATG7 regulates energy metabolism, differentiation and survival of Philadelphia-chromosome-positive cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
ATRA-induced cellular differentiation and CD38 expression inhibits acquisition of BCR-ABL mutations for CML acquired resistance.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Aurora A Kinase Inhibitor AKI603 Induces Cellular Senescence in Chronic Myeloid Leukemia Cells Harboring T315I Mutation.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Autologous stem cell collection and autograft for patients with chronic myeloid leukemia in the era of ABL kinase inhibitors: back to the bench.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Autophagic degradation of the BCR-ABL oncoprotein and generation of antileukemic responses by arsenic trioxide.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Autophagy: friend or foe in the treatment of fusion protein-associated leukemias?
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Axitinib and sorafenib are potent in tyrosine kinase inhibitor resistant chronic myeloid leukemia cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Axl Blockade by BGB324 Inhibits BCR-ABL Tyrosine Kinase Inhibitor-Sensitive and -Resistant Chronic Myeloid Leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Backbone NMR resonance assignment of the Abelson kinase domain in complex with imatinib.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Bacterial expression and purification of active hematopoietic cell kinase.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Bag1 directly routes immature BCR-ABL for proteasomal degradation.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Balanced parental contribution to the ABL component of the BCR-ABL gene in chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Basic science going clinical: molecularly targeted therapy of chronic myelogenous leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BAX/BCL-XL gene expression ratio inversely correlates with disease progression in chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR and BCR-ABL regulation during myeloid differentiation in healthy donors and in chronic phase/blast crisis CML patients.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR gene expression blocks Bcr-Abl induced pathogenicity in a mouse model.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR gene recombines with genomically distinct sites on band 11Q13 in complex BCR-ABL translocations of chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
bcr Rearrangement without juxtaposition of c-abl in chronic myelocytic leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Bcr-Abl activates AURKA and AURKB in chronic myeloid leukemia cells via AKT signaling.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR-ABL activates pathways mediating cytokine independence and protection against apoptosis in murine hematopoietic cells in a dose-dependent manner.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR-ABL activity is critical for the immunogenicity of chronic myelogenous leukemia cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR-ABL activity measured by 50% inhibitory concentration for imatinib, p-CrkL/CrkL ratio or p-CrkL ratio in CD34+ cells of patients with chronic myeloid leukemia does not predict treatment response.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Bcr-Abl Allosteric Inhibitors: Where We Are and Where We Are Going to.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR-ABL alternative splicing as a common mechanism for imatinib resistance: evidence from molecular dynamics simulations.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Bcr-Abl and inhibition of apoptosis in chronic myelogenous leukemia cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR-ABL and JAK2V617F Mutation Co-existence, Rare or Just Unexplored.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR-ABL antisense oligodeoxynucleotide in vitro purging and autologous bone marrow transplantation for patients with chronic myelogenous leukemia in advanced phase.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR-ABL breakpoint and prognosis in chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR-ABL but not JAK2 V617F inhibits erythropoiesis through the Ras signal by inducing p21CIP1/WAF1.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Bcr-Abl dependent post-transcriptional activation of NME2 expression is a specific and common feature of chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR-ABL disrupts PTEN nuclear-cytoplasmic shuttling through phosphorylation-dependent activation of HAUSP.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR-ABL down-regulates the DNA repair protein DNA-PKcs.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Bcr-Abl efficiently induces a myeloproliferative disease and production of excess interleukin-3 and granulocyte-macrophage colony-stimulating factor in mice: a novel model for chronic myelogenous leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR-ABL enhances differentiation of long-term repopulating hematopoietic stem cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Bcr-Abl exerts its antiapoptotic effect against diverse apoptotic stimuli through blockage of mitochondrial release of cytochrome C and activation of caspase-3.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR-ABL exon 7 deletion and novel point mutation in patient with chronic myelogenous leukemia and TKI resistance.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR-ABL expression in different subpopulations of functionally characterized Ph+ CD34+ cells from patients with chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR-ABL expression in leukemic progenitors and primitive stem cells of patients with chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR-ABL fusion genes and laboratory findings in patients with chronic myeloid leukemia in northeast Iran.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Bcr-Abl fusion sequences do not induce immune responses in mice when administered in mouse polyomavirus based virus-like particles.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR-ABL gene amplification and overexpression in a patient with chronic myeloid leukemia treated with imatinib.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR-ABL gene expression is required for its mutations in a novel KCL-22 cell culture model for acquired resistance of chronic myelogenous leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR-ABL gene rearrangement and expression of primitive hematopoietic progenitors in chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR-ABL Gene Transcript Types of Patients with Chronic Myelogenous Leukemia in Yogyakarta, Indonesia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR-ABL in chronic myelogenous leukemia--how does it work?
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR-ABL inactivates cytosolic PTEN through Casein Kinase II mediated tail phosphorylation.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR-ABL Independent Mechanisms of Resistance in Chronic Myeloid Leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Bcr-Abl induced tyrosine phosphorylation of emi1 to stabilize skp2 protein via inhibition of ubiquitination in chronic myeloid leukemia cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Bcr-Abl induces autocrine IGF-1 signaling.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR-ABL induces the expression of Skp2 through the PI3K pathway to promote p27Kip1 degradation and proliferation of chronic myelogenous leukemia cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR-ABL induces tyrosine phosphorylation of YAP leading to expression of Survivin and Cyclin D1 in chronic myeloid leukemia cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR-ABL inhibitors in chronic myeloid leukemia: process chemistry and biochemical profile.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR-ABL inhibitors: Updates in the management of patients with chronic-phase chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR-ABL insufficiency for the transformation of human stem cells into CML.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Bcr-Abl is a "molecular switch" for the decision for growth and differentiation in hematopoietic stem cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR-ABL is not an immunodominant antigen in chronic myelogenous leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Bcr-Abl kinase domain mutations and the unsettled problem of Bcr-AblT315I: looking into the future of controlling drug resistance in chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR-ABL kinase domain mutations in chronic myeloid leukemia: not quite enough to cause resistance to imatinib therapy?
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR-ABL kinase domain mutations in tyrosine kinase inhibitors-naïve and -exposed Southeast Asian chronic myeloid leukemia patients.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR-ABL kinase domain mutations, including 2 novel mutations in imatinib resistant Malaysian chronic myeloid leukemia patients-Frequency and clinical outcome.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Bcr-Abl kinase down-regulates cyclin-dependent kinase inhibitor p27 in human and murine cell lines.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Bcr-Abl kinase modulates the translation regulators ribosomal protein S6 and 4E-BP1 in chronic myelogenous leukemia cells via the mammalian target of rapamycin.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR-ABL maintains resistance of chronic myelogenous leukemia cells to apoptotic cell death.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR-ABL mediated repression of miR-223 results in the activation of MEF2C and PTBP2 in chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR-ABL mediates arsenic trioxide-induced apoptosis independently of its aberrant kinase activity.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR-ABL messenger RNA levels continue to decline in patients with chronic phase chronic myeloid leukemia treated with imatinib for more than 5 years and approximately half of all first-line treated patients have stable undetectable BCR-ABL using strict sensitivity criteria.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Bcr-abl mRNA expression in patients with chronic myeloproliferative disorders--absence of bcr-abl fused clone except chronic myelocytic leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR-ABL mutants spread resistance to non-mutated cells through a paracrine mechanism.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR-ABL mutation testing to predict response to tyrosine kinase inhibitors in patients with chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR-ABL mutations in chronic myeloid leukemia - not only detection.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR-ABL Mutations in Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors and Impact on Survival.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR-ABL mutations in chronic myeloid leukemia treated with tyrosine kinase inhibitors and impact on survival.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR-ABL mutations in chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR-ABL nuclear entrapment kills human CML cells: ex vivo study on 35 patients with the combination of imatinib mesylate and leptomycin B.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
bcr-abl oncogene renders myeloid cell line factor independent: potential autocrine mechanism in chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Bcr-Abl oncogene stimulates Jab1 expression via cooperative interaction of ?-catenin and STAT1 in chronic myeloid leukemia cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Bcr-Abl oncoproteins bind directly to activators of the Ras signalling pathway.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR-ABL PCR testing in chronic myelogenous leukemia: molecular diagnosis for targeted cancer therapy and monitoring.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR-ABL point mutants isolated from patients with imatinib mesylate-resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Bcr-abl positive blast crisis of chronic myeloid leukemia emerging in a case of metastatic colorectal cancer 3 months after completion of an 8-month course of cetuximab and irinotecan.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR-ABL positive chronic myeloid leukemia with concurrent JAK2(V617F) positive myelodysplastic syndrome/myeloproliferative neoplasm (RARS-T).
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR-ABL promotes neutrophil differentiation in the chronic phase of chronic myeloid leukemia by downregulating c-Jun expression.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR-ABL promotes PTEN downregulation in chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR-ABL protein expression in peripheral blood cells of chronic myelogenous leukemia patients undergoing therapy.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR-ABL rearrangement frequencies in chronic myeloid leukemia and acute lymphoblastic leukemia in Ecuador, South America.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR-ABL rearrangements in children with Philadelphia chromosome-positive chronic myelogenous leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Bcr-Abl reduces endoplasmic reticulum releasable calcium levels by a Bcl-2-independent mechanism and inhibits calcium-dependent apoptotic signaling.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Bcr-Abl regulates osteopontin transcription via Ras, PI-3K, aPKC, Raf-1, and MEK.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR-ABL regulates phosphatidylinositol 3-kinase-p110gamma transcription and activation and is required for proliferation and drug resistance.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Bcr-Abl regulation of sphingomyelin synthase 1 reveals a novel oncogenic-driven mechanism of protein up-regulation.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR-ABL residues interacting with ponatinib are critical to preserve the tumorigenic potential of the oncoprotein.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Bcr-Abl resistance screening predicts a limited spectrum of point mutations to be associated with clinical resistance to the Abl kinase inhibitor nilotinib (AMN107).
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
bcr-abl RNA in patients with chronic myelogenous leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR-ABL SH3-SH2 domain mutations in chronic myeloid leukemia patients on imatinib.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Bcr-Abl signaling through the PI-3/S6 kinase pathway inhibits nuclear translocation of the transcription factor Bach2, which represses the antiapoptotic factor heme oxygenase-1.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Bcr-abl signals to desensitize chronic myeloid leukemia cells to interferon alpha via accelerating the degradation of its receptor.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR-Abl Silencing by Short Interfering RNA: A Potent Approach to Sensitize Chronic Myeloid Leukemia Cells to Tyrosine Kinase Inhibitor Therapy.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Bcr-abl silencing by specific small-interference RNA expression vector as a potential treatment for chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Bcr-Abl stabilizes beta-catenin in chronic myeloid leukemia through its tyrosine phosphorylation.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR-ABL stimulates mutagenic homologous DNA double-strand break repair via the DNA end processing factor CtIP.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR-ABL suppresses autophagy through ATF5-mediated regulation of mTOR transcription.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR-ABL Testing by Polymerase Chain Reaction in Patients With Neutrophilia: The William Beaumont Hospital Experience and the Case for Rational Laboratory Test Requests.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR-ABL Transcript Level as Compared to LDH and Uric Acid Among Chronic Myeloid Leukemic Patients.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR-ABL transcript variations in chronic phase chronic myelogenous leukemia patients on imatinib first-line: Possible role of the autologous immune system.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR-ABL transcript with an e19a2 (c3a2) junction in classical chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR-ABL transcripts are early predictors for hematological relapse in chronic myeloid leukemia after hematopoietic cell transplantation with reduced intensity conditioning.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR-ABL transcripts are not detected in cord blood or the peripheral blood of the newborn child whose mother developed chronic myeloid leukemia while pregnant.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR-ABL translocation in a dog with chronic monocytic leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR-ABL tyrosine kinase activity regulates the expression of multiple genes implicated in the pathogenesis of chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR-ABL tyrosine kinase inhibition induces metabolic vulnerability by preventing the integrated stress response in K562?cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR-ABL tyrosine kinase inhibitors for chronic myelogenous leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia: using guidelines to make rational treatment choices.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR-ABL tyrosine kinase inhibitors promote pathological changes in dilator phenotype in the human microvasculature.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR-ABL Tyrosine Kinase Inhibitors: Which Mechanism(s) May Explain the Risk of Thrombosis?
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Bcr-Abl ubiquitination and Usp9x inhibition block kinase signaling and promote CML cell apoptosis.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR-ABL uncouples canonical JAK2-STAT5 signaling in chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR-ABL V280G Mutation, Potential Role in Imatinib Resistance: First Case Report.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Bcr-Abl with an SH3 deletion retains the ability To induce a myeloproliferative disease in mice, yet c-Abl activated by an SH3 deletion induces only lymphoid malignancy.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR-ABL, ABL-BCR, BCR, and ABL genes are all expressed in individual granulocyte-macrophage colony-forming unit colonies derived from blood of patients with chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR-ABL-expressing cells transduced with the HSV-tk gene die by apoptosis upon treatment with ganciclovir.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
bcr-abl-Induced cell lines can switch from mast cell to erythroid or myeloid differentiation in vitro.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR-ABL-mediated inhibition of apoptosis with delay of G2/M transition after DNA damage: a mechanism of resistance to multiple anticancer agents.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Bcr-Abl-mediated protection from apoptosis downstream of mitochondrial cytochrome c release.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Bcr-Abl-mediated redox regulation of the PI3K/AKT pathway.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Bcr-Abl-mediated suppression of normal hematopoiesis in leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR-ABL-mediated upregulation of PRAME is responsible for knocking down TRAIL in CML patients.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Bcr-abl-positive cells secrete angiogenic factors including matrix metalloproteinases and stimulate angiogenesis in vivo in Matrigel implants.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR-ABL1- positive chronic myeloid leukemia with erythrocytosis presenting as polycythemia vera: a case report.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR-ABL: a multi-faceted promoter of DNA mutation in chronic myelogeneous leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR-ABL: an anti-apoptosis gene in chronic myelogenous leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR/ABL kinase inhibition by imatinib mesylate enhances MAP kinase activity in chronic myelogenous leukemia CD34+ cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Benchmarking 2D/3D/MD-QSAR Models for Imatinib Derivatives: How Far Can We Predict?
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Beneficial effects of combining nilotinib and imatinib in preclinical models of BCR-ABL+ leukemias.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
beta-Catenin is essential for survival of leukemic stem cells insensitive to kinase inhibition in mice with BCR-ABL-induced chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
beta-Glucuronidase is an optimal normalization control gene for molecular monitoring of chronic myelogenous leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Betulinic acid induces apoptosis in human chronic myelogenous leukemia (CML) cell line K-562 without altering the levels of Bcr-Abl.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Beyond BRAF in Melanoma.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Beyond chronic myelogenous leukemia: potential role for imatinib in Philadelphia-negative myeloproliferative disorders.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Beyond genomics.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Biodegradable charged polyester-based vectors (BCPVs) as an efficient non-viral transfection nanoagent for gene knockdown of the BCR-ABL hybrid oncogene in a human chronic myeloid leukemia cell line.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Biological therapy for pediatric malignancy: current perspectives.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Biology and treatment of chronic myelogenous leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Biology and treatment of chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Biology of chronic myelogenous leukemia--signaling pathways of initiation and transformation.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Biology of chronic myeloid leukemia and possible therapeutic approaches to imatinib-resistant disease.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Blockade of the Bcr-Abl kinase activity induces apoptosis of chronic myelogenous leukemia cells by suppressing signal transducer and activator of transcription 5-dependent expression of Bcl-xL.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Blockade of the interaction between Bcr-Abl and PTB1B by small molecule SBF-1 to overcome imatinib-resistance of chronic myeloid leukemia cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Blockade of Y177 and Nuclear Translocation of Bcr-Abl Inhibits Proliferation and Promotes Apoptosis in Chronic Myeloid Leukemia Cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Bone marrow-derived mesenchymal stromal cells promote resistance to tyrosine kinase inhibitors in chronic myeloid leukemia via the IL-7/JAK1/STAT5 pathway.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Bone metabolism, growth rate and pubertal development in children with chronic myeloid leukemia treated with imatinib during puberty.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Bortezomib induces apoptosis in primitive chronic myeloid leukemia cells including LTC-IC and NOD/SCID repopulating cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Bortezomib treatment causes remission in a Ph+ALL patient and reveals FoxO as a theranostic marker.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Bosutinib for Chronic Myeloid Leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Bosutinib in the management of chronic myelogenous leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Bosutinib in the treatment of patients with Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia: an overview.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Bosutinib Therapy in Patients With Chronic Myeloid Leukemia: Practical Considerations for Management of Side Effects.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Bosutinib treatment for Philadelphia chromosome-positive leukemias.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Bosutinib: a novel second-generation tyrosine kinase inhibitor.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Bothrops moojeni L-amino acid oxidase induces apoptosis and epigenetic modulation on Bcr-Abl+ cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Breakpoints on chromosomes 9 and 22 in Philadelphia chromosome-positive chronic myelogenous leukemia (CML). Amplification of rearranged c-abl oncogenes in CML blast crisis.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Brefeldin A Induces Apoptosis, Inhibits BCR-ABL Activation, and Triggers BCR-ABL Degradation in Chronic Myeloid Leukemia K562 Cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Bruton's tyrosine kinase is not essential for Bcr-Abl-mediated transformation of lymphoid or myeloid cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
c-Abl and Parkinson's Disease: Mechanisms and Therapeutic Potential.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
c-abl function in normal and chronic myelogenous leukemia hematopoiesis: in vitro studies with antisense oligomers.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
c-Abl in oxidative stress, aging and cancer.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
c-Abl kinase inhibitors overcome CD40-mediated drug resistance in CLL: implications for therapeutic targeting of chemoresistant niches.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
c-abl Oncogene and chromosome 22 "bcr" juxtaposition in chronic myelogenous leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
c-Abl tyrosine kinase and inhibition by the cancer drug imatinib (Gleevec/STI-571).
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
c-Abl-dependent Molecular Circuitry Involving Smad5 and Phosphatidylinositol 3-Kinase Regulates Bone Morphogenetic Protein-2-induced Osteogenesis.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
c-CBL is not required for leukemia induction by Bcr-Abl in mice.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
c-Jun blocks cell differentiation but not growth inhibition or apoptosis of chronic myelogenous leukemia cells induced by STI571 and by histone deacetylase inhibitors.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
C-kit expression in pediatric solid tumors: a comparative immunohistochemical study.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
c-kit ligand stimulates tyrosine phosphorylation of a similar pattern of phosphotyrosyl proteins in primary primitive normal hematopoietic progenitors that are constitutively phosphorylated in comparable primitive progenitors in chronic phase chronic myelogenous leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
C-sis and C-abl expression in chronic myelogenous leukemia and other hematologic malignancies.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
C/EBP? is a critical mediator of IFN-?-induced exhaustion of chronic myeloid leukemia stem cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
C/EBP? promotes BCR-ABL-mediated myeloid expansion and leukemic stem cell exhaustion.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
C3G forms complexes with Bcr-Abl and p38? MAPK at the focal adhesions in chronic myeloid leukemia cells: implication in the regulation of leukemic cell adhesion.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
CALR-mutated essential thrombocythemia evolving to chronic myeloid leukemia with coexistent CALR mutation and BCR-ABL translocation.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
CaMKII ?, a critical regulator of CML stem/progenitor cells, is a target of the natural product berbamine.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Camptothecin acts synergistically with imatinib and overcomes imatinib resistance through Bcr-Abl independence in human K562 cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Can clues to the molecular defects in chronic myelogenous leukemia come from genetic studies on the Abelson tyrosine kinase in fruit flies?
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Can increased immunogenicity in chronic myeloid leukemia improve outcomes?
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Can kinomics and proteomics bridge the gap between pediatric cancers and newly designed kinase inhibitors?
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Can only partial T-cell depletion of the graft before hematopoietic stem cell transplantation mitigate graft-versus-host disease while preserving a graft-versus-leukemia reaction? A prospective phase II study.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Can we afford to let sleeping dogs lie?
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Cantharidin Overcomes Imatinib Resistance by Depleting BCR-ABL in Chronic Myeloid Leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Capping of bcr-abl antisense oligonucleotides enhances antiproliferative activity against chronic myeloid leukemia cell lines.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Carboxyamidotriazole inhibits cell growth of imatinib-resistant chronic myeloid leukaemia cells including T315I Bcr-Abl mutant by a redox-mediated mechanism.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Cardiotoxicity of the cancer therapeutic agent imatinib mesylate.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Cardiovascular and pulmonary adverse events in patients treated with BCR-ABL inhibitors: Data from the FDA Adverse Event Reporting System.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Cardiovascular Issues in Tyrosine Kinase Inhibitors Treatments for Chronic Myeloid Leukemia: A Review.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Cardiovascular toxicities of BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia: preventive strategies and cardiovascular surveillance.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Cathepsin B release after imatinib-mediated lysosomal membrane permeabilization triggers BCR-ABL cleavage and elimination of chronic myelogenous leukemia cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
CBL-B is required for leukemogenesis mediated by BCR-ABL through negative regulation of bone marrow homing.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
CCN3 - A key regulator of the hematopoietic compartment.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
CCR7 is involved in BCR-ABL/STAP-2-mediated cell growth in hematopoietic Ba/F3 cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
CD-200 induces apoptosis and inhibits Bcr-Abl signaling in imatinib-resistant chronic myeloid leukemia with T315I mutation.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
CD4(+) cytotoxic T-cell clones specific for bcr-abl b3a2 fusion peptide augment colony formation by chronic myelogenous leukemia cells in a b3a2-specific and HLA-DR-restricted manner.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
CD69 partially inhibits apoptosis and erythroid differentiation via CD24, and their knockdown increase imatinib sensitivity in BCR-ABL-positive cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
CD93 is expressed on chronic myeloid leukemia stem cells and identifies a quiescent population which persists after tyrosine kinase inhibitor therapy.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
CDKIs p18(INK4c) and p57(Kip2) are involved in quiescence of CML leukemic stem cells after treatment with TKI.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Celastrol, a novel HSP90 inhibitor, depletes Bcr-Abl and induces apoptosis in imatinib-resistant chronic myelogenous leukemia cells harboring T315I mutation.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Cell cycle regulation by oncogenic tyrosine kinases in myeloid neoplasias: from molecular redox mechanisms to health implications.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Cell lines and clinical isolates derived from Ph1-positive chronic myelogenous leukemia patients express c-abl proteins with a common structural alteration.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Cell lines and peripheral blood leukocytes derived from individuals with chronic myelogenous leukemia display virtually identical proteins phosphorylated on tyrosine residues.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Cell surface antigen and molecular targeting in the treatment of hematologic malignancies.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Cell-penetrating fusion peptides OD1 and OD2 interact with Bcr-Abl and influence the growth and apoptosis of K562 cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Cell-penetrating SH3 domain blocker peptides inhibit proliferation of primary blast cells from CML patients.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Cepharanthine activates caspases and induces apoptosis in Jurkat and K562 human leukemia cell lines.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
CGP57148B (STI-571) induces differentiation and apoptosis and sensitizes Bcr-Abl-positive human leukemia cells to apoptosis due to antileukemic drugs.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Chaetocin antileukemia activity against chronic myelogenous leukemia cells is potentiated by bone marrow stromal factors and overcomes innate imatinib resistance.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Changes in cell adhesivity and cytoskeleton-related proteins during imatinib-induced apoptosis of leukemic JURL-MK1 cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Changes in molecular biology of chronic myeloid leukemia in tyrosine kinase inhibitor era.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Changes in the activity of the GPx-1 anti-oxidant selenoenzyme in mononuclear cells following imatinib treatment.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Changes in the proteome associated with the action of Bcr-Abl tyrosine kinase are not related to transcriptional regulation.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Changing the subcellular location of the oncoprotein bcr-abl using rationally designed capture motifs.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Characteristics and outcome of chronic myeloid leukemia patients with E255K/V BCR-ABL kinase domain mutations.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Characteristics and outcome of chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Characteristics of BCR-ABL gene variants in patients of chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Characteristics of BCR-ABL kinase domain mutations in chronic myeloid leukemia from India: not just missense mutations but insertions and deletions are also associated with TKI resistance.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Characteristics of BCR-ABL kinase domain point mutations in Chinese imatinib-resistant chronic myeloid leukemia patients.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Characterization and selection of benign stem cells in chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Characterization of a myeloid tyrosine phosphatase, Lyp, and its role in the Bcr-Abl signal transduction pathway.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Characterization of a reference material for BCR-ABL (M-BCR) mRNA quantitation by real-time amplification assays: towards new standards for gene expression measurements.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Characterization of ABL exon 7 deletion by molecular genetic and bioinformatic methods reveals no association with imatinib resistance in chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Characterization of BCR-ABL deletion mutants from patients with chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Characterization of dasatinib and its structural analogs as CYP3A4 mechanism based inactivators and the proposed bio-activation pathways.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Characterization of imatinib-resistant K562 cell line displaying resistance mechanisms.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Characterization of p87C3G, a novel, truncated C3G isoform that is overexpressed in chronic myeloid leukemia and interacts with Bcr-Abl.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Characterization of potent inhibitors of the Bcr-Abl and the c-kit receptor tyrosine kinases.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Characterization of the different BCR-ABL transcripts with a single multiplex RT-PCR.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Characterizing of Four Common BCR-ABL Kinase Domain Mutations (T315I, Y253H, M351T and E255K) in Iranian Chronic Myelogenous Leukemia Patients With Imatinib Resistance.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Charting the molecular network of the drug target Bcr-Abl.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Chemical and enzymatic probing of effector-mediated changes in the conformation of a maxizyme.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Chemical biology of natural indolocarbazole products: 30 years since the discovery of staurosporine.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Chemical proteomic analysis reveals alternative modes of action for pyrido[2,3-d]pyrimidine kinase inhibitors.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Chemokines as a Conductor of Bone Marrow Microenvironment in Chronic Myeloid Leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Chemokines in chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Chibby drives ? catenin cytoplasmic accumulation leading to activation of the unfolded protein response in BCR-ABL1+ cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Chitosan encapsulated quantum dots platform for leukemia detection.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Cholesterol esterification inhibition and imatinib treatment synergistically inhibit growth of BCR-ABL mutation-independent resistant chronic myelogenous leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Choosing the best second-line tyrosine kinase inhibitor in imatinib-resistant chronic myeloid leukemia patients harboring Bcr-Abl kinase domain mutations: how reliable is the IC???
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Choosing the best treatment strategy for chronic myeloid leukemia patients resistant to imatinib: weighing the efficacy and safety of individual drugs with BCR-ABL mutations and patient history.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Chromatin nucleoprotein complexes containing tightly bound c-abl, p53 and bcl-2 gene sequences: correlation with progression of chronic myelogenous leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Chromosomal aberrations in squamous cell carcinomas of the upper aerodigestive tract: biologic insights and clinical opportunities.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Chromosomal approaches to the molecular basis of neoplasia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Chromosomal in situ hybridization and Southern blot analyses using c-abl, c-sis, or bcr probe in chronic myelogenous leukemia cells with variant Philadelphia translocations.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Chromosomal localization and characterization of c-abl in the t(6;9) of acute nonlymphocytic leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Chromosome 22 breakpoints in variant Philadelphia translocations and Philadelphia-negative chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Chronic myelogenous leukemia cells convert to myofibroblasts in vitro: Effect of vascular endothelial growth factor on development of the microenvironment.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Chronic myelogenous leukemia with e13a3 (b2a3) type of BCR-ABL transcript having a DNA breakpoint between ABL exons a2 and a3.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Chronic Myelogenous Leukemia with the e6a2 BCR-ABL and Lacking Imatinib Response: Presentation of Two Cases.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Chronic myelogenous leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Chronic myelogenous leukemia: amplification of a rearranged c-abl oncogene in both chronic phase and blast crisis.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Chronic myelogenous leukemia: biology and therapy.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Chronic Myelogenous Leukemia: Disease Biology and Current and Future Therapeutic Strategies.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Chronic myelogenous leukemia: mechanisms underlying disease progression.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Chronic myelogenous leukemia: treatment and monitoring.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Chronic myeloid leukemia (CML) with P190 BCR-ABL: analysis of characteristics, outcomes, and prognostic significance.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Chronic myeloid leukemia cells refractory/resistant to tyrosine kinase inhibitors are genetically unstable and may cause relapse and malignant progression to the terminal disease state.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
CHRONIC MYELOID LEUKEMIA EXPECTED RELAPSE'S CLINICAL-LABORATORY INDEXES.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Chronic Myeloid Leukemia in a Patient with Hepatitis B Virus Infection: A Case Report.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Chronic myeloid leukemia may be associated with several bcr-abl transcripts including the acute lymphoid leukemia-type 7 kb transcript.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Chronic myeloid leukemia patient with co-occurrence of BCR-ABL junction and JAK2 V617F mutation.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Chronic myeloid leukemia patients sensitive and resistant to imatinib treatment show different metabolic responses.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation are resistant to dasatinib: Is that true for all the patients?
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Chronic myeloid leukemia patients with the e13a2 BCR-ABL fusion transcript have inferior responses to imatinib compared to patients with the e14a2 transcript.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Chronic myeloid leukemia presenting with bilateral central retinal vein occlusion and massive retinal infiltrates.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Chronic myeloid leukemia progenitor cells require autophagy when leaving hypoxia-induced quiescence.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Chronic myeloid leukemia stem cells and developing therapies.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Chronic myeloid leukemia stem cells and molecular target therapies for overcoming resistance and disease persistence.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Chronic myeloid leukemia with a rare variant BCR-ABL translocation: t(9;22;21)(q34;q11.2;q11.2).
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Chronic myeloid leukemia with an e13a3 BCR-ABL fusion: benign course responsive to imatinib with an RT-PCR advisory.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Chronic myeloid leukemia with an e1a3 BCR-ABL fusion protein: transformation to lymphoid blast crisis.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Chronic myeloid leukemia with e14a3 BCR-ABL transcript: analysis of characteristics and prognostic significance.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Chronic Myeloid Leukemia With P190 BCR-ABL Translocation and Persistent Moderate Monocytosis: A Case Report.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Chronic myeloid leukemia with p210 BCR-ABL and monocytosis.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Chronic myeloid leukemia with unusual variant Ph translocation (22;22)(q11;q13). Two cases with chimeric BCR-ABL transcripts.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Chronic Myeloid Leukemia--Prognostic Value of Mutations.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Chronic myeloid leukemia: Existing therapeutic options and strategies to overcome drug resistance.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Chronic myeloid leukemia: overview of new agents and comparative analysis.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Chronic myeloid leukemia: past, present, future.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Chronic myeloid leukemia: reminiscences and dreams.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Chronic myeloid leukemia: state of the art in 2012.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Chronic myeloid leukemia: the paradigm of targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapy.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
CircBA1 derived from BCR-ABL fusion gene inhibits cell proliferation in chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Circulating bcr-abl-specific CD8+ T cells in chronic myeloid leukemia patients and healthy subjects.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Circulating myeloid dendritic cell directly isolated from patients with chronic myelogenous leukemia are functional and carry the bcr-abl translocation.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Classification of Patients With Chronic Myeloid Leukemia on Basis of BCR-ABL Transcript Level at 3 Months Fails to Identify Patients With Low Organic Cation Transporter-1 Activity Destined to Have Poor Imatinib Response.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Classification, diagnosis and management of myeloproliferative disorders in the JAK2V617F era.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Cleavage of BCR-ABL transcripts at the T315I point mutation by DNAzyme promotes apoptotic cell death in imatinib-resistant BCR-ABL leukemic cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Clinical characteristics and whole exome/transcriptome sequencing of coexisting chronic myeloid leukemia and myelofibrosis.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Clinical detection of BCR-abl fusion by in situ hybridization in chronic myelogenous leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Clinical development of imatinib: an anticancer drug.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Clinical efficacy and safety of imatinib in the management of Ph(+) chronic myeloid or acute lymphoblastic leukemia in Chinese patients.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Clinical experience to date with nilotinib in gastrointestinal stromal tumors.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Clinical outcome in chronic myeloid leukemia after allogeneic hematopoietic stem cell transplantation: the experience of the Bone Marrow Transplantation Unit of FUNFARME/BRAZIL using FISH.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Clinical outcome of 27 imatinib mesylate-resistant chronic myelogenous leukemia patients harboring a T315I BCR-ABL mutation.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Clinical outcome of chronic myeloid leukemia imatinib-resistant patients: do BCR-ABL kinase domain mutations affect patient survival? First multicenter Argentinean study.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Clinical profile of dasatinib in Asian and non-Asian patients with chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Clinical roundtable monograph: Emerging treatment options for TKI-resistant chronic myelogenous leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Clinical Significance of BCR-ABL Fusion Gene in Chronic Myeloid Leukemia Patients.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Clinical significance of bcr-abl gene rearrangement detected by polymerase chain reaction after allogeneic bone marrow transplantation in chronic myelogenous leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Clinical significance of bcr-abl gene rearrangement detected by the polymerase chain reaction after allogeneic bone marrow transplantation in chronic myelogenous leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Clinical value of quantitative long-term assessment of bcr-abl chimeric transcript in chronic myelogenous leukemia patients after allogeneic bone marrow transplantation.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Clinico-hematological profile in biphenotypic acute leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Clonal analysis of bcr-abl rearrangement in T lymphocytes from patients with chronic myelogenous leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Clonal chromosome aberrations in Philadelphia-negative cells from chronic myelocytic leukemia patients treated with imatinib mesylate: report of two cases.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Clonal evolution of AML1-ETO coexisting with BCR-ABL and additional chromosome abnormalities in a blastic transformation of chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Clonally unrelated BCR-ABL-negative acute myeloblastic leukemia masquerading as blast crisis after busulphan and interferon therapy for BCR-ABL-positive chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Cloning, expression, purification and functional characterization of the oligomerization domain of Bcr-Abl oncoprotein fused to the cytoplasmic transduction peptide.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
CML cells actively evade host immune surveillance through cytokine-mediated downregulation of MHC-II expression.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Co-encapsulation of anti-BCR-ABL siRNA and imatinib mesylate in transferrin receptor-targeted sterically stabilized liposomes for chronic myeloid leukemia treatment.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Co-existence of BCR-ABL and JAK2V617F mutation in resistant chronic myeloid leukemia in the imatinib era: Is there a correlation?
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Co-expression of HoxA9 and bcr-abl genes in chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Co-occurrence of Myeloproliferative Neoplasms and Solid Tumors Is Attributed to a Synergism Between Cytoreductive Therapy and the Common TERT Polymorphism rs2736100.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Coexistence of breakpoint cluster region-Abelson1 rearrangement and Janus kinase 2 V617F mutation in chronic myeloid leukemia: A case report.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Coexistence of chronic myeloid leukemia and diffuse large B-cell lymphoma with antecedent chronic lymphocytic leukemia: a case report and review of the literature.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Collaborative cardiovascular management of patients with chronic myeloid leukemia on tyrosine kinase inhibitors.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Combi-targeting concept: an optimized single-molecule dual-targeting model for the treatment of chronic myelogenous leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Combination of a proteomics approach and reengineering of meso scale network models for prediction of mode-of-action for tyrosine kinase inhibitors.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Combination of EUTOS score and 3-month BCR-ABL transcript level identifies a group of good-risk chronic myeloid leukemia patients with favorable response to frontline imatinib therapy.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Combination of simvastatin and imatinib sensitizes the CD34+ cells in K562 to cell death.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Combination of the ABL kinase inhibitor imatinib with the Janus kinase 2 inhibitor TG101348 for targeting residual BCR-ABL-positive cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Combination therapies against chronic myeloid leukemia: short-term versus long-term strategies.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Combination therapy of BCR-ABL-positive B cell acute lymphoblastic leukemia by tyrosine kinase inhibitor dasatinib and c-JUN N-terminal kinase inhibition.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Combined effects of As4S4 and imatinib on chronic myeloid leukemia cells and BCR-ABL oncoprotein.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Combined effects of doxorubicin and STI571 on growth, differentiation and apoptosis of CML cell line K562.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Combined effects of PI3K and SRC kinase inhibitors with imatinib on intracellular calcium levels, autophagy, and apoptosis in CML-PBL cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Combined inhibition of ?-catenin and Bcr-Abl synergistically targets tyrosine kinase inhibitor-resistant blast crisis chronic myeloid leukemia blasts and progenitors in vitro and in vivo.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Combined inhibition of MDM2 and Bcr-Abl tyrosine kinase targets chronic myeloid leukemia stem/progenitor cells in a murine model.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Combined targeting of BCL-2 and BCR-ABL tyrosine kinase eradicates chronic myeloid leukemia stem cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Combined Therapy of ATRA and Imatinib Mesylate Decreases BCR-ABL and ABCB1/MDR1 Expression Through Cellular Differentiation in a Chronic Myeloid Leukemia Model.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Commonly used drugs in hematologic disorders.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Comparative analysis of interphase FISH and RT-PCR to detect bcr-abl translocation in chronic myelogenous leukemia and related disorders.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Comparative effect of imatinib and ponatinib on autophagy and miRNome in chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Comparative gene expression analysis of a chronic myelogenous leukemia cell line resistant to cyclophosphamide using oligonucleotide arrays and response to tyrosine kinase inhibitors.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Comparative In vitro cellular data alone are insufficient to predict clinical responses and guide the choice of BCR-ABL inhibitor for treating imatinib-resistant chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Comparative testing of peripheral blood and bone marrow for BCR-ABL transcripts in patients post allogeneic bone marrow transplantation and during interferon treatment for chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Comparison of activities between hammerhead ribozymes and DNA enzymes targeted to L6 BCR-ABL chimeric (b2a2) mRNA.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Comparison of allele specific oligonucleotide-polymerase chain reaction and direct sequencing for high throughput screening of ABL kinase domain mutations in chronic myeloid leukemia resistant to imatinib.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Comparison of bcr-abl protein expression and Philadelphia chromosome analyses in chronic myelogenous leukemia patients.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Comparison of competitive-nested PCR and real-time PCR in detecting BCR-ABL fusion transcripts in chronic myeloid leukemia patients.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Comparison of genomic DNA and cDNA for detection of residual disease after treatment of chronic myeloid leukemia with allogeneic bone marrow transplantation.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Comparison of Hepatotoxicity Associated With New BCR-ABL Tyrosine Kinase Inhibitors vs Imatinib Among Patients With Chronic Myeloid Leukemia: A Systematic Review and Meta-analysis.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Comparison of the specificities and catalytic activities of hammerhead ribozymes and DNA enzymes with respect to the cleavage of BCR-ABL chimeric L6 (b2a2) mRNA.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Competitive polymerase chain reaction as a method to detect the amplification of bcr-abl gene of chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Competitive polymerase chain reaction to estimate the number of BCR-ABL transcripts in chronic myeloid leukemia patients after bone marrow transplantation.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Complete cytogenetic and molecular response after imatinib treatment for chronic myeloid leukemia in a patient with atypical karyotype and BCR-ABL b2a3 transcript.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Complete cytogenetic response to Nilotinib in a chronic myeloid leukemia case with a rare e13a3(b2a3) BCR-ABL fusion transcript: A case report.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Complete Molecular Response in Chronic Myeloid Leukemia After Six Months of Imatinib: A Single Center Experience.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Complex Variant t(9;22) Chromosome Translocations in Five Cases of Chronic Myeloid Leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Complexity of BCR-ABL kinase domain mutations during the course of therapy with tyrosine kinase inhibitors in chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Comprehensive analysis of BCR-ABL transcript types in Korean CML patients using a newly developed multiplex RT-PCR.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Comprehensive characterization of a novel intronic pseudo-exon inserted within an e14/a2 BCR-ABL rearrangement in a patient with chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Comprehensive validation of a real-time quantitative bcr-abl assay for clinical laboratory use.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Compromised anti-tumor-immune features of myeloid cell components in chronic myeloid leukemia patients.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Computational analysis of ABL kinase mutations allows predicting drug sensitivity against selective kinase inhibitors.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Computational and Biological Investigations on Abl1 Tyrosine Kinase: A Review.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Computational Modeling of Stapled Peptides toward a Treatment Strategy for CML and Broader Implications in the Design of Lengthy Peptide Therapeutics.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Concomitant essential thrombocythemia with JAK2 V617F mutation in a patient with chronic myeloid leukemia with major molecular response with imatinib and long-term follow-up.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Conformational control inhibition of the BCR-ABL1 tyrosine kinase, including the gatekeeper T315I mutant, by the switch-control inhibitor DCC-2036.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Consequences of BCR-ABL expression within the hematopoietic stem cell in chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Considering baseline factors and early response rates to optimize therapy for chronic myeloid leukemia in chronic phase.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Constitutive activation of JAKs and STATs in BCR-Abl-expressing cell lines and peripheral blood cells derived from leukemic patients.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Constitutive activation of STAT5 by the BCR-ABL oncogene in chronic myelogenous leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Constitutive and specific activation of STAT3 by BCR-ABL in embryonic stem cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Constitutive c-jun N-terminal kinase activity in acute myeloid leukemia derives from Flt3 and affects survival and proliferation.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Continued expression of a tissue specific activated oncogene in the early steps of radiation-induced human thyroid carcinogenesis.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Contribution of BCR-ABL kinase domain mutations to imatinib mesylate resistance in Philadelphia chromosome positive Malaysian chronic myeloid leukemia patients.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Contribution of BCR-ABL-independent activation of ERK1/2 to acquired imatinib resistance in K562 chronic myeloid leukemia cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Controlling subcellular localization to alter function: Sending oncogenic Bcr-Abl to the nucleus causes apoptosis.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Conventional and fluorescence in situ hybridization analysis of three-way complex BCR-ABL rearrangement in a chronic myeloid leukemia patient.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Cooperation between RUNX1-ETO9a and novel transcriptional partner KLF6 in upregulation of Alox5 in acute myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Coordinate Modulation of Glycolytic Enzymes and OXPHOS by Imatinib in BCR-ABL Driven Chronic Myelogenous Leukemia Cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Correction: MicroRNA-1301-Mediated RanGAP1 Downregulation Induces BCR-ABL Nuclear Entrapment to Enhance Imatinib Efficacy in Chronic Myeloid Leukemia Cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Correction: MPT0B169, a New Antitubulin Agent, Inhibits Bcr-Abl Expression and Induces Mitochondrion-Mediated Apoptosis in Nonresistant and Imatinib-Resistant Chronic Myeloid Leukemia Cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Correlation between the type of bcr-abl transcripts and blood cell counts in chronic myeloid leukemia - a possible influence of mdr1 gene expression.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Correlation of major cytogenetic response with a pharmacogenetic marker in chronic myeloid leukemia patients treated with imatinib (STI571).
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Correlation of p210 BCR-ABL transcript variants with clinical, parameters and disease outcome in 45 chronic myeloid leukemia patients.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl-positive human acute leukemia cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Cotreatment with vorinostat enhances activity of MK-0457 (VX-680) against acute and chronic myelogenous leukemia cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Coupled delivery of imatinib mesylate and doxorubicin with nanoscaled polymeric vectors for a sustained downregulation of BCR-ABL in chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
CR-LAAO antileukemic effect against Bcr-Abl(+) cells is mediated by apoptosis and hydrogen peroxide.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Critical molecular pathways in cancer stem cells of chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Critical role of STAT5 activation in transformation mediated by ZNF198-FGFR1.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Crkl is the major tyrosine-phosphorylated protein in neutrophils from patients with chronic myelogenous leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
CRKL plays a pivotal role in tumorigenesis of head and neck squamous cell carcinoma through the regulation of cell adhesion.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Cross-Intolerance With Dasatinib Among Imatinib-Intolerant Patients With Chronic Phase Chronic Myeloid Leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Crosstalk between BCR-ABL and protease-activated receptor 1 (PAR1) suggests a novel target in chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Crosstalk between CML cells with HUVECS and BMSCs through CML derived exosomes.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Crosstalk between hedgehog and other signaling pathways as a basis for combination therapies in cancer.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Cryptic BCR-ABL fusion gene as variant rearrangement in chronic myeloid leukemia: molecular cytogenetic characterization and influence on TKIs therapy.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Cryptotanshinone suppresses key onco-proliferative and drugresistant pathways of chronic myeloid leukemia by targeting STAT5 and STAT3 phosphorylation.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Crystal structure of the T315I Abl mutant in complex with the aurora kinases inhibitor PHA-739358.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571).
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
CT-721, a Potent Bcr-Abl Inhibitor, Exhibits Excellent In Vitro and In Vivo Efficacy in the Treatment of Chronic Myeloid Leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
CTLs specific for bcr-abl joining region segment peptides fail to lyse leukemia cells expressing p210 bcr-abl protein.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Curcumin affects components of the chromosomal passenger complex and induces mitotic catastrophe in apoptosis-resistant Bcr-Abl-expressing cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Curcumin derivative C817 inhibits proliferation of imatinib-resistant chronic myeloid leukemia cells with wild-type or mutant Bcr-Abl in vitro.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Current perspectives on the treatment of patients with chronic myeloid leukemia: an individualized approach to treatment.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Current status of ABL tyrosine kinase inhibitors stop studies for chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Current status of agents active against the T315I chronic myeloid leukemia phenotype.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Current status of vaccination therapy for leukemias.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Current therapy of chronic myelogenous leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
CXCR4 up-regulation by imatinib induces chronic myelogenous leukemia (CML) cell migration to bone marrow stroma and promotes survival of quiescent CML cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Cyclin-dependent kinase 7/9 inhibitor SNS-032 abrogates FIP1-like-1 platelet-de
show
top
